<SEC-DOCUMENT>0001564590-21-014865.txt : 20210323
<SEC-HEADER>0001564590-21-014865.hdr.sgml : 20210323
<ACCEPTANCE-DATETIME>20210323162115
ACCESSION NUMBER:		0001564590-21-014865
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210323
DATE AS OF CHANGE:		20210323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oric Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001796280
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471787157
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39269
		FILM NUMBER:		21765027

	BUSINESS ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 388-5600

	MAIL ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>oric-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-23T13:50:33.5691428+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c72022d3c57a4886b8db69691e884c89 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:oric="http://www.oricpharma.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
oric-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001796280_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001796280_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:EntityCentralIndexKey" contextRef="C_0001796280_20200101_20201231">0001796280</ix:nonNumeric>
			<ix:nonNumeric id="F_000010" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001796280_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000319_2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428" decimals="2">0.25</ix:nonFraction>
			<ix:nonNumeric id="F_000328" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000351" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" contextRef="C_0001796280_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000352" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001796280_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000611" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_0001796280_20200101_20201231">2034-12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000614" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_0001796280_srtStatementGeographicalAxis_stprCA_20200101_20201231">2034-12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000319" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428" decimals="2">0.25</ix:nonFraction>
			<ix:nonNumeric id="F_000359" name="oric:StockTransferRestrictionsPeriod" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803_20200803">P18M</ix:nonNumeric>
			<ix:nonNumeric id="F_000476" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001796280_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000616" name="oric:CumulativeChangeInOwnershipPeriod" contextRef="C_0001796280_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000620" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoCaliforniaMember_20200101_20201231">2022-05-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000622" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoCaliforniaMember_20201231">P5Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlishares" id="F_000445" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF">3862500</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlishares" id="F_000446" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF">6749999</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlishares" id="F_000447" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF">4448780</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlishares" id="F_000448" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231" decimals="INF">4217327</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlishares" id="F_000449" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_20191231" decimals="INF">19278606</ix:nonFraction>
			<ix:nonNumeric id="F_000451" name="oric:TemporaryEquityIssuedPeriod" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">2014</ix:nonNumeric>
			<ix:nonNumeric id="F_000452" name="oric:TemporaryEquityIssuedPeriod" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">2015</ix:nonNumeric>
			<ix:nonNumeric id="F_000453" name="oric:TemporaryEquityIssuedPeriod" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">2018</ix:nonNumeric>
			<ix:nonNumeric id="F_000454" name="oric:TemporaryEquityIssuedPeriod" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">2015</ix:nonNumeric>
			<ix:nonNumeric id="F_000455" name="oric:TemporaryEquityIssuedPeriod" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">2016</ix:nonNumeric>
			<ix:nonNumeric id="F_000456" name="oric:TemporaryEquityIssuedPeriod" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">2019</ix:nonNumeric>
			<ix:nonNumeric id="F_000494" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001796280_20200101_20201231">P8Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000495" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001796280_20200101_20201231">P7Y9M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000530" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001796280_20190101_20191231">P6Y1M6D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000511" name="us-gaap:SharePrice" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20201231" decimals="INF">16.00</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000512" name="us-gaap:SharePrice" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20201231" decimals="INF">35.92</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000513" name="us-gaap:SharePrice" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20191231" decimals="INF">1.60</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000514" name="us-gaap:SharePrice" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20191231" decimals="INF">9.16</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001796280_20200101_20201231" decimals="4">0.0317</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000517" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001796280_20190101_20191231" decimals="3">0.014</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000518" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001796280_20180101_20181231" decimals="3">0.027</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000519" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001796280_20200101_20201231" decimals="4">0.0559</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001796280_20190101_20191231" decimals="3">0.026</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001796280_20180101_20181231" decimals="3">0.030</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000522" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001796280_20200101_20201231" decimals="4">0.8801</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000523" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001796280_20190101_20191231" decimals="2">0.77</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000524" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001796280_20180101_20181231" decimals="2">0.93</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000525" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001796280_20200101_20201231" decimals="4">0.9511</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000526" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001796280_20190101_20191231" decimals="2">1.04</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001796280_20180101_20181231" decimals="2">0.98</ix:nonFraction>
			<ix:nonNumeric id="F_000528" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20200101_20201231">P5Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000529" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000531" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20180101_20181231">P6Y3D</ix:nonNumeric>
			<ix:nonNumeric id="F_000532" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20180101_20181231">P6Y1M6D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001796280_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001796280_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:PreferredStockValue" contextRef="C_0001796280_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:PreferredStockValue" contextRef="C_0001796280_20191231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="oric-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001796280_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001796280_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001796280_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001796280_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:PublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:PublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:PublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_oricSeriesCAndDPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oric:SeriesCAndDPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_oricSegment">
				<xbrli:measure>oric:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200428_20200428">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-28</xbrli:startDate>
					<xbrli:endDate>2020-04-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200428">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200428_20200428">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-28</xbrli:startDate>
					<xbrli:endDate>2020-04-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-28</xbrli:startDate>
					<xbrli:endDate>2020-04-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:SecondaryPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-17</xbrli:startDate>
					<xbrli:endDate>2020-11-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:SecondaryPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-17</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20201117_20201117">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-17</xbrli:startDate>
					<xbrli:endDate>2020-11-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">oric:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">oric:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">oric:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_oricProduct">
				<xbrli:measure>oric:Product</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001796280_20200803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_20200803_20200803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:MiratiTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-03</xbrli:startDate>
					<xbrli:endDate>2020-08-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:MiratiTherapeuticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803_20200803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:MiratiTherapeuticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-03</xbrli:startDate>
					<xbrli:endDate>2020-08-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-19</xbrli:startDate>
					<xbrli:endDate>2020-10-19</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricDevelopmentAndRegulatoryMilestoneMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">oric:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricCommercialMilestoneMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">oric:CommercialMilestoneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricSuccessBasedMilestonesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">oric:SuccessBasedMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-19</xbrli:startDate>
					<xbrli:endDate>2020-10-19</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapIncomeStatementLocationAxis_oricAcquiredInProcessResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">oric:AcquiredInProcessResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-19</xbrli:startDate>
					<xbrli:endDate>2020-10-19</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricLabEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">oric:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricLabEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">oric:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricComputerHardwareAndSoftwareMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">oric:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricComputerHardwareAndSoftwareMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">oric:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_oricSecurity">
				<xbrli:measure>oric:Security</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandFourteenEquityIncentivePlanMember_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200401_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">oric:IncentiveStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200401_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMinimumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMinimumMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMinimumMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtRangeAxis_srtMaximumMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementScenarioAxis_oricScenarioOneMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oric:ScenarioOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementScenarioAxis_oricScenarioTwoMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oric:ScenarioTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_stprCA_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_stprCA_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoCaliforniaMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SanDiegoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoCaliforniaMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20191001_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SanDiegoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SanDiegoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoAndSanDiegoLocationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoAndSanDiegoLocationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoAndSanDiegoLocationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001796280_20200101_20201231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentAnnualReport" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001796280_20200101_20201231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001796280_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:DocumentTransitionReport" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from &#160;&#160; &#160;&#160; to</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number:&#160;<ix:nonNumeric id="F_000022" name="dei:EntityFileNumber" contextRef="C_0001796280_20200101_20201231">001-39269</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0001796280_20200101_20201231">ORIC PHARMACEUTICALS, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-weight:bold;font-size:10pt;">&#160;<ix:nonNumeric id="F_000023" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000024" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001796280_20200101_20201231">47-1787157</ix:nonNumeric></span></p></td>
</tr>
<tr>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressAddressLine1" contextRef="C_0001796280_20200101_20201231">240 E. Grand Ave</ix:nonNumeric>, <ix:nonNumeric id="F_000026" name="dei:EntityAddressAddressLine2" contextRef="C_0001796280_20200101_20201231">2nd Floor</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000027" name="dei:EntityAddressCityOrTown" contextRef="C_0001796280_20200101_20201231">South San Francisco</ix:nonNumeric></span>, <ix:nonNumeric id="F_000028" name="dei:EntityAddressStateOrProvince" contextRef="C_0001796280_20200101_20201231">CA</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000029" name="dei:EntityAddressPostalZipCode" contextRef="C_0001796280_20200101_20201231">94080</ix:nonNumeric></span></p></td>
</tr>
<tr>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000030" name="dei:CityAreaCode" contextRef="C_0001796280_20200101_20201231">650</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000031" name="dei:LocalPhoneNumber" contextRef="C_0001796280_20200101_20201231">388-5600</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0001796280_20200101_20201231">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0001796280_20200101_20201231">ORIC</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:exchnameen"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="font-weight:bold;Background-color:#FFFFFF;color:#000000;">Nasdaq Stock Market LLC</span></p></ix:nonNumeric>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(The Nasdaq Global Select Market)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744; </span><span style="text-transform:uppercase;"><ix:nonNumeric id="F_000012" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001796280_20200101_20201231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744; </span><span style="text-transform:uppercase;"><ix:nonNumeric id="F_000008" name="dei:EntityVoluntaryFilers" contextRef="C_0001796280_20200101_20201231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000007" name="dei:EntityCurrentReportingStatus" contextRef="C_0001796280_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000009" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001796280_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityFilerCategory" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:EntitySmallBusiness" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000018" name="dei:EntityExTransitionPeriod" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000034" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2020 (the last day of the Registrant&#8217;s most recently completed second fiscal quarter) was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000013" name="dei:EntityPublicFloat" contextRef="C_0001796280_20200630" decimals="-5" scale="6">743.3</ix:nonFraction> million. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February 28, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000014" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001796280_20210228" decimals="INF" format="ixt:numdotdecimal">36,695,019</ix:nonFraction>. </p><ix:nonNumeric id="F_000265" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:2pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Registrant&#8217;s Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#8217;s 2020 fiscal year ended December 31, 2020.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr style="height:16.75pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk</span><span style="text-decoration:underline;font-size:10pt;"> Factors</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:underline;">Selected Financial Data</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">SIGNATURES</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SPECIAL_NOTE_REGARDING_FORWARDLOOKING_ST">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report on Form10-K, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing, progress and results of preclinical studies and clinical trials for&#160;ORIC-101,&#160;ORIC-533, ORIC-944</span><span style="color:#000000;font-family:Times New Roman;">, ORIC-114 </span><span style="font-family:Times New Roman;">and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing, scope and likelihood of regulatory filings and approvals, including timing of Investigational New Drug, or IND, or Clinical Trial Application, or CTA, applications and final Food and Drug Administration, or FDA, approval of&#160;ORIC-101,&#160;ORIC-533, ORIC-944</span><span style="color:#000000;font-family:Times New Roman;">, ORIC-114 </span><span style="font-family:Times New Roman;">and any other future product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing, scope or likelihood of foreign regulatory filings and approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to develop and advance our current product candidates and programs into, and successfully complete, clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our manufacturing, commercialization, and marketing capabilities and strategy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the need to hire additional personnel and our ability to attract and retain such personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our expectations regarding the impact of the COVID-19 pandemic on our business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our expectations regarding the approval and use of our product candidates in combination with other drugs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our competitive position and the success of competing therapies that are or may become available&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our estimates of the number of patients that we will enroll in our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to obtain and maintain regulatory approval of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our plans relating to the further development of our product candidates, including additional indications we may pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">existing regulations and regulatory developments in the United States, Europe and other jurisdictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering&#160;ORIC-101,&#160;ORIC-533, ORIC-944</span><span style="color:#000000;font-family:Times New Roman;">, ORIC-114</span><span style="font-family:Times New Roman;">&#160;and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">the pricing and reimbursement of&#160;ORIC-101,&#160;ORIC-533, ORIC-944</span><span style="color:#000000;font-family:Times New Roman;">, ORIC-114</span><span style="font-family:Times New Roman;">&#160;and other product candidates we may develop, if approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the rate and degree of market acceptance and clinical utility of&#160;ORIC-101,&#160;ORIC-533, ORIC-944</span><span style="color:#000000;font-family:Times New Roman;">, ORIC-114</span><span style="font-family:Times New Roman;">&#160;and other product candidates we may develop&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our financial performance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the period over which we estimate our existing cash, cash equivalents and short-term investments will be sufficient to fund our future operating expenses and capital expenditure requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the impact of laws and regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our anticipated use of our existing resources.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk factors&#8221; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients&#8217; lives by&#160;<span style="font-style:italic;text-decoration:underline;">O</span><span style="font-style:italic;">vercoming&#160;</span><span style="font-style:italic;text-decoration:underline;">R</span><span style="font-style:italic;">esistance&#160;</span><span style="font-style:italic;text-decoration:underline;">I</span><span style="font-style:italic;">n&#160;</span><span style="font-style:italic;text-decoration:underline;">C</span><span style="font-style:italic;">ancer</span>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Collectively, our founders and management team have a decades-long heritage of identifying and characterizing resistance mechanisms in oncology, having discovered and developed groundbreaking medicines at companies such as Ignyta, Medivation, Aragon and Genentech.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At ORIC, our fully integrated discovery and development team is advancing a diverse pipeline of innovative therapies designed to counter resistance mechanisms in cancer by leveraging our expertise within&#160;three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Our lead product candidate,&#160;ORIC-101,&#160;builds upon a legacy of successful drug development by our founders in the field of nuclear hormone receptors and their efforts to elucidate the cause of resistance to the groundbreaking prostate cancer therapies that they had developed.&#160;ORIC-101&#160;is a potent and selective small molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. In 2019, we initiated two separate Phase 1b trials of&#160;ORIC-101&#160;in combination with (1)&#160;Xtandi (enzalutamide) in metastatic prostate cancer and (2)&#160;Abraxane&#160;(nab-paclitaxel)&#160;in advanced or metastatic solid tumors. In December 2020, we selected the recommended Phase 2 dose (RP2D) and initiated the dose expansion portion of the Phase 1b trial of ORIC-101 in combination with nab-paclitaxel and we expect to report interim safety, efficacy and translational data from this trial in the first half of 2021. In January 2021, we selected the RP2D and initiated the dose expansion portion of the Phase 1b trial of ORIC-101 in combination with enzalutamide and we expect to report interim safety, efficacy, and translational data from this trial in the second half of 2021. Our other product candidates include&#160;(1)&#160;ORIC-533,&#160;an orally bioavailable, potent and selective, small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regimens, (2) ORIC-944, an allosteric inhibitor of PRC2 via the EED subunit, for which we licensed exclusive worldwide development and commercialization rights from Mirati Therapeutics in August 2020 and (3) ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency towards exon 20 insertion mutations.&#160;We expect to file an IND for&#160;ORIC-533&#160;in the first half of 2021, an IND for ORIC-944 in the second half of 2021 and a CTA for ORIC-114 in the second half of 2021. Beyond these product candidates, we are developing multiple precision medicines targeting other</span><span style="color:#000000;font-family:Arial;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hallmark cancer resistance mechanisms. We believe our team and capabilities uniquely position us to be a leader in developing novel therapies to overcome resistance in cancer.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer resistance continues to be one of the most daunting challenges facing patients, clinicians and researchers in oncology today.&#160;A multitude of biological factors and pathways have been linked to resistance, which enables tumors to restore cell growth and survival by circumventing a treatment&#8217;s intended mechanism of action. Our resistance platform is focused on three areas: (1)&#160;innate resistance, which derives from an unaddressed oncogenic driver that promotes tumorigenesis&#59; (2)&#160;acquired resistance, the result of an induced or enriched oncogenic driver that arises in response to treatment&#59; and (3)&#160;bypass resistance, the activation of a compensatory signaling pathway in response to treatment.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are building a portfolio of novel agents targeting multiple resistance mechanisms by leveraging our specialized expertise in hormone-dependent cancers, precision oncology and key tumor dependencies:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Hormone-dependent cancers:</span><span style="font-family:Times New Roman;">&#160;Two of our founders, Drs. Charles Sawyers and Richard Heyman, are leading experts in nuclear hormone receptors and hormone-dependent cancers. They previously&#160;co-founded&#160;two oncology companies, Aragon (acquired by Johnson&#160;&#38; Johnson in 2013) and Seragon (acquired by Roche in 2014), that developed therapeutics targeting two nuclear hormone receptors, the androgen receptor (AR) and estrogen receptor (ER), respectively, the former effort leading to the approved drug Erleada (apalutamide). Our lead product candidate,&#160;ORIC-101,&#160;while independently developed by ORIC, builds on academic work from Dr.&#160;Sawyers&#8217; laboratory at Memorial Sloan Kettering Cancer Center (MSKCC) implicating GR as a potential mechanism of resistance to Xtandi (also discovered by Dr.&#160;Sawyers and developed by Medivation, which was acquired by Pfizer in 2016) in prostate cancer. Similarly, our product candidate, ORIC-944, an allosteric inhibitor of PRC2 via EED, is being developed as a potential treatment for advanced prostate cancer. Given the breadth of solid tumor indications in which hormone signaling pathways have been implicated in driving disease, or in the development of resistance, we believe our differentiated insight into this biology is a crucial component of our future success.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:8.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Precision oncology:</span><span style="font-family:Times New Roman;">&#160;Our precision medicine approach of utilizing biomarkers for demonstration of target and pathway engagement and ultimately for patient selection is rooted in our management team&#8217;s prior experience at Ignyta (acquired by Roche in 2018) in successfully developing Rozlytrek (entrectinib), which was approved by the U.S. Food and Drug Administration (FDA) for the treatment of ROS1-positive metastatic&#160;non-small&#160;cell lung cancer (NSCLC) and neurotrophic tyrosine receptor kinase (NTRK)-positive solid tumors in 2019. Similarly, our product candidate, ORIC-114, a brain penetrant, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, is being developed in genetically defined patient populations, including NSCLC and metastatic breast cancer. Our team&#8217;s experience in precision oncology dates back decades, including Dr.&#160;Sawyers&#8217; pivotal role in the development of Gleevec (imatinib) and Sprycel (dasatinib). We believe our team&#8217;s expertise and experience in precision oncology will allow us to develop drugs with a higher probability of clinical success within biomarker-defined patient populations, while also potentially reducing the time and cost of development.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:8.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Key tumor dependencies:</span><span style="font-family:Times New Roman;">&#160;Key tumor dependencies are abnormal alterations that promote cancer cell growth and survival and also confer specific vulnerabilities that normal cells lack&#59; these cancer-specific dependencies are compelling therapeutic targets. Our scientific team&#8212;led by our Chief Scientific Officer, Head of Drug Discovery, Head of Biology and Head of Translational Medicine&#8212;has amassed deep knowledge of key oncogenic drivers and pathways in order to identify and validate oncology targets. They most recently worked together at Genentech, where they progressed more than 20 oncology discovery programs into clinical development, with three approvals to date, including Cotellic (cobimetinib), Zelboraf (vemurafenib) and Polivy (polatuzumab vedotin). Our knowledge of innate, acquired and bypass resistance mechanisms, as well as&#160;our&#160;in-depth&#160;experience in forward and reverse translation, underpins our discovery efforts to identify key drivers of cancer resistance that can be exploited for therapeutic gain. Our resistance platform and&#160;in-house&#160;capabilities in medicinal chemistry and structure-based design enable us to pursue these resistance mechanisms. For example, our understanding of innate resistance and our medicinal chemistry expertise has led to the discovery of&#160;ORIC-533,&#160;an orally bioavailable small molecule inhibitor of CD73.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are applying our internal drug discovery capabilities to these three areas of expertise to develop innovative therapies targeting the critical cancer resistance mechanisms that we believe will bring the largest benefit to patients, including by making existing therapies more effective for a longer period of time.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio currently consists of multiple internally discovered and in-licensed programs targeting key resistance mechanisms</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in cancer</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Our product candidates are shown in the figure below:</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000001.jpg" title="" alt="" style="width:612px;height:169px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced discovery and research programs are shown in the figure below:</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000002.jpg" title="" alt="" style="width:609px;height:32px;" /><img src="gpty1lksmhba000003.jpg" title="" alt="" style="width:608px;height:118px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">GR antagonist program:&#160;ORIC-101</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GR is a nuclear hormone receptor that mediates responses to glucocorticoid hormones involved in regulating a range of cellular functions, such as metabolism, cell growth and differentiation. Roughly in parallel, two distinct and uncorrelated mechanisms of&#160;GR-mediated&#160;resistance to anti-cancer therapies began to be studied by oncology experts. The original hypothesis for our lead program targeting GR was borne out of work conducted in the laboratory of Dr.&#160;Sawyers at MSKCC in search of explanatory factors underlying resistance to anti-androgen prostate cancer therapies, including Xtandi and Erleada. His work demonstrated that GR signaling is a bypass mechanism to anti-androgen therapy, with GR taking over for AR signaling, and that increased expression of GR in prostate cancer is correlated with resistance to Xtandi. Similarly, GR has also been studied for its potential role in mediating resistance to chemotherapy, though in this case, the mechanism appears to be related to GR&#8217;s role in imparting a&#160;&#8220;pro-survival&#8221;&#160;phenotype on the tumor via certain biological processes like&#160;epithelial-to-mesenchymal&#160;(EMT) transition and anti-apoptosis. We and others have shown that GR is overexpressed across over 20 advanced solid tumors including prostate, pancreatic, triple negative breast (TNBC) and ovarian cancers, and that GR overexpression is associated with worse survival outcomes for patients treated with anti-androgen therapies in prostate cancer and chemotherapy in other solid tumors.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate,&#160;ORIC-101,&#160;is a potent and selective small molecule GR antagonist designed to inhibit GR transcriptional activity and block&#160;pro-survival&#160;signals downstream of its activation that confer resistance to anti-androgen therapies and chemotherapies. Since its initial discovery at ORIC, we have rapidly advanced&#160;ORIC-101&#160;through preclinical studies that have informed a robust clinical development plan designed to test both potential mechanisms of&#160;GR-mediated&#160;resistance. Following the successful completion of two Phase 1a trials in over 50 healthy volunteers, we initiated in 2019 two separate Phase 1b trials of&#160;ORIC-101&#160;in combination with: (1)&#160;enzalutamide in metastatic prostate cancer and&#160;(2)&#160;nab-paclitaxel&#160;in advanced or metastatic solid tumors. These trials were intended to establish safety, pharmacokinetics (PK), pharmacodynamics (PD), preliminary anti-tumor activity and a recommended Phase 2 dose (RP2D) of&#160;ORIC-101&#160;in combination with each of these therapeutics. In December 2020, we selected the  RP2D and initiated the dose expansion portion of the Phase 1b trial of ORIC-101 in combination with nab-paclitaxel and we expect to report interim safety, efficacy, and translational data from this trial in the first half of 2021. In January 2021, we selected the RP2D and initiated the dose expansion portion of the Phase 1b trial of ORIC-101 in combination with enzalutamide and we expect to report interim safety, efficacy, and translational data from this trial in the second half of 2021. To help inform which patients may be most suitable for treatment with&#160;ORIC-101,&#160;we have developed a proprietary immunohistochemistry (IHC) assay that measures GR protein expression levels as well as a proprietary GR gene activation signature that measures GR signaling activity, both of which are being utilized in our ongoing clinical trials and may be used for patient selection in future clinical trials. If either of these approaches proves to be a useful method for patient selection, we expect to incorporate the specific diagnostic test into our registrational studies and partner with the appropriate diagnostic provider to&#160;co-develop&#160;a companion diagnostic. In general, the FDA expects to review and approve simultaneously NDA and PMA submissions for a therapeutic and its companion diagnostic, respectively, so any delay in diagnostic approval could delay drug approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CD73 inhibitor program:&#160;ORIC-533</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many cancers usurp the anti-inflammatory adenosine pathway to avoid detection by the immune system, thereby reducing the effectiveness of certain chemotherapy- and immunotherapy-based treatments. Accumulation of adenosine in the tumor microenvironment is implicated in local immune suppression that leads to tumor growth. CD73 is an enzyme that controls the rate at which extracellular adenosine is produced and its overexpression is associated with poor prognosis in several cancers, including TNBC, NSCLC, melanoma and prostate, among others. Several global pharmaceutical companies are developing anti-CD73 antibodies, but due to significant medicinal chemistry challenges, to our knowledge, only one additional orally bioavailable inhibitor of CD73 is in clinical development. With our resistance platform capabilities, our medicinal chemistry team created a differentiated compound that is both potent and orally bioavailable. Our product candidate&#160;ORIC-533,&#160;is an orally bioavailable small molecule inhibitor of CD73 that has demonstrated more potent adenosine inhibition&#160;in vitro&#160;compared to an antibody-based approach and other small molecule CD73 inhibitors. ORIC-533 continues to progress in IND enabling studies and we expect to file an IND with the Food and Drug Administration (FDA) in the first half of 2021. Having conducted a preclinical collaboration with an academic key opinion leader that generated compelling single agent activity in patient derived model systems in an undisclosed tumor type, we plan to pursue a single agent clinical development path in this indication.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">PRC2 inhibitor program: ORIC-944</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dysregulation of PRC2 methyltransferase activity can lead to tumorigenesis in a wide range of cancers including prostate cancer, breast cancer, and hematological malignancies. PRC2 is composed of two druggable subunits: EED and EZH2. Several companies are developing EZH2 inhibitors&#59; however, the pharmacologic properties of these compounds result in high doses that achieve only partial target inhibition in the clinic. Additionally, preclinical studies suggest drug resistance to EZH2 inhibitors may develop via EZH1 bypass compensation or acquired mutations in EZH2. Allosteric inhibition of EED impacts the assembly, stabilization, and activation of PRC2, and may have benefits over EZH2-mediated inhibition of PRC2. ORIC-944 is a potent and selective allosteric inhibitor of PRC2 via the EED subunit and is efficacious in enzalutamide-resistant prostate cancer models in preclinical studies. We have initiated IND enabling studies and plan to file an IND with the FDA in the second half of 2021, with initial clinical development as a single agent in treatment-resistant prostate cancer.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Brain penetrant EGFR/HER2 exon 20 program: ORIC-114</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 exon 20 insertion mutations are observed across multiple solid tumors, including NSCLC, breast, gastrointestinal, bladder and other cancers. EGFR exon 20 insertion mutations are observed in approximately 2% of all patients with NSCLC and these patients have a worse prognosis than patients with NSCLC driven by other EGFR mutations. HER2 exon 20 insertion mutations are observed in approximately 1.5% of all patients with NSCLC. Approximately one-third of patients with exon 20 insertion mutations develop brain metastases, which contributes to poor prognosis.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-114 is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations. ORIC-114 has demonstrated greater brain exposure in preclinical studies compared to certain other compounds being developed against exon 20 mutations and has shown strong anti-tumor activity in an EGFR-driven intracranial lung cancer model. Currently, there are no medicines approved by the FDA specifically to treat tumors with EGFR or HER2 exon 20 insertion mutations. We have initiated IND enabling studies and plan to file a Clinical Trial Application (CTA) in South Korea in the second half of 2021.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other preclinical programs</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our product candidates, we are leveraging our resistance platform in pursuit of multiple discovery research programs that focus on our expertise within hormone-dependent cancers, precision oncology and key tumor dependencies. These programs highlight our medicinal chemistry and structure-based design expertise, thus for the most part utilize a small molecule therapeutic approach to target oncogenic drivers in solid tumors like prostate, breast, and lung cancer that relapse with innate, acquired or bypass resistance. Our most advanced discovery research program is currently in lead optimization.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our strategy </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to discover, develop and commercialize innovative therapies that overcome resistance in cancer. The key elements of our business strategy to achieve this goal include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Leveraging the insights, experience and networks of our founders and management team.</span><span style="font-family:Times New Roman;"> Our founders and management team have extensive experience identifying, discovering, developing and commercializing innovative cancer therapeutics aimed at novel targets, including Rozlytrek, Erleada, Talzenna, Xtandi, Sprycel and Gleevec. We are using this broad oncology experience together with our internal discovery and development capabilities to build a diverse pipeline of therapies targeting multiple cancer resistance mechanisms. For example, our lead product candidate, ORIC-101, while independently developed by ORIC, builds on academic work originally conducted by the laboratory of Dr. Sawyers at MSKCC.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;">Advancing our lead product candidate, ORIC-101, as rapidly as possible through clinical development by exploring rational combinations across multiple tumor types. </span><span style="color:#000000;font-family:Times New Roman;">The GR signaling pathway has been implicated in resistance to anti-androgen therapies in prostate cancer as well as chemotherapy regimens in other advanced solid tumor indications. Our clinical development effort for ORIC-101, an internally developed potent and selective small molecule antagonist of GR, will initially focus on indications where there is evidence suggesting GR-mediated signaling contributes to resistance and disease progression. In 2019, we initiated two separate Phase 1b trials of ORIC-101 in combination with (1) enzalutamide in metastatic prostate cancer and (2) nab-paclitaxel in advanced or metastatic solid tumors, and we expect to report interim data from </span><span style="color:#000000;font-family:Times New Roman;">the Phase 1b trial of ORIC-101 in combination with nab-paclitaxel </span><span style="color:#000000;font-family:Times New Roman;">in the first half of 2021 and from the </span><span style="color:#000000;font-family:Times New Roman;">Phase 1b trial of ORIC-101 in combination with enzalutamide</span><span style="color:#000000;font-family:Times New Roman;"> in the second half of 2021. Where possible, we plan to pursue accelerated development strategies in areas of high unmet need.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;">Leveraging our resistance platform in building the leading, fully integrated company focused on delivering innovative medicines that aim to overcome resistance in cancer. </span><span style="color:#000000;font-family:Times New Roman;">As of December 31, 2020, we had 61 full-time employees, including world-class discovery, preclinical and clinical development teams, encompassing all major functions necessary to take a molecule from target identification through registrational clinical trials. Together, they bring in-house expertise in medicinal chemistry, biology, translational medicine, computational chemistry, </span><span style="font-style:italic;color:#000000;font-family:Times New Roman;">in vitro</span><span style="color:#000000;font-family:Times New Roman;"> and </span><span style="font-style:italic;color:#000000;font-family:Times New Roman;">in vivo</span><span style="color:#000000;font-family:Times New Roman;"> pharmacology, computational biology, biomarker development and CMC. We have also established internal expertise in clinical development, clinical operations, pharmacovigilance, clinical pharmacology, regulatory and quality. The members of our research and development organization have collectively led and contributed to dozens of IND filings and multiple drug approvals in oncology. These internal capabilities led to the discovery and clinical development of our first product candidate and will enable us to continue to expand and advance our portfolio of additional product candidates.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;">Continuing to expand our portfolio of product candidates through both internal research activities and business development efforts. </span><span style="color:#000000;font-family:Times New Roman;">Our internally generated product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73. We expect to file an IND for ORIC-533 with the FDA in the first half of 2021. We also continue to advance our other internally generated programs as well as expand our pipeline through internal discovery activities. Simultaneously, we believe that accessing external innovation and expertise is important to our success. For example, we have in-licensed Mirati&#8217;s allosteric PRC2 program, including a lead product candidate now designated ORIC-944, as well as Voronoi&#8217;s EGFR and HER2 exon 20 insertion mutation program, including a lead product candidate now designated ORIC-114. ORIC-944 is a potent and selective allosteric inhibitor of PRC2 and is efficacious in enzalutamide-resistance prostate cancer models in preclinical studies. ORIC-114 is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency towards exon 20 insertion mutations. We will continue to leverage our leadership team&#8217;s prior business development experience as we evaluate potential in-licensing and acquisition opportunities to further expand our portfolio. We aim to be the partner of choice for academic groups and companies in the field of cancer resistance.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.99%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;">Utilizing a precision medicine approach in the development of each of our product candidates. </span><span style="color:#000000;font-family:Times New Roman;">We use biomarkers to demonstrate target and pathway engagement and plan to use them for patient selection in our clinical trials. This approach is rooted in our team&#8217;s prior experiences developing targeted therapies, such as Rozlytrek, an orally bioavailable, tyrosine kinase inhibitor approved for select tumors that harbor ROS1 or NTRK fusions. We seek to design rigorous and cost-efficient clinical programs that increase the probability of success by exploring connections between cellular-level biology and patient-level clinical outcomes. The use of biomarker-based patient selection is designed to enable demonstration of clinical proof-of-concept earlier and with fewer patients, leading ultimately to smaller pivotal trials. As part of our strategy, our in-house team of experienced translational scientists and computational biologists leverages existing technologies as well as develops proprietary assays to enable the selection and assessment of biomarkers for each of our programs. For ORIC-101, we have developed a proprietary IHC assay that measures GR protein expression levels as well as a proprietary GR gene activation signature that measures GR signaling activity. Both of these assays are being utilized in our two ongoing Phase 1b clinical trials of ORIC-101.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.99%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;">Evaluating opportunities to accelerate development timelines and enhance the commercial potential of our programs in collaboration with third parties. </span><span style="color:#000000;font-family:Times New Roman;">We own or license full worldwide development and commercialization rights to each of our programs (other than in the ORIC Territory with respect to our brain penetrant EGFR and HER2 exon 20 program, ORIC-114). We have established collaborations and intend to continue evaluating opportunities to work with partners that meaningfully enhance our capabilities with respect to the development and commercialization of our product candidates. For example, for our Phase 1b trial of ORIC-101 in combination with enzalutamide in prostate cancer, we have entered into a clinical trial collaboration and supply agreement with Astellas. In addition, we intend to commercialize our product candidates in key markets either alone or with partners in order to maximize the worldwide commercial potential of our programs.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Background on cancer resistance </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer resistance continues to be one of the most daunting challenges facing patients, clinicians and researchers in oncology today. A multitude of biological factors and pathways have been linked to resistance, which enables tumors to restore cell growth and survival by circumventing a treatment&#8217;s intended mechanism of action. Furthermore, treatment resistance in cancer emerges irrespective of therapeutic class, including targeted therapy, hormone therapy, immunotherapy and chemotherapy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our resistance platform is focused on three areas: (1) innate resistance, which derives from an unaddressed oncogenic driver that promotes tumorigenesis&#59; (2) acquired resistance, the result of an induced or enriched oncogenic driver that arises in response to treatment&#59; and (3) bypass resistance, the activation of a compensatory signaling pathway in response to treatment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview of key resistance mechanisms and ORIC team&#8217;s prior relevant experience </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000004.jpg" title="" alt="" style="width:609px;height:269px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Innate resistance</span><span style="font-family:Times New Roman;"> occurs when a key tumor dependency is not addressed, such as a driver mutation with no available targeted therapeutic. A recent example of a drug targeting innate resistance is Rozlytrek, developed by Ignyta for patients with ROS1-positive, metastatic NSCLC and NTRK gene fusion-positive solid tumors. We believe these innate resistance targets have a higher probability of technical success than other cancer targets, hold potential for meaningful clinical outcomes, and have the potential for rapid clinical development and approval timelines. Innate resistance targets have been the subject of a number of targeted therapies that have been approved over the past couple of decades. Studies have shown that treatments that target and inhibit unaddressed driver mutations have high response rates with generally good durability, including in a resistant setting. This efficacy in a refractory patient population in turn has been shown to enable a shorter development pathway, with many such agents being approved based upon single arm trials of modest size. New advances in small molecule drug discovery have created an opportunity to better target next-generation oncogenic drivers. Our pipeline includes several programs targeting innate resistance including ORIC-533, our orally bioavailable small molecule CD73 inhibitor, which we designed to address adenosine-driven innate resistance to chemotherapy- and immunotherapy-based treatment regimens&#59; ORIC-944, our allosteric inhibitor of PRC2, which was designed to address innate resistance related to PRC2 dysregulation in prostate and other tumors&#59; and ORIC-114, our brain penetrant, orally bioavailable, irreversible inhibitor designed to address innate resistance related to exon20 insertion mutations of EGFR and HER2 in lung and other tumors. While other therapies targeting innate resistance have shown technical success, our programs are distinct from other therapies and there is no guarantee that our product candidates will be approved, are more likely to receive FDA approval than other potential product candidates, or if approved, will be approved quickly.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Acquired resistance</span><span style="font-family:Times New Roman;"> arises in response to treatment resulting in a newly acquired or enriched oncogenic driver. Genomic changes in the therapeutic target, such as DNA mutation or amplification, can be evolutionarily selected to propel proliferation in heterogeneous tumors or may be acquired through the course of the disease. Specific changes in the target itself often result in loss of potency of the initial therapeutic. An example of acquired resistance is seen in chronic myeloid leukemia (CML) treated with the first-generation BCR-ABL inhibitor Gleevec, with resistance frequently driven by mutations in BCR-ABL that lead to loss of Gleevec binding activity. The second-generation BCR-ABL inhibitor Sprycel was developed to specifically address acquired resistance to Gleevec, with our co-founder, Dr. Sawyers, playing a critical role in the development of both therapeutics. Our pipeline includes one preclinical program and several ongoing discovery efforts directed towards targets for acquired resistance in solid tumors.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Bypass resistance</span><span style="font-family:Times New Roman;"> occurs when a therapeutically targeted cancer pathway is reactivated in cells to compensate for the presence of a therapeutic. Targeted therapies that induce reactivation of the same pathway indicate a key dependence on that specific pathway for tumor growth and survival. Similar to GR, this key dependency concept is illustrated in the context of BRAF mutant melanoma. Mutations in the BRAF kinase allow for unrestricted signaling of the protein that is required for tumor growth and survival. Discovery of small molecule BRAF inhibitors led to significant reduction of tumor growth and improvement of melanoma patient survival, as the innate resistance was addressed. However, following the initial profound responses observed in patients, patients began relapsing. Mechanistic exploration into the basis of patient progression revealed that some tumors were evolving to reactivate the same pathway further downstream, as the tumors compensated for the BRAF therapeutic. The development of Cotellic to target MEK further downstream in this pathway overcame the bypass mechanism and significantly improved patient outcomes.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collectively, our team has spent decades identifying and characterizing resistance mechanisms and has a strong heritage of bringing forth new and improved therapies designed to exploit resistance biology from the research lab to the clinic and, ultimately, to patients in need. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our areas of focus within cancer resistance </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our vision for patients with cancer is that therapeutics specifically addressing resistance will provide durable treatment responses, such that solid tumors can become a chronic disease with patient survival measured in years rather than months. Within the broader resistance landscape, we have specialized expertise in hormone-dependent cancers, precision oncology and key tumor dependencies, areas in which we have focused our internal discovery and external business development efforts. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hormone-dependent cancers </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two of our founders, Drs. Sawyers and Heyman, are leading experts in nuclear hormone receptors and hormone-dependent cancers. They previously co-founded two oncology companies, Aragon and Seragon, that developed therapeutics targeting two nuclear hormone receptors, AR and ER, respectively. Following the acquisitions of Aragon&#8212;whose lead product, Erleada, was ultimately approved for prostate cancer&#8212;and Seragon, and built upon academic work from Dr. Sawyers&#8217; laboratory at MSKCC implicating GR as a potential mechanism of resistance to Xtandi (also discovered by Dr. Sawyers) in prostate cancer, Drs. Sawyers and Heyman conceived of ORIC and proposed GR as our first target of interest. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nuclear hormone receptor gene family is a therapeutically rich target class implicated in a broad range of human diseases. Within this family, AR and ER are among the best-known targets that have resulted in a number of approved oncology therapies. ER has been implicated in breast and endometrial cancers, for which Nolvadex (tamoxifen) and Faslodex (fulvestrant) have been approved for breast cancer. Similarly, AR has been implicated in prostate cancer, for which Casodex (bicalutamide), Xtandi, Erleada and Nubeqa (darolutamide) have been approved. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third member of this family is GR, which is encoded by the NR3C1 (nuclear receptor subfamily 3, group C, member 1) gene and is a nuclear hormone receptor to which cortisol and other glucocorticoids bind. When glucocorticoids bind to GR, its primary mechanism of action is translocation into the nucleus and regulation of gene transcription. GR is expressed in almost every cell in the body and regulates genes controlling metabolism, cell growth, inflammation, apoptosis and differentiation. Because the receptor gene is expressed in several forms, it has many different (pleiotropic) effects in different parts of the body. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is substantial in vitro, in vivo and clinical evidence that GR signaling allows certain solid tumors to resist treatment. In some cancers GR signaling promotes tumor growth, while in others it stimulates genes that protect from cell death. Many types of solid tumors overexpress GR and are potential targets for ORIC-101, including prostate, pancreatic, ovarian, TNBC and endometrial cancers, among others. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the breadth of solid tumor indications in which hormone signaling pathways have been implicated in driving disease, or in the development of resistance, we believe our differentiated insight into this biology is a crucial component of our future success.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Precision oncology (biomarker-driven, patient-selected trials) </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical development team&#8212;including our Chief Medical Officer, Head of Clinical Development and heads of five core functions&#8212;previously worked together with our Chief Executive Officer at Ignyta, an oncology company that developed a pipeline of precision therapies, including Rozlytrek, which is now approved by the FDA in two different indications for genetically defined tumors, ROS1-positive metastatic NSCLC and NTRK-positive solid tumors. The clinical development of Rozlytrek, which was largely driven by this team, relied upon biomarker-driven patient selection via a companion diagnostic, leading to the approval of the compound approximately five years after it first entered the clinic. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Rozlytrek and Ignyta experience can be seen as a paradigm for precision oncology, in which the identification of biomarkers forms the basis of the entire drug discovery and development process, from early understandings of PK and PD modulation of target biology through to appropriate patient selection during clinical development. As part of our strategy, our in-house team of experienced translational scientists and computational biologists utilize existing technologies as well as develop proprietary assays to enable the selection and assessment of biomarkers for each of our programs. We seek to design rigorous and cost-efficient clinical programs that increase the probability of success by exploring connections between cellular-level biology and patient-level clinical outcomes. The use of biomarker-based patient selection is designed to enable demonstration of clinical proof-of-concept earlier and with fewer patients, leading ultimately to smaller pivotal trials. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our emphasis on a precision oncology approach to the mechanisms that underlie cancer resistance enables us to develop biological methods and assays that can be employed in the selection of appropriate patients for our development candidates rather than relying solely on limited clinical diagnosis information. For example, like many cancers, prostate cancer is a heterogeneous disease with different pathways contributing to potential resistance mechanisms to anti-androgen therapy that may vary from patient to patient or evolve over the course of a patient&#8217;s treatment history. In this complex resistance landscape, measuring levels of GR expression or gene activity represent potential strategies for selecting patients whose tumors are susceptible to GR inhibition through ORIC-101 therapy, enabling the possibility of identifying a subset of patients more likely to benefit from ORIC-101. To this end, we have developed a proprietary IHC assay that measures GR protein expression levels as well as a proprietary GR gene activation signature that measures GR signaling activity. Both of these assays are being utilized in our two ongoing Phase 1b clinical trials for ORIC-101. We intend to apply a similar precision oncology approach to the advancement of our entire pipeline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Key tumor dependencies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our scientific team&#8212;led by our Chief Scientific Officer, Head of Drug Discovery, Head of Biology and Head of Translational Medicine&#8212;has amassed deep knowledge of key oncogenic drivers and pathways in order to identify and validate oncology targets. They most recently worked together at Genentech, where they progressed more than 20 oncology discovery programs into clinical development, with three approvals to date, including Cotellic, Zelboraf and Polivy. The team&#8217;s approach to uncovering tumor dependencies that are key drivers of cancer resistance is biology-focused and mechanistically driven. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tumors are dependent on distinct biological drivers, or key tumor dependencies, which can be exploited to develop therapeutics. Examples of key tumor dependencies include oncogenic drivers, metabolic dependencies and lineage-specific markers. The earliest known tumor dependency occurs after normal cells acquire mutations that initiate tumor development. These early lesions continuously evolve within a given tissue in the presence of other cell types, such as endothelial and immune cells, ultimately generating a heterogeneous tumor ecosystem. The interplay between tumor cells and other heterologous cell types within a tissue impart physiological restrictions, such as limited oxygen or increased acidity, that tumor cells are forced to withstand to enable growth. This concept of evolution under selective pressure also applies in the context of an advanced tumor being subjected to therapeutic interventions&#8212;the relapsing tumors are forced to adapt in order to grow in the presence of treatment. Through these evolutionary processes, tumor cells can become exclusively dependent on distinct pathways, and these are the key dependencies that can be exploited for therapeutic gain. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our understanding of key tumor dependencies has also led to the development of an orally bioavailable small molecule inhibitor of CD73, ORIC-533, that targets adenosine within a key metabolic pathway upon which tumors become dependent. Many cancers usurp the anti-inflammatory adenosine pathway to avoid detection by the immune system, thereby reducing the effectiveness of certain chemotherapy and immunotherapy-based treatments. Accumulation of adenosine in the tumor microenvironment is implicated in local immune suppression that leads to tumor growth. CD73 is an enzyme that controls the rate at which extracellular adenosine is produced and its overexpression is associated with poor prognosis in several cancers, including TNBC, NSCLC, melanoma and prostate, among others. In addition to our GR and CD73 programs, we are developing multiple programs focused on addressing key dependencies in solid tumors, defined as either unaddressed drivers of innate resistance, acquired mutations or bypass mechanisms that cause relapse. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our resistance platform and in-house capabilities in medicinal chemistry and structure-based design enable drug discovery efforts for these resistance mechanisms. This platform, along with our forward and reverse translation expertise, underpins our efforts to address key drivers of cancer resistance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our pipeline to treat cancer resistance </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio currently consists of multiple internally discovered and in-licensed programs targeting key resistance mechanisms in cancer. Our product candidates are shown in the figure below: </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000005.jpg" title="" alt="" style="width:612px;height:169px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced discovery and research programs are shown in the figure below: </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000006.jpg" title="" alt="" style="width:617px;height:32px;" /></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000007.jpg" title="" alt="" style="width:617px;height:120px;" /><span style="font-weight:bold;font-style:italic;">GR antagonist program: ORIC-101 </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, ORIC-101, builds upon a legacy of successful drug development by our founders in the field of nuclear hormone receptors and their efforts to elucidate the cause of resistance to the groundbreaking prostate cancer therapies that they had developed. ORIC-101 is a potent and selective small molecule GR antagonist designed to inhibit GR transcriptional activity and block pro-survival signals downstream of its activation that confer resistance to anti-androgen therapies and chemotherapies. Following the successful completion of two Phase 1a trials in over 50 healthy volunteers, in 2019 we initiated two separate Phase 1b trials of ORIC-101 in combination with: (1) enzalutamide in metastatic prostate cancer and (2) nab-paclitaxel in advanced or metastatic solid tumors. In December 2020, we selected the RP2D and initiated the dose expansion portion of the Phase 1b trial of ORIC-101 in combination with nab-paclitaxel and we expect to report interim safety, efficacy, and translational data from this trial in the first half of 2021. In January 2021, we selected the RP2D and initiated the dose expansion portion of the Phase 1b trial of ORIC-101 in combination with enzalutamide and we expect to report interim safety, efficacy, and translational data from this trial in the second half of 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Glucocorticoid receptor background </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Glucocorticoids are steroid hormones secreted by the adrenal gland in a circadian and stress-associated manner to regulate metabolism, cell growth, apoptosis, differentiation and inflammation. Glucocorticoids signal through GR, a member of the superfamily of nuclear receptors expressed across a wide variety of tissues. Upon ligand binding, GR undergoes nuclear translocation, which is shown in the figure below. In the nucleus, GR binds to glucocorticoid response elements on DNA and transcriptionally activates a spectrum of genes that mediate multiple biological effects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Glucocorticoid receptor signaling mediates multiple physiological processes </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000008.jpg" title="" alt="" style="width:512px;height:223px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: GR: glucocorticoid receptor. HSPs: heat shock proteins. GREs: glucocorticoid response elements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The glucocorticoid receptor as a mechanism of resistance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiple preclinical studies have implicated GR activation as a potential cause of cancer treatment resistance in cancers of epithelial origin. Roughly in parallel, two distinct and uncorrelated mechanisms of GR-mediated resistance to anti-cancer therapies began to be studied by oncology experts. Dr. Sawyers&#8217; work has demonstrated that GR signaling is a bypass mechanism to anti-androgen therapy, with GR taking over for AR signaling, and that increased expression of GR in prostate cancer is correlated with resistance to Xtandi. Similarly, GR has also been studied for its potential role in mediating resistance to chemotherapy, though in this case, the mechanism appears to be related to GR&#8217;s role in imparting a &#8220;pro-survival&#8221; phenotype on the tumor via certain biological processes like epithelial-to-mesenchymal (EMT) transition and anti-apoptosis. We and others have shown that GR is overexpressed across over 20 advanced solid tumors including prostate, pancreatic, triple negative breast (TNBC) and ovarian cancers, which is shown in the figure below, and that GR overexpression is associated with worse survival outcomes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GR is overexpressed in multiple solid tumors<span style="font-size:10pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000009.jpg" title="" alt="" style="width:521px;height:281px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay, Block et al, Cancer Management and Research 2017:9 6472, originally published by Dove Medical Press Ltd. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melanoma n&#61;11, Renal n&#61;10, Sarcoma n&#61;14, Neck and head n&#61;10, Prostate n&#61;11, Cervical n&#61;15, Hepatocellular n&#61;10, Neuroendocrine n&#61;11, Pancreas n&#61;16, Lung n&#61;17, Gall bladder n&#61;10, Esophageal n&#61;8, Breast (non-TNBC) n&#61;10, Ovarian n&#61;11, Bladder n&#61;10, Endometrial n&#61;13, Gastric n&#61;11, and Colon n&#61;16. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overexpression of GR has been correlated with poor prognosis in patients with ER-negative breast cancer treated with chemotherapy, which is shown in the figure below, metastatic castration-resistant prostate cancer (mCRPC) treated with Xtandi and advanced endometrial cancer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Elevated GR expression correlated with worse clinical outcomes in ER-negative breast cancer </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000010.jpg" title="" alt="" style="width:340px;height:215px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Reprinted by permission from the American Association for Cancer Research: Pan et al, Activation of the Glucocorticoid Receptor Is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast Cancer, Cancer Research, August 25, 2011, Vol 71, Issue 20, 6360-6370, 10.1158/0008-5472.CAN-11-0362. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: ER: estrogen receptor&#59; GR: glucocorticoid receptor. Tumors in the top quartile of NR3C1 expression were identified as &#8220;GR high&#8221; (n&#61;18) whereas tumors in the bottom quartile of NR3C1 expression were identified as &#8220;GR low&#8221; (n&#61;28)&#59; post-adjuvant chemotherapy. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P-value is a conventional statistical method for measuring the statistical significance of clinical results. A p-value of 0.01 or less represents statistical significance, meaning there is a less than 1-in-100 likelihood that the observed result occurred by chance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA utilizes statistical significance, as measured by p-value, as an evidentiary standard of efficacy and typically requires a p-value of 0.05 or less to demonstrate statistical significance. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of other GR antagonists </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies performed in TNBC and ovarian cancer models have helped to establish that genetic ablation or pharmacologic inhibition of GR enhances chemotherapy response. We are aware of only one other company, Corcept Therapeutics, developing GR antagonists for oncology. Corcept has compounds, including mifepristone and relacorilant, that are either approved or being evaluated in clinical trials for endocrine disorders and are also being evaluated in clinical trials for their potential to reverse oncology resistance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Korlym (mifepristone) is a steroidal GR antagonist approved by the FDA in 2012 for the treatment of patients with Cushing&#8217;s syndrome, a disease characterized by elevated levels of the glucocorticoid cortisol. Mifepristone has been broadly used preclinically as a pharmacologic inhibitor of GR to examine the impact of modulation of GR on response to anti-cancer agents. Mifepristone has also been studied in multiple clinical trials across a variety of solid tumors and therapeutic regimens. Clinical trials of mifepristone were initiated in mCRPC, where the standard of care is AR antagonism, but mifepristone has since been shown to be a potent AR agonist and is therefore not expected to be a suitable treatment for mCRPC. Its potential as a combination therapy in oncology is further limited by its significant interactions with cytochrome P450 (CYP), most notably with CYP2C8, which is a key metabolic pathway for both taxanes (a major chemotherapeutic class used across multiple solid tumors) and Xtandi, and thus creates the potential for drug-drug interactions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relacorilant, currently in a Phase 3 trial for Cushing&#8217;s syndrome, is a non-steroidal GR antagonist that lacks the AR agonism of mifepristone. However, it retains many of the CYP liabilities of mifepristone, making combination development in oncology challenging. Despite these drawbacks, it is being developed in multiple oncology indications and has shown promising initial signs of durable clinical benefit in combination with nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma, ovarian cancer and other advanced or metastatic solid tumors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ORIC-101 differentiation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-101 is a highly potent and selective steroidal GR antagonist, as shown by the single-digit nanomolar inhibition for receptor binding in the figure below. Like relacorilant, ORIC-101 is not an AR agonist. However, unlike relacorilant, due to our medicinal chemistry and structure-based drug discovery efforts, we observed ORIC-101 to have reduced CYP2C8 inhibition based on our preclinical studies. While certain ORIC-101 metabolites inhibit CYP2C8, they represent a fraction of the plasma exposure of the parent ORIC-101 compound. Thus, we believe ORIC-101 has the potential to enable potent GR inhibition but with less potential risk for drug-drug interaction with other combination agents, most notably taxanes and Xtandi. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ORIC&#8211;101 is a potent and selective GR antagonist designed for oncology </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000011.jpg" title="" alt="" style="width:469px;height:257px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:13.33%;text-indent:-13.33%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: GR: glucocorticoid receptor&#59; AR: androgen receptor&#59; PR: progesterone receptor. GR antagonism, AR antagonism and PR antagonism measured by luciferase assay. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above table demonstrates the results of a series of preclinical <span style="font-style:italic;">in vitro</span> experiments that we conducted evaluating ORIC-101, mifepristone and relacorilant across a variety of properties that we believe to be important in developing a potent and selective GR antagonist. The determination of more favorable or less favorable relates to the ideal properties of a GR antagonist for a combination therapy in oncology. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In these experiments, we employed luciferase reporter assays to measure antagonist and agonist activities of the molecules on GR, AR and PR. These assays are commonly used in <span style="font-style:italic;">in vitro</span> experiments to measure the potency of molecules for nuclear hormone receptor targets such as GR, AR and PR (among other receptors). These assays have been well characterized in peer-reviewed scientific publications and are widely utilized in the scientific community. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The endpoints of these preclinical <span style="font-style:italic;">in vitro </span>experiments were the half maximal inhibitory concentration (IC50). The IC50 value represents the concentration of molecule needed to inhibit activity by 50% (i.e., a lower IC50 represents more potent inhibition). Cells were treated in the studies for 20 hours. Each molecule was compared against the other molecules. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In these preclinical <span style="font-style:italic;">in vitro</span> experiments, mifepristone was shown to be a potent AR agonist, while ORIC-101 and relacorilant were not. AR agonism is commonly accepted to be an undesirable feature of a potential cancer treatment as this activity has been shown to stimulate the growth of prostate cancer. Since ORIC-101 is not an AR agonist, it was shown that mifepristone is less favorable than ORIC-101 with respect to this criterion. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In these experiments, relacorilant was shown to not be a PR antagonist, while mifepristone and ORIC-101 were shown to be PR antagonists. Since PR antagonism is not a required feature of a GR antagonist, it was shown that relacorilant is more favorable than ORIC-101 with respect to this criterion. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we used a common <span style="font-style:italic;">in vitro</span> experiment that is accepted by Health Authorities to evaluate potential drug interaction liability mediated by CYP inhibition. Preclinical <span style="font-style:italic;">in vitro </span>experiments were used to determine direct inhibition of major cytochrome P450 (CYP) activity including CYP2C8, CYP2C9, CYP2C19 and CYP3A4/5 by ORIC-101 in human liver microsomes. The endpoint of this preclinical <span style="font-style:italic;">in vitro </span>experiment was IC50. The IC50 value represents the drug concentration needed to inhibit the activity of a specific CYP isoform to metabolize its corresponding probe substrate by 50% (i.e., a lower IC50 represents more potent inhibition). The incubation was carried out for five minutes, which was within the linear range of metabolite formation of the probe substrates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In these preclinical <span style="font-style:italic;">in vitro </span>experiments to show CYP inhibition, ORIC-101 directly inhibited CYP3A4/5 with IC50 value of 1.6 &#181;M. IC50 inhibition against CYP2C8 and CYP2C9 could not be determined via mathematical analysis as they were higher than 3 &#181;M and &#62;10 &#181;M, respectively. In contrast, mifepristone directly inhibited CYP2C8, CYP2C9 and CYP3A4/5, with IC50 values of 1.5, 4.9 and 9.5 &#181;M, respectively&#59; whereas, relacorilant directly inhibited CYP2C8, CYP2C9 and CYP3A4/5, with IC50 values of 0.21, 2 and 1.3 &#181;M, respectively. These data suggest that <span style="font-style:italic;">in vitro</span>, while ORIC-101 inhibits CYP3A4/5, ORIC-101 exhibited improved properties against CYP2C8 and CYP2C9 compared with mifepristone and relacorilant. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our current opportunities for ORIC-101 </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Resistance to hormone therapy in prostate cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have chosen GR antagonism in prostate cancer as our initial therapeutic focus due to the well-documented biology of GR signaling as the principal driver of resistance to Xtandi in patients with prostate cancer, as published in <span style="font-style:italic;">Cell </span>by our co-founder Dr. Sawyers. His work demonstrated that GR signaling is a bypass mechanism to anti-androgen therapy, with GR taking over for AR signaling, and that increased expression of GR in prostate cancer is correlated with resistance to Xtandi. We have demonstrated in preclinical prostate cancer models that GR antagonism can limit bypass resistance to Xtandi. Based on these data, we believe that ORIC-101, in combination with current standard-of-care agents such as Xtandi, has the potential to significantly improve clinical outcomes. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Prostate cancer overview </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, prostate cancer is the second most prevalent cancer in men and the second leading cause of cancer death in men. The American Cancer Society estimated that in 2021 there would be approximately 250,000 new cases of prostate cancer and over 30,000 deaths from the disease in the United States by year end. Further, according to another study, over 50,000 new cases of metastatic prostate cancer were expected in 2020, which includes patients with both hormone-sensitive prostate cancer and mCRPC. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment options for prostate cancer depend on many different factors, including the stage of the cancer. The disease is considered metastatic once the cancer has spread outside of the prostate gland to other parts of the body, such as the bones, lymph nodes, bladder and rectum. Tumors are considered hormone- (or castration-) sensitive if they still respond to medical or surgical treatment to lower testosterone levels. Tumors are considered castration-resistant if they progress despite androgen deprivation therapy (ADT), which is often correlated with rising levels of prostate-specific antigen (PSA). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In making treatment evaluations, physicians monitor disease burden in several ways, including changes in PSA levels. Increased PSA blood levels are considered by many physicians as indicative of cancer progression and alternative treatment options may be considered at that time. Current standard of care treatment for men with castration-resistant prostate cancer provides that patients should initially receive a combination of ADT and either Zytiga (abiraterone), which works by decreasing androgen levels, or Xtandi, which works by blocking androgen binding to AR. If the disease progresses despite these second-generation hormonal therapies, chemotherapy is typically the next treatment option. However, treatment with chemotherapy is generally postponed for as long as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea, decreased mental capacity and increased risk of infections. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AR remains the principal driver of castration-resistant prostate cancer progression during the transition from localized to metastatic disease. While a majority of patients with prostate cancer will initially respond to either Zytiga, Xtandi or Erleada, the vast majority of these patients will ultimately become resistant, resulting in limited survival. Based on our preclinical data, we believe ORIC-101 may overcome a key resistance mechanism to these therapies and lead to meaningful clinical benefit for patients with prostate cancer. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Illustrative prostate cancer treatment landscape </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000012.jpg" title="" alt="" style="width:599px;height:252px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An investigator analysis of Medivation&#8217;s Phase 3 clinical trial AFFIRM, in which patients with mCRPC who had previously received docetaxel were randomized to receive enzalutamide or a placebo, highlighted the potential role of GR in mediating enzalutamide resistance. A post-hoc analysis evaluated the impact of baseline corticosteroid use on clinical outcomes. Thirty percent of patients in this 1,199-patient trial were on corticosteroids at baseline. The results demonstrated that patients on baseline corticosteroids (i.e., GR agonism) had faster time to PSA progression and decreased overall survival when adjusted for other prognostic factors (e.g., age, performance status, prior therapy, disease burden, comorbidities). </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Association of corticosteroid use and inferior clinical outcomes observed in Medivation&#8217;s Phase 3 AFFIRM trial in mCRPC patients treated with enzalutamide </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000013.jpg" title="" alt="" style="width:606px;height:226px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:-4.17%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: From the New England Journal of Medicine, Scher et al, Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, Copyright 2012, Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.17%;text-indent:-9.17%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: NR: not reached&#59; mCRPC: metastatic castration-resistant prostate cancer. 241 patients on enzalutamide and 119 patients on placebo. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical data </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several mechanisms of resistance to AR antagonists have been identified that are based on abnormalities in AR and its signaling. Dr. Sawyers&#8217; laboratory at MSKCC identified GR expression as a potential resistance mechanism bypassing AR altogether. As shown in the figure below, a retrospective analysis was conducted on tumor biopsies collected from mCRPC patients who were bifurcated into two groups: &#8220;good&#8221; responders to enzalutamide (experiencing clinical benefit for greater than six months) and &#8220;poor&#8221; responders to enzalutamide (experiencing clinical benefit for less than six months). GR expression levels were evaluated at baseline prior to the start of and after eight weeks of enzalutamide therapy. This analysis demonstrated a correlation between overexpression of GR and poor clinical outcomes. Patients with a &#8220;poor&#8221; response to enzalutamide demonstrated relatively higher GR expression levels at baseline as compared to &#8220;good&#8221; responders. Furthermore, &#8220;poor&#8221; responders demonstrated significantly higher GR expression levels after eight weeks on enzalutamide as compared to both: (1) the GR expression levels of &#8220;poor&#8221; responders at baseline, and (2) the GR expression levels of &#8220;good&#8221; responders after eight weeks on enzalutamide. These findings suggest that AR-inhibition by enzalutamide induced GR overexpression and that the levels of this GR overexpression were more pronounced in patients with poor clinical outcomes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GR expression is associated with clinical resistance to enzalutamide in the treatment of prostate cancer</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000014.jpg" title="" alt="" style="width:608px;height:239px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*<span style="color:#000000;"> p &#60; 0.05, **: p &#60; 0.01.</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Reprinted from Cell, Vol 155, Issue 6, Arora et al, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade, 19, Copyright 2013, with permission from Elsevier. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Patients who continued to benefit from enzalutamide for greater than six months were classified as &#8220;good&#8221; responders. Patients who discontinued enzalutamide earlier than six months due to a lack of clinical benefit were classified as &#8220;poor&#8221; responders. Matched tumor samples include those obtained from the same patient at baseline and after eight weeks of treatment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This same observation was confirmed if &#8220;good&#8221; versus &#8220;poor&#8221; response was defined by a maximal PSA decline of greater than 50% versus less than 50%. Again, as shown in the figure below, GR expression in tumors was significantly higher in &#8220;poor&#8221; responders after eight weeks on enzalutamide as compared to &#8220;good&#8221; responders. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Elevated GR expression associated with a limited PSA response in enzalutamide-treated patients </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000015.jpg" title="" alt="" style="width:295px;height:219px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*: p &#60; 0.05 </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Reprinted from Cell, Vol 155, Issue 6, Arora et al, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade, 19, Copyright 2013, with permission from Elsevier. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, in the LNCaP xenograft model with exogenous AR overexpression (LNCaP AR), acquired resistance to enzalutamide and apalutamide correlated with the upregulation of GR expression, which is shown below. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000016.jpg" title="" alt="" style="width:609px;height:246px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**: p &#60; 0.01, ****: p &#60; 0.0001. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Reprinted from Cell, Vol 155, Issue 6, Arora et al, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade, 15, Copyright 2013, with permission from Elsevier. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Left graph&#8217;s grey shading indicates treatment period when tumors were harvested (as annotated by long hash marks on the x axis). LREX&#8217; is a prostate cancer model that was derived from an enzalutamide-resistant tumor with high GR expression. Actin was used to verify consistent sample loading for the western blot experiment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, as demonstrated in the figure on the left below, our <span style="font-style:italic;">in vitro</span> studies demonstrate that inhibition of AR leads to upregulation of GR expression. In addition, as demonstrated in the figure on the right below, our <span style="font-style:italic;">in vitro</span> studies of GR-expressing VCaP cells showed that the GR agonist dexamethasone conferred enzalutamide resistance, while the addition of a GR antagonist to counteract the dexamethasone reversed this effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000017.jpg" title="" alt="" style="width:593px;height:259px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Zhou et al. AACR-NCI-EORTC (2019). </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: CWR22PC cells. GR mRNA levels relative to untreated samples shown on left slide with GR protein levels shown as inset. Actin was used to verify consistent sample loading for the western blot experiment. Right graph: AR agonist R1881 (synthetic AR ligand) added to media. GR agonist used was dexamethasone. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mechanistically, published data suggest that AR and GR drive a partially overlapping transcriptional program. Thus, GR activation can circumvent enzalutamide-mediated AR inhibition and sustain prostate cancer cell growth. But inhibiting GR activation is only effective in the presence of sustained AR inhibition. When AR expression levels rise, and the cancer cell is able to revert to AR mediated signaling, GR expression levels fall to baseline. These findings suggest that combined inhibition of both GR and AR could prolong the duration of response with next-generation AR antagonists such as enzalutamide or apalutamide. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AR and GR have overlapping gene signatures </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000018.jpg" title="" alt="" style="width:378px;height:202px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Reprinted from Cell, Vol 155, Issue 6, Arora et al, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade, 22, Copyright 2013, with permission from Elsevier. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Venn diagram of AR and GR signature gene lists. AR and GR signatures were defined as all genes showing &#62;1.6 (or &#60;1.6)-fold change (FDR &#60; 0.05) after eight hours of addition of dihydrotestosterone (1 nM) or dexamethasone (100 nM) to charcoal-stripped media, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to this GR-mediated resistance in prostate cancer to AR-modulators, such as enzalutamide, GR may play a similar role in mediating resistance to a new class of agents called AR degraders. As demonstrated in the figure below on the left, AR degrader treatment suppressed prostate cancer cell growth driven through AR. Further <span style="font-style:italic;">in vitro</span> studies demonstrate that prostate cancer cells treated with an AR degrader had diminished activity when GR is activated through the presence of a GR ligand. This bypass escape mechanism can be reversed with the addition of ORIC-101 GR antagonist. In the graph on the right, PSA levels and other transcriptional markers that correspond to GR as a bypass mechanism of resistance for AR modulators and AR degraders were impacted and correspond to the effects on prostate cancer cell growth. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000019.jpg" title="" alt="" style="width:295px;height:176px;" /></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000020.jpg" title="" alt="" style="width:295px;height:175px;" /></p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: CWR22PC cells. Data shown as of day 19 post treatment. AR agonist R1881 (synthetic AR ligand) added in media. AR degrader used was ARV-7. Results confirmed with second AR degrader (compound 13) in US 2018/0099940 A1. GR agonist used was dexamethasone. PSA, prostate specific antigen. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Resistance to chemotherapy in solid tumors </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical data over the past decade indicate that activation of GR confers resistance to a variety of chemotherapeutic agents across an array of solid tumors that include ovarian, TNBC, prostate, pancreatic, small and non-small cell lung and urological cancers. In those settings, activation of GR signaling leads to decreased response to antimetabolites, taxanes and platinum agents, thus acting as a therapeutic resistance mechanism. At the molecular level, GR signaling drives transcriptional activation of anti-apoptotic genes such as serum and glucocorticoid inducible protein kinase-1 (SGK1), baculoviral IAP repeat containing 3 (BIRC3), and mitogen-activated protein kinase phosphatase-1 (MKP1/DUSP1), which in part mediate cell survival. In addition, GR activation has been demonstrated to regulate transcription of proteins that mediate cell adhesion and invasion. In that regard, GR-driven upregulation of integrins, the extracellular matrix protein Fibronectin-1 and the transmembrane glycoprotein Mucin-1, have been associated with pro-adhesion and protection from chemotherapy. Most recently, it has been shown that the master regulator of epithelial-mesenchymal transition (EMT), SNAI2, is a direct GR target, as well as a partial GR-induced chemoprotector. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Immunohistochemistry of HCC1806 TNBC xenograft tumors in mice dosed with paclitaxel/cortisol indicates that addition of ORIC-101 decreases proliferation, stemness and EMT</span><span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000021.jpg" title="" alt="" style="width:244px;height:198px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brown coloration &#61; amount of each indicated protein Ki67, CK5, vimentin, as imaged with DAB IHC</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical data </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-101, as shown in the figure below, demonstrated activity in combination with chemotherapy <span style="font-style:italic;">in vitro</span> using a colony formation assay. Ovarian, NSCLC and TNBC cell lines were used to assess how inhibition of GR activity by ORIC-101 affects dexamethasone-mediated chemoprotection. Based on the relative potencies of cortisol and dexamethasone, and the range of average unbound cortisol concentration in patients, a dexamethasone concentration of 30 nM was selected to simulate the expected level of GR activation at the average circulating cortisol level (approximately 375 nM) occurring in adult patients with cancer. The experiment demonstrated that co-administration of ORIC-101 reversed dexamethasone-mediated, GR-driven chemoprotection in GR positive cell lines. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ORIC-101 overcomes GR-driven chemotherapy resistance across a wide range of human cancer cell lines </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000022.jpg" title="" alt="" style="width:606px;height:283px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Jahchan et al. AACR-NCI-EORTC (2017) and additional ORIC data. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Chemotherapeutic agent is gemcitabine for ovarian cancer and paclitaxel for TNBC and NSCLC. GR agonist is dexamethasone. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effect of ORIC-101 on the response to the chemotherapeutic compound paclitaxel was evaluated <span style="font-style:italic;">in vivo</span> in the HCC1806 TNBC xenograft mouse model. The efficacy of paclitaxel was significantly diminished in tumors grown under conditions simulating human cortisol levels sufficient to drive GR activation. Treatment with ORIC-101 was effective in reversing the effects of cortisol on paclitaxel efficacy, as shown in the figure below. Paclitaxel + cortisol + ORIC-101 treatment resulted in 88.7% tumor growth inhibition relative to paclitaxel + cortisol. At Day 68, palpable tumors were present in 93.3% of mice treated with cortisol + paclitaxel and only in 6.7% of mice treated with cortisol + paclitaxel + ORIC-101. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ORIC-101 overcomes GR-driven resistance to chemotherapy in vivo </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000023.jpg" title="" alt="" style="width:339px;height:210px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: HCC1806 tumor growth curves. Tumors were grown in the presence or absence of cortisol, paclitaxel and ORIC-101. Mice were treated with paclitaxel (20 mg/kg IP, Q3D&#215;8), cortisol (100 mg/L in drinking water,<span style="font-style:italic;"> ad libitum</span>) or ORIC-101 (75 mg/kg of ORIC-101, PO, BID) starting on Day 0 for the duration of the study. Data is displayed as mean &#177; SEM. Cortisol supplementation required to activate human GR since primary glucocorticoid utilized by rodents is corticosterone. Cortisol levels intended to simulate physiological corticosteroid levels in humans. Comparable activity has been demonstrated in xenograft models of ovarian cancer, TNBC and in combination with other classes of chemotherapy. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical development plan for ORIC-101 </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the figure below, following our preclinical studies that demonstrated that GR signaling is a bypass resistance mechanism to anti-androgen modulators in prostate cancer, as well as a resistance mechanism to chemotherapeutics in a variety of solid tumors, we completed two Phase 1a trials of ORIC-101 as a single agent in over 50 healthy volunteers, and in 2019, we initiated two separate Phase 1b trials of ORIC-101 in combination with: (1) enzalutamide in metastatic prostate cancer and (2) nab-paclitaxel in advanced or metastatic solid tumors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000024.jpg" title="" alt="" style="width:503px;height:188px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1a healthy volunteer trials </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted two healthy volunteer trials with ORIC-101. Study ORIC-GR-17001 was a single-ascending dose trial that evaluated preliminary safety and PK of ORIC-101, and study ORIC-GR-17002 was a multiple-ascending dose trial that evaluated the safety, PK and PD of ORIC-101 as well as of alternative formulations of ORIC-101. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Phase 1a trials are summarized in the table below. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000025.jpg" title="" alt="" style="width:526px;height:205px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) 26 dosing events with 20 unique individual participants. Participants in fed portion were previously dosed in fasted portion (five with Lipid 2, one with Lipid 1). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Study 17001 </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In study ORIC-GR-17001, ORIC-101 was administered in a fed state via oral suspension as four single ascending doses of 120, 240, 480 and 800 mg, in cohorts of six subjects each. Overall, there was dose-proportional increase in the Cmax and area under the curve (AUC) of ORIC-101 in plasma. The trial was conducted at a single site in the United States. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Study 17002 </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study ORIC-GR-17002 explored alternate formulations of ORIC-101 with a preliminary assessment of food effect (Part A) along with a multiple-ascending dose portion (Part B). The trial was conducted at a single site in the United Kingdom. In Part A, a prototype spray-dried dispersion (SDD) powder in an oral suspension was evaluated along with two lipid capsule formulations. The oral SDD suspension and both lipid capsule formulations provided similar exposure to ORIC-101. There was also a modest food effect observed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Part B, ORIC-101 Lipid B capsules were administered once daily for 10 consecutive days at a dose of 200 mg/day or 350 mg/day, under fed conditions. Six subjects were treated at each dose level. The exposure to ORIC-101, in terms of Cmax and AUC in plasma, increased in a dose-dependent manner with approximately 2-fold accumulation. The half-life of 14-15 hours supported once daily dosing, which is shown in the figure below. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exposure of ORIC-101 from Phase 1a multiple-ascending dose study supports once-daily dosing </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000026.jpg" title="" alt="" style="width:442px;height:219px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cortisol levels can be used as a pharmacodynamic indicator of GR inhibition. Following 10 days of administration of ORIC-101 at the doses of 200 mg/day and 350 mg/day, mean plasma cortisol concentrations upon waking increased over time, to a maximum on Day 8 at the dose of 200 mg/day (approximately 44% higher than Day 1) and Day 10 at the dose of 350 mg/day (approximately 78% higher than Day 1), and then subsequently decreased in both regimens, which is shown in the figure below. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Changing endogenous levels of cortisol demonstrated biological activity of ORIC 101 in Phase 1a </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000027.jpg" title="" alt="" style="width:608px;height:222px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, as another PD measure of GR inhibition, peripheral blood mononuclear cells (PBMCs) were collected and analyzed for expression of genes known to be targets of GR signaling. In this analysis, ORIC-101 was associated with decreased expression of these key PD biomarkers of GR activity, with the decrease occurring within the first day of ORIC-101 exposure and persisting for the entire duration of 10 days of dosing, as shown in the figure below. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ORIC-101 was associated with downregulation of key pharmacodynamic biomarkers of GR activity in Phase 1a </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000028.jpg" title="" alt="" style="width:609px;height:244px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: ORIC-101 was dosed once daily for 10 days. PBMC: peripheral blood mononuclear cell&#59; FKBP5: FK506 binding protein&#59; DDIT4: DNA-damage-inducible transcript 4 protein. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Safety </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overall, 56 subjects received at least a single dose of ORIC-101 across both healthy volunteer trials. A total of 12 subjects received 10 daily doses of ORIC-101 at either 200 mg/day (n&#61;6) or 350 mg/day (n&#61;6). All observed adverse events (AEs) were Grade 1 in severity, reversible, and no AE required study subject discontinuation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In study ORIC-GR-17001, a single administration of ORIC-101 oral suspension at a dose of 120, 240, 480 or 800 mg was well-tolerated with only two Grade 1 AEs reported: pain in the extremity and nausea, one participant in the 480 mg and 800 mg dose, respectively. Both were mild, attributed to ORIC-101 and resolved without treatment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In study ORIC-GR-17002, Part A, a single administration of ORIC-101 in oral SDD suspension or lipid capsules at the dose of 50 mg or 200 mg was well-tolerated. The most commonly reported treatment-emergent AEs attributed to ORIC-101 were mild gastrointestinal AEs. These were observed in 2 participants and consisted of Grade 1 nausea in one subject and Grade 1 nausea, abdominal pain, and diarrhea in a second subject. They resolved without treatment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In study ORIC-GR-17002, Part B, multiple doses of ORIC-101 Lipid B were administered in a fed state in two cohorts of six healthy human volunteers at doses of 200 mg and 350 mg once daily for 10 days and no serious AEs were observed at either dose level. Treatment-emergent AEs occurred in two and five participants at each dose level, respectively, and were all Grade 1 and reversible. The most common AEs (reported in one of six participants at 200 mg and five of six participants at 350 mg) were gastrointestinal in nature and were deemed related to ORIC-101. These events are generally consistent with known tolerability issues with the caprylic acid formulation and could also be attributable (at least in part) to pill burden at the higher ORIC-101 dose of 350 mg (7 x 50 mg capsules). In addition, there were no clinically significant post-dose changes in electrocardiograms (ECGs), vital signs, or safety laboratory results.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">200 mg (n&#61;6)</p></td>
<td colspan="4" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">350 mg (n&#61;6)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Treatment-emergent AEs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">All</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">doses</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(n&#61;56)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grade</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grade</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#179;<span style="font-weight:bold;">2</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grade</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grade</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#179;<span style="font-weight:bold;">2</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nausea</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diarrhea</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abdominal pain</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dysgeusia</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dyspepsia</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fatigue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Back pain</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catheter site swelling</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreased appetite</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dry eye</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gastroesophageal reflux disease</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headache</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hot flush</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insomnia</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Musculoskeletal chest pain</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pain in extremity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proctalgia</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Somnolence</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vomiting</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Severity grade as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1b trial of ORIC-101 in combination with enzalutamide for metastatic prostate cancer </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2019, we initiated study ORIC-101-02, an open-label, single arm, multicenter, dose escalation followed by dose expansion trial of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide. The purpose of this trial is to assess safety, PK, PD and preliminary antitumor activity of ORIC-101 in combination with enzalutamide as well as establish its recommended Phase 2 dose. Once patients are deemed eligible, they receive treatment with ORIC-101 in addition to continuing their current enzalutamide therapy without any washout period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 27, 2020, two patients completed Cycle 1 (28 days) without DLT events and were in Cycle 2 and Cycle 3, respectively&#59; one additional patient was ongoing in Cycle 1, completing enrollment in Dose Level 1, in which patients receive 80 mg ORIC-101 in combination with 160 mg enzalutamide on a continuous daily dosing regimen. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to March 27, 2020, the DLT evaluation period for all patients in Dose Level 1 was completed with no DLTs observed. After review of safety and PK data from Dose Level 1 by the study&#8217;s SRC, enrollment and evaluation for DLT was completed for Dose Level 2 (160 mg ORIC-101 in combination with 160 mg enzalutamide on a continuous daily dosing regimen) with no DLTs observed. After review of safety and PK data by the SRC, enrollment and evaluation for DLT was completed for Dose Level 3 (240 mg ORIC-101 in combination with 160 mg enzalutamide on a continuous daily dosing regimen) with no DLTs observed.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we completed the Part I dose escalation portion of ORIC-101 in combination with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enzalutamide in metastatic prostate cancer</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, select</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the RP2D, and initiat</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the dose expansion portion of the trial. For the Part II dose expansion portion of the trial, up to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48 patients are </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expected to be enrolled </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and treated at the RP2D of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240 mg of ORIC-101 and 160 mg of enzalutamide on a continuous daily dosing schedule. Patients will be enrolled independent of GR status, with retrospective analysis of GR expression and other potentially predictive biomarkers. We expect to report interim safety, efficacy, and translational data from this trial in the second half of 2021.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000029.jpg" title="" alt="" style="width:719px;height:168px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;"><span style="font-weight:bold;font-family:Times New Roman;">Patients: </span><span style="font-family:Times New Roman;">Chemo-na&#239;ve metastatic prostate cancer with evidence of disease progression on enzalutamide</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Patients will enroll while remaining on enzalutamide (i.e., no treatment-free period)</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Exclusion of patients with rapid progression on enzalutamide <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Enrollment not limited by baseline GR status</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;"><span style="font-weight:bold;font-family:Times New Roman;">Objectives: </span><span style="font-family:Times New Roman;">Safety, PK, PD and initial evidence of clinical activity (e.g., PSA decline, imaging, CTC conversion)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Exploratory GR, AR and other biomarker data generated from archival tumor tissue&#59; pre-, post-and end-of-treatment biopsies and blood</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;"><span style="font-weight:bold;font-family:Times New Roman;">Collaboration: </span><span style="font-family:Times New Roman;">Trial is being conducted under a clinical trial collaboration with Astellas</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;"><span style="font-weight:bold;font-family:Times New Roman;">Recommended Phase 2 dose (RP2D):</span><span style="font-family:Times New Roman;"> ORIC-101 (240 mg QD) + enzalutamide (160 mg QD)</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1b trial of ORIC-101 in combination with nab-paclitaxel in advanced or metastatic solid tumors </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we initiated study ORIC-101-01, an open-label, single arm, multicenter, dose escalation followed by dose expansion trial of ORIC-101 in combination with nab-paclitaxel in patients with advanced or metastatic solid tumors in the United States. The purpose of this trial is to assess safety, PK, PD and preliminary anti-tumor activity of ORIC-101 in combination with nab-paclitaxel as well as establish a recommended Phase 2 dose. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000030.jpg" title="" alt="" style="width:718px;height:198px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;"><span style="font-weight:bold;font-family:Times New Roman;">Patients:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Part I (dose identification): Advanced solid tumors completed</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Part II (dose expansion): Previous progression on taxane-containing regimen, independent of baseline GR status</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;"><span style="font-weight:bold;font-family:Times New Roman;">Objectives:</span><span style="font-family:Times New Roman;"> Safety, PK, PD and preliminary antitumor activity</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Exploratory GR and other biomarker data generated from archival tumor tissue&#59; pre-, post- and end-of-treatment biopsies and blood</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:7pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:7pt;"><span style="font-weight:bold;font-family:Times New Roman;">Recommended Phase 2 Dose (RP2D):</span><span style="font-family:Times New Roman;"> ORIC-101 (160mg QD) + nab-paclitaxel (75 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>)&#59; no prophylactic G-CSF required</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 27, 2020, 11 patients had enrolled in this study across four dosing cohorts. In the initial cohort, Dose Level 1, patients received 240 mg ORIC-101 administered on Days 1-5, 8-12, 15-19 in combination with 100 mg/m2 nab-paclitaxel on Days 1, 8, and 15 of a 28-day cycle. Three patients with advanced pancreatic cancer were enrolled at this dose level. During the first cycle of treatment, two patients experienced DLTs. Specifically, one patient experienced Grade 3 fatigue and discontinued treatment after two weeks on study. A second patient with advanced pancreatic cancer that had metastasized to the liver experienced Grade 4 neutropenia and thrombocytopenia and Grade 5 hepatic failure in the setting of rapid disease progression. A CT scan of the abdomen on study Day 9 demonstrated disease progression, and the patient died on study Day 12. These toxicities are well-described for nab-paclitaxel (including reports of hepatic necrosis and hepatic encephalopathy leading to death), which is metabolized primarily via the liver.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After review of safety and PK data from Dose Level 1 by the study&#8217;s SRC, it was determined that Dose Level 1 exceeded the maximum tolerated doses of the combination of ORIC-101 and nab-paclitaxel. The SRC further recommended restarting the dose escalation at lower doses of ORIC-101 and nab-paclitaxel (80 mg and 75 mg/m2, respectively) but did not require the addition of prophylactic growth factor (G-CSF) for potential nab-paclitaxel-induced neutropenia. The protocol was amended and following FDA review and Institutional Review Board (IRB) approvals, three new patients were enrolled to the revised new Dose Level 1A: one patient with endometrial cancer, one patient with colorectal cancer, and one patient with a poorly differentiated neuroendocrine carcinoma of the lung. All patients completed the DLT evaluation period without DLT events. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three additional patients were enrolled at Dose Level 2A (160 mg ORIC-101 and 75 mg/m2 nab-paclitaxel) and have completed the DLT evaluation period without DLT events: one patient with gastric cancer, one patient with a large cell neuroendocrine carcinoma of the lung, and one patient with testicular cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below notes adverse events in Cohort 1A and 2A as of February 24, 2020. Adverse events were mostly Grade 1 or 2 in severity and reversible, with no Grade &#179; 4 treatment-related AEs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dose Levels 1A and 2A: Treatment-related adverse events occurring in &#62;1 patient or Grade 3 in severity (as of February 24, 2020): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.18%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dose Level 1A</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.18%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dose Level 2A</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TOTAL</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.84%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Treatment-Related AEs</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.18%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(N&#61;3)</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.18%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(N&#61;3)</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(N&#61;6)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G1-G2</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G3</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G1-G2</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G3</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G1-G2</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G3</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Any</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nausea</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (66.7)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (50.0)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 (50.0)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alopecia</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anemia</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (16.7)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (16.7)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diarrhea</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fatigue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (66.7)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Muscle spasms</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 (33.3)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hypophosphatemia</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (16.7)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (16.7)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.84%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neutrophil count decreased</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (33.3)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (16.7)</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 (16.7)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Severity grade as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) V.5.0&#59; G &#61; grade. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The status of GR expression in tumor was assessable for two patients in Dose Level 1A based upon baseline tumor biopsy. The patient with endometrial cancer showed significant GR staining of her tumor, while there was little tumor staining of the patient with colorectal cancer. A baseline tumor biopsy could not be obtained in the third patient. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patient with endometrial cancer had previously received a five-month course of paclitaxel and carboplatin to which her best response was stable disease. She subsequently received two sequential experimental agents but had disease progression on each of them. The patient then received nab-paclitaxel and ORIC-101 starting two months after her last experimental agent and eight months after her last exposure to taxane-platinum chemotherapy. This patient experienced a 33% reduction in tumor burden (per the Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) after Cycle 2 (eight weeks on study) as shown in the figure below. The tumor marker, CA-125, had also declined from 686 U/mL at baseline down to 525 U/mL. The patient experienced only Grade 1 and 2 AEs, all of which were reversible. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First on-study tumor scans for patient with endometrial cancer </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000031.jpg" title="" alt="" style="width:607px;height:183px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In patients with endometrial cancer, there are reports of successful retreatment with a taxane-platinum doublet but only in patients who previously received a taxane-platinum doublet in the adjuvant setting or in patients who had at least a six month treatment-free interval between first- and second-line treatment in the metastatic setting. Furthermore, published data are based upon taxane-platinum doublet rather than single-agent taxane retreatment. Thus, in this patient who did not respond to her initial taxane-platinum treatment in the first-line metastatic setting and who had only a four-month treatment-free interval, there would be little to no expectation of tumor regression with single-agent taxane therapy. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A baseline tumor sample from this patient showed a high level of staining for GR by immunohistochemistry (H-score 150), which declined in a follow-up biopsy after treatment with ORIC-101 and nab-paclitaxel (H-score 65), with particular reduction in the percentage of cells that stained 3+ and 2+ for GR, as shown below, indicating elimination of highly GR+ tumor cells.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Staining Intensity (%)*</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Timepoint</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Tumor H-score</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRE-DOSE</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">END OF TREATMENT</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with this decline in GR tumor expression levels upon treatment, there was also evidence of GR-pathway inhibition. As part of the study, PBMCs were collected at various timepoints to assess the expression level of three genes indicative of GR-pathway signaling activity: PER1, GILZ, and FKBP5. With GR inhibition, it would be expected that expression of one or more of these genes would decrease, although the specific pattern may vary by tumor and between patients. In this patient, during ORIC-101 treatment, there was a marked decrease in expression of PER1 compared to baseline, as well as a decrease in expression of GILZ, as shown in the figures below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000032.jpg" title="" alt="" style="width:587px;height:145px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collectively, these translational studies suggest that this patient with GR-positive endometrial cancer, who experienced tumor regression on ORIC-101 and nab-paclitaxel after prior taxane exposure, had a measurable reduction in GR-positive cells in the tumor on treatment with concurrent evidence of in vivo GR inhibition. A follow-up radiographic assessment four weeks after the initial eight-week assessment revealed further regression of the target lesions (38% reduction from baseline) along with stable non-target lesions&#59; however, the appearance of new lesions led to an overall determination of disease progression as per RECIST v1.1. The patient subsequently came off study treatment due to disease progression. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the remaining two patients in Dose Level 1A, one patient (with colorectal cancer that showed no evidence of GR-positive staining at baseline) came off treatment for disease progression after seven weeks. The other patient (with poorly differentiated neuroendocrine carcinoma of the lung and unknown GR status) came off treatment for disease progression after 10 weeks. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two patients in Dose Level 2A were ongoing (patient with gastric cancer in Cycle 3, and patient with large cell lung cancer in Cycle 2)&#59; the third patient (with testicular cancer) came off treatment for disease progression at the end of Cycle 1. As of March 27, 2020, two new patients had been enrolled in Dose Level 3A: 240 mg ORIC-101 and 75 mg/m2 nab-paclitaxel. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of October 12, 2020, enrollment was completed for Dose Levels 2A and 3A, which evaluated ORIC-101 at 160 mg or 240 mg, respectively, once daily on an intermittent dosing schedule, with 75 mg/m2 nab-paclitaxel. No DLTs were observed in either Dose Levels 2A or 3A. As planned per protocol, exploration of ORIC-101, administered on a 21-day continuous daily dosing regimen with 75 mg/m2 nab-paclitaxel, was completed, with ORIC-101 at 160 mg combined with 75 mg/m2 nab-paclitaxel and no DLTs were observed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we completed the Part I dose escalation portion of ORIC-101 in combination with nab-paclitaxel in solid tumors, selected the RP2D, and initiated the dose expansion portion of the trial. For the Part II dose expansion portion of the trial, up to 132 patients are expected to be enrolled across four cohorts, including pancreatic ductal adenocarcinoma, ovarian cancer, triple negative breast cancer, and other advanced solid tumors. Patients in Part II of the trial will be treated at the RP2D of 160 mg of ORIC-101 continuous once daily dosing and 75 mg/m2 of nab-paclitaxel on days 1, 8, and 15 of a 28-day cycle, without requirement for prophylactic granulocyte colony-stimulating factor. Eligible patients must have previously progressed on a taxane-containing regimen and will be enrolled independent of baseline GR status, with retrospective analysis of GR expression and other potentially predictive biomarkers. We expect to report interim safety, efficacy, and translational data from this trial in the first half of 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CD73 inhibitor program: ORIC-533 </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Background on adenosine and CD73 </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adenosine, a purine nucleoside base, is an extracellular signaling molecule derived from adenosine triphosphate (ATP). Adenosine is a potent suppressor of immune function and accumulates in tissues at sites of inflammation and damage. Analogously, in the context of tumors, adenosine in the tumor microenvironment is implicated in local immunosuppression that leads to tumor growth. Extracellular ATP is metabolized to AMP by the enzyme CD39, and AMP is metabolized to adenosine by the enzyme CD73. Adenosine, via its interaction with adenosine receptors, functions to suppress immune function. Multiple cell types within the tumor milieu, including cancer cells, endothelial cells and immune cells, express CD73. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Rationale for targeting CD73 in oncology </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many cancers usurp the anti-inflammatory adenosine pathway to avoid detection by the immune system, thereby reducing the effectiveness of certain chemotherapy- and immunotherapy-based treatments. Accumulation of adenosine in the tumor microenvironment is implicated in local immune suppression that leads to tumor growth. As shown in the figure below, CD73 is an enzyme that controls the rate at which extracellular adenosine is produced, and its overexpression is associated with poor prognosis in several cancers, including TNBC, NSCLC, melanoma and prostate, among others. Several global pharmaceutical companies are developing anti-CD73 antibodies, but due to significant medicinal chemistry challenges, to our knowledge, only one orally bioavailable inhibitor of CD73 is in clinical development. With our resistance platform capabilities, our medicinal chemistry team created a differentiated compound that is both potent and orally bioavailable. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CD73 has been linked to therapy resistance </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000033.jpg" title="" alt="" style="width:609px;height:281px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical data </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-533 is an orally bioavailable small molecule that potently and selectively antagonizes CD73 enzymatic function (&#60; 1nM) and fully inhibits CD73-mediated AMP to adenosine conversion both in human tumor cells and immune cells. Preclinical studies show that ORIC-533 restores CD8+ T-cell expansion and activation of adenosine-induced immunosuppression. Reversal of adenosine-induced intratumoral immunosuppression with ORIC-533 leads to significant anti-tumor responses in vivo. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000034.jpg" title="" alt="" style="width:606px;height:265px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the figure above on the left, an ORIC-533 analogue decreased adenosine production in a concentration-dependent manner in cultured human CD8+ T cells and human H1568 cancer cells. While an ORIC-533 analogue can completely block adenosine production by immune and tumor cells, an anti-CD73 antibody is unable to achieve the same degree of functional inhibition. In the figure above on the right, a single oral dose of our compound in mice achieved unbound plasma exposures that exceed the in vitro EC90 levels required for suppression of adenosine production for 24 hours. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, CD73 inhibition in vivo substantially reduced the adenosine/AMP ratio in EMT6 mouse tumors following sustained CD73 inhibitor treatment. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000035.jpg" title="" alt="" style="width:599px;height:232px;" /></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: ORIC data using syngeneic EG7 tumor model, AACR June 2020 abstract 10268, poster LB-115</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*: p&#60;0.005. ***: p &#61; 0.0006. ****: p &#60; 0.0001.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the figure above on the left, daily CD73 inhibitor treatment with our product candidate ORIC-533 significantly impairs syngeneic tumor growth and tumor size as an orally dosed single agent. Evaluation of tumors at the end of study, on the right above, show the depletion of adenosine and corresponding increase in T cells in the tumor microenvironment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When compared to other CD73 inhibitors in preclinical studies, ORIC-533 more potently suppressed adenosine production from AMP in both T cells and tumor cells, and at nM concentrations was able to rescue activation of CD8+ T cells exposed to a high AMP environment. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000036.jpg" title="" alt="" style="width:609px;height:265px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: ORIC data, AACR June 2020 abstract 4317, poster 1023</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*: Bowman et al, 2019. **: WO2019246403A1 Compound 9. ***: WO2019168744A1 Example 2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above figure demonstrates the results of a series of preclinical experiments that we conducted evaluating ORIC-533, AB680, Calithera, and Eli Lilly compounds across a variety of properties that we believe to be important in developing a potent and efficacious CD73 inhibitor. In the figure and table on the left above, human PBMCs, H1568 NSCLC cells, and human CD8+ T cells were pre-treated with compounds for 15 minutes, followed by addition of 10 uM AMP/5 uM EHNA for 1 hour. Adenosine in supernatant was quantified by LC-MS/MS. The biochemical binding assay was carried out with purified CD73 protein and compounds assessed at a wide concentration range to calculate IC50. In the figure on the above right, human PBMC-derived CD8+ T cells were activated for 24 hours with tetrameric anti-CD3/CD28/CD2 antibodies in serum free media, labeled with CellTrace&#8482; Violet and plated onto 96-well plates. Compounds at varying concentrations and 1millimolar AMP were added, and cells incubated for 72-96 hours. T cell proliferation was quantified by flow cytometry. TNFa cytokine production in cell supernatants was measured by Meso Scale Discovery immunoassay. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-533 continues to progress in IND enabling studies and we expect to file an IND with the FDA in the first half of 2021. Having conducted a preclinical collaboration with an academic key opinion leader that generated compelling single agent activity in patient derived model systems in an undisclosed tumor type, we plan to pursue a single agent clinical development path in this indication.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRC2 inhibitor program: ORIC-944<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Background </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PRC2 is a histone methyltransferase consisting of three core subunits: EED, EZH2 or EZH1, and SUZ12 and plays a key role in gene regulation and transcriptional repression, in particular during embryonic development. The dysregulation of PRC2 can lead to tumorigenesis in a wide range of cancers including prostate cancer, breast cancer, and hematological malignancies. EED is responsible for histone binding and activation of the PRC2 complex. Allosteric inhibition of EED impacts the assembly, stabilization, and activation of PRC2. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Rationale for targeting allosteric inhibition of PRC2 through EED </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PRC2 complex has two druggable subunits, EZH2, whose enzymatic function is the target of first generation therapeutics, and EED, which next-generation therapeutics like ORIC-944 inhibit. Several companies are developing EZH2 inhibitors&#59; however, the pharmacologic properties of these compounds result in high doses given more than once a day, that achieve only partial target inhibition in the clinic. Allosteric inhibition of PRC2 through EED is differentiated from targeting EZH2 and may be beneficial for a number of reasons. First, preclinical studies show that EED inhibition is active against mutants in EZH2 that confer innate resistance to EZH2 inhibitors. Second, in a similar fashion, acquired mutations in EZH2 are sensitive to EED inhibition. Third, cells treated with EZH2 inhibitors are also able to activate EHZ1 in a compensatory bypass mechanism of resistance, yet those cells are sensitive to EED inhibition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000037.jpg" title="" alt="" style="width:610px;height:247px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: EZH1, enhancer of zeste homolog 1. EZH2, enhancer of zeste homolog 2. EED, embryonic ectoderm development. SUZ12, suppressor of zeste 12. H3K27, histone H3 at lysine 27. (1) Yu et al. Cancer Res. (2007). </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical Data </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-944 is a potent and selective allosteric inhibitor of PRC2 with mechanism of action via binding the EED subunit. ORIC-944 when dosed orally once a day as a single agent significantly inhibited prostate tumor growth in an enzalutamide-resistant prostate cancer model as seen in the figure below. While cross-study comparisons of preclinical data have limitations and caveats, the ORIC-944 efficacy appears to be superior to EZH2 inhibitors in the same models<span style="font-style:italic;">. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000038.jpg" title="" alt="" style="width:323px;height:284px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enzalutamide dose 30mg/kg QD. ****p&#60;0.0001. In the figure above, once daily PRC2 inhibitor treatment with ORIC-944 significantly inhibited prostate tumor growth in an enzalutamide-resistant in vivo xenograft model, when dosed orally as a single agent. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional preclinical studies with ORIC-944 as a monotherapy and in combination regimens are being explored. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have initiated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> IND enabling studies and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plan to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">file an IND with the FDA in the second half of 2021, with initial clinical development as a single agent in treatment-resistant prostate cancer.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Brain penetrant EGFR/HER2 exon 20 program: ORIC-114 </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Background </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 exon 20 insertion mutations are observed across multiple solid tumors, including NSCLC, breast, gastrointestinal, bladder and other cancers. EGFR exon 20 insertion mutations are observed in approximately 2% of all patients with NSCLC and these patients have a worse prognosis than patients with NSCLC driven by other EGFR mutations. HER2 exon 20 insertion mutations are observed in approximately 1.5% of all patients with NSCLC. Outside of NSCLC, it is estimated that EGFR and HER2 exon 20 insertion mutations are observed in 0.6% of patients. In total, these prevalence estimates suggest a target population in non-small cell lung cancer of over 7,500 patients in the US annually, plus an additional 8,500 patients across other cancers. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Rationale for brain penetrant inhibitor of EGFR/HER2 with high potency towards exon 20 mutations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, there are no medicines approved by the FDA specifically to treat NSCLC, breast, gastrointestinal, bladder and other cancers associated with EGFR or HER2 exon 20 insertion mutations across any of the tumors in which they occur, and standard EGFR inhibitors and chemotherapy provide limited benefit for these patients. Furthermore, within NSCLC, approximately one-third of patients with exon 20 insertion mutations develop brain metastases, which contributes to poor prognosis. Several companies are developing EGFR exon 20 inhibitors&#59; however, to our knowledge none have demonstrated significant brain exposure suitable for addressing brain metastases, an area of significant unmet medical need. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000039.jpg" title="" alt="" style="width:342px;height:228px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Robichaux et al Nat Med (2018). EGFR exon 20 insertion (n&#61;9) and classical EGFR mutation (n&#61;129)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EGFR exon 20 insertions are associated with lower PFS with first and second generation EGFR TKIs, such as erlotinib, gefitinib and afatinib, compared to other EGFR mutations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical data </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-114 was designed as a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with nanoMolar potency towards exon 20 insertion mutations. As shown in the figure below, in a kinase selectivity panel, the ErbB receptor tyrosine kinases were strong hits and there were no off-targets identified for ORIC-114, unlike the comparator clinical compounds. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000040.jpg" title="" alt="" style="width:608px;height:314px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All kinome selectivity screens were conducted on a 468 kinase panel with 1 uM of either TAK-788, poziotinib, CLN-081, or ORIC-114 in a head-to-head assessment. The top 10% of hits are shown in red. Notably, ORIC-114 did not hit any of the 3F family of kinases with the potential for covalent Cys interaction in the active site. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-114 demonstrated potent anti-tumor activity in various NSCLC EGFR exon 20 insertion mutation models. In the example below, in a model carrying variant NPH, ORIC-114 demonstrated potent anti-tumor activity when dosed orally once daily at 4 mg/kg, multiples lower than the TAK-788 in vivo dose. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000041.jpg" title="" alt="" style="width:607px;height:303px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-114 was designed for brain penetrance and demonstrated potent anti-tumor activity in an intracranial NSCLC EGFR exon 19 deletion mutation in vivo model, when dosed at 2.5 mg/kg QD PO, superior to TAK-788 which was dosed at 30 mg/kg QD PO. Efficacy was measured by quantification of the bioluminescence photon flux in mice carrying intracranial PC9-Luc tumors. </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000042.jpg" title="" alt="" style="width:612px;height:299px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated IND enabling studies and plan to file a CTA in South Korea in the second half of 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other preclinical programs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our product candidates, we are leveraging our resistance platform in pursuit of multiple discovery research programs that focus on our expertise within hormone-dependent cancers, precision oncology and key tumor dependencies. These programs highlight our medicinal chemistry and structure-based design expertise, thus for the most part utilize a small molecule therapeutic approach to target oncogenic drivers in solid tumors like prostate, breast, and lung cancer that relapse with innate, acquired or bypass resistance. Our most advanced discovery research program is currently in lead optimization. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">Discovery Program A: a blocking antibody that is targeting a mechanism of innate resistance caused by a gene rearrangement found in a subset of many solid tumors.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Discovery Program B: a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers, specifically those driven by a distinct DNA amplification. Breast cancer models with this amplification have a key tumor dependency on a particular enzymatic interaction and our therapeutic approach is to inhibit this enzyme. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">Discovery Program C: a small molecule therapeutic intended to address an acquired resistance mechanism in lung cancer that is caused by a mutation that arises in an enzyme within a subset of NSCLC patients after first-line treatment with another agent. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">Discovery Program D: a small molecule therapeutic intended to address a bypass resistance mechanism to androgen receptor inhibition in prostate cancer by targeting the AR transcriptional complex, thus resulting in abrogation of AR target gene expression. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration and license agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Voronoi license agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 19, 2020, we entered into the Voronoi License Agreement with Voronoi. The Voronoi License Agreement gives us access to Voronoi&#8217;s preclinical stage EGFR and HER2 exon 20 insertion mutation program, including a lead product candidate now designated as ORIC-114. Under the Voronoi License Agreement, Voronoi granted us an exclusive, sublicensable license under Voronoi&#8217;s rights to certain patent applications directed to certain small molecule compounds that bind to EGFR or HER2 with one or more exon 20 insertion mutations and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compound worldwide other than in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan (the ORIC Territory). Under the Voronoi License Agreement, we are wholly responsible for development and commercialization of licensed products in the ORIC Territory. In addition, we are obligated to use commercially reasonable efforts to develop and commercialize at least one licensed product in certain major markets in the ORIC Territory. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial obligations under the Voronoi License Agreement included an upfront payment comprised of a $5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million cash payment and the issuance to Voronoi of 283,259 shares of our common stock issued pursuant to a stock issuance agreement (Stock Agreement) entered into between the parties on October 19, 2020. The number of shares issued pursuant to the Stock Agreement was based on a price of $28.24 per share, representing a premium of 25% to the 30-day trailing volume weighted average trading price of our common stock. The shares were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act for transactions by an issuer not involving any public offering. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also obligated to make milestone payments to Voronoi upon the achievement of certain events. Upon the achievement of certain development and regulatory milestones with respect to the first licensed product, we are obligated to pay Voronoi up to a maximum of $111.0 million. Upon the achievement of certain commercial milestones with respect to the first licensed product, we are obligated to pay Voronoi up to a maximum of $225.0 million. If we pursue a second licensed product, we would pay Voronoi up to an additional $272.0 million in success-based milestones. In addition, we are obligated to pay Voronoi tiered mid-single-digit to low-double-digit royalties on annual net sales of licensed products in the ORIC Territory. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Voronoi License Agreement will continue in effect until the expiration of all royalty payment obligations. Following the expiration of the Voronoi License Agreement, we will retain our licenses under the intellectual property Voronoi licensed to us on a royalty-free basis. We and Voronoi may each terminate the Voronoi License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Voronoi may also terminate the agreement if we discontinue development of licensed products for a specified period of time. We also have the right to terminate the Voronoi License Agreement without cause by providing prior notice to Voronoi. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Voronoi terminates the Voronoi License Agreement for cause, or we terminate the Voronoi License Agreement without cause, then we are obligated to grant a nonexclusive license to Voronoi under certain of our patents and know-how and to assign to Voronoi certain of our regulatory filings for licensed compounds and licensed products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mirati license agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 3, 2020, we entered into a license agreement (Mirati License Agreement) with Mirati. The Mirati License Agreement gives us access to Mirati&#8217;s preclinical stage allosteric PRC2 program, including a lead product candidate now designated as ORIC-944. Under the Mirati License Agreement, Mirati granted us a worldwide, exclusive, sublicensable, royalty-free license under Mirati&#8217;s rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2 and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compound. Under the Mirati License Agreement, we are wholly responsible for development and commercialization of licensed products. In addition, we are obligated to use commercially reasonable efforts to develop and commercialize at least one licensed product in certain major markets. For a limited period of time, we and Mirati are both prohibited from researching, developing or commercializing any other compound or product whose principal mechanism of action is to modulate or inhibit PRC2 by directly binding thereto. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial obligations under the Mirati License Agreement are comprised of an upfront payment of 588,235 shares of our common stock issued pursuant to a stock issuance agreement (Stock Agreement) entered into between the parties on August 3, 2020. The number of shares issued pursuant to the Stock Agreement were based on a price of $34.00 per share, representing a premium of 10% to the 60-day trailing volume weighted average trading price of our common stock. The shares were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering. During the eighteen-month period following the date of the Stock Agreement, Mirati is subject to certain transfer restrictions, and the parties agreed to negotiate and enter into a registration rights agreement, with respect to the shares. We are not obligated to pay Mirati milestones or royalties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Mirati License Agreement will continue in effect on a country-by-country and licensed product-by-licensed product basis until the later of (a) the expiration of the last valid claim of a licensed patent covering such licensed product in such country or (b) ten years after the first commercial sale of such licensed product in such country. Following the expiration of the Mirati License Agreement, we will retain our licenses under the intellectual property Mirati licensed to us on a royalty-free basis. We and Mirati may each terminate the Mirati License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Mirati may terminate the agreement if we challenge any of the patent rights licensed to us by Mirati or we discontinue development of licensed products for a specified period of time. We also have the right to terminate the Mirati License Agreement without cause by providing prior notice to Mirati. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Mirati terminates the Mirati License Agreement, or we terminate the Mirati License Agreement without cause, then we are obligated to assign to Mirati, or grant an exclusive license to Mirati with respect to, certain of our patents, know-how and regulatory filings directed to licensed compounds and licensed products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Astellas collaboration and supply agreement </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, we entered into a clinical trial collaboration and supply agreement with Astellas to evaluate ORIC-101 in combination with enzalutamide for the treatment of patients with metastatic prostate cancer. Under the terms of the clinical trial collaboration and supply agreement, we are sponsoring and conducting the Phase 1b trial of ORIC-101 in combination with enzalutamide. Astellas, which jointly commercializes enzalutamide in the United States with Pfizer, is providing enzalutamide for the trial. We maintain global development and commercial rights to ORIC-101 and rights to develop ORIC-101 in combination with other agents. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales and marketing </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to retain significant development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no sales, marketing or commercial product distribution capabilities. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates obtain marketing approval. We also rely, and expect to continue to rely, on third parties to package, label, store and distribute our investigational product candidates, as well as for our commercial products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have obtained active pharmaceutical ingredients (API) and drug product for our product candidates from single-source third party contract manufacturers. We are in the process of developing our supply chain for each of our product candidates and intend to put in place framework agreements under which third-party contract manufacturers will generally provide us with necessary quantities of API and drug product on a project-by-project basis based on our development needs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we advance our product candidates through development, we will consider our lack of redundant supply for the API and drug product for each of our product candidates to protect against any potential supply disruptions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally expect to rely on third parties for the manufacture of any companion diagnostics we may develop. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including obtaining, maintaining and defending our patent rights. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications and obtaining issued patents, or in-licensing issued patents and patent applications, in the United States and in markets outside of the United States directed to our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position in the field of oncology. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, improvements and product candidates&#59; to preserve the confidentiality of our trade secrets&#59; to defend and enforce our proprietary rights, including any patents that we may own or license in the future&#59; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio consists of issued patents and pending patent applications that we own or in-licensed related to ORIC-101, ORIC-533, ORIC-944, ORIC-114 and various other compounds and programs. As of December 31, 2020, the portfolio includes four issued United States patents, 22 pending United States patent applications, seven pending international patent applications filed under the Patent Cooperation Treaty (PCT application), seven issued patents in various markets outside of the United States, and 75 pending patent applications in various markets outside of the United States. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our patent portfolio covering ORIC-101 included patents issued in the United States, Australia, Japan, and New Zealand, along with patent applications pending in the United States, Europe, Japan, China, and other markets outside of the United States.&#160;&#160;The issued United States patents covering ORIC-101 as composition of matter, pharmaceutical compositions and related methods of use are expected to expire in 2037, absent any patent term extensions for regulatory delay. Any patents that may issue from our pending patent applications related to ORIC-101 are expected to expire between 2037 and 2041, absent any patent term adjustments or extensions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to ORIC-533, as of December 31, 2020, we have patent applications pending in the United States, Europe, Japan, China and other markets outside of the United States</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covering ORIC-533 as composition of matter, pharmaceutical compositions and related methods of use. Any patents that may issue from our pending patent applications related to ORIC-533 are expected to expire between 2039 and 2040, absent any patent term adjustments or extensions. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to ORIC-944, as of December 31, 2020, we have exclusively in-licensed from Mirati patent applications pending in the United States, Europe, China, Japan, and other markets outside of the United States covering ORIC-944 as composition of matter, pharmaceutical compositions and related methods of use. Any patents that may issue from the pending patent applications related to ORIC-944 are expected to expire in 2039 absent any patent term adjustments or extensions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to ORIC-114, as of December 31, 2020, we have exclusively in-licensed from Voronoi in the ORIC Territory a pending PCT application and a patent application pending in Korea covering ORIC-114 as composition of matter, pharmaceutical compositions, and related methods of use. Any patents that may issue from the pending patent applications related to ORIC-114 are expected to expire in 2040, absent any patent term adjustments or extensions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our patent portfolio also included issued patents in the United States, France, Germany, and the United Kingdom, and patent applications pending in the United States and Canada that are exclusively licensed to us by MSKCC. These licensed patents and patent applications are based on the academic work conducted in the laboratory of Dr. Sawyers at MSKCC and do not cover ORIC-101, any of our current product candidates, or any of our discovery and research programs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our product candidates and processes we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of oncology has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, even our issued patents may not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Competition </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our executive and scientific team, research, clinical capabilities, development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and convenience. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For ORIC-101, our small molecule GR antagonist, we are aware of several other clinical-stage GR antagonists being developed by Corcept Therapeutics. To our knowledge, there are no GR antagonists approved for the treatment of cancer and the most advanced such GR antagonist is in a Phase 3 clinical trial in combination with nab-pacitaxel in patients with metastatic pancreatic ductal adenocarcinoma. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For ORIC-533, our orally bioavailable small molecule CD73 inhibitor, we are aware of several companies developing antibodies against this target, including AstraZeneca, Bristol-Myers Squibb, Novartis in collaboration with Surface Oncology, Incyte Corporation, Corvus Pharmaceuticals, Innate Pharma, Tracon Pharmaceuticals in collaboration with I-Mab Biopharma, Gilead Sciences, Akeso and Symphogen. Other companies, such as Eli Lilly and Company, Arcus Biosciences, Calithera Biosciences and Merck through its acquisition of Peloton Therapeutics, have small-molecule programs against this target. To our knowledge, only Eli Lilly has an orally available, small molecule CD73 inhibitor in a clinical trial for patients with cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For ORIC-944, we are aware of several companies developing inhibitors against PRC2 via EZH2 inhibition that are currently in clinical trials, including Epizyme, Constellation Pharmaceuticals, Daiichi Sankyo, Pfizer, Shanghai HaiHe Pharmaceutical and Jiangsu Hengrui Medicine Co. To our knowledge, only Novartis has an allosteric PRC2 inhibitor in a clinical trial for patients with cancer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For ORIC-114, we are aware of several companies developing inhibitors against exon 20 insertion mutations that are currently in clinical trials, including Takeda, Spectrum Pharmaceuticals, The Janssen Pharmaceutical Companies of Johnson &#38; Johnson, Rain Therapeutics, Dizal Pharmaceuticals Co., Ltd., Cullinan Oncology and Black Diamond Therapeutics. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Government regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. drug development </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA). Drugs also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are considered small molecule drugs and must be approved by the FDA through the NDA process before they may be legally marketed in the United States. The process generally involves the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">submission to the FDA of an IND, which must become effective before human clinical trials may begin&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">approval by an independent IRB, or ethics committee at each clinical trial site before each trial may be initiated&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (GCP) requirements and other clinical trial-related regulations to establish substantial evidence of the safety and efficacy of the investigational product for each proposed indication&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">submission to the FDA of an NDA&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of an NDA to accept the filing for review&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">satisfactory completion of a FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA filing&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States&#59; and</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS), and the potential requirement to conduct post-approval studies.</span><span style="font-family:Times New Roman;"> The data required to support an NDA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any current and future product candidates will be granted on a timely basis, or at all. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical studies and IND </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical trials </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB must also approve the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA. The FDA will generally accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with the ethical principles contained in the Declaration of Helsinki pursuant to 21 CFR 312.120(c)(4), incorporating the 1989 version of the Declaration, or with the laws and regulations of the foreign regulatory authority where the trial was conducted, such as the EMA, whichever provides greater protection of the human subjects, and with GCP and GMP requirements, and the FDA is able to validate the data through an onsite inspection, if deemed necessary, and the practice of medicine in the foreign country is consistent with the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">Phase 2 clinical trials involve studies in disease-affected patients to determine the dose and dosing schedule required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, are conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Sponsor is also responsible for submitting written IND safety reports, including reports of serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing that suggest a significant risk for human subjects, and any clinically significant increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">Concurrent with clinical trials, companies usually complete additional animal safety studies and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process, as performed by the manufacturing facility, must be capable of consistently producing quality batches of our product candidates. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their labeled shelf life. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NDA review process </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA is a request for approval to market the drug in the United States for one or more specified indications and must contain proof of safety and efficacy for a drug. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The application must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA must be obtained before a drug may be legally marketed in the United States. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for each marketed human drug. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews all submitted NDAs before it accepts them for filing, and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies and/or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Orphan drugs </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expedited development and review programs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting with the FDA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. FDA may withdraw drug approval or require changes to the labeled indication of the drug if confirmatory post-market trials fail to verify clinical benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a drug may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Post-approval requirements </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, requirements to report adverse events and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known as &#8220;off-label promotion,&#8221; and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">fines, warning letters, or holds on post-approval clinical studies&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">refusal of the FDA to approve pending applications or supplements to approved applications&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">suspension or revocation of product approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">product seizure or detention&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">refusal to permit the import or export of products&#59; or </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FDA regulation of companion diagnostics </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A therapeutic product may rely upon an in vitro companion diagnostic for use in selecting the patients that will be more likely to respond to that therapy. If an in vitro diagnostic is essential to the safe and effective use of the therapeutic product and if the manufacturer wishes to market or distribute such diagnostic for use as a companion diagnostic, then the FDA will require separate approval or clearance of the diagnostic as a companion diagnostic to the therapeutic product. According to FDA guidance, an unapproved or uncleared companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational medical device unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. The sponsor of the diagnostic device will be required to comply with the IDE regulations for clinical studies involving the investigational diagnostic device. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same clinical trial, if the trial meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the clinical trial protocol, the investigational product(s), and subjects involved, a sponsor may seek to submit an IDE alone (e.g., if the drug has already been approved by FDA and is used consistent with its approved labeling), or both an IND and an IDE. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuing FDA approval/clearance of an in vitro companion diagnostic would require either a pre-market notification, also called 510(k) clearance, or a pre-market approval, or PMA, or a de novo classification for that diagnostic. The review of companion diagnostics involves coordination of review with the FDA&#8217;s Center for Devices and Radiological Health. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">510(k) clearance process </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain 510(k) clearance, a pre-market notification is submitted to the FDA demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet required the submission of a PMA application. The FDA&#8217;s 510(k) clearance process may take three to 12 months from the date the application is submitted and filed with the FDA, but may take longer if FDA requests additional information, among other reasons. In some cases, the FDA may require clinical data to support substantial equivalence. In reviewing a pre-market notification submission, the FDA may request additional information, which may significantly prolong the review process. Notwithstanding compliance with all these requirements, clearance is never assured. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a device receives 510(k) clearance, any subsequent modification of the device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new 510(k) clearance or require a PMA. In addition, the FDA may make substantial changes to industry requirements, including which devices are eligible for 510(k) clearance, which may significantly affect the process. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">De novo classification process </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a new medical device does not qualify for the 510(k) pre-market notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act of 1997 established a different route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk and requires PMA or that general controls would be inadequate to control the risks and special controls cannot be developed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining FDA marketing authorization, de novo down-classification, or approval for medical devices is expensive and uncertain, and may take several years, and generally requires significant scientific and clinical data. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">PMA process </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PMA process, including the gathering of clinical and nonclinical data and the submission to and review by the FDA, can take several years or longer. The applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness, including information about the device and its components regarding, among other things, device design, manufacturing, and labeling. PMA applications are subject to an application fee. In addition, PMAs for medical devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, or QSR, which imposes extensive testing, control, documentation, and other quality assurance and GMP requirements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other U.S. regulatory matters </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as, sell, market, and distribute any products for which we obtain marketing approval. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug or medical device manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Moreover, the Patient </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Protection and Affordable Care Act of 2010, as amended by the health Care and Education Reconciliation Act of 2010 (collectively, the ACA), provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal false claims, including the civil False Claims Act that can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, and/or impose exclusions from federal health care programs and/or penalties for parties who engage in such prohibited conduct&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the Federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations also impose obligations on covered entities such as health insurance plans, healthcare clearinghouses, and certain health care providers and their respective business associates and their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to Centers for Medicare &#38; Medicaid Services (CMS) information regarding certain payments and other transfers of value to physicians, as defined by such law, and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members&#59; effective January 1, 2022, such reporting obligations for payments and transfers of value made in 2021 to cover recipients will be expanded to include physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, and certified nurse-midwives&#59; and </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws that require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government&#59; state and local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and require the registration of their sales representatives, state laws that require biotechnology companies to report information on the pricing of certain drug products, and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. In addition, the distribution of pharmaceutical and/or medical device products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical and/or medical device products. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act as well as other applicable consumer safety requirements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant civil, criminal and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. patent-term restoration and marketing exclusivity </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent-term restoration period is generally one-half the time between the effective date of an IND or the issue date of the patent, whichever is later, and the submission date of an NDA plus the time between the submission date of an NDA or the issue date of the patent, whichever is later, and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (ANDA), or a 505(b)(2) NDA submitted by another company for a generic version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement with respect to one or more patents listed for the drug in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations publication. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness or generate such data themselves. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Union and UK drug development </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies r marketing of the product in those countries. Certain countries outside the U.S. have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. The approval process varies from country to country and the time may be longer or shorter that that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country and may require us to perform additional pre-clinical or clinical testing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Union drug review and approval </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical products in the European Union are subject to regulation under comprehensive legislation enacted by the European Commission in the European Medicinal Products Directive (Directive 2001/83/EC), as amended. Centrally authorized products are also regulated by Regulation (EC) No. 726/2004. This legislation is binding on all Member States together with ancillary legislation governing research. In the UK, the main legislative texts relating to human medicines is the Medicines Act 1968 and the Human Medicines Regulation 2012.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Union system for authorization of medicinal products for human use offers several routes: the centralized procedure, the decentralized procedure, and the mutual recognition procedure, as well as domestic national routes. The centralized procedure provides for the grant of a single marketing authorization that is valid for all 27 European Union Member States as well as the EEA countries of Iceland, Liechtenstein and Norway. The centralized procedure is mandatory for certain categories of investigational products, including human products containing a new active substance indicated for the treatment of certain diseases, including cancer, AIDS, diabetes and neurodegenerative illness&#59; orphan medicinal products&#59; and medicinal products manufactured using biotechnological processes. Applications for marketing authorization for such medicines must be submitted to the EMA, in which the Committee for Medicinal Products for Human Use (CHMP) is generally responsible for conducting the initial assessment of a product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decentralized and mutual recognition procedures are applicable to the majority of conventional medicinal products and are both based on the principle of recognition of a marketing authorization by one or more Member States. The decentralized procedure is available for applicants who wish to market a product in various European Union Member States where such product has not received marketing approval in any European Union Member State before. In this procedure, an application for marketing authorization is submitted simultaneously in several Member States, one of them being chosen as the &#8220;Reference Member State.&#8221; At the end of the procedure, national marketing authorizations are granted in the Reference and in the concerned Member States. The mutual recognition procedure is compulsory when a medicinal product has already received a marketing authorization in one Member State and is to be marketed in a Member State other than that in which it was first authorized. Any national marketing authorization granted by a European Union Member State's national authority can be used to support an application for its mutual recognition by other Member States. Marketing authorization applications can also be submitted directly to the Member State's national competent authority under the national route (if the centralized route is not compulsory). </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UK is no longer a member of the EU, but EU law remains applicable in Northern Ireland. There are a number of new marketing authorization routes available in the UK, Great Britain (England, Scotland and Wales) or Northern Ireland, in addition to the national procedure, which are broadly categorized as either (1) national routes (i.e.&#160;&#160;the innovative licensing and access procedure (ILAP), the national procedure, rolling review, EC Decision Procedure (ECDP), the MR/DC reliance procedure and unfettered access from Northern Ireland)&#59; or (2) international routes (i.e. Access Consortium to market a medicine in the UK, Australia, Canada, Singapore and/or Switzerland&#59; or the Project Orbis program for cancer treatments). The application procedure will depend on the relevant procedure chosen.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All granted centrally authorized marketing authorizations automatically became Great Britain (GB) marketing authorizations on 1 January 2021. Though there are several ways to obtain a marketing authorization for GB (and Northern Ireland) discussed above, the EDRCP is available for marketing authorizations approved under the centralized procedure. Under this procedure the UK's regulator, the MHRA, can rely on the decision of the European Commission on the approval of a new marketing authorization under centralized procedure for a period of two years from January 1, 2021 when determining an application for a GB marketing authorization. Applicants submit a letter of intent to submit an EDRCP to the MHRA at least 4 weeks before the submission of the application for the EDRCP marketing authorization application.&#160;&#160;The marketing authorization application is submitted after receipt of the positive opinion from the CHMP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The objective of the EMA is the comprehensive evaluation of benefit/risk profile of a new medicinal product going through the centralized procedure. This evaluation involves showing that the product has significant efficacy and safety, together with a satisfactory plan for risk management post-marketing. The CHMP is the EMA&#8217;s expert committee responsible for human medicinal products. The CHMP is responsible for conducting the initial review of centrally authorized marketing authorization applications and for assessing modifications or extensions (variations) to an existing marketing authorization. It also considers the recommendations of the Pharmacovigilance Risk Assessment Committee on the safety of medicines on the market and when necessary, recommends to the European Commission changes to a medicine&#8217;s marketing authorization, or its suspension or withdrawal from the market. The marketing authorization application is similar to the NDA in the United States. All application procedures require an application in the common technical document (CTD), which includes the submission of detailed information about the manufacturing and quality of the product, and non-clinical and clinical trial information. The main scientific principle used by the CHMP in the evaluation of medicinal products is the benefit/risk ratio based on quality, efficacy, safety, and risk management considerations. The CHMP assesses whether the data it reviews comply with the ICH-harmonized Good Practices published for GCP, GMP and good laboratory practice (GLP). The CHMP also considers whether studies concluding efficacy and safety of products have sufficient statistical power.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketing authorizations for the UK are submitted to the MHRA.&#160;&#160;As the Medicinal Products Directive is transposed into domestic law, the standards of clinical efficacy, safety, chemical control and manufacture as at 31 December 2020 (the end of the transition period for the UK&#8217;s exit from the EU) are retained.&#160;&#160;As Northern Ireland continues to apply EU law, medicines regulation for Great Britain is likely to be closely aligned with the EU for some time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two recent developments have been introduced which further expand the European regulatory framework: the Falsified Medicines Directive and the Pharmacovigilance Directive. The Falsified Medicines Directive obliges manufacturers of medicinal products to audit their suppliers of active substances to ensure compliance with GMP. It also introduces a new obligation on product manufacturers to inform the competent authority (e.g., ANSM) and the marketing authorization holder if they become aware that these products may be falsified, whether they are being distributed through the legitimate supply chain or by illegal means. The Pharmacovigilance Directive obliges marketing authorization holders to monitor the safety of authorized products and detect any change in their risk-benefit profile. A new pan-European clinical trial data information database has been created that will be complementary to the database established for pharmacovigilance (Regulation (EC) No 726/2004 with respect to centrally authorized medicinal products).&#160;&#160;In addition, Commission Implementing Regulation (EU) No 520/2012 outlines the practical implications for marketing authorization holders, national competent authorities, and the EMA. Also, Commission Delegated Regulation (EU) No 357/2014 on post-authorization efficacy studies specifies the situations in which such studies may be required. Post-authorization efficacy studies may be required where concerns relating to some aspects of efficacy of the medicinal product are identified and can </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be resolved only after the medicinal product has been marketed, or where the understanding of the disease, the clinical methodology or the use of the medicinal product under real-life conditions indicate that previous efficacy evaluations might have to be revised significantly. Brexit will disrupt the operation of pre- and post-authorization clinical trial infrastructure. The rules around GMP and pharmacovigilance in the UK currently remain similar to the EU requirements.&#160;&#160;However, the Falsified Medicines Directive will not apply in Great Britain though it is likely that the UK will implement a procedure to minimize the risk of falsified medicines.&#160;&#160;</span></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials in the European Union are regulated under European Council Directive 2001/20/EC (Clinical Trials Directive) on the implementation of GCP in the conduct of clinical trials of medicinal products for human use. The Clinical Trials Directive requires the sponsor of an investigational medicinal product to obtain a CTA, much like an IND in the United States, from the national competent authority of a European Union Member State in which the clinical trial is to be conducted. The application for CTA must satisfy detailed requirements for the protection of trial subjects including requirements relating to consent and specific rules for minors and adults unable to consent by reason of incapacity. The CTA application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the Council Directive and corresponding national laws of the Member States and further detailed in applicable guidance, including the European Commission Communication 2010/C 82/01. A clinical trial may only be commenced after an Ethics Committee has given its approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor of a clinical trial must also follow certain procedures, including obtaining a unique EudraCT number by entering specified relevant information in the EudraCT Community Clinical Trial System. In addition, Member States require that the manufacture and/or importation of investigational medicinal products be authorized. Sponsors of investigational medicinal products must ensure compliance with, among other things, GCP and good manufacturing practice (GMP) as well as requirements pertaining to safety reporting. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, Regulation EU No 536/2014 (Clinical Trials Regulation) was adopted to replace the Clinical Trials Directive. The Clinical Trials Regulation is intended to simplify the current rules for clinical trial authorization and standards of performance. For instance, there will be a streamlined application procedure via a single-entry point, a European Union portal and database. The implementation of the Clinical Trials Regulation depends on confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit, which commenced in September 2020. The system is currently planned to go live in December 2021. The new clinical trial portal and database will be maintained by the EMA in collaboration with the European Commission and the European Union Member States. The objectives of the new Regulation include consistent rules for conducting trials throughout the European Union, consistent data standards and adverse events listing, and consistent information on the authorization status. Additionally, information on the conduct and results of each clinical trial carried out in the European Union will be made publicly available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main legislation that applies to clinical trials in the UK is the UK Medicines for Human Use (Clinical Trials) Regulations 2004, which transposes the Clinical Trials Directive into domestic law.&#160;&#160;Consequently, the requirements and obligations that relate to the conduct of clinical trials in the UK currently remain largely aligned with the EU position.&#160;&#160;A CTA will be required to conduct a clinical trial in the UK, together with Ethics Committee approval.&#160;&#160;However, the sponsor of a clinical trial in the UK must be established in the UK or a country on an approved list currently limited to the EU Member States plus Iceland, Liechtenstein and Norway) or appoint a legal representative who is established on one of the aforementioned countries. Clinical trials should also be registered on an established international register such as ISRCTN registry or ClinicalTrials.gov.&#160;&#160;The UK also requires the manufacture and/or importation of investigational medicinal products to be authorised.&#160;&#160;There is no mutual recognition agreement between the UK and EU on GMP, so medicines manufactured in the UK would be subject to GMP release in the EU. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the U.S. patent term-restoration, Supplementary Protection Certificates (SPCs) serve as an extension to a patent right in Europe for up to five years. SPCs apply to specific pharmaceutical products to offset the loss of patent protection due to the lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage and reimbursement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare reform </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private third-party payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the ACA substantially changed the way healthcare is financed by both the government and private insurers, and continues to significantly impact the U.S. pharmaceutical industry. The ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the HHS Secretary as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions.&#8221; The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. Additionally, for a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been legislative and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">judicial efforts to repeal</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> replace</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or change some or all of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have passed. On December 22, 2017, President Trump signed into law new federal tax legislation commonly referred to as the Tax Cuts and Jobs Act (the Tax Act) which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In addition, the 2020 federal spending package permanently, eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018 (the BBA), among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare Part D drug plans. In December 2018, CMS published a new final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On April 27, 2020, the United States Supreme Court reversed a federal circuit decision that previously upheld Congress&#8217; denial of $12 billion in &#8220;risk corridor&#8221; funding. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supreme Court of the United States held oral arguments on the Fifth Circuit Court case in November 2020 and is expected to issue a decision by mid-2021. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. It is unclear how this Supreme Court decision, future litigation, and healthcare measures promulgated by the Biden administration will impact the implementation of the ACA, our business, financial condition and results of operations. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which will stay in effect through 2030 with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2021 unless additional congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. In 2020, under the Trump administration, HHS and CMS issued final rules in November and December of 2020 that were expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against HHS challenging various aspects of the rules. The Biden administration has also implemented a regulatory rule freeze for all federal agency rules that had not gone into effect as of January 20, 2021. The impact of these lawsuits as well as legislative, executive, and administrative actions of the current administration on us and the pharmaceutical industry as a whole is currently unknown. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. These and other health reform measures that are implemented may have a material adverse effect on our operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. These and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could have a material and adverse effect on our business, financial condition and results of operations. It is also possible that additional governmental action will be taken to address the COVID-19 pandemic. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services and medical products to contain or reduce costs of healthcare and/or impose price controls may adversely affect the demand for our product candidates, if approved, and our ability to achieve or maintain profitability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employees and Human Capital </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 61 full-time employees, more than half of whom hold doctorate degrees. Of these employees, 45 were engaged in research and development activities, and 16 were engaged in general and administrative activities. Substantially all of our employees are located in South San Francisco, California and San Diego, California. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in August 2014. Our principal executive offices are located at 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080. Our telephone number is (650) 388-5600. Our website address is www.oricpharma.com. Information contained on the website is not incorporated by reference into this Annual Report on Form 10-K or any other filings we make with the SEC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may use our website (<span style="text-decoration:underline;color:#000000;">www.oricpharma.com</span>), press releases, public conference calls, public webcasts, Twitter and LinkedIn as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. We also make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Securities Exchange Act of 1934, as amended (Exchange Act). These include our Annual Reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC. The SEC also maintains a website that contains our SEC filings. The address for the SEC website is https://www.sec.gov.<span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the ORIC Pharmaceuticals logo and other marks as trademarks in the United States and other countries. This periodic report contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this periodic report, including logos, artwork and other visual displays, may appear without the TM symbol, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in our other public filings in evaluation our business. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk factor summary</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following summarizes the most material risks that make an investment in our securities risky or speculative. If any of the following risks occur or persist, our business, financial condition, results of operations and prospects could be materially harmed and the market price of our common stock could significantly decline:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our financial position and need for additional capital </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our limited operating history</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our past and anticipated future net losses</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">uncertainty related to our ability to generate revenue and achieve profitability</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our need for substantial additional capital to finance our operations</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to discovery, development and commercialization of our product candidates</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our substantial dependence on ORIC-101</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our challenges in discovering, developing and commercializing additional product candidates</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">limitations in regulatory approval processes and product candidate approvals</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our clinical trials that may fail to satisfactorily demonstrate safety and efficacy </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our product candidates that may cause significant adverse events, toxicities or other undesirable side effects</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potentially negative clinical trial results and challenges related to FDA, EMA and other regulatory requirements</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">deficiencies in audits and verification procedures of our clinical trial data</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">adverse effects due to third parties investigating the same product candidates as us in different territories </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential delays or difficulties in enrollment and/or maintenance of patients in clinical trials</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the impact of the COVID-19 pandemic on our operations</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our inability to develop effective companion diagnostic tests for our product candidates </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">unexpected difficulties in developing ORIC-101 and other potential programs</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">profitability challenges related to our focus on developing ORIC-101 for particular indications</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">significant competition in the markets in which we operate</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">production difficulties encountered by our third-party manufacturers </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">changes in methods of product candidate manufacturing or formulation</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">market inacceptance of our product candidates in the medical community </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">limited market opportunities for ORIC-101 and other product candidates </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our inability to augment our product pipeline through acquisitions and in-licenses</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential for unfavorable third-party coverage and reimbursement practices of our product candidates</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">limitations of our product liability and insurance coverage</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to regulatory, legal and other compliance matters</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">difficulties in our ability to obtain regulatory approval of our product candidates</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">FDA, EMA and other regulatory authorities&#8217; inacceptance of data from trials conducted outside their jurisdiction</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our inability to obtain and maintain regulatory approval of our product candidates in various jurisdictions</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">burdens related to post-marketing regulatory requirements and oversight of our product candidates</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">impacts of regulatory authorities&#8217; enforcement of laws and regulations prohibiting promotion of off-label uses</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">challenges related to FDA approval of required companion diagnostic tests</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">challenges related to our ability to obtain Fast Track designation from the FDA for our product candidates</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">limitations to our ability to obtain orphan drug designation or maintain orphan drug exclusivity for our product candidates&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any delays or barriers to secure approval for accelerated registration pathways</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">changes to current regulations and future legislation that impact us adversely</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">inadequate funding of regulatory agencies that may hinder timely product development or commercialization</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential misconduct or noncompliance with regulatory standards by our employees and certain third parties </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any potential incompliance with U.S. healthcare laws and requirements</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any potential incompliance with environmental, health and safety laws and regulations</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any potential incompliance with anti-bribery, anti-corruption, export, trade sanctions and import laws or regulations </span></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to employee matters and management of our growth</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">challenges to our ability to attract and retain highly skilled executive officers and employees</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">difficulties in our ability to sell or market our product candidates</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our potential inability to grow and manage growth of our organization</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">security or data privacy breaches of our internal systems or those of commercial third parties</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">natural disasters and other catastrophic events that may cause damage or disruption</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">investigation of two of our officers by the Securities and Exchange Commission</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our potential inability to use our net operating losses and tax credits to offset future taxable income</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">U.S. federal income tax reform and additional effort and expenses incurred as a result</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">complexities related to international marketing of our product candidates </span></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to intellectual property</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">challenges to our ability to protect our intellectual property and proprietary technologies</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the potentially narrow scope of patent protection we receive</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential threats to our competitive advantage</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">our ability to operate without infringing intellectual property rights and claims of infringement by third parties </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our potential inability to obtain or maintain rights to our product candidates through acquisitions and in-licenses</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">costs associated with protecting or enforcing our patents and our licensors&#8217; patents</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">intellectual property litigation that may lead to unfavorable publicity</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">unfavorable outcomes from necessary derivation proceedings</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">patent reform legislation and related uncertainties and costs</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">changes in U.S. and international intellectual property laws and related challenges </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">claims challenging ownership of our intellectual property, including internationally</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">patent terms and access to extensions that may not adequately protect our competitive position</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our patent protection and dependence on compliance with various regulations</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potentially limited name recognition in our markets that depend on protection of our trademarks and trade names</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">difficulties in protecting confidentiality of our trade secrets</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">claims of wrongful disclosure of our confidential information or trade secrets</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">claims of wrongful hiring or disclosure or use of competitors&#8217; confidential information or trade secrets</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our product development and commercialization rights that are subject to unfavorable terms and conditions of licensors </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential business relationship disruptions due to failure to comply with license agreement obligations </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our patent protection and prosecution that may be dependent on third parties</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">intellectual property discovered through government funding and potential limits on our exclusive rights </span></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to dependence on third parties</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our dependence on third parties for production, preclinical studies and clinical trials of our product candidates</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">acquisitions or strategic partnerships that may increase capital requirements, dilution and debt</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">failure to establish commercially reasonable collaborations</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">difficulties related to collaborations for development and commercialization of product candidates</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to the securities markets and ownership of our common stock</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">market conditions and price that may limit your ability to sell our common stock</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the volatility of our stock price</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">adverse or misleading industry analyst publications regarding our business or market </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">significant fluctuations in our operating results</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">principal stockholders and management that may exert significant control over stockholder approval matters</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">large sales of our stock that could cause our stock price to fall</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">limitations related to our status as an emerging growth company and our transition after such status</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">failure of our internal controls that could impair our ability to produce accurate financial statements</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">limitations of our disclosure controls and procedures</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">liabilities related to securities litigation</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our intention not to pay dividends</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">provisions of our certificate of incorporation and bylaws that may prevent or delay a change in control</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">exclusive forum provisions in our bylaws that may limit stockholder ability to obtain a favorable judicial forum</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our financial position and need for additional capital</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history, have not initiated or completed any large-scale or pivotal clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2014, have no products approved for commercial sale and have not generated any revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. In 2019, we initiated our first two Phase 1b clinical trials for our lead product candidate, ORIC-101, and have not initiated clinical trials for any other product candidate. To date, we have devoted substantially all of our resources to research and development activities, including with respect to our GR antagonist and CD73 inhibitor programs and other preclinical programs, in-licensing of external programs, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet demonstrated our ability to successfully initiate and complete any large-scale or pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our likelihood of success and viability than it could be if we had a longer operating history.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We have not yet demonstrated an ability to successfully overcome such risks and difficulties, or to make such a transition. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant net losses since our inception, and we expect to continue to incur significant net losses for the foreseeable future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant net losses since our inception, have not generated any revenue from product sales to date and have financed our operations principally through private placements of our convertible preferred stock and the sale of our common stock in our initial public offering (IPO) in April 2020 and our public offering in November 2020. Our net loss was $73.7 million for the year ended December 31, 2020, and as of December 31, 2020, we had an accumulated deficit of $166.4&#160;million. Our lead product candidate, ORIC-101, is in early-stage clinical trials, and we plan on filing an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for our product candidate, ORIC-533, in the first half of 2021, an IND for our newly licensed product candidate, ORIC-944, in the second half of 2021, and a Clinical Trial Application (CTA) for our newly licensed product candidate, ORIC-114, in the second half of 2021. Our other programs are in preclinical discovery and research stages. As a result, we expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses in order to discover, develop and market additional potential products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business depends entirely on the successful discovery, development and commercialization of product candidates. We have no products approved for commercial sale and do not anticipate generating any revenue from product sales for the next several years, if ever. Our ability to generate revenue and achieve profitability depends significantly on our ability, or any current or future collaborator&#8217;s ability, to achieve several objectives, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">successful and timely completion of preclinical and clinical development of ORIC-101, ORIC-533, ORIC-944, ORIC-114 and our other future product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">establishing and maintaining relationships with contract research organizations (CROs) and clinical sites for the clinical development of ORIC-101, ORIC-533, ORIC-944, ORIC-114 and our other future product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">developing an efficient and scalable manufacturing process for our product candidates, including obtaining finished products that are appropriately packaged for sale&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for our product candidates, if approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">a continued acceptable safety profile following any marketing approval of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">commercial acceptance of our product candidates by patients, the medical community and third-party payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">satisfying any required post-marketing approval commitments to applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">identifying, assessing and developing new product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">protecting our rights in our intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">defending against third-party interference or infringement claims, if any&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">obtaining coverage and adequate reimbursement by third-party payors for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">addressing any competing therapies and technological and market developments&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">attracting, hiring and retaining qualified personnel.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for, ORIC-101 and advance our other programs. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency (EMA) or other regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. We have not yet met with the FDA to discuss any of our product candidates or development programs, and we are not permitted to market or promote ORIC-101, or any other product candidate, before we receive marketing approval from the FDA. Accordingly, we will need to obtain substantial additional funding in order to continue our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had $293.6 million in cash, cash equivalents and short-term investments. In April 2020, we received $138.0 million of gross proceeds from the issuance of common stock upon the completion of our IPO. After deducting underwriting discounts and commissions and other offering expenses of $12.8 million, the net proceeds we received from our IPO were approximately $125.2 million. In November 2020, we received $133.3 million of gross proceeds from the issuance of common stock upon the completion of a follow-on offering. After deducting underwriting discounts and commissions and other offering expenses of $8.5 million, the net proceeds we received from the transaction were approximately $124.8 million. Based on our current operating plan, we believe that our existing cash, cash equivalents and short-term investment will be sufficient to fund our operations into the second half of 2023. Our estimate as to how long we expect our existing cash, cash equivalents, and short-term investments, to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to the discovery, development and commercialization of our product candidates</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are substantially dependent on the success of our lead product candidate, ORIC-101, which is currently in early stage clinical trials. If we are unable to complete development of, obtain approval for and commercialize ORIC-101 for one or more indications in a timely manner, our business will be harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success is dependent on our ability to timely and successfully complete clinical trials, obtain marketing approval for and successfully commercialize ORIC-101, our lead product candidate. We are investing the majority of our efforts and financial resources in the research and development of ORIC-101 for multiple indications. ORIC-101 is a potent and selective small molecule antagonist of GR, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors.&#160;In 2019, we initiated a Phase 1b clinical trial evaluating ORIC-101 in combination with nab-paclitaxel in patients with advanced or metastatic solid tumors. In the fourth quarter of 2019, we also initiated a Phase 1b clinical trial evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide. Prior to these two Phase 1b trials, ORIC-101 has only been studied in two Phase&#160;1a trials in healthy volunteers. ORIC-101 will require additional clinical development, expansion of manufacturing capabilities, marketing approval from government regulators, substantial investment and significant marketing efforts before we can generate any revenues from product sales. We are not permitted to market or promote ORIC-101, or any other product candidate, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of ORIC-101 will depend on several factors, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the successful and timely completion of our ongoing clinical trials of ORIC-101&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">addressing any delays in our clinical trials and additional costs incurred as a result of the coronavirus-19 (COVID-19) pandemic, including those resulting from preclinical study delays and adjustment to our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the initiation and successful patient enrollment and completion of additional clinical trials of ORIC-101 on a timely basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">maintaining and establishing relationships with CROs and clinical sites for the clinical development of ORIC-101 both in the United States and internationally&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the frequency and severity of adverse events in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">demonstrating efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timely receipt of marketing approvals for ORIC-101 from applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timely identification, development and approval of companion diagnostic tests, if required&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the extent of any required post-marketing approval commitments to applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development and, if approved, commercialization of ORIC-101&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the protection of our rights in our intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the successful launch of commercial sales following any marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">a continued acceptable safety profile following any marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">commercial acceptance by patients, the medical community and third-party payors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to compete with other therapies.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize ORIC-101, which would materially harm our business. If we do not receive marketing approvals for ORIC-101, we may not be able to continue our operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">In addition to ORIC-101, our prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates other than ORIC-101. All of our current programs other than ORIC-101, including ORIC-533, ORIC-944 and ORIC-114, are in research or preclinical development. A product candidate can unexpectedly fail at any stage of preclinical and/or clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of other product candidates we may develop will depend on many factors, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">generating sufficient data to support the initiation or continuation of clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">addressing any delays in our research programs resulting from factors related to the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">obtaining regulatory permission to initiate clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">contracting with the necessary parties to conduct clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">successful enrollment of patients in, and the completion of, clinical trials on a timely basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timely manufacture of sufficient quantities of a product candidate for use in clinical trials&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">adverse events in clinical trials.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk factors&#8221; section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from any product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our product candidates, the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested or may impose other prescribing limitations or warnings that limit the product&#8217;s commercial potential. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our product candidates will ever obtain regulatory approval. Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, are only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that our product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the FDA, EMA or other comparable regulatory authorities may fail to approve companion diagnostic tests that are required for our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive results.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate with substantial evidence the safety and efficacy of such product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent receipt of marketing approval or our ability to commercialize our product candidates, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">receipt of feedback from regulatory authorities that requires us to modify the design of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">negative or inconclusive clinical trial results that may require us to conduct additional clinical trials or abandon certain drug development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the number of patients required for clinical trials being larger than anticipated, enrollment in these clinical trials being slower than anticipated or participants dropping out of these clinical trials at a higher rate than anticipated&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the suspension or termination of our clinical trials for various reasons, including non-compliance with regulatory requirements or a finding that our product candidates have undesirable side effects or other unexpected characteristics or risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the cost of clinical trials of our product candidates being greater than anticipated&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates being insufficient or inadequate&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">regulators revising the requirements for approving our product candidates.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may incur unplanned costs, be delayed in seeking and obtaining marketing approval, if we receive such approval at all, receive more limited or restrictive marketing approval, be subject to additional post-marketing testing requirements or have the drug removed from the market after obtaining marketing approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in study ORIC-GR-17001, there were two Grade 1 adverse events: pain in the extremity and nausea. Both were mild, attributed to ORIC-101 and resolved without treatment. In study ORIC-GR-17002, Part A, the most commonly reported treatment-emergent adverse events were mild gastrointestinal adverse events. These were observed in two participants and consisted of Grade 1 nausea in one subject and Grade 1 nausea, abdominal pain, and diarrhea in a second subject. They were resolved without treatment. In study ORIC-GR-17002, Part B, the most common adverse events were gastrointestinal in nature and were deemed related to ORIC-101.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in our Phase 1b trial of ORIC-101 in combination with nab-paclitaxel in advanced or metastatic solid tumors, two patients experienced dose-limiting toxicity (DLT) during the first cycle of treatment. Specifically, one patient experienced Grade 3 fatigue and discontinued treatment after two weeks on study. A second patient with advanced pancreatic cancer that had metastasized to the liver experienced Grade 4 neutropenia and thrombocytopenia and Grade 5 hepatic failure in the setting of rapid disease progression. A CT scan of the patient&#8217;s abdomen on study Day 9 demonstrated disease progression, and the patient died on study Day&#160;12. These toxicities are well-described for nab-paclitaxel (including reports of hepatic necrosis and hepatic encephalopathy leading to death). After review of safety and PK data from Dose Level&#160;1 by the study&#8217;s Safety Review Committee (SRC), it was determined that Dose Level&#160;1 exceeded the maximum tolerated doses of the combination of ORIC-101 and nab-paclitaxel. The protocol was amended and following FDA review and Institutional Review Board (IRB) approvals, three new patients were enrolled to the revised new Dose Level 1A. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients in our ongoing and planned clinical trials may in the future suffer other significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials. ORIC-101 or other product candidates may be used in populations for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, ORIC-101 is being studied in combination with other therapies, which may exacerbate adverse events associated with the therapy. Patients treated with ORIC-101 or our other product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. For example, it is expected that some of the patients enrolled in our ORIC-101 clinical trials will die or experience major clinical events either during the course of our clinical trials or after participating in such trials, which has occurred in the past.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, EMA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates previously not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early stage clinical trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Success in preclinical studies and early-stage clinical trials does not mean that future clinical trials will be successful. For instance, we do not know whether ORIC-101 will perform in current or future clinical trials as ORIC-101 has performed in preclinical studies or prior clinical trials, nor do we know whether ORIC-533, ORIC-944 or ORIC-114 will perform in current or future preclinical studies or future clinical trials as they have in prior preclinical studies. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. Additionally, while we are aware of several other clinical-stage GR antagonists being developed by Corcept Therapeutics, to our knowledge, there are no GR antagonists approved for the treatment of cancer and the most advanced GR antagonist in development for cancer is in a Phase 2 trial for ovarian cancer and a Phase 3 trial for metastatic pancreatic ductal adenocarcinoma. As such, the development of ORIC-101 and our stock price may be impacted by inferences, whether correct or not, that are drawn between the success of our product candidate and those of Corcept Therapeutics or other companies. Additionally, prior to our two Phase 1b trials, ORIC-101 was only studied in two Phase 1a trials in healthy volunteers. Regulatory authorities may also limit the scope of later-stage trials until we have demonstrated satisfactory safety, which could delay regulatory approval, limit the size of the patient population to which we may market our product candidates, or prevent regulatory approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain approval to market any of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as the interim data from our Phase 1b clinical trial of ORIC-101. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, we may report tumor responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, ORIC-101 or any other product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adverse results of clinical trials conducted by third parties investigating the same product candidates as us in different territories could adversely affect our development of such product candidate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of efficacy, adverse events, undesirable side effects or other adverse results may emerge in clinical trials conducted by third parties investigating the same product candidates as us in different territories. For example, pursuant to the Voronoi License Agreement, Voronoi retains the right to develop and commercialize the same compounds licensed to us, after a certain period, as specified in the Voronoi License Agreement, including the compound we refer to as ORIC-114, in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan and, subject to certain restrictions, to collaborate with others for such development and commercialization. We do not have control over Voronoi&#8217;s clinical trials or development program, and adverse findings from or Voronoi&#8217;s conduct of clinical trials could adversely affect our development of ORIC-114 or even the viability of ORIC-114 as a product candidate. We may be required to report Voronoi&#8217;s adverse events or unexpected side effects to the FDA or comparable foreign regulatory authorities, which could, among other things, order us to cease further development of ORIC-114.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA, EMA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. For instance, we have developed a proprietary immunohistochemistry (IHC) assay that measures GR protein expression levels as well as a proprietary GR gene activation signature that measures GR signaling activity, both of which are being utilized in our ongoing clinical trials and may be used for patient selection in future clinical trials, and utilizing such biomarker-driven identification and/or certain highly specific criteria related to the stage of disease progression may limit patient populations eligible for our clinical trials. Additionally, our approach of identifying and selecting a subset of patients more likely to benefit from ORIC-101 by measuring levels of GR expression or gene activity is, to our knowledge, untested in oncology. If these strategies for patient identification prove unsuccessful, we may have difficulty enrolling or maintaining patients appropriate for ORIC-101.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment of patients in our clinical trials and maintaining patients in our ongoing clinical trials may be delayed or limited as our clinical trial sites limit their onsite staff or temporarily close as a result of the COVID-19 pandemic. For instance, we are aware of certain ORIC-101 clinical trial sites that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">temporarily stopped or delayed enrolling new patients in response to the COVID-19 pandemic. In addition, patients may not be able to visit clinical trial sites for dosing or data collection purposes due to limitations on travel and physical distancing imposed or recommended by federal or state governments or patients&#8217; reluctance to visit the clinical trial sites during the pandemic. These factors resulting from the COVID-19 pandemic could delay the anticipated readouts from our ORIC-101 clinical trials and our regulatory submissions.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment may be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; programs. Patient enrollment for our current or any future clinical trials may be affected by other factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">size and nature of the patient population&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">severity of the disease under investigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">availability and efficacy of approved drugs for the disease under investigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">patient eligibility criteria for the trial in question as defined in the protocol&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">perceived risks and benefits of the product candidate under study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved or other product candidates being investigated for the indications we are investigating&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">clinicians&#8217; willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">patient referral practices of physicians&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the ability to monitor patients adequately during and after treatment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">proximity and availability of clinical trial sites for prospective patients&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operations and financial results could be adversely impacted by the COVID-19 pandemic in the United States and the rest of the world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, COVID-19 was reported to have surfaced in Wuhan, China, resulting in significant disruptions to Chinese manufacturing and travel. COVID-19 has now spread to numerous other countries, including extensively within the United States, resulting in the World Health Organization characterizing COVID-19 as a pandemic. As a result of measures imposed by the governments in affected regions, many commercial activities, businesses and schools have been suspended as part of quarantines and other measures intended to contain this pandemic. As the COVID-19 pandemic continues to spread around the globe, we may experience disruptions that could severely impact our business and clinical trials, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">interruption of key research and discovery or other activities related to any impact of COVID-19 contraction by or transmission among our employees, including those that are essential workers and work within our laboratory&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">delays or difficulties in enrolling patients in our clinical trials, or those conducted by third parties, and further incurrence of additional costs as a result of preclinical study and clinical trial delays and adjustments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">challenges related to ongoing and increased operational expenses related to the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">limitations in resources that would otherwise be focused on the conduct of our business or our clinical trials, including because of sickness or the desire to avoid contact with large groups of people or as a result of government-imposed &#8220;shelter in place&#8221; or similar working restrictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, or to discontinue the clinical trials altogether, or which may result in unexpected costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to assess the impact that COVID-19 may have on our ability to effectively conduct our business operations as planned and there can be no assurance that we will be able to avoid a material impact on our business from the spread of COVID-19 or its consequences, including disruption to our business and downturns in business sentiment generally or in our industry. For example, on March&#160;16, 2020, San Mateo County issued a &#8220;shelter-in-place&#8221; order, effective March&#160;17, 2020, and on March&#160;19, 2020, the Executive Department of the State of California issued Executive Order N-33-20, ordering all individuals in the State of California to stay home or at their place of residence except as needed to maintain continuity of operations of the federal critical infrastructure sectors. Furthermore, on May&#160;28, 2020, San Mateo County announced an extension of its &#8220;shelter in place&#8221; order, which is effective until further notice. On June&#160;17, 2020, San Mateo County issued a new Safer Community Order, which rescinded and replaced the &#8220;shelter in place&#8221; order and requires businesses to implement social distancing protocols and a written health and safety plan, among other things, for reopening. Should COVID-19 cases in California continue to increase, the country or state may re-institute a &#8220;shelter in place&#8221; order at any time. On June&#160;19, 2020, the FDA also issued new guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in biopharmaceutical products manufacturing. Our primary operations are located in South San Francisco and San Diego. As a result of such county and California state orders and FDA guidance, the majority of our employees are currently telecommuting, and due to modified schedules and work protocols to enable adequate physical distancing, our laboratory operations are currently operating with decreased efficiency, which may impact certain of our operations over the near term and long term. Disruptions caused by the COVID-19 pandemic have also resulted in the incurrence of increased operational expenses. Should these developments continue or worsen, our operations and our program timelines may be negatively impacted and could result in the incurrence of additional costs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, certain third parties with whom we engage, including our collaborators, contract organizations, third party manufacturers, suppliers, clinical trial sites, regulators and other third parties with whom we conduct business are similarly adjusting their operations and assessing their capacity in light of the COVID-19 pandemic. If these third parties experience shutdowns or continued business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. For example, as a result of the COVID-19 pandemic, there could be delays in the manufacturing supply chain for ORIC-101, which could delay or otherwise impact our ORIC-101 clinical program. We may also experience delays in procurement of materials for certain of our ongoing or planned studies of ORIC-533, ORIC-944 or ORIC-114 due to the pandemic, which could impact our ability to file an IND in the first half of 2021 and the second half of 2021, respectively. Additionally, certain preclinical studies for our discovery research programs are conducted by CROs or academic institutions, some of which have temporarily stopped or delayed operations in light of COVID-19. These disruptions could negatively impact the timelines of our preclinical programs. It is also likely that the disproportionate impact of COVID-19 on hospitals and clinical sites will have an impact on recruitment and retention for our clinical trials. For instance, we are aware of certain ORIC-101 clinical trial sites that have temporarily stopped or delayed enrolling new patients in response to the COVID-19 pandemic. In addition, certain of our clinical trial sites have experienced, and others may experience in the future, delays in collecting, receiving and analyzing data from patients enrolled in our clinical trials for ORIC-101 due to limited staff at such sites, limitation or suspension of on-site visits by patients, or patients&#8217; reluctance to visit the clinical trial sites during the pandemic. We and our CROs have also made certain adjustments to the operation of such trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA on March&#160;18, 2020 and generally, and may need to make further adjustments in the future, including adjustments based on recently issued FDA guidance on manufacturing, supply chain, and pharmaceutical product inspections&#59; resuming normal pharmaceutical manufacturing operations&#59; and updates on conducting clinical trials during the COVID-19 public health emergency. Many of these adjustments are new and untested, may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials. While we are currently continuing our clinical trials and seeking to add new clinical trial sites, we may not be successful in adding trial sites, may experience delays in patient enrollment or in the progression of our clinical trials, may need to suspend our clinical trials, and may encounter other negative impacts to our trials, due to the effects of the COVID-19 pandemic.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global outbreak of COVID-19 continues to rapidly evolve, with particularly significant case increases in the United States. While the extent of the impact of the current COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition and operating results.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the COVID-19 pandemic adversely affects our business, financial condition and operating results, it may also have the effect of heightening many of the risks described in this &#8220;Risk factors&#8221; section.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to successfully develop companion diagnostic tests for our product candidates, experience significant delays in doing so, or rely on third parties in the development of such companion diagnostic tests, we may not realize the full commercial potential of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exploring predictive biomarkers to determine patient selection for our clinical trials. Specifically, to help inform which patients may be most suitable for treatment with ORIC-101, we have developed a proprietary IHC assay that measures GR protein expression levels as well as a proprietary GR gene activation signature that measures GR signaling activity, both of which are being utilized in our ongoing clinical trials and may be used for patient selection in future clinical trials. If either of these approaches proves to be a useful method for patient selection, we expect to incorporate the specific diagnostic test into our registrational studies and partner with the appropriate diagnostic provider to co-develop a companion diagnostic. In general, the FDA expects to review and approve simultaneously NDA and pre-market approval (PMA) submissions for a therapeutic and its companion diagnostic, respectively, so any delay in diagnostic approval could delay drug approval. On April&#160;13, 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance and future issuances from the FDA and other regulatory authorities may impact our development of a companion diagnostic for our product candidates and result in delays in regulatory approval. We may be required to conduct additional studies to support a broader claim. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include our approved drug products, we may be forced to abandon our companion diagnostic development plans or we may not be able to compete effectively upon approval, which could adversely impact our ability to generate revenue from the sale of our approved products and our business operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates that require such tests. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. If we or such third parties are unable to successfully develop companion diagnostics, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of our product candidates may be adversely affected or we may not obtain marketing approval, and we may not realize the full commercial potential of our product candidates, including ORIC-101.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to develop ORIC-101 and potentially other programs in combination with other therapies, which exposes us to additional risks.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to develop ORIC-101 and potentially other programs, in combination with one or more currently approved cancer therapies or therapies in development. In 2019, we initiated a Phase 1b clinical trial evaluating ORIC-101 in combination with nab-paclitaxel in patients with advanced or metastatic solid tumors. In 2019, we also initiated a Phase 1b clinical trial evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer. Patients may not be able to tolerate ORIC-101 or any of our other product candidates in combination with other therapies or dosing of ORIC-101 in combination with other therapies may have unexpected consequences. Even if any of our product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also evaluate our product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA, EMA or other comparable foreign regulatory authorities do not approve or revoke their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with ORIC-101 or any other product candidate, we may be unable to obtain approval of or successfully market any one or all of the product candidates we develop.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if the third-party providers of therapies or therapies in development used in combination with our product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. For example, for our Phase 1b trial of ORIC-101 in combination with enzalutamide in prostate cancer, we entered into a clinical trial collaboration and supply agreement with Astellas. Under the terms of the clinical trial collaboration and supply agreement, Astellas, which jointly commercializes enzalutamide in the United States with Pfizer, is providing enzalutamide for the trial. If this agreement terminates and we are unable to obtain enzalutamide on the current terms, the cost to us to conduct this trial may significantly increase.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited resources and are currently focusing our efforts on developing ORIC-101 for particular indications and advancing our preclinical programs. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focusing our resources and efforts on developing ORIC-101 for particular indications and advancing our preclinical programs. As a result, because we have limited resources, we may forgo or delay pursuit of opportunities for other indications or with other product candidates that may have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development activities for ORIC-101, ORIC-533, ORIC-944, ORIC-114 and other preclinical programs, may not yield any commercially viable drugs. If we do not accurately evaluate the commercial potential or target markets for ORIC-101, ORIC-533, ORIC-944, ORIC-114 or any of our other programs, we may relinquish valuable rights to that product candidate or program through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate or program.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our products may need to compete with drugs physicians use off-label to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, there is intense competition in the field of oncology. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates. We expect to face competition from existing products and products in development for each of our programs. For ORIC-101, we are aware of several other clinical-stage GR antagonists being developed by Corcept Therapeutics. To our knowledge, there are no GR antagonists approved for the treatment of cancer and the most advanced GR antagonist in development for cancer is in a Phase&#160;3 clinical trial. For ORIC-533, we are aware of several companies developing antibodies against this target, including AstraZeneca, Bristol-Myers Squibb, Novartis in collaboration with Surface Oncology, Incyte Corporation, Corvus Pharmaceuticals, Innate Pharma, Tracon Pharmaceuticals in collaboration with I-Mab Biopharma, Gilead Sciences, Akeso and Symphogen. Other companies, such as Eli Lilly and Company, Arcus Biosciences, Calithera Biosciences and Merck through its acquisition of Peloton Therapeutics, have small-molecule programs against this target. To our knowledge, only Eli Lilly has an orally available, small molecule CD73 inhibitor in a clinical trial for patients with cancer. For ORIC-944, we are aware of several companies developing inhibitors against PRC2 via EZH2 inhibition that are currently in clinical trials, including Epizyme, Constellation Pharmaceuticals, Daiichi Sankyo, Pfizer, Shanghai HaiHe Pharmaceutical and Jiangsu Hengrui Medicine Co. To our knowledge, only Novartis has an allosteric PRC2 inhibitor in a clinical trial for patients with cancer. For ORIC-114, we are aware of several companies developing inhibitors against exon 20 insertion mutations that are currently in clinical trials, including Takeda, Spectrum Pharmaceuticals, The Janssen Pharmaceutical Companies of Johnson &#38; Johnson, Rain Therapeutics, Dizal Pharmaceuticals Co., Ltd., Cullinan Oncology and Black Diamond Therapeutics. Many of these current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources, and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA, EMA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, as well as sophisticated quality assurance and quality control procedures. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our third-party manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example, we may introduce an alternative formulation of ORIC-101 into the dose expansion phases of our ongoing Phase 1b clinical trials. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing of market introduction of the product candidate as well as competitive products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the clinical indications for which a product candidate is approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">restrictions on the use of product candidates in the labeling approved by regulatory authorities, such as boxed warnings or contraindications in labeling, or a risk evaluation and mitigation strategy, if any, which may not be required of alternative treatments and competitor products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the potential and perceived advantages of our product candidates over alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the cost of treatment in relation to alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the availability of coverage and adequate reimbursement by third-party payors, including government authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the availability of an approved product candidate for use as a combination therapy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">relative convenience and ease of administration&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">the willingness of the target patient population to try new therapies and undergo required diagnostic screening to determine treatment eligibility and of physicians to prescribe these therapies and diagnostic tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the effectiveness of sales and marketing efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">unfavorable publicity relating to our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the approval of other new therapies for the same indications.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunities for ORIC-101 and other product candidates we develop, if approved, may be limited to certain smaller patient subsets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only for a particular line of use. When cancer is detected early enough, first-line therapy, such as chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. Our current clinical trials for ORIC-101 are with patients who have received one or more prior treatments. There is no guarantee that product candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials that may be costly, time-consuming and subject to risk.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of patients who have the cancers we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for ORIC-101 and other product candidates we develop, including as a result of the selection of patients with specific biomarkers, levels of GR expression or gene activity, may be limited or may not be amenable to treatment with our product candidates. We have developed a proprietary IHC assay that measures GR protein expression levels as well as a proprietary GR gene activation signature that measures GR signaling activity, both of which are being utilized in our ongoing clinical trials and may be used for patient selection in future clinical trials. We are continuing to evaluate the appropriate levels of GR protein overexpression for determining which patients may be eligible for treatment. Regulatory approval may limit the market of a product candidate to target patient populations when such biomarker-driven identification and/or highly specific criteria related to the stage of disease progression are utilized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain significant market share for any approved product, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in augmenting our product pipeline through acquisitions and&#160;in-licenses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that accessing external innovation and expertise is important to our success&#59; and while we plan to leverage our leadership team&#8217;s prior business development experience as we evaluate potential in-licensing and acquisition opportunities to further expand our portfolio, we may not be able to identify suitable licensing or acquisition opportunities, and even if we do, we may not be able to successfully secure such licensing and acquisition opportunities. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully license or acquire additional product candidates to expand our portfolio, our pipeline, competitive position, business, financial condition, results of operations, and prospects may be materially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of such product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare&#160;&#38; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA, EMA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to regulatory approval and other legal compliance matters</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are and will continue to be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be approved for marketing. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can, and often does, change during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA policy during the period of drug development, clinical trials and FDA regulatory review.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from any particular product candidates we are developing and for which we are seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market, promote and advertise the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategy (REMS) plan as part of approving an NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ongoing clinical trials are being undertaken in the United States. We may choose to conduct additional clinical trials internationally. For example, we conducted a Phase 1a healthy volunteer trial of ORIC-101 in the United Kingdom. The acceptance of study data by the FDA, EMA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries outside the United States, the standards for clinical trials and approval may be different. There can be no assurance that any United States or foreign regulatory authority would accept data from trials conducted outside of its applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brexit and uncertainty in the regulatory framework as well as future legislation in the UK, European Union, and other jurisdictions can lead to disruption in the execution of international multi-center clinical trials, the monitoring of adverse events through pharmacovigilance programs, the evaluation of the benefit-risk profiles of new medicinal products, and determination of marketing authorization across different jurisdictions. Uncertainty in the regulatory framework could also result in disruption to the supply and distribution as well as the import/export both of active pharmaceutical ingredients and finished product. Such a disruption could create supply difficulties for ongoing clinical trials. The cumulative effects of the disruption to the regulatory framework, uncertainty in future regulation, and changes to existing regulations may increase our development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom and increase our costs. We cannot predict the impact of such changes and future regulation on our business or the results of our operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential product candidates will be harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and on-going surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements and regulatory inspection. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with current good manufacturing practices (cGMPs) and good clinical practices (GCPs) for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA, EMA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">delays in or the rejection of product approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">restrictions on the products, manufacturers or manufacturing process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">warning or untitled letters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">civil and criminal penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">injunctions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">suspension or withdrawal of regulatory approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">product seizures, detentions or import bans&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">voluntary or mandatory product recalls and publicity requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">total or partial suspension of production&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">imposition of restrictions on operations, including costly new manufacturing requirements.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates, if approved, and generate revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. For example, if we receive marketing approval for ORIC-101 as a treatment for metastatic prostate cancer, physicians may nevertheless use our product for their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates or a group of therapeutic products, and we do not obtain or we face delays in obtaining FDA approval of a diagnostic test, we will not be able to commercialize the product candidate and our ability to generate revenue will be materially impaired.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To help inform which patients may be most suitable for treatment with ORIC-101, we have developed a proprietary IHC assay that measures GR protein expression levels as well as a proprietary GR gene activation signature that measures GR signaling activity, both of which are being utilized in our ongoing Phase 1b clinical studies and may be used for patient selection in future clinical studies. Additionally, in connection with development of our potential product candidates, we may develop or work with collaborators to develop or obtain access to companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our programs. Such companion diagnostics would be used during our clinical trials as well as in connection with the commercialization of our product candidates. To be successful in developing and commercializing product candidates in combination with these companion diagnostics, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared at the same time the product candidate is approved. To date, the FDA has required marketing approval of all companion diagnostic tests for cancer therapies. Various foreign regulatory authorities also regulate <span style="font-style:italic;">in vitro</span> companion diagnostics as medical devices and, under those regulatory frameworks, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of our current diagnostics and any future diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express certain biomarkers or the specific genetic alteration that the companion diagnostic was developed to detect. If the FDA, EMA or a comparable regulatory authority requires approval of a companion diagnostic for any of our product candidates, whether before or concurrently with approval of the product candidate, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval or continued marketing of our related product candidates. Further, in April 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance and future issuances from the FDA and other regulatory authorities may impact our development of a companion diagnostic for our product candidates and result in delays in regulatory approval. We may be required to conduct additional studies to support a broader claim. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include our approved drug products, we may be forced to abandon our companion diagnostic development plans or we may not be able to compete effectively upon approval, which could adversely impact our ability to generate revenue from the sale of our approved products and our business operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of our product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek Fast Track designation from the FDA for one or more of our product candidates. Even if one or more of our product candidates receive Fast Track designation, we may be unable to obtain or maintain the benefits associated with the Fast Track designation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation is designed to facilitate the development and expedite the review of therapies for serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the product candidate and the specific indication for which it is being studied. If any of our product candidates receive Fast Track designation but do not continue to meet the criteria for Fast Track designation, or if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Our target indications may include diseases with large patient populations or may include orphan indications. However, there can be no assurances that we will be able to obtain orphan designations for our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity in the United States provides that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances. The applicable exclusivity period is 10 years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug designation for a product candidate, we may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to ensure that we will be able to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval process or entitles the product candidate to priority review.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Where appropriate, we plan to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated registration pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated approval pathway for our one or more of our product candidates. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to seeking such accelerated approval, we will seek feedback from the FDA and will otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under another expedited regulatory designation (e.g., breakthrough therapy designation), there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may face difficulties from changes to current regulations and future legislation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and continues to significantly impact the U.S. pharmaceutical industry. Since its enactment, there have been legislative and judicial efforts to repeal, replace, or change some or all of the ACA. For example, various portions of the ACA have been subject to legal and constitutional challenges in the Fifth Circuit Court and the United States Supreme Court. The Supreme Court held oral arguments on the Fifth Circuit Court case in November 2020 and is expected to issue a decision by mid-2021. It is unclear how this Supreme Court decision, future litigation, and healthcare measures promulgated by the Biden administration will impact the implementation of the PPACA, our business, financial condition and results of operations. Complying with any new legislation or reversing changes implemented under the PPACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April&#160;1, 2013, which will stay in effect through 2030, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2021, unless additional congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, HHS and CMS issued final rules in November and December of 2020 that were expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiple lawsuits have been brought against the HHS challenging various aspects of the rules. The</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Biden administration </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has also </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">implemented a regulatory rule freeze for all federal agency rules that had not gone into effect as of January 20, 2021. The impact of these </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lawsuits as well as legislative, executive, and administrative actions of the current</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> administration on us and the pharmaceutical industry as a whole is currently unknown. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. These and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, on May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (Right to Try Act), was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its products available to eligible patients as a result of the Right to Try Act.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. It is also possible that additional governmental action is taken to address the COVID-19 pandemic.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the collection and use of health data in the European Union is governed by the General Data Protection Regulation&#160;(GDPR), which extends the geographical scope of European Union data protection law to non-European Union entities under certain conditions and imposes substantial obligations upon companies and new rights for individuals. Failure to comply with the GDPR and the applicable national data protection laws of the EU Member States may result in fines up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we may process, and we may be required to put in place additional mechanisms in an effort to comply with the GDPR. This may be onerous and if our efforts to comply with GDPR or other applicable European Union laws and regulations are not successful, it could adversely affect our business in the European Union. Further, the European Court of Justice (ECJ) recently invalidated the EU-U.S. Privacy Shield, which had enabled the transfer of personal data from the EU to the U.S. for companies that had self-certified to the Privacy Shield. To the extent that we were to rely on Privacy Shield, we will not be able to do so in the future, and the ECJ&#8217;s decision otherwise may impose additional obligations with respect to the transfer of personal data from the EU to the U.S., each of which could increase our costs and obligations and impose limitations upon our ability to efficiently transfer personal data from the EU to the U.S.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the decision of the United Kingdom (UK) to leave the EU, often referred to as Brexit, has created uncertainty regarding data protection regulation in the UK. In particular, while the UK has implemented legislation that implements and complements the GDPR, with penalties for noncompliance of up to the greater of &#163;17.5 million or four percent of worldwide revenues, aspects of data protection regulation in the UK, including with respect to cross-border data transfers, remain unclear in the medium to longer term following Brexit. The UK&#8217;s relationship with the EU may, for example, require us to implement additional safeguards relating to transfers of personal data from the EU to the UK, which may require us to incur significant costs and expenses in an effort to do so. More generally, we may incur liabilities, expenses, costs, and other operational losses under GDPR and the privacy and data protection laws of applicable EU member states and the United Kingdom in connection with any measures we take to comply with them.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, state and foreign laws may apply generally to the privacy and security of information we maintain, and may differ from each other in significant ways, thus complicating compliance efforts. For example, the California Consumer Privacy Act of 2018 (CCPA), which took effect on January&#160;1, 2020, gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. In addition, the CCPA (a)&#160;allows enforcement by the California Attorney General, with fines set at $2,500 per violation (i.e., per person) or $7,500 per intentional violation and (b)&#160;authorizes private lawsuits to recover statutory damages for certain data breaches. While it exempts some data regulated by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and certain clinical trials data, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. Some observers note that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Additionally, a new privacy law, the California Privacy Rights Act (CPRA), </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved by California voters</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in November 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he CPRA significantly modif</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ied</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the CCPA, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which may require</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> us to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modify our practices </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and policies and may further increase our compliance</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> costs and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential liability.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission (SEC) and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to significant losses, including, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, as well as market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations may include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties laws, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations, also imposes obligations, including mandatory contractual terms, on covered entities, which are health plans, healthcare clearinghouses, and certain health care providers, as those terms are defined by HIPAA, and their respective business associates, with respect to safeguarding the privacy, security and transmission of individually identifiable health information&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. </span><span style="font-family:Times New Roman;">Effective January 1, 2022, such reporting obligations for payments and transfers of value made in 2021</span><span style="font-family:Times New Roman;"> </span><span style="font-family:Times New Roman;">to covered recipients will be expanded to include </span><span style="font-family:Times New Roman;">physician assistants, nurse practitioners, </span><span style="font-family:Times New Roman;">clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, and certified nurse-midwives</span><span style="font-family:Times New Roman;">&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance regulations promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing&#59; state and local laws that require the registration of pharmaceutical sales and medical representatives&#59; state laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and data privacy laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, research, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with other U.S. healthcare laws and compliance requirements, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, our current and future activities with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers are subject to regulation by various federal, state and local authorities in addition to the FDA, which may include but are not limited to, CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, our business practices, including our clinical research, sales, marketing and scientific/educational grant programs may be required to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the patient data privacy and security provisions of HIPAA transparency requirements, and similar state laws, each as amended, as applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, item, facility or service reimbursable, in whole or part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Rather, if &#8220;one purpose&#8221; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is implicated. In addition, the ACA codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed below).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for a medical or other item or service that was not provided as claimed or is false or fraudulent.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Pharmaceutical and other healthcare companies are being investigated or, in the past, have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Analogous U.S. state laws and regulations, including state anti-kickback and false claims laws, may apply to claims involving healthcare items or services reimbursed by any third-party payor, including private insurers our business practices.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA, as amended by HITECH, and their implementing regulations, imposes requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, and to report annually certain ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, such reporting obligations for payments and transfers of value made in 2021 to covered recipients will be expanded to include physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants and certified nurse-midwives.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State and local laws also require pharmaceutical and biotechnology companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, establish marketing compliance programs, restrict payments that may be made to healthcare providers professionals and entities and other potential referral sources, file periodic reports with the state relating to pricing and marketing, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register field representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, exclusion, debarment or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third-party intermediaries from offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently, the SEC and DOJ have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to, existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to employee matters, managing our growth and other risks related to our business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide higher compensation, more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we rely on our scientific founders and other scientific and clinical advisors and consultants to assist us in formulating our research, development and clinical strategies. These advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, these advisors and consultants typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. Furthermore, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. In particular, if we are unable to maintain consulting relationships with our scientific founders or if they provide services to our competitors, our development and commercialization efforts will be impaired and our business will be significantly harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently do not have and have never had a marketing or sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration and such arrangements may prove to be less profitable than commercializing the product on our own. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 61 full-time employees, including 45 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">identifying, recruiting, integrating, maintaining and motivating additional employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">managing our internal development efforts effectively, including the clinical, FDA, EMA and other comparable foreign regulatory agencies&#8217; review process for ORIC-101 and any other product candidates, while complying with any contractual obligations to contractors and other third parties we may have&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">improving our operational, financial and management controls, reporting systems and procedures.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to successfully develop and, if approved, commercialize ORIC-101 and other product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of ORIC-101 and any other product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize ORIC-101 and other product candidates and, accordingly, may not achieve our research, development and commercialization goals.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems, and those of our third-party CROs, other contractors (including sites performing our clinical trials) and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to the loss, destruction, alteration, disclosure, or dissemination of, or damage or unauthorized access to, our data or data that is processed or maintained on our behalf, or other assets. For example, we have received phishing attacks, and companies have experienced an increase in phishing and social engineering attacks from third parties in connection with the COVID-19 pandemic, and the increase in remote working further increases security threats. To the extent that any disruption or security breach were to result in any loss, destruction, unavailability, alteration, disclosure, or dissemination of, or damage to or unauthorized access, our applications, any other data processed or maintained on our behalf, or other assets, or for it to be believed or reported that any of these occurred, we could incur liability, financial harm and reputational damage and the development and commercialization of our product candidates could be delayed. We cannot assure you that our data protection efforts and our investment in information technology, or the efforts or investments of CROs, consultants or other third parties, will prevent significant breakdowns or breaches in systems or other cyber incidents that cause loss, destruction, unavailability, alteration or dissemination of, or damage or unauthorized access to, our data and other data processed or maintained on our behalf or other assets that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure or dissemination of, or the prevention of access to, data (including trade secrets or other confidential information, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to loss, damage, or unauthorized access to, or use, alteration, or disclosure or dissemination of, personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notifications and follow-up actions related to a security incident could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security breach. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in any loss, destruction, or alteration of, or damage or unauthorized access to, our data or other information that is processed or maintained on or behalf, or inappropriate disclosure or dissemination of any such information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in or, failure or security breach of our systems or third-party systems where information important to our business operations or commercial development is stored. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operations are vulnerable to interruption by fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our facilities are located in California. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, fire, earthquake, power loss, terrorist activity, pandemics or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Chief Financial Officer and Chief Business Officer have been subpoenaed for information by the Securities and Exchange Commission on a matter unrelated to ORIC.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chief Financial Officer and Chief Business Officer each received subpoenas for documents and information, in their personal capacities, from the SEC in March and April 2020. The subpoenas appear to relate to an ongoing SEC investigation into the trading of securities of certain other companies. The subpoenas state that they are a part of a non-public fact-finding inquiry by the SEC and do not mean that a conclusion has been reached regarding the conduct of the individuals. Both individuals have assured us that they have not engaged in any wrongdoing with respect to the matters at issue in the SEC inquiry. We cannot predict the course of the SEC&#8217;s inquiry and its implications for us. Nor can we predict what actions, if any, the SEC or any other governmental agency may ultimately take on these matters in the future. If action were taken against one or both of these individuals, any such action will become time consuming and distracting for them, and if such action is successful, the individual or individuals could be subject to fines, penalties and the imposition of restrictive sanctions that may affect their ability to serve as officers of our company. Regardless of the outcome, these matters may result in incurrence of additional costs and diversion of management&#8217;s attention, and may create a perception of wrongdoing that could be harmful to our business or reputation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net operating loss (NOL) carryforwards may be unavailable to offset future taxable income because of restrictions under U.S. tax law. Our NOLs generated in tax years beginning prior to January&#160;1, 2018 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law, and therefore could expire unused. Under tax legislation commonly referred to as the Tax Cuts and Jobs Act (Tax Act) as amended by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), our federal NOLs generated in tax years beginning after December&#160;31, 2017 may be carried forward indefinitely, but for taxable years beginning after December&#160;31, 2020, the deductibility of federal NOLs generated in tax years beginning after December&#160;31, 2017 is limited to 80% of our current year taxable income. As of December&#160;31, 2020, we had available NOL carry forwards of $130.8&#160;million, of which $89.2&#160;million do not expire. We also have available California NOL carryforwards of approximately $132.0&#160;million as of December&#160;31, 2020, which begin to expire in 2034 and are subject to limitation on use.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended (Code), if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change in the corporation&#8217;s ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period), the corporation&#8217;s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change taxable income may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in the ownership. Our ability to utilize our NOLs and certain other tax attributes could be limited by an &#8220;ownership change&#8221; as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. federal income tax reform could materially adversely affect our company.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2017, President Trump signed into law the Tax Act, which significantly revises the Code. The Tax Act, as amended by the CARES Act, among other things, reduces the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, repeals the alternative minimum tax for corporations, limits the tax deduction for interest expense to 30% (50% for taxable years beginning in 2019 or 2020) of adjusted taxable income (except for certain small businesses), limits the deduction in taxable years beginning after December&#160;31, 2020, for NOLs carried forward from taxable years beginning after December&#160;31, 2017, eliminates net operating loss carrybacks for NOLs generated in taxable years beginning after December&#160;31, 2020, and modifies or repeals many business deductions and credits. Our financial statements included elsewhere in this periodic report reflect the effects of the Tax Act based on current guidance. However, there remain uncertainties and ambiguities in the application of certain provisions of the Tax Act and, as a result, we made certain judgments and assumptions in the interpretation thereof. The U.S. Treasury Department and the Internal Revenue Service, or the IRS, may issue further guidance on how the provisions of the Tax Act will be applied or otherwise administered, which may differ from our current interpretation. In addition, the Tax Act could be subject to potential amendments and technical corrections, any of which could materially lessen or increase certain adverse impacts of the legislation on us. Additionally, the new administration in the United States and congressional decisions made in the near future may result in increased corporate tax, which may adversely impact our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">differing regulatory requirements and reimbursement regimes in foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">foreign taxes, including withholding of payroll taxes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">difficulties staffing and managing foreign operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is more common than in the United States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential liability under the FCPA or comparable foreign regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">business interruptions resulting from geo-political actions, including war and terrorism.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our intellectual property</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. We also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents or pending applications from third parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or the patent applications of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our and our licensors&#8217; proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although as of December 31, 2020 we owned three and licensed one issued patents in the United States, we cannot be certain that the claims in our other U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign territories, or those of our licensors, will be considered patentable by the United States Patent and Trademark Office (USPTO), courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued or licensed patents will not be found invalid or unenforceable if challenged.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">patent applications may not result in any patents being issued&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications and those of our licensors may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or in-license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents or the patents of our licensors by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents or the patents of our licensors may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review (PGR) and <span style="font-style:italic;">inter partes</span> review (IPR), or other similar proceedings challenging our owned or in-licensed patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights or those of our licensors, allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, our patents or the patents of our licensors may become subject to post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications and those of our licensors. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of our licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">we or our licensors or collaborators might not have been the first to make the inventions covered by the issued patents or patent application that we own or license&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">we or our licensors or collaborators might not have been the first to file patent applications covering certain of our inventions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">it is possible that the pending patent applications we own or license will not lead to issued patents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the patents of others may have an adverse effect on our business&#59; and</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we or our licensors were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">result in costly litigation that may cause negative publicity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">divert the time and attention of our technical personnel and management&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">cause development delays&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid, not infringed, or unenforceable in a court of law&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">subject us to significant liability to third parties&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although no third party has asserted a claim of patent infringement against us as of the date of this periodic report, others may hold proprietary rights that could prevent our product candidates from being marketed. For example, we are aware of issued patents that claim a method of treatment based upon a general mode of action. These patents appear to be licensed to a potential competitor. These claims could be alleged to cover our lead product candidate, ORIC-101, in certain treatment indications. While we believe that these patents are difficult to enforce and that we would have valid defenses to these claims of patent infringement, we cannot be certain that we would prevail in any dispute and we cannot be certain how an adverse determination would affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that a third party may assert a claim of patent infringement directed at any of our product candidates. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our products, treatment indications, or processes could subject us to significant liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially reasonable terms, if at all. Moreover, even if we or our future strategic partners were able to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates, treatment indications, or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent proceedings could compromise our ability to compete in the marketplace. If we do not prevail in the patent proceedings the third parties may assert a claim of patent infringement directed at our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our development programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain or maintain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents or our licensors&#8217; patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or our licensors&#8217; patents could be found invalid or unenforceable if challenged in court.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent or the patent of our licensors is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of sufficient written description, non-enablement, or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may also raise similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include re-examination, PGR, IPR, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our licensors, and the patent examiners are unaware during prosecution. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or the patents and patent applications of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or platform, or any product candidates that we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of our licensors and the enforcement or defense of our issued patents or those of our licensors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;16, 2011, the Leahy-Smith America Invents Act (the Leahy-Smith Act), was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we may not be certain that we or our licensors are the first to either (1)&#160;file any patent application related to our product candidates or (2)&#160;invent any of the inventions claimed in the patents or patent applications.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of our licensors and the enforcement or defense of our issued patents or those of our licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents, those of our licensors or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and those of our licensors and the patents we might obtain or license in the future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or those of our licensors or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain patent term extension for our product candidates, our business may be materially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents or those of our licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although as of December 31, 2020 we owned three and licensed one issued patents in the United States and pending patent applications in the United States and other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents, the patents of our licensors, or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights and those of our licensors in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our licensors at risk of being invalidated or interpreted narrowly and our patent applications or the patent applications of our licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop, license, or obtain.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or patent applications and those of our licensors. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. As of December 31, 2020, we had one pending United States trademark application. Our trademark application may not result in any trademark registrations being issued, and our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into and may enter in the future into non-disclosure and confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential partners, lessees of shared multi-company property and other third parties. We may become subject to litigation where a third party asserts that we or our employees inadvertently or otherwise breached the agreements and used or disclosed trade secrets or other information proprietary to the third parties. A third party has inquired about a potential breach of a non-disclosure and confidentiality agreement in view of our developments in the CD73 inhibitor program. The inquiry may progress to a claim that we or our employees inadvertently or otherwise breached the agreement and used trade secrets or other information proprietary to the third party. Defense of such matters, regardless of their merit, could involve substantial litigation expense and be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology. Failure to defend against any such claim could subject us to significant liability for monetary damages or prevent or delay our developmental and commercialization efforts, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, operating results, financial condition and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into license agreements with third parties and we may enter into additional license agreements in the future with others to advance our research or allow commercialization of product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing license agreements, and we expect that our future agreements will, impose various development, diligence, commercialization, and other obligations on us. Certain of our license agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the license.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our right to sublicense patents and other rights to third parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our right to transfer or assign the license&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the priority of invention of patented technology.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially reasonable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In spite of our best efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. For example, if Mirati terminates the Mirati License Agreement, we may be required to cease our development and commercialization of licensed products </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">directed to PRC2 and would be obligated to assign to Mirati, or grant an exclusive license to Mirati with respect to, certain of our patents, know-how and regulatory filings. Likewise, if Voronoi terminates the Voronoi License Agreement, we may be required to cease our development and commercialization of licensed products directed to epidermal growth factor receptor (EGFR, or ErbB1) and human epidermal growth factor receptor 2 (HER2, or ErbB2) with exon 20 insertion mutations and we would be obligated to grant a nonexclusive license to Voronoi under certain of our patents and know-how, and to assign to Voronoi certain of our regulatory filings. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The patent protection and patent prosecution for some of our product candidates may be dependent on third parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we normally seek to obtain the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of the patent applications and patents relating to our product candidates, there may be times when the preparation, filing, prosecution, maintenance, enforcement and defense activities for patents and patent applications relating to our product candidates are controlled by our licensors or collaboration partners. If any of our licensors or collaboration partners fail to prepare, file, prosecute, maintain, enforce, and defend such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over such activities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent applications licensed from MSKCC, which do not cover ORIC-101, any of our current product candidates or any of our discovery and research programs, have been supported through the use of U.S. government funding awarded by the National Institutes of Health and the United States Army Medical Research and Materiel Command. Although we do not currently own issued patents or pending patent applications that have been generated through the use of U.S. government funding, we may acquire or license in the future intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1)&#160;adequate steps have not been taken to commercialize the invention&#59; (2)&#160;government action is necessary to meet public health or safety needs&#59; or (3)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). If the U.S. government exercised its march-in rights in our future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our dependence on third parties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have the ability to independently conduct our clinical trials. We currently rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our current and planned clinical trials of ORIC-101 and we expect to continue to rely upon third parties to conduct additional clinical trials of ORIC-101 and other product candidates. Third parties have a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. The third parties we rely on for these services may also have relationships with other entities, some of which may be our competitors. Some of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements with a third party, it would delay our drug development activities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on these third parties for such drug development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP standards, regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are reliable and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EMA also requires us to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials substantially comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under current cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We contract with third parties for the production of our product candidates for preclinical studies and, in the case of ORIC-101, our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quality and quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. In the case of ORIC-101, we rely on a single third-party manufacturer and we currently have no alternative manufacturer in place. We do not have long-term supply agreements, and we purchase our required drug product on a purchase order basis, which means that aside from any binding purchase orders we have from time to time, our supplier could cease supplying to us or change the terms on which it is willing to continue supplying to us at any time. If we were to experience an unexpected loss of supply of ORIC-101 or any other product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the failure of the third party to manufacture our product candidates according to our schedule and specifications, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the breach by the third-party contractors of our agreements with them&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the failure of third-party contractors to comply with applicable regulatory requirements, including cGMPs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the failure of the third party to manufacture our product candidates according to our specifications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have complete control over all aspects of the manufacturing process of our contract manufacturing partners and are dependent on these contract manufacturing partners for compliance with cGMP regulations for manufacturing both active pharmaceutical ingredients (API) and finished drug products. To date, we have obtained API and drug product for our product candidates from single-source third party contract manufacturers. We are in the process of developing our supply chain for each of our product candidates and intend to put in place framework agreements under which third-party contract manufacturers will generally provide us with necessary quantities of API and drug product on a project-by-project basis based on our development needs. As we advance our product candidates through development, we will consider our lack of redundant supply for the API and drug product for each of our product candidates to protect against any potential supply disruptions. However, we may be unsuccessful in putting in place such framework agreements or protecting against potential supply disruptions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we will need to find alternative manufacturing facilities, and those new facilities would need to be inspected and approved by FDA, EMA or comparable regulatory authority prior to commencing manufacturing, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. For instance, in August 2020, we entered into the Mirati License Agreement pursuant to which we licensed from Mirati exclusive worldwide development and commercialization rights to its allosteric PRC2 inhibitor program and, in October 2020, we entered into the Voronoi License Agreement pursuant to which we licensed from Voronoi exclusive development and commercialization rights to its EGFR and HER2 exon 20 insertion mutation program worldwide (other than in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Any such acquisition or strategic partnership may entail numerous risks, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">increased operating expenses and cash requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the assumption of additional indebtedness or contingent liabilities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the issuance of our equity securities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. For instance, in connection with the Mirati License Agreement, we issued to Mirati 588,235 shares of our common stock and, in connection with the Voronoi License Agreement, we issued Voronoi 283,259 shares of our common stock, each of which resulted in dilution to our existing stockholders.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We would face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we enter into any collaboration arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates would pose numerous risks to us, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to, and the manner in which they perform their obligations under, these collaborations and may not perform their obligations as expected&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a business combination or sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborators may rely on third parties to conduct development, manufacturing, and/or commercialization activities, and except for remedies available to us under our collaboration agreements, we have limited ability to control the conduct of such activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">we may grant exclusive rights to our collaborators that would prevent us from collaborating with others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborators may not provide us with timely and accurate information regarding development progress and activities under the collaboration or may limit our ability to share such information, which could adversely impact our ability to report progress to our investors and otherwise plan our own development of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to the securities markets and ownership of our common stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not know whether an active, liquid and orderly trading market will continue for our common stock or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our IPO in April 2020, there was no public market for shares of our common stock. Shares of our common stock only recently began trading on the Nasdaq Global Select Market, but we can provide no assurance that we will be able to sustain an active trading market for our shares. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of common stock as consideration.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The price of our stock is volatile.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock is highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk factors&#8221; section and elsewhere in this periodic report, these factors include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing and results of preclinical studies and clinical trials of our product candidates, those conducted by third parties or those of our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the success of competitive products or announcements by potential competitors of their product development efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">regulatory actions with respect to our products or our competitors&#8217; products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">actual or anticipated changes in our growth rate relative to our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">regulatory or legal developments in the United States and other countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">developments or disputes concerning patent applications, issued patents or other proprietary rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the recruitment or departure of key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">fluctuations in the valuation of companies perceived by investors to be comparable to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sector&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">changes in the structure of healthcare payment systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">announcement or expectation of additional financing efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">sales of our common stock by us, our insiders or our other stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">expiration of market stand-off or lock-up agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">general economic, political, industry and market conditions, including the change of administration in the United States in 2021.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock is influenced by the research and reports that securities or industry analysts publish about us, our business or our market. We currently have research coverage from a limited number of securities or industry analysts. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including, our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing and cost of, and level of investment in, research and development activities relating to our current product candidates and any future product candidates and research-stage programs, which will change from time to time&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to enroll patients in clinical trials and the timing of enrollment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the cost of manufacturing our current product candidates and any future product candidates, which may vary depending on FDA, EMA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies or other assets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing and outcomes of clinical trials for ORIC-101, and any of our other product candidates, or competing product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">competition from existing and potential future products that compete with ORIC-101 and any of our other product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any delays in regulatory review or approval of ORIC-101 or any of our other product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the level of demand for ORIC-101 and any of our other product candidates, if approved, which may fluctuate significantly and be difficult to predict&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with ORIC-101 and any of our other product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to commercialize ORIC-101 and any of our other product candidates, if approved, inside and outside of the United States, either independently or working with third parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to establish and maintain collaborations, licensing or other arrangements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to adequately support future growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential unforeseen business disruptions that increase our costs or expenses&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">future accounting pronouncements or changes in our accounting policies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the changing and volatile global economic and political environment.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our executive officers, directors, holders of 5% or more of our common stock and their respective affiliates beneficially owned approximately 54% of our outstanding common stock. These stockholders, acting together, may be able to impact matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this Annual Report&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley Act)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation in this Annual Report and our periodic reports and proxy statements&#59; and</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the fiscal year in which we have more than $1.07&#160;billion in annual revenue&#59; (2)&#160;the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0&#160;million of equity securities held by non-affiliates&#59; (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period&#59; and (4) December&#160;31, 2025.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We incur increased costs as a result of operating as a public company, and our management devotes substantial time to related compliance initiatives. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage, particularly in light of recent cost increases related to coverage. We cannot accurately predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a public company we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section&#160;404 of the Sarbanes-Oxley Act. Under these rules, beginning with our second Annual Report on Form 10-K as a public company, we will be required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we may be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaging in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to securities litigation, which is expensive and could divert management attention.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock is volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years and we may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of their stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">establish a classified board of directors so that not all members of our board are elected at one time&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">permit only the board of directors to establish the number of directors and fill vacancies on the board&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">eliminate the ability of our stockholders to call special meetings of stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">prohibit cumulative voting&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">authorize our board of directors to amend the bylaws&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">require a super-majority vote of stockholders to amend some provisions described above.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware (DGCL), prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which may limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for the following (except for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction):</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any derivative action or proceeding brought on our behalf&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any action asserting a claim of breach of fiduciary duty&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located in South San Francisco, California, where we lease 33,322 square feet of office, research and laboratory space, under a non-cancelable lease that expires in May 2022 with an option to renew for an additional five-year term. We also lease office space and research and development space in San Diego, California under a short-term lease arrangement. We believe that these existing facilities will be adequate for our near-term needs. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings. <span style="color:#FF0000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. We are not currently a party to any material litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.  </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II_">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities <span style="color:#FF0000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market Information for Our Common Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#8220;ORIC.&#8221; since April 24, 2020. Prior to that date, there was no public trading market for our common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there were approximately 46 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments, and other factors that our board of directors deems relevant.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Performance Graph</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act, except to the extent that we specifically incorporate this information by reference therein, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following graph compares the cumulative total return to stockholder return on our common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on April 24, 2020 (the first day of trading of our common stock with a closing price on that date of $25.77) and its relative performance is tracked through December 31, 2020. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends&#59; however, no dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on historical results and are not indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.<span style="font-weight:bold;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpty1lksmhba000043.jpg" title="" alt="" style="width:497px;height:412px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registration Statements on Form S-1 (File Nos. 333-236792 and 333-237814) were declared effective by the SEC for our IPO of common stock on April 23, 2020. We started trading on the Nasdaq Global Select Market on April 24, 2020. In connection with our IPO, we sold an aggregate of 8,625,000 shares of common stock at a public offering price of $16.00 per share, including 1,125,000 shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares. The underwriters for our IPO were J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Jefferies LLC, and Guggenheim Securities, LLC. The aggregate gross proceeds received by the Company from the offering, excluding underwriting discounts and commissions and offering expenses, were $138.0 million. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registration Statements on Form S-1 (File Nos. 333-250001 and 333-250053) were declared effective by the SEC for our follow-on offering of common stock on November 12, 2020. In connection with our follow-on offering, we sold an aggregate of 5,796,000 shares of common stock at a public offering price of $23.00 per share, including 756,000 shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares. The underwriters for our follow-on offering were J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Jefferies LLC, Guggenheim Securities, LLC and Oppenheimer &#38; Co. Inc. The aggregate gross proceeds received by the Company from the offering, excluding underwriting discounts and commissions and offering expenses was $133.3 million. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the planned use of proceeds from our public offerings as described in our final prospectuses filed with the SEC pursuant to Rule 424(b)(4) on April 24, 2020 and November 13, 2020. We invested the funds received in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_SELECTED_FINANCIAL_DATA">Item 6. Selected Financial Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize our selected financial data for the periods and as of the dates indicated. We derived our statement of operations data for the years ended December 31, 2020, 2019, and 2018, and the balance sheet data as of December 31, 2020, 2019, and 2018, from our audited financial statements and related notes. Our historical results are not necessarily indicative of the results that may be expected in the future. You should read the following selected financial data in conjunction with our financial statements and the related notes appearing elsewhere in this report and the information in the section titled and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share data)</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of operations data:</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,921</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,844</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,026</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired in-process research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,843</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,422</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,725</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,345</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,186</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,569</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,371</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,186</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,569</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,371</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,686</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,008</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,703</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,883</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,363</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Unrealized loss on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,734</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,883</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,363</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.36</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14.15</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.32</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,942,476</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,899,348</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,115</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet data:</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,446</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,159</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,636</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298,997</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,093</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,734</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,245</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,202</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,150</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,221</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,119</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,894</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,058</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,266</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(166,393</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,690</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,807</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,776</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90,084</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,426</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled &#8220;Selected Financial Data&#8221; and our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties, including those described in the section titled &#8220;Special Note Regarding Forward Looking Statements.&#8221; Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section titled &#8220;Risk factors&#8221; included elsewhere in this report.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients&#8217; lives by <span style="font-style:italic;text-decoration:underline;">O</span><span style="font-style:italic;">vercoming</span> <span style="font-style:italic;text-decoration:underline;">R</span><span style="font-style:italic;">esistance </span><span style="font-style:italic;text-decoration:underline;">I</span><span style="font-style:italic;">n </span><span style="font-style:italic;text-decoration:underline;">C</span><span style="font-style:italic;">ancer. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our fully integrated discovery and development team is advancing a diverse pipeline of innovative therapies designed to counter resistance mechanisms in cancer by leveraging our expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Our lead product candidate, ORIC-101, builds upon a legacy of successful drug development by our founders in the field of nuclear hormone receptors and their efforts to elucidate the cause of resistance to the groundbreaking prostate cancer therapies that they had developed. ORIC-101 is a potent and selective small molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. In 2019, we initiated two separate Phase&#160;1b trials of ORIC-101 in combination with (1)&#160;Xtandi (enzalutamide) in metastatic prostate cancer and (2)&#160;Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. In December 2020, we selected the recommend Phase 2 dose (RP2D) and initiated the dose expansion portion of the Phase 1b trial of ORIC-101 in combination with nab-paclitaxel and we expect to report interim safety, efficacy, and translational data from this trial in the first half of 2021. In January 2021, we selected the RP2D and initiated the dose expansion portion of the Phase 1b trial of ORIC-101 in combination with enzalutamide and we expect to report interim safety, efficacy, and translational data from this trial in the second half of 2021. Our other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit, for which we licensed development and commercialization rights from Mirati Therapeutics, Inc. (Mirati) in August 2020 (Mirati License Agreement) and (3) ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations, for which we licensed development and commercialization rights from Voronoi, Inc. (Voronoi) in October 2020 (Voronoi License Agreement). We expect to file an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for ORIC-533 in the first half of 2021, an IND for ORIC-944 in the second half of 2021 and a Clinical Trial Application (CTA) for ORIC-114 in the second half of 2021. Beyond these product candidates, we are developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2014, we have devoted substantially all of our resources to research and development activities, including with respect to our GR antagonist and CD73 inhibitor programs and other preclinical programs, in-licensing of external programs, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant losses since the commencement of our operations. Our net loss for the year ended December 31, 2020 was $73.7 million and we had an accumulated deficit of $166.4 million as of December 31, 2020. Our losses and accumulated deficit have resulted primarily from costs incurred in connection with research and development activities including in-licensing and to a lesser extent from general and administrative costs associated with our operations. We expect to incur significant losses for the foreseeable future, and we anticipate these losses will increase significantly as we continue our development of ORIC-101, ORIC-533, ORIC-944,<span style="color:#000000;"> ORIC-114</span> and any future product candidates from discovery through preclinical development and into clinical trials as we seek regulatory approval for these product candidates. Our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned research and development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the novel coronavirus disease, or COVID-19, outbreak a global pandemic. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended operating activities. Beginning the week of March 16, 2020, the majority of our workforce began working from home. Disruptions caused by the COVID-19 pandemic, including the effects of the stay-at-home orders and work-from-home policies, have impacted productivity, have resulted in increased operational expenses, certain adjustments to the operations of our clinical trials, the suspension of enrollment of new patients at certain of our clinical trial sites, and delays in certain supply chain activities and collecting and analyzing data from patients in our clinical trials, and may further disrupt our business and delay our development programs and regulatory timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct business in the ordinary course. As a result, research and development expenses and general and administrative expenses may vary significantly if there is an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of our clinical trials and other related business activities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 28, 2020, we completed our IPO of our common stock. In connection with our IPO, we issued and sold&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,625,000 shares of our common stock, including 1,125,000 shares associated with the full exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of&#160;$16.00&#160;per share resulting in gross proceeds of $138.0 million. After deducting underwriting discounts and commissions and other offering expenses of $12.8 million, the net proceeds we received from our IPO were </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$125.2 million.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 17, 2020, we completed a public offering of our common stock. In connection with this offering, we issued and sold 5,796,000 shares of our common stock, including 756,000 associated with the full exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of&#160;$23.00 per share resulting in gross proceeds of $133.3 million before deducting underwriting discounts and commissions and estimated offering expenses. After deducting underwriting discounts and commissions and other offering expenses of $8.5 million, the net proceeds we received from the transaction were approximately $124.8 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third and fourth quarter of 2020, we entered into license agreements with Mirati and Voronoi, respectively. As consideration for the license granted under the Mirati License Agreement, we issued to Mirati 588,235 shares of our common stock in August 2020. The number of shares issued were based on a price of $34.00 per share, representing a premium of 10% to the 60-day trailing volume weighted average trading price of our common stock. As consideration for the license granted under the Voronoi License Agreement, we made a one-time $5.0 million cash payment in November 2020 and issued 283,259 shares of our common stock to Voronoi in October 2020. The number of shares issued were based on a price of $28.24 per share, representing a premium of 25% to the 30-day trailing volume weighted average trading price of our common stock. For a further description of these license agreements and related stock issuances, please refer to the &#8220;Business &#8211; Our collaboration and license agreements&#8221; and &#8220;Item 8 &#8211; Notes to Financial Statements&#8221; sections in the Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Operating Results</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses account for a significant portion of our operating expenses and consist primarily of external and internal costs incurred in connection with the discovery and development of our product candidates.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External expenses include:&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">payments to third parties in connection with the clinical development of our product candidates, including contract research organizations (CROs) and consultants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations (CMOs) and consultants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">payments to third parties in connection with the preclinical development of our product candidates, including outsourced professional scientific development services, consulting research fees and for sponsored research arrangements with third parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">laboratory supplies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">allocated facilities, depreciation and other expenses, which include direct or allocated expenses for IT, rent and maintenance of facilities.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also incur in-process research and development expense as we acquire or in-license assets from other parties. Technology acquisitions are expensed or capitalized based upon <span style="Background-color:#FFFFFF;color:#000000;">the asset achieving technological feasibility in accordance with management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use</span>. Acquired in-process research and development costs that have no alternative future use are immediately expensed.&#160;&#160; </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal expenses include employee-related costs such as salaries, related benefits and non-cash stock-based compensation expense for employees engaged in research and development functions.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs in the periods in which they are incurred. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We track external costs by program, clinical or preclinical. We do not track internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially in the foreseeable future as we advance our product candidates through preclinical studies and clinical trials&#59; continue to discover and develop additional product candidates and expand our pipeline&#59; maintain, expand, protect and enforce our intellectual property portfolio&#59; and hire additional personnel.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful development of our product candidates is highly uncertain, and we do not believe it is possible at this time to accurately project the nature, timing and estimated costs of the efforts necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. To the extent our product candidates continue to advance into clinical trials, as well as advance into larger and later-stage clinical trials, our expenses will increase substantially and may become more variable. We are also unable to predict when, if ever, we will generate revenue from our product candidates to offset these expenses. Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing and progress of preclinical and clinical development activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the number and scope of preclinical and clinical programs we decide to pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to maintain our current research and development programs and to establish new ones&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">establishing an appropriate safety profile with&#160;IND-enabling&#160;toxicology studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">successful patient enrollment in, and the initiation and completion of, clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the receipt of regulatory approvals from applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our ability to establish licensing or collaboration arrangements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the performance of our future collaborators, if any&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">obtaining and retaining research and development personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">development and timely delivery of commercial-grade product formulations that can be used in our planned clinical trials and for commercial launch&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">maintaining a continued acceptable safety profile of our products following approval.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any changes in the outcome of any of these factors could significantly impact the costs, timing and viability associated with the development of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries, related benefits and stock-based compensation expense for personnel in executive, finance and administrative functions. General and administrative expenses also include allocated facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, not otherwise included in research and development expenses, as well as professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. We expect that our general and administrative expenses will increase substantially in the foreseeable future as we increase our headcount to support the continued research and development of our programs and the growth of our business. We also anticipate increased expenses relating to accounting, audit, legal, regulatory, compliance, director and officer insurance and investor and public relations costs associated with operating as a public company.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Total Other Income</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net primarily consists of interest income generated from our investments in interest-bearing money market accounts and marketable securities. Other income historically had consisted of rental income from the sub-leasing of a portion of our office space in South San Francisco, California. In August 2020, this sublease expired and we reclaimed the space at that time.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Comparison of the Years Ended December 31, 2020 and 2019</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the year ended December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,921</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,844</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,077</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired in-process research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,843</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,843</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,422</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,725</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,697</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,186</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,569</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,617</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,186</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,569</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,617</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,686</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,203</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,703</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,883</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,820</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $35.9&#160;million for the year ended December 31, 2020 compared to $22.8&#160;million for the year ended December 31, 2019, an increase of $13.1&#160;million. This increase was primarily driven by $9.0&#160;million of additional external costs primarily related to the continued advancement of our ORIC-101 program and our exploratory programs. Further, we incurred an additional $4.1 million in personnel costs, of which $1.5 million was non-cash stock-based compensation, for the year ended December 31, 2020 as compared to the same period in 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We track external research and development costs by program, clinical or preclinical. External research and development expenses consist of payments to outside consultants, CROs, CMOs, clinical trial sites and central laboratories in connection with our discovery and preclinical activities, process development, clinical manufacturing and clinical development activities. External costs also include laboratory supplies as well as allocated facilities, depreciation and other expenses. Included in preclinical and other unallocated costs are external corporate overhead costs that are not specific to any one program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not track internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. Internal costs consist of employee-related costs including salaries, related benefits and non-cash stock-based compensation expense for employees engaged in research and development functions, which are not tracked by product candidate as several of our departments support multiple product candidate research and development programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our external and internal costs for the years ended December 31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External costs:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-101</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,036</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,636</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,400</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and other unallocated costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,287</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,689</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,598</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total external costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,323</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,325</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,998</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,598</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,519</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,079</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,921</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,844</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,077</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in manufacturing, as our programs advance into later stages of development and as we conduct additional clinical trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Acquired In-Process Research and Development Expenses </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we acquired the rights to certain patents, patent applications and know-how from Mirati under the Mirati License Agreement. As consideration for the asset rights, we issued to Mirati 588,235 shares of our common stock, valued at approximately $13.0 million based upon the closing price of our common stock on the acquisition date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, we also acquired the rights to certain patent applications and know-how from Voronoi under the Voronoi License Agreement. As consideration for the asset rights, we made an up-front cash payment to Voronoi of $5.0 million and issued to Voronoi <span style="color:#000000;">283,259&#160;shares of the Company&#8217;s common stock issued, valued </span>at approximately $6.8 million based upon the closing price of our common stock on the acquisition date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the assets licensed from Mirati and Voronoi were in early development at the time they were acquired, we concluded that there was no alternative future use for the assets and recorded the value of the asset rights acquired of $13.0 million and $11.8 million, from Mirati and Voronoi, respectively, to acquired in-process research and development at the closing of transactions, resulting in a total charge of $24.8 million for the year ended December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $13.4&#160;million for the year ended December 31, 2020 compared to $5.7&#160;million for the same period in 2019, an increase of $7.7 million. This increase was primarily due to $4.5 million higher personnel costs, including additional non-cash stock-based compensation of $2.6 million to support the growth of our company, and higher professional services and related costs to operate as a public company. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Total Other Income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income for the year ended December 31, 2020 was $0.5 million, compared to $1.7 million for the same period in 2019, a decrease of $1.2 million. This decrease was primarily due to a reduction in the interest income we earned on our cash reserves as a result of lower average interest rates in 2020 as compared to 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Comparison of the Years Ended December&#160;31, 2019 and 2018</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December 31, 2019 and 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,844</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,026</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,818</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,725</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,345</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,380</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,569</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,371</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,198</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,569</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,371</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,198</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,686</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,008</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,883</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,363</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,520</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $22.8&#160;million for the year ended December&#160;31, 2019 compared to $19.0&#160;million for the year ended December&#160;31, 2018, an increase of $3.8&#160;million. This increase was driven primarily by $2.6&#160;million higher personnel costs related to the addition of a clinical development team and $1.2&#160;million of external costs driven by progression of the&#160;ORIC-101&#160;trials and&#160;ORIC-533&#160;preclinical development. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our external costs and internal costs for the year</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ended December 31, 2019 and 2018 (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External costs:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC-101</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,636</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,365</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and other unallocated costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,689</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,754</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">935</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total external costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,325</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,119</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,519</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,907</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,612</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,844</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,026</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,818</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $5.7&#160;million for the year ended December&#160;31, 2019 compared to $3.3&#160;million for the year ended December&#160;31, 2018, an increase of $2.4&#160;million. The increase was primarily due to higher personnel costs related to hiring of additional employees and higher professional services. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Total Other Income</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income was $1.7&#160;million for the year ended December&#160;31, 2019 compared to $1.0&#160;million for the year ended December&#160;31, 2018, an increase of $0.7&#160;million. This increase was primarily attributable to interest income as a result of higher cash balances from the Series&#160;C and Series&#160;D convertible preferred stock financings in 2019.&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sources of Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 28, 2020, we completed our IPO. In connection with our IPO, we issued and sold&#160;8,625,000 shares of our common stock at a price to the public of&#160;$16.00&#160;per share resulting in gross proceeds of&#160;$138.0&#160;million before deducting underwriting discounts and commissions and other offering expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 17, 2020, we completed follow-on offering of our common stock. In connection with our follow-on offering, we issued and sold 5,796,000 shares of our common stock at a price to the public of $23.00 per share, resulting in gross proceeds of $133.3 million before deducting underwriting discounts and commissions and other offering expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our IPO, we funded our operations primarily with proceeds from the sale of convertible preferred stock resulting in total net proceeds of approximately $178.1&#160;million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future Funding Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if at all, that will occur. We will continue to require substantial additional capital to develop our product candidates and fund operations for the foreseeable future. Moreover, we expect our expenses to increase in connection with our ongoing activities, particularly as we continue the development of and seek regulatory approvals for our product candidates. Further, we are subject to all the risks incident in the development of new pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. Our expenses will increase if, and as, we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">advance our product candidates through preclinical and clinical development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">seek regulatory approvals for any product candidates that successfully complete clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">seek to discover and develop additional product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">expand our operational, financial and management systems and increase personnel, including personnel to support our development, manufacturing and commercialization efforts and our operations as a public company&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">maintain, expand, protect and enforce our intellectual property portfolio&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">acquire or in-license other product candidates and technologies.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our current cash, cash equivalents and short-term investments will be sufficient to fund our current operating plan into the second half of 2023. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.&#160;In order to complete the development of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding. Until we can generate a sufficient amount of revenue from the commercialization of our product candidates, we may seek to raise any necessary additional capital through the sale of equity, debt financings or other capital sources, which could include income from collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties or from grants. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, including restricting our operations and limiting our ability to incur liens, issue additional debt, pay dividends, repurchase our common stock, make certain investments or engage in merger, consolidation, licensing or asset sale transactions. If we raise funds through collaborations, strategic partnerships and other similar arrangements with third parties, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. If we are unable to raise additional funds when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based our projections of operating capital requirements on our current operating plan, which is based on several assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our working capital requirements. Our future funding requirements will depend on many factors, including:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the costs of manufacturing commercial-grade products and sufficient inventory to support commercial launch&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the cost and timing of hiring new employees to support our continued growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the ability to establish and maintain collaborations on favorable terms, if at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these or other factors with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plan may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plan.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for each of the periods presented below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,268</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,533</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,683</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(215,959</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(768</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(508</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,514</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,824</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,008</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,713</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,523</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,817</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities during the year ended December&#160;31, 2020 of $45.3&#160;million was primarily attributable to our net loss of $73.7&#160;million, adjusted for addbacks for&#160;non-cash&#160;expenses of $26.4&#160;million, which includes stock-based compensation of $5.3&#160;million, depreciation of $1.0&#160;million and non-cash stock consideration in acquisitions of $19.8 million and a net increase in working capital of $2.0&#160;million.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities during the year ended December&#160;31, 2019 of $23.5&#160;million was primarily attributable to our net loss of $26.9&#160;million, adjusted for addbacks for&#160;non-cash&#160;expenses of $2.1&#160;million, which includes stock-based compensation of $1.1&#160;million and depreciation of $1.0&#160;million and a net increase in working capital of $1.2&#160;million.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities during the year ended December&#160;31, 2018 of $20.7&#160;million was primarily attributable to our net loss of $21.4&#160;million, adjusted for addbacks for&#160;non-cash&#160;expenses of $1.4&#160;million, which includes stock-based compensation of $0.5&#160;million and depreciation of $0.9&#160;million and a net decrease in working capital of $0.7&#160;million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities during the year ended December&#160;31, 2020 of $216.0&#160;million was primarily attributable to purchases of investments.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities during the year ended December&#160;31, 2019 of $0.8&#160;million was primarily attributable to purchases of property and equipment.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities during the year ended December&#160;31, 2018 of $0.5&#160;million was primarily attributable to purchases of property and equipment, partially offset by proceeds from notes receivable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $250.5 million for year ended December 31, 2020, primarily consisting of net proceeds received from our IPO in April 2020 and net proceeds from our follow-on offering in November 2020. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities during the year ended December&#160;31, 2019 was $70.9&#160;million, primarily consisting of proceeds generated from the sale of shares of Series&#160;C and Series&#160;D convertible preferred stock, net of issuance costs.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities during the year ended December&#160;31, 2018 was $38.0&#160;million, primarily consisting of proceeds of $37.9&#160;million generated from the sale of shares of Series&#160;C convertible preferred stock, net of issuance costs, and proceeds of $0.1&#160;million from the issuance of common stock upon the exercise of stock options.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contractual </span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">bligations and </span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">C</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ommitments</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our contractual obligations and commitments as of December&#160;31, 2020 (in thousands):</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="11" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Payments due by period</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Less</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">More</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">than</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1 to 3</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4&#160;to&#160;5</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">than</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1&#160;year</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">years</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">years</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5&#160;years</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="11" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,628</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,942</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reflects minimum payments due for offices and laboratory space in South San Francisco, California and San Diego, California leased under operating leases that expire in May 2022 and December 2021, respectively.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease certain office and lab space in South San Francisco, California under a&#160;non-cancelable&#160;operating lease, with a five-year term through May 2022 with an option to renew for an additional five-year term.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, we entered into a lease agreement for office space in San Diego, California under a&#160;non-cancelable&#160;operating lease with a&#160;13-month&#160;term. In October 2019, the lease was amended to increase the office space and extend the lease term until May 2021 and in November 2020, the lease was amended to extend the lease term until December 31, 2021. The minimum payments due under the amended lease total $0.2&#160;million over the lease term.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Rent expense is recorded on a straight-line basis over the terms of the respective leases. Total rent expense was $</span>1.4<span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;">million for the year ended December 31, 2020 and $1.3</span><span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;">million for both of the years ended December 31, 2019 and 2018.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have entered into contracts in the normal course of business with CROs, CMOs and other third parties for preclinical research studies and testing, clinical trials and manufacturing services. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice and, as a result, are not included in the table of contractual obligations and commitments above. Payments due upon cancellation consist only of payments for services provided and expenses incurred, including&#160;non-cancelable&#160;obligations of our service providers, up to the date of cancellation. We have entered into agreements with certain vendors for the provision of goods and services, which includes manufacturing services with CMOs and development services with CROs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have, nor did we have any off-balance sheet arrangements, as defined in the rules and regulations of the SEC, during the periods presented<span style="color:#231F20;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgements and Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (US GAAP). The preparation of these financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. <span style="color:#000000;">These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses. </span>Actual results may differ materially from these estimates under different assumptions or conditions. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in the notes to our audited financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> D</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">evelopment </span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">xpenses</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our financial statements, we are required to estimate research and development costs incurred during the period, which impacts the amount of accrued expenses and prepaid balances related to such costs as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel and service providers to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed in the periods in which they are incurred. External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with our discovery and preclinical activities, process development, manufacturing and clinical development activities. External costs also include laboratory supplies as well as allocated facilities, depreciation and other expenses. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We allocate external costs by program, clinical or preclinical. Internal costs consist primary of employee-related costs including salaries, related benefits and stock-based compensation expense for employees engaged in research and development functions. We do not allocate internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We make estimates of accrued expenses as of each balance sheet date based on facts and circumstances known at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and&#160;non-employee&#160;stock option grants, estimated in accordance with the applicable accounting guidance, recognized on a straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. We recognize forfeitures as they occur.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options is estimated using a Black-Scholes-Merton valuation model on the date of grant. The Black-Scholes-Merton option-pricing model requires inputs based on certain highly subjective assumptions. Changes to these assumptions can materially affect the fair value of stock options and ultimately the amount of stock-based compensation expense recognized in our financial statements. These assumptions include:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair value of common stock<span style="font-style:normal;">&#8212;Prior to our IPO, as there had been no public market for our common stock, the fair value of our common stock was determined by our board of directors primarily based on valuations of our common stock prepared by a third-party valuation firm using the option pricing method (OPM) and a hybrid method of OPM and the probability-weighted expected return method (PWERM) with discounts for lack of marketability and potential liquidation events in periods through August 2019, and PWERM beginning in November 2019. Subsequent to our IPO, the fair value of our common stock is determined based upon the closing market price on the date of grant.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<span style="font-style:normal;">&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of our stock options.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<span style="font-style:normal;">&#8212;Due to our limited operating history and a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<span style="font-style:normal;">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. We have opted to use the &#8220;simplified method&#8221; for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option, which is generally 10 years.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield</span><span style="font-style:normal;">&#8212;To date, we have not issued any dividends and do not expect to issue dividends over the life of the options and therefore have estimated the dividend yield to be zero.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions underlying these valuations represent our board&#8217;s and management&#8217;s best estimates, which involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our audited financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;107 of the JOBS Act permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition time to comply with new or revised accounting standards as applicable to public companies. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (1)&#160;are no longer an emerging growth company and (2)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the fiscal year in which we have more than $1.07&#160;billion in annual revenue&#59; (2)&#160;the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0&#160;million of equity securities held by&#160;non-affiliates&#59;&#160;(3)&#160;the date on which we have issued more than $1.0&#160;billion in&#160;non-convertible&#160;debt securities during the prior three-year period&#59; and (4)&#160;December 31, 2025.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Ite<span style="font-weight:bold;">m 7A. Quantitative and Qualitative Disclosures About Market Risk</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Rate Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objective of our investment activities is to preserve principal and liquidity while at the same time maximizing the income we receive without significantly increasing risk. To achieve this objective, we may invest in money market funds, U.S. Treasury notes, and high-quality marketable debt instruments of corporations and government sponsored enterprises with contractual maturity dates of generally less than two years, in accordance with an investment policy approved by our audit committee. Some of the financial instruments that we invest in could be subject to market risk, meaning that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include a variety of securities, including money market funds, government debt securities and commercial paper, all with various maturity dates. As of December 31, 2020, we had cash equivalents and short-term investments of $293.6 million, consisting of interest-bearing money market funds and securities issued by the U.S. Treasury. Due to the nature of our cash equivalents and short-term investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe that inflation, interest rate changes or exchange rate fluctuations had a significant impact on our results of operations for any periods presented herein.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item 8. Financial Statements and Supplementary Data <span style="color:#FF0000;"> </span></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:93%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pages</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:6%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><span style="text-decoration:underline;">Balance Sheets</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS"><span style="text-decoration:underline;">Statements of Operations and Comprehensive Loss</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S"><span style="text-decoration:underline;">Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Statements of Cash Flows</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_UNAUDITED_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Notes to Financial Statements</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><br /></span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="Background-color:#FFFFFF;">REPORT OF INDEPENDENT REGIST</span><span style="Background-color:#FFFFFF;">ERED PUBLIC ACCOUNTING FIRM</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and Board of Directors<br />ORIC Pharmaceuticals, Inc.:</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying balance sheets of ORIC Pharmaceuticals, Inc. (the Company) as of December&#160;31, 2020 and 2019, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the three&#8209;year period ended December&#160;31, 2020, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three&#8209;year period ended December&#160;31, 2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2018.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California<br />March 23, 2021</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"></span>&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ORIC PHARMACEUTICALS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="BALANCE_SHEETS">BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="8" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">215,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001796280_20191231" decimals="-3" scale="3">840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AssetsCurrent" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">296,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AssetsCurrent" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001796280_20201231" decimals="-3" scale="3">319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:Assets" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">298,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:Assets" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">94,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="8" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001796280_20201231" decimals="-3" scale="3">757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001796280_20191231" decimals="-3" scale="3">152</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent - long term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0001796280_20201231" decimals="-3" scale="3">219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0001796280_20191231" decimals="-3" scale="3">765</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:Liabilities" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,221</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:Liabilities" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 11)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000058">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000059">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000073" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001796280_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000074" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001796280_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000075" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000076" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal">20,348,788</ix:nonFraction> shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; authorized at December 31, 2020 and December 31, 2019, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000077" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000079" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000078" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal">19,278,606</ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2020 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2019, respectively&#59; aggregate liquidation preference of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001796280_20201231" decimals="-3" scale="3">0</ix:nonFraction> and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; $<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,058</ix:nonFraction> at December 31, 2020 and December 31, 2019, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity (deficit):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000083" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001796280_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000084" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001796280_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001796280_20201231" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares authorized at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and December 31, 2019, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding at December 31, 2020 and December 31, 2019, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000061">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000062">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000091" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001796280_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000092" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001796280_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000093" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001796280_20201231" decimals="INF" format="ixt:numdotdecimal">1,000,000,000</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000094" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal">26,750,000</ix:nonFraction> shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; authorized at December 31, 2020 and December 31, 2019, respectively&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001796280_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001796280_20201231" decimals="INF" format="ixt:numdotdecimal">36,672,415</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal">1,984,222</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and December 31, 2019, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:CommonStockValue" contextRef="C_0001796280_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">456,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001796280_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">166,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001796280_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">92,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001796280_20201231" decimals="-3" sign="-" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity (deficit)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">289,776</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">90,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">298,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">94,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ORIC PHARMACEUTICALS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,921</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired in-process research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,345</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:OperatingExpenses" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:OperatingExpenses" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:OperatingExpenses" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">74,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">28,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">775</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001796280_20190101_20191231" decimals="-3" scale="3">289</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">73,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Unrealized loss on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">73,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000128" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001796280_20200101_20201231" decimals="2" sign="-">3.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000129" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001796280_20190101_20191231" decimals="2" sign="-">14.15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000130" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001796280_20180101_20181231" decimals="2" sign="-">12.32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000131" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001796280_20200101_20201231" decimals="0" format="ixt:numdotdecimal">21,942,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000132" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001796280_20190101_20191231" decimals="0" format="ixt:numdotdecimal">1,899,348</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000133" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001796280_20180101_20181231" decimals="0" format="ixt:numdotdecimal">1,734,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ORIC PHARMACEUTICALS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S">STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity (Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000134" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231" decimals="INF" format="ixt:numdotdecimal">10,612,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000136" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" format="ixt:numdotdecimal">1,672,087</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" scale="3">833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">44,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">43,611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C preferred stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="oric:TemporaryEquityStockIssuanceCosts" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231" decimals="-3" scale="3">198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000140" name="oric:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">3,177,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,929</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of common stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000142" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">130,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:ProfitLoss" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:ProfitLoss" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000149" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">13,789,770</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000151" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">1,802,134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,807</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">64,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C and D preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;net of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="oric:TemporaryEquityStockIssuanceCosts" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_oricSeriesCAndDPreferredStockMember_20190101_20191231" decimals="-3" scale="3">135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000155" name="oric:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">5,488,836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of common stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000157" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">182,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001796280_20190101_20191231" decimals="-3" scale="3">131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:ProfitLoss" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:ProfitLoss" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000164" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">19,278,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000166" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,984,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">92,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">90,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial public offering of common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000170" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">8,625,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">137,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">138,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance costs associated with initial public offering</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;of common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion to common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000176" name="oric:TemporaryEquityConversionToCommonStockShares" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">19,278,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="oric:TemporaryEquityConversionToCommonStockValue" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">178,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000178" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">19,278,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public offering of common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000182" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,796,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">133,307</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">133,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance costs associated with public offering of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock related to acquired-in-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;process research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000188" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">871,494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of common stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000191" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">117,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:ProfitLoss" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">73,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:ProfitLoss" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">73,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000200" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">36,672,415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">456,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">166,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" sign="-" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:StockholdersEquity" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">289,776</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ORIC PHARMACEUTICALS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CASH_FLOWS">STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">73,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:Depreciation" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:Depreciation" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:Depreciation" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:ShareBasedCompensation" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:ShareBasedCompensation" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:ShareBasedCompensation" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash stock consideration, acquisition</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="oric:NonCashStockConsiderationAcquisition" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on fixed asset disposals</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of discount on investments, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">297</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001796280_20190101_20191231" decimals="-3" scale="3">986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" scale="3">410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,268</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">23,533</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">20,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisitions of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001796280_20190101_20191231" decimals="-3" scale="3">768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">225,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and maturities of investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from notes receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:ProceedsFromSaleOfNotesReceivable" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:ProceedsFromSaleOfNotesReceivable" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">215,959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" scale="3">768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" scale="3">508</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock pursuant to initial public offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">138,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance costs associated with initial public offering</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="oric:PaymentsOfStockIssuanceCostsWithInitialPublicOffering" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,691</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="oric:PaymentsOfStockIssuanceCostsWithInitialPublicOffering" contextRef="C_0001796280_20190101_20191231" decimals="-3" scale="3">99</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock pursuant to public offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">133,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance costs associated with public offering</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="oric:PaymentsOfStockIssuanceCostsWithPublicOffering" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of preferred stock, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,929</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from stock option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001796280_20190101_20191231" decimals="-3" scale="3">131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">250,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">10,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,523</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001796280_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001796280_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,819</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001796280_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock to common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts accrued for purchase of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" contextRef="C_0001796280_20200101_20201231" decimals="-3" scale="3">43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unpaid deferred financing costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="oric:UnpaidDeferredFinancingCosts" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ORIC PHARMACEUTICALS, INC.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_UNAUDITED_FINANCIAL_STATEMENTS">NOTES TO FINANCIAL STATEMENTS </p><ix:nonNumeric id="F_000266" name="us-gaap:NatureOfOperations" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. <span style="text-decoration:underline;">Description of the Business</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC Pharmaceuticals, Inc. (ORIC or the Company) is a clinical-stage biopharmaceutical company dedicated to improving patients&#8217; lives by <span style="font-style:italic;text-decoration:underline;">O</span><span style="font-style:italic;">vercoming </span><span style="font-style:italic;text-decoration:underline;">R</span><span style="font-style:italic;">esistance </span><span style="font-style:italic;text-decoration:underline;">I</span><span style="font-style:italic;">n </span><span style="font-style:italic;text-decoration:underline;">C</span><span style="font-style:italic;">ancer</span>. The Company was incorporated in Delaware in August 2014 and has offices in South San Francisco and San Diego, California. The Company&#8217;s principal operations are in the United States and the Company operates in <ix:nonFraction unitRef="U_oricSegment" id="F_000309" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001796280_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has devoted its primary efforts to raising capital, internal research and development activities and business development efforts and has incurred significant operating losses and negative cash flows from operations. In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi, Inc. development and commercialization rights to a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 insertion mutations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;December 31, 2020, the Company had an accumulated deficit of&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001796280_20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">166.4</ix:nonFraction> million. Through December 31, 2020, all of the Company&#8217;s financial support has been provided by&#160;&#160;proceeds from the issuance of common stock and from the sale of convertible preferred stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Company continues its expansion, it may seek additional financing and/or strategic investments, however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. The accompanying financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from <span style="color:#000000;">the date of the issuance of these financial statements. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering and Related Transaction</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 28, 2020, the Company completed an initial public offering (IPO) selling <ix:nonFraction unitRef="U_xbrlishares" id="F_000311" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200428_20200428" decimals="INF" format="ixt:numdotdecimal">8,625,000</ix:nonFraction> shares of common stock, which included the full exercise by the underwriters of their option to purchase up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000313" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200428_20200428" decimals="INF" format="ixt:numdotdecimal">1,125,000</ix:nonFraction> additional shares, at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000312" name="us-gaap:SharePrice" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200428" decimals="INF">16.00</ix:nonFraction> per share resulting in gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428" decimals="-5" scale="6">138.0</ix:nonFraction> million. After deducting underwriting discounts and commissions and other offering expenses related to the IPO of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="oric:UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428" decimals="-5" scale="6">12.8</ix:nonFraction> million, the net proceeds to the Company from the transaction were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="oric:ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428" decimals="-5" scale="6">125.2</ix:nonFraction> million. In connection with the IPO, all shares of convertible preferred stock outstanding at the time of the IPO converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000317" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428" decimals="INF" format="ixt:numdotdecimal">19,278,606</ix:nonFraction> shares of common stock. On April 21, 2020, the Company amended its certificate of incorporation to effect a <ix:nonNumeric id="F_000318" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428">one-for-<span style="-sec-ix-hidden:F_000319">four</span></ix:nonNumeric> reverse stock split of its issued and outstanding common and convertible preferred stock. The accompanying financial statements and related notes give retroactive effect, where applicable, to the reverse stock split. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Secondary Public Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 17, 2020, the Company completed a secondary public offering selling <ix:nonFraction unitRef="U_xbrlishares" id="F_000320" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117" decimals="INF" format="ixt:numdotdecimal">5,796,000</ix:nonFraction> shares of common stock, which includes the full exercise by the underwriters of their option to purchase up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000322" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20201117_20201117" decimals="INF" format="ixt:numdotdecimal">756,000</ix:nonFraction> additional shares, at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000321" name="us-gaap:SharePrice" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117" decimals="INF">23.00</ix:nonFraction> per share, resulting in gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="oric:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117" decimals="-5" scale="6">133.3</ix:nonFraction> million. After deducting underwriting discounts and commissions and other offering expenses related to the secondary public offering of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="oric:UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117" decimals="-5" scale="6">8.5</ix:nonFraction> million, the net proceeds to the Company from the transaction were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117" decimals="-5" scale="6">124.8</ix:nonFraction> million.</p></ix:nonNumeric><ix:nonNumeric id="F_000267" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000267_dcnt_0671b4d5-a27c-4cb3-a56a-77da25b3ad03">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. <span style="text-decoration:underline;">Basis of Presentation and Summary of Significant Accounting Policies</span></p><ix:nonNumeric id="F_000278" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000278_dcnt_3558223f-4e7b-4898-a3b4-b8ba06e9b371">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accompanying financial statements include all known adjustments necessary for a fair presentation of the results as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the year ended December 31, 2020 are not necessarily indicative of future results, particularly in light of the novel coronavirus (COVID-19) and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended operating activities. Beginning the week of March 16, 2020, </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000267_dcnt_0671b4d5-a27c-4cb3-a56a-77da25b3ad03" continuedAt="F_000267_dcnt_42cf8631-5ea9-4341-b912-125d0a3cb87c"><ix:continuation id="F_000278_dcnt_3558223f-4e7b-4898-a3b4-b8ba06e9b371">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the majority of the Company&#8217;s workforce began working from home. Disruptions caused by the COVID-19 pandemic, including</span><span style="color:#0000FF;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the effects of the stay-at-home orders and work-from-home policies, have impacted productivity, have resulted in increased operational expenses, certain adjustments to the operations of the Company&#8217;s clinical trials, the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">temporary </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspension of enrollment of new patients at certain of the Company&#8217;s clinical trial sites, and delays in certain supply chain activities and collecting and analyzing data from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the Company&#8217;s clinical trials, and may further disrupt the business and delay the development programs and regulatory timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company&#8217;s ability to conduct business in the ordinary course. As a result, research and development expenses and general and administrative expenses may vary significantly if there is an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of the clinical trials and other related business activities. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, the Company began reporting deferred offering costs within other assets on its balance sheets. To conform to current presentation, the Company included $<ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:DeferredCosts" contextRef="C_0001796280_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20191231" decimals="-5" scale="6">1.3</ix:nonFraction> million of deferred financing costs at December 31, 2019 in other assets. This reclassification had no effect on the Company&#8217;s total assets, net loss or stockholders&#8217; equity (deficit) as previously reported.</p></ix:continuation><ix:nonNumeric id="F_000279" name="us-gaap:UseOfEstimates" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. <span style="color:#000000;">These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000280" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheets. The Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits its exposure.</p></ix:nonNumeric><ix:nonNumeric id="F_000281" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, cash equivalents and short-term investments, prepaid expenses, accounts payable and accrued liabilities are reasonable estimates of their fair value because of the short nature of these items. </p></ix:nonNumeric><ix:nonNumeric id="F_000282" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of <ix:nonNumeric id="F_000327" name="oric:LiquidInvestmentsMaturityPeriod" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:durday">90</ix:nonNumeric> days or less at the time of purchase that are readily convertible into cash as cash equivalents. These investments may include money market funds, securities issued by U.S. Government agencies, corporate debt securities and commercial paper. </p></ix:nonNumeric><ix:nonNumeric id="F_000283" name="us-gaap:InvestmentPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined </span>based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities 12 months or greater at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). <span style="color:#000000;">The Company reviews its </span>portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss).<span style="Background-color:#FFFFFF;"> </span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000267_dcnt_42cf8631-5ea9-4341-b912-125d0a3cb87c" continuedAt="F_000267_dcnt_db60a578-d3a7-498c-9789-b9c6d314607b"><ix:nonNumeric id="F_000284" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, which consist of lab equipment, leasehold improvements, computer hardware and software, and furniture and fixtures, are stated at historical cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets, which are generally three to <ix:nonNumeric id="F_000329" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20200101_20201231" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimate useful life of the asset.</p></ix:nonNumeric><ix:nonNumeric id="F_000285" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="oric:PropertyPlantAndEquipmentImpairmentLoss" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="oric:PropertyPlantAndEquipmentImpairmentLoss" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="oric:PropertyPlantAndEquipmentImpairmentLoss" contextRef="C_0001796280_20181231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize impairment losses for the years ended December&#160;31, 2020, 2019 and 2018.</p></ix:nonNumeric><ix:nonNumeric id="F_000286" name="oric:DeferredRentPolicyPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Rent</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the office facilities over the terms of the leases. The Company&#8217;s leased office facilities provide for fixed increases in minimum annual rent payments. The total amount of rent payments due over the lease term are being charged to rent expense ratably over the life of the leases.</p></ix:nonNumeric><ix:nonNumeric id="F_000287" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (CRO), and contract manufacturing organizations (CMO) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company&#8217;s discovery and preclinical activities, process development, clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company allocates external costs by program, clinical or preclinical. Internal costs consist primary of employee-related costs, laboratory supplies, facilities, depreciation and costs related to compliance with regulatory requirements. The Company does not allocate internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company makes estimates of accrued expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in its accrued research and development expenses include the costs incurred for services performed by vendors in connection with research and development activities for which the Company has not yet been invoiced.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000288" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000288_dcnt_c02cb364-4d3c-4c66-86a9-23453ddb6fc2">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000267_dcnt_db60a578-d3a7-498c-9789-b9c6d314607b" continuedAt="F_000267_dcnt_14a04bc0-3ff7-438f-8710-55e100201bb8"><ix:continuation id="F_000288_dcnt_c02cb364-4d3c-4c66-86a9-23453ddb6fc2">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 2019, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#8220;more likely than not&#8221; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes would result in a change in the estimated annual effective tax rate.</span></p></ix:continuation><ix:nonNumeric id="F_000289" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and&#160;non-employee&#160;stock option grants, estimated in accordance with the applicable accounting guidance, recognized on a ratable straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes forfeitures as they occur.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options is estimated using a Black-Scholes Merton valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, a risk-free interest rate, expected volatility of the Company&#8217;s common stock, expected term of the option before exercise and expected dividend yield. Options granted have a maximum contractual term of <ix:nonNumeric id="F_000333" name="us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. </p></ix:nonNumeric><ix:nonNumeric id="F_000290" name="oric:LicenseFeesPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Fees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Acquisitions of&#160;technology licenses are charged to acquired in-process research and development expense or capitalized based upon the asset achieving technological feasibility in accordance with management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000291" name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Offering Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. </p></ix:nonNumeric><ix:nonNumeric id="F_000292" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from&#160;non-owner&#160;sources, including unrealized gains and losses on investments and foreign currency gains and losses. The unrealized losses on available for sale investments represent the only component of other comprehensive loss that is excluded from the reported net loss.&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000293" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000293_dcnt_f8734735-ba55-4015-b947-70f1411b8b0a">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </p><ix:nonNumeric id="F_000296" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">73,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:NetIncomeLoss" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding used in computing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000337" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001796280_20200101_20201231" decimals="0" format="ixt:numdotdecimal">21,942,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000338" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001796280_20190101_20191231" decimals="0" format="ixt:numdotdecimal">1,899,348</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000339" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001796280_20180101_20181231" decimals="0" format="ixt:numdotdecimal">1,734,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000340" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001796280_20200101_20201231" decimals="2" sign="-">3.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000341" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001796280_20190101_20191231" decimals="2" sign="-">14.15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000342" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001796280_20180101_20181231" decimals="2" sign="-">12.32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000267_dcnt_14a04bc0-3ff7-438f-8710-55e100201bb8"><ix:continuation id="F_000293_dcnt_f8734735-ba55-4015-b947-70f1411b8b0a"><ix:nonNumeric id="F_000297" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000343" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,996,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000344" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,683,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000345" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">1,854,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000346" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">19,278,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000347" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">13,789,770</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000348" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001796280_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,996,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000349" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001796280_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">21,962,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000350" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001796280_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">15,644,656</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000294" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) under its accounting standard codifications (ASC) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, the FASB issued ASU No 2019-12</span><span style="font-style:italic;Background-color:#FFFFFF;">, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="Background-color:#FFFFFF;">, as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. For emerging growth companies (EGCs), the standard is effective for fiscal years beginning after December 15, 2021. The Company early adopted the new standard in 2020 and the adoption of the standard did not have a material impact on the Company&#8217;s current financial position, results of operations or financial statement disclosures.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000295" name="oric:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02,&#160;<span style="font-style:italic;">Leases (Topic 842)</span>&#160;(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. ASC 842 provides a lessee with an option to not account for leases with a term of 12 month or less as leases in the scope of the new standard. ASC 842 supersedes the previous leases standard, ASC 840 Leases. For public business entities, this ASU is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, and should be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. As amended by ASU No. 2020-05, for all other entities, this ASU is effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act, ASU No.&#160;2016-02 is effective for the Company for the year ended December&#160;31, 2022, and all interim periods within. In July 2018, the FASB issued supplemental adoption guidance and clarification to ASC 842 within ASU No.&#160;2018-10,&#160;<span style="font-style:italic;">Codification Improvements to Topic 842, Leases</span>&#160;and ASU No.&#160;2018-11,&#160;<span style="font-style:italic;">Leases (Topic&#160;842): Targeted Improvements</span>. ASU No.&#160;2018-11 provides another transition method in addition to the existing modified retrospective transition method by allowing entities to initially apply the new leasing standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company is currently evaluating the impact the adoption of these ASUs will have on financial statements and related disclosures. The Company expects to recognize a right-of-use asset and corresponding lease liability on its balance sheets for its real estate operating leases upon adoption. See Note 11 for more information related to the Company&#8217;s lease obligations, which are presented on an undiscounted basis therein. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June<span style="color:#000000;"> 2016, the FASB issued ASU No. 2016-13, </span><span style="font-style:italic;color:#000000;">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;"> (</span><span style="font-style:italic;color:#000000;">Topic 326</span><span style="color:#000000;">) (ASC 326): </span><span style="font-style:italic;color:#000000;">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;">, which introduced the expected credit losses methodology for the </span>measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments&#8212;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments&#8212; Credit Losses&#8212;Available-for-Sale Debt Securities. The guidance is effective for public business entities for annual periods beginning after December 15, 2019, including interim periods within those years. For all other entities, the standard is effective for annual periods beginning after December 15, 2022 and interim periods, therein. Early adoption is permitted. Since the Company has elected to use the extended transition period under the JOBS Act available to EGCs, the ASU is effective for the Company for fiscal years beginning after December&#160;15, 2022. The Company expects to adopt the new standard in the first quarter of 2021, using the modified retrospective approach. The Company currently does not expect the adoption to have a material impact on its financial statements.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000268" name="oric:LicenseAgreementsDisclosureTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000268_dcnt_3b908a75-d5e3-436c-b35e-401f928f48b4">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. <span style="text-decoration:underline;">License Agreements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mirati License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On&#160;August 3, 2020, the Company entered into&#160;a license agreement (Mirati License Agreement) with Mirati Therapeutics, Inc (Mirati). Under the Mirati License Agreement, Mirati granted the Company a worldwide, exclusive, sublicensable, royalty-free license under Mirati&#8217;s rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2 and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compounds. Under the Mirati License Agreement, the Company is wholly responsible for development and commercialization of licensed products. In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least <ix:nonFraction unitRef="U_oricProduct" id="F_000353" name="oric:NumberOfLicensedProductsObligedToDevelopAndCommercialize" contextRef="C_0001796280_20200803" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> licensed product in certain major markets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Mirati License Agreement will continue in effect on a country-by-country and licensed product-by-licensed product basis until the later of (a) the expiration of the last valid claim of a licensed patent covering such licensed product in such country or (b) <ix:nonNumeric id="F_000354" name="oric:NumberOfPeriodAgreementInEffect" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_20200803_20200803" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> after the first commercial sale of such licensed product in such country. Following the expiration of the Mirati License Agreement, the Company will retain its licenses under the intellectual property Mirati licensed to it on a royalty-free basis. ORIC and Mirati may each terminate the Mirati License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Mirati may terminate the agreement if the Company challenges any of the patent rights licensed to the Company by Mirati or it discontinues development of licensed products for a specified period of time. The Company also has the right to terminate the Mirati License Agreement without cause by providing prior notice to Mirati.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial obligation under the Mirati License Agreement was comprised of an upfront payment of <ix:nonFraction unitRef="U_xbrlishares" id="F_000355" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803" decimals="INF" format="ixt:numdotdecimal">588,235</ix:nonFraction> shares of ORIC common stock, valued at approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:CommonStockValue" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803" decimals="-5" scale="6">13.0</ix:nonFraction> million based upon the closing price of the Company&#8217;s common stock on the acquisition date. The number of shares issued was based on a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000357" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803" decimals="INF">34.00</ix:nonFraction> per share, representing a premium of <ix:nonFraction unitRef="U_xbrlipure" id="F_000358" name="oric:SharesIssuedPercentageOfPremium" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803_20200803" decimals="2" scale="-2">10</ix:nonFraction>% to the 60-day trailing volume-weighted average trading price of the Company&#8217;s common stock. The shares were issued in a private placement in reliance on Section&#160;4(a)(2) of the <span style="Background-color:#FFFFFF;">Securities Act of 1933, as amended,</span> for transactions by an issuer not involving any public offering. During the <span style="-sec-ix-hidden:F_000359">eighteen-month</span> period following the date of the agreement, Mirati is subject to certain transfer restrictions, and the parties agreed to negotiate and enter into a registration rights agreement, with respect to the shares. The Company is not obligated to pay Mirati milestones or royalties. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded the transaction as an asset purchase as management concluded that all of the value received was related to a single identifiable asset. Further, as the asset was in early development at the time the license was acquired, the Company concluded that there was no alternative future use for the asset and recorded a charge at the closing of the transaction for the full $<ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:CommonStockValue" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803" decimals="-5" scale="6">13.0</ix:nonFraction> million value assigned to the shares issued in connection with Mirati License Agreement.&#160;&#160;This non-cash charge was recorded as acquired in-process research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2020.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Voronoi License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 19, 2020, the Company entered into a license agreement (Voronoi License Agreement) with Voronoi Inc. (Voronoi). The Voronoi License Agreement gives<span style="color:#000000;"> the Company access to Voronoi&#8217;s preclinical stage EGFR and HER2 exon 20 insertion mutation program, including a lead product candidate now designated as ORIC-114. Under the Voronoi License Agreement, Voronoi granted the Company an exclusive, sublicensable license under Voronoi&#8217;s rights to certain patent applications directed to certain small molecule compounds that bind to EGFR and HER2 with one or more exon 20 insertion mutations and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compound worldwide (other than in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan) (the ORIC Territory). Under the Voronoi License Agreement, the Company is wholly responsible for development and commercialization of licensed products in the ORIC Territory. In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least&#160;<ix:nonFraction unitRef="U_oricProduct" id="F_000361" name="oric:NumberOfLicensedProductsObligedToDevelopAndCommercialize" contextRef="C_0001796280_20201019" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction>&#160;licensed product in certain major markets in the ORIC Territory.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial obligations under the Voronoi License Agreement included an upfront payment comprised of a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="oric:UpfrontCashPayment" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019" decimals="-5" scale="6">5.0</ix:nonFraction> million cash payment and the issuance to Voronoi of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000363" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019" decimals="INF" format="ixt:numdotdecimal">283,259</ix:nonFraction>&#160;shares of the Company&#8217;s common stock, valued at approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:CommonStockValue" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019" decimals="-5" scale="6">6.8</ix:nonFraction> million, issued pursuant to a stock issuance agreement (Stock Agreement) entered into between the parties on October 19, 2020. The number of shares issued pursuant to the Stock Agreement was based on a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000365" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019" decimals="INF">28.24</ix:nonFraction>&#160;per share, representing a premium of&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000366" name="oric:SharesIssuedPercentageOfPremium" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019" decimals="2" scale="-2">25</ix:nonFraction>% to the 30-day trailing volume weighted average trading price of the Company&#8217;s common stock. The shares were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000268_dcnt_3b908a75-d5e3-436c-b35e-401f928f48b4">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also obligated to make milestone payments to Voronoi upon the achievement of certain events. Upon the achievement of certain development and regulatory milestones with respect to the first licensed product, the Company is obligated to pay Voronoi up to a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="oric:LicenseAgreementMaximumMilestonePaymentObligationToPay" contextRef="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricDevelopmentAndRegulatoryMilestoneMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019" decimals="INF" scale="6">111.0</ix:nonFraction>&#160;million. Upon the achievement of certain commercial milestones with respect to the first licensed product, the Company is obligated to pay Voronoi up to a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="oric:LicenseAgreementMaximumMilestonePaymentObligationToPay" contextRef="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricCommercialMilestoneMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019" decimals="INF" scale="6">225.0</ix:nonFraction>&#160;million. If the Company pursues a second licensed product, the Company would pay Voronoi up to an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="oric:LicenseAgreementAdditionalMilestonePayment" contextRef="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricSuccessBasedMilestonesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019" decimals="-5" scale="6">272.0</ix:nonFraction>&#160;million in success-based milestones. In addition, the Company is obligated to pay royalties on net sales of licensed products in the ORIC Territory.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Voronoi License Agreement will continue in effect until the expiration of all royalty payment obligations. Following the expiration of the Voronoi License Agreement, the Company will retain its licenses under the intellectual property Voronoi licensed to it on a royalty-free basis. The Company and Voronoi may each terminate the Voronoi License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Voronoi may also terminate the agreement if the Company discontinues development of licensed products for a specified period of time. The Company also has the right to terminate the Voronoi License Agreement without cause by providing prior notice to Voronoi.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Voronoi terminates the Voronoi License Agreement for cause, or if the Company terminates the Voronoi License Agreement without cause, then the Company is obligated to grant a nonexclusive license to Voronoi under certain of the Company&#8217;s patents and know-how and to assign to Voronoi certain of its regulatory filings for licensed compounds and licensed products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded the transaction as an asset purchase as management concluded that all of the value received was related to a specific identifiable asset related to EGFR and HER2. Further, as the asset was in early development at the time the license was acquired, the Company concluded that there was no alternative future use for the asset and recorded a charge of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="oric:LicenseAgreementChargeRelatedToAcquiredAssets" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019" decimals="-5" scale="6">11.8</ix:nonFraction> million at the closing of the transaction which consisted of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="oric:LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_oricAcquiredInProcessResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019" decimals="-5" scale="6">5.0</ix:nonFraction> million cash payment plus the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="oric:LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_oricAcquiredInProcessResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019" decimals="-5" scale="6">6.8</ix:nonFraction> million value assigned to the shares issued in connection with Voronoi License Agreement. This charge was recorded as acquired in-process research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2020. The charge was also reflected within cash flows from operating activities, with the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="oric:LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019" decimals="-5" scale="6">5.0</ix:nonFraction> million cash payment included in net loss and the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="oric:LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019" decimals="-5" scale="6">6.8</ix:nonFraction> million associated with the shares issued as an adjustment to reconcile net loss to net cash used in operating activities. </p></ix:continuation><ix:nonNumeric id="F_000269" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. <span style="text-decoration:underline;">Property and Equipment, net</span> </p><ix:nonNumeric id="F_000298" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricLabEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,396</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricLabEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricComputerHardwareAndSoftwareMember_20201231" decimals="-3" scale="3">220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricComputerHardwareAndSoftwareMember_20191231" decimals="-3" scale="3">158</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" scale="3">140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" scale="3">140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, gross</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,515</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December 31, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:Depreciation" contextRef="C_0001796280_20200101_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:Depreciation" contextRef="C_0001796280_20190101_20191231" decimals="-5" scale="6">1.0</ix:nonFraction></ix:nonFraction> million for both years and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:Depreciation" contextRef="C_0001796280_20180101_20181231" decimals="-5" scale="6">0.9</ix:nonFraction> million for the year ended December 31, 2018.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000270" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000270_dcnt_cb2e4a86-c94d-44a7-b5c3-c33de9209a8d">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. <span style="text-decoration:underline;">Accrued Liabilities </span></p><ix:nonNumeric id="F_000299" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:AccruedSalariesCurrent" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:AccruedSalariesCurrent" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and manufacturing costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="oric:AccruedClinicalAndManufacturingCosts" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="oric:AccruedClinicalAndManufacturingCosts" contextRef="C_0001796280_20191231" decimals="-3" scale="3">963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accruals</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001796280_20201231" decimals="-3" scale="3">904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001796280_20191231" decimals="-3" scale="3">617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent - short-term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:AccruedRentCurrent" contextRef="C_0001796280_20201231" decimals="-3" scale="3">546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:AccruedRentCurrent" contextRef="C_0001796280_20191231" decimals="-3" scale="3">495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued deferred financing costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="oric:AccruedDeferredFinancingCostsCurrent" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000270_dcnt_cb2e4a86-c94d-44a7-b5c3-c33de9209a8d"></ix:continuation><ix:nonNumeric id="F_000271" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. <span style="text-decoration:underline;">Short-Term Investments</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s <span style="color:#000000;">investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity.&#160;In accordance with the Company&#8217;s investment policy, it has </span>invested funds in available-for-sale securities as of December 31, 2020. The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> investments at December 31, 2019. </p><ix:nonNumeric id="F_000300" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale investments by types and classes of security&#160;at&#160;December&#160;31, 2020&#160;consisted of the following</span> (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001796280_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">215,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001796280_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001796280_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">215,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">215,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001796280_20201231" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">215,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. At December 31, 2020, there were <ix:nonFraction unitRef="U_oricSecurity" id="F_000410" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="C_0001796280_20201231" decimals="INF">18</ix:nonFraction> securities in unrealized loss positions. These securities have not been in a continuous loss position for more than 12 months. Further, the Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">None of the Company&#8217;s available-for-sale investments had maturities of greater than 12 months at December 31, 2020. The Company has determined that there were no material declines in fair value of its investments due to credit-related factors as of December 31, 2020.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000272" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000272_dcnt_ea63d932-1104-4733-b1a0-eb7cdec357a6">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. <span style="text-decoration:underline;">Fair Value Measurements </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets&#59; </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly&#59; and </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s interest receivable, included in prepaid expenses and other current assets, accounts payable and accrued liabilities are generally considered to be representative of&#160;their&#160;fair value because of the short-term nature of these instruments. The Company&#8217;s investments, which may include money market funds and available-for-sale investment securities consisting of U.S. treasury securities, and high-quality, marketable debt instruments of corporations and government <span style="color:#000000;">sponsored enterprises, are measured at fair value in&#160;accordance with the fair value hierarchy.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000272_dcnt_ea63d932-1104-4733-b1a0-eb7cdec357a6"><ix:nonNumeric id="F_000301" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following are the major categories of assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurement at End of Period Using:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">At December 31, 2020</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<span style="text-decoration:line-through;"> </span><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">215,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">215,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">215,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">293,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">293,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">293,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">At December 31, 2019</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents in accompanying balance sheets.</p></td></tr></table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="oric:FairValueAssetsLevel2ToLevel3TransfersAmount" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="oric:FairValueAssetsLevel3ToLevel2TransfersAmount" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="oric:FairValueAssetsLevel1ToLevel3TransfersAmount" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="oric:FairValueAssetsLevel3ToLevel1TransfersAmount" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="oric:FairValueAssetsLevel2ToLevel3TransfersAmount" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="oric:FairValueAssetsLevel3ToLevel2TransfersAmount" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="oric:FairValueAssetsLevel1ToLevel3TransfersAmount" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="oric:FairValueAssetsLevel3ToLevel1TransfersAmount" contextRef="C_0001796280_20191231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> <span style="color:#000000;">transfers</span> <span style="color:#000000;">between</span> levels occurred during&#160;either of the reporting&#160;periods presented.</p></ix:continuation><ix:nonNumeric id="F_000273" name="oric:ConvertiblePreferredStockDisclosureTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. <span style="text-decoration:underline;color:#000000;">Convertible Preferred Stock</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to its conversion to common stock in connection with the Company&#8217;s IPO in April 2020, the Company&#8217;s convertible preferred stock was classified as temporary equity on the Company&#8217;s balance sheets in accordance with authoritative guidance. <ix:nonNumeric id="F_000302" name="us-gaap:TemporaryEquityTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000302_cnt_1">Convertible preferred stock authorized and issued and its principal terms as of December 31, 2019 consisted of the following (in thousands, except share and per share amounts):</ix:nonNumeric></p><ix:continuation id="F_000302_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issue Period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividend</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Rate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000435" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">3,862,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000440" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">3,862,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 - 2015</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000457" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF">4.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000461" name="us-gaap:PreferredStockDividendRatePerDollarAmount" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231" decimals="2">0.32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000436" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">6,750,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000441" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">6,749,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015 - 2016</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000458" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF">8.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000462" name="us-gaap:PreferredStockDividendRatePerDollarAmount" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="2">0.64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000437" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">4,448,788</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000442" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">4,448,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 - 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000459" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF">12.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000463" name="us-gaap:PreferredStockDividendRatePerDollarAmount" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231" decimals="2">0.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series D</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000438" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">5,287,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000443" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">4,217,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000450" name="oric:TemporaryEquityIssuedPeriod" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20190101_20191231">2019</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000460" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231" decimals="INF">13.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000464" name="us-gaap:PreferredStockDividendRatePerDollarAmount" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20190101_20191231" decimals="3">1.056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,669</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000439" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal">20,348,788</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000444" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal">19,278,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s IPO in April 2020, all outstanding shares of the convertible preferred stock converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000469" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0001796280_20200430" decimals="INF" format="ixt:numdotdecimal">19,278,606</ix:nonFraction> shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000470" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001796280_20200430" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of convertible preferred stock outstanding as of the closing of the IPO.</p></ix:nonNumeric><ix:nonNumeric id="F_000274" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000274_dcnt_9f441e77-900e-49d6-88ca-fc53c5a284ef">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. <span style="text-decoration:underline;">Equity Incentive Plans and Stock-Based Compensation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2020 Equity Incentive Plan (the 2020 Plan), which became effective in April 2020 in connection with the Company&#8217;s IPO. Upon adoption of the 2020 Plan, the Company restricted the grant of future equity awards under its 2014 Equity Incentive Plan, as amended and restated (the 2014 Plan).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Plan provides for the grants of stock options and other equity-based awards to employees, non-employee directors, and consultants of the Company. A total of<span style="font-size:12pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_000471" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200430" decimals="INF" format="ixt:numdotdecimal">2,656,500</ix:nonFraction> shares of the Company&#8217;s common stock were initially reserved for issuance pursuant to the 2020 Plan. The number of shares reserved under the 2020 Plan also included<span style="font-size:12pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_000472" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandFourteenEquityIncentivePlanMember_20200430" decimals="INF" format="ixt:numdotdecimal">241,653</ix:nonFraction> shares of the Company&#8217;s common stock that remained available for issuance under the 2014 Plan as of immediately prior to the effectiveness of the 2020 Plan. The 2020 Plan share reserve will be increased by the number of shares under the 2014 Plan that are repurchased, forfeited, expired or cancelled after the effective date of the 2020 Plan up to the limit under the 2020 Plan. In addition, the number of shares of the Company&#8217;s common stock available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year, beginning with the Company&#8217;s 2021 fiscal year, in an amount equal to the lessor of (1) <ix:nonFraction unitRef="U_xbrlishares" id="F_000473" name="oric:MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200430" decimals="INF" format="ixt:numdotdecimal">2,656,500</ix:nonFraction> shares, (2) <ix:nonFraction unitRef="U_xbrlipure" id="F_000474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200401_20200430" decimals="2" scale="-2">5</ix:nonFraction>% of the outstanding shares of the Company&#8217;s common stock on the last day of the immediately preceding fiscal year, or (3) such other amount as determined by the Company&#8217;s Board of Directors.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_9f441e77-900e-49d6-88ca-fc53c5a284ef" continuedAt="F_000274_dcnt_5546e8be-c040-4d60-8976-38262765133f">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted under the 2020 Plan and the 2014 Plan become exercisable at various dates as determined by the Company&#8217;s Board of Directors or its authorized committee and will expire no more than <ix:nonNumeric id="F_000475" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from their date of grant. Stock options generally vest over a <span style="-sec-ix-hidden:F_000476">four-year</span> term. The exercise price of each option is determined by the Company&#8217;s Board of Directors, although generally options have an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. In the case of incentive stock options, the exercise price shall not be less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000477" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" scale="-2">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock at the time the option is granted. For holders of more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000478" name="oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" contextRef="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" scale="-2">10</ix:nonFraction>% of the Company&#8217;s total combined voting power of all classes of stock, incentive stock options may not be granted at less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000479" name="oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" contextRef="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231" decimals="2" scale="-2">110</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock at the date of grant and for a term not to exceed <ix:nonNumeric id="F_000480" name="oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" contextRef="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">five years</ix:nonNumeric>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000481" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,430,368</ix:nonFraction> shares available for future issuance under the 2020 Plan. </p><ix:nonNumeric id="F_000303" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the option activity for the year ended December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000482" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal">2,683,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000488" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001796280_20191231" decimals="2">3.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000483" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001796280_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,599,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000489" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001796280_20200101_20201231" decimals="2">17.86</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000484" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001796280_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">117,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000490" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001796280_20200101_20201231" decimals="2">4.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000485" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="C_0001796280_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">169,583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000491" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001796280_20200101_20201231" decimals="2">12.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000486" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001796280_20201231" decimals="INF" format="ixt:numdotdecimal">3,996,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000492" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001796280_20201231" decimals="2">9.03</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000494">8.5</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000487" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001796280_20201231" decimals="INF" format="ixt:numdotdecimal">1,249,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000493" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001796280_20201231" decimals="2">3.07</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000495">7.8</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001796280_20200101_20201231" decimals="-5" scale="6">2.7</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001796280_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001796280_20180101_20181231" decimals="-6" scale="6">0</ix:nonFraction> for the years ended December 31, 2020, 2019 and 2018, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain stock options granted under the Company&#8217;s 2014 Plan provided option holders the ability to early exercise their stock options prior to vesting. The shares of common stock granted from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding or issued until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. As of December 31, 2020, 2019 and 2018, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000501" name="oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" contextRef="C_0001796280_20201231" decimals="INF" format="ixt:numdotdecimal">6,072</ix:nonFraction> shares, <ix:nonFraction unitRef="U_xbrlishares" id="F_000502" name="oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" contextRef="C_0001796280_20191231" decimals="INF" format="ixt:numdotdecimal">29,579</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000503" name="oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" contextRef="C_0001796280_20181231" decimals="INF" format="ixt:numdotdecimal">121,794</ix:nonFraction> shares subject to repurchase by the Company, respectively. As of December 31, 2020 and 2019, the Company recorded less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20201231" decimals="INF" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20191231" decimals="INF" scale="6">0.1</ix:nonFraction></ix:nonFraction>&#160;million of liabilities associated with shares issued with repurchase rights. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2020 Employee Stock Purchase Plan (ESPP). The ESPP became effective in connection with the Company&#8217;s IPO however no offering period or purchase period under the ESPP will begin unless and until otherwise determined by the Company&#8217;s Board of Directors. A total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000506" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200430" decimals="INF" format="ixt:numdotdecimal">290,000</ix:nonFraction> shares of common stock were reserved for future issuance under the ESPP. Further, the number of shares of common stock available for issuance under the ESPP will automatically increase on the first day of each fiscal year following the fiscal year in which the first offering period under the ESPP commences in an amount equal to the lessor of (1) <ix:nonFraction unitRef="U_xbrlishares" id="F_000507" name="oric:MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200430" decimals="INF" format="ixt:numdotdecimal">500,000</ix:nonFraction> shares, (2) <ix:nonFraction unitRef="U_xbrlipure" id="F_000508" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200401_20200430" decimals="2" scale="-2">1</ix:nonFraction>% of the outstanding shares of the Company&#8217;s common stock on the last day of the immediately preceding fiscal year, or (3) such other amount as determined by the Company&#8217;s Board of Directors. As of December 31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000509" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares had been issued pursuant to the ESPP and there were no active offering periods or purchase periods.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are valued using the Black-Scholes Merton option pricing model on the&#160;date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#8217;s anticipated stock volatility and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. Forfeitures are recognized as they occur.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_5546e8be-c040-4d60-8976-38262765133f">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines the assumptions used in the option pricing model in the following manner:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">Expected term.</span><span style="font-family:Times New Roman;">&#160;&#160;T</span><span style="color:#000000;font-family:Times New Roman;">he expected term represents the period of time that options are expected to be outstanding. Because the Company does not have sufficient historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;color:#000000;">Expected volatility</span><span style="font-family:Times New Roman;color:#000000;">.&#160;&#160;</span><span style="font-family:Times New Roman;">Due to the Company&#8217;s limited historical stock price volatility data, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">Risk-free interest rate.</span><span style="color:#000000;font-family:Times New Roman;">&#160;&#160;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">Expected dividend yield.</span><span style="color:#000000;font-family:Times New Roman;">&#160;&#160;The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of <ix:nonFraction unitRef="U_xbrlipure" id="F_000510" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001796280_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction></span><span style="font-family:Times New Roman;">.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent<span style="color:#000000;"> to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on its closing market price.</span></p><ix:nonNumeric id="F_000304" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Merton option pricing model with the following assumptions.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="9" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16.00 - $35.92</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.60 - $9.16</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000515" name="us-gaap:SharePrice" contextRef="C_0001796280_20181231" decimals="INF">1.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.17% - 5.59%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4% - 2.6%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7% - 3.0%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88.01% - 95.11%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77% - 104%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93% - 98%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50 - 6.08</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000530">6.10</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.01 - 6.10</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000533" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001796280_20200101_20201231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000534" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001796280_20190101_20191231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001796280_20180101_20181231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant-date fair value of options granted was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001796280_20200101_20201231" decimals="2">12.99</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000537" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001796280_20190101_20191231" decimals="2">5.01</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001796280_20180101_20181231" decimals="2">1.41</ix:nonFraction> for the years ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_20200101_20201231" decimals="-5" scale="6">5.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_20190101_20191231" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_20180101_20181231" decimals="-5" scale="6">0.5</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively. <ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> stock-based compensation expense has been recognized as of December 31, 2020, pursuant to the Company&#8217;s ESPP. The total unrecognized compensation expense related to outstanding unvested stock-based awards as of December 31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001796280_20201231" decimals="-5" scale="6">20.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001796280_20191231" decimals="-5" scale="6">6.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001796280_20181231" decimals="-5" scale="6">2.3</ix:nonFraction> million, respectively, which is expected to be recognized over a weighted-average remaining service period of <ix:nonNumeric id="F_000546" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001796280_20200101_20201231" format="ixt-sec:duryear">2.7</ix:nonNumeric> years for 2020 and <span><ix:nonNumeric id="F_000547" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001796280_20190101_20191231" format="ixt-sec:duryear"><ix:nonNumeric id="F_000548" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001796280_20180101_20181231" format="ixt-sec:duryear">3.4</ix:nonNumeric></ix:nonNumeric> years</span> for both year 2019 and 2018, respectively. </p><ix:nonNumeric id="F_000305" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the total stock-based compensation expense included in the Company&#8217;s statements of operations and comprehensive loss for stock options for the periods presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" scale="3">476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" scale="3">618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231" decimals="-3" scale="3">359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000275" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true" continuedAt="F_000275_dcnt_276904f3-0334-4486-bed6-2453208bd351">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. <span style="text-decoration:underline;">Income Tax</span></p><ix:nonNumeric id="F_000306" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate were as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">15,478</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,647</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,487</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,158</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001796280_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,351</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,465</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent items</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="C_0001796280_20200101_20201231" decimals="-3" sign="-" scale="3">280</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="C_0001796280_20190101_20191231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="C_0001796280_20180101_20181231" decimals="-3" sign="-" scale="3">15</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001796280_20190101_20191231" decimals="-3" scale="3">692</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">663</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,916</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,673</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,536</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of Tax Cuts and Jobs Act</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001796280_20180101_20181231" decimals="-3" scale="3">94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001796280_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001796280_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001796280_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000307" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred taxes were as follows (in thousands):</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforward</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,740</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,380</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001796280_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,353</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="oric:DeferredTaxAssetsResearchAndDevelopment" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,319</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="oric:DeferredTaxAssetsResearchAndDevelopment" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,319</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="oric:DeferredTaxAssetsResearchAndDevelopment" contextRef="C_0001796280_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,147</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001796280_20201231" decimals="-3" scale="3">214</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001796280_20191231" decimals="-3" scale="3">353</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001796280_20181231" decimals="-3" scale="3">491</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,636</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="C_0001796280_20191231" decimals="-3" scale="3">771</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="C_0001796280_20181231" decimals="-3" scale="3">255</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,836</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,823</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001796280_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001796280_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,910</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001796280_20201231" decimals="-3" scale="3">238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001796280_20191231" decimals="-3" scale="3">240</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001796280_20181231" decimals="-3" scale="3">336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000601" name="oric:DeferredTaxLiabilitiesFixedAssets" contextRef="C_0001796280_20201231" decimals="-3" scale="3">238</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000602" name="oric:DeferredTaxLiabilitiesFixedAssets" contextRef="C_0001796280_20191231" decimals="-3" scale="3">240</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="oric:DeferredTaxLiabilitiesFixedAssets" contextRef="C_0001796280_20181231" decimals="-3" scale="3">336</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001796280_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001796280_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001796280_20201231" decimals="-5" scale="6">49.5</ix:nonFraction> million at December 31, 2020 has been recognized to offset the net deferred tax assets as realization of such assets is uncertain. The valuation allowance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000608" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001796280_20200101_20201231" decimals="-5" scale="6">20.9</ix:nonFraction> million during the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had available net operating loss (NOL) carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001796280_20201231" decimals="-5" scale="6">130.8</ix:nonFraction> million. Of the $130.8 million of NOL carryforwards, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001796280_srtStatementScenarioAxis_oricScenarioOneMember_20201231" decimals="-5" scale="6">41.6</ix:nonFraction> million begin to expire in 2034 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001796280_srtStatementScenarioAxis_oricScenarioTwoMember_20201231" decimals="-5" scale="6">89.2</ix:nonFraction> million do not expire. The Company also has available California NOL carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001796280_srtStatementGeographicalAxis_stprCA_20201231" decimals="-5" scale="6">132.0</ix:nonFraction> million as of December 31, 2020, which begin to expire in 2034.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Sections 382 and 383 of the Internal Revenue Code (IRC), annual use of the Company&#8217;s NOL and credit carryforwards may be limited in the event a cumulative change in ownership of more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000615" name="us-gaap:ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20200101_20201231" decimals="INF" scale="-2">50</ix:nonFraction>% occurs within a <span style="-sec-ix-hidden:F_000616">three-year</span> period. Since the Company&#8217;s formation, the Company has raised capital through the issuance of capital stock, which on its own or combined with the purchasing stockholders&#8217; subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the Company&#8217;s NOL and research and development credit carryforwards are subject to an annual limitation, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&#38;D credit carryforwards before utilization. The Company has not completed an analysis to determine if such an ownership change has occurred.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_276904f3-0334-4486-bed6-2453208bd351">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes liabilities for uncertain tax positions based in a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">examinations by tax authorities in determining the adequacy of its provision for income taxes.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had gross unrecognized tax benefits of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001796280_20201231" decimals="-5" scale="6">0.8</ix:nonFraction> million, none of which would affect the effective tax rate if recognized. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company&#8217;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="C_0001796280_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> accrual for interest or penalties on its balance sheets at December 31, 2020 and has <ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="C_0001796280_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognized interest and/or penalties in its statement of operations for the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States and California. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.</p></ix:continuation><ix:nonNumeric id="F_000276" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. <span style="text-decoration:underline;">Commitments and Contingencies</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases certain office and lab space in South San Francisco, California under a non-cancelable operating lease, with a term through <span style="-sec-ix-hidden:F_000620">May 2022</span>, and an option to renew for an additional <span style="-sec-ix-hidden:F_000622">five-year</span> term. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, the Company entered into a lease agreement for office space in San Diego, California under a non-cancelable operating lease with a <ix:nonNumeric id="F_000621" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20190331" format="ixt-sec:durmonth">13</ix:nonNumeric>-month term. In October 2019, the lease was amended to increase the office space and extend the term until <ix:nonNumeric id="F_000623" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20191001_20191031">May 2021</ix:nonNumeric>. The lease was further amended in November 2020 to extend the lease term until <ix:nonNumeric id="F_000624" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20201101_20201130">December 2021</ix:nonNumeric>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense is recorded on a straight-line basis over the term of the respective lease. Total rent expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction>&#160;million for the year ended December 31, 2020 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20190101_20191231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20180101_20181231" decimals="-5" scale="6">1.3</ix:nonFraction></ix:nonFraction> million for both the years ended December<span style="color:#000000;"> 31</span>, 2019 and 2018.</p><ix:nonNumeric id="F_000308" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under non-cancelable operating leases as of <span style="color:#000000;">December 31</span>, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="C_0001796280_20201231" decimals="-3" scale="3">686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_0001796280_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows.</p></ix:nonNumeric><ix:nonNumeric id="F_000277" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="C_0001796280_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. <span style="text-decoration:underline;">Employee Benefit Plan</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a defined-contribution 401(k) plan for employees. Employees are eligible to participate in the plan beginning on the first day of the month following date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation and the Company has the option to make a discretionary match as determined by the Company&#8217;s Board of Directors, within prescribed limits. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001796280_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001796280_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001796280_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> employer contributions to the plan during the years ended December 31, 2020, 2019 or 2018. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item 9A. Controls and Procedures. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#212529;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Evaluation of Disclosure Controls and Procedures</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We&#160;maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms, and that such information&#160;is accumulated and communicated to management including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of <span style="color:#000000;">December 31</span>, 2020, we carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934.&#160;Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of <span style="color:#000000;">December 31</span>, 2020.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#212529;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#212529;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Changes in Internal Control over Financial Reporting</span><span style="Background-color:#FFFFFF;font-size:12pt;font-weight:normal;font-style:normal;">&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Securities Exchange Act of 1934 that occurred during the quarter ended&#160;</span><span style="color:#000000;">December 31</span><span style="Background-color:#FFFFFF;">, 2020&#160;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;">&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#212529;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Inherent Limitations on Effectiveness of Controls</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">A control system, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions&#59; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within 120 days after December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within 120 days after December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within 120 days after December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence.  </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within 120 days after December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Item 14. Principal Accounting Fees and Services.  </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within 120 days after December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The following documents are filed as part of this report:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> Financial Statements</p></td></tr></table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements of ORIC Pharmaceuticals, Inc. are filed as part of this report on Form 10-K under Item 8. Financial Statements and Supplementary Data.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules</p></td></tr></table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other schedules have been omitted because they are not required, not inapplicable, or the required information is included in the financial statements or notes thereto.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits</p></td></tr></table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The documents listed in the Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Index</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="5" valign="top" style="background-color:#FFFFFF;width:52.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed Herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000156459020019302/oric-ex31_27.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39269</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000156459020019302/oric-ex32_67.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39269</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex41.htm"><span style="text-decoration:underline;">Amended and Restated Investors&#8217; Rights Agreement by and among the Registrant and certain of its stockholders, dated June 4, 2019</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520111275/d843476dex42.htm"><span style="text-decoration:underline;">Specimen Common Stock Certificate of The Registrant</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/20/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex101.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex102.htm"><span style="text-decoration:underline;">2014 Equity Incentive Plan, as amended, and forms of agreement thereunder</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520111275/d843476dex103.htm"><span style="text-decoration:underline;">2020 Equity Incentive Plan and forms of agreements thereunder</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/20/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520111275/d843476dex104.htm"><span style="text-decoration:underline;">2020 Employee Stock Purchase Plan and forms of agreements thereunder</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/20/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex105.htm"><span style="text-decoration:underline;">Employment Letter between the Registrant and Jacob M. Chacko, M.D.</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex106.htm"><span style="text-decoration:underline;">Employment Letter between the Registrant and Pratik Multani, M.D.</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex107.htm"><span style="text-decoration:underline;">Employment Letter between the Registrant and Dominic Piscitelli</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex108.htm"><span style="text-decoration:underline;">Executive Incentive Compensation Plan</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex109.htm"><span style="text-decoration:underline;">Change in Control and Severance Policy</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520111275/d843476dex1010.htm"><span style="text-decoration:underline;">Outside Director Compensation Policy</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001796280/000119312520057039/d843476dex1011.htm"><span style="text-decoration:underline;">Lease between the Registrant and Britannia Pointe Grand Limited Partnership, dated June 5, 2015</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/28/20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="oric-ex231_2434.htm"><span style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:underline;">Power of Attorney (included on the signature page to this Annual Report on Form 10-K)</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.96%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="oric-ex311_8.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.96%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.2</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="oric-ex312_9.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="oric-ex321_6.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.2*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="oric-ex322_7.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.CAL</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:13.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:6.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicated management contract or compensatory plan.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the&#160;</span>Securities Act of 1933<span style="color:#000000;">, as amended, or the&#160;</span>Securities Exchange Act of 1934<span style="color:#000000;">, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<span style="font-weight:bold;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:47.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ORIC Pharmaceuticals, Inc.</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:47.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:48.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:47.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 23, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:48.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jacob M. Chacko</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:47.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:48.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jacob M. Chacko, M.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:47.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:48.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:47.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:48.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jacob M. Chacko, M.D. and Dominic Piscitelli as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in his or her name, place, and stead, in any and all capacities (including his capacity as a director and/or officer of ORIC Pharmaceuticals, Inc.) to sign any or all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jacob M. Chacko</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jacob M. Chacko, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Dominic Piscitelli</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dominic Piscitelli</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Richard Heyman</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chair of the Board of Directors</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Richard Heyman, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Mardi Dier</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Mardi Dier</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carl Gordon</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Carl Gordon, Ph.D., C.F.A.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Lori Kunkel</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lori Kunkel, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Richard Scheller</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Richard Scheller, Ph. D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Peter Svennilson</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Peter Svennilson</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>oric-ex231_2434.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
oric-ex231_2434.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:20pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors<br />ORIC Pharmaceuticals, Inc.:</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statement (No. 333-237840) on Form S-8 of ORIC Pharmaceuticals, Inc. of our report dated March&#160;23, 2021, with respect to the balance sheets of ORIC Pharmaceuticals, Inc. as of December&#160;31, 2020 and 2019, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the three-year period ended December&#160;31, 2020, and the related notes, which report appears in the December&#160;31, 2020 annual report on Form 10-K of ORIC Pharmaceuticals, Inc.</p>
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California<br />March 23, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>oric-ex311_8.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
oric-ex311_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, <font style="color:#000000;">Jacob M. Chacko</font>, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of ORIC Pharmaceuticals, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 23, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jacob M. Chacko</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jacob M. Chacko, M.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>oric-ex312_9.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
oric-ex312_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I,<font style="color:#000000;"> Dominic Piscitelli</font>, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of ORIC Pharmaceuticals, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 23, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Dominic Piscitelli</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dominic Piscitelli</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>oric-ex321_6.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
oric-ex321_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of ORIC Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 23, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jacob M. Chacko</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jacob M. Chacko, M.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>oric-ex322_7.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
oric-ex322_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of ORIC Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 23, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Dominic Piscitelli</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dominic Piscitelli</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gpty1lksmhba000038.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000038.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $= 40# 2(  A$! Q$!_\0
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M)M(49^8^G3BJL/B>PA.G6TAN;FR2.YM[W>N&ECE?<"!GJ.#]:->P].Y3LO\
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M>V,T$C7+.%<#)&U1G]#163W.N"?*CT.BBBH-PHHJGJ5Y+901R10B7=,D;9;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,<?\CDW_ &#Q_P"C#6Q6./\ D<F_
M[!X_]&&MBFR8]0HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 44A8*,L0![T!@PRI!'M0 M%%% !1110 4444 %%%% !1110
M 4444 %%%% !15<WUH/,S=0?N_O_ +P?+VY]*D2>%WV)*C-M#;0P)P>A^E &
M6/\ D<F_[!X_]&&MBL<?\CDW_8/'_HPUL4V3'J%%%%(H**** "BBB@ HHHH
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MQ8YKV/Y;F\D&8+/Z_P!^3T0?C@4 4OB'KUQI_AZZT_2,3:W<PMY-NJ;V$?\
M&Y'0 +GD\9XYJS\/)=:F\$:<VO1K'>;,*  "8_X"0. =N*F30;71/#^IE&DN
M+R>WD:YO)SNEG;:>6/8#LHP!V%:FB?\ (!T[_KUC_P#010 [5(KF;3+A+.5H
M[G9NB8?WAR!]#C!]C7,2:[K*?9[R"T?RKZ1F2.>-LQJNU53 Y5F^9LFNSHH
MXE-6\06T05K=[M@7EC C96X:4!&.>?NIZ=?I27.O:S"_GVY%S$R*IG^RND:\
MO\VP\Y)"KUKMZ* (+.66:R@EFC\N5XU9T&?E8CD<U/110 4444 %%%% !112
M,P52S$!0,DGM0!P/VK[-X]FMWNI09KM66.+441,%5'S0XR3QZY/%=_7$P"ZB
M\27-V&O5T^6Y$HE@:W^S,FU068D[NW)%=HCK(BNC!D895@<@CUIL2'4444AF
M./\ D<F_[!X_]&&MBL<?\CDW_8/'_HPUL4V3'J%%%%(H**** "BBB@ HHHH
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MZ(4)-72-JBLV37;&%KA9&E5H"!(/);C.<=O0$_2FP:]93+,Q?:(VP#C.X$@
MC'8E@*+H.278U**QX_$NFF"*6622'S(O- DC88&"<=.N 3BG?\)#I[':LC!@
MVUA(C)CY@#U'8D9^M%T/V<^QK45BIXHTW?*))'B5& #.A&X%0V[&,@ ,.36U
MUIW%*,H[H****"0HHHH X^3_ (17_A('MVT1#,LJQF?[./+,C$#'U!(R<=Q7
M7@ # & .@%<$+=;KQ_+=FW;?!<K$)(M.+H1M'WI<X#<]<<<5WU-["04444AF
M./\ D<F_[!X_]&&MBL<?\CDW_8/'_HPUL4V3'J%%%%(H**** "BBB@ HHHH
M**** "BBB@ HHHH **** .>UO3[>XU[17D$F9)G1]LSJ&"QNP! ('4 U?UG6
M[/0[19KHNSR-L@@B7=+._947N?Y=3@5Q'Q ^($'AKQ5HFG1V+W=YDRA1(%4%
MPT:@]3U.3QT%=9HWA][:[;5M5G%[K,B[3-C$<"_\\XE/W5]3U;J?8 JV&B7F
MJWT>K^(U0RQG=::<K;HK3T9CT>7_ &N@[>IZ9B%4DD  9)/:EK$US50@;2;.
M+[5J5S&0L*G C4\;Y#_"H_,]!2;L5"+D[(RM OM(LKG6IVUQ'071)\Z\#C;L
MC^;KZ\9_"K_]MZAJORZ'IY\D_P#+[>@QQ_54^\_Z#WKD/ ?PY30]=N;RYEM+
MH6V;=5\C!#X5MPSTZXKU"IC=K70Z*RI4YV@^;SZ?<<?K7A2TN]&NI=>O[B^F
M6,NKO)Y4<; 9&Q%X'XY/O6GX0TNPTGPY;0Z</W4JB9_WF_YV W<_TK9EABGC
M,<T:2(>JNH(_(T0P16\?EPQ)&@YVHH _(4U%)W,Y5YRAR-Z=NGW#;JVCO+26
MVFSY<J%&P<'!]ZI_V+;LI6:6XG^1TS+*20K  C]!6E156,U)K8QW\-64D;H\
MERZO(92&F)^8Y!/Y''Y>E*/#>GKY>U95"$' E.&P00#Z@%16O12LA^TGW,0^
M%=,+*669MJ[1F4\#!7^1Q5F70[&=]TL;,=S,06."6(8_JHK2HHL@=2;ZF-_P
MC&G'!83,^?OM*2<8 VY], ?E6P.!BEHIV$Y2ENPHHHH)"BBD8;D*Y(R,<'F@
M#S^[$<7CU&AGADFDNT$D")<!P,#DG=Y9P/;&*]!KSR.467BR.U2[N'2*[2 6
MTNHRM.^0#YFPG!09_(&O0Z;V$MSGFUJ_%ZUKY4,<DLQCMO,0X*@G+$AN>G3C
MJ*6Q\0374T3/"BP2!E"J"7#*@<GW!S@#&>GK6JVE6#^;NM(3YQS)\OWCG/\
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M.!Z5:H&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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?#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gpty1lksmhba000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #. @\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WC[=:"=X#
M=0><@!>/S!N7/ R.V<BI9)$BC:21U1%&69C@#\:XG4O DM_J]W>"ZMDBFE6;
MRO)8[V#HWS?-Q]S&5QG(STJ&Y\!:E=VYAFU>.1 @C5'1RN " Y&[E_TY/% '
M>22)%&TDCJB*,LS'  ]2:J_VMIO[G_B86G[_ /U/[Y?WG./EYYYXXKF+/PM>
M3Z#J=I=S/%)<70:V68^:(X8W#1HX!P0<'(SR#55_A[-/<O=RW\2RR/YCP11%
M8"?,5MF,YVX7L0<DGVH [5;^S>:.%+N!I9%W1H) 6<>H'<4DFHV,4LD4EY;I
M)$F^1&E4%%]2,\#WKE=+\%W6F,BQWUMM(4O,;4--&P4J/+9LA1SGD'OZU!?>
M [N[:ZC758Q!/YS,S0#S9&D !WMZ C(QCL.E '9QWUI-:FZBNH'MP"3*L@*#
M'7GI41U;35DDC;4+0/%CS%,RY3)P,\\<FN<3P45T75-,DOVFAO/.($L:D,SX
MVN_&2ZX X(! '&:-6\&-J)N95GMUN)&C"-)#N C6-D*GGGEV;/KCTH ZC[;:
M9D'VJ',3A)!Y@^1CT!]"<]*GKB+;P (8IXWNHI3YL+P.T7S+LE,A9CGESN*Y
M],5V] !1110 4444 %-=UCC9W8*BC+,3P!3JRO$K%/#&J$?\^DH_\<- ,\QU
M_P"-CK<O#H%A$\2D@7-UGY_=4&./J?PKG?\ A<7BW^]8?^ Y_P#BJX!?N+]*
M6NY48);'BRQ55N]SOO\ A<7BW^_8?^ Q_P#BJ/\ A<7BW^_8?^ Q_P#BJX&N
MUT]O#_V*Q^T?V9]G$<&X,/\ 2/M'FCS-W_3/;N]L8[T.G!=!QKU9?:+/_"XO
M%O\ ?L/_  '/_P 51_PN+Q;_ '[#_P !C_\ %4^6X\)7$D<S)8K$3&#^["/D
M2MD,J#&T#;R.J]>:P)_[.35;:>\DTZ:1&B\VVL8RL$@S\Q+@X! QG:,'\ZE1
M@^A4JE5?;-S_ (7%XM_OV'_@,?\ XJC_ (7%XM_OV'_@,?\ XJJMU+X:33G:
M.*RE87[$1J2KL/./<=(_*Q_^NN8U@VQUN_-GY?V4W#^3Y?W=FXXQ[8IJ$'T)
ME6JQ^T=C_P +B\6_W[#_ ,!C_P#%5;L?C5XA@E!O;.QNH\\A5:-L>QR1^E>;
M457LH=B5B:J^T?4OA3Q58>+=*^VV6]&1MDT,GWHV]#ZCT-<9XP^+L>C:C/IF
MC6:75Q Q26>9B(U8=0 .6Q]165\$I7C@UH+CF2'.?HU>9:Z2?$6J$][R8_\
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M74&\JRB:2TA B2$\D0$%8R02&$NTDYYQU-')"U^4/:U;VYR?_A<7BW^_8?\
M@.?_ (JC_A<7BW^_8?\ @,?_ (JN5UZXL[J\MY;**&*/['"KQP@A5D"_,.>2
M<]3WK+JE3AV,WB*J=N8]"@^,WBF.4-+'I\R=T,++G\0U>I>"/'UGXRBEB6!K
M6_@4-+ S;@5/&Y3W&?RKYKKT/X-R-%XMO"N,FQ8<_P"^M15I14;HWPV(J.HH
MR=[GI?CGXAVG@_R[5+<W>HRIO6'=M5%Z;F/UZ >E>92_&7Q5)(6C73XE/1!
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M>GP0Q,E]<,-JD.T1V["Q/X@#MBGR0O;E)=:K:_.=#_PN+Q;_ '[#_P !C_\
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M]'_\51_PK3QC_P! 23_O['_\57TQ11]8D'U&GYGS1_PK3QB>3HDI_P"VT?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MROW4LF[&?N(6Q^.,4>PB@6-JMV21[K_PN7PG_>O_ /P&/^-'_"Y?"?\ >O\
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MSE5&8.'7<K =1DC^8(JO4]U=27;QL^!L0( /J23^))/XU!5(S=KZ'L/P9_Y
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M(X9)!C/N/4>XJMD>HKZC\1:MX5LE6+Q#<:=G&5BN55V_!<$_I7.?\)%\*_\
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MG(X!R,9ZYH U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,[03C]* ,G6O!GAW7Y3/J>F0R38YF4E'_%E()_&L/_A6'@;_ )\Q_P"!C_\
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F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gpty1lksmhba000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Q 2@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"SXG\3Z]:^
M*M5M[?6+R*&.Y9419,!1Z"LK_A+_ !'_ -!R^_[^T>+O^1RUC_K[>L6MTE8\
MZ4I<SU-K_A+_ !'_ -!R^_[^T?\ "7^(_P#H.7W_ ']K%HIV1/-+N;7_  E_
MB/\ Z#E]_P!_:/\ A+_$?_0<OO\ O[6+119!S2[FU_PE_B/_ *#E]_W]H_X2
M_P 1_P#0<OO^_M8M%%D'-+N;7_"7^(_^@Y??]_:/^$O\1_\ 0<OO^_M8M%%D
M'-+N;7_"7^(_^@Y??]_:/^$O\1_]!R^_[^UBT460<TNYM?\ "7^(_P#H.7W_
M ']H_P"$O\1_]!R^_P"_M8M=9_9.EZC;:%#9V3VESJLCH9FN&D$>QMOW>,Y_
M2AI(I.3ZF;_PE_B/_H.7W_?VC_A+_$?_ $'+[_O[5BT\++/:17,VH""*2!9C
M^Y+$;IC$!C/J,U)/X0^SNS-J<9MH5N#<RK"V8S"P5@%SELEACI2]T=IE/_A+
M_$?_ $'+[_O[1_PE_B/_ *#E]_W]J74?#0TRPN+J>_4[)4CA58C^^WQB13U^
M7Y3SGI4D>FZ=!I6GF>QOKRZU""699+:3'E;20 %QAL;<MD]#1H'O]RM_PE_B
M/_H.7W_?VC_A+_$?_0<OO^_M:MEX-5;O3?MMU'(EPR>=!&=K*'C+KM.<GH,\
M#\:I+H-M<>(=$TY'>*.]MH9)6SD[F4EL9]<8 HT"T^Y7_P"$O\1_]!R^_P"_
MM'_"7^(_^@Y??]_:TD\.VFKQV,MC VGQS3R0N\ER)]NU&8;EP&5L*<CITJFO
MAJ*2R%Q'J2DO ]W$C0,-T"-M9B<X#=3M]NM&@6GW(?\ A+_$?_0<OO\ O[1_
MPE_B/_H.7W_?VM.X\#2V41N+J_1;=&;>R1Y(&]5CP,_Q@Y'TJ>[\(Z<S3V]G
M>/'.E]<P1&5"?,$48?:<=._S=^.*+Q'RU#%_X2_Q'_T'+[_O[1_PE_B/_H.7
MW_?VL0'(!]:6G9&?-+N;7_"7^(_^@Y??]_:/^$O\1_\ 0<OO^_M8M%%D'-+N
M;7_"7^(_^@Y??]_:/^$O\1_]!R^_[^UBT460<TNYM?\ "7^(_P#H.7W_ ']H
M_P"$O\1_]!R^_P"_M8M%%D'-+N;7_"7^(_\ H.7W_?VC_A+_ !'_ -!R^_[^
MUBT460<TNYM?\)?XC_Z#E]_W]H_X2_Q'_P!!R^_[^UBT460<TNYU_ACQ/KUU
MXJTJWN-7O)89+E5=&DR&'H:*RO"'_(Y:/_U])164]SKP[;B[AXN_Y'+6/^OM
MZQ:]PU'X8Z/J>IW-_-=7RRW$AD<(Z@ GT^6JO_"H]"_Y_-0_[^)_\35J:L92
MH3;;/&:*]F_X5'H7_/YJ'_?Q/_B:/^%1Z%_S^:A_W\3_ .)HYT+ZO,\9HKV;
M_A4>A?\ /YJ'_?Q/_B:/^%1Z%_S^:A_W\3_XFCG0?5YGC-%>S?\ "H]"_P"?
MS4/^_B?_ !-'_"H]"_Y_-0_[^)_\31SH/J\SQFBO9O\ A4>A?\_FH?\ ?Q/_
M (FC_A4>A?\ /YJ'_?Q/_B:.=!]7F>,T5[-_PJ/0O^?S4/\ OXG_ ,31_P *
MCT+_ )_-0_[^)_\ $T<Z#ZO,\9JPM_=H+4)<R+]D8M;X;'E$G)*^G/->O?\
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MJV^H6UW<3V\+L9;<@2*49=N<XZCGH>E6JI+ID %P',C^?-YS$L0<X  R,<
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MQ8_Y$P?]?4?]:[FN&^+'_(F#_KZC_K0,\1HHHIB"BBB@#K?AI_R/EC_N2_\
MH!KWJO!?AI_R/EC_ +DO_H!KWJD,**** "BBB@ HHHH **** "BBB@ HHHH
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M$@'H/6I6\431B'.F/B4,55&)( W $_+C^'GTR*=F+GCW,+_A$-:_YYVO_?\
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K HHHH **** "BBB@ I/\:** #TH[FBBD 'K^%*.E%%, HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gpty1lksmhba000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #3 50# 2(  A$! Q$!_\0
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M^S6=86=D'GQ-&V5.#P>>H(_"M&@ HHHH **** "BBB@ HHHH **** "BBB@
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M,  <"LW5]);5?LF+R6V^S3K./+53N8=,[@>.M:=%8IV.QI25F%%%% PHHHH
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M%U@F&Y&QM8X)]P*WC4A+1/7\?N(<9+6QHT4459(4444 %%%% !1110 4444
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M3GUQ3_(OO^?Y/^_'_P!>FVV[L48QBN6*T)+RV%W9S0,J'>A WKD D<&N5M_
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M==3LXIQ^:_S(=*GR74Y*7R?Z(<OBN8_>\.:P/]V.-_Y/68WQ'M%\0KI9TW4
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M    '0"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gpty1lksmhba000028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #U F(# 2(  A$! Q$!_\0
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MW_"S/%/_ #^P_P#@.M'_  LSQ3_S^P_^ ZUR-%'*@]I/N==_PLSQ3_S^P_\
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M,)>>%TW@IN"(/G5NN221UI:=B_>M\1SW_"SO%'_/]!_X#K2_\+-\4GI>P?\
M@.M:M[XAM)O$R6UO$MU);7LTD<UW)'$@^5E6-&4?=SR"W?%9,L&FWWCEDO;L
M2PM#N;?*"/.$>1&7& 0&XSD9]>]&G8&Y=)"_\+,\4_\ /[#_ . ZT?\ "S/%
M/_/[#_X#K5@Z3H7E:L4BM_-B'^A(]WCS)/+RZ'#$;5/(.>3\N35I]!\/PWMK
M%<PPP1F2#;_I9W3*T):3<,_( =N#QU[T>[V#]YW,W_A9GBG_ )_8?_ =:/\
MA9GBG_G]A_\  =:%LO#]QX;6]\N.*X<Y95N,&)_, "?,V=I3G.T]<YXQ6@^B
M^'!K<<86W,#P,1$+G)1@X +?O,-\N?NL/7':CW>POWG\QG_\+-\4_P#/[!_X
M#K1_PLSQ3_S^0_\ @.M618:2]O!"'M;R:".X^SP-=;(I3Y^/O9!'R9(R1FFM
MIGAI2\,/ERK))>!)S<D&,)&&3'.#\V0"1R*/=[#]_P#F(/\ A9GBG_G]A_\
M =:/^%F>*?\ G]A_\!UKD!R!FEJN5&?M)]SKO^%F>*?^?V'_ ,!UH_X69XI_
MY_8?_ =:Y&BCE0>TGW.N_P"%F>*?^?V'_P !UH_X69XI_P"?V'_P'6N1HHY4
M'M)]SKO^%F>*?^?V'_P'6C_A9GBG_G]A_P# =:Y&BCE0>TGW.N_X69XI_P"?
MV'_P'6C_ (69XI_Y_8?_  '6N1HHY4'M)]SKO^%F>*?^?V'_ ,!UH_X69XI_
MY_8?_ =:Y&BCE0>TGW.N_P"%F^*L?\?L/_@.M>S:!=37WA_3[NX8---;I(Y
MP"2 3Q7S6>E?1OA7_D4M(_Z](_\ T$5G-)(WP\I-N[-BO&_$7Q \1Z=XDU&R
MMKN)8()V2-3 I( ]Z]DKYT\8?\CEK'_7TU*"39=>325C4_X69XI_Y_8?_ =:
M/^%F>*?^?V'_ ,!UKD:*UY4<OM)]SKO^%F>*?^?V'_P'6C_A9GBG_G]A_P#
M=:Y&BCE0>TGW.N_X69XI_P"?V'_P'6C_ (69XI_Y_8?_  '6N1HHY4'M)]SK
MO^%F>*?^?V'_ ,!UH_X69XI_Y_8?_ =:Y&BCE0>TGW.N_P"%F>*?^?V'_P !
MUH_X69XI_P"?V'_P'6N1HHY4'M)]SKO^%F>*?^?V'_P'6C_A9GBG_G]A_P#
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MV_R0I(Z$-RVQMISQQSTZT<[#ZO \:_X5UXJ_Z!@_[_I_C1_PKKQ5_P! P?\
M?]/\:]?DU^>'(>S1F5F1@DN<$'&>GW<X&3SSTXJ_:ZE',(TE CG9VCVC)&Y2
M0<'&/X33YV'U>!XC_P *Z\5?] P?]_T_QH_X5UXJ_P"@8/\ O^G^->^4E+VC
M#ZO$\$_X5UXJ_P"@8/\ O^G^-'_"NO%7_0,'_?\ 3_&O?**/:,/J\3P/_A77
MBK_H&#_O^G^-'_"N?%6?^08/^_Z?XU[Y11[1A]7B>!?\*Y\4_P#0+'_?Y/\
M&C_A7'BG_H%K_P!_D_QKWVBCVC#ZO$\"_P"%<^*L8_LL?]_T_P :/^%<^*L8
M_LP8_P"NZ?XU[[11[1A]6B>!?\*X\4D8.EC_ +_)_C4USX"\87DYFN; RRD!
M2[3QY( P!U[  5[O11[1A]7B>!?\*Y\59S_98_[_ *?XT?\ "N/%.,?V6/\
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MZ\5?] P?]_T_QKWRBCVC#ZO$\#_X5UXJ_P"@8/\ O^G^-'_"NO%7_0,'_?\
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M-B12&CZ<K[Q9PAMFS.WJO/!]>I_.DGAC@^PQ1($C6< *HX'RM5ZJE[_K;/\
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M/<)Y,EPJ2+"$B4;<G#9C.&)]< ?6NJ%[;-)-&)X]T(S(-WW![URG@=526_\
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M *^W_G6+6UXP_P"1SUG_ *^W_G6+7IP^%'R5;^)+U9] _#G_ )$+2_\ =?\
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M:O\ ='Y5TTZ"E&]SRL3F#I5'#EO8^H[>_L[MBMM=P3,HR1'(&('X58KQWX.
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M/^1SUG_K[?\ G6+7IP^%'R5;^)+U9] _#G_D0M+_ -U__0VKS/XJ_P#([O\
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M=6_] :OH>OGCP#_R/>D_]=6_] :OH>L<3\1VY5_"?J%%%%<YZ84444 %%%%
M!1110 C[BC!" V."1D UR7A)%&KZM^Z"2*VR0K"R D,V3RQY/7Z8KJ;I))+2
M:.%_+E:-E1_[K$<&L?P]I>HZ<TYU"=9MP CQ<22;%]/F'KSGD\^@%-"9I?V9
M98D'V9,2DEQCKFFG2-/(Q]DCY4)P.PZ?R'/M5VBD,HO&D5_8QQJ%14<*H& !
MA:Y/XL_\B7_V]1_UKKY_^0G9_P"[)_2N0^+/_(E_]O4?]:NE\:.?%_P)^AX?
M75_#;_D?=.^DO_HMJY2NK^&W_(^Z=])?_1;5Z%3X&?.8;^-#U1[!XW57\$:P
M&4,/LS'!'<<BOG/8O]T?E7T;XU_Y$K6/^O5_Y5\YUAAOA9W9K_$CZ&MX4BC?
MQ?HZLBE3>1Y!'^T*^E*^;O"7_(XZ-_U^1_SKZ1J,3\2.C*OX<O4****YCU0K
MYFU__D9-4_Z_)?\ T,U],U\S:_\ \C)JG_7Y+_Z&:Z<-NSR<V^"/J9U?1/@;
M_D1]'_Z]EKYVKZ)\#?\ (CZ/_P!>RUIB?A1AE7\27H<;XE^)FKZ+XCOM-@L[
M)XK=PJLX?<05!YP?>L6'XLZU '"V-@=[LYR'ZDY_O5B^/?\ D>M7_P"NJ_\
MH"USE5"E!Q6AA6Q=>-224MFSZ*\&ZY<^(O#D.I74<4<KNZE8@=N V.Y-=!7&
M_"[_ )$6U_ZZR_\ H9KLJXIJTFD>]AY.5*,GNT@HHHJ38\F^,W^OT;_=F_\
M9*\NKU'XS?Z_1O\ =F_]DKRZO0H?PT?-9A_O$OZZ'I/P<_Y#.J?]>Z?^A&N]
M\8^*CX3T^WNOL?VKSIO*V^9LQP3GH?2N"^#G_(9U3_KW3_T(UM?&+_D7]/\
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MI616.>^=OO53JRDK,SHX.E2ES06H[SK[_GR3_O\ _P#UJ/.OO^?)/^__ /\
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ME!9CC/ _"MNOF3X;_P#)1-%_ZZM_Z+:OINHJ04'8UP]9U8W84445F= 4444
M%%%% !1110 A( ))P!ZUR?@Z$1W>HN!<E2_RR.08W&2?EX#$YZDC\374SQB:
M"2(XPZE>5!'/L>#7)^#8;Z&^O5O;81,$7#BW6+?R>3M49/XFFA,O1OJ8@NPX
MNM[%<G;R#O._9[;,8]^G-(1J@C1G>[\HQ ,JK\RKYO7@9WE.O^-='12"QCVK
M79N--%TF'\ABS%OF+87J,5ROQF_Y$/\ [>XOZUVT_P#R$[/_ '9/Z5Q/QF_Y
M$/\ [>XOZU=/XT9U_P"%(^?:[+X5?\E'TS_=E_\ 1;5QM=E\*O\ DH^F?[LO
M_HMJ[9_"SQZ/\2/J?25075Y!91B2XDV(3M!()Y_"I)IHK>)I9I$CC7[SNP '
MU)K(U/6-,:R(74K,GS(^DZ_WU]Z\]'N-V-B-UEC5U.589!Q3JI+J^F.X5-1M
M&9C@ 3J23^=7: 3N%%%% PI&944LS!5 R23@"EKS6]^,NBVEY<6<^EZCYD$K
M1.,1D94D'^+VJHQ<MB)U(P^)V/1H9X;A2T,J2*#@E&!'Z5)7D]C\9=!LK..
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M*NIZ,#U% ')^#!+]KOV,86(':"+418;<<J>!R.F!D#UKL*H6&C:?I3.;&U2
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MA1X%3XV?2OPO_P"2<:1_N2?^C&KQ_P"+'_)1]0_ZYP_^BQ7L'PO_ .2<:/\
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M_P"/C0_]V;_V2O(:]>^.O_'QH7^[-_[)7D-=U'X$>-B_XS/5/@;_ ,AS5_\
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M!<29)PQQ]S_9;\C1JP5D9MWX9\)+%=(OAFW7R'$;N(%&,@'<,GGK@=R:DL]
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IET[2;32_.^RHR^:VYMS%L>@&>@'.![U>HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gpty1lksmhba000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ E(# 2(  A$! Q$!_\0
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MG_QK?/A_28KK]Q++<"9;YHMP5HPD.\*<]23@<TV'PEI\D]JHU"5DNXGNH%4
MN\*H#C !^<L6'3^$\470<L^YA?\ "0ZW_P!!G4/_  *?_&C_ (2'6_\ H,ZA
M_P"!3_XUN-X3L%$R?;+HR[[E83Y8"_N8P_S \Y.<<4_P]IMM<>%&N_[.6YN3
M=O'N^Q/<$*$4@85AMY/7FBZL'+*]KF!_PD.M_P#09U#_ ,"G_P :/^$AUO\
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MY%'M$'U:7<^> S#&&88.1@]#2=L9X]*^B/\ A#/#7_0$L?\ OR*/^$,\-?\
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MG\R!0 ^BL]=39YWB&GW>] "P^3C.<?Q>U:':@5PHHHH&%%%% !1110 4444
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M /HMJ^FJX\1\2/5P/\-^H4445@=H4444 %%%% !1110 4444 %%%% !1110
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MA)J5F:N2E!M=CY8[44=J*]$\$0]#7U5X/_Y$O1/^O&'_ - %?*IZ&OJKP?\
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M?4W@K_D2=$_Z\HO_ $$5S8C9'?@/C9O4445RGIA1110 4444 %%%% !1110
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MIE/B_P!='_OC^=;,Y%N?8 Z"O(/CM_JM"_WI_P"25Z^.@KR#X[?ZK0O]Z?\
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MU/2+B&V%O(F\;6Y.,< D]J]B_M!?^?:Z_P"_)KEK-.6AZF$BXT[-'SS\5/\
MDH^J?2+_ -%K7&UZ;X^\'>(]<\:7VHZ?H]Q+:RB/8Y*KG"*#P3GJ#7,/\//%
ML2%WT.=5'4[T_P#BJZ(3CRK4\^K2FZDFD]SF:]:^!?\ Q_ZW_P!<H?YO7&_\
M*X\8?] *X_[[3_XJO0_A3H&L^&;O5)-6TNY@6=(Q&0 ^2"V?ND^HJ:LHN#LR
M\-3FJJ;1ZS7R)J7_ "%;W_KXD_\ 0C7UA_:"_P#/M=?]^37SK>_#SQ;-J%U+
M'H=P4DF=U.].06)'\59T&DW<Z<;"4DN57.0HKIF^'GBY"H;0YP6.U?G3D_\
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MIES.;=I3)E0F-P7'WB/0UQTG::N>MB4Y4FD>&T5U'_"N/&'_ $ I_P#OM/\
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MPVT2Q(7B!; &!GWK&M4C-:'5A:$Z<FY&M7DOQU .F:-D?\MY/_017IWD7O\
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MKA_^$YNO^?*'_OX:/^$YNO\ GQA_[[/^%']JX7^;\&/^S<3_ "_BCN**X?\
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CBBB@ HHHH&>CZ9_R"K/_ *X)_P"@BBBBOKZ?P(^2G\3/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gpty1lksmhba000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #] E@# 2(  A$! Q$!_\0
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M2%:G-VBSHJ***@U/*_C;_P @"Q_Z^A_Z":\MT72=,U#2[V\N[N:%M/'G3QJ
M?,B(PNSCAM^T'/&&SVKU/XV*S:!8A5+?Z4.@S_":\5C>[ABFBB\Y(YUV2J <
M.N0<'VR ?PKLH_ >5BM*UVKG4>(O"NGZ1H?VV&><S;X$ :5) [/&'8$* 8R
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M:IIQBBAE.'MU(&T^H'I7FE=1XP\37/B;4?->.1($_P!7'M/'UKF?+D_YYO\
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M@.O!)^U/3****XSUCB?''C#1_#ES:VNIVMU,TZ&1# %P #CG)KDO^%F>$O\
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M]#QSTH]C 3QE9;_D>O\ _"S?"7_0,U/_ +Y3_P"*H_X6;X2_Z!FI_P#?*?\
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M (JO'J*/80#Z[5/8?^%F^$O^@9J7_?*?_%5Z%X/U.PUO0TU+3H9HH9&90LH
M8%3@]*^7*^B?A#_R3VU_Z[2_^AFLZM.,8W1T8;$3J3M([NBBBN8[SP_XY?\
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M])M[&V/EF-I2\FU2S!\<!L97@$'![UHR^)K4KOCLI)+D(RQRW+*QCW+M*Y4
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M/%D"",_8'(C4+Y!D'E2?<^9ACEALX/T_%O\ PE>V-8@MW/$#(9!<RAO.W(%
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MX5CXQ_Z S?\ ?Z/_ .*HYX]P]C4_E9R5%=;_ ,*Q\8_] 9O^_P!'_P#%4?\
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M3';R1YD1PC."D052N(P!QG.3[BL6NM_X5CXQ_P"@,W_?Z/\ ^*H_X5CXQ_Z
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MOWB.%W9+E,*>V%&3_@:O-X@V6TQDM)!<1R"/RE.5).W'SXP/OCK1S,.6(_\
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MT[4KB2_^RSR)*N94615QN*%>?R?'U7WK:I<S#D1C_P!C7O\ T']0_P"^8?\
MXBC^QKW_ *#^H?\ ?,/_ ,16Q11S,.1&!<:'JSK_ */XGOHF]6@A<?\ H(K&
MNM \>*3]C\7V\@[":Q5?U&:[BBFIM?\ #(3I1??[V>5W=E\7+<GRK^QN0/\
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M_!_Y+_\ Q-']OZ9_T/\ !_Y+_P#Q-'(_ZN'M5_5CM**XO^W],_Z'^#_R7_\
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M%Q7\5A@>E&!Z445H<X8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%%
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MY,DELQ,#THP/2BBJ)# ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** -#1_P#CYN?^O.X_]%M6=@>E:.C_ /'S<_\
M7G<?^BVK/I=2GL@P/2C ]***9(8'I1@>E%% !@>E&!Z449% %BRL9K^<PP!
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M7H3A?;/-7M/NK^>XG2\M%AC49C8 \_.RX.>IP >/6BP&C1110 4444 '4XK
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MO'^[5:J6QE+<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KFKV'0+RXN-4GO'40X\YP"%VE3'C./F&3U&>172UD-X>MI+9;62YNW
MM48,D/FX50,X48&<<_7@>E &7=:5H[R/!<ZI*9H5+RNR*<*40#G;@$*JXQSS
MFE$6CQLS)J<T;S3F9'$ #Q2!N2QVY&"^/GX^:M ^&+-BIDGN7VPB$98 X  !
MR!DXP#@\9YQ3G\.P2NTDEW=.\NX3L2N9@Q7(/' ^11QBG<#+M[31;>2.\?5+
MIGM90!/(I5-P9R0?EVG)+@G_ .M75(ZR1K(N=K@,,C'!]JQSX9M&MIK9YI6M
MYY/,D0!%+');!8 $@$YY/85L1J4B1&=I"J@%VZM[GWI .HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *KW%_:6DL45Q<1Q22_<5C][D#^9 _&K%4KG2[:
M\OX;JX4R>2A58R?E.6#9/K@J.#Q0!FO-IT]_<:@^KP26XB\@PO'D(K9!"G_:
M(YX.<8[4AM]*CTRWB&I1I!;6KVH<8P1)&#N^NT;OSJ2#PS%:%'MKR9)HRKI(
MRA]K#<,X/8AS\O3N*1O"UH5VK/,!]D:V/0Y)S^\_WL,1Z8- %,:?I\B-%'KD
MB0R1OMB VG:[@.>>N2< XXW=ZT=.N=+TNQ>V34DDB@E*@L<E-S'"\#GG(&![
M5%)X7MYO(:2X?S(-NQHT"8 ?<1CT/0TC^%XWC\O[=.478(D905158D#'?KC/
M%,1N1NLL:R(<HPRI]13JCAC,,$<1;=L4+D#&<>W:I*0PHHHH **** "BBB@#
M$U'09+_5&O!<1Q P-;@!#NPRD%\_WAGCV+#O44'AK_38+BX>!5C<OY-LA1 =
MBJ, ^N,FN@HHN!S4/AB>&6(B[A !R\@B_>+PPVH3T'S9[<YZUH:-I+Z:9#(T
M'S1QQA;="JG8"-Q!_B.>?I6K11< HHHH **** "BBB@#)U86SWEBLVH26TJ/
MOAC"!A*V0HX(.2,\>F<^]53<:((;K;=L%GO$N'*1G+/D;=H ^924ZC/?FM*]
MTN*^NK:XDEE5[8[H0A "L>I]\CY?H355?#=EF(2O-.D)01)*595122$QCD9/
M?G@<T 46MM(^V IJ-RDDD^^1$4\L'+#=\N5 9\9XSG%6]$M],M+NXCL;V::5
ME_>K(20Q5CEP2,'DD''%22^';269Y!-<1F23?((V W?-N Z< 'ICGDU8L])A
ML[GSDEF<*K)%&Y&V)6;<P7C/)]<TP+]%%%( K6M_^/=/I636M;_\>Z?2I9<"
M6BBBD64[JWDEEW*!C&.M0?8IO0?G6G13N)Q3,S[%-Z#\Z/L4WH/SK3HHN+E1
MF?8IO0?G1]BF]!^=:=%%PY49GV*;T'YT?8IO0?G6G11<.5&9]BF]!^='V*;T
M'YUIT47#E1F?8IO0?G1]BF]!^=:=%%PY49GV*;T'YT?8IO0?G6G11<.5&9]B
MF]!^='V*;T'YUIT47#E1F?8IO0?G1]BF]!^=:=%%PY49GV*;T'YT?8IO0?G6
MG11<.5&9]BF]!^='V*;T'YUITF?:BX<J,W[%-Z#\Z/L4WH/SK2HHN'*C-^Q3
M>@_.C[%-Z#\ZTJ*+ARHS?L4WH/SH^Q3>@_.M*BBX<J,W[%-Z#\Z/L4WH/SK2
MHHN'*C-^Q3>@_.C[%-Z#\ZTJ*+ARHS?L4WH/SH^Q3>@_.M*EHN'*C,^Q3>@_
M.C[%-Z#\ZTZ*+ARHS/L4WH/SH^Q3>@_.M.BBX<J,S[%-Z#\Z/L4WH/SK3HHN
M'*C,^Q3>@_.C[%-Z#\ZTZ*+ARHS/L4WH/SH^Q3>@_.M.BBX<J,S[%-Z#\Z/L
M4WH/SK3HHN'*C,^Q3>@_.C[%-Z#\ZTZ*+ARHS/L4WH/SH^Q3>@_.M.BBX<J,
MS[%-Z#\Z/L4WH/SK3HHN'*C,^Q3>@_.C[%-Z#\ZTZ*+ARHS/L4WH/SH^Q3>@
M_.M.BBX<J,S[%-Z#\Z/L4WH/SK3I*+ARHS?L4WH/SH^Q3>@_.M*BBX<J,W[%
M-Z#\Z/L4WH/SK2HHN'*C-^Q3>@_.C[%-Z#\ZTJ*+ARHS?L4WH/SH^Q3>@_.M
M*BBX<J,W[%-Z#\Z/L4WH/SK2_"BBX<J,W[%-Z#\Z/L4WH/SK2I:+ARHS/L4W
MH/SH^Q3>@_.M.BBX<J,S[%-Z#\ZT(5*0JIZ@4^BE<:204444#"BBB@ HHHH
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M)ZGZT 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.-;&.,PJ6C#1J"A#$$#TYQT]: ,B'Q;<R6OG/!:0^9.8HWFF*QH!O)+M_P
MP/<U-I_C""_U>SLA$J+<VPDW;\E9"-P3IS\H)S]*WA868611:0 2'+CRQ\Q]
M^.:>EK!$@2.")%4[@JH  ?7ZT:!9DU%%%(84444 %5-3L(]4TN[L)698[F%H
MF9.H##!Q[\U;HH!ZGF'_  H_0L?\A+4?S3_XFFGX*>'PX0ZKJ 8C=C<F<>OW
M:]1K*U/2&U%W_?\ EI)&J$A<D8)_^*/Y"M/:S[F'U:E_*>?O\&O#4432OK-Z
ML:ML+%X\!LXQ]WKGBF)\'O#$MRULFLWQF4D%-R9XZ_P]LUW[^'XI+$6<D\GD
M^:TK; %+$@]3]23^526FB):7BW7GO)-\WF%AP^[';H#QU'O1[6?</JU+^4X"
M+X+^')U+1:O?.J\$J\9 XS_=J3_A2&@Y_P"0GJ/_ 'TG_P 378?\(I!Y'EK.
M5/=E0#<!MP#CJ/EZ>YI9?#"%%\JY965BV2HRQXQD]>V/H:/:R[A]7I?RG'?\
M*1T''_(3U'_OI/\ XFC_ (4CH/\ T$]0_P"^D_\ B:[6QT)K2ZMY&E4K$AWJ
MHVJSX &%[ #=^+&HH/#*B+]_,#)AL;$&T$G.?<]B>XXH]K/N'U>E_*<?_P *
M1T#_ *">H?\ ?2?_ !-'_"D=!S_R$]0_[Z3_ .)KKE\-'[<C/)&]LGS$%?F8
MY4[?9/EZ>]/C\+QQ[-MU)\KELD9)!&,<G\S_ "H]K/N'U>E_*<:/@GX?+%1J
MFH9&/XD[_P# :/\ A2?A_>(_[5U#<1D#<F<?]\UV<?AE$5%-W(=H ^X. #GY
M?0^_7KZU9LM&6QN(FB?]W&IXQC+%57_V7)]S1[6?</J]+^4X7_A1^A?]!+4?
MS3_XFN_T/2(=!T2TTNWDDDBMDV*TF-Q&>^*T**F4Y2W9<*4(.\4%,EABGB:*
M:-)(V&&1U!!^H-/K*_M=GN"D<4>Q#EFDEV_+O*<<<G*G]/6I-"+5+J"QE@MH
M["WE:1&<B1EC54CQW(QD;N!]>15)/$VD6\DDDMH\$XD\@%(<EU#,H((ZK\A^
MF*F?6]*O(X%OK)FDP)1')"'\O@$-_P"/#F@ZEH\H;S--.[[VUX%RV,L3U[<G
M\:8AC>)=$,S^9!(/*=I/,>WXW*&&0?4[& /M6SI]S;WMJ98(RBEV5T9-I#@X
M8$>N16;)?:*C\6J.I7<TBPKM&=_!SW/S_F?6EM-<T^*)(X8/)MQ\L:H@'S9(
MVX'&<JW3TH W*P+O79XO$#:1!%;F0PF99))"!T/R$ ?>[X_NY-7;'68-0DC$
M*2!) VUG7!R IZ>A# U>\F(ON,2;L[L[1G.,9^N.*0SF(O%Y6?28;J*!7OHA
M+(4D.(@_^K'(YR00>E58O&\]Q"FVSMX)L*95N)BH4F-I, XYR%&#_M5V'V>'
M:5\F/:0 1M&..GY4U[*UD #VT+@8P&C!QCI^5/06IC1>*(O[->]GMW51<>2D
M:D;C\@;G) '&>_;WIM[XCC?0[J\MK0RQQRI !. %DW%0>.N/F[XK=:WA=&1X
M8V1CEE*@@GU-9FK:KIFFR16M[$&%SEMHC# XYR12 P7\0_9KA;0Z59^6L )"
MJ0!\C2;0<;>"OW<Y[CI5TZS$-6TR.UM+,^=;B1IP1F)2P!4$=N:&\2:2D4"1
M6)&^159'B5!$N0-Q_!N,?I1%K.BD11-I@$P952-(%/SL5!"].A9<GC\:8BD/
M%L&H0NT5I8ES<E0;E\*T:HSHY..IVD#T-:.E^*+>_P!=.GK;K%YMNLNXGYFD
MVAF0C'4*R\^Q]*74M5@AN;R)].M)8K*/GS9%#EA&9 %4CD8XZ^O'!H_X2O2(
MVP\$Z2HLDKKY/*%=P.?<[6H GL_%%G>W4-M!!.7E?:O"X P3N// X/'7VJC_
M ,)BRW\MI):+&8IF4NS_ "F,3+$'!Q_M-GT*^]:NDZG8:E-,MM;/#)$VYQ)$
M%))+*3Q[J0?I6BUM P(:&,A@0<J.0>2/QH'N<J/&4IOXHOLD1@<X,@D]7D52
M/8[!^=-7QC<#2X+N:"SB:9&E_>S[$"JJG;GG+'=Q]#75?8[7>C_9H=\:[4;R
MQE1Z#T%-&GV0B,0L[<1D[BGE+@GUQCK1H&ID:9XHAU+79=-6,(%A5XV+<LV
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M/6G);Q1RM*J .PP2/J3_ #)J6B@ HHHH **** "BBB@ HHHH **** "BBB@
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<0ONBB5#M"C:, #). /QJ:D,**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gpty1lksmhba000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A FH# 2(  A$! Q$!_\0
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/"X>*10Z,.C C(-25G6]W:6EK%;06]VD,*"-%^RRG"@8 Z>E2?VG#_SQN_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gpty1lksmhba000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #W F(# 2(  A$! Q$!_\0
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M,X&.@/M53_A6OA;_ *![_P#?]_\ &M5-)'+*A)ML\(HKW?\ X5KX6_Z![?\
M?]_\:/\ A6OA;_H'O_W_ '_QI^T1/U>9X117N_\ PK7PM_T#W_[_ +_XT?\
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M6GW&?'F\_*<8QZGJ!W'-5:]W_P"%:^%O^@>W_?\ ?_&C_A6OA;_H'M_W_?\
MQJO:(CZO(\(HKW?_ (5KX6_Z![?]_P!_\:/^%:^%O^@>_P#W_?\ QH]H@^KS
M/"**]W_X5KX6_P"@>_\ W_?_ !H_X5KX6_Z![_\ ?]_\:/:(/J\SPBBO=_\
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M@&;+9QN'0>G.,FO0S\//#1A6$V4AB5BRH;B3:">I SUX%-_X5OX6_P"@<?\
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MT;D,IR#39IH[>%I97"1H,LQZ 4 245$;B(7"VYD43,I=8\\E00"<>G(_.I:
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M4DH\JV(=*+ES,Y:30=377+Z[BF5H;E5 )NGC((CV$L@7:QSSU%9\GA#4Q#!
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M"_"EYX7M?(NM0:].TC>[$GD@]^U=92 **** "BBH+N\@LH?-N)-B9P."23Z
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MY<#C\<UJ>&)O/T96+,S+(ZG<S,<@^I=S_P"/5LTWN);&*US<GPY=2B)[EP)
MF<(TB9(#'. ..:XO69-1_L:PMTNKB6W*11%   <QHP!P!GG.,^E>C7V/L%P#
MWB;^1KR33=1O[B33_M#NT2&(MF/A0 HST] * .]T03KHMHMT'$P3#"0?,.3C
M/X8K0IJ2I,@DC8.C<AAT-.I%%NRZ/]15NJEET?ZBK= @HHHH **** "BBB@
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METTT312&>)@'4QJ9,KC=O1!MSUZC'>FA,Z;PW<7MSI[2W\1AG9^8O(\I4X'
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MA&3Z^O.,_D *VNU86H:;&9GGGOHH=Q)!?C@XX))Y QQ6=1+>US6E)[7L.&@
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M3%;'V^W^W?8]S>=_NG&<9QGIG'.*'N"V*>M?Z_2?^OY?_0'K4-96M?Z[2?\
MK^7_ - >L?Q[J?B#3;"S?086=GEVRLD7F$<<#'H3WJH0<Y**%*2BFV7;+QCI
MM]XHN= B$OVJ#=EROR,5^\!WXK.\'^+[_P 0ZGJEM>6"VT=J?E8 C;R1M;/?
MC/YTS4/#]A9Z)/J21-#J8A#N5F)97.,\YR>]5-:T?2M5@O-#TG5?+U@*'>*6
M=R&'!(;MT^I%:1Y'[J7S[>9F^=:W^7?R._!STILDBQ1/(YPJ*6/&>!69X9TV
M?1_#MGI]S<">:%,,X.1U)P,]AT_"M6L6DG9&J;:NSE-;\;6UIILCZ6T=Q? K
MLAF5D!!(SUQVKS;7GF\1F.ZN#;V]R79Y$!)49"@8//\ =KMO%7PYE\1:W/J<
M>I)"TB*HC:$L/E&.N?Z5GZ?\(81&_P#:6I.SY^3[,H48]]P/-=E)TH)2YM?0
MY:JJ3;CRZ>IT_A36[ Z/IVFB5S<11+ ?W;8+*O.#TQ]:ZBL;PUX=MO#&F/8V
MLTTL;2F4M+C.2 .P'I6S7).SDVCIA?E5PHHKF/%]UX@A2Q70+&2X<3"6=E90
M-B_P<D?>_I1&/,[!*7*KG3T4R)S)$CLC(64$HW5?8T^I**U_?1:;8S7D^?*B
M7<V!DGZ5#H^K0:UIZW=N'52Q4JXY4CM5B\2VELY8[P(;=EQ)YAPN/<UQ.L:+
M9@VRZ)J5K;QAOWJ-><#_ &ASUZU$G)._0B3DG?H=T94$BQEU#L,A2>2/I6)H
M?B>'6[ZZMH[=XC!R&8YW#.,^WTKB_LD*VXU634EF,!96M_-(F<AB %;.0",'
M\Z[#PI>:;=6(DMK>"UNI"1+$'!=MO?U(]S2YFY6%S-RL=%4-W<I9V<US(&*1
M(78+UP!FIJR=?U"PL]->._>00W ,)\L9;D'/TXJWL6]ANB>([/77F6U293$
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MG*JE"ZU]#533-.MM>V*! [PB4I',R!GW'/ //TI[Z^(9Y #'<Q$Y4QAE:/\
MWP1T_P!H?E61<>&KRX\0I<-J"FY6-9V9H^ P.  !VXHL?$]X^N7=M_9WF3/D
M;(WY#(,=\<<53H*2O![(%B&G:HM]#<FUF6+2KJ^EL]L42MC;*&+$-M].F>]8
M.F7']KZ-=W4RX^Q6_D0QCE5^7EO]X]/8?6H_#TE[J]Y<6VJ*QMX-TRPE-JER
MQR"/X@#GBM:Y46?A".6))E@6V#SQVL2%F!4%F^8@<#)ZYIWC%./6Y+4I-/I8
MT]99191@L ?/BZG_ &Q6!JNC6E_J5I/(7S(VQPK<, I(_E6U;(FHZ3'=7=L6
MD=<K]IB3>JD\?=)'OUKG]8N[ZUU;2K>QMXA TK)\T#'D1L3MVL!C Z>M13;B
M_=>NII.*DO>12_LJW3Q:J2:C;L 1((990TA]$P3D_P"%:.FSI-XO\1+#(K-%
M%:1N.RMM<X/YBLKQ!JMMI7C*UDCM%NM2ETUUMK8(-\DAD7;DX^4  DGL :YK
M1M&U70=?UK4X/$<3W8A2ZNDN;=EM[@MN9P6ZJ%VG#=?Y5I)RJ1N^PH1C3>G<
M[;1FN]3TG48=16W$:7$T(^RO(C$JYR<YR!G&,?C5"X6*S^$MPY=E5M+\QWDD
M9CN9!GEB3R>U<EHGBWQ!XB\-ZQ%X;TRV^T&YEEE9[D;T68DC8IQT&?F)[=*K
M2^&_$NK_  S\[4]7N;>*UA\Q;5]K130*H,>-AZ^I;T'%"@U+5]1MKEMY'?>(
MX[>72-&6:9DD%S:+A+AHSL8J&SM(XQW[5QVMIJ_B+Q_IDVFR[=)MI7L;=TNF
MC:8(N9RK@$\C*[NY7\:H>+M1UOP_I&CZ)>ZJM\DZQ3/<Q6A$\$:D87=R&]L\
MY6NYNH(K&^\.+IJR_8;4-Y'D63R)'$T94%F'4DX].N31%**OZ@[W,&Q^&]A;
M^/;@RWTUW']D^T,ES$LF=[,F,MDY& 0W)S6UX.\*Z7X7U/6I[!KS;%*(#&TN
M\,@C1QQCELL<?7%:*1>3XR>8VNHB 6@B-TY/E;@Y;EB?NX/TS2:%J%EJ&I:U
M"%=A)="55FA90ZB.-<C<,'E3_.HE*37D4K(D\'S,^A['M[B%EGF;$T>S(:5V
M!'KP15+QYX;L=?TZT:^>YVPW,2+''+M7]Y(J,2,<G:2 >U=1%!##GRH8X\]=
MB@9_*L[7[>^NK**&PMX96$\4K>;-Y8 1U?CY3G.,>U1S>_S(I+W;,O65HFGV
M,%E$\KQP1B-&E;<Q X&3W-7K3_7_ (570LR*74*Y +*#D ]QGO5BT_U_X5F4
M7Z***!!1110!7OR%T^Y8LRXB8[D&2.#R/>N?\$D/IURXG:9&E!7?.)2!M'4A
MFP?;BM[40ITR[#.J*87!9N@&T\GVK(\(R%M.D1]P>-E!5Y)6(&T$']YR 1R,
M<4UL)[G0  = !50Z='_:/VSS'SG=Y?&W=MV[O7H<5<HI#,/7;2"2^T>=XU:0
M7@0,?[I1\BF^([?2;+2;C5+RQ$RVD)(5"5) Z#BK.M?Z_2?^OY?_ $!ZTI(T
MFC:.5%>-QM96&01Z$4U:^HG>VAXSIT371O\ 4;B<0Q.K?9; 9=E)(Q\P&, 9
M[UU,5EX2BU5KN;4V\F0!5M9 5C1C@9SC/YGO6IXLN+SPSX5!\.64<9255*Q0
M[A&ISEMH]\#\:AN_"R>--+T:^UD36EY%&&ECCXSG!*D'IT_"NAVE[[T3T,5>
M/NK5K4Z>VTNRM(EC@MT55S@=<9Z]?6I/L=MMV^1'C9Y>-H^[Z?2I@ JA1T P
M*6N8W(3:6S;LP1G=C.5ZXZ?E2_9;?=N\E,E_,SM_B]?K4M% $(M+=2I$,8VD
MD87H3U_.D%G;!0!!'@(4 VC[IZCZ5/10! ;.V(8&",AE"GY>H'05R_C.;5;1
M;(:)I4EU*URL]PT: C:G\)]S_2NOKF?%_BH>&DL=D#3R3S#>JJ3MB'WCQW]*
MTI)N:LKD5+*+N[&[#! \<<HM@A)\P*RX96(YS[TX6=L H$$8"J5'RC@'J*DB
MD2:))8VW(ZAE/J#3ZS+,3Q!HAU/27MK,QP3': <8!4'[IQVJAH<&AM;'2'-K
M<WELA6:3R@,G/.&(YQG&:ZJL!?"6DI<W%PT#3-*2WER-\JD\G'U-0X^]S(AQ
M][F11\*:+8)827$RQSO+(R@3*&V!6*C&?7K71QZ?8QMOBL[=&QC<D:@X/O7!
MZ5H\^LV>J0R:=#9SH1Y$OELNUL\K[C Z^]=CX=TZXTK1HK2ZE$LJDDD$D+DY
MP/:E"=]EH*$K[+0O?8[;;M\B/&SR\;?X?3Z5S?B+PO;26$D]A"D4Z,9')8X9
M<'-=73)8UFB>)QE'4JP]0:T-&>*K*"N]0WX#FNP\+^'#</)-J=B3;R1*T+,W
M7/T.>GK75:9X?TW2)7ELK<QNZ[6)=FR/Q-:=1'G^TS.*E]HKI8VL<:QK!&%1
M/+48Z+Z4V:QL9$;SK6!DV@'>@(P.G7TJU65X@L+S4])DL[.:.%I2 [OG[O<#
M'K5-M+0MNRNC&\0:)=S:A%<V-I8K;0*7D5@ 9&Q@Y&.PZ4:%=:23INF/:0-<
MFU6?>8U)WD?^A$<U<33M72TC@NM>1'<>4%$"D-P> 3R3@5@Z;H6IQZWY+0M#
M#&-L=[]F0GY1P>>1GGGZ5#NMNIF[K5=3LK2VTQTWVEO;;5W19C0#'.&7CWJW
M'%'$,1HJC ' [#I67H6A+H44T4=W--'*V_$@'![D8]:UZN+;6II&]M0HHHIC
M"BBB@ HHHH **** #.*C$\+;=LJ'<"5PPY ZXHN$:2WD151F9" K_=/'0^U<
MT?#=W)"58V\<D@#.RDG##=D*,#"MN ([ =Z -^]=7TNY=&#*86((.0>#573_
M /D6K#_KVB_]!%1RV,\/AZ\A$PMY&$DF80&" DG:-PQCMTJ2P_Y%NQ_Z]HO_
M $$4 >?:W*?#?BB:XBN8HOM;?:HUDP/F("2 9ZY*@_C79P:E!<&-464LZALB
M)MN#QG/IGO7G7Q0UF:R\0^'7L[(3S6$YN&D8@ DX'E\^PR?3BK$?B.&3Q-'!
M [V$TY'_ !+[H&-AGJA'3DDX(X.<UVJ"J05]&D<LG*G)R6J;/4H!,()?)">9
MQMWYQ^.*KP7VH/:M<-:PN-S+MCDP1M)!/(]JY?2]5;^V;BVM-+*W#;A"&E_U
M1 P<YXQWI=+M?$PTV_VS!58,%\QLDMD[BGIW]JS]AR_$TMMQ^WYOA3Z['96-
MS)=VRS20&$. R N&R",]JM5YUYVH:?X<C?4;5YE=E%K(TO*+P<''."!Q2:IJ
M_F:99SVFF/;[R09&R5)&1A>>>23S3^K-O1B^LI+5&I>:3!X@\5O(69+>)-K,
M.?-9"-P'H!N _ UH6JK;ZG>0S6L212H&?S)5.U26)/3D9/3M61=:QHOAN'3&
MU"\U&T\ZWW1%4W(!PSC.WKT)[UQ-YXFNM7^*T(TW2TMA)&L4$UY;,KEASYI4
M?-R/E&1T/:IGSRVV1I2C%7YM+G4Z3I6G-=ZC''JJ7NP-&+>QF7S7'')&>@SC
MTS2Z):0'PSK5S+926\T*2(TM^B,BE-P8+L8G@CDY'/2N3T36/%NI:OXA#WD6
MD22DNNR%"4D"A54D[BBD <X//&032>'OAGK&K>'=3M-7DDCD:02V<SW!*Y))
M?@%E^;@DX)YK1UF[J4NQ*P\8V:B=%-$\GP]L=?)MK99(XY94M@R*4;;M!!8Y
M8,>OO6_++J'A^WT2V_LQ;EO.V&1+A4#2,K\<C)^M>>ZI\*-3T[P<EO%=&6Z$
MS&1+5))?-7 *K@8  ()R1QQ3/$WA?78K/P_'_P ))<!\AV:[DN-PE&<2;,'R
MP!@=<Y:AR4DHWZL%349<UCTN\O=8M_&-C:QMIFV[@=MK[_,6-&4MP#@GYN#[
M4RPUF?\ X2K5(7TDI&D:2^<I;S"A!"_*4&,[#G)^F:X36_ OV?QKI]W/J>I1
MP,%WD)-,L?3*"4ON.X[LD8QQQ2:3X:\4VGC74;^'4+VTLY(G D,4LY,(!**"
MXRQ''!()R<5E>%K7UL:J#WZ'>Z3JNCZK!=N4ED6V#O)(JL1L9RP "\D^V.QK
M+\5>*]$TCX>W]WI;!_M:M:VR,KKO=EQP&P2 #G(XXKD_"OC#Q=I^F:S)+HB"
M&"5[D+<6\T99B0#$@4'YLX.#S\QJ]\/K:Y\2>%[^XF'_ !.0C6437L3"*"W?
MG]T!ZY.3U)4 \"CD<=9 [-Z":IX^\.ZQX M&O[.XBE#0I'YUL2A9642;''!P
MH;(X..U5?$OB'Q#-K>B)H6@ZE8Z="Y\F0VH9I R$91.@VQ[B >:ZCQCX275O
M#=C'J&G37]];81$L9"D:C(W,59AR5&,\\UIC0H)8],:.ZU*U2Q0>1#YJY7Y2
MOSY#$G:2IY_QH4H)72[CLSE;7P3<67Q%M-4/B.^N;AH'G9IXE+,@95\L\\ A
MSV&,=*ZU-.NQK%]=W<UG-97,2QM 8&R%3<5R2Q!^\<\=NU2R:7))KD>IC4)U
M\N,QBW")L*D@D9QNY*@]:T:SE-L:5CEO#L^G_8]8DTJVBFF%W,1';HJ,T;-\
MF"<#'4CG'%-N8-3/P].G#2YOM7V+[(T(=6;=M"[A@D%<^XKK"Q/4D_6DH4[.
MX.-U8Y?4]36#PYI9U!6L93=6W[F7[P$<B;B<>@&?I73JXD171LJP# CN#3@2
MO0D?2DI-W&D& 1@C(I J@Y"J#["EHJ1A1110 5/:?Z_\*@J>T_U_X4 7Z***
M!!1110!0UE;IM)N!91R2W!7Y$CD6,L<_WF! 'X5F^$-,NM*TN2&[B>.1I2Y4
MB,*,@<+L[>YYKH:*!6"BBB@9E:U_K])_Z_E_] >M6LK6O]?I/_7\O_H#UJT
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MOTG_ *_E_P#0'K5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"GJ:7<FG3QV)07+KM1G. N>]0:#;WUGI,-MJ#(\T7R!T8
MMN7MG/?_  K3HI<NMQ6UN%%%%,84444 %%%% !1110 4444 %%%5M1FDMM/N
M)H5W2(A91C- "W__ "#KK_KB_P#(U3T__D6K#_KVB_\ 01437DTGAVZF9'N6
M D13" #(H) 8 D#ISU^E9<?B%;'1-)@N-+U!6N%BMX3MCP[[<@??XZ'KBG85
MS7HJG]KO/^@+J'_D+_XNC[7>?] 74/\ R%_\72'<U[+H_P!15NN;T_Q$);J\
MM8M)U%Y[5E690L?R$C(_CYX/:M#^U[C_ * FI?E%_P#'*+!<U**R_P"U[C_H
M":E^47_QRC^U[C_H":E^47_QR@#4HK+_ +7N/^@)J7Y1?_'*B&ON;IK8:-J?
MFJ@D*[8ONDD#G?CJ#0!LT5E_VO<?] 34ORB_^.4?VO<?] 34ORB_^.4 :E%9
M?]KW'_0$U+\HO_CE']KW'_0$U+\HO_CE &I167_:]Q_T!-2_*+_XY1_:]Q_T
M!-2_*+_XY0!J45E_VO<?] 34ORB_^.4R;7)8(9)I-%U(1QJ68XB. .3_ !T!
M<TKC_CW?Z5G52U#Q.EI8QS7&E:E''.Z1QL5C.6<@*.'[DTOVN\_Z NH?^0O_
M (NBP7+E%4_M=Y_T!=0_\A?_ !=5H-;:YO+JTATK4&GM2HF3$8V;AE>=_.1Z
M4!<U:*SKC4Y[2UEN9]'U!(84,CMB(X4#)/W_ $I;?4Y[JVBN(-'U!XI4$B-B
M(94C(/W_ $HL%S0HJG]KO/\ H"ZA_P"0O_BZ/M=Y_P! 74/_ "%_\70%RY16
M>NI7#7#P#1M1\Q%5V&(^ <@<[_\ 9-2?:[S_ * NH?\ D+_XNBP7+E%95AK3
M:G91WEGI6H2V\F=CXC&<$@\%\]0:L_:[S_H"ZA_Y"_\ BZ N7*GM/]?^%9GV
MN\_Z NH?^0O_ (NGZ;JRR:X=,EM+JVNOLYN LP7!3<%SE6/>@+F_1110 444
M4 %%%% !47VB R>4)H_,QG;N&?RJ1P2C!3@D<'TKF5T>Z6%9$01R-$B, Q+%
MQM&2.@P5+9'6@#2UK_7Z3_U_+_Z ]:M9.L:7<ZC-9/!?R6PMYA(P55.>",C*
MGGGZ=:5M.O47<VOW@ ZDQP__ !% &K167_9E]_T';W_OU#_\11_9E]_T';S_
M +]0_P#Q% &I167_ &;?'_F/7G_?J'_XBHK?3-5\D?:=>N3+DY\N&';C/'5/
M3% &S167_9M]_P!!Z\_[]0__ !%']FWV<?V]>?\ ?J'_ .(H U**R_[,OO\
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D<<C)/H?Q)K8HHJDDE9%));!1113&%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gpty1lksmhba000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #C E\# 2(  A$! Q$!_\0
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MH_X3GQ/_ -!F?_OE?\*Y^BBR#GEW.@_X3GQ/_P!!F?\ [Y7_  I?^$Y\3_\
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M(_6R_P"_Q_\ B:/^%5>(_6R_[_'_ .)KVZBCG8?5X'B/_"J_$?K8_P#?X_\
MQ-+_ ,*K\1^ME_W^/_Q->VT4<[#ZO \1_P"%5>(_6R_[_'_XFC_A5?B/ULO^
M_P ?_B:]NHHYV'U>!XC_ ,*J\1^ME_W^/_Q-'_"J_$?K9?\ ?X__ !->W44<
M[#ZO \1_X57XD];+_O\ '_XFC_A57B/UL?\ O\?_ (FO;J*.=A]7@>(_\*K\
M1^ME_P!_C_\ $T?\*K\1^ME_W^/_ ,37MU%'.P^KP/$?^%5^(_6R_P"_Q_\
MB:/^%5^(_6R_[_'_ .)KVZBCVC#ZO \1_P"%5>(_6R_[_'_XFC_A5?B/ULO^
M_P ?_B:]NHHYV'U>!XC_ ,*K\1^ME_W^/_Q-'_"J_$?K9?\ ?X__ !->W44<
M[#ZO \1_X57XC];+_O\ '_XFC_A5?B/ULO\ O\?_ (FO;J*.=A]7@>(_\*K\
M1^ME_P!_C_\ $T?\*K\1^ME_W^/_ ,37MU%'.P^KP/$?^%5^(_6R_P"_Q_\
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M1^ME_P!_C_\ $U[=11SL/J\#Q'_A5?B/ULO^_P ?_B:/^%5^(_6R_P"_Q_\
MB:]NHHYV'U>!XC_PJOQ'ZV7_ '^/_P 31_PJOQ'ZV/\ W^/_ ,37MU%'.P^K
MP/$?^%5>(_6R_P"_Q_\ B:/^%5^(_6R_[_'_ .)KVZBCG8?5X'B/_"J_$?K9
M?]_C_P#$T?\ "J_$?K9?]_C_ /$U[=11SL/J\#Q'_A5?B/ULO^_Q_P#B:/\
MA5?B/ULO^_Q_^)KVZBCG8?5X'B/_  JOQ'ZV7_?X_P#Q-'_"J_$?K9?]_C_\
M37MU%'.P^KP/$?\ A5?B/ULO^_Q_^)H_X57XC];+_O\ '_XFO;J*.=A]7@>(
M_P#"J_$?K9?]_C_\372^!?!&K^'O$#7M\;;R3 T?[N0L<D@^GM7I-%)S;*C1
MBG=!6->:(9YYY89(XS*V2"G'*%&)]3@]?:MFBI-3 7PV##Y<DP;8%2-@I!"
MD\\\D[N>W%6;^.Y@\-70>Z<7,4#.)H@%.5!(Q^0%:U4=:_Y 6H?]>TG_ *":
M=Q6,JV\/W4UK#*WB36=SH&.)(\9(_P!RLC6+/Q?H-P;S1]0DU2S\K$L%XJO(
MA')90NS=Z8SGZUV5C_R#[;_KDO\ (58Q34F9RHIK1V//;#X@3VMW=1ZO&]S;
MQ0+-Y]GI\L9BSG*R(Q)& ,[AQUKNK2]MK^!)[6XCFB=0RM&P((/(K)\0>'(M
M61+JU\JWU6!@\%UY2LV1G"MGJIR01[UR5IINI6GB!6TG3+#2M8M[9'N;:.4"
MWOHF+ Y"I\K!P,'_ &L9JK1DKHS4YTW:6IZ717*P^-/L\ME#KNDWND-='RQ-
M<&,PB3&=NX,<9YP2!FNI%0TT;J2>PM%%%(H**** "BBB@ HHHH XG5/$.M6\
MMY'!  D<\T<4NP'.U%*C'U)Y/%:%IJ^K#0Y)FMOM%Y'=/"T10AE4'^(+D9Z<
MC@@BJ6LZ[JEI?WL5K,6A3;\XM2?)/S?+[Y(49Y^\>F*NV.KZE'J:6^IJ%$K[
M8Q%&2 64$*3VP,_F*?0GJ.O-:O;;7K&!U6.VDA5Y5,9[ARYW=MNU?^^JH:AK
M.LV4D[PS^=#]K,46ZVY)5<[./[Q.T'_9]ZM2^)M0ANTC_LKS$DEF1-C'<P1M
MO<?>/7'I56U\6WVYS-:"422*(1$KX.?*!4$KR1O8Y/I0@;)]<UW4K.^D2S5"
MD4\<0CV;FD++NQUZ'./7BJ\6MZV6F93%*L=PR-A/E (.U5X!)7JWTIJ^(KY[
MJ&XCM(E$Z*)%B1R[$2(-F64#(#L#^/-3Q>+-0E",-+7;G+MN?IF,%1E?O#S"
M#VRIIA<LZAKLGV/3I[:Z^SVUPCLUS);%_F7&U-H_O'/Y8'6I%UFZ.A:E.NU[
MVW:7;'L((4.P4E>O0'ZXJ.[U^_M-6N;=+,30QR#YCD';^Z'RX')S(3SZ&FZC
MKE_:7UP8;)&CA=HQR<R[8@XR<<#+8_ TAE>;Q!?_ -DZ?,DR&5IRLVR/YY4W
M$)L4@C+  XXXSBKFG:[=.+Y7AGO?+F*Q2P0;5(V@X.3U!)'MWJ+1O$5]J&JO
M#-:/';O")(V*$?-M!*#WZG)[=*;IVOZGJFJ648MUM[<ES-\K$G" A,D##*3@
M^XXHL*Y37Q+J9\-37)DC^U+*,-Y."4VJ6PI/)#G9^'K4UMXDOGOG#RPE4DAC
MEA,>TQNX.Y0<Y(7C+>H([5''XNU/[8=VG;XW>- @W#RB=V5)(Y?@>W%077B7
M4;Z0>590H(I&\MI(V;+?( 1D<':S@Y]_2F%S8U:_U>6XL;;1_*,DENT\CX!C
M_A"\G^')/3G JE<>(=:2>S5[,6^^7:5,3'S?F0;1GIPS-G_9KI-*N9+S3HYI
M81"^61D7. 58KQGMQD5=I;#..NO$&JM<ZN+,PE(+=I8=T1(4 (5;(^]N#-@?
M[/UK4TO5)KS7]2M3<Q2PVX4;?+VLC=P.?F &,GUX'2MVB@+!1112&%%%% !1
M110!E7FDF>\>ZA>..0B,C*=61B06QU&#BJMOX=\D"-YDEA4,P4H02Y4*<G/3
MC([_ )5OT4!8S+#3);.&:W:Z=H6&(PHP8^.2#ZY-8^G:/=WRW3OXAU=/+N98
ME5)(\!5; ZH:ZNLG0?\ 47W_ %_3_P#H9IIM$RBGHRM_PC=Q_P!#)K7_ '\C
M_P#B*S4M?&6C7DOV::WUFSDF!074OERQ(!TR  2>:[&BGS,ATETNCDY?$VNQ
M:I%IW_",I]HEB:9 =04*RJ0#@[>HR./>GIXQ:UG>WUS1=0T^8<HT43744@XZ
M/&#S[$"M;5=#M-7DMY)VN(Y;<L8I;>9HW7<,$97G!K.;PWJ%I,)=)U^]B/&^
M*]8W,;=?[QW \]B.E/W62_:Q??[O^!^8L?COPTTCQS:FEI(H!*7J-;D@]P)
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MR7$<BN"P=\AWRVXCGA<;?;VJYJ3W3^$;QA"(I_LK@I,Y.!@YR1WQ6U5'6O\
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M.W5BQ=,A>NW<,\9&>.V1FL6#3=1D CN!<(QBQ))OW KL7"]>NX'\SSS75T4
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M7,KE:XU.PM)1%<WMM#(>B22JI/X$U9!! (.0>A%<M?-/=:W/:Q1B.")TEFF
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MMA#F:-T*M\L*OYH# ]&.W ]<%AVIK<3V-S5[B6RTT-;!4/F(F[@"-2P!/((
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M_A#X_P#H.Z__ .#%Z/\ A#X_^@[K_P#X,7I67<=Y=CHZ*YS_ (0^/_H.Z_\
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MFM+N6)UDC>]G*NAR"-YY!J_;Z?:VK2M#$%\T ..H('M5'P^JK;7JJ %%].
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M^8@@L"<,6'3IBNT!R ?6H[FVAO+66VN(UDAE4HZ,.&!ZBL3_ (0GP]_T#_\
MR-)_\53NGN91C.&D=5_7D;Y&>#5+^Q]+[Z;9_P#?A?\ "L[_ (0GP]_T#_\
MR-)_\55&QT^UT'QPMK:020VUY8$H-[,ID1\MU)P<,M%ET&Y237,E]_\ P"YK
M'A>&[^R7&FO'IMY9RF:*:"V0DDHRX((Z8:J.F>++]-+M5U/P]KC7RQ*+AHK,
M;2^/F(^;IFNOHI7[E<FMUH4=(U6#6M+AU"V658I2P"RKM92K%2"/7(-7JYO_
M (0?159S']OB5G9RD6H3HH+$DX ? Y)I?^$)TG_GMJG_ (,[C_XNG[H)SZHZ
M.BN<_P"$)TG_ )[:I_X,[C_XNC_A"=)_Y[:I_P"#.X_^+I:=PO/M^/\ P#HZ
M*YS_ (0G2?\ GMJG_@SN/_BZ/^$)TG_GMJG_ (,[C_XNC3N%Y]OQ.CI*YW_A
M"=)_Y[:I_P"#.X_^+I#X)T@C'G:I_P"#.X_^+HT[A>?;\3I**9#$L,,<2;MJ
M*%&YB3@>I/)I](L*Y'5[>^F\2)*+>>5HGC%J/(5X"F1O+L?NL/F]#P,9KKJ*
M$#"BBB@ K)T'_47W_7]/_P"AFM:LG0?]1??]?T__ *&: -:BBB@ HHHH ***
M* "BBB@ HHHH **** "BJU[?VVG0":ZE$<98(#@G)/0 #FFVNI6=\NZUN8Y5
MR!E6[D!OY$&BS%S*]BW14,EU!#"TTDR+&BLS-GH!U_*E2XBD1'2165QE2#][
MZ4!=$M9FLW\MI;)#: -?73>5;*>@;NQ_V5&2?ICO5J6^M8)((Y;B-'G)$2EN
M7P,G'X#-9_\ :.C,L>N-.FW:8$G8,!@G) !]<9R!T'H*:)FU:R9>TVPBTRPB
MM(B65!\SM]YV/+,?<G)/UJW49FB&,R(,C(RPZ>M!EC7.9%&#@Y8<4BE9*R)*
M*J1ZE9RW)MH[J)YAG*!LD8.#^()JRCJXRK!AG&0<T FGL.HHHH&%%%% !111
M0 4444 %%%% !4-Q=06B*UQ*D:L< L<9-351U.SFO84BAE2-=W[P.A.]>Z\$
M8SW]N* )!J5DS;1=1$[_ "\;A][TJ'5W63P_?NI!5K60@CN-AJG_ ,(ZC1E)
M90VW:L9"8*H"3CKR?F^G XI^JVLG_"*7T%Q<2/(+:3,J?(3@$]ORIB-&Q_Y!
M]M_UR7^0JQ5>Q_Y!]M_UR7^0JQ2&%%%% &/J<&F6BW=U>!A]L002,,D[=K=/
M3C<3]*YQ'\,K<K+']O2XD#REA(5>()G<#SGD,>!G@UUVHV'VX6V'VF&82?48
M*D?DQJA;>%=.M1;A/.*PR&78S#:[G^)ACJ,]L5<6DCGJ4Y.6B1G6^E>'9]/F
MO(O/CM(@TCL)&4!67++QU&#R/<U9T9=,CO42UAOK::1698YPR@(O\(S_  YD
MR .Y]JOQ>'[*(7"_OGCN(?)DC9_E(.<G'8G)IL6@QP313I>7C3QY DEDWDJ2
MN5Z8QA ./?O1S)]05-JSLBBL.F1:EJD1CO[>3RS<7$Y8JK)SC# YP#N(^AJ7
M3]/TG5M(M7@CF^SQJZQ[V(8Y8%B?7)4&M&72K>9[IG,G^EX$P#<,H7;M^F,_
MG4-OX>T^"Q6T:-IHPYDS*V26/&>,=L"B^@_9N^RMJ8]_8^';"YD@N!<[S$UR
MT:LQ4G<!N]-YW;1[4Y[?0!;V]\QN M]+Y2)N;+2.74@KV(\QP?2MJ^T:UU *
M)A( D31+L;& 2IS]047%57\+:>\5NC&X8VS!X29B-IW!CTQG) )S^E'-IJR7
M3=W9(DT73].A#:A8!_\ 2D7)9B>!T&/6M>JFF67]GZ=#:E][(OS-C&23D_J3
M5NI;NS>"M':P4444B@HHHH **** "L?5]&N;^^L[VSU V5Q:K(@;R1(&#[<\
M$_[(K8HIIV%**DK,P/[*\1?]#,O_ (+T_P :/[*\1?\ 0S+_ ."]/\:WZ*?,
MR/9Q\_O?^9@?V5XA_P"AF7_P7I_C2:'<:DNMZGIVH7JW@MXX9(Y!"(S\^_(P
M#_LBN@KG-LUEX_!616AU&R)="O*M"0 0?0^8?RIIWN3*/(TU??NSHZ***@V"
MBBB@ HHHH **** "BBB@"*XN(K6$RS-M0$#H223P  .2:J_VSIW)%TI 0/D
MGCCIQR>1QUY%2ZA!<7%F\5K.()6P/,*YP.^.1@X[]JSH] 56P[1&$ D0B,[0
MY0+Z]/ESCKD]: -:&>*X4M$X=0<9'3IG^M9V@_ZB^_Z_I_\ T,U)8Z6]G%-
M;J1X7&$ ^4Q\')!]<GM4'AJ(065U$'=PE[.-TC%F/SGJ3UH$;-%%% PHHHH
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M&TC[V% !Z9Z\^U;-YIDFI6MH+E84GM[E)E(!( 5\\>Y4?K6<WAR\:TOHO-M
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MD_Z&.W_\%P_^+K?HHYF'LUY_>S _LSQ)_P!#';_^"X?_ !=!TSQ)CCQ';_\
M@N'_ ,76_11S,/9Q\_O8R)76)%D</(% 9@N-Q[G':GT45)H%%%% !1110 5D
MZ#_J+[_K^G_]#-:U9.@_ZB^_Z_I__0S0!K4444 %%%% !1110 4444 %%%%
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M+N&X'VQFN?\ ^$YMCY;)8W#1NCN&R!PHY_)@RGZ9IMSXS9)A;):*EQMC8[I
MP&XKE3CN XHLPNC9T;SR+EYENHU:3Y([@Y( [Y]^N!P*U:Y6\\37%J=)<I;"
M.[ACEFY)8%BHPJYSCGJ W;('6E3QG'.<6UB\V(?.?;*ORJ$5F'N1NQCVHL%T
M7M4AU0RWAL7D/F6RJ@,@4(V6SMX^]C'7^E:UMYGV6'S1B38N\9S@XYYKFD\8
MHTH86DCPS&-;8@C+E\[,_P"\!D>E2:=XL34]2,$4(6)$E9VW;BVT(5*^Q#&B
MS"Z.E/*D9QD=1VKG;.#5HK^S\UIY(E7#%W]WR6(.,XV8&/RQ6._C>_BO(X'M
M8")# ZE0QQ&RJ9._WAO0#ZUH1^-8I0FRPD.<,Q$JD*I,8!SW/[Q<CMS19A=,
MZOM5/48YY(X?(>166>-F"$#<NX;@?;&:YJT\:3M&TES8*5\L,OD2@_/L+E3G
MZ'^5;6C:T-7>0J@6/RHY4P<\-N!!]P4-%F%TPT)+]%N!?>9DN"N]L]N>_P#+
MCT%:]%%(9SMZM[)J<WEQWXMU*[PKG]ZO&=G/&/;DY:MNR$RV-N+DYG$:B0_[
M6.:GHH BNB1:3$"0D(<"+[YX_A]ZP+ 7IO;7S$OHU^9W,A)10<XCY/.."6/H
M,>W244 %96M>>4MT@6ZW,^"\!XC']X@=?8=,GFM6B@#,TA=05KPZ@,,TVZ/$
MFY=NU>%X& #G]:TZ** "BBB@ HHHH 0]*R-"L[BT$WGQF/*H""^[>X!W/^/'
MOQ6Q10 5GZS')+I[)%:?:I"PQ&2 !SU()&0.N.]:%% $%E%Y-C;Q$R'9&J_O
M#EN!WQWJ>BB@#)N[2_EUZQN$,9M(2<KO((RK DCH?X0/3FM:BB@ K%T"RN[-
M9Q=+\S;27.,NW.X\=NG)YZY[5M5G:Y?2:;I$MU"8A(K(H,OW1N<+D\CIGUH
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gpty1lksmhba000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $: @H# 2(  A$! Q$!_\0
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M[8IYTVQ,"0&RMS"C;TC\I=JMZ@8X-3QQ1Q%S'&J%VW.5&-Q]3ZG@4 /HHHH
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MT4=: $'B72#/Y)O8U;"$%N V_=M /<_*>.V*?_PD&D$1G^T;?$CE$^?J>/\
M$?F*JP>%K&!D_>7#JJE2CN,'(<>G'$C# P!QZ4J>%[)%DW2W$CR1F)G9ADKA
M0!P.P0?K0!:77=->X$$5TDC^:(FV'.QCG&?3)4@'UJS>WMOIUG+=W3[((AEV
MP3@?A6!8^%YK>YWS7@:%9(C%$JGY8XV=E7)_VG'KP*V-9TW^U]'N;#S?*\]=
MN_;G'.>E"%*]M"M8^*='U+[1]ENMXMX_-D_=L-J^O(J[::E:WL>Z)R")#$4D
M4HP<#)4J><XY^E<]H'@R30'O)(=3+2SP^4C^0/W9[-@DY^E7[7PM:)'9F\(N
MKBTE:5)MI0LQSDMR<G)SGUIRM?0F#DX^]N7KO6;"RN8K>XGV22R)$HVD_,^=
MH)'3.TTZUU>PO#((;E"4G:W()VYD7[RC/7'M6=J'AT:C=7)DF*1RLDJLOWED
M5&0?EE6'N*K'P7;YXNY-K8\SY!DC*GY3_"Q*YR/7V%(LVTU6QDFFB6ZB+0LJ
MO\PP&;.!GIG@\5)]NM-^S[3#NW%-OF#.X=1UZUS3^!+>1</>.<;5 $84;0NW
MD*1EL=S^569?!\#M;[+IXTAE,I41CYV,OF<G].<\>] &LNL:>]F+M+N-H#%Y
MP93GY/[V.N/>KNX;=V>,9S7)KX)CMM\L%T9)O(,2>8N "8_+!XXQM[8Y-=/#
M (;..W5B52,(">IP,4 )%=PS/L1\MC.,57CUFPEDOE6<#["P6X9@0JG&>IZ_
MA3[:P^SR[_,W<8QBJUUH%G?_ &];Q?.BO @:-@/EVC (]Z!*_4M7VHV^GQ"2
M=B <X"C).%+'\@":<=0M$C@>2XCB%P!Y0D<*7SV&>_-9^J:*+I+2*W58XHED
MA*J,;4="I('J../K5:3PS-<P1)<ZD7*0FW++ J[HCM)&,G#94?-^E S:2_M)
M&"1W4+LV,*L@).02/S )_ TQ]5TZ/S?,O[9/*8+)NE4;">@//!K*T[PG:Z=K
M!U%)Y';,A$; ;1N/R_\ ?*[E'LQI$\)PK=Q3-<LZP2F2)#&. 7WD$_Q<]^WZ
MT ;3WMK$Y22YA1AG(9P",#<?TY^G-1MJNGJDKM?6P6(A9"95PA/0'GBLK5O"
M=MJVJ+?27$L; ("B 8.&^;_OI<H?8U47P1!'YWDWLJ;WR..=NYF*DYR>6[8Z
M=^<@&VVMV"K,3.,1,%;'IA3N'JH#KD^]:%<FG@Q;&UN19W+/-<VRVLID  9
MJH#[%0&/'7/TKJU&% ].* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>@&: NA:*J_;XO1ORI1?1%@ &Y..E%@NBS1110,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,;Q4MPWAJ\^S3&&0*I+B81$*
M&!8!VX4E<C)XYYKFO!"WSZG+/;74C:/AU\B6]BG,1^3:/W>0I)WGKT(S6WXU
MDE70&5-/:[B:1#*1-'&(E5@VYO,.TCCH:S_AZB+9Z@T)B$+7 $21SPR%5"
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M1,X&<=JJ?V@W_/,?G2L4VD7Z*I17K22JA0#)QUJ[0"=PHHHH&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!@^,EC?PM=K*S*"T>PJJL=_F+MX?Y<;L?>X]:J>"+YKVQN?,DWRHZ%@(8
MT"[D# ?N^#U[\U?\6-*OAF\$+('?:GS[?F#. 5&X%<D$@9XR1FH?"MI/:6]X
MIT[^SK-I]UK;,L:NB[1NR(^/O9QR3ZT =!1110 5C7G_ "&;G_L'-_Z$:V:Q
MKS_D,W/_ &#F_P#0C30GL>(K]T?2G#[P^M-7[H^E.'WA]:ZSQ3WJZ_Y!4_\
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M0?W_ -#3DN8I&"JV2?:LFI[3_CY3\?Y4["4G<U****DL**** "BBB@ HHHH
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M]*]\N>=(F/\ T[M_Z#7@:_<7Z5A1ZG=C-XCXO]='_OC^=>\:I_R![W_KW?\
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M9?\ 'R/H:M7W_'O_ ,"%%M1IZ7'?:X/[_P"AIR7$4C;4;)^E9-6;'_CX_P"
MFBPE)MFE137=8QEF 'O3/M,/_/1?SI%W):*8LT;MM5P3Z T^@ HHHH ****
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M /(OW7_7J_\ Z :^2D^XOTKFH*]ST<<VN4ZV+Q!9&>,?O>77^#W^M?1FJ?\
M('O?^O=__037R9!_Q\P_]=%_F*^L]4_Y U[_ ->[_P#H)I5U9H,$[J1X(OW1
M]*DA_P"/B'_KHO\ ,5&OW1]*DA_X^(?^NB_S%:'*CW76O^0%J'_7M)_Z":\&
M'W1]*]YUK_D!:A_U[2?^@FO!A]T?2LJ6S.S&;HL67_'_ &W_ %V3_P!"%>]S
M?ZB3_=->"67_ !_VW_79/_0A7O<W^HD_W32J[HK![2,BG1_ZQ/\ >%-IT?\
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MXCM+2?R/*DW;ML>#PI/K7!UT/@?_ )'"Q_X'_P"@&MI15F<%.I-S2N>N7O\
MQ[_\"%9M5?'%]<Z?X<,]I*8I?.1=P Z$^]>;?\)3KG_00D_[Y7_"LH0;5SLK
M5HPE9GK=E_Q\_@:LWW_'O_P(5Y[X)UW4[_Q(D%U=O+$8G.T@=1CVKT*^_P"/
M?_@0I25F73FIPNC.JS8_\?'_  $U6JS8_P#'Q_P$TF..Y8O_ /4#_>K.K1O_
M /4#_>K.H0Y;EBR_X^1]#5J]9EA4J2/F[&JME_Q\CZ&K%_\ ZE?]ZEU&OA*7
MFR?\]&_.K%F[M/AG8C:>IJI5FQ_X^/\ @)IO8E;FE1114FH4444 %%%% !11
M10 4444 87C"%)_"]Y$\R1*VSEXVD#'>N%*KRVX\8'7.*J>"6MC87'V>*PB_
M>*S):6CV^,J""RL22<'J/Z5+XV^T_P#".R>2]HL7F)YPN(Y')7<,!!&=V_.,
M8YSTQ57P'8M8Z==(T<B;I@0)+>:-L!0.LI+-_(=!0!UM%<[XO\0MH&F!X61;
MB0Y5Y$9D55(W9QWP< >I]JJ'6M6N+J:.S:%S*UPD,6P;HQ$ZC=DGDD$GG R5
MH ZVL/4?^0G>?]@QO_0C2>'];;4R\<[J+@*&"*A P ,D'H<DY^C+2ZC_ ,A.
M\_[!C?\ H1IH3V/E=?N+]*</O+]135^XOTIP^\OU%>B?/'UE?_\ (OW7_7J_
M_H!KY*3[B_2OK6__ .1?NO\ KU?_ - -?)2?<7Z5SX?J>AC_ +)-!_Q\P_\
M71?YBOK/5/\ D#7O_7N__H)KY,@_X^8?^NB_S%?5VO?\BWJ?_7G+_P"@&BON
M@P.TCP=98]H_>)T_O"I()(_M,/[Q/]8O\0]17GZ@;1P.E3VH'VVWX'^M3_T(
M5KR'$IZGUAK7_("U#_KVD_\ 037@P^Z/I7O.M?\ ("U#_KVD_P#037@PZ#Z5
MSTMF>AC-T6++_C_MO^NR?^A"O>YO]1)_NFO!++_C_MO^NR?^A"O;M?\ ^1>U
M'_KVD_\ 032J[H>$=HR*FY?[R_G3HV7S4^8?>'>O$P3@<G\ZM::3_:UER?\
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MJ?\ H8KS7PI_R-FF?]=OZ&O2O'?_ "*%Y]4_]#%*?QHJA_!E_70\=K:\(_\
M(VZ;_P!=3_Z":Q:VO"/_ "-NF_\ 74_^@FM);,Y:?QH]DO/^/9OPK,K3O/\
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MW_ZZI_Z$*@7[H^E3VO\ Q^V__75/_0A71T.!;GU3XF_Y%76/^O*;_P! -?*
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M'X/_ /)0(O\ KUE_I7K/Q'_Y%=?^OE/ZUG47[Q&U!OZNSSC^WM7_ .@G=?\
M?PUT_@+5+^\\2&*YO)YH_(<[7?(SD5P]=;\.?^1H/_7L_P#-:J:7*S*C)^T6
MIZ??_P"H'^]6=3?%FL#1-*CN3 9MTP3:&V]03G]*XW_A8*_] QO^_P!_]:L(
MQ;6AVU*D8RLV=Y9?\?(^AKGOB7_R +;_ *^1_P"@M3/#/BU=8UI+061BS&S;
MC)GI^%/^)?\ R+]M_P!?(_\ 06II-35Q3DI46T>6UUGPZ_Y&G_MW?^8KDZZS
MX=?\C3_V[O\ S%;3^%G#1_B(]:HHHKE/7"BBB@ HHHH **** "BBB@#&\5;?
M^$<N@UM]HR4 3S&CP2XPVY?F7:<-D<C%8'@**&\DN[^> ?;X',32_:99R2RK
MN#,^/F&T*0!QCWK;\8E1X6O"TDL6#&5DB=4*-O7:=S A0#@DD' S5+P-JLNJ
MZ?</->RW;I(H\QGC=1E <!D51QGD$9H ZJBJE]J=GIJ(UY.(@Y(7@DG R3@=
M@.I[5 ^O:6DDR->)NA7<^ 3Z=..3\R\#/44 :58>H_\ (3O/^P8W_H1K5MKR
MWO 3;RK( %)*].1D?H0?QK*U'_D)WG_8,;_T(TT)['RNOW%^E.'WE^HIJ_<7
MZ4X?>7ZBO1/GCZRO_P#D7[K_ *]7_P#0#7R4GW%^E?6M_P#\B_=?]>K_ /H!
MKY*3[B_2N?#]3T,?]DF@_P"/F'_KHO\ ,5]7:[_R+>I_]>DO_H!KY1@_X^8?
M^NB_S%?5VN_\BWJ?_7I+_P"@&BONA8'X9'R8OW1]*GM?^/VW_P"NJ?\ H0J!
M?NCZ5/:_\?MO_P!=4_\ 0A71T.!;GU1XF_Y%36/^O*;_ - -?*"_='TKZO\
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M<_\ H+5O*/NLXJ<_?7J>_P#C&]N-/\-7%S:R;)59 &P#U8#O7F7_  EVN?\
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MXOTKGP_4]#'_ &2:#_CYA_ZZ+_,5]7:[_P BWJ?_ %Z2_P#H!KY1@_X^8?\
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MI_\ 7I+_ .@&BONA8'X9'R8OW1]*GM?^/VW_ .NJ?^A"H%^Z/I4]K_Q^V_\
MUU3_ -"%='0X%N?5'B;_ )%36/\ KRF_] -?*"_='TKZO\3?\BIK'_7E-_Z
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M\_\ LIKVOXK?\DZU+_>B_P#1BTJO\1%X;_=Y_,^<*Z;X>?\ )0=%_P"NY_\
M06KF:Z;X>?\ )0=%_P"NY_\ 06K>?PLXJ7\2/J>[^/O^10NO]^/_ -"%>/UZ
MU\1[F.T\$WDTN[:KQYVC)^^*\0_X2&R])O\ OC_Z]<]%/E.W&-*I\CL_!?\
MR-^G_P"\W_H)KJ_C!_R3^X_Z^(O_ $*N$\!ZS:W7C;388Q)N9GQE>/N-7=_&
M#_DG]Q_U\1?^A4I*U1%4G?#R/GFNO^%W_)1M*_[:_P#HMJY"NO\ A=_R4;2O
M^VO_ *+:NB?PLX:/\2/JCU3XR?\ (A/_ -?47\S7SY7T'\9/^1"?_KZB_F:^
M?*SH? =&._B?([SX/_\ )0(O^O67^E>F_%F\:Q\&K,J!S]KC7!/^]7F7P?\
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M="%--1ZGSE_PJ3QCC_CPM_\ P)3_ !JUIWPM\76FJV=S)80E(9XY&"W*9PK
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M@>)PH2QE>2Z@CCF):XMRV8\HP&0H)()('3O0!IZ2ROI%HR;MIB7&[;G&.^T
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M;^VA2SF8P1R3*Q6)XW0;=Y :12&&0/Q-=O7#>.8XX9H)[J^?R9 VR!I(0$D
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M<*V6.%VJI!.>.<?>'O0!V0Z4M(.E+0!Y_P")R]QXB\U[6YC2UC7S7Q$V(RY
M>,F0%23GL3\HXXKT"N \4HMKXBMS+J+&23:]L)'A_P!';?R<%"VT\ 8.<@_6
MN_HZ %<7KHAF\210SHL,Q6-M_P!H91(N]@ /W9!..O(ZCZUVE<3KRS6WB>%8
MX+R6*[V%E\^?8[ ]!M;:H'?/7-'4#MJ*** .%UFYM_\ A*%C*S7+6NPKME=7
MB=F).!L.1C'0CIBNZKB?%5PR:Y$@N;U4"1LRP+\L9W-AB=Z]MQQ@_='TKMJ
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M:6<=[%J4UI%%(HE2-HAO4GG!D!&[TY%;]8/BU93I"&".1IEG1HVC<H4;G!R
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MK31M<O<H44IF"9H\J2#@XZ\J#^%:M% %>RM!96PA6:>8 D[YY"['\35BBB@
MHHHH *QM?NM3L88KBQ> 0A@)]]L\S*I_B 5@>/3!K9KGO&7V7^P3]K#-&)5(
M0;<,<'@[N.F>O<#O0!H:)=75[I44]X%$S%N5C*!E#$*=I)*Y&#@\\UHUB>$D
MBC\.6Z0L"JM(/E0(N=[9V@$C&>F":VZ "BBB@ HHHH **** .:\90175C:02
M N[SD1Q';M=MC?>W$#CKU[5>\,M ?#MDMO(KHD>/E4*%/I@$X Z=3]365XWO
M(4LX+;S[03>8)##,\:LZ\@;2X(Z_B1GFM?P]!%%HMNT:6P,B[F:W50K>A^4
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MLPDC"N"6C"N6!4CIN4^^,#J:["L.[\):7>74UQ)]K5YBQ<1W4B*=P ;@''(
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M0W 6.19%D$:21LW.%V%U9F],5V%95]X>L=0U&/4)C<K=11F-'BN'3:#UP <
MGUZT 3:*ACT6R0K,I$*_+.NUQQT(R<'VR<5?J.&(00I$K.P08#.Q9C]2>2:D
MH **** "L74/"]AJ6IC4)Y+L7"J%79.P5<=PO0'W'-;5% #(D\J)(PS-M4#<
MQR3]3ZT^BB@ HHHH **** "BBB@ HHHH **** "BBB@#B_&-U)#J-O''=WJ@
MPEFBM8V.""2K$AAQP3C_ &/0FNS3E <YXZ^M<?XLAN[S5K2UMK6*Y_=%F3;&
M6'/#-OYV!@OW??/:NP7.T9QG':@!:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#SS7[;4[_6+AIK&]E$)D^S>791.HQM\L;F&=K'=N'L
M.E>@IG8NX8..1Z4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gpty1lksmhba000036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000036.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $* F(# 2(  A$! Q$!_\0
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M;G8("#Z1Y;(PV>!FG:(KU+7N3_\ "RO%?_00C_\  =/\*/\ A97BO_H(1_\
M@.G^%4;SPX3XJDT>PD&"GF1O.V!M\O>?F P1UPPX/6A?"=XP64WE@EHZQM%=
MM*1%(7)"JIQG)*GJ.,4>Z*]3N7O^%E>*_P#H(1_^ Z?X4?\ "RO%?_00C_\
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M(0R!""HXQM P.V,U!>ZY?ZA8QV4\D?V=&#[(XE3<P&T,<#DXKTO_ (4]I_\
MT%KO_OA/\*/^%/:?_P!!:[_[X3_"GS1#V54X!_&&M.8R9XMR.'SY"Y<[-GS<
M?-E3@@T@\6ZN&SYEOM\M(Q']G38H7.TA<8!&XX->@?\ "GM/_P"@M=_]\)_A
M1_PI[3_^@M=_]\)_A2YHA[*J>;#7]25=JSA<6ZVP94 (17WCGUW<YJ:7Q1JD
MTZ2N]N=A<E!;($9F^\S+C!8X'/6O0_\ A3VG_P#06N_^^$_PH_X4]I__ $%K
MO_OA/\*?-$/953SR7Q3K$YD,MPCF3S-Q,8_C0(P^FT #TQ21^*-6B38LT13R
MXXPKPJP78NU2,CA@.,UZ)_PI[3_^@M=_]\)_A1_PI[3_ /H+7?\ WPG^%'-$
M/953SW2_$,ND:5<6UO$AN)+F.=9)(U=5V@CH?XLD$'VJ%?$.IK<0S^>K20PM
M -\88.C$EE<'ALDGK7I'_"GM/_Z"UW_WPG^%'_"GM/\ ^@M=_P#?"?X4<T0]
ME4//HO%FL0W#3+/$S%TD57@1EC9!A2@QA<#CCM4?_"3:K]C-J)HPA3R]XB7>
M%W[P-V,X#<BO1?\ A3VG_P#06N_^^$_PH_X4]I__ $%KO_OA/\*.:(>RJGGD
MOBG59I'=WM_WD;QR*+9 L@?!8L .6) .?:E_X2O6 \K_ &B/?(V\,85)C;:%
M+(2/E)4 9%>A?\*>T_\ Z"UW_P!\)_A1_P *>T__ *"UW_WPG^%+FB'LJIYG
M-K=_/!-!)(A2:&*!QL&2D7W/_P!?>@ZU?&R^QF1/)-M]EV[!GR]^_&?7=WKT
MS_A3VG_]!:[_ .^$_P */^%/:?\ ]!:[_P"^$_PI\T0]C4//5\6:PI@87$>^
M%T??Y*[I"@PN\XRV!TS57^VKXVAMO,3RC;?9<;!GR]^_&?7=WKTS_A3VG_\
M06N_^^$_PH_X4]I__06N_P#OA/\ "CFB'LJIYO!XAU6U^PBWNVB6R&(43A>I
M)W#HV2>]3Q^+-8A"K'/&BJ8B%$0P/+)*<>V?QKT'_A3VG_\ 06N_^^$_PH_X
M4]I__06N_P#OA/\ "CFB'LJIY9>W]QJ!MS<LK&WB\J/"@87)/X\DU6KUS_A3
MVG_]!:[_ .^$_P */^%/:?\ ]!:[_P"^$_PHYXB="H]SR.O6/@[_ ,>6K?\
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M0BVM88%)(B0(">^!BBL3O1+1110 4444 %%%% !1110 4444 %%%% !1110
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M::*"73Y@[HK3Q[A\K$9QGGIS[TVK G<VJ*YK3M<N8O!\6LZBZ7$DH5E2%!&
M6(4+R3W/4TU_%Z"[2S%I()VCW.RNKK&QW <CAAE#G'3\\%@N=/17(0>);^3P
MQJVHMY/GVL$<D>$XRT*.<C//+&I+7Q%J=IY<>J64C&:20Q/L$3>4B!F9DW-S
MR0 #DX[46"YU=%<;-XT>6&-[>#R<!G<,5DRA@>1""#C/R\@__7IJ>-)[:XG%
MY:,ZF<QPI#C(140LQ/K\XXHLPNCM**Y:Z\:16D#3R6,GE"XDA'[U=S+&VUG"
M^@.*B7Q?+'+(;JV"A'GC2.-P=Q69(ERQ/R\MSGCO19A='745RZ>,HWFC06$V
M-RK,PD4B,F4Q<?WAN'4=JZBD.X4444 %%%% !1110 4444 %%%% !1110 44
M44 %(S*HRS #U)I:Y3QLL?V>RDD7=LD<C<B,GW>AW*PW'^$8Y/>@#JZ:[I&,
MNRJ.F2<4VW_X]XN"/D'!&"./3M5'6;"2_@B6(*7C?<I9\!3@@-T.<9Z&@#0W
MI_?7KMZ]_2E# YP0<'!P>E<R?#]WG)^SG@H3D_,26/F]/O#/3]:LP:?=:?:7
MD@E6)A'D-& WF%=QW-D=3D9^G6F*YO44V-BT2,>I4&G4AA1110 4444 %%%%
M !2,H92K %2,$$=:6B@"L^GV4B;'L[=DV"/:8@1M!R%Z= >@H73[)  EG;J%
MQC$0&, @=O0G\S5FB@"I_96G;MWV"USMVY\E>F,8Z=,5*;6W*,AMXBC/YC+L
M&"V<[C[Y&<U-10!6NM.L;UT>[LK>X9/NM+$K%?ID4IL+-GWFT@+$YW&,9SD'
M^8!_ 58HH JG3;$M,QLK8M/Q,?*7,G^]QS^-3Q11P1+%#&D<:C"HBX ^@I]%
M !1110 4444 %%%% !1110 45CZUXHT?0(IGU"\6-HH_,,8Y=AVP.^:K:!XT
MT3Q'!"]E=;9920()1MD!'4$4[.UR>>-^6^IT-%9VIZH;"2"&*UDNKB?<4B1@
MORJ,L<DX[C\ZQ?\ A.K-IY5BM99$2+S05==Q'EA\E>H'S 9]>*5AW.KHK*LM
M:6\=W-N\-IN98KF1U"R$-M(QG(.>F>M4K;Q4LZ0R&PF19;G[.067<A/W=RG!
M&?Y46"YT5%4=*U(:G;22^0\#QRM$\;D$AE//2KU PHHHH *SKW7M+TZY^SWE
M[%#*0#M<]CT_D:T:XO5D@O?&$,+S+Y+*B-''.@\QAN!W+O!R,\$*3R:$)G9A
ME(!!!!Z$'K2!T.,.IW=,'K6?J&EBY6V$.V,P;E1LGY 8V7C\Q6=;Z'<QW,4I
M2WC7>K;48_N=I!.WC^+'/3KWI@='152S:7S;F*64R^7( K, #@J#V'O5ND,*
M*** $(#*58 @C!![U3.CZ8UL+<Z=9F!6WB(P+M#>N,8S[U=HH @%E:B:.86T
M/FQ+LC?RQN1?0'L/:I\#THHH B^RV_V7[-Y$7V?;M\K8-F/3'3%1C3K%3$5L
MK<&)2L9$2_(#U XX%6:* (!96BPO"+6$12 !T$8VL , $=^ !^%2-#$TB2-&
MA>/.QBHRN>N/2GT4 55TVP2/RTLK94R6VB)0,D8)QCN#@TKZ?92 ![.W8!_,
M ,2G#8QNZ=< <U9HH K2:=8S(%ELK>10Q8!HE(!/4].I[T'3[(F0FSMR901(
M?*7Y\XSGCG.!^56:SKC7M*M=7@TF>_@COYQF*!F^9A_D?C3U$VEN65L+-555
MM( JJ%4",8 !R!] >1[U8HHI#"BBH9KNVMWB2>XBB>5ML:NX4N?09ZF@":BB
MB@ HHHH **** "BBB@ HHHH **** "N-\<0,#;7(61UVLKHD2G '\1)Z8SZ=
MZ[*N4\8_:!/8&*?R_P#6!/+WA]V.H*NHQCL336XGL=-:_P#'I#PP^1>&Z].]
M.DDCB0O(ZHHZLQP*2#/V>/)).P9)ZGBJ6L:8VJ6RQ+<-"4<.,*&!(/&01VI=
M0Z%DW]H"0;J$$/Y9^<<-Z?7VJ.ZN(9M/O!%*CE(W5MK [3@\&LIO#LQ<G[1'
M]QH1E#_JV)))Y^]\WTJ0Z0UKIUYON#_J=J&+*DJH8C=ZGYN?I3#4T+N]CTW1
MIKZ4,T=M;F5@O4A5R<?E7,>$/B/IGBBUN))Q'ILL+A?+GN%^<'D$$XS[UUI@
MCN;'R)D5XI(]CHPR&!&"*Y.#X::-9B5;&ZO[6.5MS1QRJ5_\>4TK^0U%/7FM
M\CK([VTE4O'<PNH&25D! %%K>VM]#YUI<PW$1)'F1.'7([9%<+JGPKL[VSG2
M'5+M9F0A#(D6W/;.U <?0UD^&OA9K>E6;D>*;K3;AGR8[$[HR.Q(;&3^%/0;
MB]TU8]7I-R[MN1NQG'>N O/#_C'2[.XNU\9M=)#&TA2>V6/@#/WES_*N)\.>
M,-:U5VO9;AQ-&PC-PS)&.1PNYEV9]B0#]:+/H%X6UDD^Q[M4 O+<W9M1,OGA
M=Q3/.*XQ=;U.T!.IW>IV2@<R3Z6DL8_X'$6&/<XK&\!S:IK$FI2QZ_IFH26M
MVQ0C,@W,/OX&, C@?CZ5-]2U33BY<RT/4Z*YN0^,(FR$TJ=/1&=&_48_6N<L
M)/&%OK#W6MQ7,<:[@K6T0G3:3D#:IR!C@\'H*7,-46TVFOO/1Z*YZSUF.^E\
MJ#7;3SNGDR6Y23_OEF!_2IIKRY4W,4&IVMQ=VZ;WMHX09!Z9&_BG=$.$ENC;
MHK$TV?4[^%I#=P!0V%=;<E7]QE@?;IVINIW6I:=%&PNX'+D@%X=B# SRV[@^
MGJ:9)NU'+/% %,TB1AF"J6.,D]!5& :E/!',MW$H=0P5[4@C/J-U5K_1[[4-
MIDO8 55DR+<\ANO!8_GUH VZ*STAU2*-42:S*J !F-__ (JJ>H:CJFGB-GCM
M&1B1O&_ (Z+WY/0>] &Y16;'>:D8T>33!\P!*K.-P]B"!S^-,N=>@LTS=6MW
M$Q^ZABW%CWP02/>@#5HJ&VNH+R!9K>598V&0RG-34 %%%% !1110!#=6L%[;
M2VUU"DT$JE7C<95@>Q%1V&G6>EV:6=A;1VUNF=L<:X SR:SM>7Q*8+C^PI--
M5O)/E"Y1RWF8/<''IU%4_"R^,!IM@/$,FG&41_Z0(U;S<XXR0=N>F<#'7% 6
M5[FW?Z99ZFB+=P[]A)4AF4KD8."I!Y'!'>J\GA_2I4\MK--N2<*2O5 A'!Z;
M0!CIP*-7AGED@*Q3S0 .'C@EV,6.-ISD<#GOW!K,F37IK@J(Y!"IRN77T(ZC
MDC!'7OZ=*!&M'HFF1W,EPMG&9)#D[LL <[CA3PO// '-1CP[I(*G[)DA]_S2
M,<GC&<GD# P#P,#%9<4'B&WMR8Y)79F =92C$ *@++[GYO;VJ;/B%1$6W.[2
M#>%"!57Y,^_/SGKU'YL#:L;"VTZ Q6L6Q&;<V6+$GU)))/  _"K-0VMN+6V2
M 2RRA!C?*VYC]34U(84444 %<=?6LP\:Q- IDB+Q/,IN6^4\X(3< !QZ'FNQ
MKB+NX-UX\A"QJ@@98RTML"3R3E6P>#TSD8]*:W$]CMZ*:V2I ;:<<'TKG;?4
M=06:Q,TXDCG);9L"R,I;"\8Q@#DX(ZTAFS:_\?E]_P!=5_\ 0%JW5'3Y#+<7
MKF-X\RK\KC!^XM7J "BBB@ HHHH **** "BBB@ HHJO?7D&G6,]Y<MMA@0R.
M?8#^= %?4]8MM+6(2B26XF)6&VA7=)*1UVCT'<G '<US#^+[J7Q#'H;76EZ9
M?R ;;>8/<."1D E=J!L<XW&MS0M/F'F:MJ*?\3.\ +@\^1'U6)?0#OZMD^E+
M)X3T2;Q$FO26"-J2 8FR>H& <9QD#C.*I66YDU-ZH9_9OB!N6\0Q+[1V"C^;
M&L.\^'1O_$5OKUSK4K:C;[2CBV0+E?NDKW(S7<T4*36Q3IQ>YA_V5KG_ $,C
M_P#@%%7/:SX9\9W/B#3+BR\4,MI$?WV5$>WGGY%&U\CCFN]HH4F@E335OU,/
M^R=:_P"AEF_\!(?\*P-;^&P\1ZG9WVJZ[=S/;8 "Q(F5SG P.#GO7=TTNJD
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MEG_WW2?\)QX8_P"@Y9_]]U\[4AZ'Z4?5H]P_M:I_*CZ.F\9>'+>3RY=9M$?
M."_8@$?H13/^$X\,?]!RS_[[KPW5[:>[UXPVT+RRM!"0B#).(4)_2LRXMI[1
M]EQ"\39(PXP>.M)8>+ZERS.JF_=5D?0O_"<>&/\ H.6?_?='_"<>&/\ H.6?
M_?=?._EOY)FV-Y0;87QQNQG&?7%,R/6G]6CW(_M6K_*CZ+_X3CPQ_P!!RS_[
M[H_X3CPQ_P!!RS_[[KY^@TZ^NE#6]G/*"I8%$)R <$_GQ3CI>H"+S#97&SR_
M-W>6<;/[WTH^KP[E?VG6_E_,]_\ ^$X\,?\ 0<L_^^Z/^$X\,?\ 0<L_^^Z^
M>/*D_=_NV_>_ZOC[W../7GBIY]-OK:)I)[.>*-',;,Z$ ," 1]02/SH^KQ[B
M_M2K_*OQ/H-_&7AR...1]9M%24$H2_W@#@_J*9_PG'AC_H.6?_?=>%7D4DVE
MZ*D2,[^1,=JC)P)7)_0$U333KZ0J$LYVWE57"'DL,J!]1R/:DL/'N5+,ZJ>D
M4?0/_"<>&/\ H.6?_?='_"<>&/\ H.6?_?=>!+I&I,P"V%RQ+,HQ&3DKU'X5
M!%:7,T9DBMY7176,LJD@,WW5^IQP*?U>/<G^TZW\OYGT)_PG'AC_ *#EG_WW
M1_PG'AC_ *#EG_WW7@1T?4Q-)"=/NO,C7>Z^4<JOK^A_*HX].O9;9;F.UF>!
MFVK(JY!.<8'J<\4?5X=Q_P!IUOY/S/H'_A./#'_0<L_^^Z/^$X\,?]!RS_[[
MKP)M'U-6=6T^Y!1E5@8SP6Z#\:KR6T\+S)+#(C0G$H9<;#TY]*/J\.XGF=9;
MQ_,^A?\ A./#'_0<L_\ ONG_ /"9>'/L_P!H_MBT\K?Y>_?QNQG'Y5\^1:9?
MSQI)#93R1NC.K*A(95."1[ D#\:O06T]SX<\B"&268ZA@1HN3Q$<\4GAX]RH
MYE5?V3W+_A./#'_0<L_^^Z/^$X\,?]!RS_[[KP(Z/J817.GW05G\L'RCRV<8
M^N01566*2"1HYHVC=#M96&"#Z4_J\>Y+S2LMXK\3Z'_X3CPQ_P!!RS_[[H_X
M3CPQ_P!!RS_[[KP%-(U*1I%2PN6:-%=P(SE5894_0CD4QM/O4C@D:TG5+@@0
ML4.)">@'K1]7CW'_ &G6_E_,^@?^$X\,?]!RS_[[H_X3CPQ_T'+/_ONO FTC
M4D:56L+@&)=\@\LG8O/)_(_E39-+U"&-Y)+*=$C4.[%#A5/0GTS1]7AW#^TZ
MW\GYGO\ _P )QX8_Z#EG_P!]U-:>+= OKJ.UM=6M99Y3M2-7Y8^U?.BVT[SQ
M0I"[2S8\M O+YZ8'?-='X+L;NW\9Z---:S1QM<$!W0@$@,#^H(_"E*A%*]RJ
M>959S4>4^@J***Y#V0HHHH **** *MWJ$%D4\_>JMU<*2J\XY/;DBJ\>MV4C
MQH#(&<@8:,C;G&TMZ Y&/K4M[IJWT\+R32A(L_NAC:V>,G(ZXR,]LFJ\>@V\
M<JR>=.S KO)(^<+C:#QVVCICWHT%J:M%4K&-(KF^2-%1?-!PHP.46KM PHHH
MH H7FG?:M0T^[\W;]CD=]NW._<A7'MUS6"?!$8N&GCO61Y(KE)0(_E<REMK8
MSU4-CW&*ZVBBXK'.OX3M5L4M;9U@40-"_P"[W!MVW+ $\'Y15[4]+FO9+.YM
M[H6]Y:,S1R&/>IW+M8%<CC\>U:E%%PL<C+X6GO-9=KJ5GMOL7ER3.%S/.5*"
M3:.A568?EZ4UO V]'5K] 6B*;DM@K!C%Y77/W,<[/7O7844[L+(Y-?!$2Q00
M?:]\$'"J\6XLOG)+ACGYC\A&>^?S6W\%1VVIVMVMWE;=BPC\O 'SNX"X/RCY
M\'@YQVKJZ*+L+(P_^$9M'U2_U&4+)<7)!B9E_P!3^["<<X)ZG/O5!/!,,;V?
MEW*I'!%"C;(0'S'GE&S\FXGYNN:ZNBBX6.0M?!+VFUHM0B66,Q>6PM0!A%=,
ML-WS,1(<GCD4+X&5;2:V-Y&T<MJ("[VJM("(Q&"&)X7@';Z]ZZ^BB["R.2G\
M$BXD9VO4!D=RX%N,*&V9*<_(PV<-SP?:M#2O#<6E:C]L2569DF5\1[2Y>7S
M2<\XZ5NT478604444AA1110 4444 %%%% !111F@ HHHH **** "N;\??\B)
MJ_\ UQ_J*Z2LSQ!IT6K:#>6$\K0QSIM:1!DKR.U.+LTR*J<H-+L?-%%>I?\
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M(&. =H8#\/F#?45-J7B^35K.:&>U6-FC95V-D%F*[F.>_P N?K76?\*NT?\
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M +ZH"Q6JQ8_\?L/^]_2E^PR_WH_^^JFM;22.ZC8LF >QI D;-%%%(T"BBB@
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M8K\N,8X/(P:OT4"*#:+IS$DVJ<^A(QUR!Z Y.0.#FI[:RMK0N;>)8]YRV/\
M/ Y/%6** "BBB@ HHHH *CF_U+?2I*CF_P!2W3IWH HT4<?WE_[Z%'']Y?\
MOH4R K%?7&BDN)9!;"VAE>$1^;B9F7'.#Q@Y_ 8/M6UQ_>7_ +Z%0/9VDDCR
M/;VS2.NUW95)8>A/<4#.<D\8[LM;VBNAQMW/@C@9R>G!XXZU/_PE]M& L]G<
MI,J;I47#;.,CD'!S^G>MS[#9;=OV:UV^FQ,4K6=H[!F@MF89P2JDC(P?TXH
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M *Y('XG)_($UJU6_L:VW1'[&W[K 0?-@ 8P,>@(!QZC-7/*D_P">;_\ ?)H
M913_ "I/^>;_ /?)H\J3_GF__?)H 63_ %,/T/\ ,U'4\D<GE0_NWX!_A/J:
MC\J3_GF__?)H 913_*D_YYO_ -\FCRI/^>;_ /?)H S[C4!;ZE;VA@8K,/\
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M@#==J@!1],UCVFK:;J&H1ZGK.K:=&83FTLEN59821]]SG#28XXX7G&>M;O\
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ME1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:*
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LXBHS^M6J**0T%%%% !1110 8HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gpty1lksmhba000041.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000041.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $P F # 2(  A$! Q$!_\0
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M4EM+BY:W>::) #A6.Y2#@9*D8-/M?"EE=S7J11:E(ULD1$$4T#NY=B.&!VX
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MW.S+SQG^&BT1N53N=+_PMS7?^?+3_P#OA_\ XJC_ (6YKO\ SYZ?_P!\/_\
M%5@P^#]0N+A8X9[216@,ZR([,I4/L( "Y)##GCWID?A'5);*.[40[)' 4%CG
M:7\L-TQC=[YQSBBT0YJIT/\ PMS7?^?+3_\ OA__ (JC_A;FN_\ /EI__?#_
M /Q59</@]-D?FZE!+*;J6V>.W8\%(RYPQ&,@CGVJE#X2U&;R%62U,TK1!XO,
M.^'S1E"XQP#[9QGFBT0YJIT/_"W-=_Y\M/\ ^^'_ /BJ/^%N:[_SY:?_ -\/
M_P#%5RL^A7,%[86PFMY?MQ @DB<E"2^SDX[,".E6Y_"-]!;O,+JQE"([[8Y2
M6(1]CXX_A8C/Z9HM$7/4-_\ X6YKO_/EI_\ WP__ ,51_P +<UW_ )\M/_[X
M?_XJL6U\(3O<W,=W>00) ]Q$S@DY>) Q[=.1S]>*=IO@VYO#8RS7<$5K=$KY
MB[B5.PN!R.<@'ID"BT1\U4V/^%N:[_SY:?\ ]\/_ /%4?\+<UW_GRT__ +X?
M_P"*K!_X16:5+>2*YMXXI8(6\VXEPK22%@JK@9YV]^G<U#-X7OX+"2ZE>W5H
MXFF:W+GS0BOY;'&,<-[T6B'-5.D_X6YKO_/EI_\ WP__ ,51_P +<UW_ )\M
M/_[X?_XJN<MO#LEYI=O>1SQ0JT4TTKSOA%2-U7(P,_Q57;0;Q=5O--)B-U:Q
MO(5#9\P*-Q"^IQR*+1%SU.YU?_"W-=_Y\M/_ .^'_P#BJ/\ A;FN_P#/EI__
M 'P__P 56'-X2NHK1L21M=QM*'C#Y!\N-7*KQG> QSVX-,/A#40[1F:T$P9D
MCB,IW3.J!W5>.2H.#G'/%%HCYJIO_P#"W-=_Y\M/_P"^'_\ BJ/^%N:[_P ^
M6G_]\/\ _%5S&D^'+O6;836\UK&&F,"+-(5+OLWX''H#4Z^$[UG&;JQ6%UB,
M5PTI$<IDSL53C.3@]0,8HM$7/4M<Z#_A;FN_\^6G_P#?#_\ Q5'_  MS7?\
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M21L_WRC$97/?%-D\17\L%O&5M5>W6-(KA;=1,@3&W#]>,5WO_"G!_P!!P_\
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MV54X;_A*M7WQ/Y\6^,[BPA4&1MA0,YQ\Q"D@$U375KM;FPN,QM)8(L<&Z,$
M*21D=^2:]%_X4X/^@X?_  %_^RH_X4X/^@X?_ 7_ .RHYHA[*J<./%FJK>S7
M<9M8YIL&39;( S DA\8^^"3ANM4]/UF^TLL;6106E29BZ!LNA)4\^Y->B?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HYYX[:%
MII6VHO4XS4E5[ZT6^LY+9F*JXY(^N: *_P#;6G]KC/&1A&.>G XY;D<=>:NP
MRQSPI+$P:-QN5AW%8R>&XXQ&$NI!Y3"2/Y1\LG W?3  Q5A[&.QMK8123;HY
M(DSYK8(W '(SCG)[4]!:FI1112&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5+__ %,7_7>+_P!#%6ZJ
M7_\ J8O^N\7_ *&* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %#63(NDW$D4TD,D:%U:,C.1]0:N1IY<2H
M79]HQN8\GZU4UG_D"WG_ %R;^57J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&3689YM3)2S<QVF<-<CJ_M'_ /%?EZ@\J;5#NN4:&SZK >&E]W]!_L_GZ5I
M!0    , "@#-U*WBM?#]U##&$C6%L ?YY/O6G5'6?^0+>?\ 7)OY5>H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAE?UJX)%8*0RD-]T@]: LT.HHHH$%%%% !1110 4444 %%%% !1110 4444
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M9#/I@C2+R6'F)@1D_=//W2>WK5"?1M$77_ME]?6[3,3(D$WE*3N&WDXW,O.
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M(.%4#J3^G)[4 7(95G@CE7.UU##/7!&:61!)&R-]U@0:S-(O9)VFMY8HXO)
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M28I6$MP^I3:G=S1(1'&2A&T9]=R@9Y.":[04M%-*QG4J2J6;"BBBF9A1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%>3?VC??\_MQ_W];_&C
M^T;[_G]N?^_K?XUX?]MP_D9Z_P#9$_YD>LT5Y-_:-]_S^W/_ '];_&C^T;[_
M )_;C_OZW^-']MP_D8?V1/\ F1ZS17DW]HWW_/[<_P#?UO\ &C^T;[_G]N?^
M_K?XT?VW#^1A_9$_YD>LT5Y-_:-]_P _MS_W];_&I8KC5IU9H9KV14Y8H[$#
MZTUG47HH,3RF2U<T>J45Y:DNL20&=)+YH1GYU9B..O-(DNL2/LCDOG8J'PK.
M3M/0_2G_ &PO^?;%_9;_ )T>IT5Y/_:%_NV_;+G=G&/-;.:=]KU,-(OVF[W1
MC+CS&^7Z^E+^VH_R,?\ 9,_YT>K45Y0;W41&LANKH(Q(#&1L$CK0+[4#&T@N
M[HHI +>8V 3VH_MJ'\C#^R9_SH]7HKR;^TK[_G]N/^_K?XT?VE??\_MQ_P!_
M6_QI?VW#^1C_ +(G_,CUFBO)O[2OO^?VX_[^M_C2C4+]ONWER<#)Q*U']MP_
MD8?V1/\ F1ZQ17DW]I7O_/[<?]_6_P :4ZA?@ F\N0#R"96YH_MN'\C#^R)_
MS(]8HKR;^T;[/_'[<?\ ?UO\:/[1OO\ G]N/^_K?XT?VW#^1A_9$_P"9'K-%
M>3KJ%^QPMY<D^@E:D_M*^_Y_;C_OZW^-']MP_D8?V1/^9'K-%>3C4+\@D7ER
M0.I\UN*#J%^ ";RY /0^:W-']MP_D8?V3/\ F1ZQ17DW]I7O_/[<?]_6_P :
M/[2OO^?VX_[^M_C1_;</Y&']D3_F1ZS17DW]HWW_ #^W'_?UO\:/[2OO^?VX
M_P"_K?XT?VW#^1A_9$_YD>LT5Y-_:5]_S^W'_?UO\:/[2OO^?VX_[^M_C1_;
M</Y&']D3_F1ZS17DW]I7O_/[<?\ ?UO\:<;[4%17:[N@C$A6,C8..M']MP_D
M8?V1/^9'J]%>3?VE??\ /[<?]_6_QIWV[4?+,GVNZV [2WFMC/I1_;</Y&']
MD3_F1ZO17DW]HWW_ #^W'_?UO\:/[2O?^?VX_P"_K?XT?VW#^1A_9$_YD>LT
M5Y-_:-]_S^W'_?UO\:/[2OO^?VX_[^M_C1_;</Y&']D3_F1ZS17DW]I7W_/[
M<?\ ?UO\:?%>:E-((XKF[D<]%61B336=P;LH,'E,UJY(]6HKRK[3JNQW\^\V
M1G#MO;"GT/I33?:@(Q(;NZ"$[0WFM@GTH_MJ/\C%_94G]M'J]%>3?VE??\_M
MQ_W];_&C^TK[_G]N/^_K?XTO[;A_(Q_V1/\ F1ZS17E(O-292PN;LJ%W$B1L
M8Z9^E,_M*^_Y_;C_ +^M_C3_ +;A_(P_LF;^TCUFBO)O[1OO^?VX_P"_K?XT
M?VE??\_MQ_W];_&E_;</Y&']D3_F1ZS17DPU&^) %[<G/ _>MS^M.:^U%)3$
MUU="0':5,C9!],4_[;A_(P_LF?\ ,CU>BO)WO]0C=D>[N593@@RL"#1]OOPH
M;[9<X/0^:V#1_;</Y&']DS_F1ZQ17E#WVHQ.4DN[I''56D8$4W^T;[_G]N/^
M_K?XTO[;@OL,%E,W]I'K-%>3?VE>_P#/[<?]_6_QI5O]0=U1;NY9F.% E;)-
M']MP_D8?V1/^9'K%%>3'4+\,5-Y<@C@CS6X_6C^TK[_G]N/^_K?XT?VW#^1A
M_9$_YD>LT5Y-_:-]_P _MQ_W];_&GK>:DX)6YNR "Q(D;H.I_"FL[@]H,7]D
MS7VD>K45Y-_:-]_S^W'_ '];_&C^TK[_ )_;C_OZW^-+^VX?R,?]D3_F1ZS1
M7ESOK,<'G.]\L6,[V9@,?6F&XU4.(S/>!V7>%+MDKC.?IBJ><);TV2LK;VFC
MU2BO*3=ZFHCW7-V/,&4S(WS#V]:F8ZVDBQL=0#OG:I+Y..M"SA/:FP>5M;S1
MZA17E7VG5?*:7S[SRT.UFWM@'T)J/^T;[_G]N?\ OZW^-)YU!;P8UE,WM-'K
M-%>3?VC??\_MS_W];_&C^T;[_G]N?^_K?XTO[;A_(Q_V1/\ F1ZS17DW]HWW
M_/[<?]_6_P :/[1OO^?VY_[^M_C1_;</Y&']D3_F1ZS17DW]HWW_ #^W/_?U
MO\:EMM0O3=P WEP09%!'FMZCWIK.X-VY&)Y3-*_,BC172_\ "$ZE_P ][;_O
MIO\ "C_A"=2_Y[VW_?3?X5Y']GXG^1GJ?7L/_.<U172_\(3J7_/>V_[Z;_"C
M_A"=2_Y[VW_?3?X4?V?B?Y&'U[#_ ,YS5%=+_P (3J7_ #WMO^^F_P */^$)
MU+_GO;?]]-_A1_9^)_D8?7L/_.<U6U9WUM';V#-=20_9&9WA13F5LY!!''(P
M.:M_\(3J7_/>V_[Z;_"C_A"=2_Y[VW_?3?X5I2PF+INZ@9U,3AJBLYD/]K6R
MPJD85)DMCY<V&PLC$EEQTZ$@'%$]_9W*R0K>/;1I,A#JAS)&J!0!CN"">?6I
MO^$)U+_GO;?]]-_A1_PA.I?\][;_ +Z;_"MW#&M6=/\ K[S'GPB=U/\ K[C.
ML[ZWAU2WN=TR,)"T\LC!BPSG@ <$_P!:2+41]@OHI9&_TB96**.2-V6.?7H*
MTO\ A"=2_P">]M_WTW^%'_"$ZE_SWMO^^F_PK-8?&)6Y._XJQ;K81N_-V_!W
M*.J7]G=K81P+(L$(.Z,X^4$]!ZG ZU>;4M.&V(M$\9DD==L.U4^7$>1CG&3V
M-'_"$ZE_SWMO^^F_PH_X0G4O^>]M_P!]-_A5JGC5)R]GO;\"'/"-*//M?\2+
M^TM/0N4CA.XR,P,6=Q" (.1QDY-*M_IGFESY0P4\PF#/G*$Y"\?*2V?2I/\
MA"=2_P">]M_WTW^%'_"$ZE_SWMO^^F_PI\F,_P"??]?>+FPG\_\ 7W%4WEA]
MF$&(MJQQ $Q9.[=N<D]3@<=>:F;4+'SKCRIEC\V%8SB+Y1E_F .T'[OJ*D_X
M0G4O^>]M_P!]-_A1_P (3J7_ #WMO^^F_P *%3QB_P"7?]??YC<\(_M_U]Q'
M'J.G/+=RRB)0S.L47DC&S!V]!U)Z\BG)J>G_ ">84D,<,2)NCXP!\Z]#R3_^
MNG?\(3J7_/>V_P"^F_PH_P"$)U+_ )[VW_?3?X4*&-2_A_U]XG+"/[?]?<9U
MW<V3:1'%#L$P(.%CQQR3DD9SVX)S5Z673K2.&VN/+D58X0\:1?,&R&9BW?@X
MQFG_ /"$ZE_SWMO^^F_PI/\ A"=2_P">UM_WTW^%)4<6FW[/70IU<,TE[3S(
MO[2M(S(R2Q^?Y$BB5(-JG<1M7&.RYY]Z6?4-,!+011?)&YA4Q]"5 53Q]3WZ
M=:E_X0G4O^>]M_WTW^%'_"$ZE_SWMO\ OIO\*?)C;6]G_7WD\V$WY_Z^XJ7U
M_;/8W4-LZ@R21Y CV[PJ<GIQ\U2"\L9K2&WEN%54MXT!,1)4[\OVZXQ4_P#P
MA.I?\][;_OIO\*/^$)U+_GO;?]]-_A2]EC.9MT]_Z[E>TPEDN?;^NQ"^I6.R
M;RTARZRL 80<,S@*.G0*,TLE]IA:=D$81GDW)Y/,HV@)@X^7GD]*E_X0G4O^
M>]M_WTW^%'_"$ZE_SWMO^^F_PI^SQG_/O^OO)YL)_/\ U]QGRW5I+JMJOR+8
MPE 2(\%@ ,D\9.2*L)J-E+:2^;#$)Y&<%!&!D'A0"!QCZCGUJQ_PA.I?\][;
M_OIO\*/^$)U+_GO;?]]-_A4QHXQ-OV>Y;JX1I+GV);N2SL"IE2 _/(\4?DC(
M4)A%/K\QSGVJC]NT][*%72+S6V^;F+HV[);@=,<8!Z'I5C_A"-1_Y[6O_?3?
MX4O_  A.I?\ /:V_[Z;_  JY0Q;;M3T(C+"I:U-1@OM,^WM*6C"&,*?W/W3D
MD[?EY[?>'XU%#>:>L4:!XTD6-?WKP;@,N2XQCKC JQ_PA.I?\][;_OIO\*/^
M$)U+_GO;?]]-_A2]GC/^??\ 7WCY\)_S\_K[BJ]]I_D2QQ11JC13,%,>3O9O
ME&>V!S45I=VEOIP5MC3A96 9,C>0%7\ADU?_ .$)U+_GO;?]]-_A1_PA.I?\
M][;_ +Z;_"I]CC.:_L^EBO:X6UN<SVN+*37&F+*L"H-I$?#,% R1CC)]JNG4
M=,2Z+1K$8WFW/F'.4$> .G&YLT__ (0G4O\ GO;?]]-_A1_PA.I?\][;_OIO
M\*(TL9&]J?6XI5,+*UY]+?UH9^DW5C;03&Y13*6!&]<@I@Y4<'J<>GUJREYI
MB0V4;>6Y1L7#>3]X8)7Z@$X/<XJ?_A"=2_Y[VW_?3?X4?\(3J7_/>V_[Z;_"
MB%'&1BHJGL$JN%E)R<]_Z[$ OK%2#NB><B*-Y?(PI^8EF"X[# Z<U5LY;-M6
MN)I9_L]N2Q5%# .">%..0/6M'_A"=2_Y[VW_ 'TW^%'_  A.I?\ />V_[Z;_
M  H='%MINGM_7<:JX5)I3W_KL5[C58I+*4F;?.Z21M&J$*6=\E_IM  [U%!>
M6<&GH@*&<1$9:/=AV<9/([*/UJ[_ ,(3J7_/>V_[Z;_"C_A"=2_Y[VW_ 'TW
M^%'LL;S<W)TM_6HO:82UN?K?^M"O->Z:T-Z%"#S)&,82+#$< #D8QCG@@BGW
M&HZ8&D>"*$E(W\D&/H3@!3P.G)[_ %J7_A"=2_Y[VW_?3?X4?\(3J7_/>V_[
MZ;_"J]GC/^?8N?"?\_/Z^XC.IV,B0BX<2H$A1D$6, $M)V]<=*C>^LE5F#0R
M7(CV>8(,*27!R%Q_"O?%6/\ A"=2_P">]M_WTW^%'_"$ZE_SWMO^^F_PH=/&
MO_EW_7W@IX1?;_K[C/\ M=HNJ:A<HJ!&5Q;J8\KDD ''TR:N2:AIKS'Y80!+
M(8V\GA?D 4D8Y!;)Q4G_  A.I?\ />V_[Z;_  H_X0G4O^>]M_WTW^%3&CC(
MJWLQRJ81_;&6]_IB70DWQ*RO'YKM;Y\U0O.T8^7+?2D34=-86[2*H8R+)+E"
M6#!BS-G'.>G7OTJ3_A"=2_Y[VW_?3?X4?\(3J7_/>V_[Z;_"K4,:O^7?]?>3
MS83_ )^?U]Q2TF[LENYKF^<;GDR59-P*DDGL>>GI4<]W!/\ V7$9 ((1^]4)
MC82V3]>,5H_\(3J7_/>V_P"^F_PH_P"$)U+_ )[VW_?3?X5FJ&+Y%#V?]7OW
M-/;87FYN?^K6[$$^I6,L4TA"%Y Y,9B^9I"^5;=Z!<<4^XO]' _=0A_WN#^[
MP2C$%S^'*BI/^$)U+_GO;?\ ?3?X4?\ "$ZE_P ][;_OIO\ "K]GC/\ GW^!
M'-A/Y_Z^X@N=1L56=[=(&F\O9$?*XY?/0@#@#]>]1Z1>VEI"DCO&LRR.[AHM
MQ?Y?D"G''-6_^$)U+_GO;?\ ?3?X4?\ "$ZE_P ][;_OIO\ "I]EC.?G]F/V
MF$Y.3G_K[BN;S3C%$#Y1&8BJ-"<H1RY<]6R?3-2K?Z4+N63"$E4VEH_EP,[E
M'R\]N2!QWI__  A.I?\ />V_[Z;_  H_X0G4O^>]M_WTW^%4J>,_Y]_U]XG/
M"/\ Y>?U]QGW5S9/I"11;!,&!VI'VR2<DCJ.G!YJU'JD$5C#&LR[EMUA"F+.
MTE\N3QSP!4W_  A.I?\ />V_[Z;_  H_X0G4O^>]M_WTW^%2J.,4N94^EOZU
M&ZF$:LY];_UH1-=:2T%X 4!F=BJ^5]W+#!'']WGK^%4]5O+:ZB @2,-]H=AM
MC"XCP HZ<YY-:/\ PA.I?\][;_OIO\*/^$)U+_GO;?\ ?3?X43HXR<>7V80J
MX6,N;G_K[C/6YM'73H9Y6:WMXV>90#\[DYV_H!FKKZQ:-.+[YI)EMGC$4R]6
M+< XXQ@G\J?_ ,(3J7_/>V_[Z;_"C_A"=2_Y[VW_ 'TW^%.-+&QVA_70)5,)
M+>?]/<S-0N+.YN99@9F>8*R-NP(?52,<@=L5<M]2M%OYBTN+=(UA@WJS*R!@
M6R!SN.,_6I_^$)U+_GO;?]]-_A1_PA.I?\][;_OIO\*4:.,C+F5/^OZ8W5PK
MCRN?]?TBO<:I;/I4T:2.99=W#*=^6?<<GIMP!QUS6%72_P#"$ZE_SWMO^^F_
MPH_X0G4O^>]M_P!]-_A6=7"XNJTY0V5BZ6(PM--1GN<U172_\(3J7_/>V_[Z
M;_"C_A"=2_Y[VW_?3?X5E_9^)_D9K]>P_P#.<U172_\ "$ZE_P ][;_OIO\
M"C_A"=2_Y[VW_?3?X4?V?B?Y&'U[#_SG-5+;?\?D'_75?YBN@_X0G4O^>]M_
CWTW^%/A\&:C'/$YFML*ZL<,>Q^E.. Q*DO<8I8W#M/WC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gpty1lksmhba000034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $* E\# 2(  A$! Q$!_\0
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M5_Z!G_D9_P#&C_A7/A7_ *!G_D9_\:?M$+ZO(\$HKWO_ (5SX5_Z!G_D9_\
M&C_A7/A7_H&?^1G_ ,:/:(/J\CP2BO>_^%<^%?\ H&?^1G_QH_X5SX5_Z!G_
M )&?_&CVB#ZO(\$HKWO_ (5SX5_Z!G_D9_\ &C_A7'A7_H&?^1G_ ,:/:(/J
M\CS73M,\/2>'K>6_FMEE8Q.\D<V) #+M=2-W4+SPO'7)K3:VT.:.SM;I=.1H
M4N#%;0W6Z,DRKC+%QSLR<%A_2NW_ .%<>%?^@6/^_P _^-'_  KCPI_T"Q_W
M^?\ QJ7)&BI278\UEM/#8M9(HDA^:&[D6<W!,B%'_=C ."2/;FK$NG>&EO;=
M=EH8C.RPB*\R9X?+R'DR<*V['&5SR..M>A?\*X\*_P#0+'_?Y_\ &C_A7'A7
M_H%C_O\ /_C1S(/92[(\_-KH,8EMVEM9K9+F:58EG*KQ;94?>)^_QP3SP":;
M;:?X6E66:1;=6>&&1H1<8$0:(ERA+#D/@8.XCICFO0O^%<>%?^@6/^_S_P"-
M'_"N/"O_ $"Q_P!_G_QHYD'LI=D>7^&--TVZTE[F_@MG47R0R2SSF+RX2A+%
M>1EAC('-21VV@L\,$-O9RS#3EFC,]PR+/.6P5<[@%PO...:]0_X0#PW]F-M]
M@;R"XD,?GOM+ 8!QGKBH_P#A7'A7_H%C_O\ /_C1SJXE1DE;0X33X/#]G?S3
M6,EFX22=&DFN<&(>3\@C!/S@L6&<'H*J0Z5X<S%+/+:K;RO:;-MS\P!C/F;A
MG*@N "3TKT;_ (5QX5_Z!8_[_/\ XT?\*X\*_P#0+'_?Y_\ &CF0_92[(X+2
MQI\!DADATFWF^V64L@ANRPC7<=Y5B>HXR 3C/Y5/L/A][)9':U(;#&?[2?.,
MYFPT93/W-G.<>^:](_X5QX4_Z!8_[_/_ (T?\*X\*_\ 0+'_ '^?_&CF0>RE
MY'DGB*#2O)A?3(H(7^UW$!6.8N#&K#RW.2>H)YZ'%;UU%X=:[*3"WN%'G1B4
MW!RD4,("[<'JSY(S7>_\*X\*_P#0+'_?Y_\ &C_A7'A7_H%C_O\ /_C1S*P>
MRE>^AY%HT6CG0[J\U!4:YM)0RPER&N0R$*F,] ^"2.U=,JZ(R&TG:QEMXIH(
M97:;YO*CA+ML.>C29''^%=O_ ,*X\*_] L?]_G_QH_X5QX4_Z!8_[_/_ (T.
M28HTI+L>8>3H,^A->?9[2 O;2,VVY;S8IP<1QJA/((Y)(.<GD5R=>]_\*X\*
M_P#0+'_?Y_\ &C_A7/A7_H&?^1G_ ,::FA.A)]CP2BO>_P#A7/A7_H&?^1G_
M ,:/^%<^%?\ H&?^1G_QI^T1/U>1X)17O?\ PKGPK_T#/_(S_P"-'_"N?"O_
M $#/_(S_ .-'M$'U>1X)17O?_"N?"O\ T#/_ ",_^-'_  KGPK_T#/\ R,_^
M-'M$'U>1X)17O?\ PKGPK_T#/_(S_P"-'_"N?"O_ $#/_(S_ .-'M$'U>1XA
MI/\ R&K#_KYB_P#0Q7TS7,1?#WPQ!/'-'INV2-@ZGS7X(.1WKIZB4KF]&FX7
MN5=2_P"07=_]<'_]!-?,:_<'TKZCEC6:)XG&4=2K#U!ZUS ^''A4#']F?^1G
M_P :(R2%6IN=K'@E%>]_\*Y\*_\ 0,_\C/\ XT?\*Y\*_P#0,_\ (S_XU?M$
M8_5Y'@E%>]_\*Y\*_P#0,_\ (S_XT?\ "N?"O_0,_P#(S_XT>T0?5Y'@E36<
M<<M];QRNB1O*JNSDA5!/))'(%>Z_\*Y\*_\ 0,_\C/\ XT?\*X\*_P#0,_\
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MA"S%N%&68L< < 9/ ["AI=!Q<KZHTJ*0$$ @Y![BEJ2PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &NJNA5U#*>"",@
MUA:OJ>E:,S?:=,G9%C\QI8;(NBCGJP&!TK?IDL4<\312QK)&PPR.N01[BFO,
MF2;6ASFCZ[HVN>0;32[CRYE)65[$B/CK\^,=L=:OWA@@N8[:WTR">9T:4J0J
M *I /)'7)&!^HK2@MX;:(100QQ1CHD:A0/P%17FGVM_L%U"LFS.W)(Z]1QV/
M<=#0VKZ"BI<NKU.?EUFU@B$LNCP+'(SK"V5.[:^P[OE^7KGC-6I;CRM)FU'^
MQ[1HE59(DW ,R%03GY3@@G&*O#0M-4N1:*"QSG<WRG.[Y>?EYYXQ5LVENUG]
MD,*_9]FSR\<;?2BZ"TNK,RZN],T]5^VV<4;^7YDGEP[UC'J3CIG@51.OZ*)#
MFQ3R0N3((AD'(&",>IZ]*W;G3;.]D#W%NLC!2OS=P>Q]?QJ$Z%IC+M-HIR,$
M[CDCZYS1H#4NA.EG9.BNMK!AAD?NQ7,^)_$=KX:M[F4^&;RZ6!5/G1VZ"$YQ
M_'U&,^E==&BQ1K'&H5$ 55 X '04XC(P:$]=1R3:T=CF= U>UUU(6_X1N\LU
MDA$HDN;9!&>G .<GKQP*=JEVEC>RPQ:9#(BQPMO$:X3?(5.[)!Z#C KI*:44
M]0#GU%%U<.5VM<Y&ZU)[;YWL; K'+,KQQQAG?:P"!02">O) ./2FV.K^=?6<
M$EE9'S& D*1+@9Y&"">G'3/?.W%=?Y:;@Q1<@Y!QTH$,:E2L:#;G;A1QGKBG
M="Y7?<?5?[#9_P#/K!_W[%6**DLK_8;/_GT@_P"_8H^PV?\ SZ0?]^Q5BB@"
MO]AL_P#GT@_[]BLS6)#IRPFS\-OJ9<D,+?R5\O'KO9>OMZ5MT4 <!X>UKQ#>
M321ZQX#^SK]H\I9(&BVJN<%FW,"?7Y0?;-=/JZ)9Q6S6MA!*\EPD93RU&5.<
M\GI6Q10)HXW[3=/:AS;V%N7@9@9(0/+83!/F;!&-I].O-5#J\Y5R+*"/(54#
M0)N ^7+G. ,Y.">#CMW[VBJNB'!]RA96UM<6%O-)9P!Y(U=@(@,$C/0C-3_8
M;/\ Y](/^_8JQ14FA7^PV?\ SZ0?]^Q1]@L_^?2#_OV*L44 (JJBA54*H&
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M'9@<@CVK1KC+D?\ ")>-H[M#MTC7I1%<+_##>8^1_82 ;3_M!?6NSH ****
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M<T]/_P!1)_UWE_\ 0S5JJ>F/YEHS@,-TTIPPP1\Y[5<I#*+_ /(<@_Z]I/\
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M_IC-A"3[!MA_"NIJI.^IG3BHWB@HHHJ34**** "BBB@ HHHH **** "BBB@
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MX>TUMI$)!7E?G) . .F<?PC\JU:*/9P[![6:ZLQK3PY:01!9B\[[LERQ&1P
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M%SP>YX%7ZQ?%5T+70I<D?O6$6TJ"&W=1RR@<=\T 5O!;N^BN7DBD_?M@QNC
M# XRG&1TKHZQ/"\$$.DAK>ZCN8YG\[>BX W ?+C<V,<<9JYJUY)9VT;1O'&7
MDVF2095!@G)Y'IC\:;W$MB_5'4=^;3:5V_:$W9'/X51_MBX>[M8T2(>;&A,3
M9W%F#$\]@I49X[THU!KBSTLSKB>>1&.Q3LSSD _A2 VZYW4_ _AW5]0DU"]T
MY7O9,9G65U88& 1@C!  KHJ*:;6P.*EHT<EY/B3PUS;N^OZ:O_+*5@MY$/\
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M(H DT[_CT_[:R?\ H;5:JKIW_'H?^NLG_H;5:H **** "BBB@ HHHH ****
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M]=Y?_0S5JJNG_P"HD_Z[R_\ H9JU0 4444 %%%% !1110 4444 %%%% $%Y
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M=$V8^BF)+'(SJCJQ0X8 YP?0T^F(**** "BBB@ HHHH **** "BBB@"KI_\
MJ)/^N\O_ *&:M55T_P#U$G_7>7_T,U:H **** "BBB@ HHHH **** "BBB@
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@3;G[3"9GF*&-GD?<2/EQGZ!5 ]A6I13NPL%%%%(#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gpty1lksmhba000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "J F4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W\G R:K.V
MYLTKN6^E+&FXY/2F(DB7"Y]:?112&%%<WJOB.ZL-;>SBM!-%#%%-)M#%MK,P
M8Y VC:%SR>>E*?&NFK%'(\-VJR,J)F,?-(RJZIP?O%6!].>M5RLCVD>K.CHK
MF&\<Z8MO-,T%X%AP''EKD'+\8W<D>6QX["I;3QGIM[>16\4-T/-<(DC1@*22
MZCOGDQMV[4<K#VD.YT5%%%26%%%% !1110 45R<?CRPCB<WL,T;QO(K&-=R\
M-(%&<YR1&>W6BQ\:"XU.6RFLY%G$CI%!&,R-M9P<Y.WHF>OYU7)(S]K#N=91
M7(7GCZSC>6&TMII)(UD+.X 0!5)W<')!P1Q5F7QSI42@^7=MN1I4VQCYXU#D
MN.>G[MNN#QTYHY)![6'<Z:BFHZR1JZG*L 0?:G5)H%4=9NI[#1;V\M_+\RWA
M>4"125.T$XX(]*O5A>)M;&B01/<6T<UG.LL<F\_Q["R+CN&P5_$4TKLF;2C=
MF=)X\M+*6.TNX9I;IE!+0( A.T.P&6XP".M07?Q(L;>.Y":?>/<0*I:/Y<?,
M 5^8$C!!Y/:J<_BG2S-;LNDVRWF MQ*T0!C. ,HP&2.HS[5'8:QX;TQ;B*32
MGDMSLDBDDB62219% +$=EQM''KR*UY5V.9U)=)&A=>,;^'6=7M5MK;R=-19"
MK9WR [,J#G /S''![5U&GWCWOVMBBJD5P\,9'\07 )/_  +</PKE;/Q+HEQ*
MUU<Z1'%*D:7'$"M)%'M0[V;T&Y>F3TXXKH-#UNQU=)EL8I(ECPY5T"Y#Y(88
M/<AO>IDM-C6G*[^*YKT45%=2FWM)I@ 3'&S@'O@9K,V):SM1U&2SU#2[=$1E
MO)VB<MU4"-FX_P"^:YV+X@6Q^Q/+:R"*>$[F7G,P\O*)D\@;SR<=*?=>+M'U
M P0_V9->%YE2,30J "2JDC<<C&\=AUJU!]49.K%K1DT_CW2X#,##=,(I&3(0
M?,%+*Q'/8J<]\8-7=%\1#6M2NHHH2EK'!'+$[8W/N>12< \#Y.,\US=EXETR
M\N46[T6S$4Y01A8%9II"D9&,\#F7'../QK1D\5Z3IVH-:V>E2)>3.%DVQ(G.
M"3N(/)4GD>]-Q[(B-36[EH=A17+P^.=.>UM9&CN&>XPD?EQ\2/\ *&5<D="P
MZX_&N@L;R+4;"WO8,^3/&)$W#!P1GFH<6MS:,XRV98HHKE(O&#)]AEN;3,.H
M%A;) =T@(D5 &!P.=P[\=*$F]@E)1W-K5=1DL)M-1$1A=7:P-N[ JQR/?Y:R
M+OQWIEI)=(T%TYMW9#M0?.5SOQD]MI/TYJE)XSTS4Y(XYM->:T,NQ!+&K,[X
M0#:"< @R8.:C?Q)X=E^<Z1'Y'D-<3++;)O*JH*D<X/!(P3GL*M1[HQE4_ED;
M6C>)5UK5I8((2MHMN)8Y'^\_[QT)QG@?)WYK?KC&\6Z18WIALM(DCO)?]9^Y
M2/&%9CN(/)4C!'7-6X_'&G&VMG:*X=KCB/RXQB1A@,%R1T)QSC\:3B^B*C4C
M:S9U%%06=W%?V,%Y 28IXUD3(P<$9%3U!L%%8?B'6KG27LH[6!9I+EI% *LQ
MRJ%@ %&><8]LU3'CG3HE47D%U;R#<)5*!A&5(5NAR0&.,X]^E5RMD.I%.S9U
M%%<E?>-DLKN'?:/':O LY:0?.5.[H 2.@R.:FC\:6DNI+:I!.SL-JP[!YAD!
M.1UVXVC/6CD8O:PVN=/17.0>+K:\UZVTRUB<EY'61I!C "N05QG/*$5T=)IK
M<J,E+8****1045QTOC"_BO)%73!-;K?&T+1[@5Q*J#DX5BP)( /&.:L/X_T9
M4#!+MU,2R@I%D$';GG/!&\9SC%5R2,_:P[G4T5BV'B:SU:2YBT])9I(4++D
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M9?-OD+QGRR HQD;L_=)Y !ZD&B[86BM+DGVZ^_Z!,_\ W^C_ /BJ/MU]_P!
MF?\ [_1__%52@\6Z7<7TEG&TIGCO6L70IT<(SYZ_=(5L'U%5K?QSILUE+=/;
M7T$:6WVM!-" 9HL@%DP2#@D<'!Y%+E?8?/'^8UOMU]_T"9_^_P!'_P#%4JWM
MZ74'2IE!."3+'Q_X]5$^*K)=8?3WM[M0EPMJ;DQ#R?-90P7.<Y(8=L9-3Q^(
M;2>ZU*UMXKB:>P WQHG,G^YD@-@\'T-%GV#F7<M3W5U',4CTZ69!T=9$ /YG
M-1_;K[_H$S_]_H__ (JL3_A/=/\ L=M<FPU%5NI'CA#HBE]HRQY?&!TY-:,G
MB:TBU&PL#;W37%Y$)E1(PWEH3C+8/J><9QUZ<T<K[!SQ?4C-G"=V?#"'<26S
MY/).[/?_ &F_[Z/K3!IUJ(]@\+1[3R1F'U)]?4G\S70T4<P^1'._V9:?-_Q2
ML?S')_U//7W]S^=2?8X3OSX80[R2W,/)((/?N&8?B?6MZBCF8<B,Y;R\10JZ
M/,% P )8^/\ QZGQWEX\BJ^F3(I."QEC('OPU7J*5RK/N4IKN[CE98]-EE4'
MAQ(@!_,YJM<M+>Q+%=:"TT:NKA9'B8!@<@\MU!K6HHN)KS.>&G6JNSCPK&&9
MMQ/[GDYSZTTZ79DDGPI$26W$_N>OYUT=%/F8N1'/K86Z!0OA= %8.,&+@CIW
M_P XJQ;;[/=]FT!H=P"GRWB&0,X'WNV3^=;%%*X<B106]O"ZAM*F4$X+&6/C
MW^]2W%S<[I(AI<LT9^7=YD>&'T)J]11<JWF<]_9UKEC_ ,(M'DJ$)_<]!C Z
M_P"R/R%.-G"W7PPG7/6+KD'U_P!E?R%;]%/F9/(C ^PP!-@\+H%QMQ^YZ8 ]
M?15_(>E1C2[,-N'A2(-QR/)[?C["NCHHYF'(C!6SA1MR^&5!^7!!BXVXQW[8
M'Y"K<$]Q;Q1P0Z+)%"@"JJR1@*/8!JTZ*5QJ-BG-=W4<S)'ITLJ#HZR( ?S.
M:QKO2X+Q6#^'G0O*DKF.2(%RK!P#ST)'/K72T4)V!QON8 L8%D5QX80,NW:0
M8>-N,8Y[;1^0IDFFVLJA9/"L;* % /D\ =!U]JZ*BGS,7(CG?[,M-Y?_ (1:
M/<>K9BR?QS4BV<*ON7PRH;*G(,7;IWK>HHYF'(C-@GN(8XX(M&DBA0!%59(P
M$4<< -T%3SW5U%*4BT^691T=9$ /YG-6Z*5RK>9EO-<22Q2OHDC21$F-C)$2
MA(P<?-QQQ5=H$:19&\-@NKLX):+[S<L>O<UN447%RG/?V=:[-G_"+1[0,8_<
M]/S]Z<]C!)OW^&$;><L28N?UK?HI\PN1&#;V<-K<BXM_#*13 DAT,0(SGIS[
MG\S5X7M[G_D$SC_MK'_\56A12N-1ML5+BYN8I=L5A+,N,[UD0#Z<FHOMU]_T
M"9_^_P!'_P#%5H447'9]S'PVPI_PCYVF7SB-\6/,SG=UZYYS53^R[,9QX4B&
M5V\>2....OL/RKHZ*.8GD1C6ZM9R/);>'S"S@!C&\2Y Z=#4L$UQ:PK#;Z))
M%$OW422( ?ANK4HHN/E,_P"W7W_0)G_[_1__ !52W%S<Q.HBL))@1DE9$&#Z
M<FK=% [/N9_VZ^_Z!,__ '^C_P#BJKD,8V0^'SL:7SF7?%@OG.[KUR <UL44
M7%R^9SHTRT!)'A6,$KMR/)'''O[#\JE6UC1)HT\-*J3IY<J@Q .N,8(STQ6[
M13YF+D1DVKS65NL%MH<D4*_=1)8P!]/FJ;[=??\ 0(G_ ._T?_Q5:%%*X[>9
M4FNKJ-E$>GRR@J"2LB#!].347VZ^_P"@3/\ ]_H__BJT**+CL^YCL'=)D;P^
M2LSB252\6'88P3SR>!^0JL=.M3(9#X6CWG.6_<YYZ]^M=#11<GD1AP0+;,S0
M>&Q&63RSL:(97TZ].E2VK2V, AM=">&('.R.2(#/_?5:]%%Q\MC/^W7W_0)G
M_P"_T?\ \54LMU=((_+T^67<N6Q(@VGTY/\ *K=%%QV?<RY9KB9HVET21VC)
M9"TD1VD@@D?-Z$C\:I+I]LD9C7PNBH5"E08@,#H.OL/RKH:*+BY;G/\ V"WR
M#_PB\8QG&/)QR,'OZ<4B:;:QOO3PM&K8QD>3GH1Z^A/YFNAHI\S%R(Y\V%N=
MV?"Z?-C/,7;IWK0^VWH&!I$W_?V/_P"*K0HI7&HVV&1,SQ*SQF-B.4)!(_+B
MBGT4BCC[E_#=GXJN]1O(C-?YC"L\ ;R2J_P''&<UDV</A6RNFN(I+CS)DGCN
MCY'_ !\)*Q8AN.,9P",''!S5;Q%_R,-[_OC_ -!%9E?.5<XQ,*DHJUDVMO\
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M446#F9M*P=0PZ$9%%,@_U$?^Z**DT/-/$7_(PWO^^/\ T$5F5I^(O^1AO?\
M?'_H(K,KXC$_QI^K_,^OH?PH^B_(*MZ;:I>7RPR;]NUG*I]YMH)P/<XJI6C%
MISAUVS.LJ;68JAPF>?O9Z@5-*+<D[7*J22BU>QHV^C6<]LMSY4B>8J[8)9PA
M4EBOWL<YQQQ39='LH8'N%6YG1-W[L':S?O-H/3C'TJ@]I?2AY)KGAG\LF24_
M,PZ#_#Z&I#;:DKK,;PA]QC5_..=_=,^OZ>]=EXVM[/\ KO\ \#;H<EI7^/\
MKM_P1;;2X9-62&?SHK>24QHI*^;GT89X^N*E&E68LK>61YTW&(O(.0V\M\JC
MU&!W[U6BTRY-PLAN8T)?!FWDD-DY[9R,'_&D>RN@BQ-=*$C'FA'D(VCNP'^3
M4122UI]_T+;;>DRM?P+;:A<P)G9%*R+D\X!JO6G_ &1<23KY\Z+YC',C,3G@
MG/OP":S*YJD'%W:M<Z*<DU9.X5L^%?\ D9+7Z/\ ^@FL:MGPK_R,EK]'_P#0
M35X3^/#U7YD8G^#/T?Y':77%T_U'\JYG_A$[0Q1AY"TJW;7!D8$Y4NS[ "<
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M3O\ A/?$W_02_P#(*?X4>\+]WW?W?\$YKR)O^>,O_?!I?(F_YX2_]^S72_\
M">>)?^@E_P"04_PI?^$[\2_]!+_R"G^%/W@_=]W]W_!.:\B;_GA+_P!^S2^1
M-_SPE_[]FNE_X3OQ)_T$O_(*?X4O_"=>)/\ H(_^04_PH]X7[ON_N_X)S?DS
M?\\9?^^#2^3-_P \9?\ O@UTO_"<^(_^@C_Y!3_"MK0?B!=^;]GU>8%&/RW
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M3&U:(PD*5\H84?*.!5"N>=:4).-HZ?W5_D;PHQE%2N]?-FS]L\/_ /0)N?\
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M_H6K_P#\#3_C3AJG@K_H6[__ ,#3_C7)"GBCE%SOLON.L&I^"_\ H6[_ /\
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M?_CO_P 73YD+V4_ZL<6*<*[0>!M(_P"ASTS_ ,=_^+I1X'TG_H<M,_\ '?\
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M!7Q->+E7DEW?YGUU%I48M]E^1!5BQM?MM]#;;MOF-@MC.!C)X_"I&T]E7)E
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M1P ]*> /2FBG"F(< /2G@#TIHIXH$. 'I3P!Z4P4\4Q#@!Z4\ >E-%.% AP
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MB$7 )K<HHYF-4TCYPUCP?XEFUW4)8M"OGC>YD9&$7# L<$53'@OQ1_T +_\
M[]5]-T57M&9/#Q[GS,/!GB?_ * %_P#]^J>/!OB;_H W_P#WZKZ6HH]HQ?5H
M]SYK'@WQ-_T ;_\ []4X>#O$O_0"O_\ OU7TE11[1A]6CW/F\>#_ !+_ - *
M^_[]4\>$/$G_ $ [[_OU7T;11[1B^JQ[GSH/"'B3_H!WW_?JG#PCXC_Z E]_
MWZKZ)HH]JP^J1[GSP/"7B+_H"7O_ '[IW_")^(O^@)>_]^Z^A:*?M6+ZI'N?
M/H\)^(?^@+>_]^Z7_A%/$/\ T!;W_OW7T#11[5A]3CW/ /\ A%/$/_0&O?\
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MORH\B;_GDWY5KT47#E,CR)O^>3?E1Y$W_/)ORK7HHN'*9'D3?\\F_*CR)O\
MGDWY5KT47#E,CR)O^>3?E1Y$W_/)ORK7HHN'*9'D3?\ /)ORH\B;_GDWY5KT
247#E&0@B% 1@A1D44^BD4?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gpty1lksmhba000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. F(# 2(  A$! Q$!_\0
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MY21#M96C0%3Z$;:;_P )YXI_Z#,__?"?X55\574=[XHU&ZAN(KB&:4O')$,
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MS_[_ /\ ]:C_ (59XG_N6?\ W_\ _K5[G11[1A]7@>&?\*L\3?W+/_O_ /\
MUJ/^%6>)_P"Y9_\ ?_\ ^M7N=%'.P^KP/#/^%6>)O[EG_P!__P#ZU'_"K/$_
M]RS_ .__ /\ 6KW.BCG8?5X'AG_"K/$W]RS_ .__ /\ 6H_X59XG_N6?_?\
M_P#K5[G11[1A]7@>&?\ "K/$W]RS_P"__P#]:C_A5GB?^Y9_]_\ _P"M7N=%
M'.P^KP/#/^%5^)\?<L_^_P#_ /6KV+0+.;3_  _I]E<;?.@@2-]IR,@8.#6C
M12<F]RX4HPU1Y_\ $/PCJOB6_L9M.6 I#$ROYDFWDD'TKC/^%6>)_P"Y9_\
M?_\ ^M7N=%"FTK$RHQD[L\,_X59XG_N6?_?_ /\ K4?\*L\3_P!RS_[_ /\
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MG_N6?_?_ /\ K5[G11SL/J\#PS_A5GB?^Y9_]_\ _P"M1_PJSQ/_ '+/_O\
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MH **** "BBH+RX^RVKS;=VWMG% $]%4!<Z@1G["G_?T4?:-1_P"?%/\ OZ*
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M8HR0GS>6WSN5ZD$8X SBK-MJ^L2WEK:ZA?2V=SY,#1QPVF_[4SDERP*Y "@
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M^W;AV) Q@UW7A:PO[7Q;XDGO(IMLR602=UP)F6'#D=CSUQ0!UF)?[Z_]\_\
MUZ,2_P!]?^^?_KT^B@!F)?[Z_P#?/_UZ,2_WU_[Y_P#KT^B@!!G')&:*6B@
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MS-<.R[",DCD+4EHD<;?9I;C<A^8#) 8FG(%333(3YT:9V*>C'.,FJUK-=S3
M"-6C/W@4PN*>K)'W=Y+!<-']G4!> 7!;(IR9NK )*#%&TGROG.#[CTJ66?[.
MKLLGF6^0$W+NP?8^E$-U;7<HB=Y']%<  G\*.@#+*RNK>Y9&QY)X)!_(BNUT
MBXEN;/,IRR,4W?WL=ZY(>;#E$N%$,(Y9UR?H34NGZX;9]D=R&RQ)1EPASZ'M
M2=V-';T5GV&IB\D:)HO+D49QNR"/:M"I*"BBB@ JEJ__ "#)OP_F*NU2U?\
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M!8O]GDM5GADB3)0A]JR,Q'(&<G/? S0!Z%1110 4444 %%%% !1110 4444
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MK_\ (,F_#^8H N+]T?2EI%^Z/I2T %%%% !1110 4444 ,,>3G>X]@:3RO\
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M%M<(J2L,HR'Y7_\ KUHZ,TKV,U6@W8W**.U%9&H4444 %4;W4XK%PCH[N5+
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M?VQBA >JPW=O<33Q0SQR20,$E5&!*,1G!]#@@_C3+G4;.SN;:WN;F.*:Z++
MC'!D*C<<?0 FO(+ZQU/3;KQ<FFPZI%--JT$L[H)B'LV"EV0KR?FR#L^8+QV%
M7M-M]4EN?"\EP;VZACU"^,,DT$JF.$P,%!,F7VYS@O@G(HZ >E6.O:5J4D$=
ME?PSM/!]IB"-G?%G;N'MGBM&O$])A\26V@64>EPWL5XGA-Q$FQEVS>>. #QY
MFW.,\UW?@1[9A>BR_P"$@-L!'\VK%]OF8.[R_,^?/][MGI0!V-%%% !1110
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MM /L\ZC(93P1Z'VKJES.FTCECRJHFST^BJ4.-2TR!Y0R>:BN0K8P:;_9%O\
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:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gpty1lksmhba000035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000035.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I E@# 2(  A$! Q$!_\0
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MG(&2>2,<&BT0YZIT_P#PMS6_^?'3_P#OE_\ XJC_ (6YK?\ SXZ?_P!\O_\
M%5R$6BWTMC'?>4%M9'VJY=06^8*2%)R0"<<59N?#&IP+=2I#YEO TH+[E#,(
MVPYVYSQWQFBT0YZG<Z;_ (6YK?\ SXZ?_P!\O_\ %4?\+<UO_GQT_P#[Y?\
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M_P!\O_\ %5DZ=X'O+U%^T74-I,UT;;RI""1A=S-U].@&<]>G-49/"]ZTRI9
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MTSNR,>M27GA2]AGU$6SQ30V4K1L2X#D*0"VWL,D46B/GJG0?\+<UW_GST_\
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MB"P;D X)R.I&<<5$FOW"ZQ?:@T$$@OMXN+=P3&ZL<E>N1SC!SGBNY_X4Z_\
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MJZ=#9W"H!&$#.K-E]J[5R,[1QZ"NX_X4Z_\ T&Q_X#?_ &5'_"G7_P"@V/\
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M4YD78O$GS,09,GYB0W/TQVS0!U=%,B\SRE\XJ9,?,4'&?:GT %%%% !1110
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MW.$7Z9Y/L#5/PUHHT!K>Q:4S7'V9I;F<]9IG?<[GZDG\,"@#IJ*** "BBB@
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MW;$.#YR*I02<C <YVAQQ[E3737$PMX'F9694&2%&33Z"ZDE5-2_X\6_WT_\
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M]I_M:#SQ$%\N3;L))ZKUS6A527_D*6W_ %SD_FE6Z0Q"0H))  ZDU#]LM?\
MGYA_[^"IF4,I5@"",$'O7!ZEJT-S\0],T'1HM*F:U+OJD4D9$D2%!M*\8/7W
MZB@#NHYHI03'(C@==K9I]1Q00P B*)(P>2$4#-24 %%%% &5I]A9_P!IWU]]
MD@^U^>5\_P L>9C:O&[KBM6N4\%^)XO$CZL8K*YM?(N>?/ &[(QQ_P!\_J*Z
MNF[IZDP::N@HHHI%!1110!'%!%#N\N-5W,7.!U)ZFI*** "JFI?\>+?[Z?\
MH8JW534O^/%O]]/_ $,4 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBN?\9>([#PQX:NK^^ E 7;';B3:\['^%>_N<=!DT ;%]?6NFV,U[>SQV]M
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M66ZM GFB%$WN/EC#2@%C[ '--6V,VY;O1%A$\2^7&'FT\N+9@Y"-_K_X2/\
M9_QK5LOM(LH1>M&UR$'FF,84MWQ[5R7]KZ]+%<7EM-$T,5O!*\,UN$*%QN8
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MF&W41;DEWD8' )]<>M7ZDT04444 %%%% !1110!4E_Y"EM_USD_FE6ZJ2_\
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M5IH8Y"ARI=0=OTH J?:(YM6@5-^5CDSNC9>Z^HYK0JI+_P A2V_ZY2?S2K=
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M/_?QO\: +E%4_P"R[/\ YY'_ +^-_C4\$$=NFR)2%)SU)_G0!+1110 4444
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0<D#'4]:NT44AA1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gpty1lksmhba000037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000037.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X F,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#H/'WB?7-+
M\73VMCJ4T$"Q1D1IC )'/45S/_";^)_^@U<_DO\ A6A\3?\ D>;G_KC%_P"@
MUR%;Q2L<%24E)ZF__P )OXG_ .@U<_DO^%'_  F_B?\ Z#5S^2_X5@44[(CG
MEW-__A-_$_\ T&KG\E_PH_X3?Q/_ -!JY_)?\*P**+(.>7<W_P#A-_$__0:N
M?R7_  H_X3?Q/_T&KG\E_P *P**+(.>7<W_^$W\3_P#0:N?R7_"C_A-_$_\
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MH5V,1*5C$N<_P@J>_>N7!R ?6A68FYK=G0?\)OXG_P"@U<_DO^%'_";^)_\
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M\LK;=Y,+A4W')^Z#_6CW0?.E=LN?\)OXG_Z#5S^2_P"%'_";^)_^@U<_DO\
MA6!13LB>>7<W_P#A-_$__0:N?R7_  H_X3?Q/_T&KG\E_P *P**+(.>7<W_^
M$W\3_P#0:N?R7_"C_A-_$_\ T&KG\E_PK HHL@YY=S?_ .$W\3_]!JY_)?\
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M )ZW_P#W^'_Q-'_"IO#W_/6__P"_P_\ B:.=!]7F>+45[3_PJ;P]_P ];_\
M[_#_ .)H_P"%3>'O^>M__P!_A_\ $T<Z#ZO,\6HKVG_A4WA[_GK?_P#?X?\
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MOWJR)\B[3\I7(;T*D#GGOGJ+0,MK&&@2!@.8HSE5]@<#^5#!$]%%%(84444
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MZ?3[Z._LTN$!&>"IZ@]Q6M.O&H[(YZV&G25Y;#?['T[_ )\H/^^!1_8^G?\
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M "BBHKF=+6UEN),^7$A=L#)P!DT 2U7OK9;RRFMVZ2(5SZ'M5(Z[&(HG-G=
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M1D\>H':JFEZ)+I\]@[21D6VGBT8*,9;*G(]N#57_ (1^]RMOYML+2*XFN8W
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ML1""V0%E]U'<_K6\*+O>1IB\RA*FX4^I-?Z?#J,'ES#!!RK#JI]JPCX9NPQ
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M:17"1L)6G^5BW4(P&UL>F03G@46"Z.BHKFCXL:*VBN9]/*PW4+2VFV4%GP0
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MB\Z7F/[[#H#NZ#V'O5&3Q+J4-M&[VD.]U5]W(50R;MIR1\V>,_I6[=ZK!9W
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MTMXW66!Y2X8.\DK,S;MN<L3G^%<>F.*UJ* ,M?#^G*YDV2M*94F,C3N6+J"
M22?0D8Z$<4B^'-,6*2+R7:-T\L(TSD1KG.$!/R\@'C'0>E:M% 6*EAIMMIRR
MBW5\S/YDC/(SL[8 R223T JM#X=TJW,!BM%4P+*D?S'Y1(<OW[G\NU:E% &9
M'H&G13QRI P:,1[1YC8'E@JIQG&0#C-)?Z+#<Z)>:=!B);K>6)R1ECECU[G-
M:E% &5_PC^G^65V2^89!+YWGOYH8#:"'SGIQC/2D?PUI3QI']G945/+*I*RB
M1<D[7P?F&23SGJ?4UK447"Q#;6D%H)! FP22-*W).6/4U-110 4444 %%%%
M!1110!5GTZUN;A)YH@TB8P<D9P<C(Z'!Y&>E.2RMHQ;A8@!;_P"IY^YQC^1I
MFIZE::1ITU_?3"*WA&7<C/L !W)/&*X^]\8ZO>JW]D:'<K H)::66)'_  !)
M _'\JI1;(E4C'<ZLZ+IQ(/V8< C&XXYSU&<$_,W/;-)-H>G7#*TEO\R[<%79
M3\H(4\$<@$\UYS+XMGMAOO(_$%JW>5AO0?\ ?!(_2NH\+>+X=6E6U:\@NMX/
ME3QD L1R5=>S8_/%-P:5R(UH2=CJ8;6&!W>-,.X4,Q)).!@9)]JFHHJ#8*2E
MK'UK4;NS>U@M+8R-=.8_,[1G'!/^>U.,7)V1%2HJ<>:1S>N>%)I=?B-FI%O=
MMF0CI$>K'\>WO7;6MM%9VL=O"NV.-=JBL+0M2U-KJ/3K^$R.MN)6NEZ$D\#I
MCI_*NBK:M.;M&70X\%1HIRK4U9RWOT\OO%HHHK [PK"UO6KBSN%T^RMV>\FA
M:2)S]T$>OX _I6[7-^)?$-AIK"Q>.:XU"2,O'#;@;U!X#$D@ 9X]^>*N%N;5
M7,<0I.F^65BUHFLR:A--9W%NT=S;(GFM_"S$<XK:KS&?7M?B")<Z3?PQ%0=E
ME<1%S[L<@Y/X?2JL'C46MRJM?W]A*3Q%JB,4;V).1^1%5*%W=&-*MR12F[O[
MCUBBLW1-7BUG3Q<( KJ=DB!MVUO8]P>H/H:TJRV.M--70444V1BD3L%+%5)"
MCJ?:@8ZBN,_MW6]G]JBU MA$RFS_ (MP8+GIGN*Z^"1I8(Y&0HS*&*'JI(Z5
M<Z;AN<]#$PK-J*?S73N24445!T!1110 4444 %%%% !1110 54U'3X=3M1;S
MY,?F)(1@'.U@V#GL<57_ +>L3>O:*9WE23RG*6\C*K<<%@,=QWJ_#,D\*RIN
MVL,C<I4_D>: &0V5K;K&L-O#&(P0@1 -N>N/3-5IM'LWMKB&"&.U:X_UDD,:
M@MSGGC!^AZY-6WN(4GB@:11+*"47NP'7'TR*EH S=+T6UTN(A 'D:0R&0HJD
M$@#Y0H 48 &!Z58.FV)DAD-G;EX>(F\I<I]/2K5% %0:98"66465OYDW^L;R
MER_?GCGFGQV-I#<R7,5M"D\GWY5C 9OJ:L5'/<16T?F32*B;@N3ZD@ ?B2*
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M;YK>6$HJ2&*1A(&9'"Y;Y1SM'(W>OMS4VFZQ>7^M)%+;-;6TED+B-68,6RV
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M%%.T;0OR'C'+$D5=6YU"5D:VU2Y^SBZMK>/:BD-&\:EFR5Y.2>>U%@N=M17
MW6KZO"/):\:-(EG$4\A"F5TE95!PC;R%"_* ,YK06ZU1[KSY+R=0=16U,"H
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)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gpty1lksmhba000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #\!0X# 2(  A$! Q$!_\0
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MH_A+4O$/PGCTK6TEAOXF9[)K@$20X^X#GD#J,'HI'H*<J2CNR:>)=3:/X_\
M /3J*\>TJ;5?B-J6FZ/K%M)#::(-VJ;_ /EXG4E54^Y .?J_M7L       X
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M^9_$VKV5[:F+$:6Z %7R.3B->,9[UPW]MZM_T$[W_P "'_QH_MO5O^@G>_\
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MI>+=:L[J+39/-@2UC 8MP<$A%P,@'OTQQG->D5X3_P +C\2?\\-._P"_+_\
MQ=+_ ,+B\2?\\-._[\O_ /%4I*4APJ4X;7/=:*\+_P"%P^)/^>&G?]^6_P#B
MJ7_A<'B/_GAIW_?IO_BJGV;+^L0/<Z*\._X6_P"(_P#GAIW_ 'Z;_P"*I?\
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M_P"_^@H^US_W_P!!18.9&I167]KG_O\ Z"C[7/\ W_T%%@YD:E%9?VN?^_\
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M;)N7SD=#UZBGRLE55U1Z3<3Z4ND:EJ(\-Z1YFG:NUG"OV?"LF0I+C^(X)Z\
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M?_$4^9$>RGV//13A7H7_  IOQ%_S^Z7_ -_9/_B*7_A3GB'_ )_-+_[^R?\
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M-%+= _($!*I[\XY_"NI_L_\ Z:_^._\ UZSG43T1U4,,U[TBC15[^S_^FO\
MX[_]>C^S_P#IK_X[_P#7K*YU\K*-%7O[/_Z:_P#CO_UZ/[/_ .FO_CO_ ->B
MX<K*-%7O[/\ ^FO_ ([_ /7H_L__ *:_^.__ %Z+ARLHT5>_L_\ Z:_^._\
MUZ/[/_Z:_P#CO_UZ+ARLHT5>_L__ *:_^.__ %Z/[/\ ^FO_ ([_ /7HN'*R
MC15[^S_^FO\ X[_]>C^S_P#IK_X[_P#7HN'*RC15[^S_ /IK_P"._P#UZ/[/
M_P"FO_CO_P!>BX<K*-%7O[/_ .FO_CO_ ->C^S_^FO\ X[_]>BX<K*-%7O[/
M_P"FO_CO_P!>C^S_ /IK_P"._P#UZ+ARLHT5>_L__IK_ ..__7H_L_\ Z:_^
M._\ UZ+ARLHT5>_L_P#Z:_\ CO\ ]>C^S_\ IK_X[_\ 7HN'*RC15[^S_P#I
MK_X[_P#7H_L__IK_ ..__7HN'*RC15[^S_\ IK_X[_\ 7H_L_P#Z:_\ CO\
M]>BX<K*-%7O[/_Z:_P#CO_UZ/[/_ .FO_CO_ ->BX<K*-%7O[/\ ^FO_ ([_
M /7H_L__ *:_^.__ %Z+ARLHT5>_L_\ Z:_^._\ UZ/[/_Z:_P#CO_UZ+ARL
MHT5>_L__ *:_^.__ %Z/[/\ ^FO_ ([_ /7HN'*RC15[^S_^FO\ X[_]>C^S
M_P#IK_X[_P#7HN'*RC15[^S_ /IK_P"._P#UZ/[/_P"FO_CO_P!>BX<K*-%7
MO[/_ .FO_CO_ ->C^S_^FO\ X[_]>BX<K*-%7O[/_P"FO_CO_P!>C^S_ /IK
M_P"._P#UZ+ARLHT5>_L__IK_ ..__7H_L_\ Z:_^._\ UZ+ARLHT5>_L_P#Z
M:_\ CO\ ]>C^S_\ IK_X[_\ 7HN'*RC15[^S_P#IK_X[_P#7H_L__IK_ .._
M_7HN'*RC15[^S_\ IK_X[_\ 7H_L_P#Z:_\ CO\ ]>BX<K*-%7O[/_Z:_P#C
MO_UZ/[/_ .FO_CO_ ->BX<K*-%7O[/\ ^FO_ ([_ /7H_L__ *:_^.__ %Z+
MARLHT5>_L_\ Z:_^._\ UZ/[/_Z:_P#CO_UZ+ARLHT5>_L__ *:_^.__ %Z/
M[/\ ^FO_ ([_ /7HN'*RC15[^S_^FO\ X[_]>C^S_P#IK_X[_P#7HN'*RC15
M[^S_ /IK_P"._P#UZ/[/_P"FO_CO_P!>BX<K*-%7O[/_ .FO_CO_ ->C^S_^
MFO\ X[_]>BX<K*-%7O[/_P"FO_CO_P!>C^S_ /IK_P"._P#UZ+ARLHT5>_L_
M_IK_ ..__7H_L_\ Z:_^._\ UZ+ARLHT5>_L_P#Z:_\ CO\ ]>C^S_\ IK_X
M[_\ 7HN'*RC15[^S_P#IK_X[_P#7H_L__IK_ ..__7HN'*RC15[^S_\ IK_X
M[_\ 7H_L_P#Z:_\ CO\ ]>BX<K*-%7O[/_Z:_P#CO_UZ/[/_ .FO_CO_ ->B
MX<K*-%7O[/\ ^FO_ ([_ /7H_L__ *:_^.__ %Z+ARLHT5>_L_\ Z:_^._\
MUZ/[/_Z:_P#CO_UZ+ARLHT5>_L__ *:_^.__ %Z/[/\ ^FO_ ([_ /7HN'*R
M"T_X^D_'^5:E58;/RI5?S,X[8JU29<59'*?$'_D P?\ 7TO_ *"U>;5Z3\0?
M^0#!_P!?2_\ H+5YM7KX+^$?%9[_ +X_1!11176>.%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% %_1/\ D/:=_P!?47_H0KV6O&M$
M_P"0]IW_ %]1?^A"O9:\O'_$CZSAW^%/U,?SI?\ GJ__ 'T:/.E_YZO_ -]&
MF45QGNC_ #I?^>K_ /?1H\Z7_GJ__?1IE% #_.E_YZO_ -]&CSI?^>K_ /?1
MIE% #_.E_P">K_\ ?1H\Z7_GJ_\ WT:910 _SI?^>K_]]&CSI?\ GJ__ 'T:
M910 _P Z7_GJ_P#WT:/.E_YZO_WT:910 _SI?^>K_P#?1H\Z7_GJ_P#WT:91
M0 _SI?\ GJ__ 'T:/.E_YZO_ -]&F44 >>_%36=4T[^R?L6I7EMYGG;_ ")V
M3=C9C.#SU/YUYV/%7B+_ *#^J?\ @9)_C7;?&#KHO_;?_P!IUYD*TBM#EJ-\
MS-H>*O$7_0>U3_P,D_QIX\4^(?\ H/:I_P"!DG^-8HIXJK(SYGW-D>*/$/\
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M5S;OQ(LDI8@>HR>O\ZYH4X4<J8*I).Z9[?!??:H$G@N&DB<95@QP14GG2_\
M/5_^^C7E_ACQ&^D3^1<$M92'D=3&?4?U%>EHZR1K(C!D895@<@BL)1Y6>C2J
MJHKDOG2_\]7_ .^C1YTO_/5_^^C3**DU'^=+_P ]7_[Z-'G2_P#/5_\ OHTR
MB@!_G2_\]7_[Z-'G2_\ /5_^^C3** '^=+_SU?\ [Z-'G2_\]7_[Z-,HH ?Y
MTO\ SU?_ +Z-'G2_\]7_ .^C3** '^=+_P ]7_[Z-'G2_P#/5_\ OHTRB@!_
MG2_\]7_[Z-'G2_\ /5_^^C3** '^=+_SU?\ [Z-'G2_\]7_[Z-,HH ?YTO\
MSU?_ +Z-'G2_\]7_ .^C3** '^=+_P ]7_[Z-'G2_P#/5_\ OHTRB@!_G2_\
M]7_[Z-'G2_\ /5_^^C3** '^=+_SU?\ [Z-'G2_\]7_[Z-,HH ?YTO\ SU?_
M +Z-'G2_\]7_ .^C3** '^=+_P ]7_[Z-'G2_P#/5_\ OHTRB@!_G2_\]7_[
MZ-'G2_\ /5_^^C3** '^=+_SU?\ [Z-'G2_\]7_[Z-,HH ?YTO\ SU?_ +Z-
M'G2_\]7_ .^C3** '^=+_P ]7_[Z-'G2_P#/5_\ OHTRB@!_G2_\]7_[Z-'G
M2_\ /5_^^C3** '^=+_SU?\ [Z-'G2_\]7_[Z-,HH ?YTO\ SU?_ +Z-'G2_
M\]7_ .^C3** '^=+_P ]7_[Z-'G2_P#/5_\ OHTRB@!_G2_\]7_[Z-'G2_\
M/5_^^C3** '^=+_SU?\ [Z-'G2_\]7_[Z-,HH ?YTO\ SU?_ +Z-'G2_\]7_
M .^C3** '^=+_P ]7_[Z-'G2_P#/5_\ OHTRB@!_G2_\]7_[Z-'G2_\ /5_^
M^C3** '^=+_SU?\ [Z-'G2_\]7_[Z-,HH ?YTO\ SU?_ +Z-'G2_\]7_ .^C
M3** '^=+_P ]7_[Z-'G2_P#/5_\ OHTRB@!_G2_\]7_[Z-'G2_\ /5_^^C3*
M* '^=+_SU?\ [Z-'G2_\]7_[Z-,HH ?YTO\ SU?_ +Z-'G2_\]7_ .^C3**
M'^=+_P ]7_[Z-'G2_P#/5_\ OHTRB@!_G2_\]7_[Z-'G2_\ /5_^^C3** '^
M=+_SU?\ [Z-'G2_\]7_[Z-,HH ?YTO\ SU?_ +Z-'G2_\]7_ .^C3** '^=+
M_P ]7_[Z-'G2_P#/5_\ OHTRB@!_G2_\]7_[Z-'G2_\ /5_^^C3** '^=+_S
MU?\ [Z-'G2_\]7_[Z-,HH ?YTO\ SU?_ +Z-'G2_\]7_ .^C3** '^=+_P ]
M7_[Z-'G2_P#/5_\ OHTRB@!_G2_\]7_[Z-'G2_\ /5_^^C3** '^=+_SU?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]&CSI?\ GJ__ 'T:XM3WKHM_V?\ ]-?_ !W_ .O1_9__ $U_\=_^O53SI?\
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M5*K^9G';%6JS;661KE SL1SP3[5I4F7$Y3X@_P#(!@_Z^E_]!:O-J])^(/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .(JU-)&$Z,G*Z/#Q3Q7MW_"FO#O_/[JG_?V/_XBE_X4YX>_Y_-4_P"_L?\
M\13YT1]7F>)BGBO:O^%.^'O^?S4_^_L?_P 13O\ A3_A_P#Y_-3_ ._L?_Q%
M/VB%]7F>+"GBO9_^%0^'_P#G\U/_ +^Q_P#Q%+_PJ/0/^?S4O^_L?_Q%'M(B
M^K3/&A3Q7L?_  J30?\ G[U+_OY'_P#$4O\ PJ;0?^?O4O\ OXG_ ,11[2(O
MJU0\>%/%>O\ _"J-"_Y^]1_[^)_\12_\*IT+_G[U'_OXG_Q%/VD1?5:AY"*<
M*]=_X55H?_/WJ/\ W\3_ .(I?^%5Z'_S]:C_ -_$_P#B*/:1%]5J'D=**];_
M .%6:'_S]:A_W\3_ .(I?^%6Z)_S]:A_W\3_ .(H]K$/JM0\F%+7K/\ PJ_1
M/^?K4/\ OXG_ ,12_P#"K]$_Y^M0_P"_B?\ Q%/VL1?5*AY.*DBC>618XU+.
MQPJ@9)->J?\ "L-%_P"?K4/^_B?_ !%:&E>!M)TBY-Q"UQ++C"M,RG;],**/
M:Q!82HWJ9'AGPXFD0">X56O7')Z^6/0?UKH:T?L$7]Y_S%'V"+^\_P"8K%RN
M[L[HT^561G45H_8(O[S_ )BC[!%_>?\ ,4KE<K,ZBM'[!%_>?\Q1]@B_O/\
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M8(O[S_F*+ARLSJ*T?L$7]Y_S%'V"+^\_YBBX<K,ZBM'[!%_>?\Q1]@B_O/\
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M8(O[S_F*+ARLSJ*T?L$7]Y_S%'V"+^\_YBBX<K,ZBM'[!%_>?\Q1]@B_O/\
MF*+ARLSJ*T?L$7]Y_P Q1]@B_O/^8HN'*S.HK1^P1?WG_,4?8(O[S_F*+ARL
MSJ*T?L$7]Y_S%'V"+^\_YBBX<K,ZBM'[!%_>?\Q1]@B_O/\ F*+ARLSJ*T?L
M$7]Y_P Q1]@B_O/^8HN'*S.HK1^P1?WG_,4?8(O[S_F*+ARLJVG_ !])^/\
M*M2J\=I'%('4MD>IJQ29<58Y3X@_\@&#_KZ7_P!!:O-J])^(/_(!@_Z^E_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB_\ 0A7LM>7C_B1]9P[_  I^IB4445QGNA1110 4444 %%%% !1110 4444
M%%%% !1110!YA\8.NB_]M_\ VG7F:UZ9\8.NB_\ ;?\ ]IUYFM:1V.2K\3)E
MJ5:B6I5JS%DRUT<_C+Q#>::VGW&IR/;,@C9=BAF4=BP&X^^3SWKG%J9:+(7,
MUL2K3Q3%IXJC,D%/%,%30Q23RI%$A>1SM50.2:"22"&2XF2&%"\CG"JHY)KU
M#PWX=CT:W\R7:]XX^=_[OL*9X9\-1Z/ )YP'O7'S-V0>@_QKH:RG.^B.ZA0Y
M?>EN%%%%9G4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?WG_ #%6J*+A9'+^)/ FE^*/LOVV>\C^S;]GD.HSNQG.5/\ =%88^#7AT?\
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MV"+^\_YBC[!%_>?\Q5JBBX615^P1?WG_ #%'V"+^\_YBK5%%PLBK]@B_O/\
MF*/L$7]Y_P Q5JBBX615^P1?WG_,4?8(O[S_ )BK5%%PLBO':1Q2!U+9'J:L
&444AG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gpty1lksmhba000026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #< ;L# 2(  A$! Q$!_\0
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M184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY7>7>K^-/&L$D^F><N3$ED9&\E4')61U]"06]P!7H]AX7UV*W\A=3L-'MO\
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MCO$YF?7K>W@EE!DA3S@&1=J"3(*%G7#9'/!X KL:Y#Q+#<7&M6C6\-O,(]B
MLL+;9"V<2;_F"E>0%YS^%=<*?02W%HHHI#,OQ DCZ/<>6JMM1B04W=CS]X8Q
M_D5-<W4]C9K(\7VE@<.8\)U/'!/OZUB>/[K5[;PK<)HMK+/>3?N]T:Y\M/XF
M/X#'XURFM^./%&D^'K=]9\.6\<ET0(S'.005()#)C(X'KW%7&+:T,9U8P;N=
MWKDMO%IL=W?R&U2.1/,9IR@52PW D$ \5PM_?7.M&VUV2!OL_FB'P]ITO6:4
M\"YD![ <@'H.>]&J^'=<\;Z);:EJNOP6MG,4ECL[> M%&K8PS,Q!9AGN,5T/
MA6WDUJ_'B*Z.^"&/[+IH*[04'#RX[%R./:J245<RG*4Y<J5K_P!7_KJ7-.\/
M0Z1%IEMY\[S;W>>42LOFR%26<X/4G]*Z6JT]BEQ<1S-+,K1_="/@?E5JLV[G
M1"*BK(****184444 %%%% !1110 4444 %%%% !1110 A4,"" 0>H-8-]X,T
M&_E,S6"07':>U)A<?BN/UK?HIIM;$RA&6DE<Y7^P?$6G<Z5XB:XC'2#4XA*/
M^^UPW\ZYA/&/B>U\<O9WFC^:$C"2V]G&6)49.]&.,C)[_3K7J-4U_P"0O(<?
M\NZ?^A-5J?=7,)T'IR2:U,0>/='C.V^CO]/;O]KLW4?F 16E9^)=$U#_ (]-
M6LI3_=69<_EUK4(!&",@]C69>>&]$U#_ (^])LY2?XFA7/YXS4^Z:6JKJF:8
M(89!!![BBN8/@+1HVW6+WVGMV-I=N@'X$D4G_".Z]:_\>/BRZ8#HE[;I,/SX
M-%H]&'/46\?N?^=CJ:*Y?S/&UI]Z#1M04?W'>!C^>11_PE&JVQQJ'A34D ZO
M:LEP/T(/Z4<CZ![:*W37R.GQD8/(K"U+P7X<U9_,NM)MO.[31+Y4@/KN7!JL
MGC[P_NVW-S-8O_=O+=XOU(Q^M;%IK6EWX!M-1M)\_P#/.96/\Z+2B'/3GI=,
MY_\ X0_5-.YT/Q5J$"CI!? 74?T^;Y@/QH_M+QKI?_'[HECJL0ZR:?/Y3_\
M?$G]#7744<W<?LTOA=CA=0^(FCQBUCU&WU'3)Q<QEH[RU9,#/)W<J0.O!K:B
M\=^%)3A/$.G9]#.H_G57QGX>TS718#4K.YN5CE 412%0 Q&>A'/%;2:'I7V:
M.)].MG5$"CS858X [DCDTWRV)7M.9JZ&Q>(]#F_U6LZ<_P#NW2'^M6X[ZTE_
MU=U _P#NR UFS>$/#<_^LT'36_[=4']*IO\ #SPA)U\/V2_[B;?Y4O=*_>>1
MTH((R"#]*6N3/PU\*_\ +/3Y8?\ KE=2K_)J;_PKK24_U%]K4'_7+4I1_,FB
MT>X[S[?C_P  ZZBN2_X09D'[CQ3XCB_[?0W_ *$II/\ A$=:C_U'C;5Q_P!=
M8XG_ )K19=Q<TOY3KJ*Y+^P/%T?^J\:;O:;3(C^H(I/[.\=Q_<\0:1-_UTL&
M7^3T<J[ASO\ E?X'74R8R+$QA5#(.@<D#\P#7*X^(,8^_P"')_PF0G^=5-2U
MWQOI&G3WEUH>DSQ1+DBVNI"Q[<+LR:.4'426J9UUA//<VD<\\<<?F*'54<MP
M1GG(%6JYCP%K-QK7A2UEO+>2"ZA'DRH\93)'1AGL1BNGI-6=BHR4HIH****1
M04444 <IJ&A@7-Q%)JEI!8WMRMS)'+$/.WC;PCEA_='."1VKJJX?Q@EC+X@L
MHYUB6<QH5DEN$C&T/T4,K'//;';O7<T^@EN%%%%(9S_C#7+30M#DENI63SLQ
M1JB;F<D'C'T[UDZM\0O#@T6.:*]\YYBN(8AF1.03N'\.,=ZV_%6E6&K:'-%?
MVS3K&#(FS.Y& .""*HZQX/T&;0H[4Z=$L=N5\LQY5AR!]X<G(/>M(\EE<Y:J
MKW?):UCC_%QU[QO;VL^D65S%I&=L9ED5//9B 'VYZ>F:]/TV VNF6ENV-T4*
M(<#'( '3M4$UK!8Z=:VMM&(X(I84C0=% <8%:-*4KJQ=*CR2<V[MA1114&X4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !586%JMT;D0J)CU?O5F
MB@+!1110 4444 %%%% #7C252LB*ZGJ&&16/>>$?#U\=UQHUFS?WEB"G\Q@U
MM44TVMB90C+XE<Y?_A!K"#G3]0U73SV%O>-M'X-D4G]B>)[4?Z'XH$ZCHE[9
MJW_CRX-=313YWU(]A#IIZ:'FGBW5/'6FQ6:BVLY 9@1-8Q/)N8=%96Z9KHHM
M;\5B%#+X2#.5&[9J$8Y^A'%;>H^<?($5O)+ME5VV%1@ ^Y%75Y4'!&>Q[53F
MK;&<:,E)OG?X?Y',_P#"0^(5^_X/N?\ @-[$?ZTW_A)]87[W@_4_^ RQ'_V:
MNIHJ;KL:>SG_ #O\/\CE_P#A++X??\)ZT/\ =1&_DU+_ ,)A(/O^&?$"_2T!
M_DU=/11==@Y)_P WX(Y@^-H%^_HFO)];!C_(TW_A.]-'W[#6$_WM/D_PKJ:*
M+Q[!RU/YOP.7_P"$_P!#'WQ?I_O6,O\ \32CX@>&^]Y,O^]:RC_V6NGHHO'L
M'+5_F7W?\$YK_A/_  OWU>-?]Z-Q_,4R?XA>%HK:25=7AD*J2$C!+-[ >M=,
M8T/5%/U%4[_2;#4;*:UN[2*2&1<,NW'ZCFFN435:VC7W?\$H>$]>LO$&B136
M9?\ <@0R+(N&5@!6[6/X9T:PT71H8K"#REE597^8DLQ R236Q4RM?0NGS<BY
M]PHHHI%A1110!R'B9IX]>M7MK34'D,:AI+>9T0H'.5.U2">1C)_B],UUU<1X
MAAFU;7ECA@O]]J44A&0H!NR7VB4'D>H[5V]/H);BT50N]5AL[I('21LA2[*!
MB,,VU2>>Y],TDFKP1WS6S)+A6V&4+E0^W?M]<[>>E(8_5IHH=+NO-E1-T3@;
MF R<&H]0E\[3O]'C:X#D8,."."#US[4R2^@U#P_-=1AECEA<J)%VMP".1VK3
M& .*9+5RK/;?;HHR9)X "'VKM!R#D9R#TQ5I1M4 DG ZGJ:6BD58**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDWF>4WDA#)VWYQ^E/HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGJHD.E77ELJGRFR2N>,'/<5<'2@ HHHH **** "BBB@ HHHH **** "BBB@
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M@GK0 3MX>M)+1+JWM[<W2%X_-0*.-O!/8_,.*E$7ATS20@6!EC=4= 5RK,<
M$>I/%5[G1])N+.WM?MP2.WM&M$Q*I.UMO//?Y!^M0'P_I7FM(NJ,K!]\'[Q/
MW),HE../FRX_BSQQ0&I;9_#"YW/IXPN\_,OW<XS^?%78]*TJ:)9([2W='&59
M5!!'J*QD\.Z0EA/:_P!HAA,D:,SO&3\C,P/3U8_TQ6W8O96%C!:+?)(L*! \
MDP+''J: %_L;3?\ GQ@_[XILFC:;Y;?Z#!]T_P %6?MUI_S]0?\ ?P4R2]M/
M*?\ TJ#[I_Y:"D,32_\ D$67.?W"=?\ =%6ZJ:5_R"++_K@G_H(JW0 4444
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M3'U$QL@:RN@7;:O"\G!/][V- %ZBJGVV3_GQNOR7_P"*H^VR?\^-U^2__%4
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MW[%'V&T_Y]8/^_8IGVV3_GQNOR7_ .*H^VR?\^-U^2__ !5 #_L-I_SZP?\
M?L4?8;3_ )]8/^_8IGVV3_GQNOR7_P"*H^VR?\^-U^2__%4 /^PVG_/K!_W[
M%'V&T_Y]8/\ OV*9]MD_Y\;K\E_^*H^VR?\ /C=?DO\ \50 _P"PVG_/K!_W
M[%'V&T_Y]8/^_8IGVV3_ )\;K\E_^*ILFH&*-I'LKH*H+,<+P!_P*@"X
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<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gpty1lksmhba000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !W F$# 2(  A$! Q$!_\0
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M_H&7OYI_C3O^%N:8?^89>_FG^-')(/;T^YZ'17GO_"VM,/\ S#;S\T_QI?\
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M^595_P"%+T.O ?[U3_Q+\SOKO_CZ?\/Y5FZIJ=OI%@][<AS$K*N$ )R3@=2
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MDEK:S!47J=O+'N2?6K7DP?\ /S_X[5>BI-U9*R18\F#_ )^?_':/)@_Y^?\
MQVJ]%(+ECR8/^?G_ ,=H\F#_ )^?_':KT4!<L>3!_P _/_CM'DP?\_/_ ([5
M>B@+ECR8/^?G_P =H\F#_GY_\=JO10%RQY,'_/S_ ..T>3!_S\_^.U7HH"Y8
M\F#_ )^?_':/)@_Y^?\ QVJ]% 7+'DP?\_/_ ([1Y,'_ #\_^.U7HH"Y8\F#
M_GY_\=H\F#_GY_\ ':KT4!<L>3!_S\_^.T>3!_S\_P#CM5Z* N6/)@_Y^?\
MQVCR8/\ GY_\=JO10%RQY,'_ #\_^.T>3!_S\_\ CM5Z* N6/)@_Y^?_ !VC
MR8/^?G_QVJ]% 7+'DP?\_/\ X[1Y,'_/S_X[5>B@+ECR8/\ GY_\=H\F#_GY
M_P#':KT4!<L>3!_S\_\ CM'DP?\ /S_X[5>B@+ECR8/^?G_QVCR8/^?G_P =
MJO10%RQY,'_/S_X[1Y,'_/S_ ..U7I 0<X(.#@X/0T!<L^3!_P _/_CM'DP?
M\_/_ ([5>B@+ECR8/^?G_P =J:UCB6;*3;SCIC%4:LV/_'Q_P$T,:W-*BBBI
M-#RSQO\ \C1-_P!<T_E57P[-:07T[7OE^48&7$F.I(''OC-6O&__ "-$W_7-
M/Y5GIH=_+!;2PQ"47"ET56&< XYKVX6=&*;M='P=?G6.J2A&[4G^9T-U%H%R
M+.%9[4"W9(V8R;-\88AB<=20 ?7FCS]',4:!K,% F7W -CRF'X_-@'ZUSRZ%
MJCE0MF^64,!N4'!Z=^_:G0:!J4\BI]G\L$,=TC #@$_AT./6HY(6^,T^L5G*
MZHZOR9NRVFC6$MQ%)Y$+^4R!1(7;:44Y(.<-G.*J&PTB;Q%96UJ%DMW#^8%D
M)!QDJ<Y)!P!G^0Z5FSZ-J>Z21H7F"C+29R3\H8]>3@$5$^F:C:30AH)(I97\
MN/##);TX/!Y_6JC%6^/4FI5E?6C9)KIY[=M=C7,.@*(!((-\DJ+/Y<S,(AM)
M.TYY&<<\XR:LV6E:3=2($BADE+(LZ),QCCR&SL;N>%X)-8!T34@<?8W)W; %
M(/.<=CZ\9]:EBTK58XY!"LJLS;'C1\ C;NR2#MQCWH<5;2?XA"I+F]ZCIZ?\
M#^ONMJ16^@237*-]G2.-%5&\Y@6)3);)./O<8%$L'AXF1%6!<>8%<3MV52IZ
MGJ2PZ=JRO^$?U(QP,L 9IBP5 XW#:<'//K48T74C&CBSD*R$!<8R<YQQG(Z'
MKZ4<L?Y_Q$ZE1*WL5_X#\_U)-<BL8KJ/[ 8O+9,E8Y"^TY/4Y/./3\A5[P3_
M ,C3!_US?^594FDW\4<LDEJZI%]\\<# .?<8(Y'K6KX)_P"1I@_ZYO\ RIU+
M>QDD[Z$8;F^NTVX\MY+3;J=]=_\ 'T_X?RK&\0::^K:/)9QK&S,RL!(Y49!S
MG.#^H(]16[<P2O<.RH2#T-1?9I_^>9KQT['W,HWNCB)/#&NS(L<VI0/&OEG:
M"P0[=N (\;4V[6P1UW<XJ?3_  WJD-W+)>7J2@V4ELCK*^5+!<87&% VGD=>
MM=A]FG_YYFC[-/\ \\S5<[,_8J]SB(?#OB)8;:U?5 EO%C<8[J3>1B,%<XZ#
M:V#G^+M4D7A_Q'&80=:9@I4DM.Y*MA-S=/G!*N IX&[-=G]FG_YYFC[-/_SS
M-'.P]BCF-*T;5K#4K6:;4'GMUMMDZRW#R;I.Y4'@<]SGV KH3]UOH:F^S3_\
M\S0;6?:?W9Z&I;N7&/*K(^=/#^KIHM]=W#1O(TEM+"@5BOS-C&2I! X['-=!
M'XLTJZF6?4M)B>=U+3NELC%I#)DCYCG!3"Y)R.M9W_"O_%FXG^P[CJ?XD_\
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M'E.[*;D NP7(P!T&?\,4^:E?87LL4DO?7]?(IQ>)[J%]ZVMKN#,RD*1MRP;
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MY]34SVU-L.G>\=B]11161V!1110 4444 %%%% !1110 4444 %%%% !1110
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MNO\ OZ/\*/\ A =&_O77_?T?X444?6*O\S#^S<)_S[7W!_P@.C?WKK_OZ/\
M"KFF>$].TF^6\MFG,J@@;WR.?PHHI.O4:LY%0R_"PDI1@DT:TEI'(Y=MV3Z&
MF_88?5OSHHK.YUV0?88?5OSH^PP^K?G111<+(/L,/JWYT?88?5OSHHHN%D'V
M&'U;\Z3[!"1C+\^]%%%PLCBA\'O#(.?,U#DY_P!>/_B:D'PD\-KTDO\ _O\
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CZM^=%%%PL@^PP^K?G3XK6.%]R[LXQR:**5PLB:BBB@9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gpty1lksmhba000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "J F4# 2(  A$! Q$!_\0
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M4#!+MU,2R@I%D$';GG/!&\9SC%5R2,_:P[G4T5BV'B:SU:2YBT])9I(4++D
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M9?-OD+QGRR HQD;L_=)Y !ZD&B[86BM+DGVZ^_Z!,_\ W^C_ /BJ/MU]_P!
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MCY'_ !\)*Q8AN.,9P",''!S5;Q%_R,-[_OC_ -!%9E?.5<XQ,*DHJUDVMO\
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M446#F9M*P=0PZ$9%%,@_U$?^Z**DT/-/$7_(PWO^^/\ T$5F5I^(O^1AO?\
M?'_H(K,KXC$_QI^K_,^OH?PH^B_(*MZ;:I>7RPR;]NUG*I]YMH)P/<XJI6C%
MISAUVS.LJ;68JAPF>?O9Z@5-*+<D[7*J22BU>QHV^C6<]LMSY4B>8J[8)9PA
M4EBOWL<YQQQ39='LH8'N%6YG1-W[L':S?O-H/3C'TJ@]I?2AY)KGAG\LF24_
M,PZ#_#Z&I#;:DKK,;PA]QC5_..=_=,^OZ>]=EXVM[/\ KO\ \#;H<EI7^/\
MKM_P1;;2X9-62&?SHK>24QHI*^;GT89X^N*E&E68LK>61YTW&(O(.0V\M\JC
MU&!W[U6BTRY-PLAN8T)?!FWDD-DY[9R,'_&D>RN@BQ-=*$C'FA'D(VCNP'^3
M4122UI]_T+;;>DRM?P+;:A<P)G9%*R+D\X!JO6G_ &1<23KY\Z+YC',C,3G@
MG/OP":S*YJD'%W:M<Z*<DU9.X5L^%?\ D9+7Z/\ ^@FL:MGPK_R,EK]'_P#0
M35X3^/#U7YD8G^#/T?Y':77%T_U'\JYG_A$[0Q1AY"TJW;7!D8$Y4NS[ "<
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M3O\ A/?$W_02_P#(*?X4>\+]WW?W?\$YKR)O^>,O_?!I?(F_YX2_]^S72_\
M">>)?^@E_P"04_PI?^$[\2_]!+_R"G^%/W@_=]W]W_!.:\B;_GA+_P!^S2^1
M-_SPE_[]FNE_X3OQ)_T$O_(*?X4O_"=>)/\ H(_^04_PH]X7[ON_N_X)S?DS
M?\\9?^^#2^3-_P \9?\ O@UTO_"<^(_^@C_Y!3_"MK0?B!=^;]GU>8%&/RW
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M3&U:(PD*5\H84?*.!5"N>=:4).-HZ?W5_D;PHQE%2N]?-FS]L\/_ /0)N?\
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M_H6K_P#\#3_C3AJG@K_H6[__ ,#3_C7)"GBCE%SOLON.L&I^"_\ H6[_ /\
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M?_CO_P 73YD+V4_ZL<6*<*[0>!M(_P"ASTS_ ,=_^+I1X'TG_H<M,_\ '?\
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M!7Q->+E7DEW?YGUU%I48M]E^1!5BQM?MM]#;;MOF-@MC.!C)X_"I&T]E7)E
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M1P ]*> /2FBG"F(< /2G@#TIHIXH$. 'I3P!Z4P4\4Q#@!Z4\ >E-%.% AP
M]*=@>E(*=3)%P/2G #TIM.% "@#TIP ]*;3A0(4 >E.P/2D%+3$+@>E. 'I2
M4X4"% 'I6CI&KW>C77G6S?*?OQM]UQ[_ .-9PIPHW!-IW1ZYH^M6FM6WFV[;
M9%_UD3?>0_U'O6C7F/AC2=1O;]+JTD:VBB;YKC'_ (Z!WKTZN>:2>AZ=&<IQ
MNT%%%%2;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %)D @$@9Z>]+6)XCT[4-0BM&TV18KB!W<.7VE28RH(X]30M63)V5T
M;=%<J^F^*%E=HK_<JLPB62X."A,F-W'7!CY]JJ)HOBM6>3^T'\QP%+?:<G:"
M^!Z9^9#GO@CGO7*NY'M'_*SM:*:@81J';<P4!CCJ>YIU2:FO!_Q[Q_[HHH@_
MU$?^Z**@U1P&NZ3J,^N7<L-E.\;."K*O!X%5(=+UB#S NFRL)%VL'BR",Y_I
M7IU%>1/**<IN?,]?U/3CFDXP4.5:'FR6>N1*!'ITJ[00I$/*@]0/;_&F#3M<
M5Y76RN5>5P[LJ8.0<_SKTRBC^R(?SL?]J2_D1YM+9Z[,V7L)OOJ^T0@#(SCC
M\3^=*;37&E68Z;)YJC D\GYN_P#B:](HH_LF/\[%_:<OY$>;?8M<\DQ'3Y64
MH(R6BRVT9P,_C_*DCLM=B$82QG C!"_NO4$?U->E44?V1'^=C_M.7\B/-Q:Z
M\%V'3Y67YLJT((.<D_S-*8/$#9WV$K@]0T(.?8UZ/13_ +)C_P _&+^TG_(C
MS&?2]:N9?-FL+AGQC/EXK0\.:5J%MKUO+/9S1QJ&RS+@#Y37?444\IIPJ*IS
M-M.X3S.<H.'*DFK&;<PRM<.5C8@]P*H3:+;W*R+/I\<BR/YCAD!W-C&3[XX^
ME=#17KW9Y3@GN<V- LE  TN' Z#RACKG^9)I\&C6]MGR-/CCRA0[4'*GD@^H
MKH:*?,Q>S1Q\OA#3Y9K=UL?*6%@XBB10KD$$9XSV'?H*N#0;,%2-+A&P@K^Z
M'!  'Z ?D*Z2BCF8O91.:_X1ZQ!!_LJ'(.[/ECKQ_@/R%6;734LEV6UF(4+;
MB$7 )K<HHYF-4TCYPUCP?XEFUW4)8M"OGC>YD9&$7# L<$53'@OQ1_T +_\
M[]5]-T57M&9/#Q[GS,/!GB?_ * %_P#]^J>/!OB;_H W_P#WZKZ6HH]HQ?5H
M]SYK'@WQ-_T ;_\ []4X>#O$O_0"O_\ OU7TE11[1A]6CW/F\>#_ !+_ - *
M^_[]4\>$/$G_ $ [[_OU7T;11[1B^JQ[GSH/"'B3_H!WW_?JG#PCXC_Z E]_
MWZKZ)HH]JP^J1[GSP/"7B+_H"7O_ '[IW_")^(O^@)>_]^Z^A:*?M6+ZI'N?
M/H\)^(?^@+>_]^Z7_A%/$/\ T!;W_OW7T#11[5A]3CW/ /\ A%/$/_0&O?\
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MORH\B;_GDWY5KT47#E,CR)O^>3?E1Y$W_/)ORK7HHN'*9'D3?\\F_*CR)O\
MGDWY5KT47#E,CR)O^>3?E1Y$W_/)ORK7HHN'*9'D3?\ /)ORH\B;_GDWY5KT
247#E&0@B% 1@A1D44^BD4?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gpty1lksmhba000029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "I M # 2(  A$! Q$!_\0
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M3K>@\':S<V4-W#%;NLT)GCC%POF.GJ$SDTFHHI2J/9LO?\+*\5_\_P#%_P"
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M%?\ S_Q?^ Z?X5RF"%#%2%/0XX-!5@P4JP8] 1S3Y4+GGW.K_P"%E>*_^?\
MB_\  =/\*/\ A97BO_G_ (O_  '3_"N4P<[<'=G&,<YK7;PMK$=TEM):B.=[
M0W@C=P"(AU)]#QTZTK1!3J/9LU/^%E>*_P#G_B_\!T_PH_X65XK_ .?^+_P'
M3_"N4PW]UN!DC'2M32O#NH:S;37%H+<0PN$=YIUC )Z#FBT04ZC=DV:__"RO
M%?\ S_Q?^ Z?X4?\+*\5_P#/_%_X#I_A7.W^FWFEW\EC>0-'<1]4'S9'8C'4
M>]5@"02%) ZD#I3Y4'//N=7_ ,+*\5_\_P#%_P" Z?X4?\+*\5_\_P#%_P"
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M  _PH]G+L'MZ7<[K[);?\^\7_? H^R6W_/O%_P!\"N%_X6C!_P! F7_O\/\
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MS[Q?]\"N%_X6C!_T"9?^_P /\*/^%HP?] F7_O\ #_"CDEV#V]+N=U]DMO\
MGWB_[X%'V2V_Y]XO^^!7"_\ "T8/^@3+_P!_A_A1_P +1@_Z!,O_ '^'^%'L
MY=@]O2[G=?9+;_GWB_[X%'V2V_Y]XO\ O@5PO_"T8/\ H$R_]_A_A72Z!XHL
M?$*.+??'/&,O#)U ]1ZBDXR6XXU:<G9,U?LEM_S[Q?\ ? IR6\,;;DB16]54
M"I**DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BHKB=+6W>:3.U>N!DU6_M(?\ /G>?]^:
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M5(-0CLX8%G*VT;)YUP09'!.0#CL.@HUT$U&SM\C)HHHJC(**** "NZ^&!/\
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M?5F8_P">@_*E9]RE*/8V;/1()=+A,D-RUS<&-AMP"@+2 X![83J:D'AVQ$L
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MQ.!SR.@ZFHI-+NTU!K*)#-,$$F(\C*D9S@X(X/.>E7H_$LWEHD\$;L&<M)&
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M?I)_Z :YVNB\#?\ (XV/TD_] -3+X6:4OC1[+1117(>P%%%% !1110 4444
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M26-9$>5)DB9B1$ZD8*^G P?8UW?_  K/2/\ G[O?^^E_^)H_X5II'_/W>_\
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M^!5=M=E:8R^1&"7A;&3_ ,LR2/SSS7>_\*TTC_G[O?\ OI?_ (FC_A6FD?\
M/W>_]]+_ /$T<\ ]A6.'7Q%)^Y,EG%(T /DDNPV$KM)]_P#ZU5=0U>348P)8
MMKE@SL)&(8@8X4G"^O%>A?\ "M-(_P"?N]_[Z7_XFC_A6FD?\_=[_P!]+_\
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M_P"@K/\ DO\ A1_PEWB#_H*S_DO^%8M%'*NP>TGW-K_A+O$'_05G_)?\*/\
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M>YB,+Z\#DGUK!II1?0F4IJVIM?\ "7>(/^@K/^2_X4?\)=X@_P"@K/\ DO\
MA6+13Y5V)]I/N;7_  EWB#_H*S_DO^%'_"7>(/\ H*S_ )+_ (5BT4<J[![2
M?<ZS1/'.JVVH1+?7!NK5W"R!U&5![@CTKUNOGJ/_ %T?^^/YU]"UC526QW82
M<I)IL****R.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gpty1lksmhba000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "P 2@# 2(  A$! Q$!_\0
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M :/YB #R#3/%GAI- -H\!G:*0-%*TRX_?)][;Q]TYR*/='^\M>XW_A//%/\
MT&9O^^$_^)H_X3SQ3_T&9O\ OA/_ (FJ]YH@_MC2].L6+2WUM!(/,;H\@R?P
MJTW@N]-T;>"Y@FDQ&RJH8%E9]A.#R-IQG/8@T>Z%ZG<;_P )YXI_Z#,W_?"?
M_$T?\)YXI_Z#,W_?"?\ Q-/C\'S>3!=/=PO;R3*,)D%XC+Y>]21C/?'7'-1:
MAX7DMK&]U"&X1[>"XDC$8!9U57*#<0,*>_.*/=#]YW'?\)YXI_Z#,W_?"?\
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MUS_A3VG_ /07N_\ OA/\*/\ A3VG_P#07N_^^$_PHYT'L)GD=%>N?\*>T_\
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M **** "BBB@ HHHH **:[I&A>1E51U9C@"H?M]G_ ,_<'_?P4 6**K_;[/\
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M&4PHTMPJLVT\#YE!"CJ6YZ>U,"B+_P 6-.\(L;/>BJQ_>#H<X[^QJ3[3XO\
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7_BP<\TAFFN<#(P>^*6BBD,**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gpty1lksmhba000027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #? F$# 2(  A$! Q$!_\0
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M.L9H3_PDEPH\TEED '\</G@OCV(V_A3T["U[D)\3>*U6-FU34PLO^K)+ /\
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M_P#?_P#^M7N-%'.P^KP/#O\ A5WB;_GG9_\ ?_\ ^M1_PJ[Q-_SSL_\ O_\
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M /K4?\*N\3?\\[/_ +__ /UJ]QHH]HP^KP/#O^%7>)O^>=G_ -__ /ZU2/\
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M>=G_ -__ /ZU'_"KO$W_ #SL_P#O_P#_ %J]QHHYV'U>!X=_PJ[Q-_SSL_\
MO_\ _6H_X5=XF_YYV?\ W_\ _K5[C11[1A]7@>'?\*N\3?\ /.S_ .__ /\
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ML<S!R%7"C#.>B YZ]\]/>M2:,31-&690PQE6P1]#6:/#]BH&T2C'S#$AX?\
MOC_:H OVUS'=6R3QYVN,@$8(]C[U-6=>6D$.AS0+&#''"Q4-SR 3GZYYS6C0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!SLOB"XAGFB,<#&']X2I/SIQ
MPOJ>>O3@\5?TO4GO89GF5!L"MF/)&&4-CZC-71:6PZ6\0^??]P?>]?K[T^.&
M*$$11H@)W$*N,GUH 2&:.XA66)MR-T.,5)5/3/\ CP3_ 'G_ /0C5R@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BF32QP1-+*X2-1EF/:JG]KV!SBX4[4WG
M/ SCGCKGC'6@"34O^07=_P#7%_Y&K54KV5)]&N)8F#H\#%6'0C%7: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BL:7Q!'#/Y4EM*A$@5F8C:@QG+$9
M[<'GD5<L=2CO8Y'V-$$ 8^81]TC(/Y4 +IG_ !X)_O/_ .A&KE4M*96TZ-E(
M926((.01N-7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJO?7UMIM
ME+>7DZ06\0W22.>%'O6!_P +"\(_]!^S_P"^S32;V)<HK=G3T5S'_"PO"/\
MT'[/_OHU8LO&WAK4+R*SL]9M9KB9ML<:-RQ]J.5]A<\>YOTC,%4LQP ,DTM1
M7'_'M+_N'^5(LY?_ (69X-_Z#D/_ '[D_P#B:7_A9G@W_H.0_P#?M_\ XFOF
M@=**Z_J\>YY7U^IV1]+'XF^#0,_VY#_W[D_^)KJD=9$5T.58 @^HKX^;[I^E
M?7EE_P >%M_UR7^0K*K34+6.K#8B56]UL6****Q.L**** "BBB@ HHHH ANF
MF2W<P>4)<?*920H^N*H:9=WLUY<P7$MI,(,!F@1DPQ (')((P?6I]92*31[M
M)DC=3$<+( 06Q\O7C.<8K'\%67V+2I%-LT#.X9@R.N3M'/SC^7%,74Z"ZCEF
MM9(X)O)E9<+)MW;3ZX[UD?\ "._/$ZSHDD6&#)#@LP.1N.<L,\X/?G-;M%(9
MEW%DEOX>FMBS-Y<3'<"5R<$YX]^U:E5=2_Y!=W_UQ?\ D:M4 %%%% !1110
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M^$BNOIB,Y-$LDC,>V9D+ERK3,023DYYY!/8U8M;*"S1E@0J&.3EB>V .>P'
M%6:*0RGI?_'@G^\__H1JY5/3/^/!/]Y__0C5R@ HHHH **** "BBB@ HHHH
M***0L!U('UH 6BF[T_O+^=&]/[R_G0 ZBD#*3P0?H:6@#EOB/_R3W6_^O?\
M]F%?,M?37Q'_ .2>ZW_U[_\ LPKYEKKP_P +/+Q_QKT"NE^'O_)0=$_Z^/\
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M+4?^OH?^@"IQ'P&V6_[POF>D5YQ\8O\ D7]/_P"OO_V1J]'KSCXQ?\B_I_\
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M_P >TO\ N'^52U%<?\>TO^X?Y5YQ[Y\@CI10.E%>F?."-]T_2OKRR_X\+?\
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M:;X\U"ULM8O;>W18ML44I51F-2<#ZU[?IG_'@G^\_P#Z$:^>OBK_ ,E&U/\
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M=;_Z]_\ V85\RUKA_A9S8_XUZ!72_#W_ )*#HG_7Q_[*U<U72_#W_DH.B?\
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M2_\ HQJ[2O.G\3/?H_PX^AXA\<O^0YI'_7L__H0KRNO5/CE_R'-(_P"O9_\
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M ,*E\8_\^$'_ (%)_C6E"22=V<^,ISG-.*N<372_#W_DH.B?]?'_ +*U:/\
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M6\C9;9GE\N(2#.]@.G. !N!R3V!K=3)122,D<XZ4V*"."%88D"QH,*H[5)0
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MW )J2[\-Q7#!TNYTD6)$21CO8,KAPQ+?>.1CGM4L'AZWMH)H8Y7"2626?09
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MNM2B@+&7_8%C_?O?_ Z;_P"+H_L"Q_OWO_@=-_\ %UJ44!8R_P"P+'^_>_\
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DQ!;H5C!+?,Q8DDY)))))R>]3T44 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gpty1lksmhba000039.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000039.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #E 5<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"3Q)XJ\06O
MBC5+>#6+R.&*ZD5$63A0#P!46G:MXYU<2'3K[5+H1$!S&^=N>F:S?%G_ ".&
ML_\ 7Y)_Z%6GX=O-/M?"&NKJ$1N%>:W*P)<>4[X)Y!ZX'>O0LE"Z78^:4YRK
M.,I-+7KV*MWXG\6V-R]M=ZMJ,$Z'#1R/@BH?^$R\2_\ 0=O?^_E=#9:L-?DU
M.^M[734U=5@BLX+UE9%@7(;!DX9NF2><=*MB+21>:G_PC\>D2W8O(@ZW10Q+
M#L'F>7OXV[\].<=*5TM'$ODG+6-1V^?G_E^1R?\ PF7B7_H.WO\ W\J]INL^
M-]8D=-.O]3N609?8_"_4]*NZW<Z19:#>+HT-BXGU.:)':-7=8=B_=SR!NS@U
M4TN,ZMX*DTBRN8(;Y+_[1)'-,(O-CV8!!) .T]J+QM>Q-IJ?*YM^C&'6O&X>
M=#?ZHK02+%*&;!1V.%!^IZ56G\5^*;6XDMY]9OXYHV*.C2<J1U%;L#Q10:Q;
M76L0ZB_VW3U:=GXD"O\ ,!D\A>F>E74GTFWU"W1(-+>.XUZ>*9I$1\6Y(Q@G
MHOH?:E==B^2;7QM?/S9R\GB;Q;%:PW,FKZ@L$^[RI#)P^TX./I4/_"9>),9_
MMV]_[^5TUC#HP72XR+$S+_: A65E*&4/^Y$F>WIGBBQ@VZG=W%X=#6\BMH3)
M!;)$V26^8_.?+5@/O8SQC S3YH]A>SJZ6F_O\KG/_P#"3>+?L7VW^UM0^RB3
MRO-\SY=^,[?KCFM"UNOB%>V:7=K/J\UO(,I(C9##VJ;Q3]@AT;5;:Q>W$7]M
MB2*.)P1L,/4 =LUH:5J>C0VOA.*]2,W"0R>5<^>P6VD\PE?,0$94G'6DVK72
M_JPXQ:GRRF]N_G8Y1O&'B96*MK=\K X(,F"#2?\ "9>)?^@[>_\ ?RNPT]--
M.F3/J$5E<W37%R=4.^$9/)4JS'(7NI3//6J,\.FS>!-P6RMGCM4*L/*D\Z3=
MV(Q(LA[@Y%'-'L)TZMK\[_$YW_A,O$G_ $';W_OY1_PF7B3_ *#M[_W\KL_$
M5IIML=4BO[?3(+!7MOLGV<()]Y*^9D#YON[LYXZ8J.\BTO[0HNXM(2W_ +3M
MQIAMC'E[?=\_F8/*[<9W=\T*47T&Z557]_\ /S_R.0_X3+Q)_P!!V]_[^4?\
M)EXDQG^W;W_OY73^?I5U+&\EGI)^S:X\,48*1*\&TX#$=1G&">,U;>VT4>(8
M9)GM#</8RF&W>. ,DP(V[]I\IB1G;G'3FCFC_*"IU7M4.-_X3+Q+_P!!V]_[
M^4?\)EXE_P"@[>_]_*L>()[.R\607%O:P!81$]Q"I1T=QRW"_*,]P.,YKK+F
M'PK90SM";.5]/5[Z,':?/\T/LB]]AV<4VXI)\I$8U9-KVFWFSE)/$/C&)%>3
M4]2"M#]H#;\CR\XW^PS3+GQ/XMLIA#=:OJ$,A0.%>3DJ1D'\172V=Q!%I,UM
M9&P\^?P]&2K[/GE#G<#GO@YQ]*BUB]L;V#4[606+K#H]O)!*%7S#, HP'ZD@
M9&WVI75_A+Y)<MU-W]3"LO$7C#4KD6UCJFI7$Y!;RXWR<#J:K'QCXE'!UR^&
M/^FE;'A*\L="T:[U2YOWMKJYF2" P1B6144AW.W(P&P%S6ZVGVXBU2_T6+2[
MC[3>P3VS7?ED(DBDNGS' (.>#V]Z;<4[6%"%2<$U-W]3BO\ A,O$G_0=O?\
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MIW5O^@I9?]\-7L=%'MYA_9V'[?B>.?\ "G=6_P"@I9?]\M1_PIW5O^@I9?\
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M10 4444 %%%% !1110 4444 %%%% !115>_NUL-.N;QU+);Q-*RCJ0H)Q^E
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M!X);:7RI$9E;!P&QE3C(!Y'8UI4 %%%% !1110 4444 %%%% !1110 4444
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M! I8GW.P_P#?5=#0!0T[28=-:9TEGFEFV[Y9WW,0HPHS[#\?6K]%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5#<V\5W;2031K)&XPRMT-35%<QM+
M;R1K*\+,N!(F,K[C- 'GGP[WQZ_K$#SP$Q@!H53:T9R>,8Z?C7I%<-X#BO8[
MC4/-MW%F6_<W'EJBS<G)P!G/N:[F@ KSCQM_R%=0_P"O6W_]&&O1Z\W\;?\
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M5[=I]-O(;J)6VEXG# 'TJO=Z,;B^DNH+ZXM&F54G6';^\"DXY(RIY(R.WX4
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MXFD8*NQ]V]<A?G;_ &3N_P \XL?\)1+_ -"[K/\ X#C_ !H_X2B7_H7=9_\
M <?XT6?<?M8?R#8]?NS?"VF2WC&)%+X8_,I8;B,Y"_+GOUZBK&IWICU6QMHK
MXQ32%6\LX";=W).1DD] !WYJM_PEQ\_R?[ UCS0N[;]G&<>O6G_\)1+_ -"[
MK/\ X#C_ !HLR?:1O=1'W^KZC;W=PD$,!BC+ ;PV3MC$AZ<<YQ_G%1#7[Z6X
M2"*"#?))LPP8F#YL?/\ 4<C&/ZT[_A*)?^A>UK_P'_\ KT?\)1+_ -"[K/\
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gpty1lksmhba000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A F(# 2(  A$! Q$!_\0
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M3A_YXW?_ ("R?_$U%F;<R+M%4O[3A_YXW?\ X"R?_$T?VG#_ ,\;O_P%D_\
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MLI,:3+EE)([=B<_E5Z=+F34GJTA]EK/A30I)+.PN%\Z63#QK(SMN7:F"6/&
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M(DC9L@ !T)!SN STSQUJXGC'0)&VC4%#!7=@T;KM"?>W9'RXQWQ27=KH]_\
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gpty1lksmhba000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $< E\# 2(  A$! Q$!_\0
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M<?CK_H,+_P!^%J[;?$_XC7?,6IJ!W9X%45SVE:.D:I-<Q[Y6&0AZ)Z9'K6A
M;D3R">7S%!VA4CP!]:SE4['%5Q=KJGT.CC\?>.R!O\0J6)Q^[MD('UI[^._'
M0'R>(@6[9MDK"EC8*6B<1MCGC@\4^)MR %OG &[%9\\C@EC:UN=/3T+%S\2O
MB/:@LVJ*ZC^)(%-4/^%Q^.O^@PO_ 'X6K/).2<8ZCUK)U71([M&F@0)..<*.
M'_\ KU<:G<Z*&8J3Y:BL:%O\8O'+7,*MJZE6D52/(7H2*[#XS^*M>T'Q)IL&
MDZM=V44MD)9$@D*AG+')^M>+0*5OH5(((F4$'L=PKU+X^_\ (UZ3_P!@Y?\
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M)%!QG&?W@/\ P&I'\&RO#<1F]B)E1/WI@)D)4)\I;/,9V?=_VC1H%V=:'4G
M8$XSC-?*/B6S6X^*GB&:09CANB?J>U?2>A^'DT>XDG9TED>&.)6V$% N<@$D
MG!)Z>U?/_B4B/QMKF(V9I+]\D=L =:B;LM#GQ<Y1HNVYF0L9D>3(^;(1U[CM
M3X8WCMUC9@S 8)'&:>O?( P>,=ZBEC#)B3F/N!D5SG@\W-)QV0_<NX(5^9>*
M=WXXIHQ'A>-QX IK3;2'/^K/'3G-!+@Y/W1TDBQQ^8Q^0=>.GO2HZ2+F-PPZ
MYI05=,C[I]>] P!@  #@ #I2(TY;-:G/:[9K'J%I=(N!),BOCUR.:[3X^_\
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M;NXNI$G58Y"KQ1XZ/N4R9/HP11^)J!/"KK&3OA\[Y-CD$E &<LH/H=^.WTI
M=$]Y!&D;/)M\QE500<Y;IQVS4RL&&5((SC@URZ^&+@(L?FVZL&#?:%5O-/3C
M/3 QQ]!TK1T#2)-(AE21U)?;PA)'RC&>@Y/^2:>@:FQ1112&%%%% !1110!S
M.HZ7J$FMFYAMXYLRQ-%.[_ZE%^\N,@C/)R,YS@TS0-#O=-U,3W$:!'CD!,9
M()?/S\_/QC![<BNIHJ>57N<_U:'/SG'V?AW4;"R:>*1ENI"%EBA*H3'O).&Z
M%\8Y...*?-8>(Y%*.YE5[1HV!D4*'VG'U.<9R,=\]JZVBCE0OJL$K)M?,Y)-
M*UFWEN);??YB&62(O,")"75E7V! (-7-.M-<AU>,W=R\MJ(AN.X8)VC(QUSN
MSSCI70T4*-@CAHQ::;^\*^8/$<AD\;^(X5<JT=\3D>A%?3]?(WC"_P#[/^*F
MOR'_ %;715Q[>M$E=%8FFZE)J.Y:>0)#\S'=C''6B21;6VWSN6"XR>Y-07<2
MS>3)&X60D%2/XJGD1VB!!5G'*D]O\:YSP^2*4;O=ZC%F$\>6'RYQ@ [AZ?2E
M!6U4XC<@N -I+$Y[^U$$+(N7?<[\NP]:F7Y0%S].:!3E!-QCL+M!?/((].],
M$F^0JHRJ?>)'\J4JY4#<ON0/Y4\ *,#@ 4C"Z2UU,_6)O+M(E/62>-1_WT#7
M1?'W_D:])_[!R_\ H1K@-3U 7VK6ZQG,,4RJON=PR:[_ ./G_(UZ3_V#E_\
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MW;,VVRQ!$9<RM<[(PF'V';C';WJ.,Q!Y/*N6%OT+N,Y)]J6XFM'M(T@@(!8
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M+#T]JAIF%6$F[=&/VM/=3RJJ84;=C8 'L?\ $5D2PVK*V]?LTJG!0G.?I6G
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M\D(Y+%W8[5 Y(R.GJ1[#FNAHHN%@HHHI#"BBB@ HHHH **** "BBB@ HHHH
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M:34T]%_2(?&$;2^+M::,E0E](LI S@9X-<_(@BF2*'E@.6(P236]XCO?LGQ
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BJQANBQ(N\#/ \L<4GD77_/Y_Y"% %JBJ
MOD77_/Y_Y"%'D77_ #^?^0A0!:HJKY%U_P _G_D(4>1=?\_G_D(4 6J*J^1=
M?\_G_D(4>1=?\_G_ )"% %JOB?Q3_P C?K7_ %^R_P#H5?9WD77_ #^?^0A7
MRMXBO/!2^)M46YT35I)Q=2"1TO556;/) QP* ./M[YHD6*3<T2MN4*<%3[5M
M121W]QYB2(& !C.<%3[BG_;O G_0 UG_ ,#U_P#B:7[=X$_Z &L_^!Z__$U+
MBF9SIJ6VC+B6LRRPSS"-Y4&,J<#FF201F9D:)@)!E2.@SUS4::WX-CQMT?7.
M.G_$Q4X_\=I7UWP=*1OTC7#CI_Q,5_\ B:CV;[G,L-.]^8K3.+>[@M826QA'
M8)N8Y/8=S5W4=,F@B<B>9AYZPML@YV,NX%<'D]C[]Z@&J^"E.5T/6P<YS]O7
M/_H-/.M^#SUTC73SGG45ZGJ?N]:M12.F%.,59ZLKW_A5(+2Y>"X>=X3AX@@W
M!2 03SZ'G\*Z#XQ#%_X9!&"-%B'ZFL5M9\&X9CHVN'.23_:"Y/\ X[7>?$M_
M!IN]!.LPZQO;2XS"+5UP(\G ;/4U1H>-03-!)N R.ZGH1Z5JK/#J4_SF*/./
MD<_H#6QN^&O_ #P\1_\ ?24;OAK_ ,\?$?\ WU'2:)E%/7J9+Z3DN8[1U_YY
M[7W#\:)K"6-8WG#*BC"NV P^M;<5[\/(/]4/$Z#T#I4DNI_#^X4)*/$C@'(R
MT=*TC/EJ7W5CEEB?[*)DDRI8K(,<J?8UK6?AUKNS%XES&V+=YRFTGD%AM/3)
M^7/&>OUQ=6Y^'*G(B\2?0LF*G35/ ,:[8SXF12"I"R( 0>W7I56-4NYCVWAP
M:A'#*+V,/-"TJQ[3D;6VE?<\9X]0*ZKRC!^S_>PLK*R:Q@JPP0<#K68-3\ !
M@P_X24$9P0Z=SG^?-=Y9)X-O?@MJ$TKZNNDI?^9(SE3.TG'3MB@H\)4E6##(
M(.1BM_2]:B1/)NQA22=_)Y]ZU\?"[_J9?R2C'PO_ .IE_)*3BGN95:4:D>60
MAMK6:UF%K(@65-I"$$?_ *ZR8]#8R@,&5 "26?!SVSBME&^&,9RC>)U/J-@J
MR-4^'87;]H\3D>X0U'*ULSGA0JTTU&5[]S+2W-LYN@A!1<*8P/F)]:=I"WU_
MK*V*7,?*Y:3;G QG@9Y.2!BKK77PW9 AF\4;!QM&P"FK-\,E "MXE&.G$=-0
M[FD:"=_::D-UHMW?7-E;WD[ 2VWV@B&,':2VW:.?FQU)]CZ5H>$-"73_ !QX
M<NH)_M,+W:!I%7Y5//'Y@X]A5=;KX;)]R3Q,N/[H05N^"Y_ +^,]'33W\0&[
M^TJ85G">7N[9QVJK66AO&,8*T59'!>-/^1ZUW_K]D_G6=:W@A(61"RCH0<,O
MN/\ "O3/%UG\,X?%^JI?WFN&\^T,TWD("@8]0*Q?(^%'_/UXC_[]K3!JZ.7F
MNKB[*Q1B-T P@ Y'Y]ZJ2VMPD;"1#M!R6'3FNS\GX4YR+OQ'_P!^Q4@/PN''
MV[Q(>W,8-)*VPE'ET1QC6%[/+A8C)P.4Z5>DMY[2RB60!"DF\+NW'FNJ-W\-
M2FW^TO$H'^S&HJ''PLW[_MOB0O\ WC&#2L^I/+-O6UC+U'3Y8([D_:IFFA$0
M\B2':Z[]V<XX!&!QSU]J6X\)Q*+@6]U)-)&H=(C'AY <\X.".0>O8$^E:[3_
M  R=MSZEXF9L8RR FD,OPQ)R=0\2EO7RUSZ4TK;&B26Q[Q\*%9/AKHZ,I5EC
M8$'J/F-=G7#_  MUO0M4\+BST!KQK;3V\HM=KAV)YS^M=Q3 *0D $DX ZDTM
M>??%;6I[#1K;3[=RAO682LIP=BXR/Q)%-*[L3.7*KLU+_P")'AJPN&@-V]PR
MG#&WC+J#]>A_"M?1?$FD^((V?3KM9609>,@JZ_53S7A?AG2+'6K[['<SW,<T
MC!8D@C4X'\3L3QM7T')[52L=0N-"UA+RSE_>VTAPPR Z@\@CT([5HX+8YE7E
MN]CZ4>6.(H)'52[;5R<;CZ#WX-$<L<H8QNK[6*MM.<$=1]:R[^W?6;3398'>
M-#,DY9'VLJ[6Z'UY%9(T+4HI'1)'9&F9HY3<$-'F3)8@?>)7C\,=ZS.JYUF:
M6N/_ +$UXK,OVS *$KB8YRIV*/;='DG_ &C4\>CZN(XT2Z:-75R^^7)C*EC$
M!CMEN?\ = YHL%SJ:0D $DX ZUR^GZ3J%M+'<77G2) KNL'GYR^U<=.N2&ZY
MZY[U>U.RO+J[@EC1GC\O 3SS'Y3YSN./O<<?_KI!<V4D26-9(V#(P#*P.00>
M].KCF\/ZI#:0P6TCB)8X_,B6<Y:0(02">F#M/X>U3-H.H$/(TTC3D2D-]I8
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MK596CA6.4A5$88,#M1LYST^8C'TJ*RUB_MEV37$1>0>8UQ<[M@/S$( #P3C
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M)W*)#,C;,+VJ6X$BL62,F-5P6#9*U0:ZGA8P+-F,==AQG\:L"%'MF>(OM/!
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M#.MXUN1&V,\CL3QV.._2BPKF[17-1ZG=OJ42"Y!+2)$+<@8*M#O+GO\ >_#
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MI]% $0MH!(9!!&'8Y+!!DGUS2B"$# B0#;M^Z.GI]*DHH B6V@10JPQJH
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M]?K_ ,A7K%,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU_\ J':A_P!^?_KT?VO_ -0[4/\ OS_]>@#1HK._M?\ ZAVH?]^?_KT?VO\
M]0[4/^_/_P!>@#1HK._M?_J':A_WY_\ KT?VO_U#M0_[\_\ UZ -&BL[^U_^
MH=J'_?G_ .O1_:__ %#M0_[\_P#UZ -&BL[^U_\ J':A_P!^?_KT?VO_ -0[
M4/\ OS_]>@#1HK._M?\ ZAVH?]^?_KT?VO\ ]0[4/^_/_P!>@#1HK._M?_J'
M:A_WY_\ KT?VO_U#M0_[\_\ UZ -&BL[^U_^H=J'_?G_ .O1_:__ %#M0_[\
M_P#UZ -&BL[^U_\ J':A_P!^?_KT?VO_ -0[4/\ OS_]>@#1HK._M?\ ZAVH
M?]^?_KT?VO\ ]0[4/^_/_P!>@#1HK._M?_J':A_WY_\ KT?VO_U#M0_[\_\
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M-'J$BE3U! '%>I5C^'/#&E^%=/:QTF%HH'D,C!G+DL>IR:V* "BBB@ HHHH
MS)[:_34Y+JT^S,LD*1E9BP(*ECV'^U^E-:+5';<]MIC$,&!)8\CH>G6M6B@#
M-SK7_//3_P#OM_\ "F>7JVQD\C3=C9W+N?!SUSQ6K10!C_9=1\HQ?8]*\L@
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(CTJW10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gpty1lksmhba000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #' /4# 2(  A$! Q$!_\0
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M9!TZ/=&7,P^T?=56C''R\G$H].AJ.7QPR6]Y,NG#%O,(QNG .,N#D8R#\F<
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M#)!QDU;^U6^S?Y\6W=LSO&-WI]?:I&345G_VYI@<(;R-6,GE#=D9;<4QSWW
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M.[F0$J2P.&!_$#FN)MQU2^9U))Z-E>V1]+WWEO A: O;P;QD3DG.?7GUJ?\
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M$DDI48*A3V]C_*MRYTV&*:\U1YR(Y("IB& BGJQ^IXS6./%/V?3TB6WDG>3
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M?I\%\=1EO)GC2&XX+$_[0Z =\UT%CJ-R+:^= GE18^S@)T)_A./3BB[:\O\
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MW*^<;3[>G/\ .FB3>U80/IUNLY4*2,(3][CI7&7]_))9N^Q$C0^;'SG< <%
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M@VCPEC&RD@L,$\G/%%&@"0:%:B5@T@4[B._)HKS9_&SNA\*-.BBBI*"BBB@
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M9WFW.O/RA?1<=JA_X1:\,LS!40,, ^9G\<5UQK0>KT,)4I+8PQ,9;EE+!D5
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>II@=!IOVG^SH1=DF<+AR<9/OQQ5NBBD,**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>gpty1lksmhba000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $" =8# 2(  A$! Q$!_\0
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MPTT3R!&$LL"N_F<=<XZCKC-=-I%Q96XO9?">BSSPM)&K@R&W@;@Y,8?N. <
M9IV!2.QR,XR,XSB@,I7<&&/7-<!JUA>Q>(/$+6<MU-=7&B%HRQSM8NV$3'3
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M6?8.9=SJ**YO_A8'A/\ Z#]E_P!]T?\ "P/"?_0?LO\ ONBS#FCW.DHKF_\
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M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8Y/F1C/4G^5/J-_\
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M .-,BR*]%6/.@_Y\X_\ OX_^-'G0?\^<?_?Q_P#&@+(KT58\Z#_GSC_[^/\
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M_O\ K_C6IXS_ .1WUW_K^E_]"-8=>M'9'DS:YV6/LC_\];;_ +_K_C1]D?\
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MMH '<9S1T ZFBL[03(?#^G^=&\<@MT#(YRP.T=:T: 04444 %%%% '*^/_\
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M*M\;/9PG\%'LWEKG.6_[Z-'E+ZM_WV:?161TC/*7U;_OLT>4OJW_ 'V:?10
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MC/R[0#C'4G\J>I"=.[W2VZ;.W]=RMK-Q;W\<4D4\&ZVBV,L41B1]SL?D4],
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M_P A#6_^N4/\WHH^!?\ R$-;_P"N4/\ -Z*Y*WQL];"?P4>TT445D=(4444
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M7YU_<OY3!HRTARI' (],4'5M2-R;C[?<^<5V&3S3G;Z?2NF_X59XM_Y\8/\
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MTR^G\BUOH)I=I;8C@G ZG'XU?K)O?^1FTG_KE<?^R4 :U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% ' ^*/\ DE.L9_YZS?\
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MK77[*-8H%'E00 )&SIAV&WC/49^?)^E=12T[CL<_]GU[SUC-R_E[P)) 4&Y
M1C:,9!QG.?7BJB6WB)[E)I0X=-PC(DCPN[9G=ZKD'IS75T47"QS^D6VLV]RD
M5TP%HD6T*,'' QSG.<[O:JMI8:Y9VQ9'F:1\*Z/*A/"(-P/KD-_]:NJI*+A8
MP]-BUL3PR7TI*YVR)E,;=IYXYSNQWK/FT.^FA\H6X27YA/<%U/VC+@@X/7 &
M?FZ8P.M=92T7"QR2Z'?Q-M\D2QH[%U5E59E+JV O1<@=.F0?6M"73[JXT6YM
M$MUM8GC;RH8Y2'#9) )' !]!QVZ5NT47"QS5QI%W.^HC8Z^=%,!*DNTR[MNQ
M>#D8P1^/N:N7(*^(='!ZB"<'\DK8K)O?^1FTG_KE<?\ LE,+&O1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <Q=:5IS7<S-I]
MJ69RS$PKDDG)/2HO[(TW_H'VG_?E?\***M$,/[(TW_H'VG_?E?\ "C^R--_Z
M!]I_WY7_  HHH$']D:;_ - ^T_[\K_A1_9&F_P#0/M/^_*_X444 ']D:;_T#
M[3_ORO\ A1_9&F_] ^T_[\K_ (444 ']D:;_ - ^T_[\K_A1_9&F_P#0/M/^
M_*_X444 ']D:;_T#[3_ORO\ A1_9&F_] ^T_[\K_ (444 ']D:;_ - ^T_[\
MK_A1_9&F_P#0/M/^_*_X444 ']D:;_T#[3_ORO\ A5[2-.LK>\,L%G;Q2!"
MZ1*IP>HR!110QK<WJ***@L**** "BBB@ HHHH **** "BBB@ HHHH **** /
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>gpty1lksmhba000040.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000040.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $[ F$# 2(  A$! Q$!_\0
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M[UE_WX_^O1_PM/Q-_>LO^_'_ ->N+HHY4'M)]SM/^%I^)O[UE_WX_P#KT?\
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M=ZS3X6E5/M#:C9BQ^SI<"[._80S%%&,;L[@1T]Z+1"]3N:W_  M/Q-_>LO\
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MGXF_O67_ 'X_^O1_PM/Q-_>LO^_'_P!>N+HHY4'M)]SM/^%I^)O[UE_WX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8U3(_P"*:O1_VW@_^+JU?W]Y:RHEOI-Q>*RY+Q21J%/I\S"M&BBP^97V_/\
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M9[N62T601RA HD/0# '4D#DT ==17#MKU[;>%-9274(Y=2TW:3=(%(9&PP;
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MJ%8T9R+RV)"C)P)5)-)[%TU>:-JBBBF0%%%% !7-W_A"&ZU*XOK/4K_39;H
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MJ*E%,=A^]_[Q_.E#M_>-,'6EJ65%$$6K(]V;;:ZR D99< X]#5]9P>&XJO\
M6J[W)>7R( 3)NP6QPM(;2-0'(XI:@4E>E2JVX55C,=1112 *SM<OCINCSW8A
M6;RROR,>#E@/ZUHUG:Y8-J>CSV:2)&TA7YWZ## _TI/8J%N9<VQH8HHS13)%
MHHIKML4F@!DLNP8'WJSKJT@O55;A"X4[A@XP:G8ECD]35>]E^SV,T^XKY2&3
MCOCG%/8I+L3G"KR<*!U/H*Y+_A8>D_VC]F\J?R=^S[1QMZ]<=<5S-M\0]0DO
M3]IBA:RG;:\:CE0>.#6)XC\.7.@:@JR$2VTQW0R XRO7!]"*Y:F(;5X?,]G#
M9=%3<,1HVM#VT2*7V YRNX$#@BEWJLBH3\S9QQ7*>&-8O-5TK[9+%''Y+^3$
M$Y)3'?Z'O6M83^??F65R6 *@GI^%=,9*2NCR)P=.;@^AJRL4A=E&2!P,U!<7
M1MHD!!>5AT!_6JHNS<RJK*BQI)RV3GVJP8S<WN./*7[V>_TJ=Q^;)["%HX2\
MA!=SDD#'%6JBEN(X0<MR"!M'7)Z"A9O,?:@SM.'S_#_C5HP;NR-]1MH)_*:3
M$F0",=S6@IR,U6,49;<8U+'J2*D5L-[4,$R:BBBD4%%%% !2,P5<FEJK,^YL
M#H*$ QW+MDU7@M+>U9S!$L9D.6QW-3"O-?B#KVH:=JMOI]E</"HQ<;AU+'C
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M!IV 8\N<=322N.3LBW]*BN+B.U@::7.Q>N!FHQ>QG<51V4,%# ?>/M4R!VB
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M R3M./SJ6YLXYF+K(89#P64]15=[5O/7S'\Q5P58 #GN#]:!:H@F@>27[;:
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M %QBK%2PCDFF]AHFHHHK,L*0*H)( !/4^M+10!&D$,>[9$B[SEMJ@;OKZT\
M 8 P!T I:* "L/Q9_P @B'_K^M?_ $<E;E9VM7D=C91RRVZSJUQ#&$;L6=5#
M?@3G\*3V+IMJ:L:-(>12T4R#/F%X93Y+QA.VX46XNPQ^T-&1CC:.]6G&#25=
M]#.VI#<NL=M([9P!U7J*SXIV:)FDC,:H "SGK6KP>HIGD1&3S3&"_K0%BB6D
M6WD?YDP#@D?>^@JO:2&10\J98+G!/?\ PJU>WD5N[,@W38QG^@]ZI^;A4!',
MAQUYSV']:-0L3M)O ,@)8R!03TZ=JL-\UP&^;;N(*@_>':J$D,5W=PP,?]2Q
MD'&<X_ES5B;[T+XYR1S[\U$V5$=-.(R%=LQYP#T(_P#KTR25A )$4R(?XP^"
M152ZN)/-<[2RIALH<M^([5:THKN,(1VB<;MS# SW_P BIC-I@U<@F/EIYR2.
MC 9#;>?I5FPNIIL>8\98G#)T(^GK4EQ:RH&:!LY[-S^E5K*VA+@+M5AAI(2<
MX/8@UK>^Q-C2F5WA98Y/+<CA\9Q4-E;7,4N;BZ\X'H,8Q5FI8ADY]*;T0UN3
M5B^*Y9(?#5U)$[(X,>&4X(^=:VJSM<ELX='GDU"(S6H*[T7J?F&/UQ63V-J;
MM->IHT4G/K13(%ICKD?2GT4 5Z#P,GH*>ZXYJG)').<.YC09 5><^YJ[D$4E
MZLDBQ0G(;C([_P" JE<:>4E5VE+KO!(<]/\ =K4B@BA'[M%4G@D#!-9<S7=[
M=/'"GE^7P&?_  H$PNID@5)1&S?,3P,X]_TJ:V0"R\] 3+*-JG&#@GBGBPC>
MX42IYBJOS%NA/08J6Y*0PJH(14&1Z#%3)Z#6Y' ^Z_$4HR=I;!QP?I4<J-'*
M(X=F7<(W&3UYR/I5JV9);QI5#'*##8XJ;9MO<@'#KG@< _6LK%$, *2>093Y
MBG=D#C;Z?2KO48(ICHQD1TP.S9'4>E/JD!6-LL4QE3(#?> [U*.2 .]24]$Q
MSWJU(5ARC:H%+112*"BBB@ J%A@U-367<*:8FB*JMS>16PVEU\S'"DU+,9<A
M8\#/WF/4?2JZ640;+YE)[R &J)*KVK:A")FDD0]5P=N3[^U0VL$=O%Y;88DD
ML0, ^]6M4N9K>%5AA+ES@GM]/K5:#3[D6\INCOR/DC7^'V)I=1$%G(M[=+;&
M-U1 =RE>"/J.E6KIYD$[@,(4X7!'4>_:KEO:0VJ!DA17"_,RC&:J&XCDCFMU
M+2$X)5%R:B942>1$>QMW4(I91MW=-QJM )S";N64B..0\ ?>0=/PK4ECWV6U
M<JP3*\<@C^M/BP]NN5P&7[I'2HL,;;#]R&#.5;YE##!4>E+/;QW$91U!^HIT
M2ND85VW$=#C'':GU2 KQJT<:HQ9F4?>;O5B)?XC^%*%W5(!@8%7S706%HHHI
M#"BBB@!KC(SZ5#5BHG&WFJ3):&$A5+$X ZFL^6_66588'R&XR.__ -:I98I;
MDD2.8D!("H<[AZG_  I\-O% /W<:JQ&"0.33$95SI>V1)#*SKNW%7.>?]GT%
M)=S1VZ+,(F<AN-HR<>M-N)+^_NWCMXO*\L\,_;ZBK8TZ-[E!-&)5"98MT)[8
MI"&6J@V#72*S2R9521M."?>G6[L=2CAGR6VEL-@8(]JL7'E6\$:Y6.->1Z"B
MU>.XO?/4,<Q ;MN%_.LY;E+8J72R13$6^S>SA&P,DY/?\*LPH8I_LS3-YA.]
M"HZ+Z?2K+)MOT8 D.O. , CN34LB,71T(!!Y)'4>E389)U&#55[55N!/'E3T
M<#^(>]6A2U:=@(1D].]647:N*:B#.ZI*INX)6"BBBD,**** "BBB@ K-UNPE
MU&QC@A90RW$,I+'C"2*Q_05I5B>*F9=)A*L5/VVV&0<?\MDI/8NG?G5C;HHH
MID#77</I4-6*B=<<U29+1&Q"J68X Y)/:L][]9Y5A@;(;@D?YX%3R0R7!/FN
M54$[50]?<^]21PQQ#Y$5>,$@<FF29-UI2(ZR>8S MN97.<GV]!3;RX2WC658
M]Y#<8(SCUI+C^T-0NWCB3R1&>&;M_CFK@TY#<IYD2RJJ?,SC.3VP.WK2#T([
M4!M/:Z56,DF0FX;2 32V[.-3BAF!+%"3N(ZCOBK-TT5O;JO$<:],#@46KK<7
M:SB-\&(#>1@5G+<I+0J7@DCD9;9E$A8)@#G)_P#K582(Q7!MFDD+NV]&4?=
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MK-W5@?Y5(,,/WRG8IP<?>B]P?2@"]LOD899BH^8;6ZG_  IT,UP);9/.?<[
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M@ $" ,6&T8+=30[")****0PHHHH **** "BBB@ HHHH **** "BBD8A5))
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ML;$$?E0)'DG:H&34E16V?L\>9/,^7[^/O>]2U)04444 %%%% !1110 4444
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40 9]<4--CC*,6I+H34444S,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>gpty1lksmhba000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #< 2@# 2(  A$! Q$!_\0
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MV!Q^&.,F@#8HK/,2QZ]&Z[@9;>0O\QP<,@''3N?SK0H **** "BBB@ HHHH
M**** "BBN2@\>0W<9EL_#^OW4&]D6:&T4HY5BI()?ID&@#K:*Y?_ (3.3_H5
M?$G_ (!K_P#%T?\ "9R?]"KXD_\  -?_ (N@#J**Y?\ X3.3_H5?$G_@&O\
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MF1(HR[/MP, #N2R@>I(%2+K4$VCPZG;13SQ3 %$1,-SZ[B N.<Y(QB@#3HK
M'BW3R@E6.Y,)0%9=@VEM@DV=<[MISZ>]:.FZI!JD32VX?8N 2P&-Q&2OU'&?
MK0 LG_(:MO\ KWE_]"CJ[5*0C^V[<9&?L\O_ *%'5V@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/(?B#_R-DO\ UQC_ )&N7KJ/B#_R-DO_ %QC_D:Y>NJ'PH\BM_$844451D7M
M$_Y#VG?]?,?_ *$*]XKP?1/^0]IW_7S'_P"A"O>*QK;GH8/X6%%%%8G8<#\3
M!%,FE6T^(8GDD8W:VLT[PD*.%$1! ;."<X_IM>"=7M]4\.6J0V_V:2VB2.6!
M;=XDC..BAP./S^M<_P")_'U]HGB::Q@?2/*A,,0@NY_*DD:4$B3=G"HN!G@]
M_:NUT:::XT>TFGO+:\F>,,\]K_JG/JG)X_&A; 7Z*** *4G_ "&K;_KWE_\
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MGY&K4;0SXFB9)-NY ZD''.&&?J.?I4M %#^VM._Y^D_(T?VUIW_/TGY&K]%
M%#^VM._Y^D_(T?VUIW_/TGY&K]% %#^VM._Y^D_(T?VUIW_/TGY&K]% &?\
MVYI@8*;R/<1D#G)I?[:T[_GZ3\C5THI<.5&X @''(!QG^0_*G4 >/>-B;SQ1
M-/;1S31&- 'CB9@<#U KGOL]S_SZW/\ WX?_  KZ"HK156E8Y986,I-W/GW[
M/<_\^MS_ -^'_P */L]S_P ^MS_WX?\ PKZ!I:?MF3]3CW/#-$CEAU[3Y9;>
MX2-+A&9FA< #/4\5[)_;6G?\_2?D:OT5$I<QO2I*FK(SSKFF!@IO(PQZ#G)I
M?[:T[_GZ3\C5THI=7*@LH(!QR,]:=4FI\]?%"VN=2\<W%S8VEU<P&"("2*!V
M4D#GD"N-_L?5?^@5?_\ @+)_A7UO25O&NXJUCBG@HSDY-[GR5_8^J_\ 0*O_
M /P%D_PH_L?5?^@5?_\ @+)_A7UK13^L/L3]0CW/EWPWINH6_BC29IM.O8XH
M[R)G=[9P% 89)..E?2G]M:=_S])^1J_164YN;NSHH4%2329G_P!N:8&"F\CW
M$9 YR:7^VM._Y^D_(U>**7#E1N (!QR <9_D/RI:@W/(/'#&\\3236T<TT1B
M0!XXF89^H%<Y]GN?^?6Y_P"_#_X5]!45HJK2L<LL+&4G*Y\^_9[G_GUN?^_#
M_P"%'V>Y_P"?6Y_[\/\ X5] T4_;,GZG'N>%Z1%-%K5A));W"(EPC,S0N  &
M')XKV;^VM._Y^D_(U?HJ)2YC>E25--(JV^I6=U-Y,%PCR;2VT=<#O^HHJP40
MNKE074$!L<C/7^5%2:F7J\EEJ>B:I9+?VJ[H'AE=I 5B+ K\W/'XUQ,7P\O(
M+6XM;378!-<;&5PI#B./>L>,'.%#(,_[/O6C)\/A_9]TR/%+J$]PTFZ1V5%0
MS-( I49!^8<D-R.F*DTWP=JUGK>G:K+J5L\MG$EH8TAVJT 3# $="7.[ X^4
M4 0R^"]0FEO$.L1J]Q*\ZHK29B5E9=B_-]T$[L\<EO;$=]X)O(K.>&'6X[:.
M9]P,CO\ *0TK*02W!"L@^D=%WX)UV:]O+F+6%1YFQO$T@>1-[L 3SLP'7 7C
MY!ZU8O?!VL7B3H^H1.QF>2.:220L=T<BC*_=4KO ^4<@?A0!T^A:<^E:8+:2
M596,TLI91@'?(S_^S5I5PEUX.UYXI1;ZX\9E?>Z_:) &_>2$8/.W"LG0=4KK
MUNXK9%AE>5Y$4!F\ICN..N0,4 7*XC5I/$ES%K5J1<0Z9M*Q7D4/^DH=PXC1
M&RZXS\WRMZ UUG]I6W_3;_OP_P#A1_:-M_TV_P"_#_X4 >;6,/B>?4+"#.J6
MNY!'%)^\,8AQ.'DD#$X<GR6 8[AD =ZW_#%SJ5GJ<-A?I?70DC=(KE@WEJB,
MW)W<Y)X!/. GJ:ZK^T;;_IM_WX?_  H_M&V_Z;?]^'_PH MT54_M&V_Z;?\
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M58K"T2Z9I8PZR-'A 2@DVGG(.UAVQVS72UFVFA:58W4=S:V$$,T<0A5T3!"
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>gpty1lksmhba000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "] ?@# 2(  A$! Q$!_\0
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M?22I+''M7:S%ICY;I\QZ'[PX/3KGM2MIL5S7>DB*Y\:>,[.62.XOY4:,@/\
MN4(!(R!D#'0TP>.O&!V8OYSYGW,6Z_-]/EYJ"_\ %LE_I4]C]D6(2G[ROGCY
M>HQR<KP<BK=CXK@-I!I\T)M84A:,S+(Q()0+\I RN<9SSW'2G;R%S:_$1_\
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M*T\+?\^#_P#?]_\ &C_A6GA;_GP?_O\ O_C7744<S#V<.QR/_"M/"W_/@_\
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MX/\ ]_W_ ,:ZZBCF8>SAV.1_X5IX6_Y\'_[_ +_XT?\ "M/"W_/@_P#W_?\
MQKKJ*.9A[.'8Y'_A6GA;_GP?_O\ O_C1_P *T\+?\^#_ /?]_P#&NNHHYF'L
MX=CD?^%:>%O^?!_^_P"_^-'_  K3PM_SX/\ ]_W_ ,:ZZBCF8>SAV.1_X5IX
M6_Y\'_[_ +_XT?\ "M/"W_/@_P#W_?\ QKKJ*.9A[.'8Y'_A6GA;_GP?_O\
MO_C1_P *T\+?\^#_ /?]_P#&NNHHYF'LX=CD?^%:>%O^?!_^_P"_^-'_  K3
MPM_SX/\ ]_W_ ,:ZZBCF8>SAV.1_X5IX6_Y\'_[_ +_XT?\ "M/"W_/@_P#W
M_?\ QKKJ*.9A[.'8Y'_A6GA;_GP?_O\ O_C1_P *T\+?\^#_ /?]_P#&NNHH
MYF'LX=CF+/X?^'+"]AO+>S=9X'#QL9G.".G&:*Z>BB[92BEL@HHHI#"BBB@
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M /%4?\+J\,_\^VI_]^5_^*KP.BCV$ ^NU3WS_A=7AG_GVU/_ +\K_P#%4?\
M"ZO#/_/MJ?\ WY7_ .*KP.BCV$ ^NU3WP?&KPQG_ (]]3'_;%?\ XJNJ\/\
MC#1/$Z-_9EZLDJ#+PN"DBCUVGM[BOEFK.GZA=:3J$%_92M%<P,'1A_(^QZ$5
M+P\;:%0QTT_>V/KJBJ.CZBFKZ-9:C&,+<PI*!Z9&<5>KD/43NKH****!A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>&?'#_D9=,_Z\S_Z&:]SKPSXX?\ (RZ9_P!>9_\ 0S6M'XSEQG\)GE]%;'AW
M3;/4KNZ6_E:*WM[5IRROMZ%1R=IXY]*U6\'0WC6K:3J!DAF&XF:,AE4M)M?
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M7_@.G^%'UA=@^H/^8^2MR_WA^=&Y?[P_.OK7^P])_P"@79?^ Z?X4?V'I/\
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MP1XB!(_L_..XE7_&C_A"?$7_ $#C_P!_4_QK?FCW.#V4^S.?HKH/^$)\1?\
M0./_ ']3_&C_ (0GQ%_T#C_W]3_&CFCW#V4^S.?HKH/^$)\1?] X_P#?U/\
M&C_A"?$7_0./_?U/\:.:/</93[,Y^BN@_P"$)\1?] X_]_4_QH_X0GQ%_P!
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MLY]C HK?_P"$*\1?] UO^_B?XT?\(5XB_P"@:W_?Q/\ &CF7</9S[&!16_\
M\(5XB_Z!K?\ ?Q/\:/\ A"O$7_0-;_OXG^-',NX>SGV9@45O_P#"%>(O^@:W
M_?Q/\:/^$*\1?] UO^_B?XT<R[A[.?9F!16__P (5XB_Z!K?]_$_QH_X0KQ%
M_P! UO\ OXG^-',NX>SGV9@5Z;\,HW72+V0CY7N,*?7"C-<W8^ -;NIU6XB2
MTBS\SNX8_@!UKU#2]-M](TZ&RM@1'&.IZL>Y/N:SJ35K(Z<-2DI<S1=HHHK
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M/5S_ -_* +=%5/L/_3U<_P#?RC[#_P!/5S_W\H MUX9\</\ D9=,_P"O,_\
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M@]I(V-9UN/5(5CCLDMPLF_Y2/0C'3MG ]A6/1132L2Y-N[/J#P#_ ,B#H?\
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3%%%% PHHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>gpty1lksmhba000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 54# 2(  A$! Q$!_\0
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MOS#'J,5PG@)E?Q1K3J<JUI:D'U!,M=];P1VL"01#"(, $YK@_ G_ "-FN?\
M7K;?^A2TX[,B>\?7]#T&BBBI- HHHH *Q-)_Y&+7O^ND/_HL5MUCW'AZ*:^G
MNX[Z_MI)R#(()MH) P.WI0!L45B_\(Z?^@UJ_P#X$_\ UJ/^$=/_ $&M7_\
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M6OXMLB?O=B_OOD'/(QQTXK-L=(ORVD_Z9?1;KBX'$8_<_>^;D?Q>_KQ7H%%
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M)ZCU -:*\D]#GDU3:U/5:*;&_F1J^UEW '##!'UIU9G0%%%% !1110 4444
M%%%% !4=P<6TISC"'G.,<>O:I*CN#BVE.<80\YQCCU[4 ,LCNL+=MV[,2G.X
MMGCU/)^IJ>H+)MUA;MNW9B4YW%L\#N>3]:GH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ..N(XYO&4+N)HYUE4[7DC(V@8&!OR
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M3U!9-NL+=MV[,2G.XMGCU/7ZU/0 4444 %%%% !1110 4444 %%%% !1110
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MIZ@LFW6%NV[=F)3NWEL\>IZ_6IZ "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 445A:;XFCU"XM8FLKBW6[5VMY'9") A^;H21^(H
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M_P# )O\ XY44-EKL32DZM:2>8^\![-ODX P/WG3C/XFMFB@9E^1KG_01L/\
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M-<_Z"-A_X!-_\<H\C7/^@C8?^ 3?_'*U**0RE86UW T[WEXMP\K J$C*)&
M, $GZ]>]%7:* "BBB@ HHHH ;)&DL31R*&1P593T(/45#:64%C&8[="JL=S9
M8L2<8Y)YZ #\*** +%%%% !1110 56OK"WU&%8KE69%<2#:[*0PZ'((HHH F
MBC$,2QJ6*J, LQ8_B3R:?110 4444 %%%% %:YT^TO'C>XMXI&C8,C,N2"#D
M<_6K-%% !1110!SVJ:2]QK]HR>;]DN1_IRK]U_+^://ISP?4#%9L=UXF\JZ\
M];C<9%7$<0_=_.>5.TY7;CH&^O7!13$$<OB:339;B:2ZBG$<"B(0+R2/WAP
M3GZ9QZ&M[2K%&AM[^YM6BOWC#2!VR0Y !.!\NX@#) %%% (U:***0PHHHH *
M1E5U*L 5(P0>A%%% %:ST^VL PMXRNX $EBQP.@R3T'85:HHH **** "BBB@
M"*:WCG:(R)N,3^8G/1L$9_4U%::=:V+R-;Q;"_7YB<#).!GH,D\#CFBB@"U1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>gpty1lksmhba000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #@ @$# 2(  A$! Q$!_\0
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M8KIUU'36B=TO+4QP@,S"1<(#T/MFF7.K:?:K"SSQ,9641*C EMS!00.XR>M
M&=I.MW5W;7[3+'+-;IYBI"/E.0<*&!.>G?!'<5GRZ]>[8Y(KFTN)?*+!HT<*
MC'9\K#.#C)[Y^E=$NJV"QJS3Q1L\9E\LNN\KC). >> :=:ZEI]TL'DW$):XC
M$L:;@&93SG'6@#!GUZ^MFN!)<6A>"0QM#Y3!]HVYDZ\ @D\\8QS4$OB"<ZC/
M-'.GE+OAC(!9#^\0!L9 )Y/)(%=--J6GV\SQSWEM'*H^97D4,!UY'XTDNH:?
M"K![B#B(R[ P)* 9R!W&!1<#DT\2:B6^TF1#OB6,1[0%4^>Z-+RV.@'?'(YQ
M6M+J5Y/H-G=&9+>1KR-))$ *LGF;3WP 1[FM+^V---OYJW$3;H#.(PPWLF-W
M"_2GIJNG/9+<_;+86Y(7<9%P#C.#SU]J .;LM5U>.VL[?SH7>X"%))(V)0&0
MJ<\_,<8/:I#XEO4*N[6[!F/G1A"#:@2JAW\]P2><=.XK=75[(W$T18((20\C
MD!1@*>N>GSBI&U/35V[KVU'FKN&95^8>ON.#0!SL_B>ZS.\4MK'%&[>49$)^
MT#S=F%.>H'/?J.U)!J^I6=LBR31.DS2;9)$)\@"?9N8Y^8 -[=/2N@DL=/U/
MRKHA9DP-A20[& .1D X(S4AU+3A'(YO+;9&VR0F1<*3V/I0!SY\37$<<HD:W
MW#"P/M($_P"^*%E&>1C!X_E4BWEX/#,,QU#]\M^L<LQ0?*OG[2I&>./TK735
M;27418HK&09"D*-O"JW!^C"I7U'3XWEC>\ME:/F16D4%?KZ=10!RL&N:I8Z;
M#O9)_.3<KLIS$/-V$L2V&X(ZX_*NGT>\FOM-CGG"!RS+E""& ) /!(YQZFGC
M4=/9M@N[8G:&VB1?NGH?H<C\Z;<:M86:1F6YB4/*(5 8??R%Q^!//I0!>HJG
MI^J6FIQ;[696(^\FX;D^H[=*N4AA1110 444R4,8V"G#$$ ^] !YJ%R@==PY
M(SR*Y6?Q'>)<O(AB\I&*^7C[W/K5;^QM39V @;S$.6??C>/8]ZTM"TJ2.Y>Y
MN+8("NU5<<Y]<5Q2J5:C44G$RO*3LM"WHVJW%_+,DJ+M7D,@X'L:V:CBACA!
M$<:H"<D*,9-25U04E&TG<T5TM0HHHJQF;K=M<W5DJ6N=P<%@&QD<\5S$.I7]
MG:S6T9V@,1L899?4 UW!JHVFV;W/VEK=3,#G=[USU:,I2YHNS(E%MW1REE?W
M&FWF=DC!E^9)"1]#]:ZS3[U;^S6=1MR2&7T([5'?:7;Z@R--O#(" RG!Q5FV
MMH[6!88EPB]**-.=-M-W01BT34445T%A1110 4444 %%%% !115:>^MK;_62
MC/\ =')H LTA( R>*P9_$#.=EM'SZGDU3<:A=G,KE1Z,?Z4[ =%)?VL7WYDS
MZ YJLVMVB_WS]%K&73 ?OS,?H,5(-,M^^X_\"H$:7]O6W]R3]*<NN6IZK(/P
MK*.F6YZ%A^-1-I9'^KF/XB@#HHM2M)>%F4'T;BK08,,@@CVKC&M;N+^'>/;F
MFI=RP-P9(R/0T6&=M17+PZ[<)]YU<?[0J]'X@4_?A_[Y:D!M45G)K-HW4LOU
M6K"7]J_W9T_$XH LT4@=6^ZP/T-+0 5\]>-K&>Q\8ZFDZG][,9D)_B5N0?Z?
MA7T+65KGAS2_$,"Q:C;"0I]R13M=/H151E9F56GSJR/!M9U8:G9:4'EEEN+:
MW:.=Y.I)<D8/<8(KVSP-8SZ=X-TZWN5*R["Y4]5W,6 _(U5TOX=>'M+NUN4M
MY;B5#E/M#[@I]<=/SKK*<I)Z(FE3<7>1CZOI$VH7*R12PH#;R6SB2/<=KE<D
M<]1BJ3^%I'00_:D\J)I'A)CRY9V#?.<_,,C\?PJ?6]1N;+4;=+;9ND0*#)DJ
M,RQKG //#&LFXOK^74XGENBJV[B-DA#*KD7 0L1GNHZ<]ZE&S+;:#<M?6WF;
M6$ES)/<O&@6,QG:?+P3DDLJG\ZN:OH=QJ5WYD=TD<>(\J5/5'W=B,Y]^E9MM
MXDO[R>."%[;=,T160QG"!]^>-V3C:.N#SR*DM]<U6<VD1-JLET(V#")L1AMX
M(QNY^X#VZT]1:$W_  C#I]D>*XB$ELHVYC^5V$F_GGIU_'FK<>B.-,MK226(
MM%=_:6*QX4_O"^ ,\=:RT\1ZAY,/GO;(]Q%%(C+&<)NW@CE@#]S.21U^E4XO
M$5](5O&(E+I%(EJF1@^7*3C!Y!*#U_2C4-#4?PJQBA$=PB-#RNU2H8^:7YP0
M<<]N_-*GAB:)52.XAVL\3R[HV8@I(7^0D\9R>N?7O4*Z[J,US':V\]E+NR?M
M*1L4_P!67VXW=00._0CO6S'J@?0C?Y02+;"9T&6"$INP0.:6H]#)7PM<!K8&
M]0QPM&V A&=JE2.N.^<G)[4^T\,2P7<$TMS&ZH8G8 ./FC0(,#=CD 'D'O5-
M/$]VS>4US9Q8D8&:1/E(\H.!@.1G.1UZ>].E\4WRV[S^5 D@##[(RGS$Q%O\
MP\_=SQTZ'KFC46AKOH@?4GNV>,[KM+C!3)^6+R\9_'-9T'A)H64&Z#1[5)X;
M(81[.!NQCOR/455N/$%^EQ'(D\,\<(E/[E2$N#Y0<+U/(.>G\ZEN/$MY!N"S
M6<T<;<W$:\.-H;"J6Y(SS@D],#K1J&A+)X7O)Q&)+Z+"@<+&0/\ 5&/IG'?.
M3D]JDC\.745PEX+BU-RBB,)Y!\HJ$V],YW>_IQ4$7B"YCOXHLQ"![AD(.6<Y
ME91P2"!C'0''< 59U/7YK/6EM8VB*!XD="GS'?GG.1TXZ ^^*-1Z$*>$6A38
MMRDBJN%$B'TB Y!!'^JZCID>E3P^&G5!YUPDS[X&+-'SB.1GQGO][&3SQDU7
MAU[4=EJMQ):1_:8X9?/\LA(0X?(.6YY4 '(^]4UIJ=Q'X<TJ5KB,/<L$DN9@
M2BC#'/4=< #)[T:BT-+3;*>RB>T8HUO\[JZ\-N=V8C'H 164?#-QY5HHN8 U
MD L.R-D+J%9?G8'.<-VXSGUK%CO]1N=.MRE\Z,L?F,ZECYA$+N._3(Z=^,YJ
MXGB"_L(6MU"2_9XL?O3\[D0^9YF2VXC/&,8QWIV87-?3O#IT^^AG6=62)2 @
M4C^!%[D_W<_C68V@7EY>&V>)8[6)IB)9$!+[Y5?&0QW9P>P[9J9O$&I0:@+6
M58&*!-V%V^9N4L67+9P.G0]#R*AEUC4F6U\ZXACW"*5C&A4,'BD.PY/JHP?<
M4M0T-";PVT\LJM/&+=I99T C^<.ZE<$YZ#.?P'I4-KX7FMMS_;$DEW12J6CX
M\P,&D/7^,@'V]ZHW'B.\,)MX944M;NH(0ED<0;]V2V2<^V/<U+_;]U D^V>W
M(19)5DD!(G*JF$7G@G/;/; ZT]0T-2RT:;37MY+=HG:.$0,"NW(,FYF^N"?Q
MK<KG].U>^N-1@2=81#<-.JHJD-'Y; #)SSG// Z5T%)C04444AA1110 5 )F
M:]>$ ;4C#$]\DG _2IZJ6HS>7LG_ $T5/R4?XF@"W115::_MH/ORKGT')H L
MT5C2^(8%SY<9;W)Q5-_$-P_^K11]%S0!TM%<JVK:@_0R#Z)3/M^HG^*>G8#K
M:*Y'[?J&<[IZ/[1OQ_%/18#KJ*Y'^U;X'_62_B*<-8O1_&_XK18#K**Y0:W>
M?WV_[XH_MF^/1G_[XHL!U=%<G_:.HOT,WY8IN-0F^\7&?[ST6 ZF2Z@B&7E1
M?QK.N->MH@?+!<_D*R5TZ1N99L>RBK,=G!$<A,MZMS185R.34;^^XC!1/;@4
MR/3LG=/(6/H.E7J* &I''&N$4*/84ZBBF(**** "BBB@ I&56^\H/U%+10!
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M>#N*47'=!FBBBM"0HHHH 7-)110 4444 %%%% !1110 4444 %%%% !1110
M4444 4M1N6MTA E$"22;7G8 B,8)[\9.,<^M49=6N(X7BBVR3"-9%GD0J-K$
MJ&*^N<?J:VZ8L:(\CJ@#R$%V[MCUH QGU]T*KY4(+$@%G("XW9#<?>^4<#^\
M*1-=E6=5DAXDDX4Y!1>GIS@JQ-;912ZN5!=<[6[C/7^5.H PXM<N)_+\NUB.
M2 Q+G );'''/ 8Y]O>M:TF:XLX9G38TB!BN>F:FHH T=/55ML* ,L3Q5NJUC
M_P >W_ C5FI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_/\ .\E?,SG=CO23V<%TZM*FXKQUQD>E<:PU2.JEML9\C[DL4@FA25<@.NX
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MH:A:3E;)XU5+22X8/$7W%64!>HP#DUFZCK^HV"SQF5&E@:0@^1@2A=A Y/\
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M#@@CD5+7=&2DKK8Q::=F%%%%,04444 0RVL,W+H,^HX-53I[H<P3$>S5H44
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MOX%X4#^M:<<20H$C4*M8=\YN;WRUZ%MH^E("?38?+@\S !?GIVJ]2*H50HZ
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M:LZSH":P4!F,*!#&X13EE)!QD$>G0Y'M5@Z'IY9R8#AVW%?,;:#N#$@9P,D
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MBFR2)$A>1U1!U9C@"@!U%(K*Q8*02IPP!Z'TH+*'"$C>P)"]R!UH 6BC!HH
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M5[.%K>#8^,Y)XJQ2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>gpty1lksmhba000042.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000042.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $L F4# 2(  A$! Q$!_\0
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MBC\':=/<01P7EX-\EN&WHOW9HV=<8[C;@^N:C@\+VZ:'*\UO>/J$MK;S(NT
MQ,\S(>#VX'7U[470<LS!_P"$AUO_ *#.H?\ @4_^-'_"0ZW_ -!G4/\ P*?_
M !KIY_".GV%M>.ZWEPWV&22)2!NC=)50G@8/7\.>O!IE]X/M3=7Q62:/][<+
M$88AY$ B0-^\.<KN[?UHNA\DSF_^$AUO_H,ZA_X%/_C1_P )#K?_ $&=0_\
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MU.0RG!'T-.\^;&/.EQ@+C>>@Y ^@->^?\*^\*_\ 0'A_[[?_ !H_X5]X5_Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5.[OFM9[>/R"ZS.$W!AD$GL.I[D^@!JY5:6
MQMY[N*ZD0F:($(P<C /)X!P>@H ?;W4%TK-;S)(%;:Q4YP?0U-5&R_X_]1_Z
M[+_Z+2KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%)D9QD4M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 4K/_C_U'_KLO_HM*NU2L_\
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M$D+;74CT/;C(^A-4]1\*V.H7,<X>6V9(!;GR0GS1@Y"_,IVXR<%<'D\UNT4
M8<OA:RFA:)I)PK7,MSPP^](C(1TZ8<XJ+_A$+4))"E[?);2KB2W20!';R_+W
MGC.< <9VY&<5T-% &!;^$K&UU!;N&:=0'65HALVLZJ%W$[=W0#(!QGG%;]%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW,_'*[]B_DN/US5^B@"""RM;7_46\4>>I50"?J:GHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS3DU*RD.!<Q!O[K-M/Y&F1RLM44@((R#D'N*6@04444 %%%% !1110 4444
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M(****9F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4K/\ X_\ 4?\ KLO_ *+2KM4K/_C_ -1_Z[+_ .BTJ[0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *R+ZUO9[VVD6-#Y<X82*Q&V/(R"">I]0#TQWS6O10!BVMO
MJ7VW4"+R(9F7&;8\_NUZ?-5SR-2_Y_H/_ 8__%U!I[WC:G<";SO*^;(=<*#O
M.S:>_P O6M6@"CY&I?\ /]!_X#'_ .+H\C4O^?Z#_P !C_\ %U>HH H^1J7_
M #_0?^ Q_P#BZ/(U+_G^@_\  8__ !=7J* */D:E_P _T'_@,?\ XNCR-2_Y
M_H/_  &/_P 75ZB@"CY&I?\ /]!_X#'_ .+H\C4O^?Z#_P !C_\ %U>HH H^
M1J7_ #_P?^ Q_P#BZ@L_[4N;*"=[R!&D0,5^RGY21T^_6A=;_LDWE$B38VT@
M9.<<<=ZIZ,;C[ !<F1F5B \@(9Q_>P>1]* '^1J7_/\ 0?\ @,?_ (NCR-2_
MY_H/_ 8__%U>HH H^1J7_/\ 0?\ @,?_ (NCR-2_Y_H/_ 8__%U>HH H^1J7
M_/\ 0?\ @,?_ (NCR-2_Y_H/_ 8__%U>HH H^1J7_/\ 0?\ @,?_ (NCR-2_
MY_H/_ 8__%U>HH H^1J7_/\ 0?\ @,?_ (NJ][_:MM:23)=P.RXPOV4\\X_O
MUK5EZM]O5HGLG?A9 45003L.TD_7'YT 3>1J7_/_  ?^ Q_^+H\C4O\ G^@_
M\!C_ /%T:2TS6C><92!(PC,PPY3/&:O4 4?(U+_G^@_\!C_\71Y&I?\ /]!_
MX#'_ .+J]10!1\C4O^?Z#_P&/_Q='D:E_P _T'_@,?\ XNKU% %'R-2_Y_H/
M_ 8__%T>1J7_ #_0?^ Q_P#BZO44 4?(U+_G^@_\!C_\71Y&I?\ /]!_X#'_
M .+J]10!G*]]#?P1331312AL[82I4@#'.XUHU@:I_:0FNO*GG\O,;1B.(GL^
M5!7GDA<GMFMR(LT*%UVL5!*YS@^E #Z*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:GJ$
M>EZ?->RQO(L>,K'C<<D  9('4U;JKJ-A%J=A+9SLZQR 9,9PPP000?J* *EO
MXAL)5Q/)]DF$K0M#.0&#K@D<$@\$=#SFIO[:TPR1H+Z O(0$4.,MD C'X$'\
M15$^%+ R0RF2Y>:*7S]SRY\R3<&RPQ_L@<8XXJO9>#[2.QM8KEW:6&=I]T3%
M1N+ X'?: %4<]!3T%J:-UKUG::LFG3>8)&A:8N%RB@9."?4@,0/135?3_%NC
MZA;B87*P<H"LQ"G+C*CTZ?E4EQX9TVZU!K^59/M;2*XF#X9=HP%'MC/'^T:@
MD\'Z7*(PQG(C"!1OR/E0)W'=0 ?IVHT#4N7>N6MOIMU?0!KR.U+"98&4E=OW
MNI X]*0:_IZ1DW=Q':2JJM)#+(NZ/=TS@D<_6I1H]J-(GTP;_L\XD#_-S\Y)
M;!^K&JM[X9T^^$OG>;F61)"5;HR(4&./[I(_&C0-2:X\0:5;2>7)>1F3S$C*
MJ=Q!<X7IV]Z(O$.CS%A'J5JQ52QQ(. !DG\JJCPEIRW;7*O<K(2I7$GW-K!@
M!QTR.E-;P?I3P>0RS-'L"8+]A'Y8_3]:- U+C^(=(15)U" [HS(H#Y+*,\@?
M\!;\C5RTNHKZSANH&W0S('0XQD$9%9:>%=-1 O[TXVY);&XJ7.3@?]-&_2M2
MSM4LK.&UC9V2% BESEB ,#)I:!J3T444#"BBB@ HHHH **** "BBB@ HHHH
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M_?*_XT?VAAOYT'U+$?R,Z:BN9_X3?3O^>%U_WR/\:/\ A-]._P">%U_WRO\
MC1_:&&_G0?4L1_(SIJ*YG_A-]._YX77_ 'RO^-'_  F^G?\ /"Z_[Y7_ !H_
MM##?SH/J6(_D9TU%<S_PF^G?\\+G_OE?\:/^$WT[_GA=?]\K_C1_:&&_G0?4
ML1_(SIJ*YG_A-]._YX77_?*_XT?\)OIW_/"Z_P"^5_QH_M##?SH/J6(_D9TU
M%<S_ ,)OIW_/"Z_[Y7_&C_A-]._YX77_ 'RO^-']H8;^=!]2Q'\C.FHKF?\
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+^9X.,J*I6E)'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>gpty1lksmhba000033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $: F(# 2(  A$! Q$!_\0
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MIR#+-/*9';' &3V&3P/4T 7Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJCK%S
M?VFDW$^F6(OKU%S%;&41B0YZ;CP*MQEVB5I$V.0"RYSM/IF@ >2., R.J G
M+''-/KF-1^PQ>(9Y=<@62U>W1;5I(C(BG+;QC!PQ^7W(Z=*IVDVKV=K8VB?:
M$2]S'!O3<ULHD)!;/_3(]^Z@4["N=G17"MK.N8OV\[9,D<Y,.PL82I_=D#8
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M44?5H!_:E?LCZ7T/7K'Q#8&]T]W:$2&,ET*G(QV/UK3K@OA)_P B?+_U]O\
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M,C287:/N[MO+=1R>.F*=@N=?2,P52S$!0,DD]*XU5UVXC>2YNKV"=I;6)DB
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MMMKSQ!$\&^.8,[?N@81\Q.&XX]@:Q)2'=V5 @8DA1T7VK>;7+,27!CAN2+O
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M'UI=@_LF?\R/FK(]:7(]:^E/^$6T#_H#6'_@.O\ A1_PBV@?] :P_P# =?\
M"CZTNP?V3/\ F1\UY'J*,CUKZ4_X1;0/^@-8?^ Z_P"%'_"+:!_T!K#_ ,!U
M_P */K2[!_9,_P"9'S7D>M)D>M?2O_"+:!_T!K#_ ,!U_P */^$6T#_H#6'_
M (#K_A1]:78/[)G_ #(YCX2?\B?)_P!?;_R6N]JO9V%II\)AL[:*WB+;MD2!
M1GUP*L5RSES2;/7H4W3IJ#Z!1114FI2NM6LK.X6">8JYVY^1B%W'"[B!A<G@
M9Q5.3Q)9)J4=HL@92)3+*<JL?ECYN2,-SP<'BH=7\-MJEX\QOBBL(]J-'O\
M+*-GY>0!GOP3[BHIO"@N$^SRWS&R5)TCB$0#*)>N6SS@]./KFGH+4T#X@TQ8
MA(UPPS((PIB<.6(+ ;<9Y )''-*?$.E*L+&\7;*@=6"L0%)P"QQ\HSQSCD53
MLO#2VMQ#<&:+S(YA*?*@$88!&0#J3_&3G/TQ40\+,D$T$>H%(KF,Q7(\H$NN
MYF^4Y^4X<C/-&@:E^?7K)$N/*F5GA!W;PRIPP5L-@@X)P<9Q3TU[3'N)(!=J
M'CW[MRE5&S[_ ,Q&#COS6;+X4\V:Z87NQ9U8%8XMN<L""^#AB,8!P#SR34UQ
MX9BNK86\MPWE[[EFPN"1-NR/PW?CBC0-33L]1M=0#FVD+%,;E9&1AGD'# '!
M[&J:>)M'>W>X6]'E(H<L48 J6VY&1R,D#C-+H^BC2C.Y>)Y)0H)BA$8PN<=R
M2>3W^@%95AX9NI=+LTU"[(E@A6..,1C]V Z.02#\Q^0#/%&@:FS'KNFRSI M
MS^\?  9&49(R%)(P&QSM//M5:+Q-83:A]GCDS#Y2OYQ# $LX10 1R"3P1Q22
M^'1-<2AKH_8IKD73P;/F+X'\>?NY .,9]ZK_ /",3%55]3+>5#'# ?( V;'#
MJ6Y^8_* >GX4:!J:<^N:;;EA)<X*NT9"HS$%0"W '09&3TYJK#XDM);B5"5B
MBBEDC>24E00B!BR\8(P?6HH_#UU!*US#JFV\D>4O*8 1M?;D!<\$%!@Y/OFF
MS>%%N&F$MZ[12-(V-@W O&$)ST/*@]*- U+W_"1:7Y7F&Y(S((PIB??N(+ ;
M<9Y )''-7K6Z@O;:.YMI!)#(,JP[UE1Z#*=0BO[J]\ZY216)6+8I54=0N,G'
MWR2<UH:99#3K%+42&3:SMN(Q]YBW]:6@:ENBBB@84444 %%%% !1110 4444
M %4-1ZQ_C5^J&H]8_P ::$S/>*.0J9(T<H<KN4'!]J9':PQ!@$W%I#(S/\Q+
M'OGZ<?2IJ*8B!;*V6995A0,J[5 4849SP.QYZT[[-;Y)\B+)&TG8.GI]*EHH
M C$$(7:(8PO3 08]*DHHH **** "BBB@ HHHH ***7% "44UI$3[S@?C4#7T
M"_Q9^E %JC%43?D_ZN%C^%-,MW+_ '8Q2&7F94&68#ZU6>_B4X0%S[5 +4,<
MRNS_ (U,J*@PJ@?04 ,^UW+?<AP/>D\^\'\ _2IJ* (/MMPGWXC^52)J,;'#
M BGTQX8Y!\R T 64ECD^ZX-28K*:T9>8I"/9J5;JX@XD4D>N,T :=%5$U")_
MO<&K"S1/]V04 7++_CY'T-:=9EE_Q\CZ&M.D-!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 451UC5(-%TFXU&Y29X8%W.L,9=R,X
MX4<GK5N.02Q+(H(5U##(P>?:@!]%8ZW3KXCU"&28B%+.*5$8X ^:0,P_(9_"
ML;3_ !%?Q:; \D<4T<%K:R3R22'S7\WC@8QGO[]*+"N=C17*-XEU'; %LHB]
MS+,L(3>^$C8J2P SDG&,=*D'B6\F59XK.&.%'MXYDFEQ(&E*],#! #?CS3L%
MSIZ*Y*_\0W$VC1M$!#+/!+)N1N4*2*O'UW&DU#Q/=JUW%;I"%:*Y\B=0Q"M$
MI.<D -T/ S@^M%@N==17+1^)+Q;Q;=K(RQQ-%#/(BMR[*K%@<8P-PX)R:ETK
M5+W4-:M9)O*CM;BP:>**.0MU=,;N.H![>IHL%SI**Y5]>OHI+I+:WBD\G[3,
MYGE;[L;@8''?/T%:=[J=RITQ+*&)GOFQ^^8@( A?/ Y/&*5@N:]%<G;^*[VX
M@>:/3"R21/);@DKG#  $D8).<_+Z8[BI$\1WT_EQP0V9F"3/+YCO&%\LKQ@C
M()#=^G7FG8+G445S4/B>:X"74=K&++SHH&#N?-W2*I! QC WCZX)J*+Q+J36
MB2M80-)/;"X@2.0D_?52#D<GY@0!R<8HLPNCJJ*Y.3Q9<[(T@LUFG6.268*L
MF!L;;MP5RI]=W ]ZOZKJ5S;MI,\.$AE=GGC898J(F? QWX_/%*P7-VBL72M8
MN;RZC@NH(4,]J+N(PR%L(2!M;(Z\CD<'GTK:H&%%%% !1110 4444 %4-1ZQ
M_C5^J&H]8_QIH3*5%%%,04444 %%%% !1110 4444 %%+BH)[F.!>3EO2@!\
MLJ0IN<_051,\]T?D^2/UIH1[J3S)<A.R^M6AP, 4AD M4ZN2Y]S4JQHOW44?
MA3J* "BBB@ HHHH **** "BBB@ HHHH C:")_O(*B-FO\#LOZU9HH ?I"3QZ
M@H9MR;3S715BZ;_Q^#_=-;5(:"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH PM9N/#OVI8=76V>:--X$L1;8I[DXX!P>O'%5
MI9O#<&O2W-S<6[7&V$+O3*PX!*D-C R&!Y/I4MSI5[=Z_?21W<UI;2VL49:-
M$;S""^1E@<$ C\ZI-:W&G_VOIUMI5S/%<11Q6Q&WRR!"J?,Q/&,<\4Q'07&F
MZ;)9B&XM8#;QDR .HVJ>23[=3GZUBW^GZ/-+::K->1)9A4DB B7&$&Y=K8R%
MXSC^6:T8--N38?8;]K:ZM%A1%3RSN8J!]XDX/(]!6+/I=_+X;2V-JQDM])\I
M(^,F5@ 0.>H"X_X%0!NSZ;HUI%<7D]K:1(59II60 8."<GZ@&I5TC3#*;E;&
MW,DF6+^6,G<,'\P>?6J&H@:[H%] VF7"R+$WE1W,8&Y]IVD<D=:GU>.Z.A+%
M;P/+(?+5U5B"%R-QX()X[ C/K0!831]-CFAF2Q@$D*A8V"#*@=,?3M2+::7I
MD_VE+>"WEG?RMZH 6+'[OXFN8M=(U*>+RKN.[6*-;KRE\XIR2ABZ,?\ :P"3
MBG_V?J4MY927=K=RW*W5O+YWFCRTB"+N!&>H;=GCJ<T6"YOWKZ+II+78MXFG
M#J05RSACE^!R03R:AN-:T&V>U\VXBRJAK9E1F&"I VD CIGIVI+M;BQ\0-J2
MV4UW#+:K!^XVEXV5B>A(X;=U_P!FFR6UW+%HC&R2W:*[\V6&%@5B4I(/Q^\,
MX[F@"S;66B7?VI[>TM7,AV3XB')(#$'(]P:JII&AWU]Y<4=O(+ -%);! 55G
MVMD^^!^IIEK<7.G7VJHVEWLOG71FB>-5*,/+4#G/'*D=*HZ9I6N:9=6]R6MY
M)+J)TN"L9^20DR*[_-\P#%EXQ]X4 ;]Q;Z3;WUO=7$-LEU(XBAD91N9L' 'O
MC/X4KV&F,4LWM(6Q"56,QY CR./IG'Y5AZEIFNSZI8W3BRN?*GBV[=Z>4!G>
M0#GK]<\#WJSK]G?W5VHMA/Y1A56,4FWGSHR>_7:&Y],T@+\NFZ,3;6,UG:G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  /7/MUI_P _4'_?P4?;K3_GZ@_[^"O(\#T%&!Z"C^W)?R?C_P  /[(C_/\
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M4QREBHQL\Y1MX/(/\7;CZT_WZO9KN+]P[:/0636XV:1O(+L5+(SXXDW$AC]
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MQ1]@L_\ GT@_[]BC^RO[_P"'_!#^TO[OX_\  /),CU%&1ZBO6_L%G_SZ0?\
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M_@A_:7]W\?\ @'DF1ZBC(]17K?V"S_Y](/\ OV*/L%G_ ,^D'_?L4?V5_?\
MP_X(?VE_=_'_ (!Y)D>HHR/45ZW]@L_^?2#_ +]BC[!9_P#/I!_W[%']E?W_
M ,/^"']I?W?Q_P" >29'J*,CU%>M_8+/_GT@_P"_8H^P6?\ SZ0?]^Q1_97]
M_P##_@A_:7]W\?\ @'DF1ZBC(]17K?V"S_Y](/\ OV*/L%G_ ,^D'_?L4?V5
M_?\ P_X(?VE_=_'_ (!Y)D>HISRM(VYY"['NS9->L_8+/_GT@_[]BC[!9_\
M/I!_W[%/^R_[_P"'_!%_:7]S\?\ @'DF1ZBC(]17K?V"S_Y](/\ OV*/L%G_
M ,^D'_?L4O[*_O\ X?\ !'_:7]W\?^ >29'J*,CU%>M_8+/_ )](/^_8H^P6
M?_/I!_W[%']E?W_P_P""']I?W?Q_X!Y)D>HHR/45ZW]@L_\ GT@_[]BC[!9_
M\^D'_?L4?V5_?_#_ ((?VE_=_'_@'DF1ZBC(]17K?V"S_P"?2#_OV*/L%G_S
MZ0?]^Q1_97]_\/\ @A_:7]W\?^ >29'J*<)"$*!R$)R5SP37K/V"S_Y](/\
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M_P $7]HJ]^3\?^ >3QSO%N\N5DW##;6QFF9'J*];^P6?_/I!_P!^Q1]@L_\
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5E14P  P!@#H!17T\59)'S[=V?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>gpty1lksmhba000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #+ 7L# 2(  A$! Q$!_\0
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M/#J;=+W?WY"?Z5R==SIL/V?3H(SU" GZGFIGL:T5K<M4445F=(4444 %%%%
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M9CD66,.AX/Z5AU-;7#6[YZJ?O"DT5%V-BBFHZR('0Y4]#3J@T"BBB@84444
M%%%==X9\-%BFH7Z84?-%"PZ_[1_H*3:0XQ<G9%SPIH)M(QJ%TF)W'[I3_ OK
M]374445@W=W.N,5%604444B@HHHH **** "BBKFG:=+J$VU?EC7[[^G_ ->@
M$FW9$NDZ:U_<988@0_.?7VKL54*H50  , #M4=O;QVL"PQ+M11P*EK)NYUPA
MRH****184444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G'CWX80:^
M9-3T<1V^J'F2,\)<?7T;W[]_6O"KRSN=/O)+2\@D@N(CAXY!@BOKRL#Q-X/T
MCQ7:^5J$&)E&([B/B2/Z'N/8\5O3K..CV.*OA%/WHZ,^6Z*[3Q3\,]<\.,\\
M49U"P'(G@7YE'^TO4?49%<774I*2NCS)PE!VD@HHHJB HHHH **** )8+AX'
MRO*GJI[UJPS).FY#TZ@]16+3D=HV#(Q5AW%)HI2L;E%4X+]6PLWRM_>'0_X5
M<R,9!!![U%C1-,*<B/)(J1JS.QPJJ,DFM32_#M_JA#(GE0=Y9!@?@.]=SI.A
M6>D)F%=\Y'S3/]X_3T%2YI&D:;D8^@>%!;E;O455I1RD/4)[GU/M75T45BVV
M=,8J*L@HHHI%!1110 4444 %%2V]M-=2;((V=O8<#ZUT6G^'XXB)+LB1QR$'
MW1_C2;2*C!RV,O3-'EOB)'S';_WN[?3_ !KK(((K:%8HD"HO0"G@ # & *6L
MV[G3""B%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N2\0_#GP[XB9YIK3[-=-UN+;Y&)]QT/XBNMHIIM:HF4(R5I(\&UGX
M,:W9LSZ5<P7\796/E2?KP?SKA]1\/ZQI#$:AI=W; ?Q/$=O_ 'T.*^L*" 1@
MC(/4&MHUY+<Y)X&F_A=CX\R#T(I:^K+WPMH&H9-WHUC*3U8P+G\\9K!O_AMX
M0V[AHL2D_P!R21?Y-6BQ"?0YY8&:V9\XT5[BWP]\+"3 TOC/_/Q+_P#%5LZ?
M\-O"+<MHT;8_O2R'^;53K11"P<V[71\ZY ZFKVGZ-JFK.$T_3[JZ)_YY1$C\
M^E?3=GX0\.V!S;:)8H1W\D$_F:V%540*BA5'0 8 J'B.R-HX#^9G@6C_  <\
M0WY5]0>#3H3UWMYDF/\ =''YFO2M!^%_A[1$R\4E[.1S)<-D ^H4<"NTI:QE
M5E(ZJ>%IPV1SUSX9[VLV/]B0?UK)GTJ^M\[[=R!_$GS#]*[>BI4F6Z47L>>'
M@X/!]#17?R6\,W^LB1_]Y0:J2:/I[ DVJ?AD57.0Z+Z,XNBNH?2+$'B#_P ?
M;_&G1:/8$\V^?^!-_C3YD3[-G*TJJSG"*6/HHS7;)I-A&<K:Q_B,_P ZLI&D
M8PB*H_V1BIYRE1?5G'P:+?S_ /+'RU]9#C_Z]:]KX;@3#7,AE/\ ='"_XUN4
M4G)FBI10R*&.! D2*BCH%&*?114F@4444 %%%% !1110 4444 %%%% !1110
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>gpty1lksmhba000032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "2 DP# 2(  A$! Q$!_\0
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MS3]0TN26_P!/6^%JCS1Q$G)8*>!CN>E<9X"FTU]<VVEEIGGF"0O-8E_W8RF
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M+Y; J"!C^'YAC.3QUK=EC2:)XI%#(ZE64]"#U%9=MX?@M%?R[J[,AA$$<K2
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M )\],_[]O_\ %5O>#/BEKGB'Q;8Z5=VU@D$Y?<T2,&&$)&,L>XKQFNO^%_\
MR4;2?K+_ .BVJ9TXJ+=BZ5>HYI-]3Z5HHHKB/8"BBB@ HHHH **** "BBB@
MHHHH **** ,W5WUI(HO[&ALI9"Q\P7<C* /;:#S6186/B&X\36VI:O#IT4=O
M;R1*+65V)+E3SN _NU;\4^(W\-V$=PMC+=&1]F0=J1?[3M@X7WQ69X2U35=>
MU"]O+O4K-[6V?R4M[)=T3$JK;MYY.,X[=Z:V)=KV-_7+R>TT]?LS!)IIXH$<
MKD)O<+NQWP":K6-_<0QZM%=2FY?3WXD*A2ZF,.,XXSR1Q6E?6,.H6;VTVX*Q
M!#(V&5@000>Q! -5[;1X[5<+<7#L\C2S-(P)G)7;\_'0#& ,=!2'U,:TO-9D
M-M#]NB>;4+'[2CO$ MNP*;@ .HVOQG/(Z\U';:IJ%S/'90W[/!/=M'#?^4FY
MXTC+/M&-I^8;0V,=?K5]O"=FUG-;&ZO0CPBW1O-&Z*+(.Q3CH< '.20,9J8>
M'T^SQQ-?WKM"X>"7<@:$@%<+A0,8)&"#3T%9F=/KB?\ ")W0U"7_ $@I<P;D
MB;#E"RYX!QG@_C716'_(.MO^N2_R%4+NRAT[PM>6L&[8EM*<LV2Q()))[DDD
MU?L/^0=:_P#7)/Y"@:+%%%%(84444 %%%% !1110 4444 %%%% !1110 451
MU#5(M.:,26]Y+O!(^S6KRXQZ[0<?C6<OBZP>>2!;356FC 9T&G394'."?E[X
M/Y4 ;]%5K&^2_MS-'%<1*&*[;B%HF_)@#CWJS0 4444 %%%% !1110 4444
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M.'_(TZ=_UY?^SM7F->G?'#_D:=._Z\O_ &=J\QKOI? CQ,3_ !6%%%%:&!]
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M#/X5\E[F_O-^=!9CU9OSJOJ_F9?7_P"[^)]A*RM]U@?H:6O(O@5_QY:YR?\
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M'.%R0>5^7W%1/XH3^Q[>_CLWW7%PUND,TBQ$%2P)8GA>$)I=(TN_AN[66^$
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M._TKYQKWWX9_\B%I_P!9/_1C5C7IQC&Z1WY?B*M2JU-W5CK:***Y#V0HHHH
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M,M/^N*?R%<V(Z'H8!MN19K'\5_\ (GZU_P!>,W_H!K8K'\5_\B?K7_7C-_Z
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M\B&?^OR7^E>AUYY\&?\ D0S_ -?DO]*]#KSZGQ,]VA_"B%?*'B?_ )&W6?\
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M%J]=KR3X2Q7/ARUU5-7L+^U:>2,QAK21MP .>BGUKT?_ (2"Q_NWO_@#-_\
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M YCO;LR^2+>*5F4M#&#D*O&/Q.2<"MBBI*,J30;:2_:Y,TX1IEN'MPP\MY5
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M)9S:A9VD-LSAEO879XF :-0V2PSQQ6?J7AJ*3[.2T^H/+>0FY>Y=6/E)NXP
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M1B*3TC..OZBNQTQ)8]*LTGB2&98$#QI]U#M&0/84N@^MBO\ \([HO_0)L?\
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M 4444 )WK&\511S>'KB.5%D1B@*L,@_,.U%% &I:QI#:PQ1(J1H@"JHP ,=
M*FHHH>XEL%%%% PHHHH **** "BBB@ I*** ,'Q9;PW.GVT5Q#'+&UU'E)%#
@ ]>QK>4!5    X ':BBGT%U"EHHI#"BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>gpty1lksmhba000031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "X F # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P ^)_COQ-H?
MCN[L--U62"U2.-EC"C )'-<=_P +3\:_]!R;_OE?\*O?&;_DIE]_UQB_]!K@
M:!G8?\+3\:?]!R;_ +Y7_"C_ (6GXT_Z#DW_ 'RO^%<?2JK,P5022< #O0!V
MUI\2/'5[<I;P:U,SN?[J\>_2NWM_%?B2*W1)=8FDD ^9R!R?RKD= T@:9:;Y
M%!N9!EC_ '1Z5O6UE<7D@C@A>1CT"KDTQ,U?^$P\0Y_Y"DOY"@>+O$1_YBDN
M/<"M?3OA]>S*'O9H[4?W6.6_^M76V'AG0M.'$,<[@<O,=U C@H?$OB6618X]
M1GDD8X5%49-;]K:^.)0&GU'[.IY_>,,C\*W+'1[#19[J>TVM-</E6Q_J5_NB
MIR2W))/N: *$-AK8(^T>)G^D48/\ZMK;S(</KFH2$=<*JT[I2^_ZT +@C_F(
MZ@?^!K_A44D$[_ZO6M0B/OM8?RJ09)Z=:"/0T 95S9>)<$V/B,2D<[)H]A_/
MI7-:CKGC#2GVWMQ-$#T?:"I^AKNAD>M!.Z,Q2*LD3#YHW&Y3^% 'G'_"9^(/
M^@D__?(I?^$S\0?]!%_R%=%J?@JQO&,NGRBSD/)B<$QGZ'J*Q_\ A M6WX\Z
MSQZ^;0!5_P"$S\08_P"0B_Y"KVG:SXQU9L64\TB]W( 4?B:V-+\&:?8L)+YQ
M?3#H@XC7_&NA+'RPBA5C7A4484?A0!F6MGK^ =0\1LI[I;QAB/Q-:<89%YU'
M4)/<NH_I28)I=IH >6R/^/R_'TD'^%1-&[_=U;48_P#OD_TI<8_PH&Y<XR.,
M&@"K)9:@W^I\3W:^GF0J15*:P\5_\NWB&*;T!^0_RK8]O6DY/;K0!R=T?'5H
M-S2W+J/XHMK#]*QY?%/B2)MKZA<1L.JNH!_E7HP=H\;78=^#2S,ERA2Z@AN!
MZ2(#^M 'FA\6^(P#_P 3.;\A7+:]XW\;:9+YL6N3M:N?E)5?E/H>*];O/">B
M7F3%%+92==T1W+^1KE]8^']TUM(L)2^MV&&$?WOKM/\ 2@#S+_A:?C7_ *#D
MW_?*_P"%'_"T_&G_ $')O^^5_P *P-:TFXT;47M;A&&#E2PQD5G4BCL/^%I^
M-/\ H.3?]\K_ (4?\+3\:_\ 0=F_[Y7_  KCZ.U 'V5X8N9KWPMI=U<R&2>:
MUC>1SU9BHR:UJQ/!_P#R)FC?]><7_H(K;H$%%%% !7F_Q'U_5=(U:RBT^]>W
M22 LRJ!R=U>D5Y+\6?\ D-Z=_P!>[?\ H5 '/CQKXE)_Y"\WY"G_ /":>)/^
M@M-^0K! PM%,1O?\)GXD_P"@M-^0H_X33Q)_T%IOR%8-+WH W?\ A-/$G_06
MF_(?X4?\)IXD_P"@M-^0K!H/6@#>_P"$T\2?]!:;\A1_PFGB3/\ R%IOR%8/
M:B@#>_X33Q)_T%IOR'^%'_":>(_^@M-^0K!HH WO^$T\2?\ 06F_(4G_  FG
MB3_H+3?D*PJ.O:@#=_X33Q)_T%IOR%'_  FGB3_H+3?D/\*PJ* -[_A-/$G_
M $%IOR%*WC/Q&#_R%IOR%8(&2*&.6)H W/\ A-/$G_06F_(?X4[_ (3/Q&PX
MU6;(]A7/TH.#F@#>_P"$T\2?]!:;\A_A1_PFGB3_ *"TWY#_  K#)5N>A_2C
M8>V* -O_ (33Q)_T%IOR%+_PFGB3_H+3?D*PRA'7C-&WCAA0!N?\)IXD_P"@
MM-^0I/\ A-/$G_06F_(5B;6]/RIN#Z&@#=_X33Q)_P!!:;\A2_\ ":>)/^@M
M-^0K!P<T4 ;O_":>)/\ H+3?D/\ "E_X33Q)G']K3?D*PL'TI* -T^-/$G_0
M6F_(?X4?\)IXD_Z"TWY#_"L*B@#=_P"$T\2?]!:;\A1_PFGB3_H+3?\ ?(K"
MZ44 ;O\ PFGB3_H+3?D/\*/^$T\28_Y"TW_?(K"HH VO^$U\2_\ 06F_(?X5
MU'@'Q)K.J>)A;7U_)/#Y#-L8#&1BO.V&?PKK_AC_ ,C>/^O=_P"E '"_&;_D
MIE]_UQB_]!K@:[[XR_\ )3+[_KC%_P"@UP-(I!74^$M(-Q)]ND3*J=L2XZMZ
MUAZ1I=SK.K6^GVL;/-.X4!1^9KZ3\-^%K/PY:1*0DUXB@!L?+']/?WH!F1HW
M@MY%6XU1V@C;E8E_UC?X"NPM88+"'R;*%($'!VCD_4]:>69B2223W)H_6F2*
M?<Y)%(QZ;>!2=Z4<'% "8Y]*.>HI?E[G]*7D'C\LT )@X''-* 4.6''84A';
M_(I3U]3Z4 &2QXH*D=>*-Q(Q_*D +$84G\* &FE_G4@MI21\I'UJ46A.<MT]
MJ *Q'M1Q5@6I(RK#=Z&F+"S/MQCW]* (P!G@4G7O5HPHIV!R3WXI3:QD_>*^
M^: *N#1WQ4[6C X1U:HS#*@R4/UH 81BE(/'<4F[!IV5;'&,4 -X[9I0,^A]
M.:5@<<8QUX%)PIY% #:/?-&><\8- &30 <B@'!R#R.XI3C!]<TWGM0!SGCOP
MO%XLT"2(1Q_VA"-]O-C#$CJI/<&OFN6-X96BD4K(A*LI'((KZXZ&O$/B[X9&
MGZJFMVRX@O3B8 <+(._XB@:/,Z#THH/2D4?8O@__ )$S1O\ KSB_]!%;=8G@
M_P#Y$S1O^O.+_P!!%;=!(4444 %>4?%<?\3O3S_T[M_Z%7J]>4?%;_D-:?\
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M&!_#ZF@#F/%NO2W,TMA 1Y"L1*X_C;_ 5R>X[3DXQWJ7#&V; +8Y/<U ?K3
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MX5J&(?)6BHM[22M]ZVMZ6-*[NKC4+]II@LDLK8/EC:#Z<5/=Z-=Z9:K/>(8
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M1%UC4"90PMX,%P.C'L*]:GE6V@6"$!3MP O112 CN&\ZY.#\B<?C0VW>%8@
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M298^@)X% %19IYI#"S#:V<''6N2\:O<Q6-K-#*Z+'.5?82,''%=I--;OMQ(
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MP_XXU[4Y=0U'1=2FN)>K& \#L![444#1G_\ "#>*_P#H7M1_[\FC_A!O%?\
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E  C6M_\ 0)N_^_9KJ? .BZE8^)A-=6$\$?D,-[I@9XHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>gpty1lksmhba000030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #' L\# 2(  A$! Q$!_\0
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MBC_H-7'_ 'RO^%<_119!SR[G0?\ "<^*/^@U<?\ ?*_X4?\ "<^*/^@U<?\
M?*_X5S]%%D'/+N=!_P )SXH_Z#5Q_P!\K_A1_P )SXH_Z#5Q_P!\K_A7/T46
M0<\NYT'_  G/BC_H-7'_ 'RO^%'_  G/BC_H-7'_ 'RO^%<_119!SR[G0?\
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MN/R3_"NA6^TFWMYI;B329=732IO,>*-&A:;>/+"C&TOCT%<WXLDLIM6AGL3
M5DM(6E\@ *)=OS<#@'VH5GT)ES)7N/\ ^$Y\4?\ 0:N/^^5_PKM/AGXBUC6-
M>NX-1U"6YB2VWJK@8!W 9X%>5UZ#\(?^1EOO^O/_ -G6B25ATI2<UJ<]XX_Y
M'?5_^NP_]!6N?KJ_&FE:E/XSU66'3KN2-I@5=(&(/RCH0*PO[%U;_H%7W_@,
M_P#A5)Z$3B^9E&BKW]BZM_T"K[_P&?\ PH_L75O^@5??^ S_ .%.Z)Y64:*O
M?V+JW_0*OO\ P&?_  H_L75O^@5??^ S_P"%%T'*RC15[^Q=6_Z!5]_X#/\
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M;B]AC%R]Q)MCA!4LNW:!CYNIR6.2*Y/^Q=6_Z!5]_P" S_X4?V+JW_0*OO\
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MF!#:8#2Q,H)WCC)%3)Z&E)/G1ZY1116!WA1110 4444 %%%% !1110 4444
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MM8P[?4[.9-4F57TXR;&+P2%G?,@. I(Q^%6D\3Z>C22^1.2YW>4>0#YF_CG
M&/\ 9Z]ZTO\ A5\W_05C_P"_!_\ BJ/^%7S_ /06C_[\'_XJCFAW!4ZRZ'&Z
MC<QW#Q^7<W5QL4Y>XZ\L3@#)P/QZU2KO_P#A5\__ $%H_P#OP?\ XJC_ (5?
M/_T%H_\ OP?_ (JJ]I$AX>JW>QP%=U\,?^0IJ'_7!?\ T(U+_P *OG_Z"T?_
M 'X/_P 577>'?#EMX=M'BA=I99#F25A@MCH,=A4SFG&R-:%"<9IR1M4445@=
MX4444 %%%% '-^/ 3X/O/JG_ *&*\<KW^]M(;^SEM+A-\,JE77U%<%+\+SYK
M>1JF(\_*)(<D?B#6M.:2LSCQ-&<Y)Q//:*[_ /X5?/\ ]!:/_OP?_BJ/^%7S
M_P#06C_[\'_XJM/:1.;ZO4['&Z1/';:Q:32D"-)1N)[=L_AUIS:E=PVS6)6V
M*QY0.(4+#'</C/XUV'_"KY_^@M'_ -^#_P#%4?\ "KI_^@K'_P!^#_\ %4<\
M2E0JI62.>36HC.K_ &F\MS]FAB:2-0Q+(<G()Y!]<_6JL]_I]Q?22-I@CBDD
M+'RIF#*I/;G&?PQ75_\ "KY_^@M'_P!^#_\ %4?\*OG_ .@M'_WX/_Q5+F@-
MTJSZ&$VLV,MO%:2M<,D1C;[0(E#/L8D+MS@##8SFDL-3B2&^NY;B: O?QS^7
M#@EQ\YVGD<>];W_"KY_^@M'_ -^#_P#%4?\ "KY_^@K'_P!^#_\ %4<T.X_9
MUNQF0>)+"&-=JW*DF,[1D[,9W '=C'/  %0GQ%;BS6&-I4:--I)A5O-_=A><
MGCH>N>#6S_PJ^?\ Z"T?_?@__%4?\*OG_P"@M'_WX/\ \52O ?)7[&(WB**1
M[S?+=!9I)#&1R45D  Z^HZ4MSJUM>O).'D)CMIP[.-N\R<* N3SDY.,#VK:_
MX5?/_P!!:/\ [\'_ .*H_P"%73?]!6/_ +\'_P"*I\T!>SK=C@**[_\ X5?/
M_P!!:/\ [\'_ .*H_P"%7S_]!:/_ +\'_P"*I^TB9_5ZG8X"KVC?\AW3O^OF
M/_T(5V/_  J^?_H+1_\ ?@__ !5:V@> 8-(OTO;FZ-U+&<QJ$VJI]>IR:3J1
ML5##5.971V5%)2USGIA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6!XQUB;1?#\EQ;<3R.(D8
MC.TGO^0-;]<=\2?^19C_ .OI/Y-51W1G5;4&T>9OJ>H2N7>_NF8G))F;_&F_
MVA>_\_MU_P!_F_QJO1759'D\S[EC^T+W_G]NO^_S?XT?VA>_\_UU_P!_F_QJ
MO5S2E5]8L4=0RM<1@@C((W"E9 FV[7(QJ%Z>E]<_]_F_QH_M"]_Y_;K_ +_-
M_C78ZG;M>KKD%SI]M:PVLRK:7*V_E<EPN,_Q#%5)?#&G+/-&9;V%+2[2VF=U
M#>:&&=R #/X<\<U*DNILZ4[Z,YG^T+W_ )_;K_O\W^-']H7O_/[=?]_F_P :
MZ?\ X12R-XS^;*MDMJ\X?SE82[6 ^5@N0.1G*Y%4HM,M[+QU96*,9[?SX^)4
MY(.#@@C^E',B?9S6YB_VA>_\_MS^$S?XT?VA>_\ /[=?]_F_QK6TW07O]=F@
MNXYK:W'FR;C&5W!<G )'^/%7U\*V=W>O9V=S*9C%#<1A^@C8X?J!G Y!XR*?
M-$%";5SFO[0O?^?VZ_[_ #?XT?VA>_\ /]=?]_F_QKIK?PSI5U:/<)>3!)9)
MEMSG)58^[ *<YZGD8%9^O0*D^BK!;H6DL(6**O\ K&/KCJ30FFP<))7;,G^T
M+T_\OUU_W^;_ !H_M"]_Y_;K_O\ -_C6[XA02Z+87;6D=O<":2&<+#Y)5A@A
M O<#^]UKFJ:LT3.\7:Y8_M"]_P"?VZ_[_-_C1_:%[_S^W7_?YO\ &J]%.R)Y
MF=CX(\17\>N0:?/<23VUP2NV1BQ1L9!!/TKU:O$O"/\ R-NF?]=?_937MM<]
M569Z&$DW#4****S.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ\YZ]!R30F^PI15KW,>BBBJ,C:\(_P#(VZ9_UU_]E->VUXEX1_Y&W3/^NO\
M[*:]MK"KN>C@_@?J%%%%9'6%%%% !1110 4444 %%%% !1110 4444 %%%%
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MT+[_ )_KK_O\W^-'L7W#ZXNQ[]17@/\ :-]_S_77_?\ ;_&D_M&^SC[==?\
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MW!N;D JAV[53/7 ]:ZNBBI;;=V:P@H*T0HHHI%!1110 4444 %%%% !1110
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M]NU>'K]P?2MZ/4X<9NA:***U.$*[K3D=SX?LETJWN+.ZM0;F1K;)&2P)W]B
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MMWQ);V5G+9VMI:QQ;K>*:2;>Q+%ASD$X [UU6LI-=Z)<?:Y?LEMMA_CCEMV
M('[DC#*<<]*'+8E4KW5]CS<1AC@)DGH *4Q[<9CQGIE>M>A6FDV-EKEM*EHM
MH8;]([602EOM490Y;D_CD8'.*JS:7:3V*3"V-[=K9!X[5IFPQ,I#$<\8'8<=
MZ.<KV#MN</Y7S;?*.[^[MY_*AH2@RT3*/]I,5T/BJZGLO&-W<6DS0S(J;71N
M5_=J.M;NJ^=K&I7UE/(]QY>F)/;0E_\ EMM'('<\FGS;,E4TVU?5' ;%_NC\
MJ-J_W1^5=TVBZ5:%O-T^.1A-9PE6E8;?,4;SP?4YIO\ 8FCS3P8MA$%O+BW$
M8F/[_P L'8"2>"2.V*7.A^PEW.'VK_='Y4;5_NC\J[1]*TRVTNXOKC38TO([
M-97LFE;;$^_:.^>1S@GM4&JZ19)X;6]MK1;=U2-F,K,&8MUVG)5P?08(%/F0
MG2DD<EM7^Z/RK:\+:C<:;X@LS [!)95BD0'AE8XZ?C6-5[1O^0[I_P#U\Q_^
MA"J:T(@VI)H]YHHHKC/9"BBB@#Q#Q7_R-FJ?]=S_ "%8];'BO_D;-3_Z[_T%
M8]=<=D>-4^-A5JVT^XNXVDB5!&K!2\DBHNX]!DD9-5:T(KBTFTM;&[>6(1S-
M*CQQA\A@ 01D<\<&FQ12;U+-C;Z[: I9W$MH9)3&8Q<"(NZXR,$C)Y'YTR"+
M6H;AKF*::"61/,DF:?9\I8CYF)]01@\\5=/B2 W%N_V4,B3LS!T#.J;452K'
MHXVY^M17&J65UIZV$DEP(PB?OS&"Q=6<\C/0A_7K4:]C6T>C*0FUBSN9+&.>
M[2:5_FBCD)\PMWXZY'?O4IM-:-M-8EIO(MW*M 9AMW@;B N?F('/%5[FYL@N
MRRMI8W4C;</,V\@#!^7H,_I6FVMV4E\UTPF!ANY+F%0H^?<H&&YXY4>O&:>I
M*MU902XUC2+6%HKBZM(+D&2,)(4#XP,X'X<U7?4+]X'ADN[DPRL7=&D.UR3R
M2._-.N+L3Z=8P$NTD!DW%NF"1C'X"GZAJC7]I:P&VMXO(3;NCC"D\D]N@YZ?
MC3L)OS(&DO2+>-C<8BSY"G=\O?Y?Q]*L33ZLZ_;9Y[IO,5H3*SDG:,;E/H.>
MAK5_X2"VFN+EYY+K:\S/"<GY%*;<'# X]@14UUXCL9761'NBJ!]UN5PDVZ-5
M^8[O4'UI7?8JT?YCFK=[FW;S[9I8V4$&2/(P#UY%,\J3Y1Y4GS_=&P_-]/6N
MCM=4L[;2H9$$MO&MS(3:1R&02_NP,,6/0Y]#WJ23Q!8&T>WBDNU9]P68@EX@
M5 SDMR>,'&W@T7?87)&VYRI!!((((Z@CI15B^F2>]EE22:16/#S'+MQC)JO5
M&;"O6/AO_P BNW_7R_\ (5Y/7K'PW_Y%=O\ KY?^0K.K\)TX3^(=?1117.>D
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 <UX\_P"1/O/]Z/\ ]#%>.U['X[!/@^]P,X*$_3>*\<KHI;'G8OXT
M%%%%:'*200R7-Q'!$"TDC!%&>YIWV61K@1+RK/L60Y"-SC.3VJ73+E;+5+:Y
M<92.0%L>G0U*FIW4 ^QO>3S6"MM:%9"JR(#T'H"*3N4K6U)?[$<QB<7MN;4\
M"X^;;G=MQC&>O?&*SIK>2WN9+:13YL;E"HY^8''%:\^MVL\DBFSF%M(J#R1,
M (PC94+A>!R<^N<U ^O737S7BPVBS%RX;[.I(/U(_6DN8IJ'0<WA^YBF\N>>
M"+"1G<6) :0D*O Z\'/88JI%I=_<23)#;22- ^R3;_"W/'Z&M ^(%E2..XLU
M,2)%\L1$>7C)(/3H<D8IMIJEND%U/=(TMP]['<I&C[>1N.>AXR1[T:CM"^A6
MM=$U&[>$);L%E/RN_ Z'&>XZ&F/I5\@9E@=U1 S,HZ97=^. >U:L7B>.).-/
M 9F1I-K@ D'G'RYYR>I.*C/B0_94@6&9!$FV,QS;?X OS<<],\8]*+R"U.VY
M330=3)</:O'LC:3YR!G: 2/KR.*B?2KR,2":)HF2,R!'ZL <-CW'4BKG]NH7
MN]]J2MS+)(0),%=RA>N.V*EEUJ"Z:29HBDB02HI=@SR-(-N"0!D 9.3S[T:B
MM#N8/XT4451F%7M&_P"0[I__ %\Q_P#H0JC5[103KVG #)^TQ\?\"%#V''XD
M>\T4E+7&>T%%%% '&>)_ W]LWQO[*X2"=P!(L@.UL=^.AK _X5EJW_/[9?\
MCW^%%%6JDEH8RP].3NT'_"LM6_Y_;+_Q[_"C_A66K?\ /[9?^/?X444_:2)^
MJTP_X5EJW_/[9?\ CW^%'_"LM6_Y_;+_ ,>_PHHI>TD'U6GV#_A66K?\_ME_
MX]_A1_PK+5?^?VR_\>_PHHH]I(/JM/L'_"LM5_Y_;+_Q[_"C_A66K?\ /[9?
M^/?X444_:2#ZK3[!_P *RU;_ )_;+_Q[_"C_ (5EJW_/[9?^/?X444>TD'U6
MF'_"LM5_Y_;+_P >_P */^%9:M_S^V7_ (]_A111[20?5:8?\*RU;_G]LO\
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7J%">^!WHHI.<AJA33ND=32T45)J?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>gpty1lksmhba000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P F$# 2(  A$! Q$!_\0
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MJ%I<V&G6M@D:11Q$RJ(@'#[VP"V,MA2.^*/D)JRO<K_\)%K7_09U#C_IZ?\
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M_P :/[0OO^?Z[_[_ +?XU6HH"[+/]H7W_/\ 7?\ W_;_ !H_M"^_Y_KO_O\
MM_C5:B@+LL_VA??\_P!=_P#?]O\ &C^T+[_G^N_^_P"W^-5J* NS31==E-N(
MSJ;FY!,&UY#YN.NWGG'M57[?J'F>7]MN]^<;?.?.?3&:[K1/%>DV6FZ5'<3L
M+BQCC6,A&.PNY$O;LF#5*UUG0[;2T(EC:Z2=)US;?.K"?<V#MY^3N2<],#%3
M?78TY5;<Y-K[4$D,;7MVK@[2IF<$'TQFEFO-2MYGAFN[V.6,X='F<%3Z$9XK
MIM2U72KBWO3%>6WFR7$SR9L=S7&Y@8RK$#9M'!Z<Y.#FK<_B'0KS5VN;H0R;
M;V<PR"WQB-H@$9OE^;#\\@GOBB_D'*NYQT-WJ5Q,D,-W>R2R'"(DSDL?0#/-
M O=1*.XO+PJF-[><^%STSSQ79:=KV@VVKM<I);VNV[221Q:%_.C$>"$^7*'?
MEN@Z_A6)H.KVUEIFI6UQ*JB:>WF5&BW^:J/EUZ<$CUHN*WF8O]I7O_/_ '7_
M '_;_&C^T;W_ )_[K_O^W^-=9+JNAVD<YM)K>>8I>/$QM. SNAB&&'8 ^PJ2
M?7/#TU^KO%;>7'=N82EI@(K0@!F7 W 2\X-%_(?+YG'_ -I7O_/_ '7/_3=O
M\:/[1OLX^WW7_?\ ;_&NCO\ 6--&GWR6AMI+Z6.WC:=;4*LK /YKH"/DR"H[
M$]:AT^^TA?"5Q97;1I=-O*E(-TC$D;<D@@C@\@J1[T7\A6UW,+^TKW_G_NO^
M_P"W^-']I7O_ #_W7_?]O\:[.]UK0$BWVK6TEQ';W"1,;0<DA/*R-@&00W8X
M]35BTU'1M4UR&**&T(6Y=XP+0 >5]F.XD8&?W@)P?PHOY#Y?,XA;O4WADF2Z
MO6BC(#N)GVKGIDYXSBH_[2O<9^WW7_?]O\:ZZ/6]!3"7!CN%8V9NC#;E$N&1
MG+L%P. "OIG%20:UX?&LRR2_9?+:!$>9;<_,0Q)*C9C.T@<J <=1UHOY!R^9
MQW]H7W_/]=_]_P!O\:/[0OO^?Z[_ ._[?XU#-Y?GR>428]YV$C!QGCCMQ3*9
MG=EG^T+[_G^N_P#O^W^-']H7W_/]=_\ ?]O\:K44PNRS_:%]_P _UW_W_;_&
MC^T+[_G^N_\ O^W^-5J* NRS_:%]_P _UW_W_;_&C^T+[_G^N_\ O^W^-5J*
M NRS_:%]_P _UW_W_;_&I+;4+XW< -]=$&5/^6[>H]ZI5+;?\?EO_P!=4_\
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M%_X$)_C1_P *T\5?\^$7_@0G^->[T4>T8?5X'A'_  K3Q5_SX1?^!"?XT?\
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M:>*O^?"+_P "$_QKW>BJ4FM#*=&,G=GA'_"M/%7_ #X1?^!"?XT?\*T\5?\
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M?:+WP[<P6X=%>3[3"VW<P4' ;)Y(KI::\:2ILD174]0PR*=2&%%%% !1110
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M*FL9_(-PN^5'#*&"G[I/<UMTWRT\SS-B[\;=V.<>F:0#J***!A1110 4444
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M +@':">":I:1>W&H6 N+B 0,S$! <\ X_GFH<US*/4I1?*Y&A1115""BBB@
MHHHH ***1@2I ."1P<=* %HKEAK5_%$DCSP2(Y>2,F+:945U0*.>IR3^7O5V
MRU:X_M#['?>6DFXJNP9W'@@9!(&!^>1TIV%<GU+_ )#&B_\ 7>3_ -%/6K6)
MJ,Y/B/1X/(F 621O-*C8?W3\9SG/X5MT@"BBB@84444 %%%% !1110 4444
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M31I(G7:Z@C]:6.-(HU2-%1%& JC %.HK4Q"BBB@ HHHH **** $H  Z#%!(
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M*** "BBB@ HHHH 9(7$;% "X'R@G@FJ6CWL^H6 N;B 0,S$! <\ X_GFM"D
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M89<=A]*SO#WARQU72A=7!F$A=E^1@!@?A797G_'E<?\ 7-OY&L3P7_R+R_\
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MFXDCD:2QEB91\J,Z$O\ 3!Q^=1+>WA8 Z5<*">29(^/_ !ZFYJR1*IM2;O\
MB2:;<M>:=!<.JJTBY(7H*MU7L;465E%;!BPC&-Q&,U8H5[:CE:[L%%%%,044
M5ROB7POJNMZA'<6/B6[TV-8]AAB!VDY^]PPY_P *$#.JHKR?Q'X8\0^'] NM
M4/C'4)_("GR]SKNRP'7>?6K.D^#?$.J:19W_ /PFFH1_:85EV9<[=PSC._FJ
MLNY-WV/3Z*YSPOX>U+0FN3?Z_<ZF)0-BS X3'<9)ZUT=24%%%% !6;J\6J2Q
MQC2YXHF#?.9!G(]N#6E143ASQ<;V]"H2Y97.6DL?%<D;1M?VQ5@5/ '!_P"
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MTN9]WFZ29-R[&WF,Y7T.3T]J68M<Q&*?2FEC/5)#&P_(FK]%(94%S< 8&GS
M?[Z?_%4?:KC_ *!\W_?:?_%5;HH AAEED)$EN\0'0LRG/Y$U-110 4444 %%
M%% !1110 57EGFC?:EI)(,?>5E _4U8HH J?:KC_ *!\W_?:?_%4UY990!)I
MDC@$, S1G!'(/7K5VB@"C'))"I6+3'0%BQ"M&,D\D]>M)"6ME*P:2T2EBQ$9
MC4$GJ>#UJ_10!4^U7'_/A-_WVG_Q5'VJX_Y\)O\ OM/_ (JJ'BJPN-2T-K>U
MC,DAFB<H"O*JX+?>X/ /!X-8%GIGB:S2QAMT>&".9V<"9/N,Y.&7H" >-N0.
MV*8F==]JN/\ GPF_[[3_ .*H^U7'_/A-_P!]I_\ %5R=M9>+Q]C66>0(DI+L
M9%+,,IRPSC;C>, GKT':*WT/Q%;VOEPR20$0_P#+.9<EQ%A03Z;Z+!<['[5<
M?\^$W_?:?_%5'(S3',NE._RE?F,9^4]1UZ&L[1(-=CU2\DU24M V?+ *E>O&
MT#D87@].?7K704@*#EI;<V\FDL\)&TQL8RN/3&<8IZSS(@1-.E55&  \8 '_
M 'U5RB@94^U7'_0/F_[[3_XJIX9))%)>%HCG&&(/\B:DHH 0YQP,U5^U7'_0
M/F_[[3_XJK=% %3[5<?] ^;_ +[3_P"*J)OG<N^D%F+!B28R=PZ'KU':M"B@
M"A,6N HGTEI0C!E#F-MI'0C)ZU)]JN/^@?-_WVG_ ,55NB@"I]JN/^?";_OM
M/_BJ/M5Q_P ^$W_?:?\ Q58GB72M0O\ 5-,GLT#);ON8^8%VG>AR<]MH;E>>
MW0FH]5L_$LFML;"ZVZ>Y3)W@%0V%? _V0NX>[FF(W_M5Q_T#YO\ OM/_ (JC
M[5<?\^$W_?:?_%5R7V'QCY #74F_S\OM=,]#@KS]S./E/Y4T:5XIM[.\BAE?
M<]P98/*E4!4+N2IR1R<JV0>AQVP2P7.O^U7'_0/F_P"^T_\ BJB3]VZNFD%6
M4$*5,8(!.2!SW/-6[?S?L\7G "78-X!R-V.>>_-2TAF?D_:/M']DMYX7;YN8
M]V/3.<XJ7[5<?] ^;_OM/_BJMT4 5/M5Q_T#YO\ OM/_ (JK2DE02,$CH>U+
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>gpty1lksmhba000043.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpty1lksmhba000043.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &= ?(# 2(  A$! Q$!_\0
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M:K<*T8("GC(/7 K(\,7NJ6UQ\/IKC7M2NEUN&>:[2ZE#*S_9PRJO P,Y('-
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M%% !1110 4444 %%%% 'GPT;Q9=>(K[[1<WL.FSS@_NKW ""7(\O!W*#'P0
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M7D[U)3S\]<@MU^[\N[FO0Z* /+VEUF#7[#3]0O=1$XC#32073>7#!Y3YWJ%
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M78#!;' SZU#'_P A"X_W$_\ 9JCM-6TZ^O+JTM+V">XM2!/'&X)C)Z9J2/\
MX_[C_<3_ -FH LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(&
M##(((SC@T +16=/K^E6\JQ/?0M,R.ZQ1G>[!!EL*N2<8[?2J[ZY<2QN;#1;^
MX;R5EC,BK CY.-N7((8#DY6@#9HK*8Z_*[!%TZV02)M+%YF9,?/D#:%;H!R1
MW]J@N-(U26V8_P!N7#7*O(\055BCPPPJL "2%Z]<YH V(;B&Y0O#*DBAF0E3
MD @D$?@014E8F@:1/HX>!4ABL_+4)&LSRMO&06+, 3D8_*MN@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YGQCX8N?$L.GBTODLIK2Y$PF\O<ZCH2C
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M[IZJWHP/U!'%5]6\'/?VVIPVNIM9IJ5U'/<*L(9718U0Q$9'RMM^;GD$CH:
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M%W"#GRIEX8#U'<'N"#WH U**** "BBB@ HHJO?70LK">Z,9D\I"^Q3RV!TH
ML45S,GC;3;+4/L>I3VEO(58A8KD3/N!'RE%&X'GT[&I?^$PL7 :VL-8NE/1H
MM-FVGZ%E H Z&BN<_P"$N_ZE[7Q_VY?_ %Z>OB^T S-INM0 =2^F3$#\54T
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M=S!2ORCR_P#5*=W)SN..-N<UVMK:P65K%:VL*0V\*A(XXUPJJ.@ H EHHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y!]B\4K::
MK ]OXA#OJV8;E+DET4@[G*!\,JC;M"D*QQN4;30!Z_5:/_C_ )_^N:?S:N8\
M,VFO0^*]9DU W?V-BVTSS;D=O-<QF(9^4"(H",#D=SDUTMOYGVZX\PH3M3&P
M$<9;K0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK"\3>)H_#4
M=@\EG-<?;+I;<%&5%C)[LS$ >P)Y/% &[5>/_C_G'^PG_LU96@>*+;Q!=7D$
M-O-";?#(TF,31EY$#K@\ M$XP<'CWJ\EU;+?SDW$0^1!RX]6H OT5!]MM/\
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M'% %FBH/MMI_S]0_]_!1]MM/^?J'_OX* )Z*@^VVG_/U#_W\%'VVT_Y^H?\
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M4B2!6*DHP."."/J* 'T444 %%%% !1110 445 EY:R.J)<PLS,RJHD!)9?O
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M<4:.&)SM257^4G)SG!QBO5J* /([KP5XMCFN1!/<;I[OS[BXM+L(9V-O&JN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD\26$.G?;91-&@F\AD:,AE?T/8?7- &O17/)XRTT)(URL]N(Y'C8O&2%*LP
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M"VMVD,QC,NTH0 H8J3GI]X$=>H--OO$5EIUZUK.)2ZJ'/EQEL##$D\< !2:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>50
<FILENAME>oric-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-23T03:30:48.1547854+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c72022d3c57a4886b8db69691e884c89 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:oric="http://www.oricpharma.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oricpharma.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.oricpharma.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" id="Role_StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>100040 - Statement - STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&apos; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" id="Role_StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>100050 - Statement - STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&apos; EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" id="Role_StatementSTATEMENTSOFCASHFLOWS">
        <link:definition>100060 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>100090 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100100 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>100110 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestments" id="Role_DisclosureShortTermInvestments">
        <link:definition>100120 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100140 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensation" id="Role_DisclosureEquityIncentivePlansAndStockBasedCompensation">
        <link:definition>100150 - Disclosure - Equity Incentive Plans and Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTax" id="Role_DisclosureIncomeTax">
        <link:definition>100160 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan" id="Role_DisclosureEmployeeBenefitPlan">
        <link:definition>100180 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100200 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100210 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>100220 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables" id="Role_DisclosureShortTermInvestmentsTables">
        <link:definition>100230 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100240 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables" id="Role_DisclosureConvertiblePreferredStockTables">
        <link:definition>100250 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationTables" id="Role_DisclosureEquityIncentivePlansAndStockBasedCompensationTables">
        <link:definition>100260 - Disclosure - Equity Incentive Plans and Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxTables" id="Role_DisclosureIncomeTaxTables">
        <link:definition>100270 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100280 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Description of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100310 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100320 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100340 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>100360 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails" id="Role_DisclosureShortTermInvestmentsAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Short-Term Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails" id="Role_DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails">
        <link:definition>100380 - Disclosure - Short-Term Investments - Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100390 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails" id="Role_DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails">
        <link:definition>100410 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails" id="Role_DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails">
        <link:definition>100440 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails" id="Role_DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails">
        <link:definition>100450 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" id="Role_DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails">
        <link:definition>100460 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails" id="Role_DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails">
        <link:definition>100470 - Disclosure - Income Tax - Schedule of Provision for Income Taxes and Income Taxes Computed (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100480 - Disclosure - Income Tax - Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" id="Role_DisclosureIncomeTaxAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Income Tax - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Commitment and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" id="Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails">
        <link:definition>100510 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" name="TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_TemporaryEquityConversionToCommonStockShares" name="TemporaryEquityConversionToCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_TemporaryEquityConversionToCommonStockValue" name="TemporaryEquityConversionToCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_PublicOfferingMember" name="PublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_TemporaryEquityStockIssuanceCosts" name="TemporaryEquityStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_SeriesCAndDPreferredStockMember" name="SeriesCAndDPreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_NonCashStockConsiderationAcquisition" name="NonCashStockConsiderationAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" name="PaymentsOfStockIssuanceCostsWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_PaymentsOfStockIssuanceCostsWithPublicOffering" name="PaymentsOfStockIssuanceCostsWithPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_UnpaidDeferredFinancingCosts" name="UnpaidDeferredFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_LicenseAgreementsDisclosureTextBlock" name="LicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_ConvertiblePreferredStockDisclosureTextBlock" name="ConvertiblePreferredStockDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_DeferredRentPolicyPolicyTextBlock" name="DeferredRentPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_LicenseFeesPolicyTextBlock" name="LicenseFeesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_DescriptionOfBusinessLineItems" name="DescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_DescriptionOfBusinessTable" name="DescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_SecondaryPublicOfferingMember" name="SecondaryPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" name="UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" name="ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_LiquidInvestmentsMaturityPeriod" name="LiquidInvestmentsMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_PropertyPlantAndEquipmentImpairmentLoss" name="PropertyPlantAndEquipmentImpairmentLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" name="NumberOfLicensedProductsObligedToDevelopAndCommercialize" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="oric_LicenseAgreementsLineItems" name="LicenseAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_LicenseAgreementsTable" name="LicenseAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_MiratiTherapeuticsIncMember" name="MiratiTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_VoronoiIncMember" name="VoronoiIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_DevelopmentAndRegulatoryMilestoneMember" name="DevelopmentAndRegulatoryMilestoneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_CommercialMilestoneMember" name="CommercialMilestoneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_SuccessBasedMilestonesMember" name="SuccessBasedMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" name="AcquiredInProcessResearchAndDevelopmentExpenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_NumberOfPeriodAgreementInEffect" name="NumberOfPeriodAgreementInEffect" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_SharesIssuedPercentageOfPremium" name="SharesIssuedPercentageOfPremium" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_StockTransferRestrictionsPeriod" name="StockTransferRestrictionsPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" name="LicenseAgreementMaximumMilestonePaymentObligationToPay" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_LicenseAgreementAdditionalMilestonePayment" name="LicenseAgreementAdditionalMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_LicenseAgreementChargeRelatedToAcquiredAssets" name="LicenseAgreementChargeRelatedToAcquiredAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" name="LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" name="LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_LabEquipmentMember" name="LabEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_ComputerHardwareAndSoftwareMember" name="ComputerHardwareAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_AccruedClinicalAndManufacturingCosts" name="AccruedClinicalAndManufacturingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_AccruedDeferredFinancingCostsCurrent" name="AccruedDeferredFinancingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_FairValueAssetsLevel2ToLevel3TransfersAmount" name="FairValueAssetsLevel2ToLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_FairValueAssetsLevel3ToLevel2TransfersAmount" name="FairValueAssetsLevel3ToLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_FairValueAssetsLevel1ToLevel3TransfersAmount" name="FairValueAssetsLevel1ToLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_FairValueAssetsLevel3ToLevel1TransfersAmount" name="FairValueAssetsLevel3ToLevel1TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_TemporaryEquityIssuedPeriod" name="TemporaryEquityIssuedPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" name="MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="oric_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_IncentiveStockOptionsMember" name="IncentiveStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_DeferredTaxAssetsResearchAndDevelopment" name="DeferredTaxAssetsResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="oric_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="oric_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_ScenarioOneMember" name="ScenarioOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_ScenarioTwoMember" name="ScenarioTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_CumulativeChangeInOwnershipPeriod" name="CumulativeChangeInOwnershipPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="oric_SouthSanFranciscoCaliforniaMember" name="SouthSanFranciscoCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_SanDiegoCaliforniaMember" name="SanDiegoCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="oric_SouthSanFranciscoAndSanDiegoLocationsMember" name="SouthSanFranciscoAndSanDiegoLocationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>51
<FILENAME>oric-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-23T03:30:48.1547854+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c72022d3c57a4886b8db69691e884c89 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="oric-20201231.xsd#TemplateLink" roleURI="http://www.oricpharma.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets" xlink:href="oric-20201231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="oric-20201231.xsd#Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" xlink:href="oric-20201231.xsd#Role_StatementSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="oric-20201231.xsd#oric_NonCashStockConsiderationAcquisition" xlink:type="locator" xlink:label="oric_NonCashStockConsiderationAcquisition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PaymentsOfStockIssuanceCostsWithPublicOffering" xlink:type="locator" xlink:label="oric_PaymentsOfStockIssuanceCostsWithPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" xlink:type="locator" xlink:label="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="oric_PaymentsOfStockIssuanceCostsWithPublicOffering" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="oric_NonCashStockConsiderationAcquisition" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10210.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="oric-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="oric-20201231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="oric-20201231.xsd#oric_AccruedDeferredFinancingCostsCurrent" xlink:type="locator" xlink:label="oric_AccruedDeferredFinancingCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="oric-20201231.xsd#oric_AccruedClinicalAndManufacturingCosts" xlink:type="locator" xlink:label="oric_AccruedClinicalAndManufacturingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="oric_AccruedClinicalAndManufacturingCosts" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedRentCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="oric_AccruedDeferredFinancingCostsCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails" xlink:href="oric-20201231.xsd#Role_DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails" xlink:href="oric-20201231.xsd#Role_DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="oric-20201231.xsd#Role_DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DeferredTaxAssetsResearchAndDevelopment" xlink:type="locator" xlink:label="oric_DeferredTaxAssetsResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DeferredTaxLiabilitiesFixedAssets" xlink:type="locator" xlink:label="oric_DeferredTaxLiabilitiesFixedAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="oric_DeferredTaxLiabilitiesFixedAssets" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="oric_DeferredTaxAssetsResearchAndDevelopment" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="oric-20201231.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>52
<FILENAME>oric-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-23T03:30:48.1547854+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c72022d3c57a4886b8db69691e884c89 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="oric-20201231.xsd#TemplateLink" roleURI="http://www.oricpharma.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:href="oric-20201231.xsd#Role_StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityConversionToCommonStockShares" xlink:type="locator" xlink:label="oric_TemporaryEquityConversionToCommonStockShares" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityConversionToCommonStockValue" xlink:type="locator" xlink:label="oric_TemporaryEquityConversionToCommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:type="locator" xlink:label="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PublicOfferingMember" xlink:type="locator" xlink:label="oric_PublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="oric_PublicOfferingMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="oric_TemporaryEquityConversionToCommonStockValue" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="oric_TemporaryEquityConversionToCommonStockShares" order="12100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="13180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="13240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="13360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="13720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="13900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:href="oric-20201231.xsd#Role_StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical">
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityStockIssuanceCosts" xlink:type="locator" xlink:label="oric_TemporaryEquityStockIssuanceCosts" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SeriesCAndDPreferredStockMember" xlink:type="locator" xlink:label="oric_SeriesCAndDPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="oric_SeriesCAndDPreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="oric_TemporaryEquityStockIssuanceCosts" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="oric_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" xlink:type="locator" xlink:label="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" />
    <link:loc xlink:href="oric-20201231.xsd#oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:type="locator" xlink:label="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="oric_SecondaryPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DescriptionOfBusinessTable" xlink:type="locator" xlink:label="oric_DescriptionOfBusinessTable" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="oric_DescriptionOfBusinessLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="oric_DescriptionOfBusinessTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_DescriptionOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_DescriptionOfBusinessTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="oric_SecondaryPublicOfferingMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_SharePrice" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="oric_ProceedsFromIssuanceOfCommonStockGross" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11090.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PropertyPlantAndEquipmentImpairmentLoss" xlink:type="locator" xlink:label="oric_PropertyPlantAndEquipmentImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LiquidInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="oric_LiquidInvestmentsMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" xlink:label="us-gaap_DeferredCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="oric-20201231.xsd#oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredCosts" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="oric_LiquidInvestmentsMaturityPeriod" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="oric_PropertyPlantAndEquipmentImpairmentLoss" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10610.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="oric-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="oric-20201231.xsd#oric_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="oric_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="oric_OptionsToPurchaseCommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" xlink:type="locator" xlink:label="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" xlink:type="locator" xlink:label="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementChargeRelatedToAcquiredAssets" xlink:type="locator" xlink:label="oric_LicenseAgreementChargeRelatedToAcquiredAssets" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementAdditionalMilestonePayment" xlink:type="locator" xlink:label="oric_LicenseAgreementAdditionalMilestonePayment" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" xlink:type="locator" xlink:label="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" />
    <link:loc xlink:href="oric-20201231.xsd#oric_UpfrontCashPayment" xlink:type="locator" xlink:label="oric_UpfrontCashPayment" />
    <link:loc xlink:href="oric-20201231.xsd#oric_StockTransferRestrictionsPeriod" xlink:type="locator" xlink:label="oric_StockTransferRestrictionsPeriod" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SharesIssuedPercentageOfPremium" xlink:type="locator" xlink:label="oric_SharesIssuedPercentageOfPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="oric-20201231.xsd#oric_NumberOfPeriodAgreementInEffect" xlink:type="locator" xlink:label="oric_NumberOfPeriodAgreementInEffect" />
    <link:loc xlink:href="oric-20201231.xsd#oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" xlink:type="locator" xlink:label="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" />
    <link:loc xlink:href="oric-20201231.xsd#oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SuccessBasedMilestonesMember" xlink:type="locator" xlink:label="oric_SuccessBasedMilestonesMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_CommercialMilestoneMember" xlink:type="locator" xlink:label="oric_CommercialMilestoneMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DevelopmentAndRegulatoryMilestoneMember" xlink:type="locator" xlink:label="oric_DevelopmentAndRegulatoryMilestoneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_VoronoiIncMember" xlink:type="locator" xlink:label="oric_VoronoiIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_MiratiTherapeuticsIncMember" xlink:type="locator" xlink:label="oric_MiratiTherapeuticsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsTable" xlink:type="locator" xlink:label="oric_LicenseAgreementsTable" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsLineItems" xlink:type="locator" xlink:label="oric_LicenseAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="oric_MiratiTherapeuticsIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="oric_VoronoiIncMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_2" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="oric_DevelopmentAndRegulatoryMilestoneMember" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="oric_CommercialMilestoneMember" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="oric_SuccessBasedMilestonesMember" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_NumberOfPeriodAgreementInEffect" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="us-gaap_CommonStockValue" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_SharesIssuedPercentageOfPremium" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_StockTransferRestrictionsPeriod" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_UpfrontCashPayment" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementAdditionalMilestonePayment" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementChargeRelatedToAcquiredAssets" order="12250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" order="12290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="oric-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ComputerHardwareAndSoftwareMember" xlink:type="locator" xlink:label="oric_ComputerHardwareAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LabEquipmentMember" xlink:type="locator" xlink:label="oric_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="oric_LabEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="oric_ComputerHardwareAndSoftwareMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails" xlink:href="oric-20201231.xsd#Role_DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10390.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="oric-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10480.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails" xlink:href="oric-20201231.xsd#Role_DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityIssuedPeriod" xlink:type="locator" xlink:label="oric_TemporaryEquityIssuedPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="oric_TemporaryEquityIssuedPeriod" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="11060.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="oric-20201231.xsd#oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_IncentiveStockOptionsMember" xlink:type="locator" xlink:label="oric_IncentiveStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="oric_TwoThousandTwentyEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="oric_TwoThousandFourteenEquityIncentivePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="oric_IncentiveStockOptionsMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11880.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureIncomeTaxAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="oric-20201231.xsd#oric_CumulativeChangeInOwnershipPeriod" xlink:type="locator" xlink:label="oric_CumulativeChangeInOwnershipPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" xlink:type="locator" xlink:label="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ScenarioTwoMember" xlink:type="locator" xlink:label="oric_ScenarioTwoMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ScenarioOneMember" xlink:type="locator" xlink:label="oric_ScenarioOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_IncomeTaxTable" xlink:type="locator" xlink:label="oric_IncomeTaxTable" />
    <link:loc xlink:href="oric-20201231.xsd#oric_IncomeTaxLineItems" xlink:type="locator" xlink:label="oric_IncomeTaxLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="oric_IncomeTaxLineItems" xlink:to="oric_IncomeTaxTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_IncomeTaxTable" xlink:to="srt_StatementScenarioAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="oric_ScenarioOneMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="oric_ScenarioTwoMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="oric_IncomeTaxTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="oric_CumulativeChangeInOwnershipPeriod" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10630.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SouthSanFranciscoAndSanDiegoLocationsMember" xlink:type="locator" xlink:label="oric_SouthSanFranciscoAndSanDiegoLocationsMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SanDiegoCaliforniaMember" xlink:type="locator" xlink:label="oric_SanDiegoCaliforniaMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SouthSanFranciscoCaliforniaMember" xlink:type="locator" xlink:label="oric_SouthSanFranciscoCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="oric_SouthSanFranciscoCaliforniaMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="oric_SanDiegoCaliforniaMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="oric_SouthSanFranciscoAndSanDiegoLocationsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10430.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>53
<FILENAME>oric-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-23T03:30:48.1547854+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c72022d3c57a4886b8db69691e884c89 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent - long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 11)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, $0.0001 par value; no shares and 20,348,788 shares authorized at December 31, 2020 and December 31, 2019, respectively; no shares and 19,278,606 issued and outstanding at December 31, 2020 and December 31, 2019, respectively; aggregate liquidation preference of $0 and $178,058 at December 31, 2020 and December 31, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 200,000,000 shares and no shares authorized at December 31, 2020 and December 31, 2019, respectively; no shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 1,000,000,000 shares and 26,750,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; 36,672,415 shares and 1,984,222 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and stockholders&apos; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Excluding Acquired In Process Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development In Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:type="locator" xlink:label="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:to="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityConversionToCommonStockShares" xlink:type="locator" xlink:label="oric_TemporaryEquityConversionToCommonStockShares" />
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityConversionToCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion to common stock shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TemporaryEquityConversionToCommonStockShares" xlink:to="oric_TemporaryEquityConversionToCommonStockShares_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityConversionToCommonStockValue" xlink:type="locator" xlink:label="oric_TemporaryEquityConversionToCommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityConversionToCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion to common stock value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TemporaryEquityConversionToCommonStockValue" xlink:to="oric_TemporaryEquityConversionToCommonStockValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_PublicOfferingMember" xlink:type="locator" xlink:label="oric_PublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="oric_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_PublicOfferingMember" xlink:to="oric_PublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C and D preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C and D preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Net Of Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance costs associated with offering of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityConversionToCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion to Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityConversionToCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion To Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityConversionToCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion to Common Stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityConversionToCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion To Common Stock Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion to Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion to Common Stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to acquired-in- process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to acquired-in-process research and development (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityStockIssuanceCosts" xlink:type="locator" xlink:label="oric_TemporaryEquityStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TemporaryEquityStockIssuanceCosts" xlink:to="oric_TemporaryEquityStockIssuanceCosts_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_SeriesCAndDPreferredStockMember" xlink:type="locator" xlink:label="oric_SeriesCAndDPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="oric_SeriesCAndDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C and D preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_SeriesCAndDPreferredStockMember" xlink:to="oric_SeriesCAndDPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_SeriesCAndDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C and D Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_SeriesCAndDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C And D Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issuance Costs</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_NonCashStockConsiderationAcquisition" xlink:type="locator" xlink:label="oric_NonCashStockConsiderationAcquisition" />
    <link:label xml:lang="en-US" xlink:label="oric_NonCashStockConsiderationAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash stock consideration, acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_NonCashStockConsiderationAcquisition" xlink:to="oric_NonCashStockConsiderationAcquisition_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" xlink:type="locator" xlink:label="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of stock issuance costs with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" xlink:to="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PaymentsOfStockIssuanceCostsWithPublicOffering" xlink:type="locator" xlink:label="oric_PaymentsOfStockIssuanceCostsWithPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="oric_PaymentsOfStockIssuanceCostsWithPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of stock issuance costs with public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_PaymentsOfStockIssuanceCostsWithPublicOffering" xlink:to="oric_PaymentsOfStockIssuanceCostsWithPublicOffering_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_UnpaidDeferredFinancingCosts" xlink:type="locator" xlink:label="oric_UnpaidDeferredFinancingCosts" />
    <link:label xml:lang="en-US" xlink:label="oric_UnpaidDeferredFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid deferred financing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_UnpaidDeferredFinancingCosts" xlink:to="oric_UnpaidDeferredFinancingCosts_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_NonCashStockConsiderationAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash stock consideration, acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_NonCashStockConsiderationAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Stock Consideration Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on fixed asset disposals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of discount on investments, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisitions of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and maturities of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from notes receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Notes Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock pursuant to initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance costs associated with initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs With Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock pursuant to public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_PaymentsOfStockIssuanceCostsWithPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance costs associated with public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_PaymentsOfStockIssuanceCostsWithPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs With Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts accrued for purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Fixed Assets Acquired1</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_UnpaidDeferredFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid deferred financing costs</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_UnpaidDeferredFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Deferred Financing Costs</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of the Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="oric_LicenseAgreementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementsDisclosureTextBlock" xlink:to="oric_LicenseAgreementsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="oric_LicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementsAbstract" xlink:to="oric_LicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_ConvertiblePreferredStockDisclosureTextBlock" xlink:type="locator" xlink:label="oric_ConvertiblePreferredStockDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="oric_ConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ConvertiblePreferredStockDisclosureTextBlock" xlink:to="oric_ConvertiblePreferredStockDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_ConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans and Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_DeferredRentPolicyPolicyTextBlock" xlink:type="locator" xlink:label="oric_DeferredRentPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="oric_DeferredRentPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred rent policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_DeferredRentPolicyPolicyTextBlock" xlink:to="oric_DeferredRentPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_DeferredRentPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DeferredRentPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accrued Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseFeesPolicyTextBlock" xlink:type="locator" xlink:label="oric_LicenseFeesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseFeesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseFeesPolicyTextBlock" xlink:to="oric_LicenseFeesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseFeesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseFeesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Fees Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">New Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Total Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provision for Income Taxes and Income Taxes Computed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Components of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments under Non-cancelable Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_DescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="oric_DescriptionOfBusinessLineItems" />
    <link:label xml:lang="en-US" xlink:label="oric_DescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of the Business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="oric_DescriptionOfBusinessLineItems_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DescriptionOfBusinessTable" xlink:type="locator" xlink:label="oric_DescriptionOfBusinessTable" />
    <link:label xml:lang="en-US" xlink:label="oric_DescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of the business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_DescriptionOfBusinessTable" xlink:to="oric_DescriptionOfBusinessTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_DescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to Purchase Additional Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="oric_SecondaryPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="oric_SecondaryPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Secondary public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_SecondaryPublicOfferingMember" xlink:to="oric_SecondaryPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_SecondaryPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secondary Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_SecondaryPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secondary Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:type="locator" xlink:label="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" />
    <link:label xml:lang="en-US" xlink:label="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts, commissions and other offering expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:to="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" xlink:type="locator" xlink:label="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" />
    <link:label xml:lang="en-US" xlink:label="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance initial public offering, net of issuance cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" xlink:to="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and other offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts Commissions And Other Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from IPO</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering Net Of Issuance Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock outstanding converted into shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Converted1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="oric_ProceedsFromIssuanceOfCommonStockGross" />
    <link:label xml:lang="en-US" xlink:label="oric_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ProceedsFromIssuanceOfCommonStockGross" xlink:to="oric_ProceedsFromIssuanceOfCommonStockGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from secondary public offering excluding underwriting discounts and commissions and other offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No 2019-12</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201912 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" xlink:label="us-gaap_DeferredCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_LiquidInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="oric_LiquidInvestmentsMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="oric_LiquidInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquid investments maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LiquidInvestmentsMaturityPeriod" xlink:to="oric_LiquidInvestmentsMaturityPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_LiquidInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquid investments maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LiquidInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquid Investments Maturity Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of related assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_PropertyPlantAndEquipmentImpairmentLoss" xlink:type="locator" xlink:label="oric_PropertyPlantAndEquipmentImpairmentLoss" />
    <link:label xml:lang="en-US" xlink:label="oric_PropertyPlantAndEquipmentImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property Plant and Equipment Impairment Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_PropertyPlantAndEquipmentImpairmentLoss" xlink:to="oric_PropertyPlantAndEquipmentImpairmentLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_PropertyPlantAndEquipmentImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_PropertyPlantAndEquipmentImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, maximum contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Maximum Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares outstanding used in computing net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="oric_OptionsToPurchaseCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="oric_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_OptionsToPurchaseCommonStockMember" xlink:to="oric_OptionsToPurchaseCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti dilutive securities excluded from computation of net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, early adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Early Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, early adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" xlink:type="locator" xlink:label="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" />
    <link:label xml:lang="en-US" xlink:label="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of licensed products obliged to develop and commercialize.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" xlink:to="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsLineItems" xlink:type="locator" xlink:label="oric_LicenseAgreementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementsLineItems_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsTable" xlink:type="locator" xlink:label="oric_LicenseAgreementsTable" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementsTable" xlink:to="oric_LicenseAgreementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_MiratiTherapeuticsIncMember" xlink:type="locator" xlink:label="oric_MiratiTherapeuticsIncMember" />
    <link:label xml:lang="en-US" xlink:label="oric_MiratiTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Mirati Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_MiratiTherapeuticsIncMember" xlink:to="oric_MiratiTherapeuticsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_MiratiTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mirati Therapeutics, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_MiratiTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mirati Therapeutics Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_VoronoiIncMember" xlink:type="locator" xlink:label="oric_VoronoiIncMember" />
    <link:label xml:lang="en-US" xlink:label="oric_VoronoiIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Voronoi Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_VoronoiIncMember" xlink:to="oric_VoronoiIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_VoronoiIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voronoi Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_VoronoiIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Voronoi Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_DevelopmentAndRegulatoryMilestoneMember" xlink:type="locator" xlink:label="oric_DevelopmentAndRegulatoryMilestoneMember" />
    <link:label xml:lang="en-US" xlink:label="oric_DevelopmentAndRegulatoryMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_DevelopmentAndRegulatoryMilestoneMember" xlink:to="oric_DevelopmentAndRegulatoryMilestoneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_DevelopmentAndRegulatoryMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development And Regulatory Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DevelopmentAndRegulatoryMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Milestone [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_CommercialMilestoneMember" xlink:type="locator" xlink:label="oric_CommercialMilestoneMember" />
    <link:label xml:lang="en-US" xlink:label="oric_CommercialMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_CommercialMilestoneMember" xlink:to="oric_CommercialMilestoneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_CommercialMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_CommercialMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_SuccessBasedMilestonesMember" xlink:type="locator" xlink:label="oric_SuccessBasedMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="oric_SuccessBasedMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Success based milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_SuccessBasedMilestonesMember" xlink:to="oric_SuccessBasedMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_SuccessBasedMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Based Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_SuccessBasedMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Success Based Milestones [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in-process research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" xlink:to="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired In-Process Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquired In Process Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of licensed products obliged to develop and commercialize</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Licensed Products Obliged To Develop And Commercialize</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_NumberOfPeriodAgreementInEffect" xlink:type="locator" xlink:label="oric_NumberOfPeriodAgreementInEffect" />
    <link:label xml:lang="en-US" xlink:label="oric_NumberOfPeriodAgreementInEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of period the agreement in effect.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_NumberOfPeriodAgreementInEffect" xlink:to="oric_NumberOfPeriodAgreementInEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_NumberOfPeriodAgreementInEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of period the agreement in effect</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_NumberOfPeriodAgreementInEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Period Agreement In Effect</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_SharesIssuedPercentageOfPremium" xlink:type="locator" xlink:label="oric_SharesIssuedPercentageOfPremium" />
    <link:label xml:lang="en-US" xlink:label="oric_SharesIssuedPercentageOfPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued percentage of premium.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_SharesIssuedPercentageOfPremium" xlink:to="oric_SharesIssuedPercentageOfPremium_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_StockTransferRestrictionsPeriod" xlink:type="locator" xlink:label="oric_StockTransferRestrictionsPeriod" />
    <link:label xml:lang="en-US" xlink:label="oric_StockTransferRestrictionsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock transfer restrictions period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_StockTransferRestrictionsPeriod" xlink:to="oric_StockTransferRestrictionsPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront payment shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront payment value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issue price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_SharesIssuedPercentageOfPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_SharesIssuedPercentageOfPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Percentage Of Premium</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_StockTransferRestrictionsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock transfer restrictions period</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_StockTransferRestrictionsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Transfer Restrictions Period</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_UpfrontCashPayment" xlink:type="locator" xlink:label="oric_UpfrontCashPayment" />
    <link:label xml:lang="en-US" xlink:label="oric_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_UpfrontCashPayment" xlink:to="oric_UpfrontCashPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" xlink:type="locator" xlink:label="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement maximum milestone payment obligation to pay.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" xlink:to="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementAdditionalMilestonePayment" xlink:type="locator" xlink:label="oric_LicenseAgreementAdditionalMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementAdditionalMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement additional Milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementAdditionalMilestonePayment" xlink:to="oric_LicenseAgreementAdditionalMilestonePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement maximum milestone payment obligation to pay</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Maximum Milestone Payment Obligation To Pay</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementAdditionalMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement, additional milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementAdditionalMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Additional Milestone Payment</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementChargeRelatedToAcquiredAssets" xlink:type="locator" xlink:label="oric_LicenseAgreementChargeRelatedToAcquiredAssets" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementChargeRelatedToAcquiredAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement charge related to acquired assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementChargeRelatedToAcquiredAssets" xlink:to="oric_LicenseAgreementChargeRelatedToAcquiredAssets_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" xlink:type="locator" xlink:label="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement cash payment related to acquired assets charge.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" xlink:to="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" xlink:type="locator" xlink:label="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement shares issued value related to acquired assets charge.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" xlink:to="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementChargeRelatedToAcquiredAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement charge related to acquired assets</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementChargeRelatedToAcquiredAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Charge Related To Acquired Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement cash payment related to acquired assets charge</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Cash Payment Related To Acquired Assets Charge</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement shares issued value related to acquired assets charge</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Shares Issued Value Related To Acquired Assets Charge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_LabEquipmentMember" xlink:type="locator" xlink:label="oric_LabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="oric_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_LabEquipmentMember" xlink:to="oric_LabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_ComputerHardwareAndSoftwareMember" xlink:type="locator" xlink:label="oric_ComputerHardwareAndSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="oric_ComputerHardwareAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer hardware and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ComputerHardwareAndSoftwareMember" xlink:to="oric_ComputerHardwareAndSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_ComputerHardwareAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Hardware and Software</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ComputerHardwareAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Hardware And Software [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_AccruedClinicalAndManufacturingCosts" xlink:type="locator" xlink:label="oric_AccruedClinicalAndManufacturingCosts" />
    <link:label xml:lang="en-US" xlink:label="oric_AccruedClinicalAndManufacturingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and manufacturing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_AccruedClinicalAndManufacturingCosts" xlink:to="oric_AccruedClinicalAndManufacturingCosts_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_AccruedDeferredFinancingCostsCurrent" xlink:type="locator" xlink:label="oric_AccruedDeferredFinancingCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="oric_AccruedDeferredFinancingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued deferred financing costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_AccruedDeferredFinancingCostsCurrent" xlink:to="oric_AccruedDeferredFinancingCostsCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries Current</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_AccruedClinicalAndManufacturingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical and manufacturing costs</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_AccruedClinicalAndManufacturingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical And Manufacturing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRentCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent - short-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Rent Current</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_AccruedDeferredFinancingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued deferred financing costs</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_AccruedDeferredFinancingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Deferred Financing Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available for sale, Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities in unrealized loss position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position Number Of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Portion At Fair Value Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosure Item Amounts [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimate Of Fair Value Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="oric_FairValueAssetsLevel2ToLevel3TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value, assets, level 2 to level 3 transfers, amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:to="oric_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="oric_FairValueAssetsLevel3ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, assets, level 3 to level 2 transfers, amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:to="oric_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="oric_FairValueAssetsLevel1ToLevel3TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, assets, level 1 to level 3 transfers, amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:to="oric_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="oric_FairValueAssetsLevel3ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, assets, level 3 to level 1 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:to="oric_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer between level 1 to 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer between level 2 to 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer between level 2 to 3</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level3 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer between level 3 to 2</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level3 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer between level 1 to 3</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level3 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer between level 3 to 1</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level3 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityIssuedPeriod" xlink:type="locator" xlink:label="oric_TemporaryEquityIssuedPeriod" />
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityIssuedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TemporaryEquityIssuedPeriod" xlink:to="oric_TemporaryEquityIssuedPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityIssuedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issue Period</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TemporaryEquityIssuedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issue Price per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Annual Rate per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Rate Per Dollar Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding shares of convertible preferred stock converted into shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of additional common stock capital shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="oric_TwoThousandTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="oric_TwoThousandFourteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan and two thousand fourteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:to="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan and 2014 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan And Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_IncentiveStockOptionsMember" xlink:type="locator" xlink:label="oric_IncentiveStockOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="oric_IncentiveStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_IncentiveStockOptionsMember" xlink:to="oric_IncentiveStockOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_IncentiveStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_IncentiveStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Stock Options [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:to="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock initially reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock remained available for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number of shares available for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number Of Additional Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" />
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award minimum percentage of combined voting rights of common stock holders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" />
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award stock options not be granted at less than fair market value of common stock at date of grant percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" />
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options not be granted at less than fair market value of common stock at date of grant maximum term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price as a percentage of fair market value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage required for holders of combined voting power to be eligible for incentive stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Minimum Percentage Of Combined Voting Rights Of Common Stock Holders</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of options may not be granted at less than fair market value of the common stock at the date of grant</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Not Be Granted At Less Than Fair Market Value Of Common Stock At Date Of Grant Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term of options may not be granted at less than fair market value of the common stock at the date of grant</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Not Be Granted At Less Than Fair Market Value Of Common Stock At Date Of Grant Maximum Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options, Forfeited and cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Options outstanding Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited and Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Options outstanding Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" />
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award number of shares subject to repurchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" />
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award shares issued subject to repurchase liabilities recorded.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares subject to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Subject To Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities with shares issued with repurchase rights</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued Subject To Repurchase Liabilities Recorded</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued under ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation expense related to outstanding unvested stock-based awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation expense related to outstanding unvested stock-based awards expected to be recognized over weighted-average remaining service period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Reconciling Items</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of Tax Cuts and Jobs Act</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" xlink:to="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provisions for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_DeferredTaxAssetsResearchAndDevelopment" xlink:type="locator" xlink:label="oric_DeferredTaxAssetsResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="oric_DeferredTaxAssetsResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_DeferredTaxAssetsResearchAndDevelopment" xlink:to="oric_DeferredTaxAssetsResearchAndDevelopment_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DeferredTaxLiabilitiesFixedAssets" xlink:type="locator" xlink:label="oric_DeferredTaxLiabilitiesFixedAssets" />
    <link:label xml:lang="en-US" xlink:label="oric_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_DeferredTaxLiabilitiesFixedAssets" xlink:to="oric_DeferredTaxLiabilitiesFixedAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DeferredTaxAssetsResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DeferredTaxAssetsResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Fixed Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_IncomeTaxLineItems" xlink:type="locator" xlink:label="oric_IncomeTaxLineItems" />
    <link:label xml:lang="en-US" xlink:label="oric_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_IncomeTaxLineItems" xlink:to="oric_IncomeTaxLineItems_lbl" />
    <link:loc xlink:href="oric-20201231.xsd#oric_IncomeTaxTable" xlink:type="locator" xlink:label="oric_IncomeTaxTable" />
    <link:label xml:lang="en-US" xlink:label="oric_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_IncomeTaxTable" xlink:to="oric_IncomeTaxTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CALIFORNIA</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_ScenarioOneMember" xlink:type="locator" xlink:label="oric_ScenarioOneMember" />
    <link:label xml:lang="en-US" xlink:label="oric_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ScenarioOneMember" xlink:to="oric_ScenarioOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Begin to expire in 2034</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario One [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_ScenarioTwoMember" xlink:type="locator" xlink:label="oric_ScenarioTwoMember" />
    <link:label xml:lang="en-US" xlink:label="oric_ScenarioTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_ScenarioTwoMember" xlink:to="oric_ScenarioTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_ScenarioTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Not expire</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_ScenarioTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Date</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_CumulativeChangeInOwnershipPeriod" xlink:type="locator" xlink:label="oric_CumulativeChangeInOwnershipPeriod" />
    <link:label xml:lang="en-US" xlink:label="oric_CumulativeChangeInOwnershipPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_CumulativeChangeInOwnershipPeriod" xlink:to="oric_CumulativeChangeInOwnershipPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" xlink:type="locator" xlink:label="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative change in ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" xlink:to="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Percentage Of Value Decline In Equity Securities To Be Considered Other Than Temporary Impairment</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_CumulativeChangeInOwnershipPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative change in ownership period</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_CumulativeChangeInOwnershipPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual for interest or penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties not recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_SouthSanFranciscoCaliforniaMember" xlink:type="locator" xlink:label="oric_SouthSanFranciscoCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="oric_SouthSanFranciscoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">South San Francisco, California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_SouthSanFranciscoCaliforniaMember" xlink:to="oric_SouthSanFranciscoCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_SouthSanFranciscoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco, California</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_SouthSanFranciscoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco California [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_SanDiegoCaliforniaMember" xlink:type="locator" xlink:label="oric_SanDiegoCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="oric_SanDiegoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">San Diego California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_SanDiegoCaliforniaMember" xlink:to="oric_SanDiegoCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_SanDiegoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Diego, California</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_SanDiegoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">San Diego California [Member]</link:label>
    <link:loc xlink:href="oric-20201231.xsd#oric_SouthSanFranciscoAndSanDiegoLocationsMember" xlink:type="locator" xlink:label="oric_SouthSanFranciscoAndSanDiegoLocationsMember" />
    <link:label xml:lang="en-US" xlink:label="oric_SouthSanFranciscoAndSanDiegoLocationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">South San Francisco and San Diego locations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="oric_SouthSanFranciscoAndSanDiegoLocationsMember" xlink:to="oric_SouthSanFranciscoAndSanDiegoLocationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="oric_SouthSanFranciscoAndSanDiegoLocationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco and San Diego Locations</link:label>
    <link:label xml:lang="en-US" xlink:label="oric_SouthSanFranciscoAndSanDiegoLocationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco And San Diego Locations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extend the lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contribution amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>54
<FILENAME>oric-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-23T03:30:48.1557909+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c72022d3c57a4886b8db69691e884c89 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/role/TemplateLink" xlink:href="oric-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="oric-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets" xlink:href="oric-20201231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="oric-20201231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="oric-20201231.xsd#Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:href="oric-20201231.xsd#Role_StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityConversionToCommonStockShares" xlink:type="locator" xlink:label="oric_TemporaryEquityConversionToCommonStockShares" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityConversionToCommonStockValue" xlink:type="locator" xlink:label="oric_TemporaryEquityConversionToCommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:type="locator" xlink:label="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PublicOfferingMember" xlink:type="locator" xlink:label="oric_PublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="oric_PublicOfferingMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="oric_TemporaryEquityConversionToCommonStockValue" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="oric_TemporaryEquityConversionToCommonStockShares" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="13230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="13350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="13710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="13890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="14070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="14250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="14430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="14610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:href="oric-20201231.xsd#Role_StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical">
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityStockIssuanceCosts" xlink:type="locator" xlink:label="oric_TemporaryEquityStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SeriesCAndDPreferredStockMember" xlink:type="locator" xlink:label="oric_SeriesCAndDPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="oric_SeriesCAndDPreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="oric_TemporaryEquityStockIssuanceCosts" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" xlink:href="oric-20201231.xsd#Role_StatementSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="oric-20201231.xsd#oric_UnpaidDeferredFinancingCosts" xlink:type="locator" xlink:label="oric_UnpaidDeferredFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PaymentsOfStockIssuanceCostsWithPublicOffering" xlink:type="locator" xlink:label="oric_PaymentsOfStockIssuanceCostsWithPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" xlink:type="locator" xlink:label="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="oric-20201231.xsd#oric_NonCashStockConsiderationAcquisition" xlink:type="locator" xlink:label="oric_NonCashStockConsiderationAcquisition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="oric_NonCashStockConsiderationAcquisition" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="oric_PaymentsOfStockIssuanceCostsWithPublicOffering" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="oric_UnpaidDeferredFinancingCosts" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:href="oric-20201231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="oric-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreements" xlink:href="oric-20201231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreements">
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="oric_LicenseAgreementsDisclosureTextBlock" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="oric_LicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsAbstract" xlink:to="oric_LicenseAgreementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="oric-20201231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilities" xlink:href="oric-20201231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestments" xlink:href="oric-20201231.xsd#Role_DisclosureShortTermInvestments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="oric-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="oric-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="oric-20201231.xsd#oric_ConvertiblePreferredStockDisclosureTextBlock" xlink:type="locator" xlink:label="oric_ConvertiblePreferredStockDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="oric_ConvertiblePreferredStockDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensation" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTax" xlink:href="oric-20201231.xsd#Role_DisclosureIncomeTax" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTax">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="oric-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan" xlink:href="oric-20201231.xsd#Role_DisclosureEmployeeBenefitPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oric-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="oric-20201231.xsd#oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseFeesPolicyTextBlock" xlink:type="locator" xlink:label="oric_LicenseFeesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DeferredRentPolicyPolicyTextBlock" xlink:type="locator" xlink:label="oric_DeferredRentPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="oric_DeferredRentPolicyPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="oric_LicenseFeesPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="oric-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="oric-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables" xlink:href="oric-20201231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables" xlink:href="oric-20201231.xsd#Role_DisclosureShortTermInvestmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="oric-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables" xlink:href="oric-20201231.xsd#Role_DisclosureConvertiblePreferredStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationTables" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxTables" xlink:href="oric-20201231.xsd#Role_DisclosureIncomeTaxTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="oric-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="oric_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" xlink:type="locator" xlink:label="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" />
    <link:loc xlink:href="oric-20201231.xsd#oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:type="locator" xlink:label="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="oric_DescriptionOfBusinessLineItems" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="oric_SecondaryPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DescriptionOfBusinessTable" xlink:type="locator" xlink:label="oric_DescriptionOfBusinessTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="oric_DescriptionOfBusinessTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="oric_SecondaryPublicOfferingMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessTable" xlink:to="oric_DescriptionOfBusinessLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_SharePrice" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="oric_ProceedsFromIssuanceOfCommonStockGross" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />
    <link:loc xlink:href="oric-20201231.xsd#oric_PropertyPlantAndEquipmentImpairmentLoss" xlink:type="locator" xlink:label="oric_PropertyPlantAndEquipmentImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LiquidInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="oric_LiquidInvestmentsMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" xlink:label="us-gaap_DeferredCosts" />
    <link:loc xlink:href="oric-20201231.xsd#oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredCosts" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="oric_LiquidInvestmentsMaturityPeriod" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="oric_PropertyPlantAndEquipmentImpairmentLoss" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="oric-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="oric-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="oric-20201231.xsd#oric_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="oric_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="oric_OptionsToPurchaseCommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" xlink:type="locator" xlink:label="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" xlink:type="locator" xlink:label="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementChargeRelatedToAcquiredAssets" xlink:type="locator" xlink:label="oric_LicenseAgreementChargeRelatedToAcquiredAssets" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementAdditionalMilestonePayment" xlink:type="locator" xlink:label="oric_LicenseAgreementAdditionalMilestonePayment" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" xlink:type="locator" xlink:label="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" />
    <link:loc xlink:href="oric-20201231.xsd#oric_UpfrontCashPayment" xlink:type="locator" xlink:label="oric_UpfrontCashPayment" />
    <link:loc xlink:href="oric-20201231.xsd#oric_StockTransferRestrictionsPeriod" xlink:type="locator" xlink:label="oric_StockTransferRestrictionsPeriod" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SharesIssuedPercentageOfPremium" xlink:type="locator" xlink:label="oric_SharesIssuedPercentageOfPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="oric-20201231.xsd#oric_NumberOfPeriodAgreementInEffect" xlink:type="locator" xlink:label="oric_NumberOfPeriodAgreementInEffect" />
    <link:loc xlink:href="oric-20201231.xsd#oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" xlink:type="locator" xlink:label="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsLineItems" xlink:type="locator" xlink:label="oric_LicenseAgreementsLineItems" />
    <link:loc xlink:href="oric-20201231.xsd#oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SuccessBasedMilestonesMember" xlink:type="locator" xlink:label="oric_SuccessBasedMilestonesMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_CommercialMilestoneMember" xlink:type="locator" xlink:label="oric_CommercialMilestoneMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DevelopmentAndRegulatoryMilestoneMember" xlink:type="locator" xlink:label="oric_DevelopmentAndRegulatoryMilestoneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_VoronoiIncMember" xlink:type="locator" xlink:label="oric_VoronoiIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_MiratiTherapeuticsIncMember" xlink:type="locator" xlink:label="oric_MiratiTherapeuticsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsTable" xlink:type="locator" xlink:label="oric_LicenseAgreementsTable" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="oric_LicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsAbstract" xlink:to="oric_LicenseAgreementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="oric_MiratiTherapeuticsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="oric_VoronoiIncMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="oric_DevelopmentAndRegulatoryMilestoneMember" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="oric_CommercialMilestoneMember" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="oric_SuccessBasedMilestonesMember" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="oric_AcquiredInProcessResearchAndDevelopmentExpenseMember" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsTable" xlink:to="oric_LicenseAgreementsLineItems" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_NumberOfPeriodAgreementInEffect" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="us-gaap_CommonStockValue" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_SharesIssuedPercentageOfPremium" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_StockTransferRestrictionsPeriod" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_UpfrontCashPayment" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementMaximumMilestonePaymentObligationToPay" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementAdditionalMilestonePayment" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementChargeRelatedToAcquiredAssets" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_LicenseAgreementsLineItems" xlink:to="oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="oric-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ComputerHardwareAndSoftwareMember" xlink:type="locator" xlink:label="oric_ComputerHardwareAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_LabEquipmentMember" xlink:type="locator" xlink:label="oric_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="oric_LabEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="oric_ComputerHardwareAndSoftwareMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="oric-20201231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="oric-20201231.xsd#oric_AccruedDeferredFinancingCostsCurrent" xlink:type="locator" xlink:label="oric_AccruedDeferredFinancingCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="oric-20201231.xsd#oric_AccruedClinicalAndManufacturingCosts" xlink:type="locator" xlink:label="oric_AccruedClinicalAndManufacturingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="oric_AccruedClinicalAndManufacturingCosts" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedRentCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="oric_AccruedDeferredFinancingCostsCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureShortTermInvestmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails" xlink:href="oric-20201231.xsd#Role_DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="oric-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="oric-20201231.xsd#oric_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="oric_FairValueAssetsLevel3ToLevel1TransfersAmount" />
    <link:loc xlink:href="oric-20201231.xsd#oric_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="oric_FairValueAssetsLevel1ToLevel3TransfersAmount" />
    <link:loc xlink:href="oric-20201231.xsd#oric_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="oric_FairValueAssetsLevel3ToLevel2TransfersAmount" />
    <link:loc xlink:href="oric-20201231.xsd#oric_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="oric_FairValueAssetsLevel2ToLevel3TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="oric_FairValueAssetsLevel2ToLevel3TransfersAmount" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="oric_FairValueAssetsLevel3ToLevel2TransfersAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="oric_FairValueAssetsLevel1ToLevel3TransfersAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="oric_FairValueAssetsLevel3ToLevel1TransfersAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails" xlink:href="oric-20201231.xsd#Role_DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TemporaryEquityIssuedPeriod" xlink:type="locator" xlink:label="oric_TemporaryEquityIssuedPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="oric_TemporaryEquityIssuedPeriod" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" xlink:type="locator" xlink:label="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="oric-20201231.xsd#oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_IncentiveStockOptionsMember" xlink:type="locator" xlink:label="oric_IncentiveStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="oric_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="oric_TwoThousandTwentyEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="oric_TwoThousandFourteenEquityIncentivePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="oric_IncentiveStockOptionsMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:href="oric-20201231.xsd#Role_DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails" xlink:href="oric-20201231.xsd#Role_DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="oric-20201231.xsd#Role_DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DeferredTaxLiabilitiesFixedAssets" xlink:type="locator" xlink:label="oric_DeferredTaxLiabilitiesFixedAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="oric-20201231.xsd#oric_DeferredTaxAssetsResearchAndDevelopment" xlink:type="locator" xlink:label="oric_DeferredTaxAssetsResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="oric_DeferredTaxAssetsResearchAndDevelopment" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="oric_DeferredTaxLiabilitiesFixedAssets" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureIncomeTaxAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="oric-20201231.xsd#oric_CumulativeChangeInOwnershipPeriod" xlink:type="locator" xlink:label="oric_CumulativeChangeInOwnershipPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" xlink:type="locator" xlink:label="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="oric-20201231.xsd#oric_IncomeTaxLineItems" xlink:type="locator" xlink:label="oric_IncomeTaxLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ScenarioTwoMember" xlink:type="locator" xlink:label="oric_ScenarioTwoMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_ScenarioOneMember" xlink:type="locator" xlink:label="oric_ScenarioOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="oric-20201231.xsd#oric_IncomeTaxTable" xlink:type="locator" xlink:label="oric_IncomeTaxTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="oric_IncomeTaxTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxTable" xlink:to="srt_StatementScenarioAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="oric_ScenarioOneMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="oric_ScenarioTwoMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxTable" xlink:to="oric_IncomeTaxLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="oric_CumulativeChangeInOwnershipPeriod" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="oric_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SouthSanFranciscoAndSanDiegoLocationsMember" xlink:type="locator" xlink:label="oric_SouthSanFranciscoAndSanDiegoLocationsMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SanDiegoCaliforniaMember" xlink:type="locator" xlink:label="oric_SanDiegoCaliforniaMember" />
    <link:loc xlink:href="oric-20201231.xsd#oric_SouthSanFranciscoCaliforniaMember" xlink:type="locator" xlink:label="oric_SouthSanFranciscoCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="oric_SouthSanFranciscoCaliforniaMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="oric_SanDiegoCaliforniaMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="oric_SouthSanFranciscoAndSanDiegoLocationsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="oric-20201231.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:href="oric-20201231.xsd#Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>oric-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:oric="http://www.oricpharma.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="oric-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001796280_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001796280_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001796280_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_oricSeriesCAndDPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">oric:SeriesCAndDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200428_20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-28</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200428_20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-28</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-28</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:SecondaryPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-17</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">oric:SecondaryPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-17</instant>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20201117_20201117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-17</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">oric:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">oric:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">oric:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_20200803_20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:MiratiTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:MiratiTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803_20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:MiratiTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="C_0001796280_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2020-10-19</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-19</startDate>
            <endDate>2020-10-19</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-19</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricDevelopmentAndRegulatoryMilestoneMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">oric:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-19</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricCommercialMilestoneMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">oric:CommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-19</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricSuccessBasedMilestonesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">oric:SuccessBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-19</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-19</startDate>
            <endDate>2020-10-19</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapIncomeStatementLocationAxis_oricAcquiredInProcessResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">oric:AcquiredInProcessResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">oric:VoronoiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-19</startDate>
            <endDate>2020-10-19</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricLabEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">oric:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricLabEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">oric:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricComputerHardwareAndSoftwareMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">oric:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricComputerHardwareAndSoftwareMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">oric:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandFourteenEquityIncentivePlanMember_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200401_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">oric:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200401_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">oric:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMinimumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMinimumMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMinimumMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtRangeAxis_srtMaximumMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtStatementScenarioAxis_oricScenarioOneMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oric:ScenarioOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtStatementScenarioAxis_oricScenarioTwoMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">oric:ScenarioTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_stprCA_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_stprCA_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoCaliforniaMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoCaliforniaMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20191001_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoAndSanDiegoLocationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoAndSanDiegoLocationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">oric:SouthSanFranciscoAndSanDiegoLocationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_oricSegment">
        <measure>oric:Segment</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_oricProduct">
        <measure>oric:Product</measure>
    </unit>
    <unit id="U_oricSecurity">
        <measure>oric:Security</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001796280_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001796280_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001796280_20200101_20201231" id="F_000006">0001796280</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001796280_20200101_20201231" id="F_000010">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428"
      decimals="2"
      id="F_000319_2"
      unitRef="U_xbrlipure">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20200101_20201231"
      id="F_000328">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_0001796280_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000351">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001796280_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000352">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="C_0001796280_20200101_20201231" id="F_000611">2034-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_0001796280_srtStatementGeographicalAxis_stprCA_20200101_20201231"
      id="F_000614">2034-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428"
      decimals="2"
      id="F_000319"
      unitRef="U_xbrlipure">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <oric:StockTransferRestrictionsPeriod
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803_20200803"
      id="F_000359">P18M</oric:StockTransferRestrictionsPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001796280_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231"
      id="F_000476">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <oric:CumulativeChangeInOwnershipPeriod contextRef="C_0001796280_20200101_20201231" id="F_000616">P3Y</oric:CumulativeChangeInOwnershipPeriod>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoCaliforniaMember_20200101_20201231"
      id="F_000620">2022-05-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoCaliforniaMember_20201231"
      id="F_000622">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000445"
      unitRef="U_xbrlishares">3862500</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000446"
      unitRef="U_xbrlishares">6749999</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000447"
      unitRef="U_xbrlishares">4448780</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231"
      decimals="INF"
      id="F_000448"
      unitRef="U_xbrlishares">4217327</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000449"
      unitRef="U_xbrlishares">19278606</us-gaap:TemporaryEquitySharesOutstanding>
    <oric:TemporaryEquityIssuedPeriod
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231"
      id="F_000451">2014</oric:TemporaryEquityIssuedPeriod>
    <oric:TemporaryEquityIssuedPeriod
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231"
      id="F_000452">2015</oric:TemporaryEquityIssuedPeriod>
    <oric:TemporaryEquityIssuedPeriod
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231"
      id="F_000453">2018</oric:TemporaryEquityIssuedPeriod>
    <oric:TemporaryEquityIssuedPeriod
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231"
      id="F_000454">2015</oric:TemporaryEquityIssuedPeriod>
    <oric:TemporaryEquityIssuedPeriod
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231"
      id="F_000455">2016</oric:TemporaryEquityIssuedPeriod>
    <oric:TemporaryEquityIssuedPeriod
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231"
      id="F_000456">2019</oric:TemporaryEquityIssuedPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001796280_20200101_20201231" id="F_000494">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001796280_20200101_20201231" id="F_000495">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001796280_20190101_20191231" id="F_000530">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20201231"
      decimals="INF"
      id="F_000511"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20201231"
      decimals="INF"
      id="F_000512"
      unitRef="U_iso4217USD_xbrlishares">35.92</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20191231"
      decimals="INF"
      id="F_000513"
      unitRef="U_iso4217USD_xbrlishares">1.60</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20191231"
      decimals="INF"
      id="F_000514"
      unitRef="U_iso4217USD_xbrlishares">9.16</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001796280_20200101_20201231"
      decimals="4"
      id="F_000516"
      unitRef="U_xbrlipure">0.0317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001796280_20190101_20191231"
      decimals="3"
      id="F_000517"
      unitRef="U_xbrlipure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001796280_20180101_20181231"
      decimals="3"
      id="F_000518"
      unitRef="U_xbrlipure">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001796280_20200101_20201231"
      decimals="4"
      id="F_000519"
      unitRef="U_xbrlipure">0.0559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001796280_20190101_20191231"
      decimals="3"
      id="F_000520"
      unitRef="U_xbrlipure">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001796280_20180101_20181231"
      decimals="3"
      id="F_000521"
      unitRef="U_xbrlipure">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001796280_20200101_20201231"
      decimals="4"
      id="F_000522"
      unitRef="U_xbrlipure">0.8801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001796280_20190101_20191231"
      decimals="2"
      id="F_000523"
      unitRef="U_xbrlipure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001796280_20180101_20181231"
      decimals="2"
      id="F_000524"
      unitRef="U_xbrlipure">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001796280_20200101_20201231"
      decimals="4"
      id="F_000525"
      unitRef="U_xbrlipure">0.9511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001796280_20190101_20191231"
      decimals="2"
      id="F_000526"
      unitRef="U_xbrlipure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001796280_20180101_20181231"
      decimals="2"
      id="F_000527"
      unitRef="U_xbrlipure">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20200101_20201231"
      id="F_000528">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000529">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20180101_20181231"
      id="F_000531">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20180101_20181231"
      id="F_000532">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001796280_20201231"
      id="F_000058"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001796280_20191231"
      id="F_000059"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001796280_20201231"
      id="F_000061"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001796280_20191231"
      id="F_000062"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001796280_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001796280_20200101_20201231" id="F_000032">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001796280_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001796280_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001796280_20200101_20201231" id="F_000033">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001796280_20200101_20201231" id="F_000022">001-39269</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001796280_20200101_20201231" id="F_000005">ORIC PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001796280_20200101_20201231" id="F_000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001796280_20200101_20201231" id="F_000024">47-1787157</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001796280_20200101_20201231" id="F_000025">240 E. Grand Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001796280_20200101_20201231" id="F_000026">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001796280_20200101_20201231" id="F_000027">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001796280_20200101_20201231" id="F_000028">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001796280_20200101_20201231" id="F_000029">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001796280_20200101_20201231" id="F_000030">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001796280_20200101_20201231" id="F_000031">388-5600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001796280_20200101_20201231" id="F_000019">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001796280_20200101_20201231" id="F_000020">ORIC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001796280_20200101_20201231" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001796280_20200101_20201231" id="F_000012">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001796280_20200101_20201231" id="F_000008">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001796280_20200101_20201231" id="F_000007">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001796280_20200101_20201231" id="F_000009">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001796280_20200101_20201231" id="F_000011">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001796280_20200101_20201231" id="F_000016">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001796280_20200101_20201231" id="F_000017">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001796280_20200101_20201231" id="F_000018">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001796280_20200101_20201231" id="F_000034">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001796280_20200101_20201231" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001796280_20200630"
      decimals="-5"
      id="F_000013"
      unitRef="U_iso4217USD">743300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001796280_20210228"
      decimals="INF"
      id="F_000014"
      unitRef="U_xbrlishares">36695019</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000265">
&lt;p style="margin-top:2pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the Registrant&#x2019;s Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#x2019;s 2020 fiscal year ended December 31, 2020.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">78446000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">89159000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">215154000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">3097000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">840000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">296697000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">89999000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">1981000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">2241000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">319000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">1853000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">298997000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">94093000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">757000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">152000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">8245000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">5202000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">9002000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">5354000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">219000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">765000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">9221000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">6119000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000073"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000074"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000075"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000076"
      unitRef="U_xbrlishares">20348788</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000077"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000079"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000078"
      unitRef="U_xbrlishares">19278606</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">19278606</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">178058000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">178058000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000083"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000084"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000091"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000092"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000093"
      unitRef="U_xbrlishares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000094"
      unitRef="U_xbrlishares">26750000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">36672415</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">36672415</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">1984222</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">1984222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">456196000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">2606000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">-166393000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">-92690000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">-31000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">289776000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">-90084000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">298997000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">94093000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">35921000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">22844000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">19026000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">24843000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">13422000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">5725000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">3345000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">74186000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">28569000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">22371000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">-74186000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">-28569000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-22371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">306000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">1397000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">775000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">177000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">289000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">233000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">483000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">1686000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">1008000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-73703000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">-26883000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">-21363000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-73734000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-26883000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-21363000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001796280_20200101_20201231"
      decimals="2"
      id="F_000128"
      unitRef="U_iso4217USD_xbrlishares">-3.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001796280_20190101_20191231"
      decimals="2"
      id="F_000129"
      unitRef="U_iso4217USD_xbrlishares">-14.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001796280_20180101_20181231"
      decimals="2"
      id="F_000130"
      unitRef="U_iso4217USD_xbrlishares">-12.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001796280_20200101_20201231"
      decimals="0"
      id="F_000131"
      unitRef="U_xbrlishares">21942476</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001796280_20190101_20191231"
      decimals="0"
      id="F_000132"
      unitRef="U_xbrlishares">1899348</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001796280_20180101_20181231"
      decimals="0"
      id="F_000133"
      unitRef="U_xbrlishares">1734115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231"
      decimals="INF"
      id="F_000134"
      unitRef="U_xbrlishares">10612499</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">69337000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="INF"
      id="F_000136"
      unitRef="U_xbrlishares">1672087</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">833000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">-44444000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_20171231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">-43611000</us-gaap:StockholdersEquity>
    <oric:TemporaryEquityStockIssuanceCosts
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">198000</oric:TemporaryEquityStockIssuanceCosts>
    <oric:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="INF"
      id="F_000140"
      unitRef="U_xbrlishares">3177271</oric:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">37929000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000142"
      unitRef="U_xbrlishares">130047</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">79000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">79000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">469000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">469000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-21363000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-21363000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="INF"
      id="F_000149"
      unitRef="U_xbrlishares">13789770</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">107266000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000151"
      unitRef="U_xbrlishares">1802134</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">1381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-65807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-64426000</us-gaap:StockholdersEquity>
    <oric:TemporaryEquityStockIssuanceCosts
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_oricSeriesCAndDPreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">135000</oric:TemporaryEquityStockIssuanceCosts>
    <oric:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000155"
      unitRef="U_xbrlishares">5488836</oric:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">70792000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000157"
      unitRef="U_xbrlishares">182088</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">131000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">131000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">1094000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">1094000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-26883000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">-26883000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000164"
      unitRef="U_xbrlishares">19278606</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">178058000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000166"
      unitRef="U_xbrlishares">1984222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">2606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">-92690000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-90084000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="INF"
      id="F_000170"
      unitRef="U_xbrlishares">8625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">137999000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">138000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">12790000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">12790000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <oric:TemporaryEquityConversionToCommonStockShares
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231"
      decimals="INF"
      id="F_000176"
      unitRef="U_xbrlishares">19278606</oric:TemporaryEquityConversionToCommonStockShares>
    <oric:TemporaryEquityConversionToCommonStockValue
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">-178058000</oric:TemporaryEquityConversionToCommonStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000178"
      unitRef="U_xbrlishares">19278606</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">178056000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">178058000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231"
      decimals="INF"
      id="F_000182"
      unitRef="U_xbrlishares">5796000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">133307000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">133308000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">8546000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_oricPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">8546000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000188"
      unitRef="U_xbrlishares">871494</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">19843000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">19843000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000191"
      unitRef="U_xbrlishares">117093</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">443000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">443000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">5278000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">5278000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-73703000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-73703000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-31000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-31000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000200"
      unitRef="U_xbrlishares">36672415</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">456196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">-166393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">-31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">289776000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">-73703000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">-26883000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-21363000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">970000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">1028000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">903000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">5278000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">1094000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">469000</us-gaap:ShareBasedCompensation>
    <oric:NonCashStockConsiderationAcquisition
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">19843000</oric:NonCashStockConsiderationAcquisition>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">-8000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">-15000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">-299000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">2258000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">-234000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">297000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">4303000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">986000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">-410000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">-45268000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">-23533000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">-20683000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">667000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">768000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">525000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">225485000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">10000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">193000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">17000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">-215959000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">-768000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">-508000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">138000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <oric:PaymentsOfStockIssuanceCostsWithInitialPublicOffering
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">12691000</oric:PaymentsOfStockIssuanceCostsWithInitialPublicOffering>
    <oric:PaymentsOfStockIssuanceCostsWithInitialPublicOffering
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">99000</oric:PaymentsOfStockIssuanceCostsWithInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">133308000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <oric:PaymentsOfStockIssuanceCostsWithPublicOffering
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">8546000</oric:PaymentsOfStockIssuanceCostsWithPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">70792000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">37929000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">443000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">131000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">79000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">250514000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">70824000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">38008000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">-10713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">46523000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">16817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">89159000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">42636000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001796280_20171231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">25819000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">78446000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">89159000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">42636000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">178058000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">43000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <oric:UnpaidDeferredFinancingCosts
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">1244000</oric:UnpaidDeferredFinancingCosts>
    <us-gaap:NatureOfOperations contextRef="C_0001796280_20200101_20201231" id="F_000266">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. &lt;span style="text-decoration:underline;"&gt;Description of the Business&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ORIC Pharmaceuticals, Inc. (ORIC or the Company) is a clinical-stage biopharmaceutical company dedicated to improving patients&#x2019; lives by &lt;span style="font-style:italic;text-decoration:underline;"&gt;O&lt;/span&gt;&lt;span style="font-style:italic;"&gt;vercoming &lt;/span&gt;&lt;span style="font-style:italic;text-decoration:underline;"&gt;R&lt;/span&gt;&lt;span style="font-style:italic;"&gt;esistance &lt;/span&gt;&lt;span style="font-style:italic;text-decoration:underline;"&gt;I&lt;/span&gt;&lt;span style="font-style:italic;"&gt;n &lt;/span&gt;&lt;span style="font-style:italic;text-decoration:underline;"&gt;C&lt;/span&gt;&lt;span style="font-style:italic;"&gt;ancer&lt;/span&gt;. The Company was incorporated in Delaware in August 2014 and has offices in South San Francisco and San Diego, California. The Company&#x2019;s principal operations are in the United States and the Company operates in one segment.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception, the Company has devoted its primary efforts to raising capital, internal research and development activities and business development efforts and has incurred significant operating losses and negative cash flows from operations. In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi, Inc. development and commercialization rights to a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 insertion mutations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&#160;December 31, 2020, the Company had an accumulated deficit of&#160;$166.4 million. Through December 31, 2020, all of the Company&#x2019;s financial support has been provided by&#160;&#160;proceeds from the issuance of common stock and from the sale of convertible preferred stock.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As the Company continues its expansion, it may seek additional financing and/or strategic investments, however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives. The accompanying financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from &lt;span style="color:#000000;"&gt;the date of the issuance of these financial statements. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Initial Public Offering and Related Transaction&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 28, 2020, the Company completed an initial public offering (IPO) selling 8,625,000 shares of common stock, which included the full exercise by the underwriters of their option to purchase up to 1,125,000 additional shares, at a price of $16.00 per share resulting in gross proceeds of $138.0 million. After deducting underwriting discounts and commissions and other offering expenses related to the IPO of $12.8 million, the net proceeds to the Company from the transaction were $125.2 million. In connection with the IPO, all shares of convertible preferred stock outstanding at the time of the IPO converted into 19,278,606 shares of common stock. On April 21, 2020, the Company amended its certificate of incorporation to effect a one-for-&lt;span style="-sec-ix-hidden:F_000319"&gt;four&lt;/span&gt; reverse stock split of its issued and outstanding common and convertible preferred stock. The accompanying financial statements and related notes give retroactive effect, where applicable, to the reverse stock split. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Secondary Public Offering&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 17, 2020, the Company completed a secondary public offering selling 5,796,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase up to 756,000 additional shares, at a price of $23.00 per share, resulting in gross proceeds of $133.3 million. After deducting underwriting discounts and commissions and other offering expenses related to the secondary public offering of approximately $8.5 million, the net proceeds to the Company from the transaction were $124.8 million.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001796280_20200101_20201231"
      decimals="INF"
      id="F_000309"
      unitRef="U_oricSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001796280_20201231"
      decimals="-5"
      id="F_000310"
      unitRef="U_iso4217USD">-166400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200428_20200428"
      decimals="INF"
      id="F_000311"
      unitRef="U_xbrlishares">8625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200428_20200428"
      decimals="INF"
      id="F_000313"
      unitRef="U_xbrlishares">1125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200428"
      decimals="INF"
      id="F_000312"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428"
      decimals="-5"
      id="F_000314"
      unitRef="U_iso4217USD">138000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <oric:UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428"
      decimals="-5"
      id="F_000315"
      unitRef="U_iso4217USD">12800000</oric:UnderwritingDiscountsCommissionsAndOtherOfferingExpenses>
    <oric:ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428"
      decimals="-5"
      id="F_000316"
      unitRef="U_iso4217USD">125200000</oric:ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428"
      decimals="INF"
      id="F_000317"
      unitRef="U_xbrlishares">19278606</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200428_20200428"
      id="F_000318">one-for-four</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117"
      decimals="INF"
      id="F_000320"
      unitRef="U_xbrlishares">5796000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20201117_20201117"
      decimals="INF"
      id="F_000322"
      unitRef="U_xbrlishares">756000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117"
      decimals="INF"
      id="F_000321"
      unitRef="U_iso4217USD_xbrlishares">23.00</us-gaap:SharePrice>
    <oric:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117"
      decimals="-5"
      id="F_000323"
      unitRef="U_iso4217USD">133300000</oric:ProceedsFromIssuanceOfCommonStockGross>
    <oric:UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117"
      decimals="-5"
      id="F_000324"
      unitRef="U_iso4217USD">8500000</oric:UnderwritingDiscountsCommissionsAndOtherOfferingExpenses>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001796280_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_oricSecondaryPublicOfferingMember_20201117_20201117"
      decimals="-5"
      id="F_000325"
      unitRef="U_iso4217USD">124800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000267">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. &lt;span style="text-decoration:underline;"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accompanying financial statements include all known adjustments necessary for a fair presentation of the results as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the year ended December 31, 2020 are not necessarily indicative of future results, particularly in light of the novel coronavirus (COVID-19) and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended operating activities. Beginning the week of March 16, 2020, &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the majority of the Company&#x2019;s workforce began working from home. Disruptions caused by the COVID-19 pandemic, including&lt;/span&gt;&lt;span style="color:#0000FF;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the effects of the stay-at-home orders and work-from-home policies, have impacted productivity, have resulted in increased operational expenses, certain adjustments to the operations of the Company&#x2019;s clinical trials, the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;temporary &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;suspension of enrollment of new patients at certain of the Company&#x2019;s clinical trial sites, and delays in certain supply chain activities and collecting and analyzing data from &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;patients&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; in the Company&#x2019;s clinical trials, and may further disrupt the business and delay the development programs and regulatory timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company&#x2019;s ability to conduct business in the ordinary course. As a result, research and development expenses and general and administrative expenses may vary significantly if there is an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of the clinical trials and other related business activities. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the third quarter of 2020, the Company began reporting deferred offering costs within other assets on its balance sheets. To conform to current presentation, the Company included $1.3 million of deferred financing costs at December 31, 2019 in other assets. This reclassification had no effect on the Company&#x2019;s total assets, net loss or stockholders&#x2019; equity (deficit) as previously reported.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&#x2019;s financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. &lt;span style="color:#000000;"&gt;These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheets. The Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits its exposure.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of cash, cash equivalents and short-term investments, prepaid expenses, accounts payable and accrued liabilities are reasonable estimates of their fair value because of the short nature of these items. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of 90 days or less at the time of purchase that are readily convertible into cash as cash equivalents. These investments may include money market funds, securities issued by U.S. Government agencies, corporate debt securities and commercial paper. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined &lt;/span&gt;based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities 12 months or greater at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). &lt;span style="color:#000000;"&gt;The Company reviews its &lt;/span&gt;portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss).&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, which consist of lab equipment, leasehold improvements, computer hardware and software, and furniture and fixtures, are stated at historical cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets, which are generally three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimate useful life of the asset.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did not recognize impairment losses for the years ended December&#160;31, 2020, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Rent&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the office facilities over the terms of the leases. The Company&#x2019;s leased office facilities provide for fixed increases in minimum annual rent payments. The total amount of rent payments due over the lease term are being charged to rent expense ratably over the life of the leases.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses and Accrued Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (CRO), and contract manufacturing organizations (CMO) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company&#x2019;s discovery and preclinical activities, process development, clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company allocates external costs by program, clinical or preclinical. Internal costs consist primary of employee-related costs, laboratory supplies, facilities, depreciation and costs related to compliance with regulatory requirements. The Company does not allocate internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company makes estimates of accrued expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in its accrued research and development expenses include the costs incurred for services performed by vendors in connection with research and development activities for which the Company has not yet been invoiced.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 2019, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#x201c;more likely than not&#x201d; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes would result in a change in the estimated annual effective tax rate.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and&#160;non-employee&#160;stock option grants, estimated in accordance with the applicable accounting guidance, recognized on a ratable straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes forfeitures as they occur.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of stock options is estimated using a Black-Scholes Merton valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, a risk-free interest rate, expected volatility of the Company&#x2019;s common stock, expected term of the option before exercise and expected dividend yield. Options granted have a maximum contractual term of ten years. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;License Fees&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Acquisitions of&#160;technology licenses are charged to acquired in-process research and development expense or capitalized based upon the asset achieving technological feasibility in accordance with management&#x2019;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Offering Costs &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from&#160;non-owner&#160;sources, including unrealized gains and losses on investments and foreign currency gains and losses. The unrealized losses on available for sale investments represent the only component of other comprehensive loss that is excluded from the reported net loss.&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(73,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares outstanding used in computing&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,942,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,899,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,734,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14.15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,996,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,683,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,854,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,278,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,789,770&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,996,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,962,047&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,644,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) under its accounting standard codifications (ASC) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In December 2019, the FASB issued ASU No 2019-12&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. For emerging growth companies (EGCs), the standard is effective for fiscal years beginning after December 15, 2021. The Company early adopted the new standard in 2020 and the adoption of the standard did not have a material impact on the Company&#x2019;s current financial position, results of operations or financial statement disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No.&#160;2016-02,&#160;&lt;span style="font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&#160;(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. ASC 842 provides a lessee with an option to not account for leases with a term of 12 month or less as leases in the scope of the new standard. ASC 842 supersedes the previous leases standard, ASC 840 Leases. For public business entities, this ASU is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, and should be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. As amended by ASU No. 2020-05, for all other entities, this ASU is effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act, ASU No.&#160;2016-02 is effective for the Company for the year ended December&#160;31, 2022, and all interim periods within. In July 2018, the FASB issued supplemental adoption guidance and clarification to ASC 842 within ASU No.&#160;2018-10,&#160;&lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&#160;and ASU No.&#160;2018-11,&#160;&lt;span style="font-style:italic;"&gt;Leases (Topic&#160;842): Targeted Improvements&lt;/span&gt;. ASU No.&#160;2018-11 provides another transition method in addition to the existing modified retrospective transition method by allowing entities to initially apply the new leasing standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company is currently evaluating the impact the adoption of these ASUs will have on financial statements and related disclosures. The Company expects to recognize a right-of-use asset and corresponding lease liability on its balance sheets for its real estate operating leases upon adoption. See Note 11 for more information related to the Company&#x2019;s lease obligations, which are presented on an undiscounted basis therein. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&lt;span style="color:#000000;"&gt; 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="color:#000000;"&gt; (&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Topic 326&lt;/span&gt;&lt;span style="color:#000000;"&gt;) (ASC 326): &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;"&gt;, which introduced the expected credit losses methodology for the &lt;/span&gt;measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments&#x2014;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments&#x2014; Credit Losses&#x2014;Available-for-Sale Debt Securities. The guidance is effective for public business entities for annual periods beginning after December 15, 2019, including interim periods within those years. For all other entities, the standard is effective for annual periods beginning after December 15, 2022 and interim periods, therein. Early adoption is permitted. Since the Company has elected to use the extended transition period under the JOBS Act available to EGCs, the ASU is effective for the Company for fiscal years beginning after December&#160;15, 2022. The Company expects to adopt the new standard in the first quarter of 2021, using the modified retrospective approach. The Company currently does not expect the adoption to have a material impact on its financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000278">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accompanying financial statements include all known adjustments necessary for a fair presentation of the results as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the year ended December 31, 2020 are not necessarily indicative of future results, particularly in light of the novel coronavirus (COVID-19) and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended operating activities. Beginning the week of March 16, 2020, &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the majority of the Company&#x2019;s workforce began working from home. Disruptions caused by the COVID-19 pandemic, including&lt;/span&gt;&lt;span style="color:#0000FF;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the effects of the stay-at-home orders and work-from-home policies, have impacted productivity, have resulted in increased operational expenses, certain adjustments to the operations of the Company&#x2019;s clinical trials, the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;temporary &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;suspension of enrollment of new patients at certain of the Company&#x2019;s clinical trial sites, and delays in certain supply chain activities and collecting and analyzing data from &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;patients&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; in the Company&#x2019;s clinical trials, and may further disrupt the business and delay the development programs and regulatory timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company&#x2019;s ability to conduct business in the ordinary course. As a result, research and development expenses and general and administrative expenses may vary significantly if there is an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of the clinical trials and other related business activities. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the third quarter of 2020, the Company began reporting deferred offering costs within other assets on its balance sheets. To conform to current presentation, the Company included $1.3 million of deferred financing costs at December 31, 2019 in other assets. This reclassification had no effect on the Company&#x2019;s total assets, net loss or stockholders&#x2019; equity (deficit) as previously reported.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:DeferredCosts
      contextRef="C_0001796280_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20191231"
      decimals="-5"
      id="F_000326"
      unitRef="U_iso4217USD">1300000</us-gaap:DeferredCosts>
    <us-gaap:UseOfEstimates contextRef="C_0001796280_20200101_20201231" id="F_000279">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&#x2019;s financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. &lt;span style="color:#000000;"&gt;These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001796280_20200101_20201231" id="F_000280">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheets. The Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits its exposure.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001796280_20200101_20201231" id="F_000281">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of cash, cash equivalents and short-term investments, prepaid expenses, accounts payable and accrued liabilities are reasonable estimates of their fair value because of the short nature of these items. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000282">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of 90 days or less at the time of purchase that are readily convertible into cash as cash equivalents. These investments may include money market funds, securities issued by U.S. Government agencies, corporate debt securities and commercial paper. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <oric:LiquidInvestmentsMaturityPeriod contextRef="C_0001796280_20200101_20201231" id="F_000327">P90D</oric:LiquidInvestmentsMaturityPeriod>
    <us-gaap:InvestmentPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000283">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined &lt;/span&gt;based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities 12 months or greater at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). &lt;span style="color:#000000;"&gt;The Company reviews its &lt;/span&gt;portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss).&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000284">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, which consist of lab equipment, leasehold improvements, computer hardware and software, and furniture and fixtures, are stated at historical cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets, which are generally three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimate useful life of the asset.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000329">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000285">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did not recognize impairment losses for the years ended December&#160;31, 2020, 2019 and 2018.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <oric:PropertyPlantAndEquipmentImpairmentLoss
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000330"
      unitRef="U_iso4217USD">0</oric:PropertyPlantAndEquipmentImpairmentLoss>
    <oric:PropertyPlantAndEquipmentImpairmentLoss
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000331"
      unitRef="U_iso4217USD">0</oric:PropertyPlantAndEquipmentImpairmentLoss>
    <oric:PropertyPlantAndEquipmentImpairmentLoss
      contextRef="C_0001796280_20181231"
      decimals="INF"
      id="F_000332"
      unitRef="U_iso4217USD">0</oric:PropertyPlantAndEquipmentImpairmentLoss>
    <oric:DeferredRentPolicyPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000286">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Rent&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the office facilities over the terms of the leases. The Company&#x2019;s leased office facilities provide for fixed increases in minimum annual rent payments. The total amount of rent payments due over the lease term are being charged to rent expense ratably over the life of the leases.&lt;/p&gt;</oric:DeferredRentPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001796280_20200101_20201231" id="F_000287">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses and Accrued Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (CRO), and contract manufacturing organizations (CMO) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company&#x2019;s discovery and preclinical activities, process development, clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company allocates external costs by program, clinical or preclinical. Internal costs consist primary of employee-related costs, laboratory supplies, facilities, depreciation and costs related to compliance with regulatory requirements. The Company does not allocate internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company makes estimates of accrued expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in its accrued research and development expenses include the costs incurred for services performed by vendors in connection with research and development activities for which the Company has not yet been invoiced.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000288">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 2019, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#x201c;more likely than not&#x201d; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes would result in a change in the estimated annual effective tax rate.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001796280_20200101_20201231" id="F_000289">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and&#160;non-employee&#160;stock option grants, estimated in accordance with the applicable accounting guidance, recognized on a ratable straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes forfeitures as they occur.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of stock options is estimated using a Black-Scholes Merton valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, a risk-free interest rate, expected volatility of the Company&#x2019;s common stock, expected term of the option before exercise and expected dividend yield. Options granted have a maximum contractual term of ten years. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1 contextRef="C_0001796280_20200101_20201231" id="F_000333">P10Y</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1>
    <oric:LicenseFeesPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000290">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;License Fees&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Acquisitions of&#160;technology licenses are charged to acquired in-process research and development expense or capitalized based upon the asset achieving technological feasibility in accordance with management&#x2019;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.&lt;/span&gt;&lt;/p&gt;</oric:LicenseFeesPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000291">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Offering Costs &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. &lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000292">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from&#160;non-owner&#160;sources, including unrealized gains and losses on investments and foreign currency gains and losses. The unrealized losses on available for sale investments represent the only component of other comprehensive loss that is excluded from the reported net loss.&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000293">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(73,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares outstanding used in computing&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,942,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,899,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,734,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14.15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,996,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,683,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,854,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,278,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,789,770&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,996,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,962,047&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,644,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000296">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(73,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares outstanding used in computing&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,942,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,899,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,734,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14.15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">-73703000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">-26883000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">-21363000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001796280_20200101_20201231"
      decimals="0"
      id="F_000337"
      unitRef="U_xbrlishares">21942476</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001796280_20190101_20191231"
      decimals="0"
      id="F_000338"
      unitRef="U_xbrlishares">1899348</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001796280_20180101_20181231"
      decimals="0"
      id="F_000339"
      unitRef="U_xbrlishares">1734115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001796280_20200101_20201231"
      decimals="2"
      id="F_000340"
      unitRef="U_iso4217USD_xbrlishares">-3.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001796280_20190101_20191231"
      decimals="2"
      id="F_000341"
      unitRef="U_iso4217USD_xbrlishares">-14.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001796280_20180101_20181231"
      decimals="2"
      id="F_000342"
      unitRef="U_iso4217USD_xbrlishares">-12.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000297">
&lt;p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,996,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,683,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,854,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,278,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,789,770&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,996,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,962,047&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,644,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000343"
      unitRef="U_xbrlishares">3996174</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000344"
      unitRef="U_xbrlishares">2683441</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001796280_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_oricOptionsToPurchaseCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000345"
      unitRef="U_xbrlishares">1854886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000346"
      unitRef="U_xbrlishares">19278606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="INF"
      id="F_000347"
      unitRef="U_xbrlishares">13789770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001796280_20200101_20201231"
      decimals="INF"
      id="F_000348"
      unitRef="U_xbrlishares">3996174</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001796280_20190101_20191231"
      decimals="INF"
      id="F_000349"
      unitRef="U_xbrlishares">21962047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001796280_20180101_20181231"
      decimals="INF"
      id="F_000350"
      unitRef="U_xbrlishares">15644656</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000294">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) under its accounting standard codifications (ASC) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In December 2019, the FASB issued ASU No 2019-12&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. For emerging growth companies (EGCs), the standard is effective for fiscal years beginning after December 15, 2021. The Company early adopted the new standard in 2020 and the adoption of the standard did not have a material impact on the Company&#x2019;s current financial position, results of operations or financial statement disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <oric:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000295">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No.&#160;2016-02,&#160;&lt;span style="font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&#160;(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. ASC 842 provides a lessee with an option to not account for leases with a term of 12 month or less as leases in the scope of the new standard. ASC 842 supersedes the previous leases standard, ASC 840 Leases. For public business entities, this ASU is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, and should be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. As amended by ASU No. 2020-05, for all other entities, this ASU is effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act, ASU No.&#160;2016-02 is effective for the Company for the year ended December&#160;31, 2022, and all interim periods within. In July 2018, the FASB issued supplemental adoption guidance and clarification to ASC 842 within ASU No.&#160;2018-10,&#160;&lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&#160;and ASU No.&#160;2018-11,&#160;&lt;span style="font-style:italic;"&gt;Leases (Topic&#160;842): Targeted Improvements&lt;/span&gt;. ASU No.&#160;2018-11 provides another transition method in addition to the existing modified retrospective transition method by allowing entities to initially apply the new leasing standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company is currently evaluating the impact the adoption of these ASUs will have on financial statements and related disclosures. The Company expects to recognize a right-of-use asset and corresponding lease liability on its balance sheets for its real estate operating leases upon adoption. See Note 11 for more information related to the Company&#x2019;s lease obligations, which are presented on an undiscounted basis therein. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&lt;span style="color:#000000;"&gt; 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="color:#000000;"&gt; (&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Topic 326&lt;/span&gt;&lt;span style="color:#000000;"&gt;) (ASC 326): &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;"&gt;, which introduced the expected credit losses methodology for the &lt;/span&gt;measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments&#x2014;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments&#x2014; Credit Losses&#x2014;Available-for-Sale Debt Securities. The guidance is effective for public business entities for annual periods beginning after December 15, 2019, including interim periods within those years. For all other entities, the standard is effective for annual periods beginning after December 15, 2022 and interim periods, therein. Early adoption is permitted. Since the Company has elected to use the extended transition period under the JOBS Act available to EGCs, the ASU is effective for the Company for fiscal years beginning after December&#160;15, 2022. The Company expects to adopt the new standard in the first quarter of 2021, using the modified retrospective approach. The Company currently does not expect the adoption to have a material impact on its financial statements.&lt;/p&gt;</oric:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <oric:LicenseAgreementsDisclosureTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000268">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. &lt;span style="text-decoration:underline;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Mirati License Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On&#160;August 3, 2020, the Company entered into&#160;a license agreement (Mirati License Agreement) with Mirati Therapeutics, Inc (Mirati). Under the Mirati License Agreement, Mirati granted the Company a worldwide, exclusive, sublicensable, royalty-free license under Mirati&#x2019;s rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2 and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compounds. Under the Mirati License Agreement, the Company is wholly responsible for development and commercialization of licensed products. In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least one licensed product in certain major markets. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless earlier terminated, the Mirati License Agreement will continue in effect on a country-by-country and licensed product-by-licensed product basis until the later of (a) the expiration of the last valid claim of a licensed patent covering such licensed product in such country or (b) ten years after the first commercial sale of such licensed product in such country. Following the expiration of the Mirati License Agreement, the Company will retain its licenses under the intellectual property Mirati licensed to it on a royalty-free basis. ORIC and Mirati may each terminate the Mirati License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Mirati may terminate the agreement if the Company challenges any of the patent rights licensed to the Company by Mirati or it discontinues development of licensed products for a specified period of time. The Company also has the right to terminate the Mirati License Agreement without cause by providing prior notice to Mirati.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial obligation under the Mirati License Agreement was comprised of an upfront payment of 588,235 shares of ORIC common stock, valued at approximately $13.0 million based upon the closing price of the Company&#x2019;s common stock on the acquisition date. The number of shares issued was based on a price of $34.00 per share, representing a premium of 10% to the 60-day trailing volume-weighted average trading price of the Company&#x2019;s common stock. The shares were issued in a private placement in reliance on Section&#160;4(a)(2) of the &lt;span style="Background-color:#FFFFFF;"&gt;Securities Act of 1933, as amended,&lt;/span&gt; for transactions by an issuer not involving any public offering. During the &lt;span style="-sec-ix-hidden:F_000359"&gt;eighteen-month&lt;/span&gt; period following the date of the agreement, Mirati is subject to certain transfer restrictions, and the parties agreed to negotiate and enter into a registration rights agreement, with respect to the shares. The Company is not obligated to pay Mirati milestones or royalties. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded the transaction as an asset purchase as management concluded that all of the value received was related to a single identifiable asset. Further, as the asset was in early development at the time the license was acquired, the Company concluded that there was no alternative future use for the asset and recorded a charge at the closing of the transaction for the full $13.0 million value assigned to the shares issued in connection with Mirati License Agreement.&#160;&#160;This non-cash charge was recorded as acquired in-process research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2020.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Voronoi License Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 19, 2020, the Company entered into a license agreement (Voronoi License Agreement) with Voronoi Inc. (Voronoi). The Voronoi License Agreement gives&lt;span style="color:#000000;"&gt; the Company access to Voronoi&#x2019;s preclinical stage EGFR and HER2 exon 20 insertion mutation program, including a lead product candidate now designated as ORIC-114. Under the Voronoi License Agreement, Voronoi granted the Company an exclusive, sublicensable license under Voronoi&#x2019;s rights to certain patent applications directed to certain small molecule compounds that bind to EGFR and HER2 with one or more exon 20 insertion mutations and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compound worldwide (other than in the People&#x2019;s Republic of China, Hong Kong, Macau and Taiwan) (the ORIC Territory). Under the Voronoi License Agreement, the Company is wholly responsible for development and commercialization of licensed products in the ORIC Territory. In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least&#160;one&#160;licensed product in certain major markets in the ORIC Territory.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial obligations under the Voronoi License Agreement included an upfront payment comprised of a $5.0 million cash payment and the issuance to Voronoi of&#160;283,259&#160;shares of the Company&#x2019;s common stock, valued at approximately $6.8 million, issued pursuant to a stock issuance agreement (Stock Agreement) entered into between the parties on October 19, 2020. The number of shares issued pursuant to the Stock Agreement was based on a price of $28.24&#160;per share, representing a premium of&#160;25% to the 30-day trailing volume weighted average trading price of the Company&#x2019;s common stock. The shares were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also obligated to make milestone payments to Voronoi upon the achievement of certain events. Upon the achievement of certain development and regulatory milestones with respect to the first licensed product, the Company is obligated to pay Voronoi up to a maximum of $111.0&#160;million. Upon the achievement of certain commercial milestones with respect to the first licensed product, the Company is obligated to pay Voronoi up to a maximum of $225.0&#160;million. If the Company pursues a second licensed product, the Company would pay Voronoi up to an additional $272.0&#160;million in success-based milestones. In addition, the Company is obligated to pay royalties on net sales of licensed products in the ORIC Territory.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless earlier terminated, the Voronoi License Agreement will continue in effect until the expiration of all royalty payment obligations. Following the expiration of the Voronoi License Agreement, the Company will retain its licenses under the intellectual property Voronoi licensed to it on a royalty-free basis. The Company and Voronoi may each terminate the Voronoi License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Voronoi may also terminate the agreement if the Company discontinues development of licensed products for a specified period of time. The Company also has the right to terminate the Voronoi License Agreement without cause by providing prior notice to Voronoi.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If Voronoi terminates the Voronoi License Agreement for cause, or if the Company terminates the Voronoi License Agreement without cause, then the Company is obligated to grant a nonexclusive license to Voronoi under certain of the Company&#x2019;s patents and know-how and to assign to Voronoi certain of its regulatory filings for licensed compounds and licensed products.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded the transaction as an asset purchase as management concluded that all of the value received was related to a specific identifiable asset related to EGFR and HER2. Further, as the asset was in early development at the time the license was acquired, the Company concluded that there was no alternative future use for the asset and recorded a charge of $11.8 million at the closing of the transaction which consisted of the $5.0 million cash payment plus the $6.8 million value assigned to the shares issued in connection with Voronoi License Agreement. This charge was recorded as acquired in-process research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2020. The charge was also reflected within cash flows from operating activities, with the $5.0 million cash payment included in net loss and the $6.8 million associated with the shares issued as an adjustment to reconcile net loss to net cash used in operating activities. &lt;/p&gt;</oric:LicenseAgreementsDisclosureTextBlock>
    <oric:NumberOfLicensedProductsObligedToDevelopAndCommercialize
      contextRef="C_0001796280_20200803"
      decimals="INF"
      id="F_000353"
      unitRef="U_oricProduct">1</oric:NumberOfLicensedProductsObligedToDevelopAndCommercialize>
    <oric:NumberOfPeriodAgreementInEffect
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_20200803_20200803"
      id="F_000354">P10Y</oric:NumberOfPeriodAgreementInEffect>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803"
      decimals="INF"
      id="F_000355"
      unitRef="U_xbrlishares">588235</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803"
      decimals="-5"
      id="F_000356"
      unitRef="U_iso4217USD">13000000.0</us-gaap:CommonStockValue>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803"
      decimals="INF"
      id="F_000357"
      unitRef="U_iso4217USD_xbrlishares">34.00</us-gaap:SharesIssuedPricePerShare>
    <oric:SharesIssuedPercentageOfPremium
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803_20200803"
      decimals="2"
      id="F_000358"
      unitRef="U_xbrlipure">0.10</oric:SharesIssuedPercentageOfPremium>
    <us-gaap:CommonStockValue
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricMiratiTherapeuticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200803"
      decimals="-5"
      id="F_000360"
      unitRef="U_iso4217USD">13000000.0</us-gaap:CommonStockValue>
    <oric:NumberOfLicensedProductsObligedToDevelopAndCommercialize
      contextRef="C_0001796280_20201019"
      decimals="INF"
      id="F_000361"
      unitRef="U_oricProduct">1</oric:NumberOfLicensedProductsObligedToDevelopAndCommercialize>
    <oric:UpfrontCashPayment
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019"
      decimals="-5"
      id="F_000362"
      unitRef="U_iso4217USD">5000000.0</oric:UpfrontCashPayment>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019"
      decimals="INF"
      id="F_000363"
      unitRef="U_xbrlishares">283259</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019"
      decimals="-5"
      id="F_000364"
      unitRef="U_iso4217USD">6800000</us-gaap:CommonStockValue>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019"
      decimals="INF"
      id="F_000365"
      unitRef="U_iso4217USD_xbrlishares">28.24</us-gaap:SharesIssuedPricePerShare>
    <oric:SharesIssuedPercentageOfPremium
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019"
      decimals="2"
      id="F_000366"
      unitRef="U_xbrlipure">0.25</oric:SharesIssuedPercentageOfPremium>
    <oric:LicenseAgreementMaximumMilestonePaymentObligationToPay
      contextRef="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricDevelopmentAndRegulatoryMilestoneMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019"
      decimals="INF"
      id="F_000367"
      unitRef="U_iso4217USD">111000000.0</oric:LicenseAgreementMaximumMilestonePaymentObligationToPay>
    <oric:LicenseAgreementMaximumMilestonePaymentObligationToPay
      contextRef="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricCommercialMilestoneMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019"
      decimals="INF"
      id="F_000368"
      unitRef="U_iso4217USD">225000000.0</oric:LicenseAgreementMaximumMilestonePaymentObligationToPay>
    <oric:LicenseAgreementAdditionalMilestonePayment
      contextRef="C_0001796280_us-gaapContingentConsiderationByTypeAxis_oricSuccessBasedMilestonesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_20201019"
      decimals="-5"
      id="F_000369"
      unitRef="U_iso4217USD">272000000.0</oric:LicenseAgreementAdditionalMilestonePayment>
    <oric:LicenseAgreementChargeRelatedToAcquiredAssets
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019"
      decimals="-5"
      id="F_000370"
      unitRef="U_iso4217USD">11800000</oric:LicenseAgreementChargeRelatedToAcquiredAssets>
    <oric:LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge
      contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_oricAcquiredInProcessResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019"
      decimals="-5"
      id="F_000371"
      unitRef="U_iso4217USD">5000000.0</oric:LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge>
    <oric:LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge
      contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_oricAcquiredInProcessResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019"
      decimals="-5"
      id="F_000372"
      unitRef="U_iso4217USD">6800000</oric:LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge>
    <oric:LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019"
      decimals="-5"
      id="F_000373"
      unitRef="U_iso4217USD">5000000.0</oric:LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge>
    <oric:LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge
      contextRef="C_0001796280_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_oricVoronoiIncMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201019_20201019"
      decimals="-5"
      id="F_000374"
      unitRef="U_iso4217USD">6800000</oric:LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000269">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. &lt;span style="text-decoration:underline;"&gt;Property and Equipment, net&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,748&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,466&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,485&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,515&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,981&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,241&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense for the years ended December 31, 2020 and 2019 was $1.0 million for both years and $0.9 million for the year ended December 31, 2018.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000298">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,748&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,466&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,485&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,515&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,981&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,241&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricLabEquipmentMember_20201231"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">4396000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricLabEquipmentMember_20191231"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">3748000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">1710000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">1710000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricComputerHardwareAndSoftwareMember_20201231"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">220000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_oricComputerHardwareAndSoftwareMember_20191231"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">158000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">140000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">140000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">6466000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">5756000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">4485000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">3515000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">1981000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000388"
      unitRef="U_iso4217USD">2241000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001796280_20200101_20201231"
      decimals="-5"
      id="F_000389"
      unitRef="U_iso4217USD">1000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001796280_20190101_20191231"
      decimals="-5"
      id="F_000390"
      unitRef="U_iso4217USD">1000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001796280_20180101_20181231"
      decimals="-5"
      id="F_000391"
      unitRef="U_iso4217USD">900000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000270">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. &lt;span style="text-decoration:underline;"&gt;Accrued Liabilities &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical and manufacturing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,072&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;963&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent - short-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued deferred financing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,202&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000299">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical and manufacturing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,072&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;963&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent - short-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued deferred financing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,202&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">3723000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">1883000</us-gaap:AccruedSalariesCurrent>
    <oric:AccruedClinicalAndManufacturingCosts
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">3072000</oric:AccruedClinicalAndManufacturingCosts>
    <oric:AccruedClinicalAndManufacturingCosts
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">963000</oric:AccruedClinicalAndManufacturingCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">904000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">617000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">546000</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">495000</us-gaap:AccruedRentCurrent>
    <oric:AccruedDeferredFinancingCostsCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">1244000</oric:AccruedDeferredFinancingCostsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">8245000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">5202000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000271">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. &lt;span style="text-decoration:underline;"&gt;Short-Term Investments&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s &lt;span style="color:#000000;"&gt;investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity.&#160;In accordance with the Company&#x2019;s investment policy, it has &lt;/span&gt;invested funds in available-for-sale securities as of December 31, 2020. The Company had no investments at December 31, 2019. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="color:#000000;"&gt; cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale investments by types and classes of security&#160;at&#160;December&#160;31, 2020&#160;consisted of the following&lt;/span&gt; (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. At December 31, 2020, there were 18 securities in unrealized loss positions. These securities have not been in a continuous loss position for more than 12 months. Further, the Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;None of the Company&#x2019;s available-for-sale investments had maturities of greater than 12 months at December 31, 2020. The Company has determined that there were no material declines in fair value of its investments due to credit-related factors as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000403"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000300">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="color:#000000;"&gt; cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale investments by types and classes of security&#160;at&#160;December&#160;31, 2020&#160;consisted of the following&lt;/span&gt; (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001796280_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">215185000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001796280_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001796280_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">215154000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">215185000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">215154000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000410"
      unitRef="U_oricSecurity">18</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000272">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. &lt;span style="text-decoration:underline;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows: &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Observable inputs such as quoted prices in active markets; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s interest receivable, included in prepaid expenses and other current assets, accounts payable and accrued liabilities are generally considered to be representative of&#160;their&#160;fair value because of the short-term nature of these instruments. The Company&#x2019;s investments, which may include money market funds and available-for-sale investment securities consisting of U.S. treasury securities, and high-quality, marketable debt instruments of corporations and government &lt;span style="color:#000000;"&gt;sponsored enterprises, are measured at fair value in&#160;accordance with the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Following are the major categories of assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurement at End of Period Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted Market&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;At December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;span style="text-decoration:line-through;"&gt; &lt;/span&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;293,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;293,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;293,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;At December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in cash and cash equivalents in accompanying balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No &lt;span style="color:#000000;"&gt;transfers&lt;/span&gt; &lt;span style="color:#000000;"&gt;between&lt;/span&gt; levels occurred during&#160;either of the reporting&#160;periods presented.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000301">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Following are the major categories of assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurement at End of Period Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted Market&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;At December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;span style="text-decoration:line-through;"&gt; &lt;/span&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;293,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;293,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;293,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;At December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Included in cash and cash equivalents in accompanying balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">78446000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">78446000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">78446000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">215154000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">215154000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">215154000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">293600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">293600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">293600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">88159000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">88159000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001796280_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">88159000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000423"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000425"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <oric:FairValueAssetsLevel2ToLevel3TransfersAmount
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000427"
      unitRef="U_iso4217USD">0</oric:FairValueAssetsLevel2ToLevel3TransfersAmount>
    <oric:FairValueAssetsLevel3ToLevel2TransfersAmount
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000429"
      unitRef="U_iso4217USD">0</oric:FairValueAssetsLevel3ToLevel2TransfersAmount>
    <oric:FairValueAssetsLevel1ToLevel3TransfersAmount
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000431"
      unitRef="U_iso4217USD">0</oric:FairValueAssetsLevel1ToLevel3TransfersAmount>
    <oric:FairValueAssetsLevel3ToLevel1TransfersAmount
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000433"
      unitRef="U_iso4217USD">0</oric:FairValueAssetsLevel3ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000424"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000426"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <oric:FairValueAssetsLevel2ToLevel3TransfersAmount
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000428"
      unitRef="U_iso4217USD">0</oric:FairValueAssetsLevel2ToLevel3TransfersAmount>
    <oric:FairValueAssetsLevel3ToLevel2TransfersAmount
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000430"
      unitRef="U_iso4217USD">0</oric:FairValueAssetsLevel3ToLevel2TransfersAmount>
    <oric:FairValueAssetsLevel1ToLevel3TransfersAmount
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000432"
      unitRef="U_iso4217USD">0</oric:FairValueAssetsLevel1ToLevel3TransfersAmount>
    <oric:FairValueAssetsLevel3ToLevel1TransfersAmount
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000434"
      unitRef="U_iso4217USD">0</oric:FairValueAssetsLevel3ToLevel1TransfersAmount>
    <oric:ConvertiblePreferredStockDisclosureTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000273">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. &lt;span style="text-decoration:underline;color:#000000;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to its conversion to common stock in connection with the Company&#x2019;s IPO in April 2020, the Company&#x2019;s convertible preferred stock was classified as temporary equity on the Company&#x2019;s balance sheets in accordance with authoritative guidance. Convertible preferred stock authorized and issued and its principal terms as of December 31, 2019 consisted of the following (in thousands, except share and per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="20" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issue Period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Annual Rate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,862,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,862,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 - 2015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,750,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,749,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015 - 2016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,448,788&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,448,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018 - 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series D&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,287,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,217,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,669&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,348,788&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,278,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&#x2019;s IPO in April 2020, all outstanding shares of the convertible preferred stock converted into 19,278,606 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There were no shares of convertible preferred stock outstanding as of the closing of the IPO.&lt;/p&gt;</oric:ConvertiblePreferredStockDisclosureTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000302">Convertible preferred stock authorized and issued and its principal terms as of December 31, 2019 consisted of the following (in thousands, except share and per share amounts):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="20" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issue Period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Annual Rate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,862,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,862,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 - 2015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,750,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,749,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015 - 2016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,448,788&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,448,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018 - 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series D&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,287,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,217,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,669&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,348,788&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,278,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000435"
      unitRef="U_xbrlishares">3862500</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000440"
      unitRef="U_xbrlishares">3862500</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000457"
      unitRef="U_iso4217USD_xbrlishares">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231"
      decimals="2"
      id="F_000461"
      unitRef="U_iso4217USD_xbrlishares">0.32</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">15450000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000436"
      unitRef="U_xbrlishares">6750000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000441"
      unitRef="U_xbrlishares">6749999</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000458"
      unitRef="U_iso4217USD_xbrlishares">8.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231"
      decimals="2"
      id="F_000462"
      unitRef="U_iso4217USD_xbrlishares">0.64</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">54000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000437"
      unitRef="U_xbrlishares">4448788</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000442"
      unitRef="U_xbrlishares">4448780</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000459"
      unitRef="U_iso4217USD_xbrlishares">12.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231"
      decimals="2"
      id="F_000463"
      unitRef="U_iso4217USD_xbrlishares">0.96</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">53385000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231"
      decimals="INF"
      id="F_000438"
      unitRef="U_xbrlishares">5287500</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231"
      decimals="INF"
      id="F_000443"
      unitRef="U_xbrlishares">4217327</us-gaap:TemporaryEquitySharesIssued>
    <oric:TemporaryEquityIssuedPeriod
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20190101_20191231"
      id="F_000450">2019</oric:TemporaryEquityIssuedPeriod>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231"
      decimals="INF"
      id="F_000460"
      unitRef="U_iso4217USD_xbrlishares">13.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20190101_20191231"
      decimals="3"
      id="F_000464"
      unitRef="U_iso4217USD_xbrlishares">1.056</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">55669000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000439"
      unitRef="U_xbrlishares">20348788</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000444"
      unitRef="U_xbrlishares">19278606</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0001796280_20200430"
      decimals="INF"
      id="F_000469"
      unitRef="U_xbrlishares">19278606</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001796280_20200430"
      decimals="INF"
      id="F_000470"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000274">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. &lt;span style="text-decoration:underline;"&gt;Equity Incentive Plans and Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Equity Incentive Plans&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company&#x2019;s Board of Directors adopted, and its stockholders approved, the 2020 Equity Incentive Plan (the 2020 Plan), which became effective in April 2020 in connection with the Company&#x2019;s IPO. Upon adoption of the 2020 Plan, the Company restricted the grant of future equity awards under its 2014 Equity Incentive Plan, as amended and restated (the 2014 Plan).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2020 Plan provides for the grants of stock options and other equity-based awards to employees, non-employee directors, and consultants of the Company. A total of&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;2,656,500 shares of the Company&#x2019;s common stock were initially reserved for issuance pursuant to the 2020 Plan. The number of shares reserved under the 2020 Plan also included&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;241,653 shares of the Company&#x2019;s common stock that remained available for issuance under the 2014 Plan as of immediately prior to the effectiveness of the 2020 Plan. The 2020 Plan share reserve will be increased by the number of shares under the 2014 Plan that are repurchased, forfeited, expired or cancelled after the effective date of the 2020 Plan up to the limit under the 2020 Plan. In addition, the number of shares of the Company&#x2019;s common stock available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year, beginning with the Company&#x2019;s 2021 fiscal year, in an amount equal to the lessor of (1) 2,656,500 shares, (2) 5% of the outstanding shares of the Company&#x2019;s common stock on the last day of the immediately preceding fiscal year, or (3) such other amount as determined by the Company&#x2019;s Board of Directors.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options granted under the 2020 Plan and the 2014 Plan become exercisable at various dates as determined by the Company&#x2019;s Board of Directors or its authorized committee and will expire no more than ten years from their date of grant. Stock options generally vest over a &lt;span style="-sec-ix-hidden:F_000476"&gt;four-year&lt;/span&gt; term. The exercise price of each option is determined by the Company&#x2019;s Board of Directors, although generally options have an exercise price equal to the fair market value of the Company&#x2019;s stock on the date of the option grant. In the case of incentive stock options, the exercise price shall not be less than 100% of the fair market value of the Company&#x2019;s common stock at the time the option is granted. For holders of more than 10% of the Company&#x2019;s total combined voting power of all classes of stock, incentive stock options may not be granted at less than 110% of the fair market value of the Company&#x2019;s common stock at the date of grant and for a term not to exceed five years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, there were 1,430,368 shares available for future issuance under the 2020 Plan. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the option activity for the year ended December 31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,683,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,599,409&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(117,093&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(169,583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,996,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000494"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,249,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.07&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000495"&gt;7.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,465&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total intrinsic value of options exercised was $2.7 million, $0.1 million and $0 for the years ended December 31, 2020, 2019 and 2018, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain stock options granted under the Company&#x2019;s 2014 Plan provided option holders the ability to early exercise their stock options prior to vesting. The shares of common stock granted from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding or issued until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. As of December 31, 2020, 2019 and 2018, there were 6,072 shares, 29,579 shares and 121,794 shares subject to repurchase by the Company, respectively. As of December 31, 2020 and 2019, the Company recorded less than $0.1&#160;million of liabilities associated with shares issued with repurchase rights. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company&#x2019;s Board of Directors adopted, and its stockholders approved, the 2020 Employee Stock Purchase Plan (ESPP). The ESPP became effective in connection with the Company&#x2019;s IPO however no offering period or purchase period under the ESPP will begin unless and until otherwise determined by the Company&#x2019;s Board of Directors. A total of 290,000 shares of common stock were reserved for future issuance under the ESPP. Further, the number of shares of common stock available for issuance under the ESPP will automatically increase on the first day of each fiscal year following the fiscal year in which the first offering period under the ESPP commences in an amount equal to the lessor of (1) 500,000 shares, (2) 1% of the outstanding shares of the Company&#x2019;s common stock on the last day of the immediately preceding fiscal year, or (3) such other amount as determined by the Company&#x2019;s Board of Directors. As of December 31, 2020, no shares had been issued pursuant to the ESPP and there were no active offering periods or purchase periods.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options are valued using the Black-Scholes Merton option pricing model on the&#160;date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#x2019;s anticipated stock volatility and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. Forfeitures are recognized as they occur.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines the assumptions used in the option pricing model in the following manner:&lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-style:italic;font-family:Times New Roman;"&gt;Expected term.&lt;/span&gt;&lt;span style="font-family:Times New Roman;"&gt;&#160;&#160;T&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;"&gt;he expected term represents the period of time that options are expected to be outstanding. Because the Company does not have sufficient historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-style:italic;font-family:Times New Roman;color:#000000;"&gt;Expected volatility&lt;/span&gt;&lt;span style="font-family:Times New Roman;color:#000000;"&gt;.&#160;&#160;&lt;/span&gt;&lt;span style="font-family:Times New Roman;"&gt;Due to the Company&#x2019;s limited historical stock price volatility data, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-style:italic;font-family:Times New Roman;"&gt;Risk-free interest rate.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;"&gt;&#160;&#160;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-style:italic;font-family:Times New Roman;"&gt;Expected dividend yield.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;"&gt;&#160;&#160;The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero&lt;/span&gt;&lt;span style="font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#x2019;s common stock and the general and industry-specific economic outlook. Subsequent&lt;span style="color:#000000;"&gt; to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock is determined based on its closing market price.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Merton option pricing model with the following assumptions.&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="9" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$16.00 - $35.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.60 - $9.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.17% - 5.59%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4% - 2.6%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.7% - 3.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88.01% - 95.11%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77% - 104%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93% - 98%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.50 - 6.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000530"&gt;6.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.01 - 6.10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant-date fair value of options granted was $12.99, $5.01 and $1.41 for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized stock-based compensation expense of $5.3&#160;million, $1.1&#160;million and $0.5 million for the years ended December 31, 2020, 2019 and 2018, respectively. No stock-based compensation expense has been recognized as of December 31, 2020, pursuant to the Company&#x2019;s ESPP. The total unrecognized compensation expense related to outstanding unvested stock-based awards as of December 31, 2020, 2019 and 2018 was $20.6 million, $6.9&#160;million and $2.3 million, respectively, which is expected to be recognized over a weighted-average remaining service period of 2.7 years for 2020 and &lt;span&gt;3.4 years&lt;/span&gt; for both year 2019 and 2018, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below summarizes the total stock-based compensation expense included in the Company&#x2019;s statements of operations and comprehensive loss for stock options for the periods presented (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,094&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200430"
      decimals="INF"
      id="F_000471"
      unitRef="U_xbrlishares">2656500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandFourteenEquityIncentivePlanMember_20200430"
      decimals="INF"
      id="F_000472"
      unitRef="U_xbrlishares">241653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <oric:MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200430"
      decimals="INF"
      id="F_000473"
      unitRef="U_xbrlishares">2656500</oric:MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20200401_20200430"
      decimals="2"
      id="F_000474"
      unitRef="U_xbrlipure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231"
      id="F_000475">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000477"
      unitRef="U_xbrlipure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders
      contextRef="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000478"
      unitRef="U_xbrlipure">0.10</oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders>
    <oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage
      contextRef="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000479"
      unitRef="U_xbrlipure">1.10</oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage>
    <oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm
      contextRef="C_0001796280_us-gaapAwardTypeAxis_oricIncentiveStockOptionsMember_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231"
      id="F_000480">P5Y</oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandTwentyEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000481"
      unitRef="U_xbrlishares">1430368</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000303">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the option activity for the year ended December 31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,683,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,599,409&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(117,093&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(169,583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,996,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000494"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,249,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.07&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000495"&gt;7.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,465&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000482"
      unitRef="U_xbrlishares">2683441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001796280_20191231"
      decimals="2"
      id="F_000488"
      unitRef="U_iso4217USD_xbrlishares">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001796280_20200101_20201231"
      decimals="INF"
      id="F_000483"
      unitRef="U_xbrlishares">1599409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001796280_20200101_20201231"
      decimals="2"
      id="F_000489"
      unitRef="U_iso4217USD_xbrlishares">17.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001796280_20200101_20201231"
      decimals="INF"
      id="F_000484"
      unitRef="U_xbrlishares">117093</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001796280_20200101_20201231"
      decimals="2"
      id="F_000490"
      unitRef="U_iso4217USD_xbrlishares">4.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_0001796280_20200101_20201231"
      decimals="INF"
      id="F_000485"
      unitRef="U_xbrlishares">169583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001796280_20200101_20201231"
      decimals="2"
      id="F_000491"
      unitRef="U_iso4217USD_xbrlishares">12.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000486"
      unitRef="U_xbrlishares">3996174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001796280_20201231"
      decimals="2"
      id="F_000492"
      unitRef="U_iso4217USD_xbrlishares">9.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">99107000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000487"
      unitRef="U_xbrlishares">1249351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001796280_20201231"
      decimals="2"
      id="F_000493"
      unitRef="U_iso4217USD_xbrlishares">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">38465000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001796280_20200101_20201231"
      decimals="-5"
      id="F_000498"
      unitRef="U_iso4217USD">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001796280_20190101_20191231"
      decimals="-5"
      id="F_000499"
      unitRef="U_iso4217USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001796280_20180101_20181231"
      decimals="-6"
      id="F_000500"
      unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000501"
      unitRef="U_xbrlishares">6072</oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase>
    <oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase
      contextRef="C_0001796280_20191231"
      decimals="INF"
      id="F_000502"
      unitRef="U_xbrlishares">29579</oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase>
    <oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase
      contextRef="C_0001796280_20181231"
      decimals="INF"
      id="F_000503"
      unitRef="U_xbrlishares">121794</oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase>
    <oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20201231"
      decimals="INF"
      id="F_000504"
      unitRef="U_iso4217USD">100000</oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded>
    <oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded
      contextRef="C_0001796280_srtRangeAxis_srtMaximumMember_20191231"
      decimals="INF"
      id="F_000505"
      unitRef="U_iso4217USD">100000</oric:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200430"
      decimals="INF"
      id="F_000506"
      unitRef="U_xbrlishares">290000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <oric:MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200430"
      decimals="INF"
      id="F_000507"
      unitRef="U_xbrlishares">500000</oric:MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200401_20200430"
      decimals="2"
      id="F_000508"
      unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001796280_us-gaapPlanNameAxis_oricTwoThousandAndTwentyEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000509"
      unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001796280_20200101_20201231"
      decimals="INF"
      id="F_000510"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000304">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Merton option pricing model with the following assumptions.&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="9" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$16.00 - $35.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.60 - $9.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.17% - 5.59%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4% - 2.6%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.7% - 3.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88.01% - 95.11%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77% - 104%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93% - 98%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.50 - 6.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000530"&gt;6.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.01 - 6.10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_0001796280_20181231"
      decimals="INF"
      id="F_000515"
      unitRef="U_iso4217USD_xbrlishares">1.60</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001796280_20200101_20201231"
      decimals="2"
      id="F_000533"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001796280_20190101_20191231"
      decimals="2"
      id="F_000534"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001796280_20180101_20181231"
      decimals="2"
      id="F_000535"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001796280_20200101_20201231"
      decimals="2"
      id="F_000536"
      unitRef="U_iso4217USD_xbrlishares">12.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001796280_20190101_20191231"
      decimals="2"
      id="F_000537"
      unitRef="U_iso4217USD_xbrlishares">5.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001796280_20180101_20181231"
      decimals="2"
      id="F_000538"
      unitRef="U_iso4217USD_xbrlishares">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_20200101_20201231"
      decimals="-5"
      id="F_000539"
      unitRef="U_iso4217USD">5300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_20190101_20191231"
      decimals="-5"
      id="F_000540"
      unitRef="U_iso4217USD">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_20180101_20181231"
      decimals="-5"
      id="F_000541"
      unitRef="U_iso4217USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000542"
      unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001796280_20201231"
      decimals="-5"
      id="F_000543"
      unitRef="U_iso4217USD">20600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001796280_20191231"
      decimals="-5"
      id="F_000544"
      unitRef="U_iso4217USD">6900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001796280_20181231"
      decimals="-5"
      id="F_000545"
      unitRef="U_iso4217USD">2300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001796280_20200101_20201231" id="F_000546">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001796280_20190101_20191231" id="F_000547">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001796280_20180101_20181231" id="F_000548">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000305">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below summarizes the total stock-based compensation expense included in the Company&#x2019;s statements of operations and comprehensive loss for stock options for the periods presented (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,094&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000549"
      unitRef="U_iso4217USD">2025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000550"
      unitRef="U_iso4217USD">476000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000551"
      unitRef="U_iso4217USD">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">3253000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">359000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000555"
      unitRef="U_iso4217USD">5278000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000556"
      unitRef="U_iso4217USD">1094000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000557"
      unitRef="U_iso4217USD">469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000275">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. &lt;span style="text-decoration:underline;"&gt;Income Tax&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate were as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,158&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,465&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,536&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of Tax Cuts and Jobs Act&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s deferred taxes were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;491&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,636&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;771&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,836&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,745&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,823&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,910&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(240&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A valuation allowance of $49.5 million at December 31, 2020 has been recognized to offset the net deferred tax assets as realization of such assets is uncertain. The valuation allowance increased by $20.9 million during the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had available net operating loss (NOL) carryforwards of $130.8 million. Of the $130.8 million of NOL carryforwards, $41.6 million begin to expire in 2034 and $89.2 million do not expire. The Company also has available California NOL carryforwards of approximately $132.0 million as of December 31, 2020, which begin to expire in 2034.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to Sections 382 and 383 of the Internal Revenue Code (IRC), annual use of the Company&#x2019;s NOL and credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a &lt;span style="-sec-ix-hidden:F_000616"&gt;three-year&lt;/span&gt; period. Since the Company&#x2019;s formation, the Company has raised capital through the issuance of capital stock, which on its own or combined with the purchasing stockholders&#x2019; subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the Company&#x2019;s NOL and research and development credit carryforwards are subject to an annual limitation, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&amp;amp;D credit carryforwards before utilization. The Company has not completed an analysis to determine if such an ownership change has occurred.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes liabilities for uncertain tax positions based in a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;examinations by tax authorities in determining the adequacy of its provision for income taxes.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had gross unrecognized tax benefits of $0.8 million, none of which would affect the effective tax rate if recognized. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company&#x2019;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its balance sheets at December 31, 2020 and has not recognized interest and/or penalties in its statement of operations for the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to taxation in the United States and California. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000306">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate were as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,158&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,465&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,536&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of Tax Cuts and Jobs Act&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000558"
      unitRef="U_iso4217USD">-15478000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">-5647000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">-4487000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000561"
      unitRef="U_iso4217USD">-5158000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">-2351000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000563"
      unitRef="U_iso4217USD">-1465000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000564"
      unitRef="U_iso4217USD">-280000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000565"
      unitRef="U_iso4217USD">17000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000566"
      unitRef="U_iso4217USD">-15000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000567"
      unitRef="U_iso4217USD">692000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000568"
      unitRef="U_iso4217USD">663000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000569"
      unitRef="U_iso4217USD">20916000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000570"
      unitRef="U_iso4217USD">8673000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">6536000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000572"
      unitRef="U_iso4217USD">0</us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000573"
      unitRef="U_iso4217USD">0</us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000574"
      unitRef="U_iso4217USD">0</us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000575"
      unitRef="U_iso4217USD">94000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001796280_20200101_20201231"
      decimals="-3"
      id="F_000576"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001796280_20190101_20191231"
      decimals="-3"
      id="F_000577"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001796280_20180101_20181231"
      decimals="-3"
      id="F_000578"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000307">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s deferred taxes were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;491&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,636&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;771&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,836&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,745&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,823&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,910&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(240&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000579"
      unitRef="U_iso4217USD">36740000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000580"
      unitRef="U_iso4217USD">24380000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000581"
      unitRef="U_iso4217USD">17353000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <oric:DeferredTaxAssetsResearchAndDevelopment
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000582"
      unitRef="U_iso4217USD">3319000</oric:DeferredTaxAssetsResearchAndDevelopment>
    <oric:DeferredTaxAssetsResearchAndDevelopment
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">3319000</oric:DeferredTaxAssetsResearchAndDevelopment>
    <oric:DeferredTaxAssetsResearchAndDevelopment
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000584"
      unitRef="U_iso4217USD">2147000</oric:DeferredTaxAssetsResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">214000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">353000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">491000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">2636000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000589"
      unitRef="U_iso4217USD">771000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000590"
      unitRef="U_iso4217USD">255000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000591"
      unitRef="U_iso4217USD">6836000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000592"
      unitRef="U_iso4217USD">49745000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000593"
      unitRef="U_iso4217USD">28823000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000594"
      unitRef="U_iso4217USD">20246000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000595"
      unitRef="U_iso4217USD">49507000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000596"
      unitRef="U_iso4217USD">28583000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000597"
      unitRef="U_iso4217USD">19910000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000598"
      unitRef="U_iso4217USD">238000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000599"
      unitRef="U_iso4217USD">240000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000600"
      unitRef="U_iso4217USD">336000</us-gaap:DeferredTaxAssetsNet>
    <oric:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000601"
      unitRef="U_iso4217USD">238000</oric:DeferredTaxLiabilitiesFixedAssets>
    <oric:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000602"
      unitRef="U_iso4217USD">240000</oric:DeferredTaxLiabilitiesFixedAssets>
    <oric:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000603"
      unitRef="U_iso4217USD">336000</oric:DeferredTaxLiabilitiesFixedAssets>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000604"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001796280_20191231"
      decimals="-3"
      id="F_000605"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001796280_20181231"
      decimals="-3"
      id="F_000606"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001796280_20201231"
      decimals="-5"
      id="F_000607"
      unitRef="U_iso4217USD">49500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001796280_20200101_20201231"
      decimals="-5"
      id="F_000608"
      unitRef="U_iso4217USD">20900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001796280_20201231"
      decimals="-5"
      id="F_000609"
      unitRef="U_iso4217USD">130800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001796280_srtStatementScenarioAxis_oricScenarioOneMember_20201231"
      decimals="-5"
      id="F_000610"
      unitRef="U_iso4217USD">41600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001796280_srtStatementScenarioAxis_oricScenarioTwoMember_20201231"
      decimals="-5"
      id="F_000612"
      unitRef="U_iso4217USD">89200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001796280_srtStatementGeographicalAxis_stprCA_20201231"
      decimals="-5"
      id="F_000613"
      unitRef="U_iso4217USD">132000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment
      contextRef="C_0001796280_srtRangeAxis_srtMinimumMember_20200101_20201231"
      decimals="INF"
      id="F_000615"
      unitRef="U_xbrlipure">0.50</us-gaap:ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001796280_20201231"
      decimals="-5"
      id="F_000617"
      unitRef="U_iso4217USD">800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_0001796280_20201231"
      decimals="INF"
      id="F_000618"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_0001796280_20200101_20201231"
      decimals="INF"
      id="F_000619"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000276">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. &lt;span style="text-decoration:underline;"&gt;Commitments and Contingencies&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases certain office and lab space in South San Francisco, California under a non-cancelable operating lease, with a term through &lt;span style="-sec-ix-hidden:F_000620"&gt;May 2022&lt;/span&gt;, and an option to renew for an additional &lt;span style="-sec-ix-hidden:F_000622"&gt;five-year&lt;/span&gt; term. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2019, the Company entered into a lease agreement for office space in San Diego, California under a non-cancelable operating lease with a 13-month term. In October 2019, the lease was amended to increase the office space and extend the term until May 2021. The lease was further amended in November 2020 to extend the lease term until December 2021. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense is recorded on a straight-line basis over the term of the respective lease. Total rent expense was $1.4&#160;million for the year ended December 31, 2020 and $1.3 million for both the years ended December&lt;span style="color:#000000;"&gt; 31&lt;/span&gt;, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments under non-cancelable operating leases as of &lt;span style="color:#000000;"&gt;December 31&lt;/span&gt;, 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,942&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Litigation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20190331"
      id="F_000621">P13M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20191001_20191031"
      id="F_000623">May 2021</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20201101_20201130"
      id="F_000624">December 2021</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20200101_20201231"
      decimals="-5"
      id="F_000625"
      unitRef="U_iso4217USD">1400000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20190101_20191231"
      decimals="-5"
      id="F_000626"
      unitRef="U_iso4217USD">1300000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001796280_srtStatementGeographicalAxis_oricSouthSanFranciscoAndSanDiegoLocationsMember_20180101_20181231"
      decimals="-5"
      id="F_000627"
      unitRef="U_iso4217USD">1300000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000308">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments under non-cancelable operating leases as of &lt;span style="color:#000000;"&gt;December 31&lt;/span&gt;, 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,942&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000628"
      unitRef="U_iso4217USD">1942000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000629"
      unitRef="U_iso4217USD">686000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000630"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000631"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_0001796280_20201231"
      decimals="-3"
      id="F_000632"
      unitRef="U_iso4217USD">2628000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="C_0001796280_20200101_20201231" id="F_000277">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. &lt;span style="text-decoration:underline;"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a defined-contribution 401(k) plan for employees. Employees are eligible to participate in the plan beginning on the first day of the month following date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation and the Company has the option to make a discretionary match as determined by the Company&#x2019;s Board of Directors, within prescribed limits. There were no employer contributions to the plan during the years ended December 31, 2020, 2019 or 2018. &lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001796280_20200101_20201231"
      decimals="INF"
      id="F_000633"
      unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001796280_20190101_20191231"
      decimals="INF"
      id="F_000634"
      unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001796280_20180101_20181231"
      decimals="INF"
      id="F_000635"
      unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682009428440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORIC PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001796280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 743.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,695,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORIC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1787157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">240 E. Grand Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">388-5600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-top:2pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Registrant&#8217;s Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#8217;s 2020 fiscal year ended December 31, 2020.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682005836728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 78,446<span></span>
</td>
<td class="nump">$ 89,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">215,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,097<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">296,697<span></span>
</td>
<td class="nump">89,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">298,997<span></span>
</td>
<td class="nump">94,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">8,245<span></span>
</td>
<td class="nump">5,202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,002<span></span>
</td>
<td class="nump">5,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent - long term</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,221<span></span>
</td>
<td class="nump">6,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.0001 par value; no shares and 20,348,788 shares authorized at December 31, 2020 and December 31, 2019, respectively; no shares and 19,278,606 issued and outstanding at December 31, 2020 and December 31, 2019, respectively; aggregate liquidation preference of $0 and $178,058 at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 200,000,000 shares and no shares authorized at December 31, 2020 and December 31, 2019, respectively; no shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 1,000,000,000 shares and 26,750,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; 36,672,415 shares and 1,984,222 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">456,196<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(166,393)<span></span>
</td>
<td class="num">(92,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">289,776<span></span>
</td>
<td class="num">(90,084)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 298,997<span></span>
</td>
<td class="nump">$ 94,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682105024008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,348,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,278,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,278,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 178,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">26,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">36,672,415<span></span>
</td>
<td class="nump">1,984,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">36,672,415<span></span>
</td>
<td class="nump">1,984,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682006155064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 35,921<span></span>
</td>
<td class="nump">$ 22,844<span></span>
</td>
<td class="nump">$ 19,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">24,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,422<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
<td class="nump">3,345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">74,186<span></span>
</td>
<td class="nump">28,569<span></span>
</td>
<td class="nump">22,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(74,186)<span></span>
</td>
<td class="num">(28,569)<span></span>
</td>
<td class="num">(22,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(73,703)<span></span>
</td>
<td class="num">(26,883)<span></span>
</td>
<td class="num">(21,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (73,734)<span></span>
</td>
<td class="num">$ (26,883)<span></span>
</td>
<td class="num">$ (21,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (3.36)<span></span>
</td>
<td class="num">$ (14.15)<span></span>
</td>
<td class="num">$ (12.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">21,942,476<span></span>
</td>
<td class="nump">1,899,348<span></span>
</td>
<td class="nump">1,734,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682008339368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Initial Public Offering</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Initial Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Initial Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,612,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="num">$ (43,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,672,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C and D preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts', window );">Issuance of Series C and D preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,177,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(21,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,789,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="num">(64,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,802,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C and D preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts', window );">Issuance of Series C and D preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,488,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(26,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 178,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">19,278,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,278,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="num">$ (90,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">1,984,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,984,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="nump">$ 133,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,999<span></span>
</td>
<td class="nump">$ 133,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="nump">5,796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs associated with offering of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,790)<span></span>
</td>
<td class="num">$ (8,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,790)<span></span>
</td>
<td class="num">$ (8,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityConversionToCommonStockValue', window );">Conversion to Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (178,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityConversionToCommonStockShares', window );">Conversion to Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,278,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion to Common Stock</a></td>
<td class="nump">$ 178,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion to Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,278,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock related to acquired-in- process research and development</a></td>
<td class="nump">19,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock related to acquired-in-process research and development (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">117,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(73,703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">$ (31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 289,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 456,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (166,393)<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">36,672,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,672,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_TemporaryEquityConversionToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion to common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_TemporaryEquityConversionToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_TemporaryEquityConversionToCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion to common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_TemporaryEquityConversionToCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682006640856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityStockIssuanceCosts', window );">Preferred stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=oric_SeriesCAndDPreferredStockMember', window );">Series C and D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityStockIssuanceCosts', window );">Preferred stock, issuance costs</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_TemporaryEquityStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_TemporaryEquityStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=oric_SeriesCAndDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=oric_SeriesCAndDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682009387976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (73,703)<span></span>
</td>
<td class="num">$ (26,883)<span></span>
</td>
<td class="num">$ (21,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,278<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_NonCashStockConsiderationAcquisition', window );">Non-cash stock consideration, acquisition</a></td>
<td class="nump">19,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on fixed asset disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on investments, net</a></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,258)<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued other liabilities</a></td>
<td class="nump">4,303<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(45,268)<span></span>
</td>
<td class="num">(23,533)<span></span>
</td>
<td class="num">(20,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisitions of property and equipment</a></td>
<td class="num">(667)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(225,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfNotesReceivable', window );">Proceeds from notes receivable</a></td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(215,959)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
<td class="num">(508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock pursuant to initial public offering</a></td>
<td class="nump">138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering', window );">Issuance costs associated with initial public offering</a></td>
<td class="num">(12,691)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock pursuant to public offering</a></td>
<td class="nump">133,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_PaymentsOfStockIssuanceCostsWithPublicOffering', window );">Issuance costs associated with public offering</a></td>
<td class="num">(8,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,792<span></span>
</td>
<td class="nump">37,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">250,514<span></span>
</td>
<td class="nump">70,824<span></span>
</td>
<td class="nump">38,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(10,713)<span></span>
</td>
<td class="nump">46,523<span></span>
</td>
<td class="nump">16,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">89,159<span></span>
</td>
<td class="nump">42,636<span></span>
</td>
<td class="nump">25,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">78,446<span></span>
</td>
<td class="nump">89,159<span></span>
</td>
<td class="nump">$ 42,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">178,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Amounts accrued for purchase of property and equipment</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_UnpaidDeferredFinancingCosts', window );">Unpaid deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_NonCashStockConsiderationAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash stock consideration, acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_NonCashStockConsiderationAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of stock issuance costs with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_PaymentsOfStockIssuanceCostsWithPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of stock issuance costs with public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_PaymentsOfStockIssuanceCostsWithPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_UnpaidDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_UnpaidDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003606376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. <span style="text-decoration:underline;">Description of the Business</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC Pharmaceuticals, Inc. (ORIC or the Company) is a clinical-stage biopharmaceutical company dedicated to improving patients&#8217; lives by <span style="font-style:italic;text-decoration:underline;">O</span><span style="font-style:italic;">vercoming </span><span style="font-style:italic;text-decoration:underline;">R</span><span style="font-style:italic;">esistance </span><span style="font-style:italic;text-decoration:underline;">I</span><span style="font-style:italic;">n </span><span style="font-style:italic;text-decoration:underline;">C</span><span style="font-style:italic;">ancer</span>. The Company was incorporated in Delaware in August 2014 and has offices in South San Francisco and San Diego, California. The Company&#8217;s principal operations are in the United States and the Company operates in one segment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has devoted its primary efforts to raising capital, internal research and development activities and business development efforts and has incurred significant operating losses and negative cash flows from operations. In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi, Inc. development and commercialization rights to a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 insertion mutations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;December 31, 2020, the Company had an accumulated deficit of&#160;$166.4 million. Through December 31, 2020, all of the Company&#8217;s financial support has been provided by&#160;&#160;proceeds from the issuance of common stock and from the sale of convertible preferred stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Company continues its expansion, it may seek additional financing and/or strategic investments, however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. The accompanying financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from <span style="color:#000000;">the date of the issuance of these financial statements. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering and Related Transaction</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 28, 2020, the Company completed an initial public offering (IPO) selling 8,625,000 shares of common stock, which included the full exercise by the underwriters of their option to purchase up to 1,125,000 additional shares, at a price of $16.00 per share resulting in gross proceeds of $138.0 million. After deducting underwriting discounts and commissions and other offering expenses related to the IPO of $12.8 million, the net proceeds to the Company from the transaction were $125.2 million. In connection with the IPO, all shares of convertible preferred stock outstanding at the time of the IPO converted into 19,278,606 shares of common stock. On April 21, 2020, the Company amended its certificate of incorporation to effect a one-for-<span style="-sec-ix-hidden:F_000319">four</span> reverse stock split of its issued and outstanding common and convertible preferred stock. The accompanying financial statements and related notes give retroactive effect, where applicable, to the reverse stock split. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Secondary Public Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 17, 2020, the Company completed a secondary public offering selling 5,796,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase up to 756,000 additional shares, at a price of $23.00 per share, resulting in gross proceeds of $133.3 million. After deducting underwriting discounts and commissions and other offering expenses related to the secondary public offering of approximately $8.5 million, the net proceeds to the Company from the transaction were $124.8 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003447768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. <span style="text-decoration:underline;">Basis of Presentation and Summary of Significant Accounting Policies</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accompanying financial statements include all known adjustments necessary for a fair presentation of the results as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the year ended December 31, 2020 are not necessarily indicative of future results, particularly in light of the novel coronavirus (COVID-19) and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended operating activities. Beginning the week of March 16, 2020, </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the majority of the Company&#8217;s workforce began working from home. Disruptions caused by the COVID-19 pandemic, including</span><span style="color:#0000FF;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the effects of the stay-at-home orders and work-from-home policies, have impacted productivity, have resulted in increased operational expenses, certain adjustments to the operations of the Company&#8217;s clinical trials, the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">temporary </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspension of enrollment of new patients at certain of the Company&#8217;s clinical trial sites, and delays in certain supply chain activities and collecting and analyzing data from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the Company&#8217;s clinical trials, and may further disrupt the business and delay the development programs and regulatory timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company&#8217;s ability to conduct business in the ordinary course. As a result, research and development expenses and general and administrative expenses may vary significantly if there is an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of the clinical trials and other related business activities. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, the Company began reporting deferred offering costs within other assets on its balance sheets. To conform to current presentation, the Company included $1.3 million of deferred financing costs at December 31, 2019 in other assets. This reclassification had no effect on the Company&#8217;s total assets, net loss or stockholders&#8217; equity (deficit) as previously reported.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. <span style="color:#000000;">These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheets. The Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits its exposure.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, cash equivalents and short-term investments, prepaid expenses, accounts payable and accrued liabilities are reasonable estimates of their fair value because of the short nature of these items. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of 90 days or less at the time of purchase that are readily convertible into cash as cash equivalents. These investments may include money market funds, securities issued by U.S. Government agencies, corporate debt securities and commercial paper. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined </span>based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities 12 months or greater at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). <span style="color:#000000;">The Company reviews its </span>portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss).<span style="Background-color:#FFFFFF;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, which consist of lab equipment, leasehold improvements, computer hardware and software, and furniture and fixtures, are stated at historical cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets, which are generally three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimate useful life of the asset.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did not recognize impairment losses for the years ended December&#160;31, 2020, 2019 and 2018.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Rent</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the office facilities over the terms of the leases. The Company&#8217;s leased office facilities provide for fixed increases in minimum annual rent payments. The total amount of rent payments due over the lease term are being charged to rent expense ratably over the life of the leases.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (CRO), and contract manufacturing organizations (CMO) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company&#8217;s discovery and preclinical activities, process development, clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company allocates external costs by program, clinical or preclinical. Internal costs consist primary of employee-related costs, laboratory supplies, facilities, depreciation and costs related to compliance with regulatory requirements. The Company does not allocate internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company makes estimates of accrued expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in its accrued research and development expenses include the costs incurred for services performed by vendors in connection with research and development activities for which the Company has not yet been invoiced.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 2019, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#8220;more likely than not&#8221; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes would result in a change in the estimated annual effective tax rate.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and&#160;non-employee&#160;stock option grants, estimated in accordance with the applicable accounting guidance, recognized on a ratable straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes forfeitures as they occur.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options is estimated using a Black-Scholes Merton valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, a risk-free interest rate, expected volatility of the Company&#8217;s common stock, expected term of the option before exercise and expected dividend yield. Options granted have a maximum contractual term of ten years. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Fees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Acquisitions of&#160;technology licenses are charged to acquired in-process research and development expense or capitalized based upon the asset achieving technological feasibility in accordance with management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Offering Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from&#160;non-owner&#160;sources, including unrealized gains and losses on investments and foreign currency gains and losses. The unrealized losses on available for sale investments represent the only component of other comprehensive loss that is excluded from the reported net loss.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,703</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,883</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding used in computing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share, basic and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,942,476</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,899,348</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14.15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,683,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,854,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,278,606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,789,770</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,962,047</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,644,656</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) under its accounting standard codifications (ASC) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, the FASB issued ASU No 2019-12</span><span style="font-style:italic;Background-color:#FFFFFF;">, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="Background-color:#FFFFFF;">, as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. For emerging growth companies (EGCs), the standard is effective for fiscal years beginning after December 15, 2021. The Company early adopted the new standard in 2020 and the adoption of the standard did not have a material impact on the Company&#8217;s current financial position, results of operations or financial statement disclosures.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02,&#160;<span style="font-style:italic;">Leases (Topic 842)</span>&#160;(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. ASC 842 provides a lessee with an option to not account for leases with a term of 12 month or less as leases in the scope of the new standard. ASC 842 supersedes the previous leases standard, ASC 840 Leases. For public business entities, this ASU is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, and should be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. As amended by ASU No. 2020-05, for all other entities, this ASU is effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act, ASU No.&#160;2016-02 is effective for the Company for the year ended December&#160;31, 2022, and all interim periods within. In July 2018, the FASB issued supplemental adoption guidance and clarification to ASC 842 within ASU No.&#160;2018-10,&#160;<span style="font-style:italic;">Codification Improvements to Topic 842, Leases</span>&#160;and ASU No.&#160;2018-11,&#160;<span style="font-style:italic;">Leases (Topic&#160;842): Targeted Improvements</span>. ASU No.&#160;2018-11 provides another transition method in addition to the existing modified retrospective transition method by allowing entities to initially apply the new leasing standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company is currently evaluating the impact the adoption of these ASUs will have on financial statements and related disclosures. The Company expects to recognize a right-of-use asset and corresponding lease liability on its balance sheets for its real estate operating leases upon adoption. See Note 11 for more information related to the Company&#8217;s lease obligations, which are presented on an undiscounted basis therein. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June<span style="color:#000000;"> 2016, the FASB issued ASU No. 2016-13, </span><span style="font-style:italic;color:#000000;">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;"> (</span><span style="font-style:italic;color:#000000;">Topic 326</span><span style="color:#000000;">) (ASC 326): </span><span style="font-style:italic;color:#000000;">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;">, which introduced the expected credit losses methodology for the </span>measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments&#8212;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments&#8212; Credit Losses&#8212;Available-for-Sale Debt Securities. The guidance is effective for public business entities for annual periods beginning after December 15, 2019, including interim periods within those years. For all other entities, the standard is effective for annual periods beginning after December 15, 2022 and interim periods, therein. Early adoption is permitted. Since the Company has elected to use the extended transition period under the JOBS Act available to EGCs, the ASU is effective for the Company for fiscal years beginning after December&#160;15, 2022. The Company expects to adopt the new standard in the first quarter of 2021, using the modified retrospective approach. The Company currently does not expect the adoption to have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003527560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. <span style="text-decoration:underline;">License Agreements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mirati License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On&#160;August 3, 2020, the Company entered into&#160;a license agreement (Mirati License Agreement) with Mirati Therapeutics, Inc (Mirati). Under the Mirati License Agreement, Mirati granted the Company a worldwide, exclusive, sublicensable, royalty-free license under Mirati&#8217;s rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2 and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compounds. Under the Mirati License Agreement, the Company is wholly responsible for development and commercialization of licensed products. In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least one licensed product in certain major markets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Mirati License Agreement will continue in effect on a country-by-country and licensed product-by-licensed product basis until the later of (a) the expiration of the last valid claim of a licensed patent covering such licensed product in such country or (b) ten years after the first commercial sale of such licensed product in such country. Following the expiration of the Mirati License Agreement, the Company will retain its licenses under the intellectual property Mirati licensed to it on a royalty-free basis. ORIC and Mirati may each terminate the Mirati License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Mirati may terminate the agreement if the Company challenges any of the patent rights licensed to the Company by Mirati or it discontinues development of licensed products for a specified period of time. The Company also has the right to terminate the Mirati License Agreement without cause by providing prior notice to Mirati.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial obligation under the Mirati License Agreement was comprised of an upfront payment of 588,235 shares of ORIC common stock, valued at approximately $13.0 million based upon the closing price of the Company&#8217;s common stock on the acquisition date. The number of shares issued was based on a price of $34.00 per share, representing a premium of 10% to the 60-day trailing volume-weighted average trading price of the Company&#8217;s common stock. The shares were issued in a private placement in reliance on Section&#160;4(a)(2) of the <span style="Background-color:#FFFFFF;">Securities Act of 1933, as amended,</span> for transactions by an issuer not involving any public offering. During the <span style="-sec-ix-hidden:F_000359">eighteen-month</span> period following the date of the agreement, Mirati is subject to certain transfer restrictions, and the parties agreed to negotiate and enter into a registration rights agreement, with respect to the shares. The Company is not obligated to pay Mirati milestones or royalties. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded the transaction as an asset purchase as management concluded that all of the value received was related to a single identifiable asset. Further, as the asset was in early development at the time the license was acquired, the Company concluded that there was no alternative future use for the asset and recorded a charge at the closing of the transaction for the full $13.0 million value assigned to the shares issued in connection with Mirati License Agreement.&#160;&#160;This non-cash charge was recorded as acquired in-process research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2020.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Voronoi License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 19, 2020, the Company entered into a license agreement (Voronoi License Agreement) with Voronoi Inc. (Voronoi). The Voronoi License Agreement gives<span style="color:#000000;"> the Company access to Voronoi&#8217;s preclinical stage EGFR and HER2 exon 20 insertion mutation program, including a lead product candidate now designated as ORIC-114. Under the Voronoi License Agreement, Voronoi granted the Company an exclusive, sublicensable license under Voronoi&#8217;s rights to certain patent applications directed to certain small molecule compounds that bind to EGFR and HER2 with one or more exon 20 insertion mutations and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compound worldwide (other than in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan) (the ORIC Territory). Under the Voronoi License Agreement, the Company is wholly responsible for development and commercialization of licensed products in the ORIC Territory. In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize at least&#160;one&#160;licensed product in certain major markets in the ORIC Territory.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial obligations under the Voronoi License Agreement included an upfront payment comprised of a $5.0 million cash payment and the issuance to Voronoi of&#160;283,259&#160;shares of the Company&#8217;s common stock, valued at approximately $6.8 million, issued pursuant to a stock issuance agreement (Stock Agreement) entered into between the parties on October 19, 2020. The number of shares issued pursuant to the Stock Agreement was based on a price of $28.24&#160;per share, representing a premium of&#160;25% to the 30-day trailing volume weighted average trading price of the Company&#8217;s common stock. The shares were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also obligated to make milestone payments to Voronoi upon the achievement of certain events. Upon the achievement of certain development and regulatory milestones with respect to the first licensed product, the Company is obligated to pay Voronoi up to a maximum of $111.0&#160;million. Upon the achievement of certain commercial milestones with respect to the first licensed product, the Company is obligated to pay Voronoi up to a maximum of $225.0&#160;million. If the Company pursues a second licensed product, the Company would pay Voronoi up to an additional $272.0&#160;million in success-based milestones. In addition, the Company is obligated to pay royalties on net sales of licensed products in the ORIC Territory.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Voronoi License Agreement will continue in effect until the expiration of all royalty payment obligations. Following the expiration of the Voronoi License Agreement, the Company will retain its licenses under the intellectual property Voronoi licensed to it on a royalty-free basis. The Company and Voronoi may each terminate the Voronoi License Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Voronoi may also terminate the agreement if the Company discontinues development of licensed products for a specified period of time. The Company also has the right to terminate the Voronoi License Agreement without cause by providing prior notice to Voronoi.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Voronoi terminates the Voronoi License Agreement for cause, or if the Company terminates the Voronoi License Agreement without cause, then the Company is obligated to grant a nonexclusive license to Voronoi under certain of the Company&#8217;s patents and know-how and to assign to Voronoi certain of its regulatory filings for licensed compounds and licensed products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded the transaction as an asset purchase as management concluded that all of the value received was related to a specific identifiable asset related to EGFR and HER2. Further, as the asset was in early development at the time the license was acquired, the Company concluded that there was no alternative future use for the asset and recorded a charge of $11.8 million at the closing of the transaction which consisted of the $5.0 million cash payment plus the $6.8 million value assigned to the shares issued in connection with Voronoi License Agreement. This charge was recorded as acquired in-process research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2020. The charge was also reflected within cash flows from operating activities, with the $5.0 million cash payment included in net loss and the $6.8 million associated with the shares issued as an adjustment to reconcile net loss to net cash used in operating activities. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003593256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. <span style="text-decoration:underline;">Property and Equipment, net</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,396</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,748</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,710</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,710</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, gross</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,466</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,485</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,515</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,241</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December 31, 2020 and 2019 was $1.0 million for both years and $0.9 million for the year ended December 31, 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003530664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. <span style="text-decoration:underline;">Accrued Liabilities </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,723</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and manufacturing costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,072</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">963</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accruals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">904</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent - short-term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued deferred financing costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,244</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,202</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682004852968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-Term Investments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. <span style="text-decoration:underline;">Short-Term Investments</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s <span style="color:#000000;">investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity.&#160;In accordance with the Company&#8217;s investment policy, it has </span>invested funds in available-for-sale securities as of December 31, 2020. The Company had no investments at December 31, 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale investments by types and classes of security&#160;at&#160;December&#160;31, 2020&#160;consisted of the following</span> (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,185</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,185</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. At December 31, 2020, there were 18 securities in unrealized loss positions. These securities have not been in a continuous loss position for more than 12 months. Further, the Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">None of the Company&#8217;s available-for-sale investments had maturities of greater than 12 months at December 31, 2020. The Company has determined that there were no material declines in fair value of its investments due to credit-related factors as of December 31, 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682008974264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. <span style="text-decoration:underline;">Fair Value Measurements </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets; </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s interest receivable, included in prepaid expenses and other current assets, accounts payable and accrued liabilities are generally considered to be representative of&#160;their&#160;fair value because of the short-term nature of these instruments. The Company&#8217;s investments, which may include money market funds and available-for-sale investment securities consisting of U.S. treasury securities, and high-quality, marketable debt instruments of corporations and government <span style="color:#000000;">sponsored enterprises, are measured at fair value in&#160;accordance with the fair value hierarchy.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following are the major categories of assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurement at End of Period Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">At December 31, 2020</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<span style="text-decoration:line-through;"> </span><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">At December 31, 2019</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents in accompanying balance sheets.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No <span style="color:#000000;">transfers</span> <span style="color:#000000;">between</span> levels occurred during&#160;either of the reporting&#160;periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682004914248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_ConvertiblePreferredStockDisclosureTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. <span style="text-decoration:underline;color:#000000;">Convertible Preferred Stock</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to its conversion to common stock in connection with the Company&#8217;s IPO in April 2020, the Company&#8217;s convertible preferred stock was classified as temporary equity on the Company&#8217;s balance sheets in accordance with authoritative guidance. Convertible preferred stock authorized and issued and its principal terms as of December 31, 2019 consisted of the following (in thousands, except share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issue Period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividend</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Rate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,862,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,862,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 - 2015</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,750,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,749,999</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015 - 2016</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.64</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,448,788</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,448,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 - 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series D</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,287,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,217,327</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.056</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,669</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,348,788</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,278,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s IPO in April 2020, all outstanding shares of the convertible preferred stock converted into 19,278,606 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There were no shares of convertible preferred stock outstanding as of the closing of the IPO.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_ConvertiblePreferredStockDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_ConvertiblePreferredStockDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682004834232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans and Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. <span style="text-decoration:underline;">Equity Incentive Plans and Stock-Based Compensation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2020 Equity Incentive Plan (the 2020 Plan), which became effective in April 2020 in connection with the Company&#8217;s IPO. Upon adoption of the 2020 Plan, the Company restricted the grant of future equity awards under its 2014 Equity Incentive Plan, as amended and restated (the 2014 Plan).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Plan provides for the grants of stock options and other equity-based awards to employees, non-employee directors, and consultants of the Company. A total of<span style="font-size:12pt;"> </span>2,656,500 shares of the Company&#8217;s common stock were initially reserved for issuance pursuant to the 2020 Plan. The number of shares reserved under the 2020 Plan also included<span style="font-size:12pt;"> </span>241,653 shares of the Company&#8217;s common stock that remained available for issuance under the 2014 Plan as of immediately prior to the effectiveness of the 2020 Plan. The 2020 Plan share reserve will be increased by the number of shares under the 2014 Plan that are repurchased, forfeited, expired or cancelled after the effective date of the 2020 Plan up to the limit under the 2020 Plan. In addition, the number of shares of the Company&#8217;s common stock available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year, beginning with the Company&#8217;s 2021 fiscal year, in an amount equal to the lessor of (1) 2,656,500 shares, (2) 5% of the outstanding shares of the Company&#8217;s common stock on the last day of the immediately preceding fiscal year, or (3) such other amount as determined by the Company&#8217;s Board of Directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted under the 2020 Plan and the 2014 Plan become exercisable at various dates as determined by the Company&#8217;s Board of Directors or its authorized committee and will expire no more than ten years from their date of grant. Stock options generally vest over a <span style="-sec-ix-hidden:F_000476">four-year</span> term. The exercise price of each option is determined by the Company&#8217;s Board of Directors, although generally options have an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. In the case of incentive stock options, the exercise price shall not be less than 100% of the fair market value of the Company&#8217;s common stock at the time the option is granted. For holders of more than 10% of the Company&#8217;s total combined voting power of all classes of stock, incentive stock options may not be granted at less than 110% of the fair market value of the Company&#8217;s common stock at the date of grant and for a term not to exceed five years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there were 1,430,368 shares available for future issuance under the 2020 Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the option activity for the year ended December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,683,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,599,409</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117,093</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169,583</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.96</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.03</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000494">8.5</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,107</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249,351</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.07</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000495">7.8</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,465</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of options exercised was $2.7 million, $0.1 million and $0 for the years ended December 31, 2020, 2019 and 2018, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain stock options granted under the Company&#8217;s 2014 Plan provided option holders the ability to early exercise their stock options prior to vesting. The shares of common stock granted from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding or issued until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. As of December 31, 2020, 2019 and 2018, there were 6,072 shares, 29,579 shares and 121,794 shares subject to repurchase by the Company, respectively. As of December 31, 2020 and 2019, the Company recorded less than $0.1&#160;million of liabilities associated with shares issued with repurchase rights. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2020 Employee Stock Purchase Plan (ESPP). The ESPP became effective in connection with the Company&#8217;s IPO however no offering period or purchase period under the ESPP will begin unless and until otherwise determined by the Company&#8217;s Board of Directors. A total of 290,000 shares of common stock were reserved for future issuance under the ESPP. Further, the number of shares of common stock available for issuance under the ESPP will automatically increase on the first day of each fiscal year following the fiscal year in which the first offering period under the ESPP commences in an amount equal to the lessor of (1) 500,000 shares, (2) 1% of the outstanding shares of the Company&#8217;s common stock on the last day of the immediately preceding fiscal year, or (3) such other amount as determined by the Company&#8217;s Board of Directors. As of December 31, 2020, no shares had been issued pursuant to the ESPP and there were no active offering periods or purchase periods.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are valued using the Black-Scholes Merton option pricing model on the&#160;date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#8217;s anticipated stock volatility and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. Forfeitures are recognized as they occur.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines the assumptions used in the option pricing model in the following manner:</span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">Expected term.</span><span style="font-family:Times New Roman;">&#160;&#160;T</span><span style="color:#000000;font-family:Times New Roman;">he expected term represents the period of time that options are expected to be outstanding. Because the Company does not have sufficient historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;color:#000000;">Expected volatility</span><span style="font-family:Times New Roman;color:#000000;">.&#160;&#160;</span><span style="font-family:Times New Roman;">Due to the Company&#8217;s limited historical stock price volatility data, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">Risk-free interest rate.</span><span style="color:#000000;font-family:Times New Roman;">&#160;&#160;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">Expected dividend yield.</span><span style="color:#000000;font-family:Times New Roman;">&#160;&#160;The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero</span><span style="font-family:Times New Roman;">.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent<span style="color:#000000;"> to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on its closing market price.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Merton option pricing model with the following assumptions.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="9" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16.00 - $35.92</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.60 - $9.16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.17% - 5.59%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4% - 2.6%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7% - 3.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88.01% - 95.11%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77% - 104%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93% - 98%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50 - 6.08</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000530">6.10</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.01 - 6.10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant-date fair value of options granted was $12.99, $5.01 and $1.41 for the years ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation expense of $5.3&#160;million, $1.1&#160;million and $0.5 million for the years ended December 31, 2020, 2019 and 2018, respectively. No stock-based compensation expense has been recognized as of December 31, 2020, pursuant to the Company&#8217;s ESPP. The total unrecognized compensation expense related to outstanding unvested stock-based awards as of December 31, 2020, 2019 and 2018 was $20.6 million, $6.9&#160;million and $2.3 million, respectively, which is expected to be recognized over a weighted-average remaining service period of 2.7 years for 2020 and <span>3.4 years</span> for both year 2019 and 2018, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the total stock-based compensation expense included in the Company&#8217;s statements of operations and comprehensive loss for stock options for the periods presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,253</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">469</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682004930440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. <span style="text-decoration:underline;">Income Tax</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate were as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,478</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,158</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,351</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,465</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(692</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,916</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,673</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,536</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of Tax Cuts and Jobs Act</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred taxes were as follows (in thousands):</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforward</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,740</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,380</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,319</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,319</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">491</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,636</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">771</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,836</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,745</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,823</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,246</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,507</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,583</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,910</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(240</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(336</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance of $49.5 million at December 31, 2020 has been recognized to offset the net deferred tax assets as realization of such assets is uncertain. The valuation allowance increased by $20.9 million during the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had available net operating loss (NOL) carryforwards of $130.8 million. Of the $130.8 million of NOL carryforwards, $41.6 million begin to expire in 2034 and $89.2 million do not expire. The Company also has available California NOL carryforwards of approximately $132.0 million as of December 31, 2020, which begin to expire in 2034.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Sections 382 and 383 of the Internal Revenue Code (IRC), annual use of the Company&#8217;s NOL and credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a <span style="-sec-ix-hidden:F_000616">three-year</span> period. Since the Company&#8217;s formation, the Company has raised capital through the issuance of capital stock, which on its own or combined with the purchasing stockholders&#8217; subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the Company&#8217;s NOL and research and development credit carryforwards are subject to an annual limitation, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. The Company has not completed an analysis to determine if such an ownership change has occurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes liabilities for uncertain tax positions based in a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">examinations by tax authorities in determining the adequacy of its provision for income taxes.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had gross unrecognized tax benefits of $0.8 million, none of which would affect the effective tax rate if recognized. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company&#8217;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its balance sheets at December 31, 2020 and has not recognized interest and/or penalties in its statement of operations for the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States and California. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682104400456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. <span style="text-decoration:underline;">Commitments and Contingencies</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases certain office and lab space in South San Francisco, California under a non-cancelable operating lease, with a term through <span style="-sec-ix-hidden:F_000620">May 2022</span>, and an option to renew for an additional <span style="-sec-ix-hidden:F_000622">five-year</span> term. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, the Company entered into a lease agreement for office space in San Diego, California under a non-cancelable operating lease with a 13-month term. In October 2019, the lease was amended to increase the office space and extend the term until May 2021. The lease was further amended in November 2020 to extend the lease term until December 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense is recorded on a straight-line basis over the term of the respective lease. Total rent expense was $1.4&#160;million for the year ended December 31, 2020 and $1.3 million for both the years ended December<span style="color:#000000;"> 31</span>, 2019 and 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under non-cancelable operating leases as of <span style="color:#000000;">December 31</span>, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,942</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,628</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682004813960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. <span style="text-decoration:underline;">Employee Benefit Plan</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a defined-contribution 401(k) plan for employees. Employees are eligible to participate in the plan beginning on the first day of the month following date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation and the Company has the option to make a discretionary match as determined by the Company&#8217;s Board of Directors, within prescribed limits. There were no employer contributions to the plan during the years ended December 31, 2020, 2019 or 2018. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682086650328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accompanying financial statements include all known adjustments necessary for a fair presentation of the results as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the year ended December 31, 2020 are not necessarily indicative of future results, particularly in light of the novel coronavirus (COVID-19) and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended operating activities. Beginning the week of March 16, 2020, </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the majority of the Company&#8217;s workforce began working from home. Disruptions caused by the COVID-19 pandemic, including</span><span style="color:#0000FF;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the effects of the stay-at-home orders and work-from-home policies, have impacted productivity, have resulted in increased operational expenses, certain adjustments to the operations of the Company&#8217;s clinical trials, the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">temporary </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspension of enrollment of new patients at certain of the Company&#8217;s clinical trial sites, and delays in certain supply chain activities and collecting and analyzing data from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the Company&#8217;s clinical trials, and may further disrupt the business and delay the development programs and regulatory timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company&#8217;s ability to conduct business in the ordinary course. As a result, research and development expenses and general and administrative expenses may vary significantly if there is an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of the clinical trials and other related business activities. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, the Company began reporting deferred offering costs within other assets on its balance sheets. To conform to current presentation, the Company included $1.3 million of deferred financing costs at December 31, 2019 in other assets. This reclassification had no effect on the Company&#8217;s total assets, net loss or stockholders&#8217; equity (deficit) as previously reported.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. <span style="color:#000000;">These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheets. The Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits its exposure.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, cash equivalents and short-term investments, prepaid expenses, accounts payable and accrued liabilities are reasonable estimates of their fair value because of the short nature of these items. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of 90 days or less at the time of purchase that are readily convertible into cash as cash equivalents. These investments may include money market funds, securities issued by U.S. Government agencies, corporate debt securities and commercial paper. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined </span>based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities 12 months or greater at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). <span style="color:#000000;">The Company reviews its </span>portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other comprehensive income (loss).<span style="Background-color:#FFFFFF;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, which consist of lab equipment, leasehold improvements, computer hardware and software, and furniture and fixtures, are stated at historical cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets, which are generally three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimate useful life of the asset.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did not recognize impairment losses for the years ended December&#160;31, 2020, 2019 and 2018.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DeferredRentPolicyPolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Rent</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the office facilities over the terms of the leases. The Company&#8217;s leased office facilities provide for fixed increases in minimum annual rent payments. The total amount of rent payments due over the lease term are being charged to rent expense ratably over the life of the leases.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Accrued Research and Development Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (CRO), and contract manufacturing organizations (CMO) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company&#8217;s discovery and preclinical activities, process development, clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company allocates external costs by program, clinical or preclinical. Internal costs consist primary of employee-related costs, laboratory supplies, facilities, depreciation and costs related to compliance with regulatory requirements. The Company does not allocate internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company makes estimates of accrued expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in its accrued research and development expenses include the costs incurred for services performed by vendors in connection with research and development activities for which the Company has not yet been invoiced.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,&#160;tax-planning&#160;strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 2019, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#8220;more likely than not&#8221; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes would result in a change in the estimated annual effective tax rate.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and&#160;non-employee&#160;stock option grants, estimated in accordance with the applicable accounting guidance, recognized on a ratable straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes forfeitures as they occur.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options is estimated using a Black-Scholes Merton valuation model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, a risk-free interest rate, expected volatility of the Company&#8217;s common stock, expected term of the option before exercise and expected dividend yield. Options granted have a maximum contractual term of ten years. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseFeesPolicyTextBlock', window );">License Fees</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Fees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Acquisitions of&#160;technology licenses are charged to acquired in-process research and development expense or capitalized based upon the asset achieving technological feasibility in accordance with management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Offering Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from&#160;non-owner&#160;sources, including unrealized gains and losses on investments and foreign currency gains and losses. The unrealized losses on available for sale investments represent the only component of other comprehensive loss that is excluded from the reported net loss.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,703</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,883</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding used in computing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share, basic and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,942,476</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,899,348</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14.15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,683,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,854,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,278,606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,789,770</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,962,047</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,644,656</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) under its accounting standard codifications (ASC) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, the FASB issued ASU No 2019-12</span><span style="font-style:italic;Background-color:#FFFFFF;">, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="Background-color:#FFFFFF;">, as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. For emerging growth companies (EGCs), the standard is effective for fiscal years beginning after December 15, 2021. The Company early adopted the new standard in 2020 and the adoption of the standard did not have a material impact on the Company&#8217;s current financial position, results of operations or financial statement disclosures.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02,&#160;<span style="font-style:italic;">Leases (Topic 842)</span>&#160;(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. ASC 842 provides a lessee with an option to not account for leases with a term of 12 month or less as leases in the scope of the new standard. ASC 842 supersedes the previous leases standard, ASC 840 Leases. For public business entities, this ASU is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, and should be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. As amended by ASU No. 2020-05, for all other entities, this ASU is effective for fiscal years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act, ASU No.&#160;2016-02 is effective for the Company for the year ended December&#160;31, 2022, and all interim periods within. In July 2018, the FASB issued supplemental adoption guidance and clarification to ASC 842 within ASU No.&#160;2018-10,&#160;<span style="font-style:italic;">Codification Improvements to Topic 842, Leases</span>&#160;and ASU No.&#160;2018-11,&#160;<span style="font-style:italic;">Leases (Topic&#160;842): Targeted Improvements</span>. ASU No.&#160;2018-11 provides another transition method in addition to the existing modified retrospective transition method by allowing entities to initially apply the new leasing standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company is currently evaluating the impact the adoption of these ASUs will have on financial statements and related disclosures. The Company expects to recognize a right-of-use asset and corresponding lease liability on its balance sheets for its real estate operating leases upon adoption. See Note 11 for more information related to the Company&#8217;s lease obligations, which are presented on an undiscounted basis therein. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June<span style="color:#000000;"> 2016, the FASB issued ASU No. 2016-13, </span><span style="font-style:italic;color:#000000;">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;"> (</span><span style="font-style:italic;color:#000000;">Topic 326</span><span style="color:#000000;">) (ASC 326): </span><span style="font-style:italic;color:#000000;">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;">, which introduced the expected credit losses methodology for the </span>measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments&#8212;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments&#8212; Credit Losses&#8212;Available-for-Sale Debt Securities. The guidance is effective for public business entities for annual periods beginning after December 15, 2019, including interim periods within those years. For all other entities, the standard is effective for annual periods beginning after December 15, 2022 and interim periods, therein. Early adoption is permitted. Since the Company has elected to use the extended transition period under the JOBS Act available to EGCs, the ASU is effective for the Company for fiscal years beginning after December&#160;15, 2022. The Company expects to adopt the new standard in the first quarter of 2021, using the modified retrospective approach. The Company currently does not expect the adoption to have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_DeferredRentPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred rent policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_DeferredRentPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseFeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseFeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682087111784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,703</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,883</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding used in computing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share, basic and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,942,476</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,899,348</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14.15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,683,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,854,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,278,606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,789,770</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,962,047</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,644,656</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682005369000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,396</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,748</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,710</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,710</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, gross</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,466</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,485</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,515</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,241</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682086735304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,723</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and manufacturing costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,072</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">963</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accruals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">904</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent - short-term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued deferred financing costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,244</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,202</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003516344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale investments by types and classes of security&#160;at&#160;December&#160;31, 2020&#160;consisted of the following</span> (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,185</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,185</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003291928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following are the major categories of assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurement at End of Period Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">At December 31, 2020</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<span style="text-decoration:line-through;"> </span><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">At December 31, 2019</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents in accompanying balance sheets.</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682097955528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms</a></td>
<td class="text">Convertible preferred stock authorized and issued and its principal terms as of December 31, 2019 consisted of the following (in thousands, except share and per share amounts):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issue Period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividend</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Rate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,862,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,862,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 - 2015</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,750,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,749,999</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015 - 2016</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.64</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,448,788</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,448,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 - 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series D</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,287,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,217,327</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.056</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,669</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.52%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,348,788</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,278,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003518840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the option activity for the year ended December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,683,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,599,409</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117,093</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169,583</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.96</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,996,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.03</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000494">8.5</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,107</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249,351</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.07</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000495">7.8</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,465</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Merton option pricing model with the following assumptions.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="9" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16.00 - $35.92</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.60 - $9.16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.17% - 5.59%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4% - 2.6%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7% - 3.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88.01% - 95.11%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77% - 104%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93% - 98%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50 - 6.08</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000530">6.10</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.01 - 6.10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Total Stock-based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the total stock-based compensation expense included in the Company&#8217;s statements of operations and comprehensive loss for stock options for the periods presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,253</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.82%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">469</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003548744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes and Income Taxes Computed</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate were as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,478</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,158</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,351</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,465</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(692</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,916</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,673</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,536</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of Tax Cuts and Jobs Act</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred taxes were as follows (in thousands):</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforward</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,740</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,380</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,319</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,319</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">491</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,636</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">771</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,836</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,745</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,823</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,246</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,507</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,583</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,910</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(240</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(336</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682004717976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments under Non-cancelable Operating Leases</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under non-cancelable operating leases as of <span style="color:#000000;">December 31</span>, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,942</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,628</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682097934760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 17, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,393<span></span>
</td>
<td class="nump">$ 92,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock pursuant to initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.92<span></span>
</td>
<td class="nump">$ 9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock pursuant to initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible preferred stock outstanding converted into shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,278,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-four<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Option to Purchase Additional Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued | shares</a></td>
<td class="nump">756,000<span></span>
</td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Secondary Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued | shares</a></td>
<td class="nump">5,796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock | $ / shares</a></td>
<td class="nump">$ 23.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds from secondary public offering excluding underwriting discounts and commissions and other offering expenses</a></td>
<td class="nump">133,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock pursuant to public offering</a></td>
<td class="nump">$ 124,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the Business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance initial public offering, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts, commissions and other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=oric_SecondaryPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=oric_SecondaryPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682086402728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LiquidInvestmentsMaturityPeriod', window );">Liquid investments maturity period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_PropertyPlantAndEquipmentImpairmentLoss', window );">Impairment of property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1', window );">Options granted, maximum contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU No 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle, accounting standards update, early adoption</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, early adoption</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquid investments maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_PropertyPlantAndEquipmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property Plant and Equipment Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_PropertyPlantAndEquipmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was early adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520240&amp;loc=SL120174030-210619<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682086386360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (73,703)<span></span>
</td>
<td class="num">$ (26,883)<span></span>
</td>
<td class="num">$ (21,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding used in computing net loss per share, basic and diluted</a></td>
<td class="nump">21,942,476<span></span>
</td>
<td class="nump">1,899,348<span></span>
</td>
<td class="nump">1,734,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (3.36)<span></span>
</td>
<td class="num">$ (14.15)<span></span>
</td>
<td class="num">$ (12.32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682091428088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities excluded from computation of net loss per share</a></td>
<td class="nump">3,996,174<span></span>
</td>
<td class="nump">21,962,047<span></span>
</td>
<td class="nump">15,644,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=oric_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities excluded from computation of net loss per share</a></td>
<td class="nump">3,996,174<span></span>
</td>
<td class="nump">2,683,441<span></span>
</td>
<td class="nump">1,854,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities excluded from computation of net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,278,606<span></span>
</td>
<td class="nump">13,789,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=oric_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=oric_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682086883320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 19, 2020 </div>
<div>USD ($) </div>
<div>Product </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>USD ($) </div>
<div>Product </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize', window );">Number of licensed products obliged to develop and commercialize | Product</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Upfront payment shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,672,415<span></span>
</td>
<td class="nump">1,984,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Upfront payment value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_MiratiTherapeuticsIncMember', window );">Mirati Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_NumberOfPeriodAgreementInEffect', window );">Number of period the agreement in effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_MiratiTherapeuticsIncMember', window );">Mirati Therapeutics, Inc | Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Upfront payment shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Upfront payment value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_SharesIssuedPercentageOfPremium', window );">Premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_StockTransferRestrictionsPeriod', window );">Stock transfer restrictions period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember', window );">Voronoi Inc. | Development And Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementMaximumMilestonePaymentObligationToPay', window );">License agreement maximum milestone payment obligation to pay</a></td>
<td class="nump">$ 111,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember', window );">Voronoi Inc. | Commercial Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementMaximumMilestonePaymentObligationToPay', window );">License agreement maximum milestone payment obligation to pay</a></td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember', window );">Voronoi Inc. | Success Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementAdditionalMilestonePayment', window );">License agreement, additional milestone payment</a></td>
<td class="nump">272,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember', window );">Voronoi Inc. | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementChargeRelatedToAcquiredAssets', window );">License agreement charge related to acquired assets</a></td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge', window );">License agreement cash payment related to acquired assets charge</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge', window );">License agreement shares issued value related to acquired assets charge</a></td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember', window );">Voronoi Inc. | Private Placement | Acquired In-Process Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge', window );">License agreement cash payment related to acquired assets charge</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge', window );">License agreement shares issued value related to acquired assets charge</a></td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember', window );">Voronoi Inc. | Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Upfront payment shares issued | shares</a></td>
<td class="nump">283,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Upfront payment value</a></td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue price per share | $ / shares</a></td>
<td class="nump">$ 28.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_SharesIssuedPercentageOfPremium', window );">Premium percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseAgreementAdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement additional Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseAgreementAdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement cash payment related to acquired assets charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseAgreementChargeRelatedToAcquiredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement charge related to acquired assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseAgreementChargeRelatedToAcquiredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseAgreementMaximumMilestonePaymentObligationToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement maximum milestone payment obligation to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseAgreementMaximumMilestonePaymentObligationToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement shares issued value related to acquired assets charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_LicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_LicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of licensed products obliged to develop and commercialize.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_NumberOfPeriodAgreementInEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of period the agreement in effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_NumberOfPeriodAgreementInEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_SharesIssuedPercentageOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued percentage of premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_SharesIssuedPercentageOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_StockTransferRestrictionsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock transfer restrictions period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_StockTransferRestrictionsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_MiratiTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_MiratiTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=oric_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=oric_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=oric_CommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=oric_CommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=oric_SuccessBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=oric_SuccessBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=oric_AcquiredInProcessResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=oric_AcquiredInProcessResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682007423592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 6,466<span></span>
</td>
<td class="nump">$ 5,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(4,485)<span></span>
</td>
<td class="num">(3,515)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=oric_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">4,396<span></span>
</td>
<td class="nump">3,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=oric_ComputerHardwareAndSoftwareMember', window );">Computer Hardware and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=oric_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=oric_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=oric_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=oric_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682004877944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 970<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682006620456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 3,723<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_AccruedClinicalAndManufacturingCosts', window );">Accrued clinical and manufacturing costs</a></td>
<td class="nump">3,072<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accruals</a></td>
<td class="nump">904<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Deferred rent - short-term</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_AccruedDeferredFinancingCostsCurrent', window );">Accrued deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 8,245<span></span>
</td>
<td class="nump">$ 5,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_AccruedClinicalAndManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_AccruedClinicalAndManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_AccruedDeferredFinancingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued deferred financing costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_AccruedDeferredFinancingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682087070024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale, Investment | $</a></td>
<td class="nump">$ 215,154,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in unrealized loss position | Security</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682099981640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 215,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(31,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">215,154,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">215,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(31,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 215,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682156296520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">$ 293,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">78,446<span></span>
</td>
<td class="nump">$ 88,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">215,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">293,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">78,446<span></span>
</td>
<td class="nump">88,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">215,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">293,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">78,446<span></span>
</td>
<td class="nump">$ 88,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">$ 215,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682005361144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfer between level 1 to 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfer between level 2 to 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_FairValueAssetsLevel2ToLevel3TransfersAmount', window );">Transfer between level 2 to 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_FairValueAssetsLevel3ToLevel2TransfersAmount', window );">Transfer between level 3 to 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_FairValueAssetsLevel1ToLevel3TransfersAmount', window );">Transfer between level 1 to 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_FairValueAssetsLevel3ToLevel1TransfersAmount', window );">Transfer between level 3 to 1</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_FairValueAssetsLevel1ToLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, assets, level 1 to level 3 transfers, amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_FairValueAssetsLevel1ToLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_FairValueAssetsLevel2ToLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, assets, level 2 to level 3 transfers, amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_FairValueAssetsLevel2ToLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_FairValueAssetsLevel3ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, assets, level 3 to level 1 transfers, amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_FairValueAssetsLevel3ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_FairValueAssetsLevel3ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, assets, level 3 to level 2 transfers, amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_FairValueAssetsLevel3ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682086930792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">20,348,788<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">19,278,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">19,278,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 178,058<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">3,862,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">3,862,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">3,862,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue Price per Share</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend Annual Rate per Share</a></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 15,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityIssuedPeriod', window );">Issue Period</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityIssuedPeriod', window );">Issue Period</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">6,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">6,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">6,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue Price per Share</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend Annual Rate per Share</a></td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityIssuedPeriod', window );">Issue Period</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityIssuedPeriod', window );">Issue Period</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">4,448,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">4,448,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">4,448,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue Price per Share</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend Annual Rate per Share</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 53,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityIssuedPeriod', window );">Issue Period</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityIssuedPeriod', window );">Issue Period</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">5,287,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">4,217,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">4,217,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_TemporaryEquityIssuedPeriod', window );">Issue Period</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue Price per Share</a></td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend Annual Rate per Share</a></td>
<td class="nump">$ 1.056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 55,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_TemporaryEquityIssuedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_TemporaryEquityIssuedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount per share used to calculated dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682104400456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding shares of convertible preferred stock converted into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,278,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,278,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682087201896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase', window );">Shares subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,072<span></span>
</td>
<td class="nump">29,579<span></span>
</td>
<td class="nump">121,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.99<span></span>
</td>
<td class="nump">$ 5.01<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,278,000<span></span>
</td>
<td class="nump">$ 1,094,000<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense related to outstanding unvested stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation expense related to outstanding unvested stock-based awards expected to be recognized over weighted-average remaining service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded', window );">Liabilities with shares issued with repurchase rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oric_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock initially reserved for issuance</a></td>
<td class="nump">2,656,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance', window );">Additional number of shares available for future issuance</a></td>
<td class="nump">2,656,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares of common stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oric_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock remained available for issuance</a></td>
<td class="nump">241,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">2020 Plan and 2014 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">2020 Plan and 2014 Plan | Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">2020 Plan and 2014 Plan | Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price as a percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders', window );">Minimum percentage required for holders of combined voting power to be eligible for incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage', window );">Percentage of options may not be granted at less than fair market value of the common stock at the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm', window );">Maximum term of options may not be granted at less than fair market value of the common stock at the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance', window );">Additional number of shares available for future issuance</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares of common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for future issuance</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of additional common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award minimum percentage of combined voting rights of common stock holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award number of shares subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options not be granted at less than fair market value of common stock at date of grant maximum term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award stock options not be granted at less than fair market value of common stock at date of grant percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award shares issued subject to repurchase liabilities recorded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=oric_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=oric_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=oric_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=oric_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=oric_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=oric_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682103804904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation - Summary of Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Beginning Balance | shares</a></td>
<td class="nump">2,683,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted | shares</a></td>
<td class="nump">1,599,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised | shares</a></td>
<td class="num">(117,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options, Forfeited and cancelled | shares</a></td>
<td class="num">(169,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Ending Balance | shares</a></td>
<td class="nump">3,996,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable | shares</a></td>
<td class="nump">1,249,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding Beginning Balance | $ / shares</a></td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">17.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">4.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and Cancelled | $ / shares</a></td>
<td class="nump">12.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding Ending Balance | $ / shares</a></td>
<td class="nump">9.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Options outstanding</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding | $</a></td>
<td class="nump">$ 99,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 38,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682086767688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">5.59%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">88.01%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">95.11%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 35.92<span></span>
</td>
<td class="nump">$ 9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682195916776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,278<span></span>
</td>
<td class="nump">$ 1,094<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,025<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,253<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682086809608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Schedule of Provision for Income Taxes and Income Taxes Computed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="num">$ (15,478)<span></span>
</td>
<td class="num">$ (5,647)<span></span>
</td>
<td class="num">$ (4,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax</a></td>
<td class="num">(5,158)<span></span>
</td>
<td class="num">(2,351)<span></span>
</td>
<td class="num">(1,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="num">(280)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(692)<span></span>
</td>
<td class="num">(663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">20,916<span></span>
</td>
<td class="nump">8,673<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit', window );">Impact of Tax Cuts and Jobs Act</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provisions for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2A<br> -Subparagraph (SAB Topic 5.EE.Q2(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=SL116722634-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682009595032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Tax - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 36,740<span></span>
</td>
<td class="nump">$ 24,380<span></span>
</td>
<td class="nump">$ 17,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DeferredTaxAssetsResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">3,319<span></span>
</td>
<td class="nump">3,319<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accruals and other</a></td>
<td class="nump">2,636<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible</a></td>
<td class="nump">6,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">49,745<span></span>
</td>
<td class="nump">28,823<span></span>
</td>
<td class="nump">20,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(49,507)<span></span>
</td>
<td class="num">(28,583)<span></span>
</td>
<td class="num">(19,910)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_DeferredTaxLiabilitiesFixedAssets', window );">Fixed assets</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_DeferredTaxAssetsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_DeferredTaxAssetsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682095769608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 49,507,000<span></span>
</td>
<td class="nump">$ 28,583,000<span></span>
</td>
<td class="nump">$ 19,910,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">20,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 130,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration</a></td>
<td class="text">Dec. 31,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_CumulativeChangeInOwnershipPeriod', window );">Cumulative change in ownership period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrual for interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties not recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment', window );">Cumulative change in ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=oric_ScenarioOneMember', window );">Begin to expire in 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 41,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=oric_ScenarioTwoMember', window );">Not expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">89,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oric_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 132,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration</a></td>
<td class="text">Dec. 31,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_CumulativeChangeInOwnershipPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_CumulativeChangeInOwnershipPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oric_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oric_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oric_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage by which investments in equity securities have declined in value to be considered other than temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=oric_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=oric_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=oric_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=oric_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682087144920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=oric_SouthSanFranciscoCaliforniaMember', window );">South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=oric_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Extend the lease term</a></td>
<td class="text">December 2021<span></span>
</td>
<td class="text">May 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=oric_SouthSanFranciscoAndSanDiegoLocationsMember', window );">South San Francisco and San Diego Locations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Total rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=oric_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=oric_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=oric_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=oric_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=oric_SouthSanFranciscoAndSanDiegoLocationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=oric_SouthSanFranciscoAndSanDiegoLocationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682005009640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 1,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 2,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682003233560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%SA6>:;>Y<K>^9BV/($2VB$AW4.[E89BUQ@SL#CO3G,\"=W9LXN].;M@YCH
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M8)YOA="O WNZK=]F%K\ 4$L#!!0    ( *."=U)EV"S3=00  *X/   8
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M+&&!RBE\^'=@]RQ)<B;PXW=%.JC7S TOGT_L7POQ(.;-E^R>)S_C4$6W W>
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MP#Z?)TF^?5'\"&3W,Z_3_P%02P,$%     @ HX)W4O)!7QV) @  )P8  !@
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MW+0WM=@TGS*6HJY%V5RN69HSJ0W@]Y6 @TMWHR?8?SZ[_ ]02P,$%     @
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M0^QS99$@[(FX(P8)'2W83#L'WB=&ZA>YL5MI6V5_]N 8=N#(P3AYFGO3@T#
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M_'+P8O+\Y2FMYP6_:K5RG<^"-)D9<T-?WF67@S$!4KE*/4F0^.=6O5)Y3H(
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MS)5^(<),>!@,L]\'[9BF W]@H,W8U?,+/&) V1H06[P2TR_[K7:>A7O#ML8
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M:>38 /-S"^XV#^Q@\]UW]A]02P,$%     @ HX)W4FM)T( 4!   60D  !D
M  !X;"]W;W)K<VAE971S+W-H965T,34N>&ULK59-;^,V$+WK5Q#JHF@!K27K
MPY93QX"3[*(!NE@C2=M#T0,MT181BE1(*D[VU^\,]1%GD?A0]&)QAO/>O*%G
M1"T/2M^;BC%+GFHAS;E?6=N<A:$I*E93,U$-D["S4[JF%DR]#TVC&2T=J!9A
M'$6SL*9<^JNE\VWT:JE:*[AD&TU,6]=4/U\PH0[G_M0?'#=\7UETA*ME0_?L
MEMD_FXT&*QQ92EXS:;B21+/=N;^>GEVD&.\"_N+L8([6!"O9*G6/QG5Y[D<H
MB E66&2@\'ADETP() (9#SVG/Z9$X/%Z8/_L:H=:MM2P2R7^YJ6MSOW<)R7;
MT5;8&W7XG?7U9,A7*&'<+SETL<G")T5KK*I[,"BHN>R>]*D_AR- 'KT#B'M
M['1WB9S**VKI:JG5@6B,!C9<N%(=&L1QB7_*K=6PRP%G5Y=*/C)M^58PLH$#
M85JSDMQ:5=PO0PL),"PL>K*+CBQ^AVP:DR]*VLJ03[)DY6N"$)2-\N)!WD5\
MDO&*%1.23 ,21W%T@B\9RTT<7_(.WQVK&Z6A^\BGAY;;9W+%32&4:34C_ZRW
MQFIHDW]/)$K'1*E+E/X_YWJ:+)^0$WQ@<Z6)581;0PH7Z&8&/(6J:U@9%\<E
M[LI^'@[<5L16#*CKALKGGW_*X^G\-T.N-U\Q=-UH+MRY!V^&%4>*FE%1E^E
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M]8-Y8 R$&E*'+44[<$AZQ3&1%8_$I[Y8@LRG,U4)8'<G2T7"L*&%T\<YW6"
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M6;MGJ=84O$:H^TI;SFSQ*)DPVE\M3@?Q07,C2N.;?<%V>S40'H9==M#E$BX
MSU++QS*08+)"T;K7Z*54OB/!X\'H (GG;+?=:/CR&9D'XE-M74T9#6NWH==S
M(EG$K$VR2/;I#2&K;(EPN4%R*&M2)%/BY/KF\G4?>TO$.\JC>BX;DD)$,:23
M![H5<@<!$5N%IBK+F5$)XN.%1!M7U+FD[E.D;2DQVU)9M]$5,2P,-/)8$]/1
MWX5)4^B$1M!OL%%BP2KUAI'W!3F;:?,>Y*T07+)+K^%1 Z1V;Y%@$%@XM.4
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M7=20A=@Y^X# T8/9D2H]#G)C)P]7%?;685-#\V'.RV %(4,'W[BS$>*(<8/
MI<RY_>,G%/=T8TH5;Y]+.Q9KZ3Y2JK$O7:LYA$CPILG;7]B^W4QVM8)M.\4'
MRH=\T30:7TIN._BB'.XLAT[L$1TN"-P[>$17Z!(Z$40!1#O!@X*E$T<#<84"
M3.Q!D L1HX3J%06<]U8O:Z^:0 Y/"@SO0PGD7OS G)X6@S% @(P!+773BZN*
MZ]E3+S3#SG-7H9#IZ%&/'CF0Z\++5SO;OAM>A.>RP_;PZ/@S$J6&6+E:X>AH
M,)_VA T/>>'#FXH?SY;&>U/P<*.0/2QMP/K*(",U'\2@?4T]_Q-02P,$%
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M87+6MHV>=ZVO],3)@+M#MJ49D8B'+LO@7F_E"@1]/1<)@#[VX#\]V"<8/FL
M*&&H-8;IX#2]NCI/IQ=G![/T_/(T/3N;$H^>G$%<S@]NHG%7@.F"%5G)0>_L
MEX/I53J[N$S/3\!<"-SE57IQ<7+PF28IXMTA N>S].3LXF#Z)#T_.TO/GYSO
M^SV(?L9RMG\T\A.7YL#0Z\+P[Q/$/^G0F!J?<[5S9/7?MGGRAJ6%(DHJM&DJ
M+M)EY,'/*@P6B,7R<[XD$?T=A^B86Q)CRMJ3EP;_2QZ]N;Y]>>1:$*XCY-^U
M[EWPN @7(&WRZ/KVYHA2(7?'RK\%R\;+YGC;7U]S>/I+Y[X5TE\KE]XN=>%"
M&:K@'+FK><B3S[BG?);:VIWE*^ST S%<-@["VI<#"1]/B.O;+\E[PP^/I[,D
M30;-F4>?S1I6X>+LY.AI<JNIY[G8>,\6D8PT;+"0.Y#4S/?].BN+_15132T9
MR:VX/!NJG5QI\N%R23<L0BH8G36L@G[FA ZI>[@Q25AYE!I5F;NHE"%^@-D4
M-71==:DQF5S9HWI$D_E& 95 I6<;KM9*I402Z 4GO1++2.<]JC;*U0TN;^C*
M!\ [1KL&1=?MGI0?FY#R551UGPSPS4IKA!PVW-9=Q[]3$.[L .V5*M>>-WX8
MPE0PVO%U'5=U\T"&7_OH=Z* -0BGHQZC*W?SN8CJK>\\_+I#MJ#YW""@,%-N
ML$^23?Y5#58/GF"@:G]+=WR3-W0'"/YWR<4_V"^>Z"&]X9_/>?WKC3U*?4(F
MBO< P 54!4#)A.'W0)H.ZW<19*IP0=Y]=%;M?D_$\3B@T/].A+SH1R%#94FF
M>J(?!1DM=_EKK<%V26>'!#-JH,0_^M",=?ZB6U5[9^%F_:3S;/](\GM08;>Y
M?@],_P4'[@S[J&_8N_]XCOI3AY)!?*/F34=]*RC,^2Z#..&GQR>S5(;2@RF\
M/)L=@26]L4_>QJ/J4*GP7ECZ<(>G,)/-4C%$\7* ]U]=K7X$-+C^\2MZ+DQP
M5UY_DXSUD0/K=':>'+%[HH^ XUUT]ZN_*/M;R'/';P'Z9A4922._ZS*HA;L;
MHRY=WC:5].J8P#V.?GB+U)M_7HQ2*_!6?H,K?!M^PNQ:?KBK?UU^_^Q=1M:!
M)E<76'HRN7ARF#3RDV+R1VO6_#-><].VIN*/*Y7!P],+>+XP,(+N#SH@_+#;
MB_\%4$L#!!0    ( *."=U(J,P",[P,   4)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;)56VV[C-A!]UU<0:E$D@&I=+<FI;2!.MFB!;M98IUT4
M11]H:6P1H425I-;9O^^0DA6[FQC;%YN7N9R9.</1_"#DDZH -'FN>:,6;J5U
M>^/[JJB@IFHB6FCP9B=D335NY=Y7K01:6J6:^U$0I'Y-6>,NY_9L+9=ST6G.
M&EA+HKJZIO++"K@X+-S0/1Y\9/M*FP-_.6_I'C:@?V_7$G?^:*5D-32*B89(
MV"W<V_!F-37R5N /!@=ULB8FDJT03V;S:[EP P,(.!3:6*#X]QGN@'-C"&'\
M,]AT1Y=&\71]M/ZSC1UCV5(%=X)_8J6N%F[NDA)VM./ZHSC\ D,\%F AN+*_
MY##(!BXI.J5%/2@C@IHU_3]]'O+P+0K1H!!9W+TCB_*>:KJ<2W$@TDBC-;.P
MH5IM!,<:4Y2-EGC+4$\O5U0Q1<2.K"4H:#3M<]649-.7R=QMV+YA.U;01I/;
MHA!=HUFS)VO!6<% D:M'NN6@KN>^1DC&L%\,[E>]^^@-]V%$WHM&5XJ\:THH
MSPWX&,L84'0,:!5=M'@/Q83$H4>B( HNV(O'!,767OR&O=?B_>MVJ[1$0OU]
MP4$R.DBL@^0-!R=YOA-UVPTEP*VI36%K<<]XIZ$D#]BEOPFER!HDV514PFLI
MO^SOL0*R$QR[T<2D3>6( JWP4.J*:+PNSG&8H^V(I1RP-(B%&RPM8E$&"[EB
M#0J+3J&<\@@\%]#JX<ZHODC2VB1574^</X'*H?H$:P?U%H6P?HZI'_Z$,_.3
M.P]=#9)J(9V'P;'SO7.5Q5X6Q,ZU64>IE^?'=>C%J5G?0R.P;:SB)]NBZ(=^
M1E-[Z+$@^SNM-.(S^>@4WF,8?0K,R==Q>E]GPT&'LR3RDBQU0B^?S;PXR7&5
MQ8D7AM,1\V4C"#R>Q&D?0IA,4+%?1I,X<JXOD&TZDFWZK63[<!+U9D@$/@-"
MXRO *.=?>M;AFTDV4'22:4/]=\\%[TRM=E+4_R7L_Z/I9:3G-#TMD1K!MB=@
MRR-8]0+V $@U.$/\"KTO$)IJ+=FVZYM$"Z-9HQ*^RL53)7@)TK:-M8I:3)2H
MW3^D:' +!44^(9T, MMM.%)Q3'6\)!62$"7 /+::_7B$?^-<:H(/K0&M#)2V
MDT6%X^@,DQ-[LUGJA5GB1%Z:QUZ2A(:/TP1;(W7N1(/,U\Q$@S!W("7"[#5_
M^"Z/PN@G)YQY499[:8!$QN;*9UZ6!<ZCT)2?6D>ZIY$7))D33KTT2;QTFK[&
M3_]D-&$#[^T 5L2^J?V4&D_'&7_;C[87\?X#X3V5>X;!<]BA:C#)D$"R'[K]
M1HO6#KJMT#@V[;+"[Q201@#O=P+Y,FR,@_'+9_DO4$L#!!0    ( *."=U+C
M 1MUQ0(  .H%   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;(542V_;
M, R^^U<(Q@XI8-2/.(\628"D[; ![1"TW788=E!L.A8J2ZXD-^V_'R4[;@HT
MV<$6*9$?/U(B9SNIGG0)8,AKQ86>^Z4Q]648ZJR$BNIS68/ DT*JBAI4U3;4
MM0*:.Z>*ATD4C<.*,N$O9FYOK18SV1C.!*P5T4U54?6V BYW<S_V]QOW;%L:
MNQ$N9C7=P@.8G_5:H1;V*#FK0&@F!5%0S/UE?+E*K;TS^,5@IP]D8C/92/ED
ME>_YW(\L(>"0&8M <7F!*^#< B&-YP[3[T-:QT-YC_[5Y8ZY;*B&*\E_L]R4
M<W_JDQP*VG!S+W??H,MG9/$RR;7[DUUKFT8^R1IM9-4Y(X.*B7:EKUT=#ARF
MQQR2SB%QO-M CN4U-70Q4W)'E+5&-"NX5)TWDF/"7LJ#47C*T,\LU@KO5YDW
M0D5.;IX;5F/%34!^X'L8/-(-!WTV"PU&LO9AUJ&N6M3D"&J<D#LI3*G)C<@A
M_P@0(L6>9[+GN4I.(EY#=DZ&<4"2*(E.X W[O(<.;_B_O-><"D.6A]F3/\N-
M-@H?S-\3D=(^4NHBI4<B/6 ?Y0T'(@MRHMJ?%?DT\ <P> <3>'69Q+;1!G(;
MU91 "LFQ_YC8D@$3N",;C6[Z[-+#RD*U 66KZ]GJXB^^\&[IYAW4^^*EP?!B
MC.LPF*13[Q:P$TK)<\*J6LD7L%;:BX-)''7_*UG5C4'<DJI\1Q4XGEH6QBI>
M@H'BT=3[VBC!3-,=%^S5RHB41NY[E(9R4A])=:NDUMXX2,=C;Q1,1F,DIC6V
M>M94#:<V_QQP6&6,VAG@#=(@G8Z\,V\P#$:Q%4[C8RDQY3BXF,:X)D&2QI^]
MB/"@_RI06S=E-%Y"(TS;BOUN/\B6;?^^F[=3\(ZJ+1.:<"C0-3J?C'RBVLG2
M*D;6KILWTN!L<&*)PQB4-<#S0DJS5VR ?KPO_@%02P,$%     @ HX)W4CB3
M>B^G @  HP4  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE51M;],P
M$/Z>7V$%A#:I6U[[-MI*[08"B8EI&_ !\<%-+HTUOQ3;H>/?<W::K(BM$E]B
M^WSW/,^=<S?;*?U@:@!+'@679A[6UFXOHL@4-0AJSM46)-Y42@MJ\:@WD=EJ
MH*4/$CQ*XW@4"<IDN)AYVXU>S%1C.9-PHXEIA*#Z]PJXVLW#).P,MVQ36V>(
M%K,MW< =V"_;&XVGJ$<IF0!IF))$0S4/E\G%*G?^WN$K@YTYV!.7R5JI!W?X
M6,[#V D"#H5U"!277W )G#L@E/%SCQGVE"[P<-^AO_>Y8RYK:N!2\6^LM/4\
MG(2DA(HVW-ZJW0?8YS-T>(7BQG_)KO7-IB$I&F.5V >C L%DN]+'?1T. B;Q
M"P'I/B#UNELBK_**6KJ8:;4CVGDCFMOX5'TTBF/2/<J=U7C+,,XNED6A&RC)
M)T;7C#/+P)"3>[KF8$YGD44&YQ<5>[15BY:^@):DY%I)6QOR3I90_@T0H;1>
M7]KI6Z5'$:^@."=9,B!IG,9'\+(^W\SC9?^1[V6C-4A+OB_7QFK\3WX<(<I[
MHMP3Y2\0W6'[E T'HBKR#.ESM3T.V('P ^6%PNXP%JW(8FL@E>+89DQNR F3
M:%&-H;(TIQ<!%A+$&K0K9N"*B9]D&G2HA1+8YX:Z5@E>!]E@G&:X)H/))'MR
M0DVLH)P@)OZ$LJFP6(UV=(4RUF!8/$Z#Z2@+/J,:C3V'@92;8!KGP2@9HXH*
ML-@E\04_(Z96VIY9T"(8YJ,@GPY[LK)SK9BDLG@B>?-JDB;I6]26YGEPKZP3
M]&]Q4/T$/8:X#@>8\'-O&ATTC@"]\>/!E;61MNVAWMI/H&7;>$_N[?BZIGK#
MI"$<*@R-S\?#D.AV)+0'J[:^#=?*8E/[;8U3%+1SP/M**=L='$$_EQ=_ %!+
M P04    " "C@G=2YP6)A=D"  !C!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6R-56UOVC 0_IY?<<JF:95: @&VJ@,D^KI)JU05NGV8]L$D!['J
MQ,R^E+)?O[,3TDPK:%_@?"_//7=G7T8;;1YMADCPG*O"CL.,:'T613;),!>V
MH]=8L&6I32Z(CV85V;5!D?J@7$5QM_LARH4LPLG(Z^[,9*1+4K+ .P.VS'-A
MMN>H]&8<]L*=XEZN,G**:#):BQ7.D![6=X9/48.2RAP+*W4!!I?C<-H[.Q\X
M?^_P3>+&MF1PE2RT?G2'+^DX[#I"J# AAR#X[PDO4"D'Q#1^U9AAD](%MN4=
M^K6OG6M9"(L76GV7*67C\#2$%)>B5'2O-Y^QKF?H\!*MK/^%3>W;#2$I+>F\
M#F8&N2RJ?_%<]^%_ N(Z(/:\JT2>Y:4@,1D9O0'CO!G-";Y4'\WD9.&&,B/#
M5LEQ-)EEVM#)'$T.7XHGM,0-)POOYV*AT!Z-(N(DSC5*:L#S"C#> ]B+X587
ME%FX*E),_P:(F%U#,=Y1/(\/(EYBTH%^[QCB;MP]@-=O2NY[O/X>O':=E[@@
MF!8I7/TJ)6UAADEI)$FT\&.ZL&3XUOP\D'/0Y!SXG(-];>;'E)8*02_A0ELZ
MAANCK86'@E^2DK\QA<]:I;)8P0V_)'O _I7U3$\PZ6LA#7P3JO2XTR<AE1L;
M\%N%F6"A5>IKDSS,>9XA))[KRG,I7[AD-9=5Q76O7;UP73JN3SNN8L?UA+F>
M6,=5ML:RV )MUW5DHH1'X3!;C6<+@GAT">8+-,W58+*\*RQQ?G:ES/5!\=)A
M(L$_SL$TYXOOR;IY!*U&^P&T%57'@RM+DM< MOL>/'1F'2!VM:79[OCQ]0G>
M!G%O>-P[';+T[LUIW(L_L?2^WPN.=K;A()AK$NK_?%^[A5'KX>=H5GZ]66Y$
M65"U QIMLT&GU>)X<:_6[ZTP*ZX;%"XYM-OY. S!5"NM.I!>^S6RT,1+R8L9
M?P70. >V+[6FW<$E:+XKDS]02P,$%     @ HX)W4C=]S:9% P  2@<  !D
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MEM?,LL5,JP-H9TUH3O"I>F\BQZ4[E(W5I.7D9Q<WC&OXQD2-<(?,U!JIXM;
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M9?>AN*+MW3 ,^Z#83"S4MGR2G#3[]2/EQ,UUN:Q D4HR23TD'U(\7TOUJ$L
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MS3J$IC0]@M=M*^\&O.Y_5#[YI_)+;G.A;66 ?)\LK3-X?7X<8>VUK+W VCO
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MJY$S^G;C$WO8*7W#FL_VX0/=4'6W7PNXLNHL,4MI)AG/D*#;J]&U\_8=<75
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MW0#L+Y2RCQ4W0?=&G/T&4$L#!!0    ( *."=U*%0=X'$0,  $P(   9
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;)56;6_:,!#^*U:T#ZW4$O)2 A4@
M%;)ID]8*E77]["8'L9K8S':@^_<[.R%-66#L"_'+/8_O'I_O&.^$?%49@"9O
M1<[5Q,FTWMRZKDHR**CJB0UPW%D)65"-4[EVU48"32VHR%V_WQ^X!67<F8[M
MVD).QZ+4.>.PD$2514'E[QGD8C=Q/&>_\,C6F38+[G2\H6M8@G[:+"3.W(8E
M905PQ00G$E83Y\Z[C2-C;PU^,MBIUIB82%Z$>#63;^G$Z1N'((=$&P:*GRW,
M(<\-$;KQJ^9TFB,-L#W>LW^QL6,L+U3!7.3/+-79Q!DZ)(45+7/]*'9?H8[G
MQO E(E?VE^QJV[Y#DE)I4=1@]*!@O/K2MUJ'%L ;' 'X-< _!(1' $$-",X%
MA#4@M,I4H5@=8JKI="S%CDACC6QF8,6T: R?<7/M2RUQER%.3V=4,47$BBPD
M*.":5K?!4[*L$L'L+=F:LQ5+*-?D+DE$R37C:[(0.4L8*'+=-IZ+8E/6/#@U
M!R26,&9YJ2$E#YC,WX529 &2+#,J@5S$H"G+U252/2UC<O'IDGPB+E%F5Q'&
MR1-G6EWA(HY_9*)4R*C&KD8)3"!N4H<[J\+UCX3K^>1><)TI\IFGD'XD<%&[
M1D!_+^#,/\D80](C@7=%_+[?[W!H?C;<&W7 X_/APQ/1!$TZ!)8O.,+W4!8@
MJ1;R!%?8<(66*SS&A?><XSUWW5*%C"S25*;M]#H*HGXP=K=M[3K,_,%P>& 6
M=YEYP>#=[(/_-XW_-R>UB($+?''_4&/0L U.JO%L*Q"F/]VBPFO8YS:68J4Q
MF<V#*A7N8X(G]@F9%5YK2#;X5BSBRI2Y^D6EU8OJ$KAR9M"2Q/=&H1]&@P.)
M_S;TAJ-1$ X/-.ZPBX+0\VZZ18X:6:*SDN2_ ZQH1^T[#WK!870=5E[8:SE=
M!==EYO<"_R VMU5G\9VL;;]2Q!;$JF(TJTU+O+.=X&!]AJVRZFSO-%6?O:=R
MS;@B.:R0LM^+,$=EU;NJB18;6\U?A,;>8(<9MGN0Q@#W5T+H_<0<T/R!F/X!
M4$L#!!0    ( *."=U+2D$BV1P,  (0*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;,U636_;.!#]*X1.6Z"-/BW)A6T@MEML@79CU-CM8=$#(XTL
M(A2IDE2<_OL=4HIB.[$WM_9B\6/>X\R\,3FSO51WN@8PY*'A0L^]VICVO>_K
MHH:&ZBO9@L"=2JJ&&IRJG:];!;1TH(;[41"D?D.9\!8SM[91BYGL#&<"-HKH
MKFFH^KD$+O=S+_0>%[ZR76WL@K^8M70'6S!_MQN%,W]D*5D#0C,IB()J[EV'
M[]=A8 '.XA\&>WTP)C:46RGO[.13.?<"ZQ%P*(REH/BYAQ5P;IG0CQ\#J3>>
M:8&'XT?VCRYX#.:6:EA)_HV5IIY[N4=*J&C'S5>Y_Q.&@":6KY!<NU^R'VP#
MCQ2=-K(9P.A!PT3_I0]#(@X 87H&$ V Z!20G '$ R!^+2 9 (G+3!^*R\.:
M&KJ8*;DGREHCFQVX9#HTAL^$U7UK%.XRQ)G%DFJFB:S(1H$&86BOABC)MJ\$
MN[=E.\$J5E!AR'51R$X8)G9D(SDK&&CR[M#XIC/:((&UV-84:1V]-,C.*.<_
MR9KQSJI-ME!TBAE+\>&AX%T)):F4;,A*-FTW^()@!\"]O_!_\%EJ33:@>F[R
MQQH,95R_02>T.VWF&\R+C<XOAAPL^QQ$9W(01N2+%*9&+P2Z<$S@8T+'K$:/
M65U&%QG74%R1.'Q+HB *7G!H]6IX.'T!OGX]/+\033S62.SXXC-\URA<>4FS
MCZ>:W53D U4"2^!0JW\_(S'Y9*#1WR^XE8QN)<ZMY();9/1+/_D%1[54'->2
MP!KBMH9:],M5S$L%TY^<NI/MU7F_B*?3-,R2F7]_J.-SNRB<IE&09,>&Z^>&
MX21-DG22CH9'29B,29A<3,)-:P/3Q$BRZ511XQ5HE6@PV*V1Q=V%/*?C$>GO
M)'\VNI7],OFS5\K_W"Y*\SA)PA/UG]N%^23)\S/BYV,*\HLI6$EQ#\JP6P[V
M_JY *0S[_W2?CNS3WTGW,'AZLH)?I?QJ./I(JFF4Y6F0GFCZDF6<Y=,L"TY4
M]0^>YP;4SK4YFKAWM']3QM6QE;IV#<3)^M*V6.[9?Z+I^[,O5.T87@,<*J0,
MKC*\-53?\O03(UO7!-Q*@RV%&];8)H*R!KA?27R@AXD]8&P\%_\!4$L#!!0
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M&LPQUP;J_9(Q^;;1HU\YZH__ E!+ P04    " "C@G=2HPQ!6UX"  #'!0
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M @8=P+<Z;$OQ?<B99=E0JQ5HYTUL;N&;Z=%4/I=N['=6TRDGG,VFFFZ0MB_
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M18)]H;;7PW9BY+HY89?2X'G=#$N\44%9 UPOI#2[B3VTNSMZ^A=02P,$%
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M[;<R![=QMYN']0N5"[QN"8<Y8KU6#PTIR[>J[&BQM-?]3&A\/&PSQ?<=I%F
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M2C>4]G*%-$5A%NC["\[5?F VJ/_M,/P/4$L#!!0    ( *."=U)#.SI"&@,
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MCX5J1H%K@'J_8TR^#?0"?7N[_!]02P,$%     @ HX)W4I%M]<"& P  20P
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MO:&NY<MDJ=TOV=2V44"RM3:2UV#T@#-1_=/'^B!V ,C3#DAJ0/(:T-D#2&M
M^AK0VP/HU(#.H0K=&M ]%-"K ;U# ?T:T'?!JD[7A69*#1T-E-P09:V1S0Y<
M?!T:(\*$3<6Y4?B5(<Z,)I)S9C"W#*$B)Q,I#!-+$!D#3;Z0\SQG-F5H22Y%
ME?@V@3Y-P5!6ZL]H<C>?DD\?/Y./A ERS<H2#?0@-.B<E0BSVI%QY4BRQY&8
M7*-VH<F%R"%OP4_?P"<>@A!/I3F:9'LTX\3+^$T^'),T.B))E$0M#DW\\.^9
M07ALX?%IVW[\\"ED6WBK^L7!\%;UV>'PDQ;X5S_\FJI]ZB]"D399FCJ^SAZ^
M.1;1@LRI(#-%,3=U)H_(A)8,4U(PZE'H- H=IY#N4;B26K_*_G^NT(9<&N#Z
M7X]"MU'H>O?P?06*6GI2 M9. H\KIJKKE%,#;1GB)[RF3_:,__CP 5,D\7C8
M:SSLO<?#(WQJ!&SPZAM0O,T_/UV7/ %5VN-8OW&L[P\_!G[*8'EHT$\:WI/?
M%/331N'T?4=JCY+(!<E05>$[W':W_)1Q2K@K=![WXNBY_$=>MHM' UCW30%U
M6NZ)]?@-'BP8P.]!V7(5MQ7+-_ VF7^%OMS4SIL6O[=<N->MR2-R)3-W];R'
MF#SK);\IC^+G"AC[2^ /:? F*OM08^7 7K"U8M0D74=BV]"'47S<&80/NR]'
MJU'ZTFCVAE&UBW"G\>"@EJZGU)C<:V&JZMZL-GWKN>O67JV/X[-)W+(^C<]F
M55?Z3%\UR?C$+)G0F+4+E(J.^^BIJOK.:F+DRK4]]])@$^6&!?;JH*P!?E](
M:;83*]!T_Z/_ 5!+ P04    " "C@G=2B^[(N&P"  #M!0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U,BYX;6R-E&U/VS 0Q[_**>(%2*-)TS;M4!H)6J%-
M&EM%87LQ[86;7!L+/V2V0^';SW9"U(U ]Z;QP_WO=W?N7;J7ZD&7B :>.!-Z
M'I3&5!=AJ/,2.=$#6:&P-UNI.#%VJW:AKA22PHLX"^,H2D).J BRU)^M5);*
MVC J<*5 UYP3]7R%3.[GP3!X.;BEN]*X@S!+*[+#-9K[:J7L+NR\%)2CT%0*
M4+B=!Y?#BZNIL_<&WRGN]<$:7"8;*1_<YG,Q#R(7$#+,C?- [.<1%\B8<V3#
M^-WZ##JD$QZN7[Q?^]QM+ANB<2'9#UJ8<A[, BAP2VIF;N7^$[;Y3)R_7#+M
M?V'?VD8!Y+4VDK=B&P&GHOF2I[8.!X)X^(8@;@6QC[L!^2B7Q) L57(/REE;
M;V[A4_5J&QP5[E'61ME;:G4F6TC.J;%5-D!$ 0LI#!4[%#E%#>>P;MX*Y!:N
M:U,KA!LJ**\Y?$%;"UB19Z?5<"\*5/!5BO.<B!P9V3"$;Q4JXOPUUAI.EV@(
M9?H,3H *N"MEK2U6IZ&QN;B(PKR-^ZJ).WXC[B7F Q@-/T <Q=']>@FG)V=_
M>PEM);IRQ%TY8N]V=+0<&BY?U6-)=<ZD=F7X>;G11MG_U*]WJ*...O+4\1M4
MF\.PKP2-:NI5KKL>L^''<9R&CSVL<<<:'V/%?:Q&E1RPDEG2CYITJ,DQU*@/
M-7F%BOI!20=*CH'&?:#D?T'3#C1]%W0G#6&N#7T+,-\"5=L"?0%,7SU@G,2S
M?V((#[K7#<(;HG94:.M^:V718&KKI9KATFR,K'Q#;Z2QX\$O2SN/43D#>[^5
MTKQLW(SH)GSV!U!+ P04    " "C@G=2AQZ@BE<"  "]!0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U,RYX;6R-5-MNVS ,_17!V$,+;'7BI)<5B8$D[K ]
M% A:='L8]J#83"Q4%T^BF_;O1TF.EQ5-UA=;%YY#'E+D9&OLHZL!D#TKJ=TT
MJ1&;ZS1U90V*NS/3@*:;M;&*(VWM)G6-!5X%D))I-AA<I(H+G>23<+:T^<2T
M*(6&I66N58K;ESE(LYTFPV1W<"<V-?J#-)\T? /W@ _-TM(N[5DJH4 [832S
ML)XFL^%U,?;VP>"[@*W;6S.O9&7,H]]\JZ;)P <$$DKT#)Q^3[  *3T1A?&[
MXTQZEQZXO]ZQ?PG:2<N*.U@8^4-46$^3JX15L.:MQ#NS_0J=GG//5QKIPI=M
MH^W%9<+*UJ%1'9@B4$+'/W_N\K '&%X< &0=('L-&!\ C#K Z+V <0<(J4ZC
ME)"'@B//)]9LF?76Q.87(9D!3?*%]F6_1TNW@G"8WZA&FA< -@<-:X%L*;EF
MG]BLJH0O#)?LFXZORY?II #D0KI3,GFX+]C)A]-)BA2'9TO+SN<\^LP.^!QF
M[-9HK!V[T154_Q*D)*!7D>U4S+.CC 649VPT_,BR039X(Z#%N^'#SV_ B_?#
MKXZH&?4U&06^T0&^A5'4U2YF?*8K=@<H+%"S(2N$*Z5QK07V<[9R:*EQ?AWQ
M.>Y]CH//\?%W8%E)E;%BU<:N5*;5^%:%(]ME8/.CY2FGO#_MI_R_%L4QBR@B
MW7O8"NPF# A',5)4\77TI_T,FH76>W4^I]D41\E?FCC8;KG=".V8A#51#LXN
MSQ-FX["(&S1-:)^506K&L*QIOH+U!G2_-@9W&^^@G]CY'U!+ P04    " "C
M@G=2 &[4&2L#   R$P  #0   'AL+W-T>6QE<RYX;6S=6%%OVC 0_BN1.TVM
M-#5 UI2L@+0A59JT3I7:A[U5ACA@R;$SQW307S]?; *E/L3ZL-$9E=CW^;[[
M[+O4;@>U60EV-V?,1,M2R'I(YL94G^*XGLY92>MS53%ID4+IDAH[U+.XKC2C
M>0U.I8A[G4X:EY1+,AK(17E=FCJ:JH4T0W+1FB+W^)H/23?]2")'-U8Y&Y*'
MT_<_%\I<O8O<\^3#R4GGO/-P=K6+G'KHC,1!XHL#B%%:C#0]2*UM>P3;AM%?
M'D:_CQRC[A^H?*_PACSVB1T-"B4W^4V(,]CHM&31(Q5#,J:"3S0'KX*67*R<
MN0>&J1)*1\86EI73!4O]Y."N&T'->9Z22Z6;V"Z"^Y[XZ3O >@0"N1"MP!YQ
MAM&@HL8P+:_MH)G<&%] D>_?KRJK<*;IJMN[(!N'YF&#3)3.F6[#=,G:-!H(
M5H <S6=S>!I5Q0 :HTK;R3F=*4D;#6L/W[&T4R;$';R0/XIGW,MB*Z\=R*IL
MNU:0[SH:-P#^;3;'O4W;>Q5O5/%'9;XL[')D,X9J8;>:%7S9C)=%*P!C[^+L
MM*K$ZK/@,UDRM_B# XX&=.T7S97F3S8:E,K4&I@FT2/3AD^W+;\TK>[9TJS+
M:5G@FGMO4//?W><9DTQ3L2W:UOXQ[_*K%?L3[%]H;GZM["H.BDPNCU^C/[&/
M763Z%D2^@70GV?%K]+>FHQ,9^_-[ZY+P[(K06B.XB@W)=[CXB4W0:++@PG#I
M1W.>YTR^N"E8>D,G]@^"9_QV?LX*NA#FO@6'9-._83E?E%D[ZQ8VPL_:]+_!
M\KII>P^TL;C,V9+E8S_4LTG3C6S'1O4-'':1ZZ:%$<S'86$$,"P.I@#S<5Y8
MG/]I/7UT/0[#M/6#2!_UZ:,^SBN$C)L/%B?LD]D67FF6)4F:8CLZ'@<5C+%]
M2U/X";-AVL #BP.1_FRO\6SC%;*_#K"<[JL0;*5X)6(KQ?<:D/"^@4>6A;.-
MQ0$/+ M8[4#\<!RHJ;!/DD!6,6W8&XPC688A4(OA&DU39'=2^(3S@[TE29)E
M802PL((DP1!X&W$$4P :,"1)FG-PYSR*U^=4O/DOV>@W4$L#!!0    ( *."
M=U*7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] A
MB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:
MU;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]
MVR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::
M1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$
M%     @ HX)W4@J#'?Z#!   F2,   \   !X;"]W;W)K8F]O:RYX;6S%FE%O
MXC@0@/^*Q5-7NAZ0!':W6E:B%&Z16$ %]1Y/;F**U<3F;*?=[J^_27*(80NC
M?9GV">(XSI=)[&_LY,NS=8_WUCZ*'T5N_*"U#6%WU6[[=*L*Z?^T.V5@S\:Z
M0@;8= ]MOW-*9GZK5"CR=M3I]-N%U*;U]<N^K:5KXPT;5!JT-5!8%=QI]>P/
M^ZM-\:2]OM>Y#B^#5OT_5RU1:*,+_5-E@U:G)?S6/G^S3O^T)LA\E3J;YX-6
MM]EQIUS0Z:OB506YEO>^+@GR_E8"R*#5[T"#&^U\J&O4[4M@?%)0N=DJ@YWH
M/"AW(X/ZR]ERI\U#U0Q<11M=1AV'_6\3Q"OW.V&TFXU.U8U-RT*9T,31J;P"
M-'ZK=[XEC"S4H+6O(J3)Q-@$")*8FJ8IJ%M=*9QZFC57'0 7Q=!=:=CAIED-
MS@=Y+7-I4B7J>'K$%!%,T5LRB8NE='# 5M5/R@?$&!.,,2_C:CU<C[^/Y^N5
M6$S$8CF^':ZGB_E*#.<W8K1 D D!F;PEY&@QOQO?KJ?7L[%8WHXG8P39(R![
M[PCY3X0@^P1D_TTAAZMO8C);_+U"=!\)NH^\=#?*IT[OJG)A-P*ZBK@NO3;*
MXQ[]B0#\Q-VCO?85VM(I#U7K&O6XN"J+0B+(SP3D9U[(&50S7HGA@U.JJHN#
MU^U08W2'EPQ4O -1OC0F^;?4N^J /\1<!8Q(:H39(\,T=:7*Q$S+.A_0ZBAZ
ME$VZS#I9;:T+EVOE"M#OD_+AU;VE/-)E%LE$:B?N9%XJ\5U)7[K7CQYED"ZS
M0D860@8Y&IRUZKP;Y1S<Y56PZ2-&I/S1919(U2'JU JZ;Y4*BB6D#[X978 3
M8U(&Z3(K!/ALH<1:_L!$E#6ZS-H8V:+036^HHP7W.D"RK$SZ2^^ES-%E5L>X
MV.7V18'1E%$;'>J[B^$H8W29E4%Z[2AWB2A_1,S^H#%CC$DY)&)V"*$Y<;'&
M64)$SDZ8?7)"=14>0'@\.8DHJT3<TY.3SCN)2=DE8K;+&?GM.3$F99B(V3"$
M!']],"G#1,R&(45X/!I1VHF8M7,0X<GGD9)-Q"P;THCB F-2VHF8M4/,]\2E
M&.(5$DH[\;MJ)\&8E'9B]B4P"K.',2GMQ.RK8A1F'V.2ZV+,YGD]BZX>R2S3
M54V98TS*/#&S>:A<XU+@=9V8,D_,;!X:\ZBG4^:)F<US*B6"*$++60G.Q)B4
M>6)F\YS)BO;/)\:D+!0S6^@L9A-0C$E9*&:VT+GD[7].O 1.62AAMM!YS/JN
M8TS*0@FSA:@<\WA 2B@+)<P6HC'Q@)10%DJ8+42GPGC&FY#O9Y@M1&/B#"FA
M+)2\YPK;48:44!9*WG7^@S.DA+)0\G;S'^3(.K&S0(,Q*0LES!8ZQM0/1L.!
MT@28%!6[H]?7"66AA-E"1YB'/'/_IAV_XZ0LU&.VT&%F>6)B>8DSI!YEH1Z[
MA0C,HR6$'F6A'K.%3BX*'^X_QJ0LU*LMU-Y_"I)!4T9E<SB%A_)4YNG2B>JG
M>8>5]*K%YDV9YR,H6YB9E=G^RY+]5S%?_P-02P,$%     @ HX)W4GQ^Z1O4
M 0  QA\  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W9.T[#0!2%
MX:U$7@"3^YCP4$)%0XO8@!4F#Y'$EF<0R>Z)0A&.14&#YE36V/+U7UB?K/'\
M)>W:LNT.>;/M\^2XWQWRHMF4TC^$D)>;M&_S3=>GP_G*JAOV;3DOAW7HV^5[
MNTY!I]-9&'[.:![G/V=.7D]]^LO$;K7:+M-3M_S8IT/Y97#X[(;WO$FI-)/7
M=EBGLFC"<7<]G</E(#?GR<WD^6W1#,]OTH3:00I!6C_((,CJ!SD$>?V@"$&Q
M?M ,@F;U@VXAZ+9^T!T$W=4/NH>@^_I!,D49IP1)(ZP)M!;D6@B\%@1;",06
M)%L(S!9$6PC4%F1;"-P6A%L(Y!:D6PCL%L1;"/16U%L)]%;46PGTUM''-H'>
MBGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z&>AN!WH9Z&X'>
MAGH;@=XVVBPAT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M1;R?0
MVU%O)]#;46\GT-M1;R?0VT>;W01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$
M>D?4.Q+H'5'O2*!W1+TC@=X1]8[_J7<NIUW*UY[O-3[_/ZDNYWO3]?&7Y??)
MT:MRP3G ;_O'+U!+ P04    " "C@G=2*F32ILH!  ";'P  $P   %M#;VYT
M96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=E6Q'@('01LVFY;%OT!-WE 1!);
MMJ'P]W7"(+6BJ(A*O9M$B>UW7VSI;#)ZVUKRO4U=-7Z<+$*P#XSY?$&U]JFQ
MU,21F7&U#O'1S9G5^5+/B8G!8,ARTP1J0C^T-9+)Z(EF>E6%WO,FOO:E:<:)
MH\HGO<?=Q#9KG&AKJS+7(8ZS=5-\2^GO$]*XLIOC%Z7U-W%"PDXFM",_!^S7
MO:[)N;*@WE2[\*+K.(MM*N;#MB*?GB]QHD<SFY4Y%29?U7%)ZJTC7?@%4:BK
M=%?TYGQRB#M,NRN_.K\K<RXPSIPZ8WT\,4>7QQV.I%W=M[$0N5">_\1C8BQ]
M]?=1>]H%%;_,CMO[8=RR.P_/NMOU>_SUC(_U+^Q#@/0A0?I0('UD('T,0?JX
M!>GC#J2/>Y ^^ "E$111.0JI',54CH(J1U&5H[#*45SE*+!R%%D%BJP"15:!
M(JM D56@R"I09!4HL@H4606*K )%5HDBJT215:+(*E%DE2BR2A19)8JL$D56
MB2*K1)%5H<BJ4&15*+(J%%D5BJP*15:%(JM"D56AR*I09,U09,U09,U09,W^
M4]9W8Y9__;NXO:>U+IM#/NO^R4\^ 5!+ 0(4 Q0    ( *."=U('04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ HX)W4M#.]6GN    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ HX)W4IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "C
M@G=29D+->=H&  "V&P  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ HX)W4A,-BX9R!0  VA4  !@
M         ("!'0\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( *."=U(:".\75@,  -D,   8              " @<44  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "C@G=29=@LTW4$  "N#P
M&               @(%1&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ HX)W4B5K7KA"!P  \B4  !@              ("!_!P  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( *."=U+R05\=B0(
M "<&   8              " @70D  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " "C@G=2\W18)<@&  !*&P  &               @($S
M)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ HX)W4L#5
M+:*$!P  3A(  !@              ("!,2X  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( *."=U*ZF"4R.A@  "A$   8
M  " @>LU  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "C
M@G=24-A2P6D*  "1)   &0              @(%;3@  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( *."=U)W_4,0] (  (\&   9
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M970Q-2YX;6Q02P$"% ,4    " "C@G=2<!GU)DH-  !1)0  &0
M    @(&U;@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M *."=U*N\&,1R@@  %D5   9              " @39\  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ HX)W4G97/'A !   NPD  !D
M             ("!-X4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " "C@G=2OQ:S*Q$#  "A!@  &0              @(&NB0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( *."=U)=9:])>AD
M .1-   9              " @?:,  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ HX)W4BHS (SO P  !0D  !D              ("!
MIZ8  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "C@G=2
MXP$;=<4"  #J!0  &0              @('-J@  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( *."=U(XDWHOIP(  *,%   9
M      " @<FM  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ HX)W4N<%B879 @  8P8  !D              ("!I[   'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "C@G=2-WW-ID4#  !*!P
M&0              @(&WLP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( *."=U)V>>]\3P,  !0'   9              " @3.W  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ HX)W4F0MZ*TT
M!0  HPL  !D              ("!N;H  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " "C@G=2YEGJ"3@$  #I"0  &0
M@($DP   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *."
M=U)8).%@>P(  'T%   9              " @9/$  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ HX)W4AGN*@%,!0  /A@  !D
M         ("!1<<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " "C@G=25CWCP+<#   O#@  &0              @('(S   >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( *."=U*%0=X'$0,  $P(
M   9              " @;;0  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ HX)W4M*02+9' P  A H  !D              ("!_M,
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "C@G=2Q&B-
M<W4%  !.&0  &0              @(%\UP  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( *."=U((E^IA+0,  /8+   9
M  " @2C=  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
MHX)W4J,,05M> @  QP4  !D              ("!C.   'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " "C@G=2+;9]7+H"  "O!P  &0
M            @($AXP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( *."=U)ER'.K6 (  $(%   9              " @1+F  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ HX)W4@.5^J_! @
M/0@  !D              ("!H>@  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " "C@G=22$WE*78#  "5$   &0              @(&9
MZP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( *."=U+$
MVT,"9@(  *T'   9              " @4;O  !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ HX)W4KER)1?!!0  \A\  !D
M     ("!X_$  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *."=U)#.SI"&@,  -@)   9              "
M@0T* 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ HX)W
M4O#,9Y9\ P  Z@H  !D              ("!7@T! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " "C@G=2D6WUP(8#  !)#   &0
M        @($1$0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( *."=U*;S,FUZ0,  $4/   9              " @<X4 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ HX)W4@UB\JE\ P  "0P
M !D              ("![A@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " "C@G=2B^[(N&P"  #M!0  &0              @(&A' $
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( *."=U*''J"*
M5P(  +T%   9              " @40? 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ HX)W4@!NU!DK P  ,A,   T
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;72YX;6Q02P4&     #T /0"B$   R"X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>143</ContextCount>
  <ElementCount>351</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Equity Incentive Plans and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensation</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Equity Incentive Plans and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationTables</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTax</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Description of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Short-Term Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Short-Term Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Short-Term Investments - Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Short-Term Investments - Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails</Role>
      <ShortName>Convertible Preferred Stock - Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation - Summary of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Tax - Schedule of Provision for Income Taxes and Income Taxes Computed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails</Role>
      <ShortName>Income Tax - Schedule of Provision for Income Taxes and Income Taxes Computed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Tax - Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Tax - Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Tax - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails</Role>
      <ShortName>Income Tax - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitment and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails</Role>
      <ShortName>Commitment and Contingencies - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="oric-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="oric-10k_20201231.htm">oric-10k_20201231.htm</File>
    <File>oric-20201231.xsd</File>
    <File>oric-20201231_cal.xml</File>
    <File>oric-20201231_def.xml</File>
    <File>oric-20201231_lab.xml</File>
    <File>oric-20201231_pre.xml</File>
    <File>oric-ex231_2434.htm</File>
    <File>oric-ex311_8.htm</File>
    <File>oric-ex312_9.htm</File>
    <File>oric-ex321_6.htm</File>
    <File>oric-ex322_7.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gpty1lksmhba000001.jpg</File>
    <File>gpty1lksmhba000002.jpg</File>
    <File>gpty1lksmhba000003.jpg</File>
    <File>gpty1lksmhba000004.jpg</File>
    <File>gpty1lksmhba000005.jpg</File>
    <File>gpty1lksmhba000006.jpg</File>
    <File>gpty1lksmhba000007.jpg</File>
    <File>gpty1lksmhba000008.jpg</File>
    <File>gpty1lksmhba000009.jpg</File>
    <File>gpty1lksmhba000010.jpg</File>
    <File>gpty1lksmhba000011.jpg</File>
    <File>gpty1lksmhba000012.jpg</File>
    <File>gpty1lksmhba000013.jpg</File>
    <File>gpty1lksmhba000014.jpg</File>
    <File>gpty1lksmhba000015.jpg</File>
    <File>gpty1lksmhba000016.jpg</File>
    <File>gpty1lksmhba000017.jpg</File>
    <File>gpty1lksmhba000018.jpg</File>
    <File>gpty1lksmhba000019.jpg</File>
    <File>gpty1lksmhba000020.jpg</File>
    <File>gpty1lksmhba000021.jpg</File>
    <File>gpty1lksmhba000022.jpg</File>
    <File>gpty1lksmhba000023.jpg</File>
    <File>gpty1lksmhba000024.jpg</File>
    <File>gpty1lksmhba000025.jpg</File>
    <File>gpty1lksmhba000026.jpg</File>
    <File>gpty1lksmhba000027.jpg</File>
    <File>gpty1lksmhba000028.jpg</File>
    <File>gpty1lksmhba000029.jpg</File>
    <File>gpty1lksmhba000030.jpg</File>
    <File>gpty1lksmhba000031.jpg</File>
    <File>gpty1lksmhba000032.jpg</File>
    <File>gpty1lksmhba000033.jpg</File>
    <File>gpty1lksmhba000034.jpg</File>
    <File>gpty1lksmhba000035.jpg</File>
    <File>gpty1lksmhba000036.jpg</File>
    <File>gpty1lksmhba000037.jpg</File>
    <File>gpty1lksmhba000038.jpg</File>
    <File>gpty1lksmhba000039.jpg</File>
    <File>gpty1lksmhba000040.jpg</File>
    <File>gpty1lksmhba000041.jpg</File>
    <File>gpty1lksmhba000042.jpg</File>
    <File>gpty1lksmhba000043.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "oric-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 143,
   "dts": {
    "calculationLink": {
     "local": [
      "oric-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "oric-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "oric-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "oric-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oric-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "oric-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 450,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 42,
    "http://www.oricpharma.com/20201231": 8,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 54
   },
   "keyCustom": 44,
   "keyStandard": 307,
   "memberCustom": 22,
   "memberStandard": 28,
   "nsprefix": "oric",
   "nsuri": "http://www.oricpharma.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oric:LicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - License Agreements",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oric:LicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Property and Equipment, Net",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Accrued Liabilities",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Short-Term Investments",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestments",
     "shortName": "Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oric:ConvertiblePreferredStockDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Convertible Preferred Stock",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oric:ConvertiblePreferredStockDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Equity Incentive Plans and Stock-Based Compensation",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensation",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Tax",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTax",
     "shortName": "Income Tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Employee Benefit Plan",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Short-Term Investments (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables",
     "shortName": "Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "oric:ConvertiblePreferredStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Convertible Preferred Stock (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables",
     "shortName": "Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "oric:ConvertiblePreferredStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Equity Incentive Plans and Stock-Based Compensation (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationTables",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Income Tax (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxTables",
     "shortName": "Income Tax (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_oricSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Description of the Business - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Description of the Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_oricSegment",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oric:LiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oric:LiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "oric:LicenseAgreementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "oric:NumberOfLicensedProductsObligedToDevelopAndCommercialize",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_oricProduct",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - License Agreements - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "oric:LicenseAgreementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "oric:NumberOfLicensedProductsObligedToDevelopAndCommercialize",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_oricProduct",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Short-Term Investments - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails",
     "shortName": "Short-Term Investments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_oricSecurity",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Short-Term Investments - Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails",
     "shortName": "Short-Term Investments - Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
     "shortName": "Convertible Preferred Stock - Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "oric:ConvertiblePreferredStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "oric:ConvertiblePreferredStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200430",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "oric:ConvertiblePreferredStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200430",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Option Activity (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation - Summary of Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Income Tax - Schedule of Provision for Income Taxes and Income Taxes Computed (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails",
     "shortName": "Income Tax - Schedule of Provision for Income Taxes and Income Taxes Computed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Tax - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Tax - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Income Tax - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails",
     "shortName": "Income Tax - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Commitment and Contingencies - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitment and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_srtStatementGeographicalAxis_oricSanDiegoCaliforniaMember_20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails",
     "shortName": "Commitment and Contingencies - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Employee Benefit Plan - Additional Information (Details)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
     "shortName": "Employee Benefit Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "oric:TemporaryEquityStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "shortName": "STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "oric:TemporaryEquityStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - STATEMENTS OF CASH FLOWS",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Description of the Business",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "oric-10k_20201231.htm",
      "contextRef": "C_0001796280_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "oric_AccruedClinicalAndManufacturingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and manufacturing costs.",
        "label": "Accrued Clinical And Manufacturing Costs",
        "terseLabel": "Accrued clinical and manufacturing costs"
       }
      }
     },
     "localname": "AccruedClinicalAndManufacturingCosts",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_AccruedDeferredFinancingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued deferred financing costs current.",
        "label": "Accrued Deferred Financing Costs Current",
        "terseLabel": "Accrued deferred financing costs"
       }
      }
     },
     "localname": "AccruedDeferredFinancingCostsCurrent",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_AcquiredInProcessResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in-process research and development expense.",
        "label": "Acquired In Process Research And Development Expense [Member]",
        "terseLabel": "Acquired In-Process Research and Development Expense [Member]"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and summary of significant accounting policies.",
        "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oric_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and summary of significant accounting policies.",
        "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oric_CommercialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone.",
        "label": "Commercial Milestone [Member]",
        "terseLabel": "Commercial Milestone"
       }
      }
     },
     "localname": "CommercialMilestoneMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_ComputerHardwareAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer hardware and software.",
        "label": "Computer Hardware And Software [Member]",
        "terseLabel": "Computer Hardware and Software"
       }
      }
     },
     "localname": "ComputerHardwareAndSoftwareMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_ConvertiblePreferredStockDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock.",
        "label": "Convertible Preferred Stock Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockDisclosureTextBlock",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oric_CumulativeChangeInOwnershipPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative change in ownership period.",
        "label": "Cumulative Change In Ownership Period",
        "terseLabel": "Cumulative change in ownership period"
       }
      }
     },
     "localname": "CumulativeChangeInOwnershipPeriod",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oric_DeferredRentPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred rent policy.",
        "label": "Deferred Rent Policy Policy [Text Block]",
        "terseLabel": "Deferred Rent"
       }
      }
     },
     "localname": "DeferredRentPolicyPolicyTextBlock",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oric_DeferredTaxAssetsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Research and Development",
        "label": "Deferred Tax Assets Research And Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchAndDevelopment",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_DeferredTaxLiabilitiesFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities Fixed Assets",
        "label": "Deferred Tax Liabilities Fixed Assets",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_DescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the Business.",
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessLineItems",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oric_DescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the business.",
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessTable",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oric_DevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulatory milestone.",
        "label": "Development And Regulatory Milestone [Member]",
        "terseLabel": "Development And Regulatory Milestone"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_FairValueAssetsLevel1ToLevel3TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, assets, level 1 to level 3 transfers, amount.",
        "label": "Fair Value Assets Level1 To Level3 Transfers Amount",
        "terseLabel": "Transfer between level 1 to 3"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel3TransfersAmount",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_FairValueAssetsLevel2ToLevel3TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, assets, level 2 to level 3 transfers, amount.",
        "label": "Fair Value Assets Level2 To Level3 Transfers Amount",
        "terseLabel": "Transfer between level 2 to 3"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel3TransfersAmount",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_FairValueAssetsLevel3ToLevel1TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, assets, level 3 to level 1 transfers, amount",
        "label": "Fair Value Assets Level3 To Level1 Transfers Amount",
        "terseLabel": "Transfer between level 3 to 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel3ToLevel1TransfersAmount",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_FairValueAssetsLevel3ToLevel2TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, assets, level 3 to level 2 transfers, amount.",
        "label": "Fair Value Assets Level3 To Level2 Transfers Amount",
        "terseLabel": "Transfer between level 3 to 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel3ToLevel2TransfersAmount",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax.",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oric_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax.",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oric_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_LicenseAgreementAdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement additional Milestone payment.",
        "label": "License Agreement Additional Milestone Payment",
        "terseLabel": "License agreement, additional milestone payment"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalMilestonePayment",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement cash payment related to acquired assets charge.",
        "label": "License Agreement Cash Payment Related To Acquired Assets Charge",
        "terseLabel": "License agreement cash payment related to acquired assets charge"
       }
      }
     },
     "localname": "LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_LicenseAgreementChargeRelatedToAcquiredAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement charge related to acquired assets.",
        "label": "License Agreement Charge Related To Acquired Assets",
        "terseLabel": "License agreement charge related to acquired assets"
       }
      }
     },
     "localname": "LicenseAgreementChargeRelatedToAcquiredAssets",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_LicenseAgreementMaximumMilestonePaymentObligationToPay": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement maximum milestone payment obligation to pay.",
        "label": "License Agreement Maximum Milestone Payment Obligation To Pay",
        "terseLabel": "License agreement maximum milestone payment obligation to pay"
       }
      }
     },
     "localname": "LicenseAgreementMaximumMilestonePaymentObligationToPay",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement shares issued value related to acquired assets charge.",
        "label": "License Agreement Shares Issued Value Related To Acquired Assets Charge",
        "terseLabel": "License agreement shares issued value related to acquired assets charge"
       }
      }
     },
     "localname": "LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://www.oricpharma.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oric_LicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements disclosure.",
        "label": "License Agreements Disclosure [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oric_LicenseAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Line Items]",
        "terseLabel": "License Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAgreementsLineItems",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oric_LicenseAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Table]",
        "terseLabel": "License Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAgreementsTable",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oric_LicenseFeesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fees.",
        "label": "License Fees Policy [Text Block]",
        "terseLabel": "License Fees"
       }
      }
     },
     "localname": "LicenseFeesPolicyTextBlock",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oric_LiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquid investments maturity period.",
        "label": "Liquid Investments Maturity Period",
        "terseLabel": "Liquid investments maturity period"
       }
      }
     },
     "localname": "LiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oric_MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of additional common stock capital shares reserved for future issuance.",
        "label": "Maximum Number Of Additional Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Additional number of shares available for future issuance"
       }
      }
     },
     "localname": "MaximumNumberOfAdditionalCommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oric_MiratiTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mirati Therapeutics, Inc.",
        "label": "Mirati Therapeutics Inc [Member]",
        "terseLabel": "Mirati Therapeutics, Inc"
       }
      }
     },
     "localname": "MiratiTherapeuticsIncMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "label": "New Accounting Pronouncements Not Yet Adopted Policy [Text Block]",
        "terseLabel": "New Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oric_NonCashStockConsiderationAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash stock consideration, acquisition.",
        "label": "Non Cash Stock Consideration Acquisition",
        "terseLabel": "Non-cash stock consideration, acquisition"
       }
      }
     },
     "localname": "NonCashStockConsiderationAcquisition",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of licensed products obliged to develop and commercialize.",
        "label": "Number Of Licensed Products Obliged To Develop And Commercialize",
        "terseLabel": "Number of licensed products obliged to develop and commercialize"
       }
      }
     },
     "localname": "NumberOfLicensedProductsObligedToDevelopAndCommercialize",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oric_NumberOfPeriodAgreementInEffect": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of period the agreement in effect.",
        "label": "Number Of Period Agreement In Effect",
        "terseLabel": "Number of period the agreement in effect"
       }
      }
     },
     "localname": "NumberOfPeriodAgreementInEffect",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oric_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_PaymentsOfStockIssuanceCostsWithInitialPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of stock issuance costs with initial public offering.",
        "label": "Payments Of Stock Issuance Costs With Initial Public Offering",
        "negatedLabel": "Issuance costs associated with initial public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCostsWithInitialPublicOffering",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_PaymentsOfStockIssuanceCostsWithPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of stock issuance costs with public offering.",
        "label": "Payments Of Stock Issuance Costs With Public Offering",
        "negatedLabel": "Issuance costs associated with public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCostsWithPublicOffering",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance initial public offering, net of issuance cost.",
        "label": "Proceeds From Issuance Initial Public Offering Net Of Issuance Cost",
        "terseLabel": "Net proceeds from IPO"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCost",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock gross.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Gross proceeds from secondary public offering excluding underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_PropertyPlantAndEquipmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Plant and Equipment Impairment Loss",
        "label": "Property Plant And Equipment Impairment Loss",
        "terseLabel": "Impairment of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairmentLoss",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_SanDiegoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego California",
        "label": "San Diego California [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoCaliforniaMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_ScenarioOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario One",
        "label": "Scenario One [Member]",
        "terseLabel": "Begin to expire in 2034"
       }
      }
     },
     "localname": "ScenarioOneMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_ScenarioTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Two",
        "label": "Scenario Two [Member]",
        "terseLabel": "Not expire"
       }
      }
     },
     "localname": "ScenarioTwoMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_SecondaryPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary public offering.",
        "label": "Secondary Public Offering [Member]",
        "terseLabel": "Secondary Public Offering"
       }
      }
     },
     "localname": "SecondaryPublicOfferingMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_SeriesCAndDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C and D preferred stock.",
        "label": "Series C And D Preferred Stock [Member]",
        "terseLabel": "Series C and D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCAndDPreferredStockMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award minimum percentage of combined voting rights of common stock holders.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Percentage Of Combined Voting Rights Of Common Stock Holders",
        "terseLabel": "Minimum percentage required for holders of combined voting power to be eligible for incentive stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfCombinedVotingRightsOfCommonStockHolders",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award number of shares subject to repurchase.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Subject To Repurchase",
        "terseLabel": "Shares subject to repurchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options not be granted at less than fair market value of common stock at date of grant maximum term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Not Be Granted At Less Than Fair Market Value Of Common Stock At Date Of Grant Maximum Term",
        "terseLabel": "Maximum term of options may not be granted at less than fair market value of the common stock at the date of grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantMaximumTerm",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award stock options not be granted at less than fair market value of common stock at date of grant percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Not Be Granted At Less Than Fair Market Value Of Common Stock At Date Of Grant Percentage",
        "terseLabel": "Percentage of options may not be granted at less than fair market value of the common stock at the date of grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotBeGrantedAtLessThanFairMarketValueOfCommonStockAtDateOfGrantPercentage",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oric_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award shares issued subject to repurchase liabilities recorded.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued Subject To Repurchase Liabilities Recorded",
        "terseLabel": "Liabilities with shares issued with repurchase rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedSubjectToRepurchaseLiabilitiesRecorded",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_SharesIssuedPercentageOfPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued percentage of premium.",
        "label": "Shares Issued Percentage Of Premium",
        "terseLabel": "Premium percentage"
       }
      }
     },
     "localname": "SharesIssuedPercentageOfPremium",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oric_SouthSanFranciscoAndSanDiegoLocationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South San Francisco and San Diego locations.",
        "label": "South San Francisco And San Diego Locations [Member]",
        "terseLabel": "South San Francisco and San Diego Locations"
       }
      }
     },
     "localname": "SouthSanFranciscoAndSanDiegoLocationsMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_SouthSanFranciscoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South San Francisco, California.",
        "label": "South San Francisco California [Member]",
        "terseLabel": "South San Francisco, California"
       }
      }
     },
     "localname": "SouthSanFranciscoCaliforniaMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_StockTransferRestrictionsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock transfer restrictions period.",
        "label": "Stock Transfer Restrictions Period",
        "terseLabel": "Stock transfer restrictions period"
       }
      }
     },
     "localname": "StockTransferRestrictionsPeriod",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oric_SuccessBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success based milestones.",
        "label": "Success Based Milestones [Member]",
        "terseLabel": "Success Based Milestones"
       }
      }
     },
     "localname": "SuccessBasedMilestonesMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_TemporaryEquityConversionToCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity conversion to common stock shares.",
        "label": "Temporary Equity Conversion To Common Stock Shares",
        "negatedLabel": "Conversion to Common Stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityConversionToCommonStockShares",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "oric_TemporaryEquityConversionToCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity conversion to common stock value.",
        "label": "Temporary Equity Conversion To Common Stock Value",
        "terseLabel": "Conversion to Common Stock"
       }
      }
     },
     "localname": "TemporaryEquityConversionToCommonStockValue",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_TemporaryEquityIssuedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issued period.",
        "label": "Temporary Equity Issued Period",
        "terseLabel": "Issue Period"
       }
      }
     },
     "localname": "TemporaryEquityIssuedPeriod",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "oric_TemporaryEquityStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issuance costs.",
        "label": "Temporary Equity Stock Issuance Costs",
        "terseLabel": "Preferred stock, issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuanceCosts",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares net of issuance costs.",
        "label": "Temporary Equity Stock Issued During Period Shares Net Of Issuance Costs",
        "terseLabel": "Issuance of Series C and D preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCosts",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "oric_TwoThousandAndTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty employee stock purchase plan.",
        "label": "Two Thousand And Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP"
       }
      }
     },
     "localname": "TwoThousandAndTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen equity incentive plan.",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan and two thousand fourteen equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan And Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan and 2014 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oric_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts, commissions and other offering expenses.",
        "label": "Underwriting Discounts Commissions And Other Offering Expenses",
        "terseLabel": "Underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "localname": "UnderwritingDiscountsCommissionsAndOtherOfferingExpenses",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_UnpaidDeferredFinancingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid deferred financing costs.",
        "label": "Unpaid Deferred Financing Costs",
        "terseLabel": "Unpaid deferred financing costs"
       }
      }
     },
     "localname": "UnpaidDeferredFinancingCosts",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_UpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment.",
        "label": "Upfront Cash Payment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPayment",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oric_VoronoiIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voronoi Inc.",
        "label": "Voronoi Inc [Member]",
        "terseLabel": "Voronoi Inc."
       }
      }
     },
     "localname": "VoronoiIncMember",
     "nsuri": "http://www.oricpharma.com/20201231",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r217",
      "r219",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r376",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r217",
      "r219",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r376",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r197",
      "r217",
      "r219",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r376",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r197",
      "r217",
      "r219",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r376",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r194",
      "r195",
      "r419",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r194",
      "r195",
      "r419",
      "r434",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r178",
      "r218",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "CALIFORNIA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update201912 [Member]",
        "terseLabel": "ASU No 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Amortization of discount on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedRentCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r33"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Rent Current",
        "terseLabel": "Deferred rent - short-term"
       }
      }
     },
     "localname": "AccruedRentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r33"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r169"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r43",
      "r44",
      "r45",
      "r408",
      "r428",
      "r432"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r83",
      "r84",
      "r85",
      "r303",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r285",
      "r286",
      "r287",
      "r288",
      "r378",
      "r379",
      "r380",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r221",
      "r223",
      "r262",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r188",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "negatedLabel": "Issuance costs associated with offering of common stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r223",
      "r248",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti dilutive securities excluded from computation of net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r124",
      "r126",
      "r130",
      "r145",
      "r299",
      "r304",
      "r325",
      "r395",
      "r407"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r40",
      "r80",
      "r145",
      "r299",
      "r304",
      "r325"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Assets, Fair Value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r136",
      "r160"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r135",
      "r137",
      "r160",
      "r397"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Available for sale, Investment"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r224",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r25",
      "r72"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r73",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r72",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r327"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "auth_ref": [
      "r86",
      "r146",
      "r147",
      "r150",
      "r255",
      "r286",
      "r310",
      "r326",
      "r340",
      "r380",
      "r421",
      "r422",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was early adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Early Adoption",
        "terseLabel": "Change in accounting principle, accounting standards update, early adoption"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r87",
      "r98",
      "r152",
      "r259",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, early adoption"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r79",
      "r80",
      "r99",
      "r100",
      "r101",
      "r103",
      "r105",
      "r109",
      "r110",
      "r111",
      "r145",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r177",
      "r398",
      "r412"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Number of shares available for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares, issued",
        "verboseLabel": "Upfront payment shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value; 1,000,000,000 shares and 26,750,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; 36,672,415 shares and 1,984,222 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively",
        "verboseLabel": "Upfront payment value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r57",
      "r401",
      "r415"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r115",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration By Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Amount Converted1",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Shares Converted1",
        "terseLabel": "Convertible preferred stock outstanding converted into shares of common stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r14",
      "r15",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "terseLabel": "Outstanding shares of convertible preferred stock converted into shares of common stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Table [Text Block]",
        "terseLabel": "Schedule of Cost, Gross Unrealized Holding Gains, Gross Unrealized Holding Losses and Fair Value of Available for Sale Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r142",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position Number Of Positions",
        "terseLabel": "Number of securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1": {
     "auth_ref": [
      "r196",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Deferred Compensation Arrangement With Individual Maximum Contractual Term1",
        "terseLabel": "Options granted, maximum contractual term"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualMaximumContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r12",
      "r394",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r36",
      "r336"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit Noncurrent",
        "terseLabel": "Deferred rent - long term"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets Goodwill And Intangible Assets",
        "terseLabel": "Intangible"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r70",
      "r167"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Plans and Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "verboseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Total unrecognized compensation expense related to outstanding unvested stock-based awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Total unrecognized compensation expense related to outstanding unvested stock-based awards expected to be recognized over weighted-average remaining service period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r88",
      "r95",
      "r97",
      "r108",
      "r151",
      "r188",
      "r191",
      "r256",
      "r257",
      "r258",
      "r287",
      "r288",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate Of Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Transfer between level 1 to 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Transfer between level 2 to 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r311",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value By Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r213",
      "r312",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r311",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Fair Value By Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r311",
      "r312",
      "r314",
      "r315",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Disclosure Item Amounts [Domain]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r198",
      "r200",
      "r205",
      "r213",
      "r312",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r198",
      "r200",
      "r205",
      "r213",
      "r312",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r213",
      "r312",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r213",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value Measurements Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r78",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r164",
      "r165",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain Loss On Disposition Of Assets1",
        "negatedLabel": "Loss on fixed asset disposals"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r166",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Property and Equipment"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r271",
      "r274",
      "r280",
      "r290",
      "r292",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination Penalties And Interest Accrued",
        "terseLabel": "Accrual for interest or penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r96",
      "r97",
      "r123",
      "r269",
      "r291",
      "r294",
      "r417"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "totalLabel": "Provisions for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r78",
      "r267",
      "r268",
      "r274",
      "r275",
      "r279",
      "r284",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate",
        "terseLabel": "Statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Income Tax Reconciliation Other Reconciling Items",
        "terseLabel": "Other permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Income Tax Reconciliation State And Local Income Taxes",
        "terseLabel": "State tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Income Tax Reconciliation Tax Credits Research",
        "negatedLabel": "Research and development credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment Policy [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r143",
      "r393",
      "r404",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Operating lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Extend the lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r80",
      "r127",
      "r145",
      "r300",
      "r304",
      "r305",
      "r325"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r80",
      "r145",
      "r325",
      "r396",
      "r410"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r80",
      "r145",
      "r300",
      "r304",
      "r305",
      "r325"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r2",
      "r32"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r112",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r47",
      "r50",
      "r55",
      "r71",
      "r80",
      "r87",
      "r91",
      "r92",
      "r93",
      "r94",
      "r96",
      "r97",
      "r102",
      "r124",
      "r125",
      "r128",
      "r129",
      "r131",
      "r145",
      "r325",
      "r399",
      "r413"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired1",
        "terseLabel": "Amounts accrued for purchase of property and equipment"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r124",
      "r125",
      "r128",
      "r129",
      "r131"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Current",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases Rent Expense Net",
        "terseLabel": "Total rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.",
        "label": "Operating Loss Carryforwards Expiration Date",
        "terseLabel": "Operating loss carryforwards, expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r51",
      "r54",
      "r56",
      "r188",
      "r328",
      "r333",
      "r334",
      "r400",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r43"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Option to Purchase Additional Shares"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r197",
      "r199",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r224",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion At Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePerDollarAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount per share used to calculated dividend payments on preferred stock.",
        "label": "Preferred Stock Dividend Rate Per Dollar Amount",
        "terseLabel": "Dividend Annual Rate per Share"
       }
      }
     },
     "localname": "PreferredStockDividendRatePerDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.0001 par value; 200,000,000 shares and no shares authorized at December 31, 2020 and December 31, 2019, respectively; no shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock pursuant to initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock pursuant to public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock",
        "terseLabel": "Proceeds from issuance of preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfNotesReceivable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds From Sale Of Notes Receivable",
        "terseLabel": "Proceeds from notes receivable"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r65",
      "r251"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r47",
      "r50",
      "r66",
      "r80",
      "r87",
      "r96",
      "r97",
      "r124",
      "r125",
      "r128",
      "r129",
      "r131",
      "r145",
      "r298",
      "r301",
      "r302",
      "r306",
      "r307",
      "r325",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r168"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Total property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r170",
      "r411"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r78",
      "r170",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful lives of related assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r207",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r207",
      "r342",
      "r344",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r78",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses and Accrued Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research And Development In Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r191",
      "r259",
      "r409",
      "r427",
      "r432"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r88",
      "r95",
      "r97",
      "r151",
      "r256",
      "r257",
      "r258",
      "r287",
      "r288",
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Summary of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of Provision for Income Taxes and Income Taxes Computed"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Significant Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Summary of Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r223",
      "r247",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r223",
      "r247",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Total Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments under Non-cancelable Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r224",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r230",
      "r236",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of common stock initially reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of common stock remained available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Options, Forfeited and cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited and Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r232",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Options outstanding, Ending Balance",
        "periodStartLabel": "Options outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Options outstanding Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Options outstanding Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r222",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r78",
      "r224",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Price per share of common stock",
        "verboseLabel": "Stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r242",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfFairValueOfStockOptionsEstimatedUsingBlackScholesMertonOptionPricingModelAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Exercise price as a percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Issue Price per Share",
        "verboseLabel": "Issue price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r79",
      "r80",
      "r99",
      "r100",
      "r101",
      "r103",
      "r105",
      "r109",
      "r110",
      "r111",
      "r145",
      "r188",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r83",
      "r84",
      "r85",
      "r88",
      "r95",
      "r97",
      "r108",
      "r151",
      "r188",
      "r191",
      "r256",
      "r257",
      "r258",
      "r287",
      "r288",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r108",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r15",
      "r16",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period Shares Acquisitions",
        "terseLabel": "Issuance of common stock related to acquired-in-process research and development (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r188",
      "r189",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion to Common Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r188",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Number of shares issued under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r188",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Offering of common stock (in shares)",
        "verboseLabel": "Shares of common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r188",
      "r191",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Options, Exercised",
        "terseLabel": "Exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationSummaryOfOptionActivityDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r39",
      "r188",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period Value Acquisitions",
        "terseLabel": "Issuance of common stock related to acquired-in- process research and development"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r39",
      "r188",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion to Common Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r188",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Offering of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r188",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r80",
      "r134",
      "r145",
      "r325"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders Equity Reverse Stock Split",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAndStockBasedCompensationAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit",
        "terseLabel": "Impact of Tax Cuts and Jobs Act"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r8",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity By Class Of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Convertible preferred stock, $0.0001 par value; no shares and 20,348,788 shares authorized at December 31, 2020 and December 31, 2019, respectively; no shares and 19,278,606 issued and outstanding at December 31, 2020 and December 31, 2019, respectively; aggregate liquidation preference of $0 and $178,058 at December 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheets",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference",
        "terseLabel": "Aggregate liquidation preference",
        "verboseLabel": "Aggregate Liquidation Preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Convertible preferred stock, authorized",
        "verboseLabel": "Shares Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Convertible preferred stock, issued",
        "verboseLabel": "Shares Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Convertible preferred stock, outstanding",
        "verboseLabel": "Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockAuthorizedAndIssuedAndItsPrincipalTermsDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of Series C and D preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r8",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Table [Text Block]",
        "terseLabel": "Schedule of Convertible Preferred Stock Authorized and Issued and its Principal Terms"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage by which investments in equity securities have declined in value to be considered other than temporary impairment (OTTI).",
        "label": "Threshold Percentage Of Value Decline In Equity Securities To Be Considered Other Than Temporary Impairment",
        "terseLabel": "Cumulative change in ownership percentage"
       }
      }
     },
     "localname": "ThresholdPercentageOfValueDeclineInEquitySecuritiesToBeConsideredOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r140",
      "r141",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r285",
      "r286",
      "r287",
      "r288",
      "r378",
      "r379",
      "r380",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r198",
      "r213",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsScheduleOfCostGrossUnrealizedHoldingGainsGrossUnrealizedHoldingLossesAndFairValueOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r266",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense",
        "terseLabel": "Interest and penalties not recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r113",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted",
        "verboseLabel": "Weighted average shares outstanding used in computing net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.oricpharma.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.EE.Q2(f))",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39927-112707"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120520240&loc=SL120174030-210619"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r449": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r451": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r452": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r453": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r454": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r455": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r456": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r457": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r458": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001564590-21-014865-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-014865-xbrl.zip
M4$L#!!0    ( *."=U*S;TQJWT,   ),   6    9W!T>3%L:W-M:&)A,# P
M,# Q+FIP9\RZ!5A4W=<W?.@4! $I">F6;D9$&$) 0+JD2[HE1D $Z1 01%!"
MD)0N8:25&FDD19#NCF'F.^!]/__[_I[W>]\OK^M#YV+./OOW6['77GNM<T!/
MH'\"UU655)0 # P,X#'X#T!/ 0H /BXN'BX./AX>'@$!/B$QQ35B(B)B&O(;
MI!2W:!D9;M'2TS.Q\G,PW>9EH:?G%.?BO2,H(B+"R"$I*R$DPR\L(G1)@D%
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MH0$H&NC4+MU<]<9339>78.UE9#PYU)+CKC2U.#BN:WJ81N3H\D#AV[ZA LZ
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MH2BSX']3R[8&HX$*J.$NK1.5OG2.8+_(H 4)G2.3BR\@I!+HM<*3709'47Z
M_T.5#+!/WH!M[X*1ZO@J)S)%JM+7?I%K=!S65C,.OW)"_.6&0 .$4V:HB[0K
MI>EWMS0K/DXL.CB!&3O<N1SVM/>/,O$G>F?'QQOP*SJ'_>[ZYEB-;C8U4U<D
M3Y#O^9CY\<FE#^$[9:)SVX:PN05P(P\B&.8WN'TDI8S6(?,FZ_"Y2C#>NL%X
MRP>IO4'^/]P[N5FR[1./4#JO*)OG$23J)0_8T[Q\[.>$XXBRP;*?]L=P,+WY
MFTZIY[6_9OPM*)Y7!7C]:JJO[@IEC6*-99$/UY4 'O7DK#A#K[%OB]Q]QQU.
M\X6:1C*_&/*/K&E@LE7%HZ47_(\<&!W75ZIH>$X\MX'R"KI*T/Q4-H[<B E;
M-&"WG[LA#*LZ'73[;ZCP=*.HJB,:^ _DRA^L"6_/B&[VE13H'VS.O*U>3LF?
MI"]WA;U))%1#:?>'\@^VWC"E&$][9])1ZE6=*_=FHJ6>N< RII &955(DX0D
MY? _T2*;%?ST4[G/JG:"MIQ1@VXL,-9T.VI_RHYGA3H;4>^RD'&',@RX9$*"
M(QZ/6MS)NFC<[M+5(TSB@O#+%OXA<ZTYE_EAO!6=XC!)X@>VM"Q;_#X%YZEG
M&NXG3[.<[OU+7S5?$:W*2@%Y5 [D6)&B@DLY4?,A(/*(-K</":X(R[7M<W!]
MY2G3C8)O@^?EB^,+,"C>1?651W: ZQ5<OB_7$K&3NP*_W?JIB2C9E5TN>WDD
MV-N*MDP,.^V=&85US&//N?+U>^LW.>4Q/.@_M3)Y>"@)AZGAE@SB#W_3HO"?
MC.K#&RZ7.2Z.K]14$7G07#S+E416(F1WG'FK'D/^E@:T0 ?1?&]XS6+4,$\O
M@3P78#AE^;[GGWNNA4QYWDKV4@ES__OUN^MK\(%<U/>4<J/545HETSROS3C9
M:^293U5>WC.UC"9L_%Q9T//S!1,5P"FS/#4N,HH:\R#3TYLFZ/KN06JU/K*[
MK3S9L<E;2;W0%^9 +4,".RD?*E!W]< 083JU"W1L^.+BO]XE/)ROG2)^](/O
MD;D-&>[H1.++E^XS4(7N^>.*DU&_@ZD&&DH+U^QGFECCS:K>#B\1:=?[0O76
M]^]L^1\QI@@<?9XRH+:4KDI&?! >#XL[Y!MRG4VV$;"OC1)>MVN#[PD973Z>
MDQ>-_5==\K$-QL!0O,]S TES!OFZ"3;OO\'F_?WR[(=&-!!?<(8&5+O'W]77
M#['%C:DD6?8\ZGCSLG4 'YN\X'WK ,^6UJZ'3Y-(PW%N]M,%.QC%M"&4H-+/
M[:N1Q)0T!04+N1VO)J*>H7T_6\7\NNQ%W91E!D74T'TLK,>6+ZN3DQOJ7->'
M*4U:;(.'C0W65LK$>. W\ZB^7V0H!2JQIBKK,U&:_E@N=)Y[P6W3M.L1(UN[
M\>%G&^4 &GB#KQ2\VO:[,6:P=XEAT,?.4!7N%^244=.P*S!5(C<,V+/YWN2N
MX-SK6B+T?>I,&*0!PQ@JGV4T4C>H[UD>H%T71[(:90_,[1X+[#)N9[Q?$D<>
MN)ZOC&[ZHI3X=% MO\$2K=^[T0<^?\+T?8.CLB;EOI;H:'N.\\LPP2?(-]%D
MSSR46U>-3'[7S"Z3T,!;YHX'"W!=M^LN#IQJXQAQFTN&JPQ9OF$_J9WU:LU-
M<TQ].(W,V\)C2CS5V6;:N3?I&$N<\":,6FR5./ZYM 9FDL9"4WE=_DT23>'(
MV;DY4)'A.O'C*=29Z.A)\+D2"E$1=<0G)9F;]-MZ/_'3S_;G#OC?NE 2JW'<
MS=U'V QL5?9C/PY2&G&U;DA7F/#_5/!^L#4U';,4G=R;O^79IA!_&(L&@G3J
MLD']#LU"7(OMJ3Y)KPFO'HN?JU9/!A7A3-B8OM<==GC<]')!8D$R'\SS\K,X
M,6>\-XU?[K,]^WP;(MG+3WCQ*U^PRPT?6\M]CW\9H_F/S7B7-A\:GP4-1!,W
MAE;FOBSEP%B*(*R$ <^M$[./&J@IZWP_^OENKMU6EUQPDDXAYY4@"X5XU'^Y
M6+9TTVR63GKOW=#QQW$."G67)I=RV@QVOV"/4O,?*+'53L*CGGIQM#K,(LF!
M5^--Y>EG)%%=2+LTF%_QV,Z?B9E]CLZUU[,>EV?"BE[+G=/\XR67^))#ZYOS
M_M.,#54_%>N0ZP94=NP^=J]S?HE*/UR\E5\':#S5R9IK,TYYG-5!YK&8;J9-
M#!%K[9)S>79&'##8QX#HI_=90NT'V[YMN#*RK#]W1W\2V[QQCRA-*"^)"JO/
M1&#8P368N]IM);9L#69E,#G(A\7$X1&?CAVNLAP^'005\208WH?RTL _SZ47
MN/R)BXJ]S\R\R1).RE:"7T,A0B:A-&U2F8=,[/*'FVH!-U^4UP101K[W7R;4
MZY8VU/@B\V5BTK-I:WB)U.[#R@(8#6_V19K>G&^""ZGO(%H0KAWP*LF8\X>5
ME_U"DDY-:U ^P9K?0_EMC2A-8GFVMF*#TP<4W15YEG=)8SLCB(--0KI5)3^'
M_?#/C2:>FW4=2/.$^<.E-OGUVX8_#Q.(C JP.I.SJ#8]HB"FJYN9&:[/?^XG
MQ45<M$M>)_CZ6)@>NG>(5[[K0N'I3_0WQ?D:Z!W0NE)S,EX>?\?O.<Q)/TS;
MB(F3IC1DQQV03NP?:;X93OSQXQ]ISGQ"4- 5XLMJE\"W8JDAI-,@4=_0UN6@
M>OX[H@R??.\/9GS]U7E2A]B+=PY8AIH5E,9*:XHUQ6[4@N>$(9G,>S1 ^G1/
MR\@(?T2CG/3(5O'+&BS"-6AV]$:4_62LH?R4U]-1BC!II0V7;HG5#*,O!VU1
MG.\P_V>?./<L^S)]@^K1O/&\C&&$+N;<-_=LWNO]2]9; +&5))XL5[Z'#0]+
M44[]&W58AWBLR^"]N.'[M@;D;*U:3/?4;GQA$L;:XK870#[N9TRWVTOZN020
MSO14++^3L8I9:)93@M9HYDH3\D#NISU\HQ9[J!SC&_#Z#C>NDI_$+2&>>_D9
M'-Z>9J2'8/7<R)GSU^]",>@;OQ?B<LS-S/2Q"PD%W_7LTCB0^[#SQ7&U4K^(
M1]5C+N]"UZV5?W)OZ,3AU3Q$ \\+#,&Z%H%\ 9\W9S03D2TIYVA::3K+UE$<
M.]*JUNLM!@]9CMYDE#_\8L]^;Q$-9+F"K7[&V+^0JBT<8S.AI3]LK9YAJZI
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M"D=L3^VVT&F4]6,L0!E%^MJ.HX:W1;PV5(<^52C&&I<<LV0^*B&/!$HSLSK
M\V'/<KK_-S3UO/OQM\U^A@>0_2Z!IKHMTJ;5@Z.<W0TYPV/)=48*L?P2PTD%
MY\5NCM=LY)\$$JDMGDE[CL-KO(J/(\9RR>Z7T%C&W*'&YL0FU<Q7!KM3![%&
M2HJQC5/XO]XU/PHW_<<#[U%FHTQ7][8LKM L3E:_ D+[ D)+!JY?K[E^A9!0
M[#X _RMT2N@H2CQD_O56G6+-.EJ#8M+M'4X!H3,XU)::H#U\?<WMPW X)H5.
MN(CN&Q[IZ//\VIK(;SQ>6'4-!Q0XY3GB@:*_U-Y*V6_DZ=?7^$Q6%/8R0V;
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M&OQXJR4\)[O&\BPO(%LNGN D O6L#AQ,0Y%I7@>E41VC+L:_BVAM&@1IR"(
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M]/?VMCSE7#"SV\'385%>F5$&IU'N UD%*YK)6MXR ;SQ8[E@$I9FFA\^29?
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MSY$J=[;6$^<Y"\(:(\AF3GTJOOW;1RE9_X&!]@L8SK/@>\"&I$9U4PI5DZ_
M"F0G>)6#9O>IO*AGS @5JFUA<_O.US^S/2A@S=B+![FAT&+(T7MC,_-6[$?6
M=\:C!GL^D9U3VWFT:0+)%T.UE0#*UTK4<X,E2?^1LP)59;T3?[M(/Z),+=7M
M[ UKC^;\4P5CA(=PP(,@66(21<?/5/\*P1E(/1.3[>"';VZ?BHI<47>MX1<#
MS0;P+Z(J,I7A#]%75A.W<\P7,<S^X?H'$D?;[MKC<T1^P<4LW+1=GM=!]G.1
MUB7/UO?_>%FD6.AX\?PX.+*/Q.\;TLQ)G6L?X2-'\V@\?$<VBO>UZ/R3D_A*
MFC&*J"86E?7RI2,]%?;??TZ2_Z=!<_GU/P!02P,$%     @ HX)W4MR=1HRG
M(0  -"L  !8   !G<'1Y,6QK<VUH8F$P,# P,#,N:G!G[7D'4%3;LNA&,A($
M04#"($$R2A0D#$H2$$90<G:0'"3'8<@H2E1 D2"9(8J2,Y)S!LD@.><\S/PQ
MW7O.^[]>W?_JU:_Z]>Z>VC6KU^JXNU=WK[W1W]"SP!4E>45Y  L+"S#&_ #T
M!" #$.#AX>/A$N#CXQ,2$A 14Y(07[Y,3$MQE8R2X3J(D>$Z/3T3*Q\[$S,/
M"ST]QQU.GMO\0D)"('8Q25$!"3Y!(8$?3+ ("0F)+Q/3D)#0"-R@OR'P?WVA
MZP%R L#MD@DV%C-PB1P+FQP+W02    +%^OG!?R^L"YAX^#BX1,0$EW&()1<
M 2YA86-?PL'&Q<7!P:S",.L #CDNQ0W^>WA7U4SPF1TH!?RB4@A8[A<U4*GW
M[[ */G7T)R2Z1DU#>YWM)CL')Y>0L,@=4;&[,K)R\@H/%)4>/]'0U-+6T86:
M/C,SM["T<G)V<75S]_ ," P*#GGQ,C3ZS=N8V+AW[^-3T](S,K.R$3F?OQ27
ME):55U1^;6QJ;FEM:^\8&!P:'AG]-C8^]WU^87%I>65U;7=O_^#PZ/CD].R'
M75@ -M:?Z_]H%SG&KDLX.-@X^#_LPKKD]@.!' ?W!C\>Q3TU?!.'J\P"?@24
M]Z-2BAH(6035=ZB>.O8376,5FF/;_6':3\O^-</\_TN6_<.P?]HU#A!C8V&<
MATT.@(%# Z_FN\%O$%/-]IF-3N90JS@M=>$&!8*N^DV#=(I+5]NIKB'FZ3K%
ME1'YQ45WHGQ&7F]L%E$RV6Z6:+]>9N!?L^9N'KVN=/+VPQ25W7*H:'U4@8$,
M5BQ6I'<>%GNV<*)'P:K;;J6^!9%;CQUM])ZL_6W?]&!]\DB@7K2@?"Z+-3[B
M\#A)4G\D2*R#(C$>EGS*H.>>@UKZSCI07,XWS)M240EUSZ$R[<$QIW':*^J1
M3D]N+G-8$Q2PS!Y_2(TPX6TO;_*7YZH@GX_!]5U/.BF07];LMY=J7SXQFPI*
MMZ;DXJ.5EA,CDJ8Q)A,5HV*-WXH1^2QL*2%^V3"8K&Z3Q+_>F%_?E@??41"R
M%@...SMO0XTUPGM[&]! U  X+%//Z[6VO)W-YM92U:ON[X*7;=42G*KW)'->
M>=^KB6A,'H\PL8RM4G91XVF0?L:CV'6OO-786KA:,4NH\FU(X\[V4!_;W+F,
MSZ'T1'C"<Z^GJ5]&A3IQPHS[>KXMZ0QVU<6J%'STE=^8]W=?[0;G])["R>$V
M)FA@>7D6#;2MC+:4S8SINJSVOX);X(5.*MRXD3452,O%3U>@S4^/U98[S;<K
M,4TSN)%U1:_MF.)4]5G4\-4%'E4-[?G%@P+-6U>_-=KCD*^HY8D<XRU14O,&
M1BXL.-2?1C"(K6H62-@S3([L0]):]O3$W%\F(-,1CR>2:,)AEC#-#!2HJ7#S
M-6_=R\(T-,#L5?B"NI_O[56E8#'[?)^^3HEH[SJI_K"HHH8U0FQ_;CT41>[;
M7:>50<M58OH7F;'J^9R$51PBFR9#QB);A,T.CFMW>=KMPN;V<FV"1:MK[C\9
M#RJC.GTP+UGEFHMM.(B7?X&X\$VVZ=E<6CW:FBASG:FJHK=KL;S0A'=>P+[K
MM(#R(3]\4?71_4@%\J!N^%8^[V9^/F_U_F+[#3LD0UM:V5,K[H@701+<66N[
MNA.T=GRZX\[6_M"@M_Q@ >YKH%N/Q$=P"S)2Q^IW9.;0P*147[\DLN"=)G&:
MM2F4R4&OEG'(>0IB&$[9;U+J&E4@H\!9'RG_6/PY/I>#DK:EG)CHB@;/0)BB
M?(*5U<'8]C'UF^:SQ*E\WT_]Y-OFQ=;M)O'+'1JO1?I+0O?TLMNP&1P48?-M
M-BZ6!^VV1<Y?=%LIGKUPX)MJ^H0K/]5:)YJK57M]!SFR\PV2$>(_\?RE;(%(
M+GU,F]@XO-+]*)<7FE&7^ ' Z:6,!A8N]4/-L3-%PI-B>K>.)&]-NW&<M#:/
M,M(F==!Y<6SI+K)ZBY>#;TX#3YXJ3FUPO45)5D8T/UI9S^ 4$ +2'GRUG^8P
MJR?06L!Y$TN/;< :9LV+O--KH])%L-MRWMN1'];((#8.YLIU@&9,J0@-:F]%
M6Z8E3CZXM\]"(X_#2(!-[R/$IV?EK[\Y]2#+_OM$A?V<AU"3"O/2YL9L!35M
M9%M&\$/W.45Y!J?!T'S+^?=+//O?]&3H1RB,QCY6D7"W?(RJ<6B9);OO$!#?
M%Z+0SS2BI_GJH4:-V:TZCWIH@W'%.,TQDUEJV0X:"-DT*X]E8%,K()^'3XM<
MJILF$@SLA96G36U@3$;5SH/E3_Q'S_@0B&D=.6*1VWE)INI%\D_)MMI-]>],
M'8)N+Z7;OR OB$JUPAMGH3K8Q.W7^5PZX<C@ATV,Q3CII O)L!@0,5+%YZ;X
M_)YTE)R^M=R<) +>DI8LVV<>:K$P$-G,(EYMM:C%]X$.H"?.;@49%GO5!!S'
M3K:B@: @[S/F-7Z+W.*I3FQ:-N.H5%^-=SD4ER_Q1_E-CKI8BU86!\^Y;L8*
M.Y0$D,J[LP0<%EZOV)WQWTK98]N90C5P*^ZI?-HRQG8L("50:U7EMB)[[<E6
M3=Z %^9%KY8M*_?M4C8-X"2;!HM,4>^=CEJCU(J'?UT>@*]0P4ZS3@;KYAQ7
MC0XNUR('D58>K):;*9,'\=S=:&#.X<^T9>,\7BQ\B=8+@][?SG0T=)X4)N<Q
MBN3=O(7RBZN+AX>)HZXMO?L+QL%Y4HB<QS:2-_\V&N@2V=^'[&9@#"W*1 -]
M/Z&L=KZO/[ "Y)Z#=DH.9L[PIGTL44+PKR.#\!4&CY]L^!H.0V$]J-#9NCDK
MRYD#TBKD*-("PR4K"]YW=WO?:#=MK/,3[&F<4TUJ.?A$]Z[;!78!&A!& ]<=
MD8\&7P$V?/6][-RMZPI?XHS/FOF67>3,]=:O&.BE[V"QJA/G<C^74[SX"%Z.
M0J[9=(M%N89F_()64'V@_3:4L[9W6Y6<^F\ ;D%VN@"_RT/_[[G_KCD75NJG
MEB(V+*^7A;3Y7@FIR=U(TIF'GUZ_B08*+)&Y204A+6A@3T@%#>@/GFI)&AZ2
MS2GT(?=!J,/'PR@3.4K-+"8U.4K@SZTE,YM\>MT80VS_D[@!O">$2>CZ,Z>:
M&IB@N253B(4ZA""5]\77ZT[.X(VGFG8(Q,3J-3(O1_JFO-Q (.&-WY"O5+J?
MKA9\]P"3,/9R[I0ZS(P+%Q=RL;CP2XT@+R0CJ+ZS;#^#V:@G-WD:5,YM8;VS
MF0):WWTH>AT^)0\3E#5D&5A*:&1H,U<VJWA#_Z(/4-UP:R3%L_I\(BXO)ZN=
M29Y)I+ L,@3F>\#P<KSBL!EB/I<O\E73'6=6B)>TY=U;#1N[^@W5/L6<XX=H
MP,,G8+0IGEM7P>4BXU(C4\<7>D^'"*/W[L>4"[MX$>QQ7QZ7V/,CBYL"ENQ$
M+Q26N!(,KPRDQG)B54')<;$G*;#H/%H+VRK.'H<$.@<]8Q9KH2(/27B^EB*M
M>0AB3O ,E>RK@3!O)I5EK%WU$'';@=PP.(?:)-:6N%^,G%WO+NVSL;W%6Y"Z
M'QC;!TMB,A6_#Z4/7V8L2?=9AY$HE]V?][+RGC#)@B"FE$DJ7BJQ=&SR^%&I
M>4:KZ"4W5G:7--:?/1L4H!"DEQLN&O+'(SBFTE,9YBO^@,CZ N>S9'9W>^V?
M4AFI(*-;6GM[F!>9W\(=P2?Y_H/3-2G[>)K(^EB2$\80X8(L]JJA-,8H1#N]
MX\U$]W;F+?DK_,22"O2A[YT-GL1B*]>P.43R3KP^V)PN/22C[W3+Y"T6J6*/
MX7<3"BM7FE!S!.IIOXFN(E>C3Y:?Q N'F90$"VO*:<?X8L7$G4^587*C,.F2
M9$&<AVM9, ?D[#HM.\E>#'9VPYKG[FC ZB->ZXF37/62BHHDT W=M85)?;);
MS _]1>C1 %G7)*G'N@XV0S"^R>J3 K/-OL@G_FE43)DRC)S?WW%^?\\2)/$8
M5^+1C:^)*I1K.**/FV\_;N:GFV;8):[D.0<YQSJ"IA6F(,=Q,Z>CF0T26H]8
M=QY\EIWGZNP+W8-1RU>,%$J\D_\V^OX92R!H?M,PR\3$/E-'P=JF"@HQS/-Z
MLZT]5#05Y%1:=<TB-;1KG8@CU?>_?'>A@< 0)6H!O4X/>D'6PFOMJ@/-GE&;
MNBX1X&"ASO=\AK)O2QKMWU"0OZER8TP8U%Q[6%';?F.7[P63#AHHWNRR+>?&
MZ_F>QDKF[8K8<(&)JXO;;#._;[*^(0>^_;@OZB0TA3VP&/&,XG;%+.(;N[BB
M!A$A8[G:V="X>8C0)O.6<NZ3N)ZH2X)MYR^Q08CZWH'DJJ=:DH=%^9HV\/EY
MU"6K$ITB-! 1<4*8;?;*22F4 R$L\>5O:<& + P-+%A\0%5D[15XUJR!OD:D
MG"Z!+]:R<I%?0SG:#O-5I5-#.8 _]U\3PP]J?_B"90"JHFXO+Q<-$!F&&&)?
MK"6?Q"UYLC4]+][0A>5/VF8CWX&7E]$ 0^84&F@=1($Z/IH]4>_IR+G[A1[K
M9#08=OXL^2;9Z2EFT6(/DX"2DY&NN=<T#+HZJ(<2B+ Y6VA5YZ("ACQ#<1U[
MW^ CD6A@OMCC-J;W1XEKK'SDT_Y#$]F(-XB*O@MW_9@.=JD-]JV82]X)<X<[
MH('0&<@:?'% UWVGQP\-R)2$H"XIZG^6W^O0%)V:8%^48T7=3P<"_ F89@.&
M-$=$$^*@V8RT?74KSI_00+T.U[VY1#)4B#@(B1M=$8.(3DQVU(^S[UII#1:"
MG-';P'>N*46Z0^700,K73C2 99I'\SVJ[[/\1NYQ*(()9OD]L;K=R:!.T-W=
M7!Z#4_L#)STK@@13B@]$QN"S0C&!7/=4>RLDULN646:S.R-1R:=T/'4[UY7&
MC8(%J(@K%XMP3,DO&T?TE/<;Q 56JQS=C[?=1P-I14T"_&A $T96MI?!QEK,
ME8"HT%7>9\"XH<7HC$0/#<P$8VJYT8FF(Z9KL)I!(>^<C'K)/>ME*?SV>.,Y
M?">?#0U\'*Z[.+'?S8)_+8E#!8B@@>/%NI:J'([E2)AA,A1#'V3/?H%GBP:V
M.^%A8C[T4G-5.@%V'DV\R<L&-91.;49:6=_LDM-7SPRB=<>[J*@1$YV,"\FZ
M)0N8" &#3S:U4M.G=+A9_^&CB-^.MJJA]%^,^-^\WB^M7_2'E/$A:!]C9OBP
M)\?E6(G?(936'H#R@>^.%\IA.;;^9\'P%T&XG7]8]?]3+=\*Z&]6?UCG'#RB
MYOG-2N$WZQ+#T$O_7Z@9><7)GY24E$Q&6O_+?ZH9(A_ZTJQ#I7H^D_^)57<$
MTAM>KT)L_3,U"/TM-6@8D79;XAYL>BV>RN/I*X:G^[76"FI6VZ,!%MF9PVYP
MC'EF")SGVD#CE;?ZG,X:)@G8X=8308DTF9O.W@P^+N$(#OE-192YC,LU/T>>
M.9U-Z3+3L'?M7[Q-7CQU&(K$.ER* "OPR_OE-4B_A]6+2&2"(KI]?4IZ^8)R
MQ!Z5VL<^JK=[]-S3;7L\$<\/ 6'.&D-^DF$8N(WM"YGKFQ])B[YVTBU5I-.Q
M%E[8_N'SN,4(Q:0<>]3ETX=^LD$3F-,@TS))PO<<.A)F>W(=/=V@Z*G&4S]3
M5GI31(\B/F!^2AKS02H,L14M'[1$)#!@SHI,B3!4Q:*ZNAH?EMX7[/\@(P99
MOM/(5B,JP0C7S6[6FQ^*CWD&LQB[6>FQ.6$0YD3JFXK%%. =G=J[V-7%3*<H
MKNI!VRHQ?S-OS%)79>@%!8?IV\\\*V_XPR6">UJVW T)A7V=51[0P\+:IS[A
M,NTGN$I5FX]DO%(:AH;?(^K(ZRZ:5ZAGL=N()IV$3H=0V;*?!'(I?YA.R\I"
MDJUOE:9KGN&\T4^#);*$4:E5+^&^?!C;+GH^::S&P\AX4U;#SV$)UT'<58/+
M,RG]T^KXY[HYT-#KYP+UM)D\5-AAC98-O5(E-/TN+-=%OT3F!>*V"#@E."2$
MAQ1FT!>AX$VJ&;+Y&UHH[/T+1>&VO*>5$1MXMWC?L$$C:P??#"WL1T#:-+9Q
MT$#;(/Z%$WQ11]WRSJX"3[1N9;J1]VY]O=@Q#4O4NFXM(>;HGTEVMH0&.A*5
MO6A9MU-H[.P+!NTDRJ('[;)@;F@ !#F!<[7LXL6?E4:P)5C3"0I\HA!3BW1*
MF$5]C%#3*[NM=$S:$1C0-V1DEHSRB-\=+#H6"-L*9X806W]A;A7)P&ZIU1F_
MC"/N.DNP6R*R:4,^ZB:*P/29)&N14YULBVM*)&]CV]:Y%Y5Q6ZAI'HDD*1B6
M?(/%PT^7+,Z%T,!^U[#3%_#30J<7(8VUS-JV^49/".VOW:'92I^69\%U"@^P
M-EX^J7H2Y0YO<GAW;^2]?PQK\992Z54GY],&KEG.6;MN5_A/O:2ZP<A](:=/
M1QQ+0OETFI^&\LT^//+8')DP7>=M;*]47;PWZS2Y_(UH!3)EGX*H_8E-IW.4
M/)44G%$51[.7R[(,(5M;39TQF!2R9U&TY>&@"D5VOS9%X)"*TX_> [T2RD7$
MPI057RZ[\(IG?.:W)'[/LB36\)!/L6U=9V:G$*E3GKPA'IYU\@93UA#4]5+<
MH'WL<C10^P/.%Q*#'6:$577K-6J>R8*AQ<71W[7KM4>FM">>OR?NDH(VSB8D
M)"N!FI(8U%!A:3=$&RQMH0N^K@G8?CV"X>5Y,3N@T+H50DS%A+&C 2KU0C_O
M1^"ER^"+@^1YR-36S357)(DD2].9:_PM->-$IMC#K'!6:878)]D/M^@@DC[V
M&8[K]<VVA7Y(3 J1ML04C71, 8IT9V^J.\!/1IU!=C,3M!YSRMLKT_BG4Q5+
M4'^'G.% ,,)NG0RV!D@H8(C>8X@P)]WK!<\FNP>3S:!$9<_,I5+<&/*+O18C
M9TD;)\\U7^S8OZA;N7KGXJ!NWC!H;N8R \7@4@1L,N#XLR?\LV1=(J<*J\%=
MBH023;E\D?X-H15>T\0LBU$\^6TT,)*K<6LL"PTDF45\P0B6Z#9Q&E#[7$1%
M]?=9IB_,J1F_PJ;_"&/'\ON//&W9")^?WOP55)<%N+B,?F&#?@;&I:[0T+B-
M0330*ZCPBYGO_U NBW82XKD7I7M>*LIM%#T#+2^Y<Q8_L#_'QMG\7HD&_BK!
M2O/FHZ7)[QD[T[4=D3<+IJ7%S+P0RI%J,MC?_"=>'&QJ>8NGK5^W72B$9Y\>
MM>"$<^#DS1$ \"N; ;W>^P8*?_.9E)LUH;KB9&C>-TPY;47B#/W:KT66Q%'=
M<??QIDMX^MD=#RG5U"T\S/_9\N:42MVH^.1/,^^/OR<_[$I215<&#5@_/<XU
MO(/):*GV9TO)'15KQYQR2F\?;WCC\>6M0KF42'NV]^]L5-\#3;#&HWAR"3Y%
M9<I#Q?!C:<#+E.W>C[U8$/PM:LHD>7I+ZD2^'JU8$2Q4+SY2/_*DP"K(46&Y
M)U#\U.RES .)F6*\>GFU!&@Y]%0]P;)Y+33M\55-7GE%O=TJ@8DF+15FT5 J
MSBH[K'E'+L\S#J25K8R^OZ(MVY? D.#%@G>5ML3+]L:0K+*!?'V+,W6/:>7W
MK!JTKR=S/* D^Z876Z]:ZP;R%#-6RK0&;O,W%=6.R"9P1-H\CF&H8*^S"K=R
M4VV9[J0<?!4_7+ANSW(=?&5:P:IT#OJM0!\VUV#;]-S3?#<KF<* FF1!&H A
M[7 2JSR8%I(]A\H&G$UKP@69V/0\HC+5TSV:;RM JKIE+F+23PG%[S ^KN*L
M *IPV^H9\."-E*<((Q,O'G7E&:/1MBSJEULIL'5KZW)!@<ATVTZ\^H;5J(<0
M\JGTH!$.>;5'K^FI<,/O'D_*69'0R5H'RYHQB;=@5>C3V]QX>7#Z8EZ2.S;F
M_L,5FMN:3%<<R:1JUCXB>DVAAN[Q(DO)DY8,/O,; F/-Q+?K9WV+MNBP $;D
M,L/^=($[.TK^!7C] QK@6LY-V8$@PV[#1^^@GJPUR[_-_Y; H#/4K+[D]L7H
M_0JUZM?%>C/L\)#QE'W0^>;I4-SOMQAY$'+A[Q:?/Q#>#)\5F$MY7065",=B
MD13 :LUP;]<_KQ WB$=!,3FL[JY$*^K<QZ6I,]<]7GN$==#N1FNL]JEL6]K"
M0OFIGJO>#6GNTCS+\9 7!?:L.IOIOG+0F\WN=-9*ES9X6H/9EV:A] $:;5T7
M.37A55WP[;)EA7>8#MZ^I[S<9?NJA$@?&C #%8O@O%&T9/Z(HQ#<XKEW2HMB
M'&;577[Y,E QK4 ;(6[B+3(;F.FT1UZQUQH11Y,6%5*B8+($/I[83Q>0&CF=
M2-FR3A@HD72T51HAN=]]C3:_>M0]?\H[:[WD%;V7L>D%=\J/<U-&+A6M$\OR
MK<T:(R]XTS@:0*"!.,Q.N_[>)5\/Y5^&!DXH,#VGNKO3N;#+Y;)A''G*TIA(
MI0\-D5 [:L<M2?>V_(/!:K9LU2\*+KRI79E&; 7D.#)=$^'W&HCN;+:SBU(5
MA/!^6#,N^)*#.9>HGZ.!2T9(JV<CPI SPAGXK#(:"'-V\Z'J%]J\*3ZVM?4@
M]K8QE.MC>9M,^:7T;+H>!?;+JK#+7_O(/FAX$-).4 V96P+1@F4)47Z#^=2R
MY<H5OI6U&&WOB<\@">"["/E\C/I]2L<8*2"DM6K'J/(+*W*6;_K56@]#C]]0
MX@%9I$$0'M6[I@??/U%GJ!>]+:B,Q]8<JEMA\T #?F0H8:9AEUMG!-/P61F,
M8N:AD1HZ5Q8ZUW/6=-J&[,';&.W#/.\$(1^YN,OE#V78IX&FT8"NI$)==B$?
ME02%(N5N^V6!CCPB@4/\4DXESE3$\%LVIPGO'Y'B[!%Q<81<2_K -EGI3 :_
MWNK<^9[*"[0"RQEV2HIWTV+XZ;FTG[&@DNH7_C,L^W].9O9+D_X;_ /F&9%+
MY1YQ?.Q/<W+C>3]-\"@TC9UU1^ Y^*K.XY, @S$)1$;Q@XP'6L51KRU]E>E!
M'Q+"TF+6++,G0]38S5S^OGFS7KB<M_'&2PK<J[+)VVV:H%7]6FX7>$4/K!1I
MG<2EJ"OF_**# .HD<.\&D9[==VHQVPIC+29D159;^U'V1O5/'D_;WTT:%X$Y
MUZRI[WNU.W.SU^U+C?0O&?&[ECIZAD\^+?W]:D8GSV"CFXLC]>/07B\=IL'N
MOW/A!%G4/W26^EOIR883284L8W+!<4Y2X3[10S(E7>['D9B_VY*XO)3 .T;_
MUY@I#JR?X".LO[R1*?"L!/VE<]="4=:05N.?#X-W;W5M%V"V\"H:(%M\--SY
M*DYQ3%J?3$WMXC-$%M-*6C=*78PO>O?'%QVU2UY%G:9M1GNR7^Q+%W,O3[\>
MCBA57$D^[@;9O.D';\=CWZ^U),.TNKG@7[",!P?.G"AHZJ.0E-YTU<02 \0S
M1@=>#;Z[$??=IUH[XHNE_E4TP)=\X?DIF:*D<60&L]_K(:@:6T33D!<*_SK;
M)*508!#-(STFF"37DV>H'>1Z">1%_*!+V2!XAQH-%#Z^U42".3QWUF*2NF_=
MA:=GY*DX"O]:7MTT*%&)]H>DP^3+)Y62^A?11],#XCW9FDS7[FVN*&2XB ^B
M8+-HH.[IFP^Z0OH6G+D(QDL_"2(%T("[C\NVWA^$L'4T(+4#GRE2'C\E6TN>
MEF#3@<EY@@*K^8\T5.0OP#[R)B_K%M^A=H]1&F.GH>#%0-#QQI,ZF[@?3T ]
M>_PS7])U?C>[14^NU@G6 \CYTN]G9N:\HI6:!_OUE"W.39->H@'OONM4*[F_
MGZ;4&'LJ?$8(+^@_4F*E&(;^!V]8_)O5O\Y*DP; \L67YG32_$WVAS$)T:%9
M*TH*/'OSS2_<Q[J3$F]LC<M;W"GY<_6KY"B?Q#/^O_VN8EB4K9AI&6W0;#7*
M$TC&JTA_M5T49]9%%&<D8P8) \\A<Q*',VH.*_S7*..9[W',L["D%)*#O+C7
MH7CVM*NK.+84U04;.41H(/>IZQ;122/5I*#Z^$G!^)[!IXF>MM)H?0D_54*5
MJBC!XQ=3X9.A=1=!Z=M\0A./FC44R?V^SH-B\1<X=RS.GA5O"UV[HL"=%=N%
M\-<"H*OUR)S"J^)/:I>>GK0^%/GTL'\J]Z%KGJ'BK2H"AXASB^(5)#2M@S)7
MW_>Y=C&Q".=$B+V<^"C^=('"W.9UVFL/BJN>N #<. M0&I3,'N7VAB2[L^U%
MHFTE,Q&(QSL=P%\ D$&,*[I9SO>R3L);'U>&CN-4*K*]ZH'<I?![,W1U="<?
M>JRW8I6G:Q!(30ZA2N 4XC]5$S54NVOL253\X[,*NUU0R]'0Z7KCF<+12)IP
M77P_P5ST4PWLJV6?</R2O*+T(+.=)UM$#2[/A-B*Z&O=#>9]FN>+>/?"/4,7
MC9.T=4TH7_MK6,Q8GG=X(HZ$$>:Y5B+^_/8PB7LL_#=;6X;87?%+/<Y&*A-L
M6Q'EM13#S'Z+'S:*"%J>:27@O9Y3'6$(IW4_SE6<(]&B>Z7+%4DCJ _00,5
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MCX6 @,5,C$?,_-\^@!T 9&@01%!#,! 2 "@R"!@R"+ '0 @ @$" _'8 _GR
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M(_1V2Z3D=W;>8)6NW:NF4[[N9+P  4# D7J3THQ3-0$!PO+Y^!]N*/ZJ<'N
M@.6W,K<="'BQO..FVC.X<2/ _OL; AMJ;BE/\;YWO_J5Z>V)$DQ\G5EW,WNF
M&4?U=1Q__77YIA ("-+<]#W5?(,-!+S6>::A>8H1JOMO9)R7\,J^# L\_6HV
MF_.*;A8"!#2]91]?(.!QYO23XECWX3DORZ_K[7^Y/.W;57HA<$?W-NW_ZJ75
M-A;*->^M!_7EUW6.OUZ/^#NH$^*U?T6P]@< &7\+ .^8OP*L6V!#]3Z#\"\
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M()"DJ=K*<T&'IFVR?X=QERMW57+@*")A7U8_H3L^9EF2-5I&2[K*9?XC<Y<
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M>$H)-KC)1 P(+3+P>I_)\"Z'UL:$[[LDVS+[CL@D#<9!S&R,A2UKRGQZJ.%
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M7C(M91LMJ-V(>:<$UN$"'ZTI-8:YDBHX;>%'K(]7>HR\N"5L^9GUZ>C<MD
M@J3!3FE5!O^>XU6W:^?VS9E>=X'8^4%\E42++K&HR341_$^(Y']03'+9^"K"
MC]8)B]L]L/SZS"*]KK$YV3GZ SR-CV&'#7I#(?/2(>:[6N-3Q\,L1_9T(&"L
M)M^!N;J8UT#,2#?M15:)//K#%=4"EMHW!U@-/X?K,X7EL8E%]VA(4_JZ2/SB
M'\NJ(E4?O1Y.D8V48$R\8MY6#"75,A6D(!C[N6".3( ,AS-U+"Z;(I14HR;T
MVA)>2+8@ KXU5NNUPZME3^5 "QM:=\7@!40XU);T^X*%I:6.Z*%JE%+V$X.
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M @7<1!KI3Y(7.4.]FA.'D923-)I,\A=7S5T.SP/-1!V'[SX;E5LVGO\P?JC
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M19#NCF'F.^!]/__[_I[W>]\OK^M#YV+./OOW6['77GNM<T!/H'\"UU655)0
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M..5GB(M#HP,M][T)Q+GW\06F'1J #Z*!75W>.GUEEKV#4YOIAB?*80X'BVB
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M;D5M4=7A^"_>GU@H=WSE,)YO:^'$9: 3&',SG-YW=1J,_N !YL.B@C+0EO\
MH4C>\K\(1Q=)[3PIV T?)UZ'I*J5W9D8P)<Y6,K)_7%?\Z86PS<P(#G:X?MC
MRRBDJ "2-YODRB00MN"U)OM*\; Q"UH!:_NZL_V'&1>,66@$?+D4<7$BNE!=
M'< 9,<[MS] .TC"VSUW1T)J?&,PR7"X\X_'/\7CMX2.MFY=S6L$Y=.#$_;$%
M<!)DWO($!GH,-A=FIJ &K8P,\BA(W*2%Q7JIJZX8R\N$ZC%R)@DU-4<T/_F3
M-;X\2F'ZR!26(+^H_^[$JO/>N4WL>8@7+LNK';8CR"9,ZJ5V;>%D'->W26C
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M0_^R;&QR'<4<$.92I6Q+@RM(N+4P1;&]"2=_5N U)WQJ=8R5>K Z%JX:O2Z
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M402T7<Q=65Q^V_5T 13F$/@2OOP<?KPQ#C9Q!,LO82ML:"!!!\D%FY?>%;C
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M/J#.74]_H8'C4;I-^'(T>&3IOIH<2TWTCRTT=F9^3<8D2?2M$ W,,PT!D6C
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MN<AEF 2E0DY/53M[MG5:WK+A6%^^VKX:D;O:$>K]5^^__Q7??[T _\>LOUZ
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M5*RSTHH5A4>QH]0H_IEQ?'X;5[W]VZ[ F*OMZX@)1$+-_9@;1K;^]Y.I":+
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MB-VVV<R[U#A:HYQCV9)=]2 82_V#VOJS_!L5N K,7]GS7L**%<6SP7QG7D#
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M[(94BS11VO0?QRTQ[ E4R.O9N(E/O5IUJ*HW?2CWKY>:A\HSY7>3O864?@H
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M@6PJ- G[_4PXDL([-7B:,V],+_3(C$'JH!^]3A Y*"!0'(N_2G+4FU]]%O,
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M3+OMGD*3^)BODG97<!NOV, W/17S1 -2X.X<VG!]\,:KCM;!MRU*502/OZ&
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M -76<ZT+^7FD[3CFKU6YQ4+^W!Z#1U;D/(Y4!9T0VN293U)9;6ZP7BP4Z54
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M$]9['+%WHA+M-KH#GE@:U381-SGR;+.Q5'=_UM_WZ8HRM*@<%:A6$E97$]A
M3,&WV'@/4X(($8I.B*P&2WY8SD4.OEK++'J%<9S*P6:J*,RGD<>P& V1GZ+=
MPB5WS&_A=(0FKW<0^&]2=K"!Y#5'[)JCTF44%/"RO"KN:./.HZ!Q0Y;K;U[7
M*G[6C9+UVC5-RPX5ZI3\HFX"PZ:2\QU(_JNCTQ$:/I\N'(3>7G[/2@WL867W
M[GM%/#8^Y)HXSDP_TV:CJX1XUJHBZ#^MP;_A87GE?V=ZOPCW1;@OPOT3X10;
MO22LN*U>@[/R+(WV8]BO_P)02P,$%     @ HX)W4NJ'UD06.@  ;ST  !8
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M<9-[+(I>2X$'R-U/C"VLMY.1J9A_<K2BAZB@VQ)#U)+MT,UR= '9_V$W_'?
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M#C T(3 AC)DTJ6HJ <)7)58!X0/482UL%S[#- +1E?P@3F+RV66Z4>N&0W\
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M0_:<I.IZ3;!P45I7L)>R6*7U .[[8*!RN;;GN(.C7^.!GM6#*JP_'Q4[%C>
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MS?!,;15!K4,W%;D+9([9[F]J:I$[W8TQM[RB96U5;ADB_]GYZP?Y?.->AG7
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M3JX]8-0?HR49O,;_0C<ETU<?XS>VHZB3.]VQ+3Q->L=[/_3<BHAG<-:1)E:
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M<OTD3"$ 'Q!CK@K._/ 3J1?8,!8T5-W>Z*[3\FAP<=P+83Z&IIU7;9^7ZYH
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MGFP30)/E#IW-\89E&EU3"N[C@<Y/=%$Z^$V8I"[X78+1Z8T2(GSCPJ9EDJ=
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M0LOC<4@L8EY:]X1X'FC12 !M7&OB$$6-$$ MD S_KB("Z*K_ N88BCL_6M)
M>6U4D0;P>X,W!%!W!P0U GU?. 7TK4F-#;A- %E<.8G^OJP^3$L %4&/=:PG
M_W3$OO@GUBF[L''#ZH4MGC./U,*A,-&3:;@[63NI=[DKXN_%XYY F_BK-X#H
MX#MM*PPSF1*QJ1K>+7\RLZ9*(;_#S'RNJ0Y/%VL].H/'05&(,45= HBKJX
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MZ966\1C2U-U3CYQ\%4H <5.E_9G?JQ"W;P%W1>@ =P%@/>0T/)++07)/8JV
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M\S6^V1:?C(#0 -YB9(4YT468C..Y9++QO_#V25-F>^MXM=#?'CE-U@L@@M@
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MRG.CMOP#5F@Q!ZN!R9E0_C=D!Y(BD_!W^,XVCN ?8%F"\F"BD3@\7\^N\C^
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MXHMGB,"<K[2U=&A^QLB 3]_,0R1IV.YAH\XUV\Q% \Y$AY 8,<7%^#Q?:JR
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M6K!>E'2ORL_Q"1@4"O O+ _>K5_*I2KQR0V?.6L3#&;&E PT;[H7H&31J5'
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M8-V_%NT/R?[W!//_OY+L/P7[6ZXI@  ##35X&*2 %'!ZP9'Q"N^?R@-I:G;
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M=(&MW.Z]F<+.#9?+[VT]RX$JY[="#XA!)_MWDJ,$2I/Y*>; D9>#' 2*3RV
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M5J.<&B%+(3]B?250X9EP#!(PCD3Y?[.F].+XAG^]5;@W+?!M0"J(6'8YXK=
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MH]]\SOSGGG_]Y]YUF[47;+OV4T]5/57O^[(:X2/P&>"FM+B4.("$A 08(+X
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M.% K9^/@U^F1VJ$Y*6&;$:)85#+  7EZPP-[EA2$!8T1??58F*(X(/Y)D35
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MUSGNE[]F-H$#=5_AP*ZJNN^V@[!T:0EDPEXE^%BAKW(;JB;,CL@/)WAZ!0Y
ML[ ;L8G")(Y^OW7?W5(HR#S/:1RN6S"H@P-YS479Y0.UY-#:8^6*RM!'X6KJ
MS"AR%!(P(570CY%D* >7D64,U#5T&@VSW#MX[T9JN/AN3&G/2JF3D@RU6?VE
M:/VV%@<T;B /NI$2L4##;#]16!!JO\D4!92C\#([]$_?_QD1H0W#><I3%)X+
M6"BB<JG.+TA\C;^^G6YZ@3R;ZCW%A<O?P1C]C!B5YR:*X96@F5=#124R4!M9
M="N\\,9K'DGBF%^JHH4$'+P.<J=_BOIG3_+7,WC5++HX(W+100LZ98@]6AOX
MX,J_/58\C56M-Z:B!AF)L)&:4IIZ[ERO2G0VO='O$&K'J J*BA>S6=$ZYY>+
M]9,T<3CRXAVYZ=<0-?8"65TXNTOOIVB28?BA0> 5S.GC4Q",T9^^A@4G78UE
MC3E 4!/Y6L\(V>L!UC CQ,G+8>E)B,:SF0L0 6*M42_E?GUO8A?E=IA..VGW
MA)?(,RP1FJGT7T+'5$SD:4U")IB@XQ=WC .G5"B>5CT9P/U0P= ?=>+'N=KW
M01\_LS20)W#11.7Q,;OTE:#/=/;\][L=UO@'IG_2$Z(_"W9#+Y#>P^" !*(1
ME8X%0@:K0.7Y+G.6;@EW9>@W[ZHY'Z&ZH%QI%1$Y.N%LYC](+=FU"4>+.-I:
M"Q/# [/QCOA*UL];WHH\V$9TXX]HB+;&:&D&':#:G%U07K9NQ81.2;X;J#Q
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M9>,M^8E.D$"IXJSV$/F<<)?AK'^$M4\<U%<#"Q2J;D&TG2]=O9PA3&NJ$0X
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MV[]TOO3U]1Y6U6I+1Z]P247%K*YZ@N?]I8*H;:@<6'Y)XD/\?,E/TS\/N*U
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M6<2C(DDA>9G#:!^8,D:L-Z"'\KPL=/318DY,;V@=:_MX#$\E+6<W2)F6S-'
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M73#A2-<>$KS4UFSZ" L;PDQUHN%%68 F]E13<YZ*_C[A9 T7G)UG0Y)_Y,"
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M"^Y)*9(6:W-)C%C(^IR]D"9W_$JWR9A155.I"5>'@9A%R4MG9=T?:G5_W((
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M7(N,_[G/_\\FX__2YY]SX8X4</9=9ZI9*&]UU)HWQ3,@YF90HIUW,_3Z@++
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MRU M')S6D5<%]0(,?J2(\_4KM55FA1?"B1$2P9 #^Y^(.C?R?=CI_7/&RW+
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MD6+\TY/UV4>E3E>JF(X;A"CM\"6AOA<! <]]- &Z3)\3.\96Y!8@ZK%WLD"
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M.N%YT>8UUO(HL<G;L=.;K%%HR B]BPRA% GDM0X)BY\J&B)W:,'A')CJ;3I
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M4H'84WSA.U7V.H5<(T1.2J$W@0Z<I;%QTAC9.>7R(LSJAGX4">9HG./&:?.
MK.DX<<.#R)PB=7-YVD1'*WJ7/AR_,1(/ZDBU)QJ6!QT00/V.E=)/DP IQR'(
M1& _UD[WP*YUIW2_$;,T@T6;*?;@7BB$_@1I'W?>11D$,!;$.+8>V+$UB Y3
MGX.U#(R3*.<--M2_21)[>,\9[DDO6U_JB\0D)?(J@N:EOA;7_U?G0UH9P0QT
MQ]=-;C97*]R;PS056Q%I[:/,']["</7Q%1672NDZIW37HNR8K<#7#<&W)4-
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MY*"[1=T#D)<VE'6J<VX*+QFR^@0">.UB8[!7Y9&ZHK$MZ]-]-\I[B-BSN,8
M4WR0&1HS^S"9;M"SBWF"/K<OK:TKZUQKW!@>ED #]WQ'$.\2"OBZ.)L<(TVC
MW4L2\-B ^U"R9R%<L "W]6DY+PGO@V6979JCRMY7>*FB_=,;ZSKYC!K3?A#
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M)X_&9)II! 9XVAJ;&T8(TL850H*]M^W@_[31*'!\3/CL-RMPBY*QJ;);&WA
M@MG-- (\B*74\X%0]BF_BKJ'4GNI,KA] I2GED>$>EJEU$.>6K)>]N@:?2
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MY^UL:#^-%$7BN2G>NX)2Z:H618%#"1X=WP:_O[ISC&S@,X/0 &[4*TQP.L,
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MQYC+^+9HL5D*,F8F&$,\F\A".H^;G)3\_%I-LK4".5SQ!<9^7N:6]IEITSV
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M\HL',UV7O6D$]5H,0-5WEALI_&+V 9&>!'5*;WM0I]=!"J7HCN#Z]-CW3BB
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M2)5K-%2!V&B;I/(KD<JENC>\%M?57I7+>A%)@"L#G_\5?X=5_<$_DAL3'!.
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M6JLS@W,;L"<^=U^=I2".S@+^&:2)-+!LC60@I5PU\6IF]!HQ;;Z;G>Q40)"
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M97 I)/I2LAHN[0I\3]NT8*#2(6.-]F7B?8(([S[JG>UT:<Y1^OEZH91M+H5
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M$Y)\^7\Y F:-/Q*K=\N9?Z,(L46?)8EO^K3A@17-9D_M*/A54'"EH;#SB+#
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MW77! ]JW_$2@7H8(3"W\PO#%&2*0;M*$V:.LPUMQKS]I(P)J)0_@ZPS(O3?
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M"Y$<E0(FC$E^:SLG@Q&*='LEQ4JM6JC9\, ;]S^ %*LZ()N!S>U+R!\0,O\
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MOQ>!04)"0D5!)41#(^2D)*7D_']]/;4!6(C U3-#6!@JX!D6#"P6S%,70 X
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MIPK60K&5'8[N&U,W20%471%QAY2(NA'^8= C2TM]FG32TKC,9EAVU,M*ZLT
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MI9L$B1P)2['371<"CW[[1@=YC1Y#J0P#QT<HM-. PBG'T#@)QMR/J-HS_#V
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MA@+/Y2?WA)?!-S14_&&C=3U#&>B%S8H4AK4\R8$U/XZR8R2(OP[8$=[(VV.
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MQ^/%5<AZ;8+,CWB+_]/*5T;%M33M#AY!@H4!!H= < \NP=UET)#!=?! &(9
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MG;WRTIR@SD52?36BLF]#ZW[XG\\O5%W#7VN[OK[JS6V=XSY)R+$YY01+'[9
M9>ED$^JYT-[$S7_>^@OII_=\$&'\O!%0%1"-YYQQ\G+B&KX,CO\/_ _%Y"IP
M8E>_FIT6TH@I__50="MS7P&OP*@A/5\VGGA)(/Y-C3M-*M8<8G'R>3KW-D_Q
MT\ .R^^8$WVGI5'W>@U58ZB@KV8D]6)UJ1W0J19=4$#ASBKVC(VC "P)#&TA
M-_BLN/T1E>#"^D&]QT)SJS=(I_\I=M>T W7LI5SZJFZT"3HVO$GC\.E'NOIQ
M^YK4",W#3\IUT;'$]S4EO@N4"/WQ3V,\EC>%/U);+P(YI4N*[HVO8O S='&6
MDJ= >OK.3])H2),B+($EMEO,*-!1<0+;2?>,E75-",)T[!IK^0_-472G)'1Y
M(6_25L63]PPR6!M:]D<")??7XYWC$[1+U7?QBX8-K<_:KVS)VQXR1O"VDEV"
M"0U,9( VD*CP#?0BK *USB:*O+U6PM%N$['-SV6J&7-*536A$/\%8CT!"N>,
M5IBM6N6<P]R:7$2&"7]4\X_C(K\'V7(2G$_MWLV_G37DW^ZXB_76O5<+UI5.
M#6%S+?%]<!YA>-CTEN:8Q*,P)7=F::Z(W)C [VJFP]'@.0R )"4J$9KU94'A
M3^UC=73,X2]!F/=Z+1[XFF2Y$0^<#SOHCMD'A>8IN+,8E9[AD*'R%^QGNEZS
M5)1;==\P4Y(I443S'JIQ+A;G[H3 5GO@BN.QCK;]:]I58<V5S=B/1)S[V?P)
M?-I+&RQ>"HZT"H#G %F2P =Y<OT"6(5%M#%/0ADBZND*+<2R)K:X!]4>60=K
MC9O,#O:@]UAC 3$D+PLHBH.",8.F>N1=[5R][ ,MX_K1&$660S9(D7;%I1C[
MB;%)STAPT)3'8Q>-(@Z+1-)@*E)1K8,ASF>-,7*=*6S^^@K.W#W" W1,A$P.
M;_0+D3#O:3G*3 BY$V)X@1PX'U,H(';2\<- Y.=01A%VBAN_:S:E]$=#]JD1
MEEU.H<MIR/*"T*KB6$Y-4[P2<ZP">G2C8/MIWOTEBZQLENT:#ECDG.,2K8C]
MX4'].4PL8>@\K/-T7%]!].U3HN](.89(4JBKL3&W_I1U!B.IG&:IJ&09#NE*
M"1-+JY0O6LJV",=R%_10I>A+G!.]XFCU,Z-K7&_O:9W\5W"5<08O^[)!QZW:
M4 _[J$]3Z=)>-Q,\B*19EKR(4N=2.W0S#9%:X/>/\3.E]N:R1V4OS&=1%OW"
M<=-AS)\M7OEW'FF-FU=7IP@8:*(U;^R>H5'6JM34L#6SO"?_1,8P/_M6CY\_
MD<4!-2E&'V!N_V(-\N&';*![;ES^CR@;-*-4G4RO"(5%N9NW<GS.O#O&;'3^
M6R;2GI3J&JC1\Y0H(G%O](4< XMZRB[8'DIA0^P]VRR?^VIT;,1D>/W4%BYK
M2FXNT].JJJF;H'@V:SCG8#QFR8L&6DZ*\JX':7SB(F,.1VG?%M(U"<QF#R0:
MD_/D'>N?.Z &4:Y!IFHW5^8,4F1/)YER$) _ 1K8*^\).^<\^H.A#-"N:*&5
ML+<V;&LRVI;FU"S7$SU2.T9C^POST0D0)U L8+A?H0MGY@$G9UD#JO"=5I[M
M&9LJ-;J]Z#=[>>\78-'M#\"BMLN7$;S@"AK"AUY A2=F*/ZH"K//L"'UBK%=
M-S+-5#]/PVX!DD0H&[/S!5V^3"DK+.]R+@UAQ7QQ:-^HZ?VLRA4#SJ>M,/,P
M.B(T+%@WR6F?S 4@77]DG&R8$O$EE[9(+4]75Q$.F0DVV #][@M0FHIU,4X@
M*JE"EN,^C76@M;Z=B+D%$%QF0<PR"N54%03H M*F;?V+,&!D<JQI17U]MJFB
MBBB<_J;TC,G(A8N>540%QFG6:1ETZD/#_$"=(*?LN*1(E.WZ<:M.6YTC6QEO
M53U.PW,RTQ-I;-!&N&?>^(Z/,N_<=36&+C;)H'WLC##"V_.T]#J8X]/XG/.E
MKU.@6#-%0L1@DL< ;S10RJ_W85 OG6CQ9Z_I]$*;&U#$";E>LG&\0>_X85A'
M1X\ M;-"L>V-9;*5:/Z[T\L^3-D^35E9D@PO^B.US:%6X,>JV,]D22G*E-0'
MAKW@V$7ZV4'!(_"]>:PL<K\K'&N#XKE-S^@A.P(99DPXMXZP=B+]\9KY\0Z8
MQ  9MMS@AISDX"-7$UIRD]%R0>D2&%YLO;]GI+(16EX+1XQ&/%-2,J.W(R(T
M,>1N-!M)T?:9CXHW=Q,MMAIAJY.-?T_LZ\#N+J2:4,"W^![D76RRC0.LKTSV
MF0:YR'ICKT[P-C'D8G4)?1ZLTS0<>B ?P?:3CC9^'LB.9/07% 0=EZM)3XD8
M%MG>T.!Y/8ZASVW:#KRO@!JH0[_+E(LRC"=B3JBPO!?DC2Q;7E"=T(N57[-!
MKW,5[6")5?!%L;AHH/^:82<';BY2JF3! \X4IA.-B63BV;L?.I0ERJ\F:M=A
M(S3J=M ?"[[HJ6AU&F#/7KZ$$<Q=<CD:#G\Q5PJ4&.=N X5GEGGM%NV_UYIH
M 24>&),ZOATT5]*.->6#/BC'! #\7>1 6G=!"LR#11ROYQ9PGZ'=)]BR.785
M&F]%8-]QV ZD<$W,[E-@6BK!4)$UFA)E/SS3KS^(B"AUR'=H?C-GMW?TF->"
MK5V \=O72RU6ON1;P#+S9QH8?:X-F=+&4R?.;'2.?G6(,*Z+;W(YH>$^Q\R5
M7<'"2-&F1GN'9W2<<N5Q_WVE7>'([9APY^XG<<L51+.OIC7:@M5;:ZIC&5&E
MB*KC[J'G^*^RRH$([O=U6[PRF)Y"%N/Y!K_.W6P2*\&8BT^4J<,]E"_^9&_%
M"GC8)_9EVXZCVX1EC#<JN/[,VQ#KTJ"VK(J[:<_#"$J.[H?K(K#2*/[@O*M[
MUC>YM(\]Q!_(\#JZ_O&1+#@4\.F-Y$5U0,#(H.U9UY9=)L$KDYL5LUL 872$
M!:')ITXFMJ7,!92MN+C)!, ^TYKSE,3VHK]MAMC^;N77A[)MU0T(]=%<7_=*
M)C!8.A4$A697"0CLZ/@HK5 ]&BK['IIM+900F?XP\XF4+6DN]EL+PJPYRA64
M;TU1P',%=R><+SV%-A.F2X9F^*SF3\G"(P9UWKEH0T2.#"#/_?6/D9%;FK5*
M1)328K;KOIIM8E($'K$%F0?9BO>-V5>K!0U-T>?!/C(UG_%"]LH=R;#24U[%
M5U-;F+(>M=.,F(6[E=?R;E66FAHO#%GQ)0PJD4N\L ]4Z791>N1[,$+1K%UE
MXZ)0+E<4\=S]<)4K#!KZH8@Z)LUQK5#43K8Z?HY,5] )=Z3@.DH_3K$.81,X
M_TG.$1$^5NWSCA&-0GX#I.7X8G*D:Z( A]VI%A:V'7'/W7*AAGW97]+H$K'U
MD' R[B0W6W7XZZH[)&GRA"^@*P4\25QJ\4QWJ3%I#P44VI#FC9*9Y[:Y(JTG
MV_\!^]XNC@!!ZWTJ1465>1M,%" =;31S0'0QWH>\O\$M6K/PBBOF!QF_/$ )
MDN\Y"/1?)\CJ4[H_:E+?6(!BYXDO" 0?<_>(+[Z0H JT/)=2;AJO::1I#EV-
MR6/7#ND,?].YO;/K51Z$P'AQYSZ2)OR1,6+PKXR1?Q]5Q]>HHVJ._;YA8/LG
MJ@;S<7V.\69]G>>C3=09!T-OCJ1FMHR"F+FHX;J<&(M0<SD]75+L NI)LL"6
M>@]"PR[Q&'J$MD*]L.LTHBS;QN7[3]L9T>E98N"V0ZI'P%Q1H>+XF.-SW<0P
M5U4$4PGK?T-;5L!O =1;%3]7;@&]GT7%;V1*\'[O*L0NMX ;R6G3D^Y;0$RQ
M-_PJ3)?J9(?DQI\)I8&B73S0:R3D"DVL;%6 SPMC:$TFOA]]#%D8$"B#E>9]
MK2I8(9M33@CU?.ZL?*3"T;[(-5[;/*0YH(^8G0QF<7!B4>[P+D:AC5X ;% 9
M5.38W8CMWT25&FT)*=O9Y^T>>9,J\61 HBR]X]I[7(>\3_Y"S"'JP:UC(J'V
MKWPSW5?%J<[IP;.FW8X.\Y(BSU$C^SEUPN*6PC$H(E74BL]9>O:6K]F1$^H9
M*]:F@^\&W$K(XNT_J>,WX$\>RJ&VYB-$J[\'Q%#*%%YQ'CQ^7VYC,.D]JE V
M]912^,)@.2<>]''B3/[G"[T26.S\(*,U#<\M8$0EP,,YLM76FT509< E5MY?
M6-C:W(:V/NC9"REN613!C3(Z_;D:G <]Z^_Y5]<)@L4:C700S&0?UY],=0NX
M': /T"XL?*#JH,^+OW&;&A]7(,WX=A! X!$Z(W&Z"M+9?.I2%CS"LKBFX$1P
MKS/K^DLG81_:IE=!%:9F*?>]#J)-YE >-A_Q//T.9XST%$,Y*!='K.+C*\EA
M+Y')GXY)5KD&L$0D/P+@B<[-L_JC(0W&O$YD_(;X-_RH1/8WGG82^[\-_]\Y
M4))_&003ZC61QC^0B=C_/#V=^B?.Q?J_P9_^MX::D9_D8C/1\U+=J&E'UM6O
M<4_=FO]LREN9?S: ;HBDEP)8M[Z3=G8+>#"1D\1>3US;<!>3(?]/H(=.+6EN
MW<3NDT!/^1"P+(_$P_]U A.:J# &.^:;OTY$E=:Z!^C-B@:B2OP8,<VSZ%DA
MKASC?<?.VRIIL/RR_NU.%.ZE"];2:O86PH-XR)LY<W9/_/O#0O@:QPU[5.TB
M?)1$_8Z[Z94QS?QTU?>[&$MW*W7B2IJAJ:4V3&'2Y+6N3O+SGD,";O&H##S;
MT9OIACMM/<F[D+D%]#!],)K,J;H%U.Z*?[]?Y*L!/^@7_^,:\.^7(7:[CBE?
MK&<S4PKI6>HXFA30TL\W<0#V8V#X[!G5,?ID&U/;^3K5']< 6XW_+^^X'5ST
M:6)M>(WEY<@2(2&1@+5;  6*J^+?<&PE]0,A _T>/F1"D1QH-P;9#1&THF9:
MOHQ3.FT>^8FZ277Q\!80EM/ALDZLMN.9>8PQ*7Y(<@L@T<F:FOUVN#E.P:)N
MLZ,8&H<?D1JDEWZUYJU.PF==NA6A^EH)[&@U=H(>1,0M_)(N$(W^^A:@: A3
M?5UB74X]=H*%T":@>TF30$?]ZSDK"2]3,=RNY4[![-FW@.BV\R:Q::^[J-A8
MZA9  S]PPQB(U_7>U,.![N.0:QSAZWQY*8;2"]J[!9A/9OZ#C)6$70.L2S9A
MZZ&Q"/YA\+;NT JRPI5&@(=Q-$E6_6>?LMB-?B?G)/_YM.!'4U5?.06WH5*)
M745UJE\U1H=*AVL"9-&OL>U/G*0&+ >-,?Y)U"#28Y?TJE@._3V& #T4QI)L
M3/G##(R/[L(K'XY&T(T<BQ7")F:+F?+C_4>JCQ RR;5PR'S?M,^>[1L!IXY6
MQKW>_KM QCW/0>B$Q-7NS \WMP?O%H O05:C:WIJ<7:-Y03?FQ2_DJ&:25HZ
MIKCK<MO=Y#T@0BGZE9)HN41U$64"7RJ$GR,02\J??6).T[W7!N(RV8$>JR+N
M:LKJF$/$2=>IL#L#VAJY//G%6>[4X=3YNO5.R[YWNEMA0M-$#-P,?KS3Y<[>
M]<_@6T!(861R\74>_]:TF"QR$9MS=R$FW.<=\IG5?A9."@N#/?N2L(BDQY>O
M*P*XX@?]GG^SNUM6E/_-;^,WOWR5?%M?Y0S55K<GLQY."(KF2B0TG4>"[%A7
MTR8ELGNI?&&O9R@D&PG[J$BBVFJ6,+UW[P2_ZQ;P21VS[$[ZY%_2S_U+^LR?
MZ[_5%*_+;9-2,4N_5&%T(6#*>L]L(<,U,X[R79%JJ@^FZK^Z.?1+K),-\>-^
MJAO:J.V!O9^XO_+:?ZGOSG0K-R;X3%F]R$YZ80/I^UT1C>1-C$96E.<%,/^]
M5VKG\NQG&<\OH%9WTS,+QY:%]4=]N_G6=,#-S-U<_:3Q3S%_R?7W\(G_-7S@
MB97F(,S(PS4C>8JZOAI4+7%V*&!8% -@^-\6U_+WT-,4GPDDBKE1>"16XRF%
MW4/UFI:IE3'&L'YXE>U+&R.*[/<J6XW>)U]7%YM<>[NI 0! .P4@"^..&@U/
M;H*]]$JRPD2YF*8UA?%M4!\-Y(&+L N+R]^?*/?=TF^I3S%WJJY(XL'XFOZ5
M^5&Z[\$BG#UA5)-8Z[/DAJCP*.K8?_ LZ@L*K+IQ"@^P$N@LI1E10D /UARN
M?.+$-JII,2E?$ME7(Z$(B;/HA"L>F?(GVQX)R26F?>8.4Z0T!/V7NH)"?1-^
M+IQ<:9D%91#C5X=(8(K\SBZ8SHW@<7@D.2G:=78#%)YGI[_%GY*?[6Q.8Y$R
MCTDK44!]9N)%>?UT)G LK+ 'OF+,S)3]J+D+9@>5%Y90EZHZ6_?6,Y,GXI#
M$EQ)C*8G#LZS2=+-8)BNR--Y9-*"24!.OQ-ET[LSY*@AT2\T5%/?1)EM \ $
M[^1&H B0)\N#QM[/*5EE?S$8!"0^M%Z%XLI^S:):URO,0HT^SLOQ$XR?+H^8
MCONX*%$%(-6[MF; )(D;&52K +TQYGOV$MM,+R"FQ]L=\/*5G$KCV!67E=FK
MXGI\IWG\>ESCD(WO,@YWWB!QB-M Q;DJB<YLFSF93?WPKN=%:I,WI-5A3 +C
M;E/^1[/:3(PUNDX?9RK %[3TUPKT*:(,CDD[+MG.GBQQH\/"(M:[Y)^[K(+_
M5<H%T$<F6VA,M. %#3ABU1**: #J4'5BXHD>:72]MW6^#YSG(>A L T4^JS5
M"WS=<%K?,W#IR)<2@2H)1(+AGY'3K*0W 9Y\]![\FL@J6>.Q()U$3^HH2,K+
M4=X2A>WMJY+0QPK*X=M;5V#!(9-B^$Q=VT+2[V(QUZEVUS._:]#01*L4S/=5
M&)J&CG815%U8J.K1I8'.!'9FJX9C2D,SI!O4=P>:U$2KOC"F0=[X^YKXUST>
M[I[/X>%!B<WQH'>1JRBDV\^S(^=E!C8E":A;^:H9X=J$6(8G/1_+V%FSLL$=
MND"GOM"C/J;'SG0UX$OB_L%_0&K5*/\>[T/S B=**T]S1:UJXF,7VB8G"[,$
MB_1>NKD40$=45TI$*61[FKF\%RW!X>V+2NI'F++R@B)7#7M:8C%ESY)O4M3H
M2[QZ/ 7V(K$^=-O?+9ZSMP /M;]JVLC7/79(;QZ>" A="K@8@U:&N,%LI%B?
M/26UM+0"+\5V98ASF*27J*E,[+)QE%ND2-'*9T/86+@ /(]P8:EEX)NANIOM
MS+^JZ.0&#0.IO+$6PEWIJ+Y9-^AS?'U=<O]KQ%5]+'?QS5L$$L:C*3);UAHM
M2G#_WH-YGQX 9B\ZA&++TD[ "G9X1^9,QW'(.[(]Y[3;]U>%'QMLY$W7I,QX
M0PL4%6/1RJ4+33QD8<AX_/ARX'4?8U,TIW4G\T5@;X^)_*X+K!I1Y[:ESBWM
M!_]5P8K,_I^C7&[=4&I2.N2JUC"YC=/:\H-T'ABL*07)$J #'9UK=W8.A6$L
M*J9Q$HIC+:68;L^9[@[\KC%$FEYDTQ31O9]R'T5GG8?GR5*\/R>65MI&&7N<
M0Y&,=Y\73XNS-*X2%T;?]_N;J&_.*\OP?E'_EM\6F#5A%;,:Y,0UL<=L5,ER
M<E'8$,&\L7<LG!JA:/CEB;1++P0=ES/72F!84A )=0Z8JA6O=H W<_RJ4I4K
M!,M9]7S'#>7A.80+84)PZ QF_18=@30!@_*@:T&Q#=ZE;=B+Q_ :S.@B">1R
M%T:OJ%Q;/HOK)?_T?^S%] ]5SNMR9XV[$S?59*RL#:SW?=3AX><Y DC\&#TN
M.]"!5SNT-3/^^FJ)8C:^CFL@D%0P]_'C.Z_Y_RE_XC_MCH^]3QO'MN[< Z_7
M/GG(^0TGU>2-.S-_>)UN3O6JNAY;@O0P""KDL:/JWS\U,]#A@*W<C@J1R'TS
MZBQ#A"+Z[\7A_]* !I&!KN[%Y"6O"U? V":6Y_6<^)74[*\Z1KYZE:[MIU]!
M2UD*"^*+.G?,&G8DM+]>3U37BW/E(&HUY8-5.33E]FN/A#],$DM1DTOX/.*_
MV;Y:<ET7NP5P?0O:+YN/K;0[N=>!HKW(C3E?P'8F.Q%Y8<M4L$-/.4PG]]8J
MI,'_&W'8(.N'!&CXP]XE?B H8C5[,R>AY:G/$-?-9POV02G C"#N,TK?LV$L
MBJ1#IO>SO:)I"GJ=XQ3<Y')-C^*;8]=J/VJ7K[] C558]80KEF;@M\I .28P
M!4:ET4)ZC=MH2"_;GIY=1*UHR-5&OQ:(63B'J(.5&+XT$*JFQLQT!@(VZ#SD
M*3!Q;:U;:-RQ$5H:5%L^2!_.E]!DQX:%PY@12]Y?A*UIJ@&*'VZ&)MAV'CI9
MCV+Y9"8W9\!4C',00\W-B0D)OP(D"[M++_;2_'J$&ENN<?-!&MKT =*.1D28
M][4.AV*NT7.)#LEFQC<]+D(:,DH(Q^TDHC-2DJ!O,M&I\=C]S]_BA%^U9+CV
M:N)=(K.29#[:U;RQ@N;A[06 9#F[;"-FD/*;XF1,16XK2@6$ST=D4F8W26<W
MG*-(21U3]?&G\^6OBJO/;1W*UA=??'1-.SA*;-_P<^T]044\/93V':;[-LJ>
M"R8RN=[ :=F=[Z( ;M3;>VMK?'_&(ZQ$OTQJ96FT'GJ1BNVU%="S)4/T6F >
M1&L\46/#QA[K58"+#V3&^:+IW-LG%GSPI(XIIX@^(4:!X<._(S'X[<S_ %!+
M P04    " "C@G=2'=^>]YQ%  !R5@  %@   &=P='DQ;&MS;6AB83 P,# Q
M-RYJ<&?LNV=45-G6-KH1!$4D1P5*R4% D)P*5"B"@F24*"!1<HX%*"!(1E 0
M*'(4,(#D(#DC.>><<RZJODUWGS[J.7WZ/>^X]_MQQRW'9HQ=S+763,\SY]Q;
MT$/H*8!03EI6&L# P #TP7\ >A2X!US"QL;!OG@)!P?G\N5+N'BD5_&N7,&C
M(B8A(*6Y!J&EN49-?8.!D_D&W2UZ:FH6 =9;M[EY>7DAS$)B@CRBG'=X><XW
MP;A\^3+>%3S*JU<I>6Y2W^3YKS_H&H#H$@;6!65,##K@ A$&)A$&NAZ   #&
M18S?/L ?'XP+F%@7L7$N7<:] @H4$0(7,# Q+V!A7KR(A07^UA/\/8!%=)'X
M)K<D-HG24QPZ6U(>GXCD2_1W/WTC4^[>8KAC8.=[&9><@I+J&B,3,PLK&R\?
MOX"@D/"]^U+2,!E9.155-74-S<=/#(V>&9N8FIG;.S@Z.;NXNKUXZ><?\"HP
M*#+J373,VW>Q<2FI:>D9F5G9.9^_%!9]+2XI+:NMJV]H;&IN:>WI[>L?&!P:
M'IF>F9V;7UA<6E[9WMG=VS\X/#H^.;<+ \#$^,?GW]I%!-IU 0L+$POGW"Z,
M"\[G D18%V]R8Q-+*N$\M26AX_&Y1'HW(OG3M\OT=Y2WR SLNG')&7BG&;?/
M3?O-LO^98;[_*\O^-.R?=HT >)@88/ PB0 H<'BR5?!*XZVMR^PCF?P->@GZ
MVK0/P#'%1[Z-HBDX4?6<1Y]7!!I8*LK-+/6GGQ9" ^M7-H]1Y6B@>AW%"S?5
M@W?M3YZA >OMG/[<Z386KJ(2]?7N6]/8[O[ATTXW6G!6:Y 6AB$ZY:35A=;5
MBR>K*#10?-1]ENJ)!J"#\,.SZL9RQR_=ZQN.-#!/WV'MD;I;/!PEB8+4S<02
M64."..)'?+$<Z>^V$W,O?_%E?U:8,!-V,XJ.6&VPF'F!<CGN?<S4H$H\ZGL5
M&D"L5I^B)F=A!WZ'2#2@@P8F#]# M37+/1KB4:76X\@T+@:>#SWT.!V?PGFV
MO^'X#,:K%"90R&J]]B*788H<K]7FN</B[DJ9_1P_&"=I.4XHG$5\D>HL^9]Z
MAOU@.=_P\@AYQ,4^HK&,N4@+1?X)5Z5$NID'R3;"-IG!CE19=%L'",>#IW0R
M#.3+92.LAK#K&8XFQO0X^IAB73VOD^8B6M# #[Y+/;U[BH+G5V^>PD.LQY:$
M'SQ1[;GG>*N8U8*Q5H[&HW@4&H,]9A*]F*?9L[<J6S@N\,B4(V[DBOPGMS6-
M0'%K+AO1J-:9U\EVK0="87\5G_P2%Y@\\6.&'NW:SX7 EW9$%0&1TPAW](C$
MZJK:TZV#UXZI3R;RYK8\4]0NQO;'4+<4IMH(7=DUV6OBU<%A"+7^744T<*XC
M9(1B<O?,&0W 1Y$6V>5;"7&U]R_;D[5)\D;<XZCE-I95$_;&N"[[7.WMUD3,
M3I-Q->\C;1U_Q^C[H4&&5Z)>E%,Q^ZQ*?3]FL*W^82/3'\.H$[O5&(J2RN)Z
M9UP.BV;4.<0+YF=6N*PK+8*Y^OB0]GHOB6P_YXW2Z+FB&,GKLG0YT=KZ-OA:
M48W2M@W4S4(,]H@?-C:#_I!Z@UK3Z\(#JP\^$7W+K+!S37V4N'![G03S)<Z"
M\NOBA+K*AP>>["BB=+^;A7&;IRSM=(0L$:/N!+?EX^<E6G1G_'LN8O=O_%NU
M"\[5UHJS>I\Y=N0D\O[S<+!.:RV3FM/0IVBJ&_'4B&65Y1,GA.&L2)NZ463G
M==EGTB52;UAW7ER 2=](3-A66)+C&/V/J;R4?_,[G\Q"9;!8V8>O \G=ZJ03
MWXI;#1=QN>,QU0/\'!#K,I;C&ZGXGU%3[:%-%D#D,QAN393WY=F>Z.]VXL%S
M:*"0"W3#YA\(_"&SR_JW%M[SJMM\<*\HY8R9,<U_$\M_>T1\N>5;<\W2U0<3
ME-VOI8RIT("CHT.(<&OYPDA28X)PN$M3\GYJ+,%P\RSTKS8N?NZP>LE#!6Y"
M*8]@HA)OH.F^;O0.HT@KGEAH-IFN8-C%CD9++99/T/)#FFJ@SBWC1_3&. O/
MYC!KFK$P$&Z<+Y.9[.!_F2&WO*B[Y_W'GVR8,K*;]LKML#YX(*./+=@HDHCL
M&Z@B[UDH*=.*<C8U5*4;ZZ*.O"'RY29]\-74%Z'5<IPO(F&L/^H9]6-RF^D.
MFSF]%;XON3 J^JC#F=5&@J"/!9,>4ZS#:MQT6V?E^\C$R/( ^4-;EJ^1W7WR
MO$]E);\)X6 NB,YU.^!RE3;_@>S!'Y']^\Y.MY>OJ7W0X&:#<;:8?"O!U8%W
M7[G(/'SB?CK ]8I77NR.XL?2PACIW49J^1NW%+[;D>+',H?+($W+<"XSNL?^
M"#K3:WX'L!/'2;WCC<E9M2P:V$#6ZR\K@FB@O^ T)>%!V-D3>!GK?KM;P&L/
MJ?Y]$2C5V#V+K E)0G\>8M9A56HW3.T")(/PY!FV(P$2%[Z=-QDXN2,ZA@8&
M*:NC[<@JE#\M]EDGQ.EMA:_"]ZCZH%NL:* Q[$C&L?H$;P5R1(H&9G7( U)'
MM(?,F$\YV<LM,L+-!8+GKC\@QKYT@XGB:J10ASQ3;!H:J!4Z+==RS9>.*;YN
M&/)R_C71PL:X;RIUL/'K)*4HC=)V>.V]/#3PW>01&JC)!',<.GUS *PV=[+@
M4RIH(,2Q.([F@X S>\:2T^%Q90QK]]PS\D\OE4N$CN_$B(2Z&7RL@&::;7X8
MO>?T78^CGH>GB323\.-=N&M-"^7250J)6?:1!?B/=J:BB&FL42^$ U 7H4<#
M[656[RE\US?3BIIWGKX92YV>CTBS97@L:I/D-%O@II*QO+Y]K?4;!]&M9RYW
MK&3IKU(:7%YQY35EER]]C08NXQ>C <F$>VC@ @)IB@9>!FBA@:3.9#3@HXCB
MZY.=/N-2<R=_T18J4!QG'-?(I!:?"]"K&M0+ST4U*8RO"BOB:3(6]=?TO8-9
MBCP1<L3UZ%FAG_T<S8 XO$IQSS9RQ>AO7&-M+D[26SA08<99H"MB8?RN((;L
M7> %/&+NPD6A@Q5SQ:.[>7@#^KK:KG;U&Z-O<)Q4KQ914"U"U_%%$EG*\!_'
M;_ZU7_HFB+\^A*HFLN<&,GQQQJ6ZP*H&[$8,1G*'NTQ=0]25\54>O#<P[%W/
M[ZB/S!O;W:2;I!RJOGG,@^],%,3I(^W\J>OOPLJ]_.31UIZY95Y&.:HSQB[P
MNNO.;2<ENBI;'V^9;X)D&M+=J=>,\JZ&Q!1SC28')M[>R"9AY>AJ*PS&=U=R
MH/[<JX+YH\+=OT3#PN,(+ANT>DC<9L.DM?#:1CV80:0V?I]AROYA0.T3CZB1
MK#Y&H_+ C20UH+PV"_\VQG$;.0WTY;;4=[NN4K^_"VW)!,E')1[/STMM5?-/
MQ36OG+ZK0];L1L7;*FX=O+>TG98&3=)Z'^6TO7%*,D:83.KC][0X:C".\P/U
MY\I\_;_QC"6SGZ5Q\8L6]Q:K80XC%]4;5Q>-+)7=B$(S@]4*CNYRI%56^S!4
MAPIB-\]% V/35(&-=XKI@6V$;I\.SJU.Z__HE33KRUKF%+>+2B(9Q.4>? +N
MZX]>%H@_*28]M<896G'F-R K+RZ.;!UO]\[%9/">+S.AHC[HL@6=TK[PBY:0
MGWBA[(K>Y>7(],]MSFZ,X4\"A@(+J0XQ@G>]-?@8 _S6-A@_NI++.C5A1%YW
MH/+L*?OR57$<PU5\YG72?&P'2!#_T1W/+6BO%19V+_:EE'JB+,A"5+A9=A^+
M5LSZ R911\ZYW<MQ*BX&] ?R9IR=;ZSD;CUGYB@-> <1'"EIT2;QD>K//W>Y
M/?0_L1CUQ)5/ 4I%7T\=>S\$WC36]$+U*U/A$[3:]V$W0AG":M7S;O%'R=*1
MQ2W+UR<G?"4=N4PUNR"&T;3#^2+&1.3O<J4;7LMLNC5R]].X:R!?SUC;]5PC
M:>GN,1.<KXJZ8O1E6W[1!2/) F\YA*\7L*SKO+P;A 8$O"2;2,%@MD-^4A3V
M(USSO5WX!]>W1PL'4[A)JN.4G,;"@R9+&V5/)P(RI[4;LXWCO'(=3:CSV.[=
M5'/220NS'>I.BHO4,.J8H;$V0P.!G<F]*"\P(Y9TKDX\Q'P8*6WB5!08^VXN
M4M4H2H]78!PJ=Z(A@08B[.710(%,]1Z&RJ-)_-'GW2E![/19[#55](2BKED[
MPC TD#)0>9"MF+K\5H5W\)IC6D_QA.L-=<.C"#4*8Q-UZI6F]M& K%3V%?9E
MO2/8GMX)EB9\B@?NQXRD/^$ZNW +ND4%K2T8H?1\?"ANT;HH1/K,-CCH1 -%
M=$:!\B&''.$AIF$_BH:90M0]N^*\],S%]<Q/M/Z?DOM<E1*^)F:K)P^OA::
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M6ZD_)64A0:[X_!+8O66>IB!DL+%9+>@_;"%^ZLGV_#;]]W3DEO.M'=JT H<
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MT-N=)3@[ .O1D8)5]6(CY!3TI!_7NC;7KA=>P=J8X@Z*98,E'X(B>5]PO!V
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M31.__*QZ.=4KFA'A5WC*<9=]SBS1Y="C4R.R(5 4(ZQBG%M3[\] I_ZV^4X
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MUY-@$1$1D=P@N4-*>H?_+L-=_O_G@?D"4!("?5A>.%CW &Q*+!Q*+$P[P P
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MD-=-G,>9"'>/M*G)YBK[B2!JGOV[&,#RE/Q33RGS'GG[0TKWL%3V!J'Q8@S
M.]Z.6)Q&V[>/EV5S,HPYJ*^MU8O/Z>Q-O#F@4CU2>_M5<CE<LL&OQ],7W&9E
MR& [6K'F*59QJN#$(G5"@@%$]^#<[H/PZ?DTH:R:P9U2";[CDJ5TMLTM]0-*
MJ<]1'6%%'DUWCY%."1-VFI/8I?LT7X=T."#.?"X%XDO].\?*YVHI&*!5*L]O
M;E&M8X^@HRQ:TP#Y^/)R_-*HKH!SOZNLL>BLLK[JN'$!9236]TXWGC';G^22
M&[YV,!?)$HW,"9<KG.I+/W=I[FQPA7]0),_(<@ ;CYZ:RQZ'S4?8QK.,QM)^
MS!)F[;U2X9AN70K7A"%HN$D*/JMPK''B%3>,W")H3YX+C>NK'%VQ>-OR1J:.
M8) I/<28BS%I0H5NKC,JD[TN<-)-F8L% UB,JU^"JO]X"UV6:';6_&C9Q%<]
MJL>S0>\5-(/BFHNR[T223:*+3GCJ:FM_'BLG>2NX=ATY=-PYPDTN.!W_A 'V
M]^7."O!>(-[=TULZ3?B6Z^VWO&UXMAY08!AUXO5A#ZP*=Y7^Z=-//0'&Q0 )
M\\VS+ZRF#>ZGNB?C.JSGXI>M9IN 17AS=0G>VF0O2 ^F'W8Q)Q8_7HI4GZ$O
MS-_.!:^@00)]=F?S,9GV&H(II#3FHSNK)78#[>&?E=J[,4#:6Y%SB#.%"LU7
M(WD33;5I=<&A*K/L<C9JJ/PG!)P#*!!.[OR8VQMC8-""&]6M^9I,W#?>\S-J
M"5G>-"ZCW<\]6U%UDZ<TK2CCM?&K-)$! Y&<^.Z4%%BHC$?)&HRJ2%-SL'TS
MX(O9>F[&J<9J=J1[K%:J@3 M3"T:XB#Y<GP9^8MGS&9;4R%"VSO:^ %MLZO
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ME#V.]-L^M,^VTDS#EL)EH!R$KU7YV'_CMG6>:UB-95XXE$"3B4>^U6@*GT'
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M,[PPO_M>W?AN^]PD;)>GW<^BMMXK7I(/-JT;%$@XCXQ2'!T1S"X?6:AU#/G
M%OXRI >48A(W&Q^C\.T4D59:,&"_P/A0): FLPL\UH7S("8/2];3--%70ZUM
MEE]T>3F[ :DW;K3_=095KUC"*(45@),+C3*T&AX],&L<.]B2%M:P?O5 M=!\
M!0YIP9FFR/V%:&O3<?T(#JY98[&F5[/$7R-J-PET6O>%]A-UME:=5*$NZ2^)
M0O*.+YPQ $5/MD]L/URQW-X60EG7M4N9=L&U$EDM;JPP)#&230C5&!E(DTF
M\!:&Z+V,2\O]5/*^Y8;0(M4M-)> 1K4^+TI[)*NL'L8GKUX&F_*%D8B<!D#&
MQH,<XI.;,SHW#$!CQ=XRWKOZ7-J6$T*P+=MEG)6PM]-*+K@FQDSO5\$1GH:4
M,]H&T]-:;&W37;FRXPKEASA580(IBS];]"CU&>="J@IGS,15W?6F[\JR*+:
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M0$\!E$#XH1!.@(0> J6'$)L!! ! R""_+N!_%H0$2DI&#J.@I*(&'R@_#I!
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M!TDO[^]N%QO\F1\\'K_)]51<]LKD>2>4(65D_EQYO;J)U9<T^NZ0K= :3ZP
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MBL\B*&M1T=M_"U.@;DU"CWJLJINH,2OWM9,/C%..R9*[^ 29C=H;9K=D.;)
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M?PEX$>!9V? ; -@.?Q<H\<M_ 5!+ P04    " "C@G=2#]FPE $2   L&
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M?[!I6^]ZA!'3]NG@<9XA[Y:?YG!\TEXZKN57_5WB(='.V5XL<_K;$*<*W]J
M*17!@''B>I*-'C4K;T#%YRX@,5U5*LRR!C@*YQ29+<M[<BJ_(4079UG%%Y#)
M%+^L["HW',:*0I<%=QK*BBD7/8WZ>I@#X7EV_FG X60T89Z>J]*1O=1,3SF8
M95BO.TNQII#B)$.44G"WL>67LH)R51\K2DM6+S&VIUQ.&DG[X6UG.=^'38>Q
MKY7:GKBN:OUDMD'-5,. 3X0!$*)"$8]S;&BZ9N&A:'B#\,7\I&;P6NA)P_\
M4$L#!!0    ( *."=U*2B470S#8  'TW   6    9W!T>3%L:W-M:&)A,# P
M,#(Q+FIP9YVY950<L+ON.[A#<?>A.,6*2W$K[EK<W;7%G8&!XNY0W&>PXH,5
M=RLPN!9OD7+ZWVOO<\Z'^^'>^V8]GY*5E5^RDC=/\KKRN@UXHRRO) ] 0$
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M(PCX127\UZNPOZLIE'^**M!)ZCW87P<J7#2=#3W4_JE;]PH(LX!T^M!;,7K
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M-R9Z39:/C/=2E..Z<6OUN%Z%FL<FY>,;(_]R>'J"Q2A&: #57=U*AJKRW,'
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MEW4!:?R.Q$+B1^O#?:G$FS^8ETIJ$A<QG+5WXGYR74^^20Z^C/9#LS&ZEAB
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M9)ZN9*G3'P(G%F[WO#$!VONPF('43<#Y".OU)E;.M+2+_C3/%)!MMIU85_Y
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M:MAGI)6F009#*W5ED)#<U5 %5>[# 4H?QZ8D3T&(XT*SB(*KN7Q:D6*H,)T
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MWI;$(RN#3YLW%=/4@1[9C2/B$8[[3:W_TCCNUB*1P-H81.N25PP4K8\;8\]
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M,4F4MH@.Q'+/Y5F]Y'+M:"J>[X<DQDQO^)CTD$U8YM6:33.J@QU!(J4ETS!
M/RR*Z2S"WWUKA\#K6[_]\XTS<NUGJ!LNO@%18^HX8LPO:A#\8(+9;+2 O0()
MKLGN9/T-G?Y!P@\/]-B68+CV#QSLR:XCA!2Q A[7@W:^ M-%,U#J>V=ML)3V
M2AWN*,&BTL/C)_8/FP?2Z]L; Y2B"@F6UG!8]\$N1[K0-Q"QIHODJ&0H^U^#
MT2N\W$9SC&5IDMM#6SEMTNDHDXH8Q&&12Y'[$&CW/R*Z'-'%E)#W<2%@ZQFS
M_^I^4B?=@4!G^0?U3M0T5^:7[[1%4@BU 9MDYZ^S!S_G'IX9EB]=W22*4)&
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M!C^9^Z'3_U)-@)@*#.5#&2M]H-T%4+<4!RL+R;C( IF[U!= =OE"O5W/\VH
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M6CL[]L0>JNNK6%C-B[#[[&]=<L1D[TS:/C\6;[)-]C/C9E_\LRIBK:?99_A
MPT_[["SRB%4U7U+S_WO-M)S _ALVRSE'S^4P;K;$PA,T8(=2%+^DK.L_^E)Q
M;B^ 2,X#DC)\&4/UOQV5'?V R7VH."Z,363YO_M>[PRO'EZ V%! ISKB2>T%
M /DWO@"&=2_ '_5;CW\_JCFV1M5QKGJ?\4DW"T<CWLF-(F[F1EV[?A26! 78
M/CE+!VL5K$PSVBL7PRLUVDF />[(3*2# A$X,O&$MW)NS]X$3,%JOP ]-R_
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M?)J8<9IMHJ,[3Z+68AVAV#%IONZT 2O1'!O+T ;0YG@O#/>=/:8%@//)45^
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M?ZJE%IRQ=J )! N3NC4/)/):*3('!YJ-4"X !1T&I+AK#A"?/ ^2D/7?Z*(
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MUEV@NBSS?YV,..\KSJV%\@;]S+GD> ',0Z&]#W-V.ZY*CSYG)=ZK<BL\"C
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M''^3<#J4(":D=MP3SM7K,Q28E=R31THI,3)916R:KN(.7=ID.7L58]H3Y8?
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M-RCJX$%]N_L<3Q>^8.AEA/8#H;&9+'+,1%Y^HIC3EQF&XM,@A0Z^Q@!SIQB
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M[_&_PM+'WR;<]KNU/R>__[5E%R*RBR0C?8<X@-9FOCK>4M%=C ]N)=)L<%/
M &^/AC.1ONK#[WJ-C+Z\]%=B1E=DR=.VS1Q+6WW]BHU<O#\?[4,P$_\'4$L#
M!!0    ( *."=U*O"(EOW$0  &)+   6    9W!T>3%L:W-M:&)A,# P,#(U
M+FIP9ZR[!51<3;,VNG'7X!X8@KOK  F>0""XNSL$)S@D!-?@"1+<78(S2' (
M[@X)[C9SR?OI^YYSOO/?>__-ZK6F5E=W5W55=S_/[@UL%K8*X"K(R,L <'!P
M@-'C'P!; )X#J,C(*,A(J"@H*&AHJ.B8!%B8&!B8I/A/< @HR:BI*,DH*&A
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MUU#_X2#=B;NY!!_-?#Z2)YH;@W!CHGI/$1\ Q7Y#]E:Q8*"WC]&^9H,6:,.
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M =;C')& 25+-[ZCN]D9S.^(FJ^J>M8)ZMG!'+QT+B!&X?"MJ8[GG;A3Q H1
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MLU^;(&K119(B$CNLF<2>)M@QA02)V$KL!"JM+$%*IAE^X/8A)/EP,\1,)&
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M_=2RU)WR$&%=PV@[5>4S\ 1%8O,$9NNYOB#6R=SZR5=_PTX*+!"8AJJB=B
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MCM$*Y*\5'<.<@Q<F/F*$N9=R_LW^PN(#.%?*.WH,C98J.F"S\+N"L]Q?L3#
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M_/13*CKALZ5TAAV1T^M=Y E.[RE!^;=\45I\[Z0??&,4_F(.]5_FMX)RNO:
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MU7IKY'I?6G^]""/OG.KD>U7;/ZTV:6!@D&75!3<5B<'U_V\" %!+ P04
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M0@N4^JA:V&C,S-JG*T,FM\2;$/=/'&A@I13S'QU1%R7;^=5H_"@/.2\ !M!
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MKT:E9-N546& 9T8F,2]HL:!9-8"NQ>T^I%0KB30_""M-WHC7!TI5XV$Y #%
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MUR;S1-^1G&SC D.+/ Y;9O@?8N2B%I4-4ZY9[LEK[WRC-QV3:C/-)-V\_I:
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M L2N?P[D[?>1^@!X6OU%JUW/,F<#2\&"Z'T)@+(/Q,=_ (J$GN,4I/QFM9T
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MTLJ"VB"&AVF%M5UK3I\H. O3-9AV>9.^YRLB6:25I=M&AW5_757,EB P:XV
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M>>"6@HR\#(""@@*8@'\ <@J0 K P,# QT+$P,3&QL;%P;A+AW<3%O4E&>(>
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M/0L6GZ=19K3^+&-]Q#(H312&PUBDV)',T+A;F63M:D%<W_B\G4$WD&:!_G:
MZ*-V-N7.T#@Z93:G"8H35@=>"JNE1/H7I*5G)K'A[I<V1QZQ/KICR1ZK?'P4
MZ6CL!)%>H*H5+K,XIX&YI[&M=-"ZBO)(.MRNVGM3I9P;T$);)FZ%GRO9D>F"
M3MGYHM2ACZ)8K".V\U/40UNW:*0?6EL!("?\/FX(=I'L1R>^$OB*=GBR6 -!
M?VV;/Q5B%DGR2?,]3R1O=X#,HFIH+#SU4LG5G8-UM&!L6TY7)?WVR U.@Z9
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MAYKO,;407%R39KW4A?HHL )6"V&:VVNZC/+:N?*3O]S$:""]9-QE\GE^KKT
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M2G@/\,>]8HC>Q^/#RKC1OU>E 5Y5^SVA[SAAP,S<]:G_!\9._JNKBU[/QI\
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M5T/D3P=X+<YI#,:ZU&G,7.$W%H/PVLD?J 8_D&91HR&ZOGL6SK-:FJ!69<%
MM)$NOJ0W67%6F+MPL.AGO8+FF_)E9FK#I>C</T5WTN*X_79"L82B77LL.U*(
MZW&SM-"FY6KJEKWGC24G9+N:I"?WBM<8S[^-N#RN>*$ 0B^/RIVC>RCUY?'<
MN^/NE]KY)8+=:X6MXWX[2U9KI2+562G,!0P*DKKID@3J)"@$R@^^D\,;9$=]
M8BTO6E0MA!-266AXCZ;DK/X9V8LW(>!5U+ :(@OY!>F"?DG"-E>$ZTWK7R04
M<GVHN/T;RB[U]91L&-#&9M-XYEO]X'<UX$16VH2+]MZL#@9$Y,-]]K#*N[JP
M.=IXHM;'VLJJQ72N'UREMD*X@*^C*T$CS8*?DEFO\?!&KJ^B1$]S>J\=T[UI
MW82#;ABP$RH=R7!Y +Y8'/%A]1<R'R GL5XH"-@V*^/@;,NI)V"D,J#(D5V9
M*!F4^^J[? /9L;:JXM4]P<)*(..QI30)2I24;;==7[N3=5/=*![^_<<FD6+A
M7">GRA^_0LJ=A2F5=U3ZDZ/UL#U<F77<[]E0Y>/<]\()9XJH,WNI]79=:I@P
MP<G8(%;OFU8J;U.FJW&9W@(5&4)(!T[9 L]C13<Z_(_6[]_BDG&9441E1-$Y
MF3D$1P7($])&6]RW4TP:XHTRK? +2@OA5IGNQ(Q7'.^CHD$3?L7 <%'\R9T\
M8X"['3++4>0A&1Y5H)OYS-V'P3=[>1J'"\=.>.8HMK3WZ.C2PLN4,4-#)3LN
M!0U)Q/;AP[!0G=OLAQ<@>7G9Y[4!3E%\G&\;R8+CI9\('6A'4E!^+0F1Y./#
M-M#D]'IL/1%3HZ*)M!9:WVU?HY9PT'X-I2KW:$ 6A*Z3*5,=.1^@N$$QI'6"
M/&IDL!J135JN,T"[WYQ/:D_#CV;-<4FU;X>FJ%V)XPW!6.#$XU7"K_?%H_80
M1R*I;Q'(?:EGB2C&HNB(BX6"-8:T)G/"MT]6-?K"7>LS#(CWW$\S^Y;&>,S[
MXE"&;F".4\)NE ^5E_0E!N( TEO7YX+10<Z.3?+ ZUS>;\0-+Y@FG=!H5Y!H
M%H\WGH(MAS CN::V^4E+>9T75;5=5PQZ60?O"R 7XN.<,1PD]Y;92TV2VIJ7
MV%LH.'J#V3MO>=5Q!B$MB:\-VP^F*3@E/LT!L4=Q4Q@;=?I)R:I0:PB]10M1
M%/9[E?N*MC+0NK5,+\')XGGIVMH0U&'!ULVMSK1"U.R\J] -!NAKLUSX<%OE
M/W5(CEN"8R4\ SWC?FT'[N6#[\P*RN'>H_:[K="'HS#@J!Y\R#0O7"ZV$@,_
M==!7T\SU^#N9LQ5C?HZGB]+@'V[!!.R>B# QB3G,8"<42;M*$FARK/^6% 0\
MO6>WCRC/CT)A@#C/[$)BGO.HV*+^$'AC0O$*>=0SP*,TI9"?(P$?7J!*OA<H
M]"VK9VNI-]0UN*>[IH VI#W:=QJ:4I4A.FW)F+0EA3?DZ.TV92G9%RTB^.X1
M5F^RU3_.SZ:AB.GW!-Y4!784YQQ-BF>>U9J9$RW/*CALL<VU/"$PHL)W7]?K
MIDX^X30<L*$=,LPW][/OX$SJ02!F$#B<';)_^DRGKE#!AM:6 ^!8ZY4KJDBU
MG7[:3EB(Z<K#E%\498H<8C<& T #$0?J <OH T*FLFS(AIH6G#?\# P,C$K,
MAUA)T5%]G+AY"[9E1A9KZIH64?2:9NW;5@6C?178MGA0"SYB#2+C&PK[99+T
M8-^8/8@/=Q'#[UY*5D2VKH\M"GX;Z/T@X1Z2![#Q^)-::8)RO&O8JP_CW A.
M2S-+=9U&.Y2Z*B<^Y@[W8("))4,7#'@4<V+L0^D-IA"8_U+69[.UC'OVS#AV
MD>$!JD"OXCRAK; T%NA=^FR.*:W5;%P,+R"KNVCGW*JM?RKKW?I!1R:XO3,L
M#+6WLV\AO;,O #KDVE@D%+5G'AT&(28*H6Z;0^*O0RZ9=B]LIAP;[61*#?H\
MG+K?Y']B]P3M29,?DD;M')61"]MCK"X:O+E4VECY9>-X: )$&$0TBDE8V+#7
M1*=Q0!<D%I942EZF>S!(TEI,L0O!7B9EIBFX?S<L2'Q3DD[!26PBCZ%LLK0[
M.($B2B##TF]Z3I) %??'TET^L5IU$P;0^ <.*%X!0YUSIF$UW*ZL!,JZ/E\)
ME"6!?X0XM8R\>4.T"/%<"LD03D? E[1W^*Y07M3NG,, _Y<SM]CI!?W3 O99
MFYY9*#F;TOHE?&%^?\G\=+"BO%638(Y-+= !!KSWE((?42&15_"<V4N!XM\D
MA7J4Z)]<@5NJV)$&_'#D\HPK@X_:'44&?QP+/)7AMCG'& ?/',& .[M5.'+W
M11B/Y<O<[?3^8E&IZ8[U':=QB&F"S?1^"FM@+I, C7.J^:)_\-!<>"0RI:UT
M@5[CAMVF:^1/UE#N!IG/'!(6P,^C&U">.6>*, ,7Y<W(E^>+E12#F1L5CRL<
M,BG2S;=MO6[=8PC>T8 !<U3]M:O,\/X#/'H):GS$2:RM3$H<ML5V>PGYN!?"
MAS00:%SI,THW=J+XDRUB/\UKV-MZ$D!"[Q[\:$ 4?>)3Z+N1WV:Q_V)6$U5Q
M_%J'CDXG%T)(?I(AVIPR83V5'UX]LD/*.-O<4?E_&IA_\Y"([S:E;J31]/,1
MA\ZH1TJ61 4R+DQ=J0DCN:.](MC2R XTQ:Y.[W?H:W>;_9L;;X<'97.LOY3I
M75/FMUNWDJHM<C0?2TOV[5K#D-/^^QXB%=[[7@\@W#/_VZGL-R)AL>!F)_A4
M3B[W]0BU*EOE]'6VN$-#O<KR6$)0)$:="RYHA#'++]:1*U..1Y2F!>X0Y#W*
MR].\*Z@BW I<13P8T.L+K[B+<)N/Y9BJLSG.4W%(X>;>:@(?S->>G(G!@1$7
MEH;W+,QP6$,O0>.,*1-?_[_03T())U=B+14[:,Z\[A2KZW<\&29XPP-H!=#C
M4Q.TMS)2UWESU.[W>5Z?CQ-7?_3>3\3,NTU8/ISH^_!"..(%,^$*S4 JM*WH
M,!(*+3WM0UEG"CR63$^M/3FJ;0G<_*0H"][9 /L#SY(S8("QMHL\7#.=2_,?
M)X JDB,,":55% D5+Z@'!_0OSF<6'D=*%H?0/S#1/3D@AK[O0XN[A$\,]IZ$
M5DM#WP^WC.KL84P(Z5F/$)=:Z2B?!"A.6RYF9U%B"$?#@*;GD@2WWD6GX"87
MDTHC3'S3NU?SU&T0+<+VQ,EJZFJKZO#2LBF>;)([GW70VE>FWR^(0&.ZS@V2
M$).G"&$SUJ?]%$]V\2B>?(2JL$*&;5KFL7$/-2VBO6>P]FW3GNUM@VXS]QR=
M,4EB+GX.>48Q@78J#B3RC:A(60_$S%?N9*J"A2T0$N8B?-3EK5B*UA++ZG"?
MR<2*( 4"D!6FG'I@URE)'>5HL4)%=&91V O'EUKFBD[NR/>U%KKT9X2R4\W,
MNLI8;BB-GT6*ALMO1E,[ZY8%H!M?"&U_EDEJFOP*M$^MM7#X-D4^O.?%I_11
M>4&VR=.RN5H>)Z;VB?MZ6DL"BV#."(<G=WZ'(0K!Y1A_[\"GUY[Q">B%J=K5
M\!#(V[H;@A*7N_"RH",SZ'9H.P2354BFM$_+>J$D8DEXS@%J:<J)UEZT(OIY
M EM1>TE3H2+D+.?2\]AKJES'#V$HQ-5V)(<<29FDNP(Q'0/+%].MLN;9&YO(
M>$90EW)$ GJ)4=^3&)/7U \A;KN-+*"1;_>N-G 4QBBC( ;1ZO&5EB-[DSJB
MG<$5 K=N4C00Q*4&)C'0E_5N@FK9!.QMEMK0M43[8F2(T6+/@^Z9]K,E>O"9
MMRR'-;6W=ER4O-N)?95F\BV-MWB)NXK!AG;@R8[+KK9$B>SS *7 EXWARB%B
M@NW#7R)6GE;%.X\(&(<54G^]:S])XZE!NWLUYJQ$3+XH:?5%G=A0!K-]<4]!
M 4G96 .W!<FJSB((KW)[T<SO.$NCNFLBDIW5;X)9^R;BNMD'ZZ<+#E/5;6A"
M\KBH=F-(I1"U\D'V%[.RN7?'_!Y<U(73&B,%^% 4:SZRDW<E9$SV1<<XMD&"
M]T)QZ5>4,$#"<B_Z9[XCM_49SH*9A"2!!EKR/[IE_^LD^P!3DH[UWV^NNS8X
MHQP*E0@"CZ)!#?/4T<46^="N7H*7F8X UN_'TS EQ#[SU$0<UM//.3P7FE1;
M( .$H[L!X,^Y;-6C3_MR>":?HVR:E,2F9#;>/>;I 3<4#HBM;)] S_6A]"5>
MC\*C&C5O"B@4O;8BEV(>JIW3MJ \.'&% >[L,."6]"6S @WTS0YX)PT&S%M6
MYSRNR58Z.!XACHC9[,=L^=3.)Q1@6VKM>#A5ZC<$F<>,+(N6-=+"6Y(-H3=\
M]"35("\="6ULU D&8/3*P("$RIF+-?!IM-C/#Y&/1W'%:$5\%;=9(&N"'(GG
M_73)\(V2+ US?WZHWQ#E1.1-[H+. NF0*0AT5I<9RPP#C6>U=A?"'7AV <^.
MFD@8\#$%2A@?# /$G&I/!F# 'K=]DVB>VL%DM;9\&985!G-;VZ ,.OU#3\Q6
M\5,U5<M;[5GR&33$IB$2#-MC?OCV@6DN8C\9:@X#O"Q2P;U3.U>'M9<*8A:
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M2E2B'7M<?\#5]W_U/[W_!+KNZ84[]4_!&;SI/"T1U!'HL34M[CGO]Z5%)$W
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MM/OSC\1.F&"%XVG.[A4R:"]YC4=-U+_V.B 'U$=_"07 )5[109J'Z]?PW:"
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M<VPO.['4%(<1NY=1&:<=AU]7N 8[.*K63"JU.>=YNJ;VQ#5X?2Y!;;[\H^A
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MD+W)"((5R*&[G87E+M>*F91496>OU#D(%X8/O=_ */(";.)H?YSF>,T>$01
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MA*-T\KJR=\VT( ^1M!&:<H3/+(OH8<,Q3SH4H&M\*(O\V$O8DNEQDZ[>)13
M2/X^S D('DOK\=UZ,#5_4G JMBPZ#%.54^+&\+)L8(<YGWULX("/(V(K1GD2
M=W>";S6T!VW[E6F52)B3N:5Y'L'T,(TA:S&R[K1#7(25&S(JWGE(_".@C<9-
M!N058)ARD5A^9.RZV_ @0C<4;CX"S.O.$:128GE^=QT*.#ZD@'C1Q_1]Y$R-
M$5CQI\MG&[_9E_F?-X,..$T3CZ=@R%7UN'"A_IR40^AB]QI);U3302Q(8?&-
M<E[)94#%A'@$HFF#5#MU\HX L@0QAW()=45)K)0&:7DD%5DW/;^U;]MK.$1]
MVU;D6#QY2_GNH+IJ8W2U*2EC_4\M>H3PU#L5;0TTM*'G@Y0!ZC[S^;HQQ@]"
M^=L?FIRXIGT\_YSX2A2+7VEP0?Q.<_7U)U;@5A<Y F_ZD!)]:TI0Y<60"DE:
MQ$A"&8Z$%0UJ8CV+1_-PW %;G^_QIER!GH98RB.TT@"^:$:]A.V'$1#CE)#$
M)^7NO$N.N_*QTL:3TKKJEM33'27(;\J=2#]B)'[^T(NOO;+2QM3)8*)G3V/^
MK6NR#0%E>8WM0CG6S$%>AV,0[8//CM1G1;KS4SHB"Z=EL0+BC"SZ:35A)HX@
MZA$"_X6- 8P0_4"@-\(B C>%+X?6,<;IA_FPG:5O#(1V)G='@0?BN]V\"UNR
M&:I?I4I"B+D(UCU$6<[0W9.R.:[3<I$G9IBI.'? 3U(/9"T\$Q*#^-#J69'#
MC@*<QJ9T&<_1'5UK(3JM [G2@KF;)^.K598LZK@,/+3&+<N"G@D^I:!YRK*8
MA>75L$VSKEZT]G.\]"FR)]PGB(JCVC2%$2,O7)(S*>PK-8&3*4KGX-U7;B9:
M)_3]$+V8<I=8A\/M&-5Q863Q@R=8VB)L'>'+]Q43A:9)L;J/CO/!HXK%90-)
MH8AE^WE=7A-B5"%2EU^>- <_3WP^DQK>1(#<O[T0MJUVBO390YM2$7.IG#:0
MS'RNWW%,,[1LE5X8T0.5)I,F#5_W0C_A1$U>(E69G[^5:4KO8<XP\9<"U3-+
M*("Z&C3:"<LR;5GMPKU9B(@#C#=%09X5Y^S%<\LND+OAR6FNIOZ//;;_>[/5
MYH<"0@4/KV$0!(9$^;1;%[_(>NY:L7EX77/Y[W?\_%1GF#!F%!=VPST8@<86
M=8EQ'-<W^X!SD'M)\#PDJ(<M?")MD$FY4[&LTOH3^*G&_?@[DC'Q0PA;EL[\
M(^B3ZO@AV6WOC^Z_]Y=99M"0U]D28_%KWJXLY<<(CK5P-&]A2:C=]^^)F9%R
MB7Z<JK#2LHP.=G]MW6S6FS?1"_1_NT(P0(\%? D(I#%X-N]$%G>QRH&P.2KM
M.AIP)[E+L\*R.(OR6OS:A$DWQE>X>_[R<_K!:@+JE]#X9C^X5"#]'N^>[9AN
MMDC:[)0$ZW-S8!#"5KCE7CF_NT\)UD<"13!?  <+M<A!TPMGIW;*HS4;T4=E
M,6E5PO8" ^SE6"[D':+!Y:$5JTF+0)?^S&V,->72?@[2<J\'U4B?KO*O[OH2
M[_"2Z*VKM!%'HMB_P.Q*25=Q7'SOHIRK30L&+LK"18>F3LS!"Z]2,#FW;\C0
MLRT\/U'\\"8:4:*,C6P2])ZYNU6 K46 KL9C:+M2FIW\9126Z?Y64.IY&_$$
M',UFVT*R&_T!"V7,0[\P-DJQC:]DG *M\O2K)QN$U;.FDE.=0"^T)RHVWIO@
ML2R#D=^J3!X:^XN'2/IK>?('44YZ/"4&Z"\=[HHFE_!]%@K"DU,TQ'<1A0)"
M=A*A !T6&.Q\ECF\C8=;8/(5,[&DM?7JS\N93Z4M+L(W#\(1+X 00&]G22\9
MO#P< >)%"*6%LV"?+S?,=_;PTN [\\53R@Y3)^K$DI'91H'Q50T(Z.T-"88A
MX,@\&",K^\[(1(1,J-US7M[Z(06,2%J>7Q=])Y+^CUPD4(9-3K!@[*S\=^+W
M._W]KB[97R#5<Z/D$N6GS_YE",J+/,&&&_*G?/,DPPWYHX,"O UR0+W;41 !
M"-[WZP/ESS^HYDGG#ZIYVYF;LWNE]%NF!?]DD@C>=S/!LC[JT?8X.A/T1F%)
M?A0^#'TP!':'\*5_R^P#&K)B>]UWX2+XK.$N4>A//&ODW/WILCC^.XCCKQI5
M9;G_SHR4<Y\$IK_2<-4],[_8>>]8R>Z[:?S6X8VLR#3[R?ZFTF]?K+> <&AN
MGG5#N49*@Z%$FBOCV[WDG FI2@J5C#&A>15A*$#8!+3;=O/\T:T>7<J$5(6;
M=M3K7VH".SL2#J\[8)TI]8'ZU'4N#X1:@G]Z[T]W$K9#H9+V]R-!"J2^@!KS
M/2$> S!&%0H#MHT%_^C IC7*VDT[\=?&!)LP+5[4,MWD1QW6!884%. N=C92
MYCUG1DZPI\T^H"63N-&9^2KAC'PM.3S.)U-!9IU<^C&>8DPB=/Q_ 5!+ P04
M    " "C@G=2:!2;<W5&  !R20  %@   &=P='DQ;&MS;6AB83 P,# S,2YJ
M<&><NW547,W2/KJ' 08G$" X!$AP=QDTN+M#@@0+[CI(\,$M$(($]T!P=PT2
M/+@&"^Y^><\YWSGG_>Y=ZW?O[?ECUI[NVM7575WU5'7-X^SC"O!,3DI6"@"!
M0,#;IP_P. ]( "C(R!!D)!0(!(**BH*&@8>)@8Z.083['!N/C)B"G(R8E)22
MAH66DHJ)FI24CI>>B8V=BXN+@I8?RL<AQ,+)Q?'72T"HJ*@8Z!B$F)B$'"])
M7W+\?VZ/[0 ."E"/\!8,H@(0<$!@'-!C-T ! " DT#\:\*\&0@ C(B%#4%#1
MT)\&U#P#$$!@, (B& D)$?&IU_>I'T#$0<)]R2Z&_%SU'83*$8\C("X;A5J\
ML@-?[><1#:>)4R J&L$+0B+B5Z]IZ>@9N+AY>/GX!23>2$I)R\C*J6MH:FGK
MZ.J9FIF_M["TLG9V<75S]_#T"OH8'!(:%AX1GY"8E)SR*37M:TYN7GY!85%Q
MU??JFMJZ^H;&SJ[NGMZ^_H'!\8G)J>F9V5]SJVOK&YN_M[9W=H]/3L_.+RZO
MKF_^D@L$@$'_T_X?Y<)YD@L!$1&,"/E++A""^U\#<!"17K(CXXJI0MXY/J?B
M"$#!$X_+KNQ I>94.\(W<?J)1D##M?KJ^"_1_B'9_SO! O]_2?9OP?XCUQR
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M8I)QX@TYX_2A$.U7([,>O%HUUT6<A;:X<F.=*YC+]#C3*]:RV7<?8=Y[U8^
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MF= GARCE9]Z_*S"!37JCL5?+O868%AQ]X-@#>!I'5J^;EBEH^!U(M/B%?(.
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M11M;=W>/-IIC<"5UWS&OCW:^&4ZZ:[E('\]T;2/SU/@;W-WM7&4J!T.Q$4S
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MN@3]YQ$'[)X9[(#/>+YR91Y__UQQ2'*4]ZIY<X^[AV)8KEQ+O>1?4$L#!!0
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MJ.E$V!W)&-]&QL&72, 7^_YAY^F5GO)]OCD<D*I;NCP'=;][7E.+"-.8W-%
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M_(*%VO!J3@*TT5?1+U%1O(L?X8GY_UY2^HF.R.PEF$OX=3$1^A$+T[7^]HV
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MACSL#F="EV4=2N=^1Z0/E ]K!I]W,NQ/(;;RE/4:7#>R,P7.R#:B)]L3A'C
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MBIO:SQTBK]G-QIM9?)PH9<$?6SJ3>W@]O->;H&,&T]GJF7G"8S$E&3S*G+Q
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MHE9W\Y4D5))3EX6.NQ3#2#P#/Y(XB%2E\QT??.;*M[=,^K;'(/?>L#@C)E.
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M V4?&V9.8]!SGV7LO +/9D/MJ%J1V#%4.SV'U0B[B>MX!0Q/>31"B0@,)1T
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M1DL(5-['5__UTD!O'&-35N69L.=0?[_7&30(9B7$::.R/F'AP5/9]ME9=.)
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M\JY<OBW:+M1V5'*F3UWY@FA[ZT=S^+8">42&Z[?"I#]1;A)K5Z@#5\R%W2N
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MB0 TH, K($5_&8-8&*;*$T$<_A-02P,$%     @ HX)W4B4.'>9I4P  +EL
M !8   !G<'1Y,6QK<VUH8F$P,# P,S0N:G!GM+QU5!U?MBU<!'=(<-?@!'<-
MX6 A2'!-<'</KL$MN%MP=PO!W?T@P1V".X='?O=VWZ3[=K]^WQA?,=8?C*K:
M>ZVUUYYSKET,'N<>5P ,:9 4"(""@@(^//T CPN &(  !P</!XL #P^/B(B
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M\$O*8,_!,X11L5']N7..@\XDG>X]VNRHCA#:)[_^9O3I^07MN;N3NEH_3_6
MNO;8?FB?"PXHNY"M,@';7 UK7(HM&DE%O7 2*14//SRJ%^G+J9.C834;T3G)
MA'U:6AZ)C%$KU>M4:*[?V^_%A53D!#ZE86/'<G]FLJQUFLP/6>-2ZPHT$J%
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M8&M.0!+DJKPW'5WI>SD^T[&VFR?D$"M02G _-%YE;"WJ_3W25EL0RY[ETO;
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M[_<.C?;/! BPU_.:%DGI?$ ,]7A[\V0?G+>\V>\)'P$R5R%9OU$+<I&P'.A
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MZF6926NU=<0P[>/JP]6DVE=#;7)^4#0E=YW(2.$$<78INMKUAI<8G?;2P#?
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MAH;L9:AC/3J_@+QW4C@:"]H(^^QLF)V9]:&F-9]+OR,& SNO[I> G@.W=8I
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ML!;ZFH=WG"E[GH;E?59=J-"VY\E6LNG@9Q4M'KF(.LFIHHI+%R%UK_5Z>58
MB#"OG,# 9XIR@3;<='F,2C'F"2_+X_$ Z1<DAHEG!4V+2/VHJ#BXZL9VLWZ
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MF4[-VYC43@PE26TU]&WU,^Y2&XU@SGC5&>UZ6;.SR@(8 2.P4J>H44@:)])
MYJ/[Z<;C ,FVW@Y&664Q+*K/S^-!^^Y&BX$$LXHAE[B]E;\=(+NQEV.AP%G2
M1]C:K^]S$CQO__*Z\L\E#>G8QV<99LTYZ^YFH,\I*AJ@8)+$ $88,NV 0FM_
MTGUL;$]/0A.A5C(3+P.0IYH/K[<*^0MJV#]E6PF2+_ SH".TQ@/U4!).R8KR
M=3EK+4E8L3B8)?D<YV@GWK0 ?]2[5QT V62R2_W\_0F9)>834?'7*Y.DG8_
M,[>5KL[C>&+)W[="DWQJ6)J"0Z*6XE?<LJ*MBIW8GL<<PRTQN($Z/("\=I*#
MY<WO1HN!O7^MQ4JGQE-EG-]ESW0, ^C"'$$Y/X0/\Z36U8O0[5 +[IE:@SK=
MV8Z1_0(:CVLA56F5?'2T*03E;O^WJ>G_Z<*@L/0\&//^SG8H',2O5W>?_=FK
M$RI$U]9I,);#E+MB8]PTB7WJB400#3%B<<(Q.Q?ZT2SMVJ>M#]B<[3*4O_D*
M[MN;-YZWE9OZRQS/Q#*$JW*3._V(P:H(1+3L5X_*G)KX'/5E*Y4V^A4^CO!J
MJ2;J_=P5,.?9C&!M28E?;7<3:E$B9<5T:N'[Z*81R-G/Z23F\68,22I2P'GL
MG1:1-O0#1KW(D*SIR0PTE24F$B#K_>FSV"; CQ$*1(]/-4@WO55=:?A"6$_%
MMR4T+%#O*-M5SEL3X4DZ=UP:?E_Q)V9Z6HOK#J>0N;GQE>M\?3^TL,A7.L%M
M=&\#"NJ603"UL.$ZJ&$E@:'H/5:W9O.28HQ6<+$%1E?Y*9? EUY#L&6[.F!"
MH +X 5M:ZO;_#9WSMP&R%E,C[32'D3$!%X*(YSTW=L$$K0G,V;SN] ST>Y&"
M=S+$M=@#;>+N]L/AB)"U'D+95WHWN;]O516.K()S:Y0<D@NCTY6PE.+R3T>E
M<8+MC<VMYE4,#^Z)=)%@)F^7VJZR!(0%#K<."HC>HZDV2PXZV+(X]7+S:50Q
M\/]5G7681'81BBKP<$3#A+\YN38ZFU!^R#:KJ[T*:<7:GX0E)IC^#&2 2M;M
MY<QKWD(LDXO'1?:Q[!GC6#=0HG_<(Y;@R.M=8<FWK=(?YWPX5)-U&VH5*I4L
MYZSK-B0I/(FYUB;X-/EJ?+$%H%AWUVCDMG[M[3*"^Y$ *_\!-/H_.=K #.6@
M_KL;1O$*'Y#F4\>,W507>6^*0\!:;AGB/%.%D1?8HWC>D[%#.FLA.SB9>POF
MXP(&T3YEJ+4TOKNT9MIP03RHTW*FS>.:59B$!&/43_SS"TQ $Y>9P7;7/]L\
M0/C)?P!02P,$%     @ HX)W4I ;0I"].P  !D8  !8   !G<'1Y,6QK<VUH
M8F$P,# P,S4N:G!GG;IU7%1K]SZ\::130#JD0[JEI$2Z&^GNKA$0!*01$$2Z
M4[I!I$$:0;J[NV=^PWG*<Y[GG/-]WSV?]=>>67O%M:ZUUKT'\A.R!&"]E)*5
M F!@8  CZ > S (2 #(B(A(B C(2$M*C1\@H:'CH:*BH:$0XN)AXI$_(R4B?
MD)!0T+#245 Q4Y.0T/,R,#]CY^+B(J?C%^;C$&+EY.)X4 +SZ-$C-%0T0G1T
M0@Y*$DJ._\\7Y"N C0QLPVK!P5 !L-@P<-@PD$Z ' !@$&!^NX!_7C"P</ (
MB$C(CU!0H5^HP0)@8>#@8.'A$!#@X:%W_:#W 7AL!!Q*=C%$7.772%1.>!P!
ML9G(U.(5[?@JHT<TG,;.@8]0'A,0$CUY2DM'S\#(Q<W#R\<O(/%"4DI:1O:E
MJIJZAJ:6MHZ)J9FYA:65M8NKF[N'IY=WT-O@D'>A8>%Q\1\2$I,^)J=D9>?D
MYN47%!955E77U-;5-S1^Z^CLZN[I[>L?&Y_X,3GU<WIF>65U;7UC<VM[Y_CD
M].S\XO+J^N;!+Q@ #N9?U__T"QOJ%RP\/!P\TH-?,+ >#U_ AD>@9$?$$5-&
M>NV$2\41@(PG'IM9T?Z(FE/E"-_8>13E,0W7\M/C!]=^\^S_YEC@_R_/_NW8
M?_R: =#@8*#)@\,&1(#+FQ-AZ96\*HLB_9D>,V,5H@5N9G(:1.HTO^(IIHU2
M%[ 4J2*X=1T"C SJX?A\U/P4KB&(>:6;LGAWM0T!+@<@P+$:Z-O<) 38[%&$
M *V&$""\3/K5V-@-:E/Q^YJ:JFK4C7X35N<>E*+L0B&PNMO=TT+NH0%*_#GF
M"BX7IK<8-/!Y<%C.CE+"DE:6J3MN9-^W0,OV-J#3U7P(L,@& ;J4(0"JBRX$
M2"<5 5^#P(P-3T>XI6OD@JN?TA@5-"7YF-4&$O!W'W!&F&>TC;-Q3:^&[+"4
M4WSW(>3S=VI7$5O#/L].I-QG]!!4_#NSW4$HUCR37X1:58:9#S'CS,2JK$.>
M?N(C=0KJ[1(@1]'_XM9@8L=LQUA9&0)G:F"AY!-]G&L9G5(X\D=-V>#'&W40
MX+D Z/X$ MRI.]6E2)Z_59%U0TJ,[:<TUB/_6+:$*'"70Q+%7RS1\:2#V(AY
M:#=$3?*4@/*CO5*'"*MH[Q"G8B+518+@9^D[ED$'L*\K!+B%9N&J2.3WT=%D
M%!(N^+B6-!#1A1L<&V?JETTI9T02\XADXOWRZ7U5H5:?>ZQ8OH/-^[BW;XIF
MG?&<96F,E"W?"1MLRO\AKM&_#X]ZI,/RT_I%+N\@.5,[R>\J[=9#)^BW*-=>
MO4;>Y[D@A#F_PJ7P$SJS^G L;90E(7/Y[P*%2AB:I4PO?'_X?"(_JN-NNSX>
MAP"'21!@I0 "!#>40H#AJ'0(X-L& ?#U[+-MS*RI?%A>"OZ<(UFAC1R)5A>.
M-DF9;#ZJU*)-F^+="]QBL+AE-Q57=1\1$_P4PQXP^3F+U?OSX/#?I+&$>EG/
MP-K=0CE"3RLSWB'NIQEJ?:)(^Y2#O^=E2;$\[<U%O\V IU@@;HA[K&:J!1Q=
M?)0C@P[%IK*;(-O?(<3^\EMC9$7=,^F+@DVL/<O>H6T"YT*]-0\B(1(UT%&$
M#9ES)XM$%1Z*BIJ9W7ZU45 @+QJYPMD^UF:1V]]'I-F?</*I7:%%'PEBK.;G
M+F#MG#D'9F(U7,N7W_M&?3+[&98$&IEW"+5KD*=B4VI G!<UR1,6J&HH-/Y6
M]UL=EK-:]D4O,3M3OZ+UB<?7@7%XJ3&/>O#--SN>I**Z,4ILZ'X="[S]P(D\
MB^&^*>31;5DMD9;ODO=?JOZ(Q\W].^K"EN_L\U2STM1XK-IZV<C?/VF+]?(9
M@&L^N>083O_L\G*R-PG1KQ<,H':<:WK#KQ<EY1VN$>HR\??Q5A'!V*F2=&#6
M:#6>XY.YD,E9"_S*@SGPE2[5D5'RJ/;+.'+B#^T4[EB99)XOQN++58&R2'"%
M^5!XJ^;_K>'K\1W>Q;/23A=N6J8S$ESAR @7]M3\ "_\:KCM#?J:SOY0/$$2
MU^1Z76,],KYW!<T29OE+:+@+W$!_%VUM 8^ 0S9E_U$W])Q!5[OF0F2:UQZ<
M;F=;B"Y3^=Q2BJ@+U?V)HGI2(R6M)OB1_L;B;^2,XNNBO'XCD[&_(Q-GV0SK
MN)D>%]+".'X:K0GJ0KOO,DIJ)!$QWN.+'=Y%SQ>KF.*.NX4:E-M97Y93W 0*
M1PJ^T#O'*/Z#&H]6Q..GBV%GR0>'E"%T42Z$V' 11F1K-U-!<L023)U7<Q'J
M7YPY,#"Y]\B1V]9TFR% >14$R"A]%5<;\L&"3I#'&QU/69OTM22>$HP>>=2=
M3<&5H7)U767@S(L4G#US#1HLIV[DLI-FT"K2W3NNQ9L+AWN4(L:]_BIK@A</
MM;!X??H0P7?_BF 9-()I#Q$4>< K.GXY([]PR>WG2VC6/,"^9]"L+?^+_MI.
M-Q_H#_.!_@01X_,&ER<G(O=_IKZJ79 )<+\NR8G^Y#&_6B:"8GVEJ\8Q0*2%
MUT%3P6_U!NC,3$\7Q=31"+W>\1!X: >'=]</X.OX)_BF0)O##V$G?\">MR*R
M#79O[+7[P3!%]*5+,7R_ T(+7@%+_$Q6?(?.6R4]/4&=]Y[*-)Q^F>XRY9]S
M,8\MK,AU?BO(Q;_U+Z'LG9]/W@#(MJ(/3S11C&+QC>C08B%^#AB]3<ZR-PZQ
MD;,/KZ*D2 4KE.C]LRTI1\G'H0P3YHM_%PP(@!Q5!M^4':##Z_ISG-Z",6!H
M],Z089#=EZ580%2%/GG#<FH E_7J>Q!#,PB9.N^AR O'(,#O77] 7!,4*MZ@
M^Z,'J+@<7ZG<2*4 )C8Y*82QZNWBIO,1:1EWK1]^-C\MEN?H>:);66U#U5]5
M&!%B_,;^? ZYI^9QZ'719X*_,?<1LR+\,%J!BLS/[,(=9#ZJ9,5$FEOM2V$F
MV:OL4L-='A[G&:T2#]R<5^J&%)R TZEF*<IU6P?HA&N;_/R: /R6:?O)D!5=
MYKBX@NP<TZ"0_C&J.M3>,%:N65T;WA N*73&"GM-NDS\;;<E"( # =9\H"@N
M<P)MP7[ <5">BH^PCR3_&Q"XD]*]2NHH+22>;>=+MFN.A=T_U98EYSELZM&S
MF/G8^O@'6F5/+<*S 68%'2/ \@/GZ1;,KHX.':^PPJ;<0W_5A_9781'PU3_[
MZR^/4A^6748WYL<189V?7L,&'[@9-<@OU64E(%3ZH(0KHEMCBSDY[ENS+$?^
M!C"!5O</(EUQ.7Z_96P<]#<)2Q0P2'+)T+?F7%B09BFFZL,1+<EIH'24P^#;
M#,^WRYZ?MSKTS8,/EF.\KF(D(I+2HA#Q?"-)4H'A_7FH[0^Z_E"KQ?">4N#'
M+M[P]"P;'_ H>SW'_;M)PPB+ZE*(.U:(7#_22IMVTWP(;;^6 .G\QI9_6^M:
MD4OS8G:$!Z$&N0-?)P>I(F>51'I=3G$P7Q9BAG#+;F!+DTCVO0%,X>X=^_V#
MTE_^'ROLYU%M]@:]>0TV86<>J)HMJ;IUN&5<L))]5\7 4^6"Z!S;]E@>_4,I
M,<X2/XHH2]V7/CP=:JCBOZ>FO06<'Z\_OW:RN\S1=/O\\H4)T'IZQP=/WIUM
MB&8=[> DY-1!XYA(%&7FP&D=8OSQ]B?\$Q9LEQ^";>B^,C_.R[%_;D\]KI5%
M.U!/X;;K0%$D<K!FBCHBN(L64+QW=;B'*2A(D=UR'8G_X/8\J#RE9OB:T$WD
MYA;::"2XSTJ]$BZ_631/V)>UU<)ZG0I]\A].M:=9/?0914Q<*7\DRT3FD+=3
MGO^TD\4!_4=I?W#*HX"9606U-2PQI'INWZO*L^^57H_;53QIH[A5'K-CN%-L
M'IRX+#217ZF60P"Q"@CP9O$^@?PHWQ <9 (!8-IN&5LM/_HPOI=X3T;7 +N@
M6*E#W&2.2)PGKH_'[YB=ZD9C0=3>19#&-'&0SR'!4*,A'TEB^YW0M$XP3%C>
M/?U7/2++"FWWB#U@.-"%FLL+_Z'"OG3".:(700J5*F:)%C,D#G&2,X.IZXI$
M\"9X\9[=%UZFL:6E[3%-6+QNGB^DVS*&)QL7_]Q*-JRU(B=O< 59ME6>MACU
M /[G>NF$\=>)KP %_JVBXG3KST(FWO$] C,S86]C!X3>\-@3X179;T; S1)Q
M0WOMM\^@&_3H.T0(L/>0;P$(<$9,?H4. ::5![$NW!Q<WE<="P\F1KG^W+?[
M;J:->M<>RDP<@_&H=T?*J>M%ROVW78*9(#'XP%O/^CK'5_8ESIIETGSM0YYE
MFV"\7>CF9 M:XH4 9M)W#%/0#OH3 GQU /='6;Z?_L'7<RQ_F,2L,2IIA:M;
MVLQ@K^T;C$'.Z!(GYT:;\YRU%;?Z6,P.;]@QB4.@L*.W0"V.,_HC>V]9VU_J
MC8;J]?*5<$8!68@YY%%E4^I*BCPS2>RSC1_Q$U2% ,M4KQWPOXQS'0-.-*/(
M0],_:;_JIB'#W\^Y#+JW_7G2#(8*>S#QY]X7EK5V65R$Z,<,5-2)-@DUPZ5_
MM -?>&T4;X$I&D;MRBCJ0@APT7!I#\7Y@>5WPLA"4RX0 ,4- FSQB!P10X#*
M[-];SR4Q_6-NU>38[(SCND(25O:3,3'\:I]*<;=/H,N-:M:QV7K)U^E975WQ
MQ#'='OC7M7FG]5]HXIL\*#::,/\"$MBW OF,0@Z%J'T'3^@)7\4R1#Q65R5S
M_\(HMB-+S<=?%+VBF\PU;4=36^=%4W?+I!>S8)'4YDGJU'Y1-O67X7U75>3$
MXT_36#DZ*Q^%_,K66?L]^0KZI4N=D(D[9WB< [Z!(E.OW1):GW.J1;30>M/%
MOG[2[U1$_\YJDE&"JF(;0H\%UFJ9.%WDMW5Q>GY9[IZO7H>][?;P[:';H(O
M$-[%5#TFW2C.E[!P+(!_#2=09791]J-W:+0GHVSU+XQ]WVF/;RB14G'\H==V
M?S.0T,[8E764TE@\FVZ.)4J"9)5H=S*G_CAP6AY/X!5V3:K[Z#?UA%7BV.0
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M\_T22S*CAVN3H[&'GM5OR*O8"1/WNG"C-7;]@/B"IJ';JT?8QOZ?55FFV[Y
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ML?7O2BI@9:.H8:2-H3U(Q4U)"P<RN$N%JVK7%3 P8); ZIXD$3]8A ,2;V-
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MYIZY?K$M?\GV"ZJ:8KCV+H5 %('&Z_(0))K3N273R7O>^L3V7UNRQD[>9PA
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M B]0O#-83"PO:/:5W?Y#]#/L0'^'2^E-_;?/J4?M+60H?MBN)4K48)NK:-W
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M+$_A.-BNQJ=T.F6@2."_5!;%^,<.UO^P@Q7R))B.>45BZ*9YU/FW;(,J]R#
M9BRT846"N6"<P_/_X43T@Q,%.6-VWT<J&9!S#@W96^WY#G=%GW#]E5NJOY@Z
M^HLB:#0T7 4D&ZOS))F)3H*^VR,BD?K7L/TNH&H0X!=3N(6PI.T_4:G@I9[3
M78_\Z2OB!W'*PL2=+1V?R=E0T8,1VMGY;OI4&T8(^ CO-.'4I7C1AON]ZI-G
M-BUQ< 1L@&][1.VC,QI6*?]M[A^C"Y^[3#XU?YF<U6YJJ6Y@('&*KOHV]+)_
M%IDB8@DMQEG*&8FO:$KD*'$ 1F:"=HL<0ZC&<5I0=BVRT\C(:5AGUS)KV22]
M)4A3H.XSRO<M*D-JW+>1A(CS&VS'IOM;F!-JC[&N(L]1&<K[M+Z2.6<C&,2Y
M*2D*Y2LZO-S>@OXR/EP$O^M-22Y^V"SM)#,O[F75&=FWK! '//T7=50\2\^[
M!)7B/(E4O. *AH7]BK\(,UC6:ZTC']M^R8RWM75WT HT-1E@"50$+6!^^TC0
MY:) IO8SH!>[F +>/B*RD^0(/BAZ(&6W /J@CV%W&J_,7X2)UVKAOZICB&U?
M<J'%U(-)L\G/"I?XT_^N_0^AJ@^V9UD+/JV59'2:@C=NF.;:=TK0>EE,DQ$6
M6$?R6O.(\=%-C>N9$A)7HWL56GBQ4"1*40&5^JF =^P([[:&JXVPSN2FW5K&
M;(F/NECO?K1O]*=T[[FLSUVO,9RZ'-./PG>J:)PXNC"($#I##+GTOAB_RE6L
M,]F-^M;4ST#WNL;E[;L.G6K'C+0?K-F2ZCR#[J+FR'C/ET=@,9"4,$G"QR:X
M_%0V5:L:&!S8XH@<:1C#WQ7P(]21?6HG?[ECF>^DM>;:@JE<VS)NZN,::3>C
M,G@1V2G554%$N,,AX'2- @U5PK?V/ZS-<+C*X^6Y30E[\\JD0B/:C:\R@E='
MULBOD(OD<G>UXE0%O:+4W9L">2+GI?FIUS>Y)Y1%2YS'K&ZN'7CXD_4R-%DH
M:-+\#U^Q[I&0S?EH*GT*I#=)[*%;2 Q'=#&@&&,[/$=(7.".?47%E_I==:_2
M?O@CDC_[X<EJ)G<L9C!W*.U"7%9U='-O>=W <Y/4F.?7[2J8MMCZZW@'3"2Y
MK9$%9>]=S!-C9DHJ/B3@+">O"SIJ:QV]33=)N_NA=@3.@??9RS33E0Z7E+T(
M@Z$H6D)#U ,U>IV738:S/F:P>GPZ8_78_9*&:"58N=?86;1'=;)L5)+RX>\@
MY)#I_P=02P,$%     @ HX)W4E> **.O8@  H6P  !8   !G<'1Y,6QK<VUH
M8F$P,# P,S8N:G!GG+H%=%Q)LBU:LF2!Q<S,S,R2Q<P,%H,%)6:6;#$S,Y/%
MS&Q9S,S,S%_NN7=N]_RY/>^]4RO6JJIS,C(C8L>.R*QZFW];!R!(BDJ( D!
M0 #Z[R_ VQ) &  )#@X!_A$2 @(""@KR$PP*+ PT- PF$C(\"BX6/AXN%@X.
M 0D=.0$1#3$.#@4[)0T#(PL+"SXY)R\'$P\=,PO3;R4@4%!0,- P&+"P&$R$
M.(1,_]?76R< $1+DTP<#4! BP =$$%!$D+=> #X  /(1Y(\+\%\7R =0L(_@
M$)!0GZ#?'ZA# 'P  07]  ;Z\2,8V/M=S_?[ ##$CTB$C(+@R I?((B *$R^
MT=F0Q$+57:B*$^<DS 9V?E"?T- Q,+%(R<@I**E86-G8.3BYA#^+B(J)2T@J
M*:NHJJEK:!H:&9N8FIE;V#LX.CF[N+KY!P0&??L>'!(3&Q>?D)B4G)*3FY=?
M4%A47/*CIK:NOJ&QJ;F[I[>O?V!P:'AR:GIF=FY^87%C<VM[9W=O_^#PXO+J
M^N;V[O[A\;==( !0D/^^_JU=B.]V?0 # P6#^&T7R ?GWP\@@GTD9 1'$E2
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M@INE;NOLSV(<Q5;Q[<%@\A42P[F(NFSRP"Q/K.'=U<>/\>6P.].QXD)$-HL
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M=:Y+OPE3BVAVF^U6F^DA;*YYLS*E,VH!F=\V)-H@IJX<ZPR&U#.!OI?*.'[
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MM.5??"6(2""ASGQ#J)';D"9$4  *_ZL(.U,+F_(4AP]A,XQ)^Z8 4D*V'-X
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M0#D,04Q3D^)#S<&M(ME 38/1//&B 9@5!*&; T16ML,3"8 TO3FPGQ$!HY/
MZ9K\BM4D!%#\$E]HO7(+K7VRE$GJ9HAQ,(5*6== ,6BU23&VRW2,09MVRO>
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MZ2;ZJJM$#'3CJXW]S&=J9EF0'^.+4C@#:_F^2OU@O^S?UA-PA[?(!)T,H?A
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M60C+6E>*\C0IR77C^V3K_6U^-M!H]=!^:8WWAR#:IX&=E@;%L=IM)]";+)/
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MBRX!^%N#BWI-/I\'D4/]8S?MJ)2LX\V]S[39IL)D>;9;R"?1H>QOH2#8J&E
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M9K(N0)$\?5#7A=^C?*VFTL+JQS[M<Y^;)0^-,4((7U[#Z,CI,SA 1TK)CBB
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M6[R1H!]O*4S!U@)4N>-S,^Q^?Y=QFW!,S@^OF53;G[=FLQG#B%.C#OZB-!E
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MJ]2$[AID>5M?2"4EKY-$]FO];G[DGK#Y3;P./:L2Q9I2\2W N#LA?[JF?_A
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M]9CO[C90?U]_4SVR6RVZ^5CWH9@1B2)V7 #5H]!8_Z=5A0V+^]$]RN*)>6W
M_-+F5(4#9E O8IFPJAA- G4#3)NMM=;,NH[>D+,U#98LM-PB.3V=(/K=-A]U
M8[Y1T^>P;F'&FA-'T)7<>5^3QJ=Y<8D3VB^= VK@7,)"L2T?XI943_L$ZXC!
MJ'B5RR :U  7)[%QJ %OYNZ]5=R #*9*MKM+21 J,_BB->:"M2< !UH1-$EB
M62?4*NL006DKT.5JCHEB']Y!*P^S0$"I!#R1#'@=&(P?QER0LD:?W>B1#'."
M"$.QHA:MJ(@(7$XSY5;YI#RUR@=!HJN7]TC>"6)5LZOX&JV7A;),<^FLV 4J
MS&F:NWBOPC7"3TBBQ-A;N9TTR; B_T8DQ!?465QG8/%^NLRAM@_;M]XJ%ZS0
M$E#Z L!#(MRNM]9FC1QF@KTMZ><C\J)JTA8L3 !^\&,>SO0L!-X MJGS%8I^
M8BT=UB=:6S/6+K#W3@[FCO;P\,-$/'-I>_#05_@^JM@2<,K0AO%M)XZ%;M_-
MQ<PACCL!C4_&7=CEZ4(A3.$FUS72MC2<(\P5"(/4RS.PIPA"4CXFX<A[3[@A
MSV\;HG82QJ\% BY*.J<B3SH$9/8)[F1^]@,+9+=&$'.TK/;7-*4\0Y2G8.W+
M6^BJ$/PASGUX**FSFFYK57!E>) REQ7?\H#.RB+:(=6>8@("A%AUM;XE'U%+
MSXJ<D%YS*8B@UQ>VUV+JP4:R_3T?CW3LGBDMM8_Q4@RWO*:F%B+)9E(XS$3H
MG$;RQO- B?!,L?+B Z>N'O=<Z[D\C?*@!P7R^Z_TQA.K*\X3@F',?:ZN7)I(
M%XC\<5-Y'+*..!\4>T=JRE+1@?TK^YFF2UF)?2%G6,O+[3/[9>-=>D-6D[P6
M/>C2$J*GKK6:S(;4]9:1J*!J?)F,#>F0>2G -\$=-YA&6/\4YD=9QT]00>-7
M^U\G$*TZ.>DI2%M_PX(;?TI^ ]F$C<VZ 9F_U_YT:[#6/-6,7/3[ LN2.7,W
M1[TU0H/ME7 C<U'"%Y'%VO6#HA,A$,+')SB)SWM0)K:EYPBDMM6KTTRV7Q(/
MM)&3<J^:4%GY-4%8XD'&4?\ 6[/815,=TEM%;4]F@Z_!S.;9O]G5M:-6@Y);
MF%-D>!1J9K_-IL1\0WBY$2IFZ@_QH@ (M_4I5\[OSG'W!2TB_T"13&H9N.+D
M9!OXF @GT\\?>)N]LI;3I-VJQ/PZ"WZD#%LBI$/"ZDEDPEM)[VH2_-5GU;-%
M_[8=SV3\Q $ -Q4/(A.CIG9W'E")YAS"T=;BL2IKP]8B*DBV=>8HPQY/?83T
M"-V#9L)FLXPE<92A_DPJ$U0]*'+[B%^JN&G-;J-CLB? 7XM$/H2-E]TQ#!O$
MN&Y/<)/M"?4]C>>_78D+;3^V\?%)*1HLZ9.: 7.&U5D)ZP4(GRLREG]BI2H[
MRE?-;?$0&K:67@VK?H_A6*\B5)/$JG4ZF&;Y [P5*Q_=6EF;!8\13!;,S5R-
M:&)-G!,6L'RC2-HO:W^,\#W?PQQ4M*RT*54]SPQQDNS]\AO5AA]4Y6'I4.9B
M7?>S;4@/SI4,/SJH);A>8V![X4Y+Y/Y!2RO;>L(2>XP7:R0J\2%+\]9U]?W4
M6$2<QMM,E:63^+[=MLIZV%8M%$JH[C1 3X 8X?YT<:J"N%Z+A+,)1&^YR(C(
MC67/[''L,N*$%' *^J'Q)*\)[H15V5-<=T-P!.GO_NY;*7^.<5J.>LO%ARR"
M?%QL(*$PP9^ I\'M3;5DY?TMOZ[FO>JI5;E@-FGOEQSA': A/UK>U0&3GWS#
MP]M45#ADCL F>7@@#<2%;R?M0M\.GY=GHATE] VXK[KP",UM23.'F_@C6V0U
MP]+/ [_N>&;QHI,:4CN:8E;;5:+7F=P!]/<+OXKHFW !HX>^5KVK]&5XT$_E
MHQ3OHP0,J\M6L61M0<^5?&TVP0!^?RW&H/+/UW@A%U+5"LQ#L,;C^*!Z*+I)
M93BF-NBMY^7!YGF''3&JH2A&"O0U40I6Q'%TC*Q23&N,ZQ;;U-2[4_-Z2ZN1
MDG=K!GF?LGQM*5L5/M>DOJOJ=<2S5D[JA;R=50=V%]M!M@^5/F)_E-$UKP(+
M>+:/[3.#/W7M;1BAFN[2=7RT\0X77]T/@AQ9Q#A64*VZ."2+YS+XEN12^L.B
M-9$]WFOFMV*+BT%.99]%"[V+A@A'G!#H1!294EX 7YM_#F8<NE[.;P'7J.L6
MX 6W09BUIUT/>=MK^6T7M-<9798!<TLBS./1R01?3OS'5UCA,4:]<D99PV<\
M;9;TK*AU#,P"=&C!XB6W5TC,R)448%\!9+L,_(;X<HE5Q:GE8TH"2IKB0<JJ
M>)K?RQ'SNC]OYGWR6E $ _3R0JCCU>K-(B6<CU9],/3G^A>XN6?QY?'F@WZ-
M[2:NK1G.$#JM<F;&17P&YBI/VD=]DS^LZBE>&:&FDJG*J83&&DLKAJ$Y9T_;
M^MZ3E6,XX".T<H,O3Q\]N"GE%.'O!   >B]69J6U?#+1]([@.8F'F&4&(::P
MPV\VM@L_%I6EGF$>O<N;H(O%H?+Q26CPS!.8RN';IR9Y<'T5-I/8G3 CB<KB
M!@SB?5?Y5?#L73R-N:(B1^,VSO=-JU!'UOLC6@AOD(9!!S]G3<S@QN[@X(GZ
MZ>_2.2\65DRJQC!1F.5!]\WLF" 7($6A4G:!WD^/G_:%RVLYA 7@>74(@Q)E
MNGKP]FS@ $(*-]ZWNU8FF[,]2:X8V;8?/+U.,"?#F_[DW6S>85.)\D%Z>@(N
MEW!U$.";';.XPY1].T&Q4E(V3FE[P?-E[I734V4.1R=<SY]?!3,0<(UNPU43
MF,+#;0G65NFTE2,GZ!@)FD0Y1!$("(7N58I^,9,CZ[626T).=T^F><%K'%HW
ME,T;VW1@>)"_[D(]PZ?*LHB1G=%8UK5=1=%[-=>6J2+K2@,+#C.2NP]R.R0D
M9C"S'H2X+@E9IKS!QAQCC/HKTC1!:DURCP52FD+2U#LD9+U[I85?[:8Q,5,,
M"L>OQ$M*&J,!G0"VW%U5GNV84]OLG/!O$>KGE\1)IQ6.#JP.F-O&U"<D;T]*
MOP &1F5/;1@>&6RY@M0SM'<M8D''4L,MB10.:A%83M+<'9+X*#B[,SGQQ]HU
M457MMYU"G\5;G]%TICTUA_7X[#-DPR2Q>PNI13A+3P]G<<GF6B1AJH+:B4*D
M"7A!7J%,,@8J."39XBWB&ZCD%5X%'P\H7??EU:WW\)A,PFG\I28]79QGW1Z9
M/H>QX@%OSO-K$YPZ9X:)!%R_5G:A:O2<4@2F5>Z0H2M0G*=79T,?.>G*DH8@
M<K:S133" (R@V:>;B>@;RTS>!6W*XJ"41M5XA7(N/[88O@? TQ$^OY$9YV#H
M$7_@KD6Q!-& EG7K:CEXT&%P!4(&Z'9Q:UYQ405E%[!FV2\6)+P-$#^:BHF-
M9Y06SHZBCM%Q7\.H:Z#_/,-I)S-IK"*%.=?OE$O'-"1DF_MJ2+#NMD1;J@XQ
M%+AWC679GYZ^]YT(Z^HB7;WS>KD2^5?[W)J4.0<+3"Y#=<_W\&R(%#OO1J40
M6#(R=0^*"IVJTGT*N)?U/C2H=KDY1L=FJ2IN!L&^$4. N<1)<0]W+)!MAX]^
MWC46& <%6:SX#H%2IG.B1P6B4'57F+,+DKP*7)RDR:Q55UOL"8H=?B%^=Y-Q
M-&^,"TDWTSXOM'VG4!XYC.&$CK%E:Q@&9\JK,&7O>I"M7,H5'5 U06.[QVBV
MZ0$U:8F;+XF#2I\3!OAKRFE*9[$W;XP5UI<QJ.1P@E< R&N<E2=<#MNZ'U+A
M3F2?J(-;",+H>#Q$1Q^H/[S5VV7);(LP\N#B:7&H2<H+V(6.PY)1MH]HYPFB
M> ![@V3[CT9QRD[!#M,> :8DI:%;=[02C\]!:9L2Z85,2\TL6N_K9V=E>OM<
M G?2^8R/?:7K7,Z3>7 3R4S8I:BSN_HE/SF8^B?@C[,<^,0Q257OZ?VF;H==
ME 7W>.Q89P5!!5-$A-4Z22$."A)-:+.RN,04IJ-__L!#Z-MVY/+XGF&-T[UI
MQK84JP96==039W3%:6_]QFL'_N[BF%\]IO^RN3;F6 .(K$0S5[* F\0W/IL1
M,(5[2A,V<'SCK,]<*4P3FF0$P6"4+O_8>+';L3A87QLW+GVQ02\RW\14;3EG
MR!V=A-LN>4SPM*T\/-)84H0LPFE81W2YLP=.1/A:*."CH,M=_KOXZ[2A$M&@
MV 0=1$$7O.LP,ZZYVGAUA ;RVB8M&<\$!IU(?99%GR<?G-FS@.3BEO#:.O80
M/AC,"Q]*3BRD])9/H/+A\ZIDMFIH^P++K?PP2;2_;PP>'N2$_<9X\[?N^W=B
MS"@T?<HM'+)MT_H,].P!HSM)OP#TR<49=R7</!Q-[6YXU6C8"G@%TJ!BH_9%
M"7D^XU4&#96?FLHN%EB/,,8MC0($G%S@ :2*/G,7>3^8'8F6>HL>>.D)$"QX
M/FL3%$F'N 8U0)R+Q':E- RN.EDF/W/Y=4OD^2:M^%F)[01C)J[V;W$@+ !F
M9G51G@+SDRVB%Z5TS<T_[</RKG4><*Z36B_PDZ5Z<2HX6Y. NR2PTWC6DDF1
M2*-L:JQ][/T0TJV=22XLB7/M(NY];;PE.,=#"Q*2(],^6*SOF9GQ/#ILKUM-
M3*?;Y_[0)1C%&RP#FVGNU&_QQ,8.\6UGS'F' <JX'B1K]<2@4=R,?I+QP?)L
M^ G;T$W]NOEF;"LS:E-1DN<$\[1Y.W=$#YV78AXWPS6MUS_-#EM%DL:@<L^)
MT9_=,.G:\GX9+LVJ)298+3*8*>(7X!<IXVQ#PN0P58*9+/H*@V#Z ,I=!L.>
M9X+;E\$<+=7AY!W_B,S9SZY0&6LDTZ0:NOT<V4G^X\*F":1>L%?@C#G!)<FO
MYZVJ>I32B>-\@P(7D9U@L<X3+1L4^1&? \$'G02K:G7^M !I78!;72V/^R%<
MJRV)#%M)&YR\; :G<OBRJ57#9V]B=T#9E\<\,@212("2)(<L%OW(X%%(:X+I
M%X990*VJFED\9>AN3  5@X7I)-3L),Q!4<H>+AA(I('$@!PLR"[$_KO8"I"3
MA9_0OSV(39GJK)"\3P$_L"/V:./]&C4IU=0UC,TUE#T 4.TVGXA_%H+*'\^'
M/UQACUTV?$^2.FG:)VO\53@)):G9T%';W."UT1BY&9FL*_I96=K0MP3%%R3?
M(INQ]HR$A_..$N-&ZV%=Z7,<5+:DI=[/9HU%8[A'=!74"!A0K9N(G-MX0X%.
M2&3?+\Q0=7Z'SZ5/9X4=<M"[]XP,#L8!JQ6TR5BX!OU2=O1D346Q*M60ON^J
M1]0V7VKD&^V5^7>N^P"Z.5D^+9X)>! S%4[8D(3^:R' ;VZAOWU,!+?;V%*=
ML9A4,D8L)7/$P:XV)4IR=SZ<ZFG"V?-0+-@'/<U6N,LT_$O(>W9 E(7:L=61
MZB/S"/+[$I(L@GMT!.CZHIRMJICO'V7M[:*[ERW2ZX.>C\"%C_<+?"6XXN"
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M$D)QQ5XX,;WU!T?/IC)(R@0D[L!Q-G@;Y](UQ!T=5Y_X9BT-[:E ZM,)@7L
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MKS!%3:I\^ZR8B$6MAZ8Y< 7'+$9-LL*ZNJW5Y)(V81-W.S(550)=!/M^3MZ
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M7O)!Z)=RHV,M#BZ]^[=:9$E;=459J'7GSVD59HM,<N:R$9$"":Q97V3I)F/
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MD[9")3/^STW06-Q._YD'RMPM_ ]02P,$%     @ HX)W4I2$BWYD,   "#4
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M33QN X9GL='*H,SJIV2%2.7%)OF;#S4%%'6R]FYBZFI3&]/QL&Q!"*'$Z1\
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M-.33C\MGE^AWXM@*,/^441AD,XF07B"BL>=@'HF\^$]]U7EF_89'ILF:[Z%
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ME6+/&R2.@*TH\E\9_AW74[ZGHR?)(6YT'_A-#!H6!RZX:&7:/K TI'_"9_-
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M\?5O?(%)K6O<+85XGMGWZ2B,K%3CJ[>/D\L&B9 AL7\7]T\X #7VNNI+,*U
M]$7NH+YP]/2$RD5=DS?+RHD$BR9,%.97C(;+K)R<8YWG@\'_&U-Y+@'6@TW9
M71-O%KI;1"VHKQF0:.$*.GN1! 4M@#_]%ZB3,<?LL\'$?LNS]+D+C\PP0?@
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M3WR\K<,X7L\4S,V:4.,ZT-=\Z$6O>/Z3J=G\.)U3#[\IXC "9VP]VM1'K-[
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MAG\4QQD4KN4,H2)0=S0]E?:.UD<MZOKE";5#?QB"/MBK29(<&N-AYG#^C][
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M*L +'#AX'+BG3@ Y  "'"/>W"_!?%]P+> 1$)&045+27SQ/JL $OX.#A7R#
M(R(B(#Q_ZOW\.0 !!_$5)8<XTFM58V0J,"ZG?VPV"K5$50>>VM@O&BX3IP!4
M-/PW!(1$M'3T#(Q,W#R\?/P"@I+OI:1E9(%RZAJ:("UM'5U3,W,+2RMK&^=/
M+JYN[AZ>@4'!(:%?PB#0N/B$Q*2OR2DYN7GY!85%Q275-;5U]0V-3<T_?G9V
M=??T]O6/3TQ.3<_,SLVOK6]L;FWO[.[MGYZ=7UQ>7=_\OOV#"PX #_>/ZW^*
M"^<9UPL$!'@$Y#^XX%ZX_9F @X!(R8'T2EP5V1C\FHK3'P57(C:[J@.5FDOM
M%YZ)TQ@:/@WW&NWI'VA_0_;_#EC _R]D_P3V?^.:!Z##PSUO'CP.0!2P-/U(
MXQ[RTW"29=56F>YE:"2?9)R?(]>0RA,@N'#=X43'=R7ZL<WH)O=1>NC#XW?:
M)\!HI-GT/E-/)E/<MQWK)\!+Y<Z5Y>HGP'?R!T_1->N;U+OI#]<;3X *?0-<
MIVPOX+60\HVN#]WC9=+#S1/@8.ROWUC?S4U KLUTKOW+[<A_U=XK/AR\O3M]
M LR4LT$$5/[/.O\-Z^371UJT!- -S\1J;)2COHC2(!OW'O[^B)\9]KW-_ G@
M(WI[X?MCXI3ONNS[2<\3P##\.X*'78F, XV3/.D%:-JF@:D'L]/G%V8HP*7'
M<\07:5FF2,KFVA$QD?=3O SE\/2\]%)+3>9'T[1Q_;+Z_?*"T'M6T=>^G@./
M][Z7NW]13&NB%7]E/LRAQ$#R57)!L(FTT#9',8O&!@ ^JG'(PEJ7:#^%=FM>
M'\X%=_0G.H%HJS4J?)K;T<UV^'O]*:%4WW^%E?NO^E_ZEUJI[8%6K-ZXSJBB
MIBPMOP"3E'!J;&(-.MKJ/@$ZRNUQ/K5\R:?18Q8[=,M5R I0XHC8V66HE4PI
M=!KYM]I:-@0ZO%:!3!UGOV2QHY*CCMFQM:.V7YH;*>H6*"5R"UBX4[6[E"\R
M46<Y99'M^5Q 2PM),T+?*.<:(ML] 6U%_X=]^SEZ+^1<OK"HB# F77^S2*B3
MFG8>C.#?8YA@@X6R7)]IY\O<31EG%DFPU/A^^+4KN$%D;EB@2^C9#*Q>*1_^
MO1W4GL&Z@7VM]/4X'S((+;&[?[.==G<!AWD##V7ID7$3?7 BZQHO%H9TI\SA
M.D_?:[<J%'U ID;PC,T(26H6FFHKU__W1"J;_E5VS3L=;:0&I D@).2#?AB,
MR7)D9V^"IZZW&?3!K>-5D^<YD]G271S:+L4'*JA]["5V>G-.#Q$>;5/:ROP/
MUO@QV2KLDK\@#WY7^16J$<69]WCGZ8#H'1";"=-^ @2I;<[G%7O8G-6U:DDO
MXB]7"2&BN_<@1$1LI^>PV:0/??@/*P_[(@^13HY^*S7*89R>[)4_XDI;YSB[
MW*"Y("P-_3$=8S5&*"^2-[HDS^21_]Y'29JC-C! 8"=CT5E^B<A%"/H$^%>_
M^,N&3KKY8,HT\TYCU47V_ZA6?@OP3I-S MR>W[J53:Q9:XJ,SD=^K;H3U']9
M\]T8O0O7E+BF$6=B.?S]6_4FV'^*KM^*"^7S]I.(/A]'LV#4)8OL\2-'#Q=/
M;+T7C-/5/_K+7)E_8>Y!>,[?_7KBW_MU8S/#EO@1_>+_6>6_;Q6MV@]A9)3?
M9C[="<Q/]&>L47M7KJZFD3@;>NE^(WP"Q%;(/D_J_7Y!*0FIW%!S6[R5@#"4
M88G]_ME%?L9K\P2X_/WV,<B6KNVU[HW=^LL'-Y76T,,,C6LL*ONO@0%.7%VJ
MS_ZJM:Y\Z_3,I9U[9A=:TY$$@173L)P6AQM-'YHG0.';NT??']'_.H@R>VLN
MTO-:RG7E5\D]\ F@].'Z_GD9\K^,2'J%X^](%/$6?'^4GM(_"/BNG#_B_NM[
M9XHK]4,PMY;=$P"MHC/S8NL)X#MRH_K7T6#@G')5YYA!PSW3]U>^$TD/3P#1
M-9F_##BQ_C=69B(W-B>!1C)$&KUPD03R3!W-F[C'M.\GOY\G_V4@$./%>"4P
M=8I9D/3&#54P;\8-U9FY!*  D6<D2XOK4GP"H"H5[@ I\"&TT0/N7=5!U*Z'
M&S-N K"1?TN#\,YRW0P+3O>?.L"\I"'_/ ]#E1/[O%S^GT<;6[T'D)'J*?N+
M.]MP+TO-**>(.3%9,P&0^FS@<G/F?UA1OXY<,G7R<N#(D"=J+P>GM#:8,LP4
M_6AJ@53[=C*P,Z4H$0A: P'?I55G(5^+[I]>/-AF_87!#'\=M4I""TVQ'E^E
M*P]#Q5AQY<D33V'_Q%98&,$3GPC\/$LD$[N%/LK(,,Q^Y]N,LH_X\3EN_\^W
MI@+G;.I<()U9MW4LC-='UJ3C)Q#;*4(0CS[&1GU=&%BV4>]!!28D-K.*[P78
MK;FY=!^##;#^+5V43M_0*I89*:[;*:W/N]-!W^BD2+.,EF\N.ZTI_PKP9E)?
M7])?%'<T:S@WL=OJ:@YDQIM+VMC^[;Y=__W?;O3;OVEX\QE8HF<@!4;8PXU9
M(-:8(P!( _E[)D]OU%GK'B3&EYG=E^E"^,W\:&*1$&F$OI)<;L(;D/];/:76
MV>32(TAM=0WD1A2K_"WT]%#>U9ZG<=60Y6U$BPD':[>>&BS6UT]/%\7(X)6Q
M"Q%,MORVY%^*.**!ATS_Q^V1&5"O\G=8MU.;W]YW<2<MM[R3#S/24F4#8F8]
M3!,>J49CV^CAH:]5X8Z9Q[P"J2=S>D&]KLJC'_$^A(GN#3P^ 3)_Y?[K(.?T
M#:O2X,_GI%^J==ZZ(BC\:)F:R>!]\K;_^8#"_V!C1]X),_NFN-_'6JWWTFJ<
M5C(8J]5<'WLQ+G 2]._=6FJ=AR@]ZH/.9%0%S-"&3O3MT2L'U+0C4L#(FH9M
M_7\"J";Q:7OI?^W+P8>%L^M6Y0O_%E=N,G)UYO\J*I/U>T?108[^/3?^%@3X
M4YC_H\K;XO_[*C/U:^0^TE/FP4?J"9"-MNO[KU/:<NYY3A%#6HP]^.;>%;&]
MDEG@H =L;D!(8C:4W&:OB!AR*H4!.1"&_U8I$?R6UZSHWVQEEG8B.\U_FFAA
ME.4DMF]S:6DK;S;-$7YM'GJ$G<"<=G+^QN@)\*T*>*C!.EB.]/C+.F?3F@_)
M:9;WFYE7^XC^\<+M)&B^()=G$#R0M=1!3,)=P?W^;1-<V'TI*#$<F;-^)3G.
MI7@?6[_5<5=+"Z?XMSDP!^Z;7R4/TX=EWK1K>F"CSE0EJT+LB?%!^H*OX52N
M%#ZFN=UW+C)2+36H^]B]J-LK+L X]VA,[N3:^6^-I)2$A[8!*:0P%Q<"^%<]
M+')8JX,8-JI27W\GG#B,W _N.IS05*6XC=M3)6/UV8]+ZRIG8_C?I)2E?"L8
M9VH(?8L#!%1ED#!<WEW6_;G1PCF70]W+ ]MHMA7IIA;%K-^Q T01M\9?B5Q@
M#YM7$WV\<6 '&E/&UWV$G*>S(10^_# TAC><=64F&*8:O4\ B,V%[X*[Z$US
MG:^OART3[;<XL'M9TUO<V"+UO7-V&!%#Y>^$J^?,/3A<_;VUZ57R1?*1''H6
M5'9A4"30EL1'I$[]SE*SYSZ<[_OU(]8C6P-#3L=@1</.HX7+T<-695!'WJ+!
MB7YEE.S,@$BH,_HC6;SVA^4EN0-PWJ).2;ED'\U'@MO/9;;2$!8V<UOM3L'N
MXN%W/)Z^1ZWD]P;RQ0=JUJ[8R_*%2J=5'_BI"XSZX#,\-J^&;$&N3;:(V]'"
M;4.]#<&0X_B-K9\O!&]CH[LC/VKHZR=,9W))IC#LC$,L3,:D< &J?T3#1=ZZ
MW$XYSAML-;;5(/&&M4>RD8PY<Z+N9;IHAZGAMTG+ED1YJ1@9!K$<R5%TN,D8
M 6ZX&55](=N9^F7<:34#"0$75CYK/EG<$.F?2.T;+6_OD>JXTTT4;1[WKX]$
MS2;*PJ(/CUL,^@"_H?9;6LA,0I<B\8?,Z;1X([;7EG<<=<2DNN8:#XO@>0][
MNM@O:$WF[S;]=8C*LTNMY>VLP<7Z?>]<L=Y!=19*6P:Q3LLGZD7:5RV1,Q@J
M]8\9RK% ITBY;X8;[*-2/FFAL.3HF'#6.V_78T[N!<9V*[F7;^._1>-@DF<0
M4(^](9<C0C@6@3#DL?_5709.:2>O1 @GRV%Y9SLA<TLD -<8_G>C2/EXG;JV
M=G@/N?,'?)Z113)>:\*-+]%M@DX6<1R= #T"0Q_U;J(\\@($N).S;1M3]-C/
M*DX<N>JJKHF1^44>GR&F7FB]?2Z@:&;HWGL)' 7QQ>@EFR20&LRU,Z:YC@SM
MI;D4;YR*?OW5S_W[6P>8HR%@M_G^!(JD5:0F#7<+'L(W=L[.:1P@QUV,Y%R^
M4X6H4M0V-5KE,%9-\ZI>(J=A]0B7+*V$F>EY%1U_//YH+IN;P1D5-40L^V81
M/B/K=LRH61#"'%]S2KKXVI!X 6A6':WFY5"'I$*-&%"T,%E$\\+[;D9+UE@*
M5P7N+X(76;&\)/:1I6P3>\0;O!D&"3F;9.;"QD)8<^0Z$"/FUF(MI:O(L9K/
M']0M2\+.SWUG\4F=Q2EJU0].30A'JU79Q<UVS2OLL!#;P.?(-+Z(4EXP(O9F
ME#GUDQ8SUA?ZQK9QD]C@VE(P-U'0.V,=*M;)9P.U&WFCE&K-!]H0Y8>D%]J\
MX"\ FB=Z.47-*F8QT%.85=)'+5\<OA%$8PY*^O#=G24G<7]+V[N8SNLEF*;Z
MG7*=G@4F]FJ<_PP\I,6CY(#^IZ#!/><\8]+A]KZ94+C])[4B0>>XN PA5:.F
MF6>^A^"J2@'^5?"BU[7I&L?794T\" SUJC0)^5\5T^\"Z.J9F3O?Q,WNC0W8
M=QB49T5 N<YJ(847='&SS6X[(!ZK'(@9(JZJ&"*N%I9]2A+$I<V!:&H[W:%P
MT3L1!88640E(^AS8$C<>1#>\#CD+:U4L-IRW$K7Y_CV4RZ#CT^U'#X\(;;B
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M$T%"SCEA<SD0N= Y6LUZQ4$,)1*IBQ2XB:6OX;2NP*BBB?2F3CK <MY';:-
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M%[V(8"1\1MX9LM16H1]7?4B[=&5;\Z3$7NQL]VUZ:98Q?&CNS$BV,55,>*]
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MT!-[V@N#9R!U>$.M:5),GT:0:NS,WT=P2=,2['L&"*Z"8@*61DUPF63(W]K
MO7:TED%PEA4$,)R(#;BDEB_JZ>Z>#[DY7'W!+=]M_%W=CODM%/D7C&TJ:9V8
M\9(4<WU\D3%1(E62!)/D]2V\CG!D\4+R!U-EL@NU;8C9%T]-1I]Q&A&UGH:'
MDC:5;Y*:[Y.IVEH,7OF,?LDEL>/>ZZ=A.03[3V+:R*$@&)T)!2I"+7I$DXEY
MNU5:.7R:"KEZ63?!9QOO8B-26C:[/W@QL)Z,:NJU%*U9,)_+(F$Y(E=>YJI4
M(;9^,PEUH?7K5?-Z]E.!A2'W@0#MOHA8/Y$$[#@XKIAQ;#B1-K''VNY(-@=*
ML1O;SXW=3E:S.)_-"^BWYX&]Y-D%[V:-2+M%0\0\U?6/$JDG-V9.2QK>(,C*
M%\]CH0,$CB;JC+WPM5- &@BEU1GEL+1H?5^Y"DI;WV7I53X%NX,CT,5#Y&LQ
M-\ZB7A/1;N@ZJBEH_EV7Z/(30-C6JG\W)(R5WD,#_VS8.:9-:V'E0&V1Y@1S
MED9[<V39.!92;/G1KY02$=<2X;[7FVL1%,H]2L5,4*X2Z\S4Z]RA&J%Y"\'I
MX&%52)^S-<J!,*)7N&P?/@PO/=1H5!5O&F==\\/H"76C8,(HMJI"&.V?MFO8
MV-"6:ZU)HL=D#[&>#QBU>U IDM)0_8AM?UQ)+F"=]#HFL=6:<IMFAH?(_.GQ
M8K:,2.@W[U(U8P3>+@([!;@Z=[H:W=W%X79Z%!$507(Q#*+@<+A?IF&:0681
M_E-M(UDYKXAF ':8.X4.9S95C:IP:?4:QX0C#:(PD>$IUK)I6IK2;--ND4N%
MC$"]Q.H]M)B=0>KMI7N?2W1U5.3C;Q;="N*5(CFEK<.)ME7B KMZ#@T[72"(
M\4X8(+X/9TWBE_C!1)U9W@1C8LU.$F99OK+D.;QBP-FG1NSDT'A,>,XGP,9W
M9<_)E%F%<"I[:6H:RXHG@&'U9A QU/Y+F%^GT]TMS@I/V_$7F^Y6\Q0>U@8:
MLR,!\F#UE/F'XY?Y^V7O-^F6 R=X;%""V(/FLRXI/2WG\^'I"0K\,BB_=(G$
M.'+(ZZ0@4N[)2P%44H\RW(X_MP7>329VGX/O9"/0P=6PRI]$=@:#1\48 S2N
M)]1F ,&B3= G+1$SJ13>2!7CY!%UW1X$HXC 2:+HP]'DSQ,$K+,9DTA;^![X
MR]9PC%&</PDOBEAISS4-I6@#=NR?V1K:IMO:#%F:FW2(!V YB@1.%X<Y%K&+
MQVR(/"3=CA5IIR\.U.6!6,S::< 3==H"MA%G6K1RT>NDI2*RIBVM :]NV&N
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M;L9I0/&$E)S$^TPXE6]4$*:-.G_V&J(."%W#LGN'S+MNI^-E.(JSD*=)'VO
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MFP8]SB4$(%/OQ:7^P/+4D2@$8_:G]$A[^>9??8_AP;G4T)'L;QI7?4<G];?
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MYVKB-@,L/DV5=)X $.7.0&=8O/[0OTF[.PRJHMU/Z*^Q:W;L34<B$D.%L,&
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M27MRGN\[PP%_P3.=(N]Q1D[;YE9$RH-(IJ-=<&?XI;*:]!I=\!X/+Q*Q%UX
MS:I;?/S]V@O;5.-S&12QC^:#Z6^%L2"?E&U'<G\..+\WXJ9:P)/S'$Z,1W#
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M=<K4-OK%CZ1FE*#/@5<U:>M"YE66>+_+Q80%*)"=O7ARW(>?DXK#7JLW4O3
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M^^CG)$@3]C6_;R%Q[=S[QN^P@W]H*JK7'6DU<!)S#<D3)*FZNVI+.*T]DXP
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M[5:$I7X*](<X2B")__^ 9*$2]J3JDW^_DQ@YX+<]#[XK702"]&)9(,[!I+!
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M&Y'ZYXD)Z=TS@_7M(#H_,M>0ZUN@<U6R]AK7""98%M?2?%&A*YF(PFU23A*
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M#CTV*4X&?[W"$CP_GXQ3\TT=3)D8P)#5>&J+U5F>HZUG$[693-)?',*>;E1
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M,W_^5H)HJJ\_ 7&A?7?A3T"-.I-(MXY[<8G^[FRUM#T3(A9\=+(NBEHRI5&
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MU"VF2CA7:00?XM7X73\!IF@?@ZMC($T#_-.@Q*^>WF,RGRGK%W,H+&=9/T:
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M+)'0@XW"EMV.)<JTR"3V2MYJ]V5!9H,A"Q/X8'FB6HY 2DHUJ*PP3HP8U=C
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MTX;R8Y@D-/ 3:E\%I'AE'+SS3R0J/4-2FJX5UK(#M;D*UKO >I(^2.7D\V7
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MOY3^?O?1V>""+K2H,^ $*+0@$N1+(*LGP91-0/[+#PL"P7J^]+(&!"C>!42
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M%H1I$5WF.Z*NBYROSYLRYDSGUGC0&#(_0VE36=3S(] ;_HH=M--%OM'#W)F
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MT7Q:+R%X11#<>&L8/%.OF"5"<./'7:O]VX_+1K-S<S</#M\YX<_""G6Y]TP
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M3$ R")82E/G1A3(MEX])]C2Z?@ *S*\[^SN&!1L#U!8+!JH^"T&;/DMIGNY
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M?(@.$/Q*>/EZL>N.I=X,JFO6[%!"T5IQ3@E%)12M$HK@KQAC+\@\5D'<&+(
M R*<OX6^A]@"<_S)J :&98XX>DD+IHP_*'%EK=B@Q)425U:)*SR^B$SS9+SR
M4] BX[/R?*Y.3^A-S$Z9OT ;ZS.4>D8#Q\(P$#/D*I@5"R0R71:6>+2>[%/B
M48E'JS3D>(QBQ8R!$S #]ZNPG8]8$/J>QUSEX].4,S."@5N1\#)2P4>*3%0W
ME2"S5CQ1@DP),JL4>GA4L?"GI2,<G.$(D41$&S1O?F^=[]5.#7B\S88@SV"
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M(:B':4N<TF2<*7X3,KJ8A6D-D/=I$KYE$;#!$O+\)\GB%DW&=J@6-=J5,'L
M9B7*4OLADSLT6>CBUU>-BT<,*, )"WL0I7>)+M@H'X$&6,&=:?LT3JQD@&LT
MBKMP!;PX'MDBHRM@]YC.A6+;E ECJ@8L*+P'EQX#FX&K>& RT%+,$RF.S_$
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MK1I%W@?AXA'#(K4FY(MHTC+R0(BN;#*@QUN*O2C"UA* V9NZ5%S9(<5 SV2
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MPKV $UX<D,A(B>8%@:^>3&W(W ^,"NJ-0Z*-VM,R/I=A(*Q_SY(:"_ *!'Q
MNH%?\*Y*FLFP'G$P\@-9%2V)E'#,O@<+3T$/H4C5\,GCVU<1KMH9R(,,@LC#
MAG3<22]&"JN!3]<>2*50>0R"RB13[;?)82K3QX VR7VT:W$]03GFFL+E>4/,
M1103H$+'A*@\6!=+5,<N')",\M:,:[B!?/U7#:P$ VP74GP*]ZCI+F[:^E1#
M?'(@V:ROT#=XP5>79[YK4Y5!"K*8.EU"/DSYRY9Y[ Y?V6.W3K:W9X5L+7P4
M&#J@!1/DF "/#@X66D=E[2R!5[@=A>(*H!@'(Y'>">(7''6N.1R*E,:)2FBH
M9]RC"=!FD4!G$>]/)Q8@RCB,V)#P)V#=3."Q\M%CT6]N'>26A#GKI0'P-RPK
M'HJP9RJYH8;JZ.8*D#0#GWGW3N![="+#N9].X .-#*4 ,?IXI$Y/.@!1C^21
M$_0X;J"L&IR)>+\L[^_QD"F]+ I\#+G"DB348B62M5T>86V4,50;;2C45.D"
MCL(9S <C7[ N/B7DYCXL3>$F]HC$Q(%&BPJ/W*_ X0?*%7"5ZLG"C1_FT)>%
MFU ]% _KNWX7C3MY%;QEB*"6)4(,1*3!O[J^38;";@RZ,B\WC"($'I]82#\O
MAB@ITE,QQ'FJ@LHJO&,+6JRU)O%Y@4,3D4(&)U&>KEDU_D!Z^@6Q6GK\3*4P
M](G*/5G"6&-FLSDI33-6%LE05V2Y*6ER#@6.ZMSP*<Z&SXF@DIIYF+;24CB-
M')^VK>AN1V:E T%!!@R4B(+V1:X28KHO7W^Y<57*E++E9<>61F6,+!633%=X
MDN&2N)Q8'HVBWGA;DT3.>BBJPJ8$KQG2DJ8H1U]Y;6FMP43*[$%I UU1'%W:
M[I*<<@I"Y>T^9-$O6@8NN4F&$4&W0/D^CK]/:R%U8G*!<,&5UUG"-0/928 O
M48=J+J%1Q_4).@F^T)Q+$F[2.X8"!<WTB_*-,G "*&MTDCV]*"OB.@DJE)0^
M*2*HC/8M%0O0>V6/PZ2_K$K01XUI[/*G ).&+.%%#(9U12.65.4N8D*#*D0F
MSD A<TR:W\5/E70N&5?B 6=!')&>AB')_J:HL\V7BNLAQ.C"A(<Z1)^#(*]H
M&9Y1?4MR4OW[:STYXPI/,[Q,@R0>-S_P'_ ^KE])DQ8-C31KC*-D8:*+2NP/
M98$R+ Z%V7MH*!&64=%LBA]OY*1!_98G_R6@*P&)[TV0?]09B"I6GMDU! J@
M:DKJ5-I4G)D:J> R\).*,?S[:TUZY50E,V*(( GH5NF%.#1.T\9$E0?!14AZ
MWLJ8RT88H3_LDG(8T0'[MXC6%GVVM%IJN,(592@091@H5E0X>?#5RNZ;>2_>
M7-4*:!9:^N<MD,IEM5":F[#N"Y)!-UGM29I'$P9:0NM0)@]F%HZ<7L)<+FUK
MA6>=!/+\8P[4^6+SEG"F2@= +NB3R2AU-N#SI!A>/,-M/!4^I_-Y*3'W/27E
MRM3;]$%1JVWS07$1=#]KH2,RL5KD4_.!<+D[B1!!T2<O'B0Y#HJ2GJJ9-.@I
MR<X$XWX7OK]/O,$J]E9W;4SD-<O3IV+T3:QGA+9EC"U!>UK7!:U#^%:Y!*NJ
M/]'09AX1'HLH#C_*9/_Z/TE_Q=9CTK),&S-)M18E>N6OHGL*=R$G2B"E#N4]
M@C):2$_G Z?Q)J6+YZ3HQ/AKU:-I,X!3(74YEM "&3*@HSI]_;0QR..)9]4+
M9U7(0EF"@%1O!W1-H2BD%.3M=76K0L_ABHMDSU"&H)K4I9[0.?ND/0=B"J"^
M^>AW*#@A#5W;E"8DL2F5P#512"HS0(V]Z6 ,16 );GQIR\CX(KE:A938$WO*
MP28 %A ;3U"]! 6=\%6C*3,!A$%,=+75^PUERF;@F2V]#+1XLCRL#%TATM-J
MP-">VKHOD"6,IJ1ZA_QDC9$H5H8J<K/#5>2V'\-H?O-A@-,<:5LH#=R()A8)
M<\JHZBT]]+4^J-(V-Z5H?*92;FY]:8^;'WA+,75")X$HD_'JI"]146K9'#O;
MW6F!+9PZLC ^?S>BG4MEV8K,@-.R,^4P$0?B4!6](=\QZGS28XKB=MHREO*Z
M23L:@@+'Y<E\9C0&Z[%N&)"G67JEB(.CU1&+:"M[Q G-()/"ZP>3&;S<4EF4
M=I!=0E+557:4(TP'V-=N*%3 9;4ZG</=]Y*X,WZ> 6=M*0K@'/L^.DQX7KE8
MZ8J2S[(=0%A!)BERV_1>!A1-C9L3A!'>.%&4.90MZ!-BH]%96%'(/,E'R+L)
MG1EEQ1CBH\6R@LYTFU4Q1M$B?P<53&8%2:O+'\EK5HQ9.0LNMF+,MT3 (>\W
M+]D*4H9>=H_JST68!Z' :UI?U.K\]6;H]'VZURJ0E'G4MTFOGI%T6:TH).<?
M=)]N&L\I:2-!]-P6B0Z%^$:R?0VODZ);6U0YP8K,&*D8'=/]FX'$41%9%A55
MI8U:K/)";CPA(,!H,4YY=*>"2&1GDG'X!%7YE0?IXTWJ)!2V+,V63*"RT 5M
M2_,J(R2-)*=V#)HHOU$0L:Y")&5IMV?7L9:)23PM7;@NA=8YD5=D9%.*YJVV
ML=EA6D=SAFEMAVR10>O)!=H^$6*V*9>UY9XG*:PW0ZT/=9\Z]]=G0--%IN+^
M?I.22T.U!)_M]#/#)!$)LRI#;L"6B4>Y[LONF%?IHFI#*B9;2S0()QQ$2: ,
M'-+S]3"<G"-JL*G(>1E&J=I1IV,19TOHRLOX2T+\4XE_LB5HD@&8EP^IA?.(
MFGZYU!0M.Y(&D_N\3Z5>ST:)(_.W\OYR5^'%H81'FNI@"U.?WJU!5<\+*'J2
M8:P\4DS$._"$ZB0@("%^QD64J6LF&CBH$#-*.G]6+^_I62V[M7?&?+E<U,XU
MDQ0T6_)6Y<FTF20EYJ6\_O)$IY>.H#!DCZ@@\G[8BU_S@BRFE[YZ:K+2'[0C
M)##FAOE9(&N*($-]8PL[FL 651>._'NQ![P%6BRSY]4 %MJA<*L$[#4MJ;M,
M ;LLWKQ, 7M-&6J9XN.WF1R,J@,H&3EXK[&*P=M;X!'83R*N,2=&ZW=K,]?A
MYC#=W*5UNZ;036?X=$_F%Q\X#4)CE9E\ %*7RDX>@-A\7*,9[5%9?P8"I3]F
MZ0HMU*Q]SW+1=6<G999U[S79^?*D/C0BHEG3(R*%9'<C*<[\CZ]%<<$1@0GU
MF%9*SLF?Z,I4DAX_?$5,JRWJ0,N"!ER SR1.3F1Z=H0QK\(+)W?%TO 2NNGV
MJSG.V8ILH57)Y 3+%:T0$XBXB?2=Q44,G\N\,G?BQ?( KMJ2AG?_\M%I\='C
M+'W5<JB^%NG 4YA8\ZJ9Q*]0@1U5;(#4)6'*32U]?EEL]2U&:,M.&7)T]T[?
M<7E;MB26(S5R$1'O"VOQ7[&)S3JX@W)(FU*9]Y7#.VM6]H.^Z0D?-Y\1RALJ
MRLH5Z5^)CD+!3;;_-VIO\'",VNDYJ,<(,[^*E]"S95,-RV4(@Z)4RK2=6Z&Y
M$ 6D]X)DZPD]G:L9J+NERE#+U!VJ$X%% ?@<A>+"0TCTOLQ:7M=D:$DI?I;B
M9RE^EN+G>HB?30YMHG6M +<)0,NI-"S%'4H"5<B<'!L\UE2&9*I0ETD[W +,
MDS>:1Q3.H"0#L<@0BTFGQO/S3>DTST_-5$9%3/G,2V#)2\3\@ZE&*.J<T0\7
M;O$LFJ$H@9M83O55E$Y>N5QYCF.U5%004*NCD>KO*G*\4#CFY>O%@Z16(0K?
M:5(,9:C#"F.2B8BTE"U=TV[C!Q7;FY0-OW)0P%'E_[2\)DIE$O/6E0.SP/@.
MN^Y!Q"\2R;1^O@G-?O<#W_.3]\V:IO'B@=1JAR]/[)HCB<MB\V9QK4]L?N1C
MBY3PR4!QDN#TS22B>)ERT<#0!LXHK]MD/E)IL3 AV:'A*(F1A$D=-\6\,MJ$
MPDU%24A_A!L!$^Y$-$8O#FA3YR$N!P2NDG=YO1Y9<@=S3P<^O(:7LI%Q$1C%
M- IEC(M( U6 PUP[MPO,PB51O1/>A^KIZ5OLA+?>HD0IFY:RZ<;(IM]54V)S
M:O_B_):ILD!B?H+'RX7./ZC4F]XOF;H.J5RP&3HE2[=6S"LX#HO+QOFZ+UM9
M$C%J,*%"MJORU%;*H1X;R4?*2Q_*LMBRMKD6XI@O+5<FDF:3\UXEA>'$^(1D
M-H<HV1( 1%.79/3^8O-B.!E#=9"'C/WD9*7LD\#I@Y@6RX,NC/9(XG%2M3[2
M23:R<#8_1=,=:F5CVE1T!8@-'A.FX"Z+'C"X0>;Z[E$A0FGRDRN+KQ>_)/8Y
M40>9V]9P?>%]2>=;GE.3VQE;%Y&$$6JB![<^5[^W!_^#46,&,S!] -)Z(.Q8
M(#_UV ,+M$Y4PG>@-^E&60P5'KQ.="*6'-8(>5*/V$8R3Z$B8E"%S3H2%7X3
M[LH6K!2M%;&!D)11LA94^E'*::'6'8M9 X\N8"DE1[!OF"H$224E0XUTW,DL
MR4M2&1;W#B5(9+J=9S"#^(CK*EKTZA,5+UM?FVM4VK)J?!:E+45124ZAX@J7
M&!,BJURJ"(%LN4LM5J 4(DLALA0B2R%R787("ZZIDW\]JX0G<41I3S$\Q.5)
M[6C0\@:B92K3$D@TQ3]S7O#@J8G2:;Q4!)5%6I#TB4G^<#()BQFYSKF#G&I5
M99V0>NX+'U9 B3YT6.8<>\8NMSI2-0XA82/F&QT6! [Y$&5C$6D'I9S&G.(R
MDW8T9323MJ5WB8-4]XVFZ!B*.MU8LSWEE6-3EI@R1GBI26Y""=6IZ<$-/()"
M+C%)V;IO,3O#K)J13]@I2D?*["F[Z;RDG/AD#&TBH5"Z"O<P Z]G#O$,C_(B
M-=B*U3#[ 6.JZC?(@-ABV>1EY:5G4P22)DNA)\KF3UX6SB%Y"_A.E+LV7:R$
MZ0>91=+[5P_-1TRKYELPX?!9-N.K.%M?UK1OLQ.,CI];!SK35^V9V? S)SIF
MR+#L:L\+'T62JXI!79,I>06%GI],7"E(RE\-,S4GII4JFMIE5#57-&&@4@VV
M&7L$_$G%76P-)E(4A,[+@0_>%:;:1TJ8D0F7D6^;H"\U>$A*%-M2:9<5&V7/
M,<VB$\I"?@Q4.<?[R?7V9 *RJA-71T-E_*!K(JQ/6U0I#*T2EA-8\?">>:(9
MG2I8I\PZJH-)TDP+XT\LWFKNDCL9L YN16OFD!?=9P#B8P-K\MS(HO=):B@O
MVT&!=[JG*V,X&E=4,S[U1:K^]41'I^I$?8GYP&_E+'M3%+,9ZD&86J-RZH1C
M3+2DEXS"Z^"&/-"0:M_"D2LZ@F5+I'!)!HXZ(*?D+5FUE%?YQ(0+5?5$?QG5
M]>:5/)%?*#$E%CD8S M@)(7O Q*$_#27G155:2?.FOABRO8X>#=99H6_.ET9
MTTQJ<Z)8.9EE5/2NEW)/\;&"_/)AEI(DS^8;H"=UL8#Y%[;#)C*2T)UCRPU
M=;DWT\[) G*LA3@S\R!6N9VGM+L]G+>';KVP9_3K+<L;,8?E:,YORSA6;#I8
MK:ELC<:U),/9&K'>8@O#M+(BRC.*NOB6%0>4Z8HUU',*U%%I71 /#27E))Y'
M4XH=*M:*)UMBYQ89J9<10$E,11$>"_K2T4BF%BYD4(!Y4M]D0@3#H6C>SE1%
MDE;?&V."J=[5E$:#KLN]D8]A/O>LHN>O)F5OR:U)7ASNVU379QH4_J$'V_&
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M<_8"77.-]TD5UH\!7<IC TM#><62N8$\>*@Z/- I%JT2G&;X##<%>'S=F?3
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MO"9S+%#<./YTOLGF<% TAQ&)C=-!Q?"V6F]Q#!UCC#@%(H6;0*=@V"_B,B7
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M<?+@)TDP-G!?,/RGZ,ZAC03OW>7?R  *<_:S18[!8D8,9P,IU69@3!#"&7H
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M/AAC) '/3W=@\S:TW*F:CN%?1/6?>[&YX!.0#K[:<7!BJJTN\-5NZ27H6J\
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M_=BOWJIX@>JM=O>6W<HV3T2HA5(%/C57"RI'59"YD:A+["5(OTU^-SSV.7B
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M)+<<1^"D14P%%$0R#Q%JP@M\MP!!RUL<S$:%!6-EQ3M5JFY8 U8CMM*8DUD
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MYXSAQ;/S,#-X;XU_Z%]OF/OYA.)A:; 6:('J[N^OAJ_6']#ZW2@WV.\-]NY
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MJ:'Z,[MO#9F%&HW,4(M3I%_!<@*#"]TL>'<G_P5?I6=,9W ]F\AHUDS'V-F
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MQ><6QAGUVTJN1X9_X2PN]M,O\5C+AY[QPV.+CZ!1VTH <!I0BUVSL:+P+>$
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M/OW?C0KQU3\*B*L3+7\.WF!.!8<NF,EX-#K!C(-ST!S*?7V++>>>S%,-!&=
M7L##0$P5/=A;CT.0!-+/L 93#%669IE7Z03_2? _*(O@7Q!7=Z.3_A6EVIO!
MH#?\\>%,UA<B.I><KY<E2%<SV-.*U1JMZSL)V1H=O;6#7\N$[+LW-YNQF&P!
M@:0G-5-%W>WR=JE +>%288U*J<Z3<#**\FV<!HJ5G>"Q''T^$)B@L)&DGGCG
MWDJG,TSJ"-O#W6^;&O(EKL.<DV@.AE>!=^,FF:BD-$^6F_<!U43J/#X_GP?:
ME@)4#ZXP6(+>Q9Q^K.>\$-WS K5-??3+<]0H]=$A]S/;#[]%HT1%Y,+1(X6:
MP?!#-0""\0G'L+=9#X;C2@(]KK&8,*[#3JY2XC1*T:""&3$NLNR&6-14::F7
MW$Y<]+/72<"W@K<5O*W@?;F"]^B;3/F%*+$C=?&+D9]@T+HH^"R#&5;1B<9S
M)S"#8?.#TP4,78U"J>/K#+?(V5XAQ_ TFR_&:SET3E$;];48_OMMHK<!?>*_
MT8A.%WV<HO^!IZ(4>^83I7AP1&.;P_\9)W$4!XOOU/"LVV^1^,W+8L38'.QW
M: P-Y=@HZ\\3J6-B";,!'_4&'-@-("-#_YD++E=_%Q%)4X$MMYZ'K PWUU]&
M.3G8?9M64%+ :%F[\]@D@=S&<<D9H,5)=:#3=/*,TLPRM26"/?%[Q.#X-[Q)
MQ_[I$LOF<1 M683J*SPY#6C.7#[FTT)VC#DX.=V[^M(TWH*V ^11)AEGGRIK
M9K-0!P402Q7V)F-A:+Y7D9T%(BQ9E(@11^!F;OLHS^^+<,PN@\/>V$]*HR;X
M69B]P\=CNV-WHNLN%084/$FIQ]BV9>J1(%.5()@K)A[-3?1&E":&%,+"DHK@
MPN-D1@*%0NES[A"RHX"OXR3T"6F<[5LJO-0Y_Q,5@[2VVWNJ9D0,&D &YK3L
MB%^PU/]7^$]'?))@DM,BSF5P#3?9,-AQXEPE"78ZS#?7/!4Z/7T]B7E@;AF@
MO(0J4MDAJT"6[8187!&5PIJ,N7UP#*]Y*?49R1DB6#^"UH,8NG0>U04LB(_<
M:IHA\"1%K?"T5-?% T&8J%/Y)QXFF7Q1J]?[S,H41P]0IMB$VN[:U"GFZ.72
M# !0#?J@DXS*;^=,K1)0TD<BGUW U[ P8DY_0Y&"KK?/\Z_^:[MFN$:]?LT6
M)&@V$8@KD/L3NXVZ9TH$:9H;U&Q#$"R\VAMUAMO[(IW(A$',]63W:8SOA'/J
M\4H4,%BV@Z7[-!>R^!/7H%J2;IS17RR--\M6RUAEUX@V2IT94B.G+YH[;+(4
M..-Z>4N6@C>J/)+J1[D2A\/R"9:"PEW^:[C7&VZ)&=R3;MC10SBP/X1'E"5J
M&N24BQAN_VAN/^IW$9L5J!!0P=L5UIUB#QJ2#@\O53UAB$?J01KZ>=6MY+?2
M[T)=./J% KU, @F?A>#>:_9 [1[0#L,]SA1G$;8VY.;&<-/4P<+'.4ASW,D#
M3^,^X('AG$-*,:V(GY10^PS#"QG];97PA<*Q([?!I39%0/ZA"ASVDOZ=RB\*
M644QDK/F$]?J!5%DQIPQ%#\1 V>F:,4*'Q&<QN^W?*]J6>B9+0CY;A>@TTUH
ME.@A5,6@J:IR7VY0P!LX*V?VG,JOP90/\G\-!H->WPB'VQ==&!N/N<CA<-M=
MY(<+FDMEYU%QM>C21UW'>>@ONW\)/^B_AKO#X@$\D(^\'5VR5[SJ&B:<^S#@
M.QHH$/A=1J/K^L%E0'L4@D'NQ\!>YK,DGLO0B#R&.Q*1RD0J0Y:]:UN9#6?.
MWZ,0'4TEDS! (T$ETX!<OLZM;BU"2\4\Y(T<'1!;'L*M9$&H>]!F06+-=G3#
M>-?G5B,Z1DI/O*?9CB;$5+[X=J^"EI,HXAL4]II^KO&#L;(0>S!SK@K&DM#B
M]%B"DV/ ZDJOMTM##N%T(C+.']SF82[#P1SDXMF=N\W0XK=AGPSU+D@@B0#G
MW%:>X,WTU%&\)1U&AGXHWA=<YS\U]^N,NZ)VS$#WH'@YC=6,KZC<-J6&4-+]
MJ5;],OJ2Y+,,L^48_$L1XPYSYW"-IQ2J3GA3]Q5)>)=?4;JO=*T+A_5Q<,7M
M4F;BZ27%XJE+A>S++, T^Q]:7U"BOQA1GU47<7/8!>=R4CH)-2^C,VFK($[,
M?A7*IO&\#*+:RD*S2^DMVT2=N+A%=$BNU;?M+PF+:*F$IO@/3JJ!A9O@CXWV
MN)J>^-2H/FVR<92'(R FJL)V=(QMS%C:[=RB<K&CXR_(7.1CMVZ I<D@=I](
M=C[':.Q!?IF#J3-:%8N52UYZ0V_'PB'>9&.*_\PNP:JO+@O-\G=OB,PZPRL(
MUOT! K#[6Z4 [*KE=LQ?W/!K$1+LK S$=LI*KQR6K;SPJJBL;D!ZT @M(WUS
M01;M96T#K^N1YWL$0NL;\D3K+B'>9&3$LKKGI<*C]'81<GN<4=>*F6M @]%,
M.TN 86D'C#!.2JLT9-&0D28@'A<=4SP)#^R R MFZ%XMF2'#18!3N(!&<!=9
M4CY_8%'P:28P(#MJ!DS0N/&&Q#JAQ)6"4B:J$C%<C"C"I]M[>YWA:/NIPUUE
M?7+/8!?&D99&NT9;/<3,72?:A4@L^OX[C8IVX=KW1["1B)LUI:J$SOU#8$<\
M@9=<0GIM%77AO5 XL RY*+F-I#K-^LKDL2HQ2%T'RL@K,XP8A4P&&ZG!O4W0
MUAP9.F\D2B-U&5,3+GV'SIHQ07 &1:JGU1LMZ;AORR(X3!QV? A0*UL,=.CU
M.[$@V%T;R;BQ:;<!0N>62,1*>;,J$!'S<,<\RI)Y=SSOZA^7*G7\^X(R(X??
MB6>@&B"I &RP(D81HF;$JB6"O Q8G3A/8Y.(:GRH7QOMAF5*5!L4O& @\L88
MG@C":T[#N;BBL8C[.7%"C%_9B,%M=[X]YG*C_?+-(9>R=[)NQ,6<_N4!EY7'
MHSGQ%N<%;XZT@*T"FXK3PQWH+7VVM+2I[.W8;CH[^4\2J[F!@]<.U1A7K>&R
M[L.%V8U*H&8UPRV+SJRWHS<$9XH8"M^*'J,C-DZQCANOT<^LZ+#.BLA-IQRV
M61*2<5W";P_--+Q68JO%KWV<51S\_^R]:W,;1Y(V^E<0WK,[4D23)B7?Y]V)
MH"G)ULS(UHKRF3C[9:,!-(BV@&Y,7TAA?OW)?#*S*JO1H"[V6B1?S >/2/:E
MNBHK*Z_/T_*!1!;J;CDF\\TR=IV+E=T#:-OG;+YON@(>S:,3SNKOALQ"V*IK
MP/+T[KG!]@^320]A@I*>]9*4"9Z<#GG9A+' DR4:"$?LQ]AA.%!X_T[XW1/R
M*!=E">=V9&'_@&\)@1*$8.I&7)&YP7*:<?1RR8B<IU-]+KWMO;_T.,R4L2_\
MRC07JVT:6VG3Z3$ZE@KQCXL.9P2>_7)!5S<9.S+QI-PSM26S#]$)O2;=#/U\
MN:JG0P*O),KCPGKA"Z&[PZ\M.G3C!+BFFCL=2K] 1I@G0&)9/-=W6R7\H]"V
M 5Y+M=\]8<9[B<8X_A!?G[&5&N=*Z&#H7I+6>LHO@T=7#^**>YZG,$/U=073
M)"#(TMZ1YBV8]!5VP]A^B<PQ[),CSTR?'R%P8+-6M>3],S?L)*081L8-S&!-
MD>*N33XE*P;.]R29U6E?KB1N4!6<+<@;1MM9-'G )U(RYO@$H61BBSKLWN13
M)!3A)R#YKLP%0A;"+6. 0*9:QZ?X>'+N =W%V6ZQ)*)0M:T$(6+5SHYJ:O=Z
M-VTCGTSRW2]R_IE'RFPLK2:8<?FJ!X @>QPK>-M],Q+\9FRS.ZU47B2S<.?5
MR;R6@-5UQ2O'7KX 5XEK/-AJ6#R8#"UW]I3M,H,?FTH&_<MOK:9@^&D$VMY:
MV"QXL%!C_'>44S%5DD7K LY7>':Q?R?@:I_$$^82,R? 2G6)\.8U,ZKEK<)8
MQR(M]Y9R8<[Y/LTVU33)4%%&A_HC/QK1PMD;.GJS"=D^C!+:=K7NOZ#!1.66
MU15_UV4>.'AW(>4&'YQN29<6>Y?6QX?1<+C439)[0%80K-1+J(#Z&BE6U :J
MO9)K#P8CDI82G$Z4RG0[*3BM5.7!5&.M@J'VBN/ WS@IPU&R5]2R2?'/OHPG
M'PER6U? 8%\"1I%7): MRM,5#B_!PA-7MZ5?SN0,0V@ZC;/LT\9W/++QND8,
M'D8U=KRMON&Y;Y8Y73I#^R*."++#YV+R/SA[^5SX@N9-?QEFQX1N;,=R5E"+
M_62ZW5[8"LD9O=?OS"8&V=5B0!"NA0/A<XKT1G459DL61!X& H_[][0DJ<T(
MV/00.J15:*3YNKBNFS>^W4\"I48[1^,^NFG<$G 5<B ^_XUNKE>W()H:@M(K
M5L5B0K.Z.ZF:H*HYKLG1;_VG!KU#$HL_U LN#NP[+Z1G+7P^,8_V+6:W;.K^
M<ND_/X:]9YRMGZN!0@O\AB>:!)E6E$UH%1P[?D97X#WDB86H(8N/?IM?D@RV
M0K80>13T/:34.;P\3NUTQ]:&]F84\7CN-<*%^'[G.T^2,A?2+?,R9UI#TC=8
M=K8V=4WOL@GY?#2U<O<7G\V3JR(1?:17E](R(_IZTY3DMS:<*)DM*V#)9CCG
MJ]B56:[!0ZHM!8(?,BA^H4OJIM.,/N_!:<^T1VW"K2P'&$P_,THL1#0O%H54
M?L20M_K(@LNZJ4D MEI*TA;%&_]=NNG#MVSJ5EKPIVSUK;D!4UR\==$MZSF[
M>%(',%99!4?71AH*%BP(CZR39CAW_[ZO7.L&GSI8KFSZ!'[DW6M]='_XO>-K
MEZ4+AZ&-*6==SV0)AV:6BL$*SPJ)3;_0J;$-!=/D<X!B-\6P\!1E9C R;_J8
M?4/6F");[P*,4)&!;'#..FJVU,E=ND3"1MQE-8/W"DM@_"I6R,D9MG+\,D,"
MMR\$;YOE=LIN:V$/_SLO$AQ>I;]U+#LL:J <".1G(N@^!2W='')."BX;S"!&
M65:+0H(>8 )6-RCY5A/%$+M)/EQV#W^Z&8:_09"$KQ:;L@ CMX8PJH5PF.48
MIPI-(AKA3E$"JJ5H2-&B"&,6E9"4??(QKKL/LJP'D[K0EF^SQ>WY9),W:O6S
M.MDAT\=>$3T8NDANDC($-RR+X(3IV)U<C>]A*[MS]LX;%3]']<SJ8D%JN18;
MKI7/'5.(JMK'M*TMF2Y7T*V NEI9=M7BXTJO]"471UD1KZ-<XI<9V5-:LABD
M%A#HH/FCL3XA.Q_IG,>G5@4M[%KV8=K+R^81N_CR::E>#B?#HT?A0\>N&)P'
M+??;A1N IUB%T,'(/#'YP-S5@[R4:\YK$5_>Q*\Y^[.=/'AY_MK?^]!>-E@9
M1XSU/@>0A$^^_O+&U?S 9][YW;!7C.KQ;:+52B[=H[WB85%"->'( ISU'.%9
ME7DV^6M.)KDL"7_L?Q?Y"@F#?,7&#IS8L?6)\C;V_*<]&[_AX8I?$?7;>RVI
M8(#)?U\OBQLWS<B,(*&\#F<RH*:[CK,2@W"'NZK5,)&H"[7Q^%8N@LD!.[()
MMA-*LW >/#IY_#5]WK25(W*[[Y3FP]&56\SI/603G W/'3YT\+$22X$$W+!5
M1K3;OK%:P2T/&)_ZZ.2+T[TCS^>_DIS(4<V.<?B0G;+&.U[J\>4!%N./=2D'
MQ;;Q*,[WJ4$+7?X^NN@#5=%M@[*X9>-)=2^MX^^N>W]_)8E1OE-)?FM*\N0C
ME.1]@8H8VZRPEM^Y64.Q(HAMHCV.%=.BQ8_?T&I5. /F_7?TP%Z@S_D$,@L/
MX0-D%J.\R0CY]J.$]/Y))WC-?YMT6O_R*,($IVETW08N$N0A'UE-+]-"]3:P
M6$\_4@*S/U0$,<P;1/"C%.4=%\$/<]T0_@O>VJXG/:+PGH')-)O\0--(LQH;
MH/2ZO]'JS>MUMK?%]R9]BIO.\RJ?YS&"Z[?&2-O"Q=_.SXT,;M!(L[_/./>-
M>(*PD\^+=3F;( 4;&==UE%HBRMN-I[<YGESDUUO.N=(@,02)]TN="W:3B^ZX
M0@\M=QFMH^"BIGAE)&G3:H&4:^_N*TN+/M>@FP<^.\?I.42<0CDD 7<?8Q\+
MYX]V0N\C0XSQUJ"SDLH/S?RK8,8P\MV?_,%)=4.]0IR#:U_!N+\#7+>,O(M;
MR9H6=D_,G24/4N0HTTTQ>F]GDG(8LYR4 "!(3YSTE,F8L]C2;SP-6H;8:I&S
M(M7L?>FP]3*5AY"C]U*W1TCN0UC\>7HBD&2$HI)!FH7N!7FS]'ZUL7-?$CPH
MAS(T,^O!U6QEVI_FU'267*U_CXW=>NZLBDM4WS7K>%4XO*21L112"*NC*;;:
MZ&1E9\\K*RG(AB%+]+;M1JQ'#R\_/7IHU97+FO"S'IUHCV:P>*2?M>VT+95S
MVSHQ_.4#R :'G\#5'CP1;19Z'+29WF*3QQ?'P>CAPQ0;"O8.>D^!M_SLR9G6
MXA5)^HL<3[&*%#N^*6;Y1HIT83^X'E )+-K@^9 &V6B+/F>&>;<+^5TNXM@4
M5R4)LDB,-3Z WV.U*O8D%Z51G3NPK6-#FPUIR'SRTJ@Y5&QHQ@N>3>V)57'I
MZB[F(OCA_A3H1A]..H8A /CYM*Q<.TB&IZYBJ*F.$\D5FJ_=BIA$W>@"\MY3
MZI+9K&[F$'%EMV+SXSKTKY 4%=R3]RNII'8N?>@9*5?ZFNU&F;68#XO5W(=+
MVX_U-3,#9VH46?&(;?6<(4!8),"^HK.H8[>*,>N73MJD,QF"M5MW==)N+4JB
M%14!$D;6N773#A>'/M$I ZTMG]7RR])"[ZALQ0=($KJT)&V4OB,[\*/I/WZ+
MJ)>F8$)A72!/'N:_(B15+3\>\JKA:5'1W?FSX774V3$"P>"44E=5*+$Q'_]0
MM[%HJZ],ATFE".,[%$80H1..XUOE[Y\]ER#C#/\I9&7EO:B>H57-FR B01Q,
MR?$.16K;X0_M*XH@9[R=T%HWEWN4O"F@57&5 Z\$ \'^5!$H&\E[;KAS1O3D
M31O?MFJ8E./)^9)92C'(HNR6FAKUKY*JMMTWO:/%)9Z&J''CHNBR70XK+GSY
MD:M:J?=:B#/ >N:"JJ";H(\H Z,]_CC7XC[*AH,@';P9UO*Q EGG;V 2LBUY
MR2G@U0K_,$ 0J:-:K9!U1^F/VO%2@RX<4E(*807N8V5R-]2F6/D*U]Q,?;&7
M['87O% !C&?O#<4H.Q5ITH<DI]IEGP.E2ZOB38@Q2#KQ#,)K:+OZ_H(;PBK<
M.#YRY]BE6H3"-E!:>I*Q7H#=<,TQ:YJD1@>[4\C"#W"#%D<^>5CXL*06CXS[
M1;]2^AF<1U96IXLK^GN0)P7$5%+[V2FTT_N ^-T!-?R"S($:)S:J(5Q!A\TZ
M3W@J17V;PC!L0'JI=4ENRQMRFM:@I<U;X^XU3>C+8776^!93H]AJ[-.@(M\\
M+6LW%C!I23PHX@'%TP-& QE$;V0G!6TJU4G/$.-CBE 8!EZK\.P@ AM(IQ-I
M%=TVY3E3G)T&D-(\AVK1I+AB-WK2F&9WU6BI(R9N?!FG#MMC#O7!Y@;L&-Y^
M93/KUSRZ(MC3,G[ JHVJ6#YUBXX#R4'!6HN.64A!>:*9*3ZNV[%QO:6(V</Z
M7W/'"U!9WM*Y?4.WQL#720[S(*]M1"Q$U1"O^QZ!'_8_N-%)7Q:^G$U@5/HS
M(F,;ZNC]Q.#NECZ:+3X?!7HFC93<@)19WU.X"]'MRHAGN</-8B8[CRI]Q:J9
M"Q_[_2+N'0*B@MXG(1=H;MY$X<M'XAW[5B:JF6DA,"PZ*+6?N3"26U.;0AD=
M!RB%F?7'#6$^U L$#E+L6PBHX24H'RWV@TGB(2RD76WK3?%=B$SU8Y/PU#SS
MI]L@B@%[Q9XC(HMT DIEUN)U3Z2$$V)<,4[ I%V2F;$+-[:C*B'233'=HA%D
M9@:K*XT-<N@M/A7C^P=J\M4!U.2/&<6YV_#W K3D]?M8##18KBP$*%^#@Y//
M7]JE_Y+X19-ORCEO8+1Y83<Z?9Q)B+I-U:5D5.FI7(]8K&D,W TGU&F^ EU-
MH7^@*_1ZT-4Z] )$C5IOJ-I3Q=MBULOAQ)@D:&UE  :ZDP&"+1^4Q09D#Q:0
M)1%J/+PL+&KJ'L:)EE4QORQV#LOQXQ$'"0Z1LIKQX:**+DR0VA 5NY?LDO'K
MM<_5QW+>N7@ABI#%U!R?RV77:]S_DH^C"HT;*\"(S$JSLP0C4DPN@:X,Z3/_
MC&-FT1QM'+DNS,TCE\,=W+O)#CXDY/LU7 <CQ[!>2<)T3!5MC?@;YPC1S45L
MED@=H;OOG/C,9S2-,HMK<%UO$1Q0"6E$0!Y<"=O<H8_0:EQR17CA$6A#+W46
M00-@N3*$ZBS,JMBVF=ML\'!4-"00Z2R6)/>3O4?G?XP'. /'@L)6GE.NIYP1
M"PG+84^\M[@1Q&8XOMHRW-[ 1-PH$3[QI&F<35\Z8\M&]4]RP 2BSZD !=V@
M'239+&MI=U.)39[")K5E\&H4\B/!- 7P07)'BA-0&O?W4.UJ&!#;FOVB&FGQ
MV+E,#\[,2-4\^ 7C@W-PI4%T>WLDV.HQ#AFS?CR]@%])1"H5S6A1DJA9CZ]#
MB6)]V#0<H5L7 8=JQ8RU$@5R\A>&<#PYB_PVB"YJ1@*38,%3'J=F3)2Y2* -
M(E+ M!!]6[&YU^1:H##877=>:PSZQ:)7$)QQV,_B]!JV T_%CJ*Y07&G(4'
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MA,.&G]<Q+$C"I_L!9]X=Z%Y^.=)HP1/'M21WNVUX**\C\C[6E>:X'XN@ -H
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M=/#QK7#/S^T@?"55:L7D[_@KH#J'=UC.%: V8R07+IR+;60[%!).UO]T&/[
MV607N5 #O7[OT$+@QZDIG9S9=A8Y-KPTEFTX\K/A-.."H"*]P'+9-!#IB@#)
M=>/ ++P^EX\MQ"XTFG;[S'DACNM, ]0ABA-Z/)V](W*X]XUF/99-$LM/H&8S
M_Y=->54S,O=X#<F#]F':'N2K[C!M=.HRHE+;KZ4RT:EVAZJZ$]/8$_SX?!C5
M5]2I_4O?BCS/L\%&X8DH2@V7.7A?"=7-YUP8BF,[+DBZ#G'R=4E$Y@. TKS)
MKX=2<SQY>E6@" 1*!@>-P">[G$CC*D?3@X,5S]PAU/WDS3J).&@UA<$#^MB>
MAH)"E&'TA..W.R.1@649<O J(%:$P7"(J*%ETO.2CZ*BD;P%'(_KPET2FJ,E
M(GF_2A"^.#G@P_XQH_C9!1/N!SAL]&?UVQ#I.IMUZ<X''4:(I:C'9^B1<GYR
MX7$IF"X^->(#N=P:!#SVIC!\!"F<4KLJ@+ FN%RCEXH2RA6"8%%<6[SAT<E)
M=G)RDH!FCD4JLY Z^*#;#- ^8GNR(\$:T.-K2GE;'@<*I5BWG4/>-5X4->J2
MD)2/P(WG/CJN,"/36;!\QR;(,$;9DKPJ&E.X3.HU[!J^\\ZNVY>)=$8 5_@G
M,;3M6AJL_RLU3R'P2?30/U@VAS'KVFSZIC;2OVJ!P" +_ 7Z0+1@RRZ8K9")
M$]!0!I=WIM2^[PJ'+BWW5;$5W/XYI]P8W;E$. ,I-[75D\YH6)\!,W&,;2Z8
M['=<+)[[AF[LPZ6+"+OYC C#JZU$$0T-6\+62>+$(AZCNRZJAE+>)H;64'1<
MYA@RM%)P?[?>"K9\A4H->>2Z8"\X*!13SCY0 F1^J2KU_GV:5A5+B%]BWX+?
M1'=&W!QNR9ELB[QQ<4$+" J"9LA[T6 9TY0DCS%>4*V:)@P"<P/+Y;7Z7M'"
M[E'3W6@2;!A#L7EQ4\+;1*:#GF-0G0DR0A9^'<,14HPK:8MU_JNL'%F>T]X.
M,ZT_9L:(0KN#0B-J8/OA#"#C/[!A3[ODQ_J:H4.E;HD<2\X4JJ,#24IR;FKS
M.X,UP6X86PS_:W^M?X:[?-JKL,\LH('^W7JQ.$*ZWPZ5D23'S^/R)P$J?=RJ
MGKTQOR)\%5+Q24U0NR-#)2K4PQ2I(]#&YZANOF9$I'0R])E(MK$75"4N9[9W
MYJY%R[9%\2;-TTJE>E0.H5:(=V0(*\X5RSP"XFI$#^^:U9O@NL?/"DGH=ZPJ
M',>Q:4O35XP#ZQ8EZ*;=Y+,2G262T-3YW PCB$2PK^);$'AQG1COH8]20:'=
MT?7!6GK:-S0O]#>R66@(4('2SJ"8S_06.3AGO! [L=:(:773X7.[G96G9/[-
MH04]RX(D8BPFQJG:NUYC91'')13[@AM,Z492#Y:*EDAN6LY1Z.2@0D,"\J&?
MW]5.RDRQ@'-F03PN09?GO%%(2VN@@9M8-;8N*>-P#^__@CS[T,WJANE- &E<
MV6IB8-=IL485T" MBB-&!Z9Q5]8Q4X:XLP\=>6XD"5,,P'RB90B6,H1])GVU
M+CK!<&:X[Z*8QSQ+>-?QY-GXE^#@%WQV5/HDGH4&449"F*GI4K;:#23!KWG*
M+L?M2)8#-DL$21]5*LD[!Y.NZB)T6ZG6%\W&;_S)&5L:'I\7< 7)R5KE751H
M8+\Z0KU%(<HP]"@]$TB'.VV^GE7;,(FC17Y28ZP'@2_*4$SXD2V963E/LB>4
M-83<R5:+A:**&MV[XWHMFGF#++"X%[-9L5+6T1@3]!_)UK ?UO IM$<Y2LH;
MK_V0+2GI&@V2DS$-0R;@5J6=VFM<I;0X@P(L![LE,%1:*1K<=?$ [P?C@RT*
M\I)L_PV%9FP]LX]>(\_Z$UKF8.+3I8M^Y?Q;U&B/3OKS"$\C9HWT $25RTX$
MUE&(7=N^(3'G/Y"(H[,N'%DAFK.UA!J VE@G.^Y-M58FJ$;U#9CI\X3\C+^&
MD[<D2WE#*EKU6-DT!0@1^&/6=3,E#T7<%?JADS+!!\]?O'CHPF,WCB[Y2+IQ
M$L'3!N-6+K91;)QASEAR-A)V"P<!2D.<90J#=$0NK"<AIM*-[L)8FMCB! UR
MM&P'N8'C,)B0WI ^C."'-&&8,YK8RR*0!%DIOW>J/*\]^A[(U5]+3,2-P_(2
M"Y(V,#:0/"^VHP*@309>W%S-Y\X=]# N_BLU9:+0J8-.61LBO 5;#TF*S"V=
MJ O ?G6E#DLL0E?)8SU&0B*.8,6^*Z*&T?65:G01+?[US'L&-JO0[H-%LLNE
M?%#+,@HZ-Q(,0ZV:0)5\'X##[TW\<=#SDM3-)CHSL=-XZR%'8Z0?HLFVUD3M
MCD4[A*6*WR(3= A-R\KRP1PG<17QLN/%"':Q>>7A_!BK-L#W1BW'>IIK4$8R
MW/[\2/=$9/OVIRVTNO:%K;8QIQW4^P0E@?$#]V"MF.;5^AKS)UGD1B<[<0(<
M^QO\]7 W-WF-FMO99+/J=8&0I[SL2VG>&G(0:^6.:&?5"AK9C<:4FEW[C/ML
M:!-EX^H6GO2[OE85ENA*^6:MNFN3Q*T8X4A8F_TGZ>@X;-_"L3=Z?,>SK*>'
M+.L?,XH4]S")$-V+G&ML34O1.UP)93:H92P:7P0DBC'X])+/,G9JI366L]E8
MLY)H:? 3QTDC';:%N';<CGKTIB@VPPJ:0?BNJQ7Y:Y2"V55^TLC7=:S3XXN[
MLMU]>DK)F5@:=65/X8(X''(+4(*&Z>E!9Q)P6,ANV1B%F(/U0+/ZR9]C<#R,
M+<.?3O^,,2*KD8=7DR3UW"OG.IA:*'3$5. MTM)8:PYWX5RA[)3L[56WA$)V
MU*:L6:W>+/;91 <G?EX<9@\F*B\@$4Y'+5?)=]#'J.$FW89)6XO5=LH7HS0.
MX;15>S.;)FR/ZM>^FD7;HT/3K.3+P*NN])J9FC.-Q.(Y[K.NY[$,-D5IBS$,
M,^%+']*F;[:6Q<E.@W4L]HVAQ=+P0]/*JVE*KJ#U5Z@O=4R$.[OS)X$8XO]#
M#@B"&K)SB9LT.!\7OJ;-^-3?L\/NSIO'KYTCB5 "D+T#H+=5U?IRUM9)@F2L
M(Q<O[X173U]<9,ZSZ)8W>!=GN%P36*9.)+P*^663C>4D[$E4B_:5_5V([KF<
M>155W<"EB;&OZ$"E+M:ZH*W/6%*FD2)!J.^=98A!)6^U$IN:98 #98%O::"/
MO OL_&>KZ<5P+$]E5;!1T27#S$P5;<POI+]NV+:5G*WEJ5B3I-#NK>TL<\\K
M+2NOCH;5ZJ[^()J<DI.C9Y'.(_^QGI$S0$^PLW('L?A>;8L0TH@]&(N=(O^D
M;&.0-XOSJ*7H:U)CFK4<G=D\U+N8(<&(DTNM>Y!9/I[\'?%V+E-A_VRK?<%7
M[#1R/*&2@S0\&L/,HQ7C^@13DX">0V>UXQWF3'&C<:\%<@O5;!O90/=H^DQ4
M?;F"#J@3*V//;&6JJ*W2G;^F]0=1L"#"22.I&9P @47!X:VB%3/$SWSPR)2Z
M3P/9[R+$@'NN1(%XO9)G)GHDM8.:T'/O?FOQ?ZB]X%+^C MCQ@G,S9CHPM1M
M,682?G=@KOP-^_R#P'D^&+KJ\?'CQP?FREL!775+!>H#@)F&'E8\"$;M[=3,
MRF*/JAUF^6IP38R)R6.SB:.((6.8')_V/_[MRV___+^*5RAJ8BSF<D MOI^*
M[X#9=\#LNTGQ<44AQYOR!ID/Z:02XW)9K^82;DJBDD-S[J"U#EKKH+4.6NN/
M-=<6?1MM+$TS6B< HV!KCB'V 8#-PP*7K;M\GEP';7909@=E=E!F!V7VQR@S
M83=H->;<%%=U+-3:#"/-'V)MW2O%<4MC#(>@U5U5'+=4H#Y <80*^:+\5R]-
M>]S 5;'R.'AE!T/F8,C<)7UT2P7J([PR+LCG-E))O',^KT%-#I- "3"WI=)%
M2]&?#HKJH*@.BNJ@J/X8156& K[6( ;2JH-9>55*"VN#RG_NXJ'_HI#Q-Q!A
MW*'*'$F' A,$M22^\3YSY F^A%6:):S U:EY[=9AY@0N?YNG&=9C("^%&BJM
MW-1N'6O^=4!_*<G!'J8^=-*U!D"Y6]SB($A# 1HCUPB:,3J(Z.T%%[LHH/(J
MOVZU+-AJBP%UL"RG94!Y3CY_6+,JT)Q* 1#:[18 SF0*W_RJD+X0.CVE&5 G
M(GF.S9,K?/9-(*M2^6/N,HR 8!>'$NYZ8<1(7+E;YI=5+:1$=[L:_BS!3?)=
M0PU:UC8"A!]HFL?F0&J_A5]9.(6"*!H+I\!?*"86^H=BXV0"CRWM2]PL(]B.
M[M7NA=RJW+:Q=3_4GZ8<,*X:=>PKL76' ,L,-UNVR\*C]D@9IM2 :3GWR-?G
M;=A9Z?R@!#K"MBHTK#;U%9N\2:E$N5JMH%^R+K$^R?BVO6^Q>1CYTN/)&=23
M5M,!84O[I#+E0C7%A"I^O+^8C[]F7ER5,T6UP12]*:2A#=7!$1V7J]0'\)*Q
M7S6V&YM0& (O@']W^#4,C<%>'D"H61+6FU6]50!TW*LM\[PH"5B<W0ZJ=1KR
MW#6ZV;0SV ()7O)YC'.AW['SG:[K7@N+=0L8V-3NU-W\\;N4Y^&CYQ$B+0#=
M/!_,U!.Y^.E;FA89!'W9\R=/,W]FI'@2NT*F;XP@=K%8W]=X\EWTZ.0T6HQ5
M6])RUJLKTPK#Q=UY\4!>^9XHKT .VAVK'&S2DBS5J'P^"7P&_72IL-.10$8Z
M)ECYJ+8(\>U,D#N"Y6!=O/HP0R#*=SAQK=G"&&6+@KEB#04D)>M=C,Z>M1D]
M_^G)[GJ%WL;0H@]]*92[* E3O+FBR\M5>,< =WJCQ/79Z%KH1S]H'RH[@7$J
MRQ*B!S8E>"Z*-TD3![Y)^F0?%,>7Q]D.*['M/6$GM@VH= %0RJWL/P?S#GE#
M*^BP/O@A)!RSS"^GB8,H8!SWK@ORT>_1!7D'7(#W=J3^E\?QLF]:-//YCJ3/
MD_/YG=;1M3:"R($?$.@8/$?MBZKN0D=6IG!O.3 9OCP]>?#F830(,H%A=_<F
MJ&HO7YSI%7,&<KYB:.V\;</#U95AI1'&9Q1X1F8R;N7J]F?H%2CF8!3KC1[Z
M)YQ-Y]AA>*D<2Z+@7N7S"%7[(ZC7C]^CM_0#_(6/=0]&Q.<#A&6X6/>$R_%U
M;6UYN]*X5XS!RCC6O!C!",0<B'@%PHD8330'5<!N,&T?$G,^"X!Z[/I@S%S5
MX>D3=!O@W^)^Y.V ^35I[% DK!=TICWZ)IN<?OOU5P/KT<#6N+]G6W3.+%HF
M7$<P<VDKIMCOKP>;8Z^T\*G:P:I>-@4LF=-'.PQ!<\/Y&M 6Q#D'5#)(OOS>
MC&@"> 634A;H3TJH>L9I>M+N% '!$=B?ELD%9WEK[9Y#W)H4A<T981Z.(JPP
M&X#/*X=!MU_*XJSOOG@_19;O&776ML0[P-/9+7<9-'ZJ.YY)M'H%9E/7'\9<
M =(?F#8\Q17FWK "\$GH7IS?^1XZ06T.VRS@8XXHBFKK<'Z3'N1(L!#WJC1/
MIFLC<.,P A.*&P\Z:\>;G+EL/W9EQTY[0)P5N VEZO"N8I8ZYM)RO+-)'<H1
M]O@ ]<K+(%Q'+^ .%LE:V >B$AOV1$#G=FH.811W)WB?1.NL.8#'WRLH]VD.
MV2?CALW].&J?!ZZW--X1$,=!7+J((6F5@WWJT69E6LQRCH94!E.6=W&_U0GN
MY-Y35[W@R'R2#4,J/<UIWBDHD*T/'&9ZQSG_/'G^_+F>A'4M1Y0P'LRYYUJL
M AKVBWI>-)5U8#/?)ZF(TV^__3H2M")2$@&8F[H7@C"=!9Z?57V-W_##^'NE
MMSN96)<52$>O.8)TY)-Y7X0V55)EY@#LS&EFYCM?J1@7KQS?\M-(E47WG]F;
MW9N>.- A0\(PX/,;-P#/;MF&A<^Y?QM0?DF <UE#&, X]J'K)R%;^9AY?5T=
M#092+Z!:!Q+LG\%?8H^SF 4H5J,YJ'<IE5*+M03RE%O++&&Z%$5J(29GC278
M^F::!42W9%XXEL$( H,O2KY_!!LFH7?F&!0YXFK0*C T %_S@+;GQ"[!:8N@
MF([- K:"#P;O1<4TLL!DYAW+)^RB7^TTV/E,0&@K&&_9Q8W.XK-#/[RK1N*Q
M:YQ8FX:Q]!0L7365UH<->0.C%+*6&]VYDO;":=G"NK:S7L.I<7+#*,A-==R!
M^G>/]U?-=Y>&])QB<2N$R#VPTWZ&_V9Q#(=>K@QM:A6;:AG9UED",@;HVX$F
MY4C\VXW"L EWG^)$1^9:^!S &J ;@4N?#=!'PPK[*/@ W2?Q)NZV-<-R?#],
M%]8R[FN\+8OX/53UD'F"5[-B/$WO'@:4[*C#P5\9\-L]FA9;);M2!41%N+:B
M_AS\$.MJ4EX;04.*0,0Q.P?PBOWJ5^0]N/'[M+&?@(3@;5KWB<XSEAIV)VE^
MA1KO,F_V0X2940@;(4O;PF4_66S\>!B&:(=X97DUY P?>#3T@'9TOV,FX\;U
MX(T"[Z'1BLAEZ0&7$F)70Z,]<FBT8^2K9OR]US&HL\1#!Q?[*-9Z C3%UB^C
M@W68 I*0K@3?<A;X/I*,[E"J4G!Y.]AB'%A2*P4OK_P3WIS.%;" ^94V?%XX
M YE,,L>1L55Y@G<,DB"; Z+@8<""[_NO7B".+[9M5ZPGKT+."0K_ORY>!1PX
M9;R/R]EQXH@E3E>-!+.>]>S)6K0H5+7\4]\2-Q/_;9>!^.Y6BPBZRR_'%\<>
M^8;V/+<RWW'5_G,?H&$EJMAW@%)M&HYG2#X3 K5$+!_D/:I6&P0$RV9^Q+)-
M?E6^K?EW,]HP];JP\Q]2TAK(*3LGO3 H,(6*P-'R3D/TH\E[\1SS*:HN@I"Y
MMX_52?D0R4PVJF9RZ3FE: Y&T*M(/MD@3#Y/GJ5/6I8;-ET%VE4>>HV-3$?/
M; F:'&!KYUP<0/_( MX&/\95DN01?;]U2HD>I@'W]0[/3'*>83X*-I+I'6UG
MJI3CV'0RO&M"1$D!%4[QRAF72@JW0#^S$>L[8!-QY-@80HUHJJL/^$3WI&+Y
MT.IU:/6ZJ6*95:5JF\D9N6-'?RMG;Z8,D<W,F'WG@M!O"BG.6B%NH(596^[(
M: '9%G'I4KQ#HS(=!(^2:,L#R8#C.,FEU+"6:/ZT6.:KQ4, 4S(R'OUI)08B
M&TZ+'ECE-2G.LLLL5Y%Q9:NPFV]RH7(D:Z1GJS;RAPXXE#AX;ZF :S+4Z?_H
M$0TJAU*O9]/3@9!S;B%EE&?C:JYO3? >%_II8G@J*FL\&6B(J#[3\MLU6="1
M;4:7)CV$A77&2M1>8%ZE34_^7<Z/)R_HO*A!H0?#4\O8/K#&_(X7UCS^C84U
MAS:@0QO0H0WHT ;TH8?JRZ;NI%H8!]798L%M)+RQSUE/:^[KT<GI"?R*?"VG
MD(; 1-?+I7S[4\,])T>>>6K(ED]R:/R<R0/>\(6VEXC./SL_>Y@-RDH1M>-C
MH0I'#B.F-DJJQ&Q+>;GV4:X.\+:<1FDD1"2Q#?X;(D'YY*JL5TG._T9[PN7O
MA>%P)7R_< %[24IB#& KZQL)4%C5*]JGGN&><[ZJY4DXM*0?5/Q!Q1]4_*?R
MFT2'06OM. OC&FOB*>RT%Q#Z?].45QR>(6^&QE7%B)0\AX2W[5;%=%5?BZ/Q
MS[Z<=/D:/A/"84BEX=HUS4K'.>C081J:"A$VIU.A1_].(_S$""B31A]/3T37
M2]/W"!*#M[1OM:5C&G+[J".ID\,@GCJ93I5H>'5^0NY\[$! 5X+03>O?$1=;
M6]WH55W..8,R:QQ[_*Q 1F)23U?:"2%DY%O,S/:F\=$D?FZ X86Q-*,/AD^\
MU">;>*>LM5OCG,M'-OCW]9(IJRYSJ543ZC==$FF,X*#AX30[G&:'T^QPFOW1
MI]DS56O2NS%Y7EE6[R53IFH& >[,;%;W5?A5K.3[:O+@Q^<OS]3K@%IKQT^3
MXFTQZPT!G=-IW-8HAXC\"1S"LR6I>"'!M@31UD?"C/;3J-'C,3$X)%I-\\@;
MW!,TE7=0N0>5>U"Y!Y7[1ZI<:,JQ\$_0O[&\Z'4Q6U;<7"<UXD_)4JS76C=W
M;B4U>M_93%/2T@I=KA69."4O;*4A42W<:"(#EAV\1$RI;6Z!91K4XBW#T0 6
MK\QK5#0OT+N6=80FT8K!H<$LI01NK*YM.V3O WNSO] &V/93E*F0]X,"A.AZ
MK9FY"=4:=D'/54=%PQZ:5H-IG4V-HJ/+/F]BAH>],*9*:NDL:NS<@[RX=K#H
M1''9CA;60C6'>0I+>#AA#B?,X80YG#"?*D3U,M POI2 2SNYZ+GHJ9)T1*C0
M=D5(*1,JFLA%[8(\U2I6&5C#>-"E)%S3_ #%MPA(FNGFOI1 Q2JI;DMB9R&%
M;:TQY\MR-6^**A1 [CHHEA&'8D?M/U>5%V]GQ4;#8BB*K7JM1A>HD%I;V66$
M(8O^'__V^)L_QU%<6-[CP?F+BX=)U6^HZ TGW,8F-Q:PB0SH#'*+$#R:2%4+
M$X <'+ *3K=RUJ[R:SW$N<J5W["LVPW7.K:N$&W/8.KKBEZW+#<*8\98(#+M
M_+5H!5X6*PDW1L9<;S+P$J+) Z)%*[J>!B\I C']E>2#XXNGV>31R:-'6I @
MLXMQ.*O"A?K:>)BFTX+"!YI$>MBIM'9<H2-Y5FY*+4<4Y)KB+>V!4+8A%<J1
M9Y0;'-#L1E-;]<R/N.'S'Y7/J$T,1<CR5^T5H7OX;XPYA_XH81*%O,MU.=DC
M-$%=V>HGZ"]:D7[N2W9O-KM''H8G'*W+^35WTLI$\A4'@^!@$!P,@H-!\,<8
M!'F5DZ8BQVRDK'B\N-H</[N^*X_>6#X?=[O,ESPBEF.S);$5]VHE?*VN\'E8
MAJV/B)!BSJ4<*T$HUU-6J3C$F TY9F_8S1NI38^NH:78X,7B0)"OP_"1AC(L
M +)KNNAY*X2.M/H/ =/22PT(()@L]%4<,6VVOET#%-DKM$Q:=U13K(HK[CT9
M7&90(NM^=0EJ7XT5[":OY&R)Z[NJ^:3;_3849:86'EJ 81JE=L4J5[27C[!N
MQBOYH_.?2 4Z#><E#\=D,5*_*[.W+S0A6T5DBWMOD'?,V3#YN!4=^73M8B:!
MF5F/F]IYF#TK\L^,+'IL2TDS*Y;'AQ;D%HLNT)-W0P9($0*"I6QF_9H-"UC;
MZUQ8RQ5, MWRVI3%'5$RV7ROZ[7D&D=9BD7'\&Q:[T^SQI%WD2<-2'7+OE7Q
MF^7= !*EX$JF[KY#%;_4!1<1G/*ZAOPNFL($S&N@ H+'H+>,(0.BE>CG=55.
M:9*_[^>71;>GJ.OTVV]/Q)UB_"*N:ZZZ])':YW)V+GWOH>5$\AK<<!Y<+/9^
MM"E88%&:,"++^EST4-<7LV7!27?[\P_:AAV\H!34(?-8/.X(\43J_-SCR8NT
MGQ'[-G.HQ@XLF;T+B3MBGJ$PC&![M?5]CJ;^XO[CXK)^78 !UY?@]=4B+Z59
MSAKB>;@C0"\)?!1#32]S$HL9H%?E59_OUK*'R1>LC="'&2=GAUP^.6?CZ10[
M\;BXG(ZQ-T6Q$6AL>E'5RNQU=<-%!(D2&0A'K&QG4"TIL6!GVPD"+\('?^(Q
MN]ORL=@+C(?IHP8S=M>/2!V+*T2'QNQ-?BG19S? B'N*/?&R+EN:[Y<R5)[Z
ME^$^WA'.Z54I<6^T-3?"]_?N/KP#NH@;PTAT5WU3#.T./0<$G0J;#\T+H4\Q
MF>\ ^;DHFS4.O$U-[BK/G[1SI/=*/='QY,D0AG1P&+FA#05AWTAFP/7@&M+A
M*86ZI2Q"XTL[<=0WPL H=35^S\SS->T&'HUPSM(6OJP;,2\S )^S<,E/H9A'
MCDQIRR@WX<1UQ;&+'CMHM_6B'>F]X+':"9!A^UW*T4Z/:UD:=-./!$>R)$<1
M/H:N[3M#<.4=RA^&R5@"JJ->E*I*M'6S$*I=3$V@(<@B_ML"2\Q=QEED=EHX
M,Z:K.Q$$S I">)% +ERHH!)5*=>FQ.0[M'(B5X&^!= U7,5%4HAL/[ D@<72
MR@ED<Y&LL%N5\/=[!P/[Q>\! WN[&ZIWG=5/,0J<.+3E:3:.."7(ZHA/U& M
M>)<$ZN**M_*[P4SO0-MW5.A@ 0"N-6L5LBKFO9L"BZ+#4$P %8".NS6E8QM^
MQOB)C%_)RI&]%J:IZ+5Y7N8Z$$PDH'?6<RS7($5K1E!=.3/AQ[R;+8_^D;^E
M26*30'JFA[]5?J@V65*U9?T;Z%?]!B8DGRH"+Y*+WT-OCH 2_IY5S7@0,&##
M9RN:T-JZZ!V_A!Q\*=KDRW&ARR;+^KI LYX"%6$&+":P5I@?&WENPYH6VQH(
MZ:JYR6WX0C\F8(KJ2$,H(JPC+Y9,XKZM0'-9U@#NCH@@)%I'W)!IDL-56-UU
MH4P(,3D *%,!4F;T;B/#:=L^_BTNBC:9 D:SY$A2QW,Q@AGC'OL33?5FQ9 "
M8R/9?\]O&HK?!5*R''%6,LTXQ4X;6_XPCTW!3:9PM\'4PJ-6B8J(M!&!A*TK
ML>&+MXQNVQ9 JYN3LW@IB*H_5[(F)A'._@HX,(*LCI %PSGYS8<U"YO-?>2J
M3+"E_56P^J>% Z4E^ZINK)ZZ>+LIQ_:=B-HO%R]?_YP)8F_%-J!<F8+9RK2U
M#N2M:$<'AO;C4;T!JR-(,MP\Q,N@M#(&8X@ARD5Z,<P8]U#^<QW!,GB^KROA
MEA"7+"BO5GT^NWU5+@K;HP #4K@--T4L?]DNV#]'PF8\M:NBNJ2I&07]]\&U
MA93 !$!_BPXLRI6&KI+P(NV#.^\9O1!02']".VXFSZMQ?F;PZS3AQ2K?#C5$
M0@4EF]LB?1YFR5#WSL]B5UV.$^2(E:[M<[J;0](J!..V! N\+M$O%<X_;H^3
M2*2L6]-V3A/0KR]U..X4ACX3&"/&%^5Z68@'"K>VQY.SL.M'+S .!P^![1"X
M(XT].YH0,WX('LE6N)U*2Z7-$'*KR;HNR0L/"$.R<]?UJI@AKD1:%5%ET$TD
MBDA\SH#TQ*]1W%+6=$_Z@ .9+#GF/,7HY>_(9U#%LK>AA5D93J?\ ^+9X5.\
M4GEP1C/Z4-'VOSSY\L'TX8-'#S'-4=U!><M\&.66K %.R7(V@<LG7R*T0OR:
M:[J^&.CW@ !+&H7?":(NQ66<-/ : <8//%1!=54\:@%5"UCE"X?C=SSYT8R)
M 0Y8Y/<R-/&%(/F3=A.K04 B=7'!220I[-E0,Y*>(0-]7@I>,XM[62UX@:0I
M9UAAQR<4D#Z;(NA*SKCKT,-ZEX%0*=@K9R:%P)0-L2>\X;5C17H:@<8=%&L[
MV?33(5R[Z0/7&LN8[ HRM]BS966-?^(#*I4,SDRQ[QK[D2JZL02.%BZ@6<7N
M,^V=T+,POG47 $^G9:UA6RFN5ZZ=3)$X682T34A.("5MB1FA*%P<E9@7-*BY
MP];3-JT=GJW4KBE2LP9H:V]SKB3-\"6.*H_QP5H.6& T78/SJE7U%&:!%U=!
M;#'7HB_][*+8HQ5J/AQU=26Q4SQ+F+BT$M1AW]\PK0++9!LL=+[9/$CO,KX:
M,49:)XF0H+AIJ-]JVHP2DE)6H4M8-,^"ZA?3:?3+4+7"8]AW]*0XMHQH(N?S
MR#:N.MN]V@RG%T=TU)35"9+"[U#HJ?P&K6+6FL/S,Z:G#\;U2P!P/83>?GR_
M1IV,P,4&4@$ZL-J"*4KN,HS<TYZ9%VD5?ZG,S/[E;Z+PO/]XQ^TQETF1?&JL
M-1^S=,0(9U]"95,,5)+>MG3,>>K)^M"T)# ZH2 +V5;T)#72Y>K<$0'HF8EN
M]BBE)ML^ 1VV@#CW&!37QX=G'T_.U2Z,KZO[KC6L440[]!1O2UJ%O E(L#X1
MW>ZH@06P%]S8MNG1C:K \HV\ACWJ&[]RV7,\9/BM 69.U(T-C)=2>W_UL[:B
M/>2?YA7"65430AE&6.736G1%8SYOWB4:2)?6QX^,F<AE!"2Z&SJF36LMAFHE
M"ROC<F&;)%FK=2&8ARO6/Y=,[L=.W@U?YTE-!**0K$J6=Y_ 8S3^,!Y/AZ>(
MF<?W1C]!,06CV>&LWW$%]3)-<\:<K>B>H99.(74=::RXEFSZ-\52D[4KKD[1
MOQ=5/G,U.N&YY[1)=;L/7XG,$0R,8. ^(6D48^-!_.>CDY/3S[]Y_/G3\X>^
M=>@8E<P2H'/YW:0D !:O<2YC<!$6=O* 'CCYJ3Z>?/WHJ\_I)5^HL>8_BWZ<
MEB%*P1;#"]0%1\]5Z1@U.3DCNX=WH']&W.D&K!E",[_\S4#X:7+"/4"D?3ML
MX(1V6\N<"4AY*,# +S@0?/KM5]\$W?4C[H@7N$]_='+ZZ,:]>P<D^_6N^+8"
M_0NGQ>/!P[\)TI;@E,JT"KTN2KH,?1L\'.UWHIU%T$R^9L4< 35X<,6>/]HJ
MK'MD.+FPX;(J(\&%7A53_/-Z70!=N;+\IPQ!SH[1MT1GSAS*RR:7PY"/XNIR
M5?CZPV1*# X0+JU,&8WCT=?#.4WEW8T7>_GIF3<*%I/G,Q+9:IY-_EX6LR4'
M)KNB%.OOI[JYSK<W?4W9NA8VP#R;W4'OOJSM'7N(/I/<J2QKY#V-GHT$A=2E
M":$6\^Z<;QX9<GT-7-D60@X6WS7C!Y#'<O;\R06GJ_-I89U[54&3.2_4R.<W
MDGY@TU\J%NMFLXR;VGU*+)8?$5M7P,AU33P$7^)G>I[-'):>,X^9OD@K4A.)
M +T'FUQ1R>R&O=7V>LKTC#0?,8 /14^7%+&Q)-7M_&M12;_0;GMP_N.+EP_3
M-,LP/J9&423;+>&],W97V]K*Y)$:^IZEQK\\,*3^X0=*JLZQ 6_0WVID).DG
M.<Y_K:W&E818J[N,_#O=S3 VN4J7:7^G.2=68@DNV1,;*5?S[X?4[]O%TVT2
M>$S4MRC?/4=6VJ"FP56)OPB(SS7X"@(Q5>Y=1IY-KK&_\?"0:+ A .%6B\ K
MAJVO0HAD!A6"\3<\6ADOU:PRTB@[AW<R:/NF+B&=)$^6,W55(7D!KMI2RR#Y
MJ$QF&S[TFL:! X']Y\K.R,":9:$G?_^Q46*=292N0+FR.>3V#<$BV#-RD4.<
M_3$+%E\H'7'F9])9Q9F\$<&X2=1Y<MCZ[\FBIM.9EI(#:SORG+!BAT7=+ZUE
MA?E+%E-YLR5H&VB:$,A+KG,19#%FJDC_Q@RIFDX*K@$=A21&[YK+,(V<\;A)
MZ/[4QF=9>&9K\&8@_7;LH"-2"&JQW1F?6MIIL$ O]@PWH43AM\/G2<[L.5RI
M54#_VO<54BB,C'KXGIA23,W2R0/-HWE=(G]1ZJLH+0_?BQ/Y#IQ42.;_33[0
MPD&Y=HK:MGWZB] +//V%RU.UD"5I,28Y)5N8U[B:/&]@+V/_@8@"=)V]/1 $
MBGL67KP#I[++Z%/^P+;KY'M:039:'SPE3P!6^<6L[E;2QCF?_(/+T<%C-AP.
M3#L?UTS6WRDFV6\XOI3?PDQU')^M<80_.'TX=&M(@(Y9_7%GH/Q7;+R*=#XL
MY1#NDB-RAK!=U$</GO_][.7#;._0.$@O/K<PSSP]GSPI9DB4LTUJ3WEZ_L2>
M\N+5YT_.V><N(XDQ+M):^J*3SE@="H)KPYE[:(;]A!-EZ#T>_6[&D^*'G".3
MU97].CE9S0+W:WK&W56TT?)L<IY7^9S^_X(^,-_4,D0N7[^X+KM_%0V/) R$
M[Z</1DSGYV8JIR.@HV!CPWF)SD[[,.'E&!P"2.M(X899*:&\(EXEY]]=CR^<
MT:?:63 ;BS3M/XP3^DEF+%T7PRWYP_</]S^ IO8T=)IS9SBO"1 QNZ FS!I!
MEU.,.N\_:GFU?_A^\D!]\51LV;&=]2V?6OFTOM+@QM,GK\Y?[MJ%^S_<TM;Q
MU!@U-8_I.)4+O*VFDOZG-B8^=&/^^$KYT6BT6Q.\N>UF4[PC(4>]-$TVWJ14
M-<PY:A]++CS6NW37M:\[3)$!3L5$,H9(46.[M5R\(GO&$CQW[62@PQQE$JR%
M) S2:>K=_ECI@MDQ3],V(9E;%3G905],KL$)JN3PNZF8?45P\LQ]$^:)X;TR
MASWY[GL&1.\HS8#9N GT89NZ+7$@U)NR"CT,"#G\^.+E7=<R/$\U N[XQ(5%
M5RR^FT;<BX1N5Z$ /P>I*'HC5H43\1W;_+*64$ICJF3?[D08W+U+"^Q:3GQ=
MRS/R0,0=S'[?U5(L^!_6\HG\=S8,ED^XY+B5(C[P%(O,";DQG7!:5D/KWQT%
M49+3B5?>9H@F*]3-< EA ]-38U'#D%(217=N>/K8]PQ$:;H(X<'W/Q\&)(:5
M!E\1U **ER.4%Z!B*_ DVP$"A+\\'!;=[%4CST/O9M5* [*<VY[&);1&:KZH
MOBHO2>.S'?2*U^,LQMQBH$^UJU'8+US@4/]D!@U73[ Z#"42CD8FE/^-*7!'
M-!^MHK#<>SX9I6PEM&9LY4F:=H(*D2>H^_N>ZDI3W#IJU#J-I/I)?7.<?,R,
M:D/B=7 D!"=]O>8)Y(BN=",J&^'DP?GK)P]#E:&@P(REU>G8D2KJ<;[.A&<3
MJV.TAFDQ@&0QN- M8;M,,]3^'3:1'"V)3+<QD-6W,44HFTU+?Q.]-A(ET[V>
M:#Q4$\>0F7Y"%G1/%A0/TN0#M6*[P5>Y8DBR$R5<I1$&K3PLNU"E/>R#?G[^
MXQ'OG+K"UO^!.>%? H&'^X=1CH<.-AAAYR\S,$:"+YBO)-.*Z["A!O4FLA#_
M_O*A'U:ZA6UP5M'!@1WKIMW5O;[E34HUVIZO CT2-Q&S#D'>@#'6[_J9NB=4
M$K-DY,-KICO-:K#%E%@Q9TF2=3Q3S:+)PV)02668#ZD\0%IA>W:<V&KF;5+A
ML2NIH5C9*+ZE5",D?)#_[B:/3]F9E;@#&9LGDP>#X"%&5/J&EOCM[K0DB0ZJ
M\.DO#S$K#>N.JI@/)V+H,V"(9=6K=D97@00],G<0N!("R'[B!7&RO7Q32&1J
MRJ7^-(=\B'+.QI<\TG.1G>(>*R[)N>L2^OJZ-G@#5PRG6W/*[3PE+[_TS8BV
M7_28?L4!2P],5RBV(,>^N*Z;-Y*Y9@X&0>.*=0!1=.U!NX=^N$;+AV]\#-IZ
MBR0QJ37%NXH<J QSJ4DM&\/+D\N'25FA2@9BS0[C+^G/:-F$R;*:?T=_4(<T
M\"[RBYQ<P<X>QCX?%,>7Q]GD[*>+%P]C/G^/E;"L5^PZ2E047C\+*UD;3>10
M;AUH@A:5+6QF,W_>;"6FAFQ"9%F=)[8[EXO07I#:4>DB7O*FHGU")ZP1%JY)
M/O1TNV&5W1+>]'68-#[C.E4F\709K<#A8N2"$2F0P!%;3H_\4@S](P=GSNX+
MMV_P I*,'P7Q'M@;<A8[PX9_P68 O!#L'N;$D/GB G)%T(,(X?#7&ET[V'%O
MH.364WJS,UL/=FN'0NG03O'_N$>PLQ\>)EHVP>5P5O!SCV><C.(7C.++1R>?
M<TD/EV4*MI(8<3 EV$);OV<)@"YS=E-.H#2$8W6^V-!MZV2\3PH6/EZ D<$^
M_O)K'NP7V)GLVZ5#"-:+63;:E&MV;ME9DT/(]R"C:)?KOK*"3$;9>/<[!C=I
MIE*396D=%LZ@'.L,I16>I2?OKML-."]%2M:D,L>R[EFUPE?_>]4*A]J$OT X
M6^ER1+N(A,K&!2ZH04N>PB&.O5@(<L(B=?7?6MDDYFK0N&LZDNJY((>ISI=:
MN3VOEO@IK?GJ"(V@KJ/%*JQ$*5O+7=P_A>M?6J-A ]:06(9\=8NL?(@Q,<#2
M]PUL6$E+E&W3;\3!%<)OZ]YJBB/LNA%ML^O*-CD=MSV,!*W:[E<H]*CIVX+;
MMGLZA$R-ZYF5Y-\P8D#&;(+6XT^ T/[R;N,MM-B(Z4WO28WK3C(&9>?-;(O;
MT3!Q?T#*EW(."\33*4_SLB9QEE@1^\XTD\%8B09^,OH]65ZGV0"N^K'@$8/M
M==-._!VWWOF@S6=_Y70L-)9MX ):/5<&3P8US71J/SV?/ @O>"TO"%<]M#!:
M6*4@TS^<OW0E'7M:!]ZG[%4C#/N&,.C=D,8[;70;UF'N:@.?ECI_?9:YC@Z%
M2!AOD@D^Z8VE"8ATWU05E-0G#G>Z%9B$SL+=O"=/% U;JB E6+V-H;6DF\.\
M:X? QCJR$4 A1:&*):/)O=ZZX "/P6H$3&_10+#;RJINK#6M7P%2S K/[-8I
MZYV\K96N898S8'&GA;?\.6F+C11XYC/#A=16W_=8W3EC:5DT7PM=P)[J3'/E
M!)^ZL-_.7I!80B-!=TQ/6'8!^%KL5*T8!)2XQ"[:Z>LL#$-TR$XX%F?F?_:5
MS0J3RWY^/OGFT><GI^R1#&2'K44<PM/8A&3)*T["=4N&D(EQ<CZ/+[GG#T'I
MV!/TGGIR'(,7MM*M4I1GB7[8F;2 (;FH@8<5X.-#6-POE.@-*=BFA?EGS^LV
M;_+SUU8>0_($,YFO,1]A'LL1!J"BLO#R %UL4B&IWIM<H']@@(^8REU$9\V'
ML?10A<$$,TW4U>_<22UVH*M3NY!Y'*UV'RL(YZD=CY.,,Y'QZ1&"SVDRP,6?
MN3[;U?LG.FLCBV<^D6$0J@JX=Z)- G&V:4AKL>.:>:^6C#EVP!]_)3[MSF$>
M+WV(HL1\7F\TXDS3M<IG8F'M/8#'SV<W@#+%O6SAZR^TGURQ5^(!,MB4@T27
M((K&0+5V! H6Q3.6[$HB<YD6HEAH)4<7?+Y>@=!AO';HJLQ#5\I1@3[$35V"
M>71XBF/[2.S;XC,R#[N&T-CDN=F16B4E>*H8@"_<B3;RA4(&)MFOX?,\*Y6H
M"$[$/;]X&.)Q."_E76*CD/*P-%T\(4@-712T^B%L+Q^E74MEZSP'SH97LJ*7
M-5E,5[!F?,S_5&Y.P !D44=F+RP4^R,2W@^=>B_.!)EHI5FHTD,3C9V5.^'G
MD5IO&5PH; B'. _7"Z\262"OU78#6759=UD(G6Y+8Z8#R/Q3$".,LBP&$X,M
M<*XQ('&@EU93&7;G"!9VNDLX7=9S>C>TR3+W_,AM9IA+DVX+<XT#1@Q8/5BR
M6=XT?'KQEXW[%W$!F?<#\!X<!;"ZK#N?$%D.FR"M12U70AVV<,<],:G(U7]%
M3WG8;Y1NZH=.#%MVQ[ZP_1J2>>W-FGDWU9?XPES9R2"DO)TSK;@8H"%[KACM
M(E\A0%(G\C/BV-T0;%C10N_+H4DIU:!2ZPQ.@<G7&)3&CBWGJE+3FIX=TS<8
MNWN#'#?9C/$SS4_Q4?KX5U3267,[-%0L1>1][F;)D!=C+":U[P"N]\XNQH<*
M8<+G5\0N2@#YT3+#951NQ'7END7(8:A%&FA%P(0=\18&R]TN@71BE?V.I4<^
M-IV5I.98+PW8O<\O7IV__LF(!1#4L[>)@!]?UE<[E7R<,)=6:A<-^%TL7W'"
M5<.V@ZSS:Q@94FX_TBJ17S*4OV!"1A!$'BLM%*TL74)&+$-S^I9&WST912A@
MR;CV=P[VL3_!!ZAIY5_N/(3<11J-=%BE@/X[2B Z+P+&$^?,7L;HQGG R.*2
M]HN7YZ11F:I$*A0JATJ(TBU]@0#QT%S*Z08=/80D)?>'GN:85"P,LMD#9<!1
MIL6B+<0H6-5MZS"[7$!FW@?5*@B#6X.Q&*EJ:H?Y6G/\ @1)]%!=^GVW?>T.
M0V2<,W"!0>ZG,"-W&P_X0LAY!*PWK+!K;D ## ."9Q&<TJJMQ4K8O1/!(.$*
MA&F]2\=C.M@!>RL#2L18A[?0S.3T,ZX_+0*BI4B0V>OF,J^LN,E:B,JT$+>O
M-,X"_SRPVNP,3\8^OMC2B.3!$6/9[//Q *X'3]/R/\[<:\E^J[6(Z6OXIDJ
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M4,KIE\>G_XXB*SVJ_%C4W7QP]@)8B/7DT6.]^DS[W3B<%,#3]=7T13./[:!
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M<=.VO;[0'L;@"DNIWET5:WB?/Q<-\DC^C^P_$U8FK$Q8^3EAY>\_SS*L%_-
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M@U,"I;=@8L9B/: %,Y9;N41"FG-9& EI$M*<"FFTOC"0L^A1,T?\'AL:+C6
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MWG<8"QDWL<:YNG?\18U=]$RAZR0"A*Y[,35&](\H<B*<6_ERZUNJE#S+=9B
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MLB 9!PY^#U[W(YDM9SWI"442BIRN*J*%!V#);.F=0XUKC+T4B">LTBEI%P[
M)"PYXZE/6)*PY%18$B2Q TYLS!^H1EC=>MGEB"=[0>DT,6*?];I(0). YE1
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M2*@$I/'PS%?^%SK:TR )A3^H%@C3[/!!AQ6HKO1:&PV0:.'.M[S<WH!7QYL
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M.P7;K!DTGM 7^YK>UA3<E[R!S6991#-[_C:SU.PIG9W\9H[TD+:T:=T@9"_
M(/@N;)5=O+*7C]>A(B[L\"H<U7SRM2)4X) 5!.1-<^4U0C'$-%E[7_CZ D9.
M"C?H<+1@K76V9ES3/^(P[[=@7L,_MP<P)8M*JJTJF+?MES @-/D8ZH)-B2V]
MOM/WY_\=<-B^P"#,W]$>EO=0Y4-Z/S=\;_CGK_EZSP&>4$_,9%^\>?W\RQP5
MP6X+ZY44*EXQ\XN;]R68[MQA"C;9^WHW@IO?-49FH NT-\,]&VYG/N/"(>3^
M79BVH2N[AAZEV+&T G[92RO^\.*9C@E^\!*FOAY&\3+DY?[:%7V5??'R]5^_
M=!XIB<\A+S!Z(F[_$]8Z>UEV T47X9_X3?_^V9-GU]EE@^[/^MH"N%V[Z33Z
MY,)4"SW1CM.=SBA,UQAUDX['-;PK%3DU&&D+#W_V?1>]4O0HJ(QGUFGM%I*[
MQY'@"_*T,AEJ%OJ"GHU^$KW3'[$Y M_OP1B"C0\+K"7 7!VB< <81$BY,M'6
M],>6*^_V#/Q'O&C\'P!'$ZE8P@D)C[4B#R@>W&E<@+PZN@0<#FZ>Z231KT2#
M-MXS<.1UKMA1[GF5V!$6-^LI U85SM$JMX# <F]_=KGW0$37&%CL:$]>R?%@
MC6U@]BS&1L#]XT 5;/ZF07("I/>;=.DO%(<QRM3<>L285&*7(PNZXJ7VDRVR
MM!V\TTQ0':QT?:,=D@<04X/T?[/F;SS1;*4H2:^\/_,VZ$.X)2QNM%P(7W33
M%S?B[T>_$;S'EVF)6_$ZBVVM01D?R-7FFPIG0G!(6H^*,A)N^<R"13ANL+JS
M+C0AX-E_#2-+,A2F9KG1)4'8I?'&94+GH',0--Y/;ZTT.+S4P'[4L(03N]B#
ML7/Y$<(URVH^'FZ+B:\5L/U(OH9X-1G99^Q"$JNCP*)C!CEH^(DH/!W4= O:
M(G"):"UC]XIVKN CZ)<0CAVQ=IBV"B*!89IJC*."\+)J<XFJTBQ^U S=!MDJ
M>I15C75H\P<3^Y&F:@9F!6,/5:;.3\QE:6,E+R$1\7MJ5 NF\5@K)$@4+U[T
M-+5\NL"N(\IOK*YO@P D^+H-EK>2R'T N.$* :\%=[\/_S$^@=F/44\99;^=
M5C5\L=RV7=-MT#"H1C"]#_R@, PB*6ZWW2U;B'HI') =<A'!=4(*EI!0A&E5
M5DB<L>[&EO.6\Y-#A;-PV3NB$]T@P;+P<L9T,(27J#K.^*GZ5J#)&\P86=<^
M7[48QHP3:4?#RFQ%;>M5O9 145BO:1NA(2UQ5YPM6"&3<V,2APW>6$/&6J&S
M3-)U;\ T4/&%P;N3'TR&QRZ.1NA&3<R5(_1$SN1KF(B'2%3DK)B)3SLS149
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M,,-%=E&^X/AK6,)^'N5%ORR[A\2:/?4UV8306"!GLP*/1@O1V!/3WL1%[?/
M^?%,V(^57+C<Z-9+M)7J'7HO>QADH]%0-.M:W":^9F4I\J1]1!BK'*DL&(9G
M7#6UW4I0$U,G")+X_S1G+$("%C&57KOZ'KS-RE"4K;@!)Q4]2-D*?=SJ @<A
M;T#8(4YJ+M2A"]H=?-I7X^O1"4J58:UPO%]XB.N'Z7"[5"!-2-F0SG;9=%1J
MY28XYVK^>D=1:ED$=TYZ+N%Z%D#17\<_<;[0%+&\+ZB%6WJ!<>\C92[07$1K
MD?GT:S6CVBNW4NCV\W@I%]GRP2&<,*Y25>H)['1]R0+UU4N%2!R (]B;K>@_
M^!(O.O[QY8,3BFT)=Z1PT5K7ZYD0)?=EDK@&C2L>\?GWV"U#JU3Y4'W:UI^*
M\![KF@)>!3MAM "H(I5.6@%4E75HPD((_UM_.WSV224C#\35N,^PAV)DJX@R
M%&16[%!5 @[;<;<7>PG/_IT:3S#UI2OAF8V\I5%27%6Y!)5[SZ6TUL6WR7.5
MAKF*NV=XOKL]#M[8"HD^]RC2W6"8^%_R\/C4LMUC>X$&3Y9_1&=+'7PT-RQ5
M3X54M- EAA<W*[)M+]$J<F,#;R!X]Z[G4ZIRDCMX>6KI7Q]XA\F%L2JU-&$V
MBY:;2$>8UH\(62S1VU:PR\(]35/6&\R)?@"FQH4T,7I*G"Q(8_KW=NFMV<%R
M:\+TH9P<^-3QW(2O8+>$[&"(X@Y4ZU>R=Q+EF#P:Q?X4*B9U7_'V4S *ER)%
M;G03FK;:8QFX1<-]Z]A:8$VY3_ &4TP\=FZR%:,B+#$0$9#5]IWD%0*U%:W4
MU(NJ'2AQ%3<#_JQU-<V>W%1KE\6VO_<PQO@7&^=Z@JJ[&QT!M ;]T)</$:$Z
MFLH.USR?7:(]$]UR=< &)A@<^ \ZKV! S5!3UWE<!CDU"FXZA"9U[7F%UJ4O
M;.)^  I67KAU$*UY/K?Q-U+2B'/:45]XMV M@#-;]%+DLG2J3<YX.)_!IY;Z
M/'!AN&A-&NMHG7D9)?!V1PX1^Z,\>++K[/]THXO%^D1GL<&J8%$,YIWDBJ#I
M_I1*%X,ODM4BRQXF&4^"< BHJY'3XE([YQ><F*'M83IH_I[X4)A5T2'#!PT.
MW95K#@DC2\)C1ZN>CRU:I)4I:RNGIS\P<H([S FS'SD3##LR2_,HDQ1CZ>8#
MN%K/P'EJ"TY.PO 49,8 WO+H;#&!J#^[J/6>YR\,9"TGA3#:8H/9Y6)#?VJ"
M;5)ND:5Y(ILS]=M@FO*)6C1LK3RJIR6/[IY"9(0JO%T8#']8><YG+JRG9\%Q
MG4/USCFC0XRUO"[)JG41(JDH78Z(DHG(Y+/>FL#>8P1WO)"TV[I@B?3<3HL-
MCXJK73BJ_QUU8(+H5C[C*;B_:;J8S"35L%/?(#D)O_^D3ORC_=C;L6B=2?3?
M7=^U79W]'0YJ\%FR9X@6K'*G'Z$*6]U:L:!@L#GC+15G4U3PCXJ& Q8QVJSA
MBW-Y)H(NN4*%]\7@:.DJ4@,5Q7M?;GG' WKXDTX;NAT#*P(JFN+651?D>L6?
M#6"Q<5U!KPV?T92\W +TY-F/&#3^WQT*EOU4@"U,;_FVJ&^)2K#*(P=7WB$L
M7LNYM*Z!$[CSU3!RZJX[J=";RB&&PRCGM0_BD7\BU3(92NSIP+CW6*@;7Y#[
MB.*AWHOG4,/"124FN A(#P4+5]^!"_%&LLHW=="O[[Y!XG!S7,E^6:R-EO-S
M^M#SLO" $B(NI.VT\((]R <66T0G6"Y)!JU1Q?'$@[I"#A,F'J#8]$)];OCJ
MEWMX,=U2T/= ^6VKSCI5S-<^1!@X33"__ZDUQ:95(H2P 646+,/E%4P*;,1=
M;5T,(!#V\LQ\2R5>I7J]RD3D$^3@+U_V,?:+#_&LD!6#":>X-)T-5G56%YFC
MCV2^EDBL&JQPE2(\FE5L*O<9 "\E J;PAB0^PV8)W\^B?;*>FHH9LJ30/T0C
M[5LJ ED2:?;\F'I,S0)&>B6(1:&'P0ED7<<#6O>;!62\SE[%YK2,S7P0!-("
MGJHX)B22*,$S47R$,@0Z= ME@5*2HB56!*C@I,$QWF,";#>VW;9&-WQK8/-@
M\\(7+W]\_B7&'0MI9-@!9%&DZF^O*<MJ,%CS?B\-Q5F#%[>A>G=\$_C5QF#Z
M [TK=O!P(+G#?W8#^HB4%L0; \MKA;P/,+8,M+[18\0 P[]]3Y8V<,Y*_\(,
MJ]2%:4"&O6A\*+C(L<8?O #?C!.\\!2KNB,LZ:^JOJ;&"MSP/L G<*86 :K/
MH,\N+?'49X<^]#2T[<1\%UJWZ1VX*&@AF^Z7E&[<>^KWR,]#$ 2_CP(__ ('
M+;N6D2&O%XMWS1 !LK"JO</C?L <.#/ZD/'@?$'8C3RYI O$"P4)+%Z'"P@>
MUR\0"A@MEOR-Q! AL]V6U'*C'C;FNRD_N5&!:AVAR;103ATNY4MIC[9U\4Y;
M:'5Q0Q!&/-9='W)2?%8E5-^E$JK?\SF^]Q _L8"6\L0,;@NK\QY0%$ ,;!X]
M>K"D<EX1@;48-B*KPQS+0)"U7C-_)#A=?4'JV1RKB^6=">">O_KOER^NGGR'
M9:\5'#GEPID5%10K@AYIN)7GHG/DS"JD,(5V9H\43A$<^OL]S[PN @]Y$2T$
M>[24Q]1S:F$:HSAX9-9,K$\DJYW6[\DTKJE5P/5W<YJCT1-Z/_9[XM.0:CY:
MC(5O$>L+)*:@,.#V8%EAOJ9U14W2.VX+9=< _6OBTX C:FTJKEE'?$,PWZ!3
MW3I"SVDS.9S96*@M16K\.O-N7WFEH+?;CQ7GYZ4(478(?LNE\V;C&Y4+XS="
M63P XJH;!^NK!(ZVIVN9^++?]'F4.RW8[X)VCE.O7L_R673^'T-+,BE$)#6L
M$J@F3KRV'%#0*VB*5%!=JL<N/&\1<DUVTDSH\P_PX/<9=P2@V'$H_L5"?+&;
MO;*N9WVQ1<_'W=#WWV!X_TB7S72<5YH(F!?<_ED662*J3T3UB:C^\R6J=^7@
MXO(?+0A/:CQG-<4),Q)FG PSL(M4\D%4!2K1,#:XHBZ(A!IG-<D)-1)JG HU
MI-"-<RU1&R%6P6D_%?/NJZ.6D.52%D)"EH0LIT(65^1-81B1@= 4GJ>9J)F]
M_%\C@@@GIBNS)OI@5P3-7:H)6\YJ*21L2=AR,FPQO309,3,E&BZ237>=3_-2
M<[97A-,\8<D937W"DH0EI\(23L? S5QN)TPNN7R/(5HFS4MI5ZWCO"4Z+"Q$
MN@-_9D3N5,@D_3Y2_N[ZCAQ9:T3KVQXXS:S\%JX1<F6\MW87I;TJ)JO/%E!^
MA:DWJ2B(BN@39I[5$D^8F3#S?# 324]@QU+_+!8?E[W0W]6^%H20QA6!6JZJ
M)LPQ4J<ZK>R-4OAA:?%B75<"J+-:3PF@$D"=.OA$C6P]49UAJ73)YAF7NC%\
M)<@XHQE.D)$@XU20,002R*0'W6+!7]"Y(+QMR$7!]:G4"<KZBLI2E/#DK*8_
MX4G"DY.9('WWOG9ZS%&>?=;S&)3R*QL'\M'X(!2@"EXF(<NY+(2$+ E93FFI
M>"JV1;G%987%0#O/)=^MJKH(\1MWE^9(N,;Z32@ HHW6!2Y?%KI@K0:]><YW
M(-F?L;]!\&*BLP9UB?J=U_.="3$]!-$NM*D&^]CK=M[)?J3+/XJ3+36LW$X(
MX\+F>D\:P3WPU-LO!!JJ@1BR]LV:G )]PZ";4B[[("U3I9&NHO:>LK/#G<P(
M>#S^:KH]\H6A9L,BE]:<A"+H&VH<1]X2$;?P]^%;Y\R?XKD8M+_NXR;F:#]T
MW&3JY$>Y<WZ9P9BU9F()%B5\\^2GS/ASP8Q=N#4F/&2>MDS)GQS+R)1_W)-6
MS)O^I&KHGRTUYKX9W!H3*EX'?[==WUPZ5\G+-GMA2D,+]>NOGGR7^P&Y)8H/
M)/AAJ@1:FP#.ZZ+D,^*7<5NTN7(V^8;**;#4MA\E\PF7P:\;XA1L1VQ0\ZXP
M]Y)>^R= #2SD3K?[7H3]G):$\HN,[=!/<IR.CK$Y*(_];#XGCXN?_X*SF?W(
M>J6O^DW1"@L4$H1B\ ]V#%%1N,=CU@W77_HL;KQV!!O: RL++NQS18X_[=I#
MC06BKMH11;P7/O,,B;GCZ),5:9'G4K5+B3Q7%&&YHUS9B/\UP@L@XXS\C ?/
M/R"2_X@\)#+3%#0BM8W?[5B'K-*N8M*&YZGH63H57[;I5IX4.J0H"A>%)SBG
M'@2_3>>TJC/@3*V-R7E)SLO_1\X+<24+=B"XO3-D0IJB1YXBU*RI;8D8>PA(
M(3W);,#]0Q2X@C-KCVTLKLOL!ROAN8<7EG9])9L#8#+@[W0'$Y\^K,/FNM41
MJ[G !ZP%2EH3"3S\MYY->"7A*>SZ5%=X7NLR 5T"NE,!W7$61T\9<P]14<Y:
MW8A(QYEN11I*V#$!R8AT@JD@(\UQTOF,C=RII.EAP4C3$ #SGOXZ6M;@2DAW
M5@LS(5U"NI-5 VZ+IC$DPA'JX@DM$.*&CPRZF ]*FH,_23H_$T+'F9N:L.:L
MED;"FH0UYV=5>4.F)D)DHFLF8CWOW4U_ ^9//]9#Q%XF/]?&AZZ?1*X\@6."
MI;-:10F6$BR=#)9J3%!)2&M+20@4^T-7"_PZ+#LN;HN#YZH\K@LQE>6(K]S9
M/:;E;&9-?T/6U1W$LPA;^@M&K,R.I$WH-3^./<8CL.TSH6S^PU>/I&Q.F)XP
M/6'ZYX+IO_\\WT-S?78/]+!<SN0D"K/?*M2\<%AIN7V-FE%W4E5_&"5UKMF>
M/DBAIQCF>>W-!/8)[$]EP(=@P]S]8K>SUNB<77S=E:/(PD\LZ:CHY5C!H#?R
MM= 652'K\IW^BFQ_%$LD+"QNNKKBZIY2I%J; D41-WTW[KFID63YB&L\3O)X
M&+Q2\*3)_NHO=FN:@9)&V;Z!#41_?O(70E 8#Q1LQ50W"Z1Z>;X$FV>URA-L
M)M@\<3B60ZFFOHD+M$F0N2NIHG=)-B[6U</R[:9HD?DO$3N<\_I(@), Y_2
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M9L 1@W?&^=3AN$P67B!!&7QI54@'!*Y .HKEN4+G!#^/#L<\.AWYF98=+T2
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MGE?^*?+A:#%@WH%S"APV8(O95]+FP6IQ[I<V0>.>XU06_!0<"#;#0[  >,6
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MSCTP[;F?W.OL]9PPB'Y"*R2@%2>;<\'JPZ5R+(TBAP$AGUNN5Q4:ETY!3GP
M'-C_A"?; G# EG.KO.QKHAOC@ 0?-;1#2'H#":!K2X4!2L='UT)&2YG0"X<_
MI7T"Z!"2^9!_7:;&;O&-UZ*1/2W#RAT7O.MLT1D+9HH,+K0MO5=@J)E%G!#5
M->?LE9H,7M)CB88?'\@?9['#=Z%&_R\F!$RO3TM,B>,&]Q310@1PN:_W1HP#
M)HH,M-H(4#ALXY5K+MV8G\GETB!1]N$]]30TCEQ;6CV]D!0* .[0F<+E+;%'
M&647<$2$:T@' >D-\5N-D;)G5M-$U0KDA,X&4^PP+O/DCW^Q8HTYY<R0.#.0
MF**SQP.RWS.1PB5S60:2>Y$#B.J68T]6 +%.LE^,WUAW3=U%?O?**SFHIB:\
M<,TQT4AY_NC]V,\Q'BFJH[>(!)7!<<(CBN#Y@:_&5&[''VL=E98C]V6#9^)8
M$#LX3O)!5>MK*05U'"B 0 6_BFK)L<C(DLX1O=M^[.UHM#E8!E[5G_3)R#!X
MX".%^B/$4(IJ$<4P]&0_F$@D::X,YJSYR6MIWR W!XZ.L)G%19@JM2PH9..U
MUH1MF#7%%A5FE^F10YVQB;*S?U)V?J2S48255^%SBUF(1DXK=1/DQE@\?$CS
M7D99!ZZ#JWAA7?=;778?,RGH_()MH[-#'AA*&M[*@Y.6EU8?B]G4&[;ZV99C
MLG"61<,G&/#WRXH=T?Y8>.K@.%NF9UW>[_1/.0;RF/A'Q%WR#^*DSE4=5SB!
M9>"5HE7HS"\YR'9$(#[0L EDU //-\QJA4LM:I")^V+VM,W+B8@:2M\$VH(?
M;[V<_'A^.ZW>YQ-X<(+RG[:%B&/0DZK=F#L"QO@&;R)?=4]0MY8HZG.1WT9V
MY'XJTNT][@5VTAJUE:R<X&L*$MG!^T:">[+Y"ZR-J$*%JB",](:**;K[8OD$
M4DK&NF 3A_RE&+I%.Z?FL,,C5=F%Q4,F#AZ?_3[M+>4*$#S:C[&H4A1)U!O"
MS5 M3R\!9KP,)*X7J/YV%!%U?^!H*AT '&]@?_9!ULE#2):]UI5?,U85-JK<
MN]/H#L7/7NQ0L2=\"G0])7HKP@WNC'$V" =,8"X*4@IB: CR)*08ST\<9FV.
MG4?7V?/C>$2<YY0E$:+WG1"WYTJ,3;)<,,]Y**,VZ;H1401S7"Z-)O8.7&3]
M\B&<U7Z^$!XUYW=,]$>]R6<FVOAM$FW\G0]&SA2$(9:QE<R;%L5H#&J"CW?M
M(%2K-;?-/#3#)OH,\'-:[T[_ +8YF(-[LO_+VO*IM\+P2WR;=<<)=R?W0\'P
MPU[D:DBQB%7WLN>T&SC70IKB\%4.0[#P-?^MA@<R_0W:1-D7SW]Z\V5.J+8A
M;2$, >EI=?WF.GMA<#3T?7^44Q_&XD=2D?87^O''-U\"\/WTAEZG,A0EI .<
M$DYXD!6#GFM%^$;WG5M4G.W>1XUCMBT6C /."(*)CD /S^,B!7Z8P>I#"0!2
M0SXZO7A8A(>Y4)U?9S]VM^C)YAEG]R8/$-R.@[>N]%PEHMP])1\Y@\6J,W($
M6^M"X))^X'>D$7.:Q+.++I*41FJ_N5@4\J/X647J"O<,#^9".HHS52(6H3^@
MQU(YB-&&+VWI)*7@;Z2B@C)YJ$*BCRWT99$*'A[5!1E!T]UI<77"NZ'E1 F-
MM@O4S$0:^G[#5Q<@;.2FIH"$ZI@TE)OEHXG3"*2'A:E!DLS&^WP2 <:3P_5+
MUMB ^>5DV5P2H%<Z-E8P@[$E;3P?@-"YAB':27H7MK-V3%0L+#:BA4X%)V!Y
M#6SLB(I,[W6D5"1-/L9*@8WD952(P(/M#QR5DT1\\+AU\$[+E\X)CSG6':H<
M<$#("]C<U"80;K/#O"Q[\EB1.<M'D*9LO(YA>"*1B(F-!;7O0"<Y%<+3A[0#
M:4=.I\YG?MP5T2[7;,P2XU4;M7[C5.79N[:[%?TO$>?I/6<?"0,B:+&[:$A,
M_(<7SZ[BYYL78?@$ H6:0NTXS9Y[WTW$Z+LK%6F%S0:^*4=I C;X.R9S>?I"
MP+G._@$;!:[04.#FB$\8^!@:540=';YG$RJ7D!EAHTJ)7RB][?(-_1)8'<$H
M9Y%K9DB?3>.<4\N[HE31<=,^YZ.9N"&U#FWQWA<>(5D*FW;MK/_*'6!W3(:>
M.XQ;N)B]N.\]FY;CP_[VLJ+-.-!:Q5R&4R,,5N0;V+ZX6[S0'N51'@ 5.1]K
MI9,"?,@-<S$Q2,-6-(^GPV6G%1:B"KTXM'(V4"#!!V;%YYO8U?0E,$;DL(Y4
MQW-?+^-SV5/6"M:_7'B,6$UP5K>HG7I[3\G\ !FH"]\6K\;!RJD]]5=$IG22
MC.!JEK[8TQ(B,Y'+3.E(\\%:LO4)M7W<D)88AC=$QS4,]$G:.PC)LJU_&R8>
MPT,],SL4?:OIN"*$)9',NA7B-2S^(VDV/%6_'S$#D6?/"UA817!;,DEZ/$*V
M!3\.+7TIY> M,_+28+G.UID/:@R/5LH6HG'1LL!C0:Z7&.R@_2(/D ?'8J.R
MI_IP4D/$KP%G\S];PK&IV:'V5!_%S6'6#RQB&XP]_!9%ZFJ[H]H<0C'T:24:
MJ7%;>P!+>.=\6FNB!Y91@*W4#:H)3*9?-.=!7)BT5 ?,[NBIR6" $K"L7NM=
M(HFXVL7PUMOC\.'F1N.S6&"!J83@R9=E?%V]WE1J3HYGDI.QS@R\NLN.B,MI
M>+'YT]O57=+ R@;*I_/(OB^M))D'G5H?8PZ+WY8"S=?9J\E"YR!HD#GLP*5Y
M+T<3VGAR]W7 ITPE[&!?41J1[2A>17P9D>49HD,!+V PMSC9\UY]V,N5SC,R
M4F"N)->,]!S?55.'2E;E+&$?X0[0AB<KRX[\?CJM--:(._1.")P?XI%[ZI81
MJEA67G/(:2S.P_[R$\R$A$%F5ZWO09<.O\)V?&1JP;[D!VF\+_OT64K71G%Y
M.UK:Y _QXZ<6<6"MBWDVSV[1JJJZO3_:.AMH:[/N%":)=.R=(>[$I5FDTVD5
MT]+"S$ N*WCZ3;ZG%Y[44CR,9S1-_ 1'C0Z?8]AWV-TG*VL>(XF'J'>^"^\]
MRIO#D"'^^KR+S[+>903#>AZYXF.0^ CMC:AN6X8QBO3?J6J(/M?2_:.W//9.
M+!S=T)^#< T5;5YNMOQ5H&V=X8%:H]T410^(:3^@_6_J, U<+VPRK3OT $1Y
M60J<N4&G@P<L<;E6^0@1;M8CGM<\7#A>Q7/Q?M^AYC"'.L/YF,\#SA >=%N2
M]]6E&93^Y.1^DGA"++X<M_K'5F:4S/YY=M.R*>I=+.9+1SI"V3#1]9T*M8OL
MM-62&LKN\:;R3^/]1?:YPOL%$N(M1H+R[/N?GOFS?T%RXB!)5!6(T+IYUOVC
M@H:[XC8<JHD'3T+3@AOP=ZFBRN04CUY%WO=#GE5?.NPPP))%3B, XF$X;!K8
M5IBTAD7 30OKKY3\;,F!"O)RBTCBPT74EO6#G"ZL5K/S*4HA-.X>0,NDZHM;
M[NETW2M4-E[T51.0Z8 94O.3TIK!4BZPEK N)Y^O,[PI927\U%>&I9NK(-,]
MF;2Z_77L#UH6VAOPM@H-TMA!(GMK(TU?FJUKG(X(>(G@XB,6R9KALA(<19>,
M8?="2KCB<KPPQ8,-6]22 &/35Y8[)O #=LQJ,'1Y,+36A"-YW/+42*'@?.][
M9%7#51U:U762"C<='%\'/RD-#*.C@N!8X&!Z[2EPS4F!RW17:<O$J,#"+/^T
MM](&(H6#+D//@4^7VO%'B+<64(\8P_NNT%9'@SP>B=CCXL^GGI;8MD>'$(:,
M"L/PU:( OXL23S)=WM-[V.F'%E%H=%-D@5-9V!*(:*^OUW0$+:3N3@4V\P>7
MK2'^XV]P?EYX-<0??I=JB*/FVR/>^M,50ISB*5Z3_1'4.BQ8WT%4K(&3@'U[
M6,JX*W9@Y,-R_12YSC/H]%@" ZIWP,9/"5H<&: \;.W+YU=[4(7;Y1O!QQ@/
MEN*G*_. N' 0]PUY:G*1KG?%H.W&4MVT*7KTM9W1')G2D1&8BP69.SGI/' X
MP3;K^NJ=,7OZ*M@?7<]7]&IF%E8!H!(&:,MW_X^];W]RV[BR_E=8WI=4A9$E
M.T[L];>I4F0Y5K*.5)*R^S-(@#.P2((!R!DS?_W7]]Q'WP8:G)&B:&:TK-K*
M6D,2CW[<OH]SSRG/\3>8[UUCW17A>NN6_1')917)(8SZ=SCBYGOU;:5@^[HY
M;SMR_X)?'L]"?JT4+.&Z%='HJN.86ZF*R5CO^T%3$X/SR/./(7(.F<K9:=T-
MP4=K^DK%YN8U_5UP/ P#"$\T;*&VUR>@;1BJ9>EU=/O:V1OW"I*/976WID^:
MHF>&0BDBAFO8'QWVXH:]M5TM84_O2Z[JN*"M+D6+Y'&*XD$H-AWK6SL3K?_+
MTLC9.10;PQ[L:+9Z5RUF4G7>-N?DH]32J7%1K^^YW="V8IH$R;0S+0;#P-O.
M+<P597//^C".\#^WS66[RW3/;[#,^/<3@^O@29*0!7$$IPJGXSMNBL*B\Q4"
MF<@X<U;XI:MF%[2O?J#\2;"8L)-P8G Z"]?O?>=A&IS'O3X< (GY# ](I96>
MM^XAF,B^$%PZVJ&W$D&&KTO'RJK^5;-$F[!O5UQ G0"0O>46W4W%P9&B!O3%
M&T[TP5R@V%!W%#?U '6A9UBU($<MV+-P@Y)N50B%*L'." =7:)ZRXG@>MB8Q
M]:H92:_=[(*1)1M/T2<SK]) \\RCUF:HSXOVBB/E ?C+0"@(9.N-O$B8-246
M4*@.U:DW&MURJ"H]8&047:]$4M&,W1322QX\K::7B@=::V-'Q65M:8 V*9;0
MB",A>M!QP8Q1&J'2DR4=I=P90E=)["ZAG.ZYB:$ UA)=R[)9[8$#"U:T?B>M
MC1$T8?LZ[N8K%Z)9QY74''+AFDOC6_4FH57"B1+13OFN)_*<9+KTP$@RYJCY
MR1O$"F@21=-]<L8OUA=*7A;BL+KSTB<NCZ6;]GTMJSZ7=I)#DF]6B#M4QZ%#
M(S!RGO04 O<T,5J7:HN:MH-61[4U5*?'@UDJ;F?4S>$M*=*9/4]59W^.JK-O
M1'5V]N#U\Y_?/.1N8U?_YM?E:9C]A5*!M"NY,FU.8Q2JI;[FOK;.X,1Y:=/7
MT0%-_<!.,:\><$=CI+VH1R_)N#O%W&'V.)G)E-/2XJF.DN.E=DC*A<#&8="Q
M](4/>U//!*P($@WH_;)GK/>)?"(I65!8='58<D9O%?SO,WI-(WZ(QYY=IJZ2
M%JYZT[4K[L"GA4UC9NVY?I7RE?R0E FR<N610CUBLJ5GP%#D,98E5BMO\!OT
MQMUS6RFD)3CHG#G8[$/\2O%()A!.UB(?<1P,96(T!DDPGH(Z$-,3Z'B50[;V
MW\LDH!I5.),Y8O_D6/2NCB -!84Y>&B'"4%WMD&99%,!+J%KAJLX(6AH%PU6
M+#P+.$!ZDTK(WBOJYKBL?=>I_'K'N]\X>5#B2,.C5;L8A,3-)A^*/9K]'/[<
MHB%A=P.'E2.9X"2%F8J\?YD?^)>ZO[73MWQF<#W'@[X(I*$PVM&"<0Z[9KN9
MF9']5!XW=J0LCH'^>:OGHD)*>-TT73)I]]QNO#S&I!2YE^@,H6AD"I4D?O;B
MHJ4#]&9D:8-^V> #^9:JJ]I-1SE[=4$40D]*0;(=9I?MBIQYLE%PZ\+D&,57
M^HQ_#F]0M6LV*8Z4D\"ENWUUX'4@;5?C>N'-EM>!%]+P'>,KC!91A^8!! 9I
M/F;LU.G1:X4#]J869<^M6>1QVEI.TS^Y.:6!#Q,* ]'7'=LU>ODY )A)MB?!
MW>V<379HQN.(JQADTH6S^2]OSN:U6#0]!;I:\U'CAB!RE-/WG<CYVBP).\6U
M!L!-%X7"#G:=;'ZJIP^7C3 \Z?>//DYL#^,G0N6='JN@^/=J4'NG.Z%B..!M
MTE/8 Z*-@9 /VG'7%T=6I?!22%'1*E;D21=*Y2/N<7R0B38*>A$&!"4K!]->
MESQO2\X,#7#(C84GV6&^WS;V#QTE9AA=['I5QRG$95>NZZNV>^<=C4QJ0>W;
MGXL1AC@>BZE1H2VD&(80LW3[K;]2_6N]L%1V8I=GZS#ES1F'%6._#[XW TD%
MT&*A]24[_Y)1U6:?R^:\66$A*$:#+U+'&$_<LWEPWI;-[@QP*  DA=Z!,C((
M=QI'\B(>7]K\"/Q U@T-^ZUKB6)*3<W0$?OK#2=*4($#H$0<8/4)]^B^&%4.
MW#P##P]BK2\)BQ0"6&5"%&ZC0;-'>"?*B&&4I;[,%$PR(H]F;P!:]T_#3[M
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M%+9%VTQ8GZ^2=DELZ'#5BV8NM,)^;-!,O5R>X7YX$6[=+&//"KT76 CW3#@
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M*G@0-<.L@UIFE-\P,<K/K[=&.2P.-I(^^0&=\OUQ^JHQSZZLF_K%Q37**6$
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MS>^5^E= 1O9#5BFIWSK#E6\%"59BW7!U>Z,*G(LP0JN(+RBX28U:$5#81GW
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MC[.35LQ!%]+LAWI9<Y^FBJ_1M/.K"N)<P$"TE4!Q3=+-"]".16'$>"SZ>7;
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M)R8(DJ?&C%XPQ+\8-#&*$E##1*%.OX4U"_[_NT('#W:(&2E=!6Y9+A+Z,AH
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MVL@I/DI"7/-^S3%R,"5&),._O?'B77(M#80CD1PECHKXI/;@YHSBB3,_\>V
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M-T=%+*0>9',?B&?>_L%D\T7VX>C5)15!D"-9M,CV2T90EW<]F! &W/3V,'0
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M36T&*I0;*U;E52G</E5Y"/-\5M$U8\.I[YP.H]/2I1*NB'AA)&VTSA4+F0I
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MF?#MKE1.;BRZ55V:4CE9U<);]H(X&<0<%DXRI!#RS;Z.U+9R+-AJ3LX3=X8
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M,](JP5**#8QI8.E-9 ]=O84$J4C?1V%EL++]4<:5ZF$^+QPSB:^^[V6'W2B
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M]9AVD,!%MI,,SZ#-X^JB$K81]DQI/H=I6SDS>@QGT;/ZIVP8!<)'B\\A#1^
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M'1W+Y]J=3F0-YF<S-54=S0R.<<T$=IDR!1)_9'&I>?.03&L(\S26VD^4(82
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M[=)"H]^_6/V:C:\P>0[3?N-\O @P&1&F[GC3-":+)S@YX>CDCEH_G#Y6->D
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M F#7^532^+K!#=A@UITN;&K>RZZ%96%XE95Q(_@;&^2Y]H>7/XM@S7I]9[(
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M%#I4D.RGY[T;X;&V#JJS]J'8#/1+P?&T@1UT:=M_.BUV6N^,N,WM9#%T7"C
M[H9&Q+-Q%UG"VZ@)907>+;JLK<==<$8*TTA9Q\XYI0<X"'29R1.$HVW\@!Z>
MR9&;8$RZP(.:-I6.%SZ4@[?0P^DPKLXK"Y)E@,D5^T%_I--V.-%\(N^101ZY
MW=1],/CSQ,));UP'FE CL>TQ9ZWBU.70_V0X$[VR)) F!IW3FLZO'LDFX60D
M/JQ/.<,>@ K4<%,*[+>_ZSD.'TM:D%@ UW"G#3RUA!<0(<+S%3MQX7KP;DG[
MQIZX'0/MRM,ZD:KYVA4M<L3K-?A6:!;_Z$0T'A[@#ZRM\RDU/7;JYYL/D^DG
MO8EMZS4PXHXQ6L/)1#]<)!,Z\N*ZY.],MB_DZGS>#UD@TZ:M.R]/0$A+6BOI
M-NH8M,4'//CW3M=:V E(=/*:_@%R'3#%LF\Y\]]U[9UP0F=8-?@8>W&P2T(%
MY;S+V<;#A3=NLQ3]']JB)H$IJB9CN]EDDS"W5YX7;O*5-"O9F[<R3MI$W\!^
M840/TIC:)&\!)N0$W2:>O=T89?ZVJU<7VO;AFT$HLM81I,<.GR/&>%(LT7VW
M<:E"@>#7F6HM@XNVS 4Z%'T[P#.Y=HW56:P%PW_9],EBJV5'<U\*OX/D]+G.
M#M<L12M8-.$4*YD3:RF:(OF"7U?]RXQDS$CN5XJQHMX 1J<KO9-05$W#10,:
M5IOMU?AJ(N'K 39<7<01%#Y74D5GZ55<:%:Z)/$W0B>BJE$?F8FA([4) V:P
MNA-H#IO$ZD_@]1H$$&C95S.+$F.21]#K#4(@-FJ/4.(7O5%&TRDVK)H\KX[?
MDNXI$-S(-AFAG[!@AC)P_57B0;_29C'T]HRDL^G"#GW>X, U>$JBIJ>?RU$=
MU='G%Q$D\BFJZ-"ES3:I*Q5N>N-[)4-78_21$(^&\!#CWJ#OT<R2"S-GS<Q9
M\T_'6:,I%4'UV+I?SWV="HE7FJ^6VF"#? >=9-X$0.;U0?'H)DD]"S3(V8A;
MFZ7!(Z9A,>6U.$?^+O('A&-'E?+\<1#Y"\+^,1T5!8$I37I$.(B0YK.O9[PD
M'BYCG7MJ./#7S<QH>% [8S:ULZF]35-K0@2!WD-XZJZ(EJ3''13A/J19=<H\
MDJ0I!X"B-($)'0YUP,96"#/-%<S<S>3,A[6&9J,T&Z7;-$I,4*7H\"D;(V'V
M,!B=G9P#F_[9GLSVY&#BR7%C,HV3F:C^VE@1@0&S#W-82V2V.;/-.1B;\W%R
M6%'::C8W![4Z9G,SFYO;-#>;O"E2I-#F%IJ A1!\1Q+:4ZF_2Q4I!*IT55?P
M0X:=>=R1@[EC_+M\GZB2"%CO&$2 D L$)RPK@9T)E]06:72%MA9[M&<S=5"K
M:C93LYFZ+3,UL$G&<F1@N80+K#+&*V^YUYXA1(5+U1^*P2@,= LPF(IX_\E.
MC=TK;^!;RTYZM V,X]*5&0:#1&.(]RQVPF:8Q":SJ!HLSA5N5MPYO"4YV[C9
MQMVR*T9(KBW<M(=<A5^Y%JF;<FP6VPAE9D@D44FM1LJ1QJUJU^.>OMOR/#V0
MJ] X>(9<QDX0$2P35FMD'4$JM2/&-Q%)BJ__*67%I5[#>L#R[!IW[5<%8!_1
M__0[A.A#\?=A^"_4D]Y>I/#R*]>U0H-P7F/K/7K?]QZ]?,;4Z6LXZ9J+'G@7
MN]LK8A(-G?:,)X0/PE>95]6B??<TD!!:E_'+)]QY'Z4K1@:".(A_97A@KBS+
M?N %):X+6M PJPL$+U*WK.F/G>AG8:$-:FWK6H^$AB=--^ZJJM].:3>-I7=[
M6$/J8Y 6VV+GY3TZ*1\%>K6XEV%T4!E"75=(%W6RW)W(/QE&O6"V4&%NM]!Y
MHGL[73PBP'2:73) <GPTM&_4?#\T&!''LK(RP B]9?J$#(8$.29DY!6P.KDN
MKID0%D'!SED8]A1I/!@C[/F.Y#X&BGRZ^'MUY:@3V2H*&:HEG-.N58>*IY>Z
M0D;GF$F$B-0=@;+R%'N?X(X1%IS-A 6?\SG>3&*51PBX;>5H< 0@N%^:R"<;
M";N6^BOD1.N1JCV;/,KP<:1/-VKCL]EE+RA!0!SLE:^$KVR84PY,,Q @K=KI
MYUT/NI<)NLA$_+O1YD<D Z\)?_D7.A,%S#[2U"KF*N^?G/ O3\X0=?A>]3V'
MF!+"4\],^P2.*X#^J3P]J/:VR363T.SFJ1RE[:U@2L(M7*J"B+'P7)EVE-(;
M=GF#):LD9N5A45J!, ;>JD>EA'T]=\R)BHLTJ].K)O#J^)&/:'E-&ZLPS8 G
MDDVT*\7SH^R7F$XL8<>:I^:F9KWBTFDON1#<R]L20]Q$<_SH<'F"=8KF2XR9
M^[TVMJG:$#%AMA*NO1JPW,F!FTSW:;!/I5WTD]H#,.[Z6E''>+*0&32EHCZF
MKM=-<6V5FG;Q2DA%J>D("3-AG2JG(YVW&Z3])<^DB^K8:VR0QE_\WLDWDL4J
MO\P+[ >"B:>IU<:CT&N$[Z'+2H"#VK><>*Y4YBOF#=NX_'^[FE=E[<#U96JM
M\66+W@KF=%BXAA@XV3P%'K$:J:.X'5XU!QK/"FY[2.-YIP77$P6X24.D/A0K
M&X$+'ZE8*)_X4''G;K3IO^A1LJ&3C$0EN(6%XM=0'A)?!!\.[VFQB(VK/SN&
M1QB^LL[1B.-H!2GLB&?,=K,;UM38OR9.4";@'=GCE<D%2LNK5V B-_]X^^&Y
M*Y+IQM!.R, 27SM+2['WTB+)R7F^\K$O,J+A49_S+'DI5SI=TRT^= \KDX&%
M:YW0)52KMQ?PGF315BFQ5#?,5KBB0&G9"K=KMW'2FW?NB'TU748GC!+U\M>Y
MUX+ZQHZ\.?''8?LL3A0L1W)*\ L5MG2$B0(K@Y1*72GM],1O.3YMP=P'D5@J
M[N%\J39,01.'4; F')*]Q-U)$.C,V4*J.50J+0S86/\%5MJC[AP96![<?W"?
M7XTD@3)FL=NG*8D=QYZ_OR_7K(H1_-W (!\(\J_7OPNR0,AD#B=3A:34,(@D
M'IB7%_D2:?T\9[3R/;Q8M=42EM_T*TW*]MWDG?3+X:7>]U50E8\^B )[>P3U
M_)N%4;O'.PLL9:DNXDM7P1K!9._9MS\TBU=.*.?!G#^^@+,X@?@?EM)_5>AY
M/4]AE].]WZ3Y55I^R4)XHF]CUO"$K2$CPRVBBQ)L0HV+?^X/G2LL<X7EGZ_"
MHLY&9B("8M=OE/$C#6WQY'W,$)2#FNO9>,S&XS;+LQ17;+4P:Q@GT/M?0A1+
M03RSQ(U$'K,U.:C)GZW);$UNTYH@7Y.RB!&U(O@=[8ZK';.].+SIG>W%;"]N
MRUZ@6A46@CTHS%<&II)K0O8NY#%KYL@4PB]6H8W$<;(<23F[@G. 35.M\M23
M&S-I.@=,6)3SE<K90AW4@IHMU&RA;M.CR1"(WQC<:E!V\OG>M&U%ZY&RTRQM
MG3<J*,^2W8SC R>(P (-([[JIN.V(LS]FG3OQM7GHND7,L*S93JHA31;IMDR
MW99EJIU:'+!*;]W."IBAU5+J7OR3]VR8$[T4$5<A..^C!#SH"[_J01R1^M=L
MAPYJV<QV:+9#MV:'2.)U:%?ZT1;)%#/YIW(^B,]#S\]R[C9VDQX*V]N"*LBI
MAH&B#6B\+(D*)WLH1F1$YF[%@UM[LS&;C=EM&3/TA/+2^$*J:+8@D95.%1\T
MY>0Q7CO%\7LS9/1@5)J9E#0(H*?A'W5JM>E;M7<]\ _>DX!\ZW7C6/'/F%7[
M839OU"1&R7<D%VWN=GMDU/' Y/PZG$/()L79+@+^C8#[";N)>A,,ST146:A;
M) K 9,96#\Q<%B)(R> KZCN#T'T!CWY"D,4(C"%+!Y./:7E.>IEP6=<VVH[2
M0ZH;@61%HVY0:U)5?/C:(XC"%3K\+!3CS]\I$"&]/+TX-2'(Q[[^[KODP<.O
M%\U%6CO30+K95"6#5CW8;^QFD_ ^>S?]T(/O'B8/OOY^S[T2WY3'B$ >(Y;P
MXMFJ2FWB\4Z!A=8>.RPY<RO$'D:Z$^0L@ >AZP_E7574>JA2P?TG\7<0SAV0
MDH7JM03U"[\Q6%9)Y'D&'9SCB$L4:#UV[/&+,1WH**='GJKOO!R.PC2D7R1T
MV208/<=(U@SA6]ALU(E^5$D08E%$:9Q[R]UD!9\KW-ZZZ4\SJ_QH3X"7OQH0
M(:'X2:%'7N/2&EUT;)$=5Q^6>@PU#(\*K$7BP[M87(U1KUX(/-87'XI#LG&%
MJ3JIT2C7JK[+4<7J JTNV^  OB_A#4[H4T$CBL80AA<;;A*Q]\',BS)O@.>/
M&A-J59+FVEY.F.ZF:9.[UG3[8&ZZ_<P4$-R?MZ9N<.,,^*X;4I\E,^ #6^+9
ML(;>RR1?8/OA>=7F'ME.% 5Y0TT5)]@]WVUT7W';PSLP-2+=1?)N*<7LF5M3
M)>/2J&NPY%=L>,C"'9AN\:'I*'-S6(*.'7:>2&L!S )8&>X6ZZCY!V:*Y1S7
MHK85IM?7H<"D$5]%X]4&P=*B8EH011&%\$R=X[5F6K@',IX^?[P-_VSN*HTX
MBB#$G@1L_8!_LU0+DG.0[R$_:I-4T64L:I<Y7-O<_3@EGBYI[?RM*_*+JLIL
M6Z4RH_\I^>BD=X!+]ZHVYVE/U>#X3F0:FK:Q^\439,3-P'R($JF7K_<-+DG,
M$C"0W",6/Q:."&]Z!#9P#RA^@LXG)XBKD(/;J51OHZ)N%'Y>:0L)?'@:8@%V
MN&O:>F?29G;->+(0EHVWOD]8'=ROB&KRGI3#MDJ/MY%&35-KPQ2 ^HK:E$\G
MM%!HI)<I_-W3#NCM25Z-E!_%=M%XQVN;8RVXQH9TP%OJ@<^ILSSET! V+8]B
MMT=O&&*OKL9[>$]9&OUC;H]89MAJQ_4>2[D#HM&*A$?6XRG.I>/>06(<B)76
MN;,\Q64 MTYKD>8#XX>=CH&AQIMQ\TAP=WYN,096'5??]C('8XDZ RCO"(&"
MYC/(@4/2.K-&J),<3!V7NA=-NG:RZAQF3-+5[FZT!4?Y"9Q0825:HOY4&AWF
MP5YBWRW\PE?=8,<OO6 E'Q"<7>@Q)3'VR;NO=",;(:=$@H,*[N%>84HDLQ Y
M# /5PW@YD^_*7#48$\9K^+KCAA(==LVSLR\D&YT0,,6WT.R'H<"!+<S&3F[%
MDO6CQNC8@]!G:[5F)<Z'1GTT1#P^_51 ;(O40JKW-Y8&\%W=HGD[(H5II.%4
M0Q:71M#D)!'-0<H 8BOJ5>2CW@A3KYDMJG^N\EJE$ NY%:A=<R3Z9C%6^AR9
M<!4K)NLY%JTGYGI[ _9:'X$<@!6<C"IE2AR7@>."3G8?X2:2&PSQIXTUI4BF
M*<IK%;IMF-WJZ1TR?M*L7LCI/GU;S1V\SPW%ZX0;AI4D%"7"_A%E**C#W:LD
MFV5G3^>N&5M2PQ5EJ6M,%AW?87)=K_D(UG?<0U2QK.5PVC#6@7P;G!F?ZM?O
M2<K_>/.&DB*:-!)&J]:?Z.KU7I_;&^4G$9*?D3RCIB7#,3(UE[*<D**"N0=U
MEB)?F'-&(T]P](9>>^7E:"UW_9C,^H),>U/V,FN!JHCB);'$!?C2+<5P?3XH
M8CAG_R[?"&-Z""7IP.9\O,TH9(Y<<J>:F]?:E\D\*+, [2F[B4? <]Y[?WA)
MCJ#5:$5/*3'JPJ<[U=-41SSB"5,]4:X+*4D0PM3/2[9^9#CR<N113A>/XQ6?
MEY=5<:FDCV/97PI MD0*%77QL[7L@R'6</GJ:N[LG]$(,QKAGP*-$)M;]H=,
MU)CE#5(B2P8X<ZQ<JM9"39R0;UE3'B@)4R();:O$)_J8W1TOJ/RQ+C*+>6TK
MWNS.)IX@.#[Q*7?$Q_OT%=*&O%4DO)M1I0>U4F?3-YN^PS!]:$4PD[F]2!L*
M"VHV*@SJN5&H,AT04HA$431>DX(DI#GH'*<!L#/P6L_6PP$\PW5/CT/*&@F6
MJ<%A]."C45\U- &MJU7L!X*U3!4>1-F3L4PA\4:EA9,:-3B8>:C-^"\@-1JG
M6$SJ5WQ>SO/XX!U#;V%%@Z6!2>G"EW(8Q-OX3DRYEU31(<)H;54*1Z]V-/2A
MF$%<I7-O^.%MV/D$F$^ PSD!:DQDD&FQ"2LVV&37(T6 'MFQP'/W)3T3J9EC
M?I+R8$B7E5'*H)?&9(&%.-= U_+%B2!"H4F7B(:5\R]\ /"S@VT6^C]]G-D6
M'M32G6WA; L/QQ9R'6N D%$H9E[V"B=$9L[PK-@Q%<\U073C=OAG_,H2S*+J
MN@PK=5N7BE/,A@S]Y=YSL2/-4,Z4^>]AQ+K"((:&2!A"(?CK.()@SB;QH%;P
M;!)GDW@8)I&A7%C#$]4RE#[R<A6A+#PL>":A8TMP*1B58@-0[59XF8JQ9_(3
M76 BEY /<9D(RBIRQY@R ]H-^#<NC!)\04IUC-6*RE+R^"PZ#'?$#T1<_H(K
MD(HZW<M?UH%EKC9H1A'>WT.YP:O,CN9A;8+9JLY6];:L:AI9+[9V!NB$("+5
M"HX)]3?(L;8MC%G3R@_:J;RU0!Y3C:H,O&/T#KW,+;<(,:A,R 3D?K,1.Z@U
M-QNQV8C=EA$35!F$M6!L@CY(,%9#*!-Y3 +'(<A10"&;#!\8*/;_2+UIMC@'
MM4!FBS-;G,,(1CWFA3JJ,(0DQ'3BB=40AKXFP&*]<"@_*F+'^_2DM%+=-5X8
M>4P[W6M%#Z^#7:),N'2%C5G24GV)S3F(C#SO=1]-/ PZ8"[CSE&'1BDBKOC=
M51!79U*CAZO#U%,V[\\],M6;"1_)'> ! /Q!3_P>EONN]&T_?,^^[?G$FD^L
M^<2Z*R?6YY_G:SKL#^Z!AF<Z J<Z+[M:YPUV;K97V+PYS/)29Y>73E7R)FZ*
MP$)=Q:E9C\]:2W<L$ZPD'] ZP9+)T6VQ(QV\COB(3.MEW@I,(<)F6>(23V(=
M@8;G0.>@=OE\;,S'QNT'.H3=%Y(!-6TL64]D?.%7B39WBW5*N9&4P B#%E)R
M\AG5V^OHW&L:J8<M2+\/K>1LP@YJQ<TF;#9A!V'"+)V$IFT*EV9,4G*]X1E#
M 4C+,CAA3&A"-2]IJ_*][K-!.JCU,QNDV2#=OD'J)8\)R=DI2P-3LS"%\*JC
MYGB;1*W=.29>RQ&:4FSVX>]Y>@]!"UWT>C8UR4R8];XL"%'S<@K9W%A)/SC_
MFV8HE80/FF]@7PRN4;LM$DGYQY)B7%Y>NL8'TI3-O<* &^EC/?%)CSAF/!R>
M[>I!;8/9KLYV]7#L*EH1\N1.\%_CY:)5)02-QKY$B;TF*+R-0 .0'B21BI9P
M#J:-\K&0B?341LS=&*$3C-O9=SF]Y1UYZ%G$Y.#6Z6SX9L-W6X8O!G%ZDEYF
MKNOI(!G&-RVC!Q%>2\Y%=87-MLA)7H19IT+&K4BO&K&/3-BX6,%U"V[W1D8I
MME9:@/^DPB23C&OO47K_LROO%;$W*>1 X*V&6YY'7MQ<2\7;5[LX9LXYX>][
M"R;,T^^FTFCK$@@N_NCRC(< 3PUL>:A3"EV$YXVH:3P+@Q+O1L(C"$X6*AO/
M#E?G074^^C!=#PGF, @R! JY9Q'V.M%TMUW5B:1"@?^N]ZB2'#G;W$MD7M H
M[-G+%[AS'\% %HL']Q_<5]K:*QBT$A/SRP*%:0,]]IYQ6;R>5HVI2M(967&?
MSA(BU](O 6'\^R5MLO2/Q4]%M033\9KY.9[3G5GE!/PI;(31,!D>#]5Y:K).
MC.9T8=ZE<[OI&J:NU,787WBZU/B]F-RZ2/&)U^9+\F'B,(<H-Z]YD=A0N;]R
M9*62'!"NKJN<-3WH@T0I)YE!6<7T!OA!3YT=9%EN\%C$NFT83-?XD/)WI&JG
M;;*S;RH4UM@PA.XKBF"-7U7>N!_7IQBN:Q%GN:,7(YKSO=I!=@Q[5S0,B($.
MI<]96WLY)<]_G,04XH%,FT66EHB@4_<^/%S\8(T?=KK1\1* $CF[-8O\@GFS
MN*RPD:+X0'+36[=?^(*ZAZ?M/[SO!=P2;(V^-BT^)?:')79%^C5%AW&5DC<2
M=7Z%RE7P ;PUTC,*ZTVR:*J-"V)4;(VXW86X'7B3\NUE"\$5A3>? \0>@S>I
MQN25490+G-XH%([MBG!"I77"X2-I.^3(^X^<%2UR5<@0X)7@15&J+'JEP Q>
MK5M7,A%Y5ZJW(F1!*/104U4V,'N*2XB#S#QNJ<@-*.^;/.B1KZ:_U57JY0XB
M&02K6U&Z\U2$EM+UFA;0#9R01#*TA6N\.4PYC!\=W=.%X8_7>=#'0.:_KFF8
MVKV]@/5-(<_]']#_U$_1K\Y^0/?38WI<T;@K.M/UB[B(J@QL*Z=FE<I/[R0B
M'3/CZ)PZF%,'=S]U($ZJMF(:,9XM^.O*QM&T7:9,R@.JCZG*3.)IP8DG!&Q7
M7PZ.H8SXF6 _J5V^FINM#FQ)S39JME&W::.$'<-H8L6<&A@9@CN.:E@,[@%;
M$PE^J%T1)S8/%LN6F85#>38^![569N,S&Y_;,CY607!E1%1Z,GO6$ T\&2;Y
MG8DK#G(MS,9E-BZW5KB5?! Z+VV^RK>4ES.,X6A*SNOJ"@T.J^,8.IPY8#K@
M53";E=FL'(#/ J:E<.=I8:,<W[+PCY*(JE^WU,?@D;@([2W;>F:D/K0E,-N4
MV:;<EDV)[(=4#CM6]4 %<E*A0O<%N\H9)B:RM'G3=,C&0G\S]7E+#L.,-[.U
M.:C%,5N;V=K<9LJW=JNZRUMMQ\P<5HTZ5GU^RQIU3566;FZM/*QIGNW&;#=N
M+:'2KP%U8QE9TMXQNII&Q@R!7A/HPV3Q>Y7#IY$L%&76DQ%TH@(BF0.9GF*V
M3@>UF&;K-%NG@TWWHNC-AI,QU"J]SLNT7$5RDK9:32WBJ.W(>CO4/5AF8HT(
MD^W[4-(R+7;-;(T.;/',UFBV1K=EC?KH=XRYL%?$<]T$.#J$6BN77S*$+W W
ML' -?:P.8HFSB3FH%3&;F-G$W):)D1X)1 #GD9VYMA4&>QBPE?F?CK?[JYFW
M^^!6_&Q"9Q/Z>4SHP=%D']P#C=#^A/B9D.)MC7XMUPDN7%JT%ROD,=NF.PJ:
M&PB#W6;V4@]K1\PF=C:QM^6E,L_A_E9JE%%%B4(-<_.2& ,: CQH0[I\L< 4
MG6^,8\Z!V=P<U.J8S<UL;@ZA1BF"5Q#L^JR;X<B7]#]8EKDO[1 G?;8BLQ6Y
M-:>%R/W&R&\(]9 (S3*1&GD,!",OZ6,759'-FJ:'M@!FBS);E-NR*."'Y+5W
M0R1UW[00$9U4ZS5UDH#=..FV1D-C-A\'-=NS^9C-QVV9#\R]J@8$LE3N%F7:
M=C6VGN5-VK3BA@BG*"=F%V!%ZG,',0["*5FLN*$L[N,7__WLR<G9]PNX?^8V
M^6JF/#^XQ3%;F]G:W):U$6+-A5M5907F(5EL*]0_72'9IF=Q#-SG!H.0",<A
MYE5($(?J1YQZV>1EWJAJZFB7+/SRP?T'9Y^4T/S6>3'?4/M-)'R&!EV%%Y<5
MZ5<@\SEA6>DOZ6));)JUCB8'F_2Q>,B1\"USS:K.E^]%:)F(YA QFJ:+K$Y1
MD6C%+-^L0^1/H/)&')W'2_3[;&W1O55MUSPC?965G0[<YL)K#S-6&*D_,4E0
MDW;G!;93R>=T)%$9*F]0&P]G;?3;08)*$PY+Y%HFGBY..&R$P#M0$8<R2Z]J
MPG.;$>G@76(IWL1,XWV>XKQ<%QV3^A(]8A")%D)&&FNF\KUNQOT4+JNNO69.
M3A>_PIAW=<V<[+2G_)U)$R>%;4S*-RG+@\$3EMUFB8(1URZ^T\6SV&3H(UY=
M5'QU[,RAUN";+[A]ZVU39:[0I->(8DZT!"VE<6^=TGZ@5)GGZ/4J0&E.<K4;
MYUK1\O&)^X9-)+_D<+FS$%"1OT4.85WB.$2PANB]J]JP*_O!6KF4^#-E,N #
MW,ZD3Q*V-H\/K*N.1@E9HXL=:1#QMBK0YE[F32Y\ZW*TA?X"'H!&Q=WP[UU=
MRK=7:8?STWLI).^,MS")&7V$_7N;AO7%Z-PC#;36@YWM':-1IB';I&]Q,\#7
MUQW#3P97":(3.'FUR_(5TT[WAWGX56P&24G<H*BN>BN/E_!YEV?$(WW<IA/'
M_X\NK5O2":&CO2QCTNP;3(I?X#05\13E;4_]HVOL?.R;P=/%CV@02=4!&;KA
MO[3)\$F,?@&L3E>R19L4GT4Q#=]HB)W-H@TC]')*Q*((?++_PLT=]0"MNS)3
M]E[;T]AMP7:7O+Q@'A&Q7WH0%)&]_ 4M:[6#.)RB;QTBU.=8(=<]BD)LT+#@
MY1H8EN!#U?  9<?"%/">U]P+KWF)- _Q%-'9PFSD-/[\+Y[Q'2<#>'FL7+1!
MTN@]#4I#";-&3#<)N.$S^=OAZBAA61[Y=C&<\;P2X<CH1!X#UB"/RPJEB4F^
M!<WWR3)%(OGT"LY2G)R,UK+;;(MJYX)TR7F-PXM,SOX0QV\D"_ZZ>-@D-.(5
M1ORG,(V3.=:$9\^&3NL*_P2?R_+:B:P".SFK"F;T?YT(E,+3HFI/27:.-M*E
MB)?J4WJ-J]IQZRZ*+M67>"SQ%)\N'C72T0)#MBQT"UVAP*IC42!X$7# <%SP
M!20<;)R.C,:%=&_:Z3Z(X1.>-%6+':F>]'Q;^[-(4.3HA'!0 N_:XCZ6$=.W
MU ?<@"]EQF1\^QSYNHWD9\8W;6S>LXZ6:4H3ZMI=B#"]0L=&'$ZV9(CI C<8
M"Z A]".I#B]$$^E A2.@GR!8@PVOKN"G611A3B[.R<6[GUSLB2+0@52M^:PB
M<"<:%&Z#)!\L+Y,X:K<.FE%<9/9.M"K"WLGA]XAV@G>#Q!.=^(3>%$80 T12
MV4XWWIEC63T^QM9]QW4NW1[4\ISMW6SO;LO>#93XP$DJD+$O5[;0ON@+Y6^#
ME01SR%]"BS<;EH-:![-AF0W+;3I2XCUA=-9AJ-;5JL;Y(>Z/S5=1<)PY"*)5
M4/;')X^2Q=/GCP+;J"&I@-& D2L75MFA:R^J&LT?9E&%4X<=+%(;I3P61^]_
M=,C=P_&G/)9J[9%!A)@VR/V%=!\E]<(0S,C;0UO5LYF<S>0M(F_1=A&K8*QE
MC;5!5$PNP592^DO4CXD/E6),VR\T84CWZ2//5NB@%LULA68K="!9KZIKL0S(
MDGN]\ ]K)B]>/7M\<G;_+/'.FG@]GMY]X+)5GH65U+O['YAMT4$MG=D6S;;H
M-FU1Z1Q5ZD4_>-&5$6MJ7X:XUG^1 X75OP)>']%J@J]"TU.X=_CWTA*PSF;G
MH%;);'9FLW-;9L=+"U<E%\S<N[QIU2,*>L)Q6DI,#G_9<:I'O:.;.T=4:8RI
MK*S2<0%_;U;IUH,9%'-KT0K(25,5>29HLTVEF3;+?5][N-EL^0YJH<Z6;[9\
MMV7YT$1EKDAW9'Q,:KQVESE\#OM\MF"V+E,"/WCS%OI_]EFWV= <U+J8#<UL
M:&XSLO,8JLQMT.VQZ:2;.TSY6DR2RVPU<*HC@#BFQP&?_X0TTU_/--,'MXMF
MLSR;Y<]CE@^.U?G@'FA"DC)OWOYEZ4JWS@FVLLX+ETC#"J%%\LVRJQNF=D1"
M B0VX81 [1KLV5/H[[4'&E[OLV4?9O_\H/;M?!#,!\%M^><]+#!IRM78(HZM
M:!_HI#,=I5:7M3-KP+&2+%Q.%T17&9$Q3%$ 0<)55;]%>TA&KKW(ZXQRF?EL
MP0YLP<T6;+9@!V+!7(.[FFA1J.TS+]L4.QIZVK[<LT_X88^0JXG+:":Z/+SE
M,-N7V;X<B'U),_<'IAL+Y*S8(E^&!FCG=7757LR6XZ F>K8<L^6X+<L14CA=
MB5U(C7-EH##+\J;NMLSII'0_-3& ,82C8=8@80N9/9+#6@:S79GMRFW9%?$W
MTM6JZDH%UP>1(3(;!EI&#HSYK.2I9X;M@UL#LU&9C<IM C7(:&@!2GC,(*XI
MJJ6AWI;JE+!O+UQYF8/U0<-S]TFR5]T&@7((T'7KM6/M V:1$UHRH2YD4C.T
MOM25T!.7A 'L2@&CI(&BM;HQ%R;1W:7R4R+=[MIG/Z160W"P$.7!:)\(*R+S
MX2&&!GFCET0F6,+7UEUQNGA&=$?X0LT%O1%^IL:HM^('W:;$6L<W8/H^F"E8
M$LH@;H@U#0,O<DC"79FFC]]\=#AX&-.BJ<Q8TB53^ !S*DTR\WI^8B3/]9RW
MGF>7&(SU]=8":50>P6<1Y25E!T>H@3TUZSYBX/A&\ -_A8@.(!Q8I<20S(Q_
M6#/)F9HQ,)D;PN[X&Z.?IB:8]WPJ)CF8)$R/6;H73;=$@2 ,:8K=Z>(U"7@L
M+/FA?I*_5ZVPCQE'<G%U@?_GF'AZ@P^+8XYHTZIK"J$C7V%2I:5^'Z6W[8W/
M<1,-PQB5V(54+*PFFR2JR_1<-"*ORA[I*2Q !)T)*70@9L8O4M_X$EGZ6:G6
MO7-U&WU;:1")V7*3MB3- E/YN^ 3S+-XT.^1TTT^HA7_Q(%#C 3F#\\25'&X
MS]23,$*KCFQXA=A A[O ,)3JK, %OOXWR]8]V!Q" I+7BO; :Z9PS2*G9GQ&
MCJQHM^"L(@LKCN^[?,,)1'#??$FU:TE[B]LZC&2!<.[:!9,0R1S9P'.'I8M$
MZ2V]7#'+(NAD,ZV))R[MS_7B1\HSI-@OE[ ZP/CU7,'*#$V?U!76;2:AA[Q.
M?0YG"<M)H"10!2>GAB866(Y6@#2!X!U0XI!^1TP%H2ZS27^G3N)ZB^4;8MHO
MFY0>1$X3-A!H9TAA-<L;L#_$H=Y1@\R*JLU$IM!PMP_RQ%>--!+",G!R$@SF
MF#(SNZICK*ES!5E9.(MVQ' +5I0(Z&O')+9$\&ZVJ,P8S:+_8,-> SSX>5UU
M6^+7M_9 CV1&9,+SH-7(!.NS4\Y[N1(3Y4:7'LH^ZE+EB<6IS-'&P$XLB6D7
M.RBS2[2WC:SHZ,WX^_A()6RIIH']5NQ$V6/T?K9)J7&.BO@I3M$F[S;"'[SF
M1\_C 4^$51HL 6XE,E%T0KE+.?@CD8^Q.3O>,^*UBGRF]JBU,@PD+CYJC*2'
M3/2V-JJ",\WG+Q3S1V[I/]&0L>>2LIN"])G>#N/]$MUV=#!OK7J07(6V%/YL
M3I-48H'!L^$V*ZGWN7%PF/-O$Q])9-W*W4S>9G'<<_D8/!>LU9LQVS-[+&&"
M-R<M.>_.K.0J5@&JK93:2]C_$<F);4]!_8G\3CZC2(%#V*#!/.DS$"./<O)'
M?^(6JM%K>9)O/#[RPELLF.E+2\\3GQ:O[-5\B"EW(QYR6A"O@RK+(WCYJU[H
MB1^1[Q#'/[[2NG;H>:"2AZ/3?6P31.,I&C4MK#I_]K_JX)MG7WWE.U?3QJ_(
MX !!E(K,_KI#C88,2]_TW)I8[@E=I)K"-M&+T8![1.KI;IT"OSKR,2"@%HTL
M4DW$R>,*L\A$[!+5RZ(P ">AE$!>MX"$CFQ"5%R( ]G <X?^&+R,CQ]&;\:X
MYJ(@38WA7BRPH 7.9IVR$TP;14+,(S]@WG\V4 IA33H(LCO^L]MLP21 6(9!
MX-^T /@:?]5M>>_"_GAP_^S!XMY_OOC;:_S-E^R6P]4*;.M.&U;WP1P^4^,O
MZ:&FG@8_'<Z5%F>-/#P-(B$(VDCQD3K?\<4K4A,:72.>9"->+ ($9=O14R_!
M3^-ZG%Q0QDF<F?;G(L-<9+C[18:EHPHDZL2T+=/]:"JS*M$MN:H6.Y>*OPRF
M 3\4,KC!KTHH@!4J1()EE3NU6)A-UN]2!)MO)JY! ?6JJC%]4U'NI=CYTU+,
M_7.?F/,B-$_R9M4UC?+ /J+$:D[/_*._SV-U/^DSKS03OUZ\X'0R6%X],3!?
M452DXZ/JF(\X\?^*K/$,_3BH]3X;T-F WI8!90??N&="F;;9@N62-AG'EA.=
M1S"R#9> 8G<.S-!K3N7R8O[J_E?:FO,ZK9<I^*<G+]X5;A=\T_L/$BKS8:H7
M[GIO^+DO9SMU4,MJME.SG3I<.V4<-JIZ4LRH9:>LVK9!(?DEQY>/.;0%4^.Q
M;"\P-42U@K^1UF!0#$:B$27[!V,(#F"]6=25&$.TC03?+^3FE;6;1FV0\/WL
MHE(-(Y!OYR5!&MC#(P%F?P6O#C#F=<Y&\J#6]&PD9R-Y6T92(TT3_U5@Z<X%
MLQ.,64 L1#JOH\&BM%O7 F@"NZERX83;JZMWN[XUNCD(^*[0(7TSTR$=W,:9
M+?%LB3^/)3XX]J&#>Z QS9JX7L1UQ3BE@'5</*[@SLM<9.JSR[Q!+]P"SRXK
M1,=5Y=2YYA6U>T U!8R=XZ]+I ))5Q==:Z3G,>PPH%*E(KG;P/1_>#R U@Z3
M/57<%;+A(ZR:Z%\YU*))8]97'#R2BP]!%N$222(=?P&Q#,)^25HV;00$%CZ"
M]<$=Y_7S2T3K^3N?+GX5^"_!"#DB3!'59?$0 HSSRXU7VTT>#OY+X,7:K4EE
MG,K54A#OP1F:=.-N=LWFPTJ</9P^X=='8D(+PC?*=1(QFQOV$WW3[]#K"$MI
M:*.WV FB K<?L?<<?Z&>IAP,$F(?IFOCLHP)(Y_618Y(1ZQE$^2K6O]U<>_L
M2W9&B+P4^QRR=*?YT34XZS!Y6*5"!UR4EQ78CE!A$ISXU[/3^]_R59;P5.*N
M2S^'-!>P\WWO@;D;3@1>[0_X6+[>4<95*U&,'H,YAOU3IUP9@W]YX &G5=I%
MX?"1__7;^_=/[_.5-_($6/<'D]WN+!;GPA64:8&Q/0G8'7FVA_UGJ_JOG#=-
M!X\2O_G@Q?'BJZJ\='6;X]+.W+*U#Y%U"KA"PT'HNMJY$QIE#F1\I+*X]]67
M'MK--Q)\]]?'OX(%PR/-, C@"0TDM+K!?&37XV^6CC&? CS3OAW&7(6CG+I=
MFFKC;#_,C6Z06K-&1M?G[N2S @2JT\R =D<AUAJP6G"J7(Q6E3:B'36BBR7]
MM,4_D_Y^,XP$G_.=1O2'V%PG?J!,KTCFV)FRV%=5?2?Y>;H5'!HY-=/D)6PW
MZE_#H\DG,XL=,;==.>JNHM8JY4U"H#RZ8$A/Z8\+JJIC$E1:2QH^V@Q+"G/#
MD;7J"+0_>NQ17QH^+BQ/[D9C""#,/'8<8-KXR+?TH[%YO-+E8+MT"G>>%HD]
MPFFZR?M0#@B/)LURAN/S97BQ1/Z6K!;=\/)UT99DE@EJRZ(-1@D/O"S[,P0X
MHSF_!O)VJB>/8.0&H-%1*)G6&8/Q?_J.N]6UV'CV_<.OXF*C_<27R42=DG__
MI,JRDQ]A<MXN?L4VO==MC6V"K] KW-"@O*QAR[",+WV+H'7P2?AOW2%65<H/
M,H25J4@D6I)X_?0Q_?67M,G2/TX)V&>V99@ZV#Q-59:N\/I6O&5[>/5T@[-.
M8R.[EZ=N:N\^AWE#E#(M)N[TDV_(*Q ]+:DZ,,%(%3?OQ60CM/;H.V&;FCN+
MK>+!(  HG1EDXGD&^?2')\=#ONF\J"!^$XV+N QX@$4W#@9/U^BP&6GRG>A)
M\I9O'GC>J7\$?\671'N%QP[COJLE637M7>*)XBZP19&'7MP&K!:^ND!KY3BR
MM2S9P68.>9BL\6PZO'3NJ D/9@N61\(,EO"D:4W3 +?%^A7,/#P2?[()7#"-
MM^(4#/ U*)(23T$-;+'S3@..7]-2CQG7I&1MU2KWB&%T*&3Q8\M+>N59@42%
ME6CWL+0S<5.8AZ='N]ST[T[,4Y@4\2MD@FGDV/_-X;UY _$*=O6ET_[C)17\
MXCZT\'MT,!!BQA#[M!EI^CORD^59P+\E8^Z"VO/AFAW,/6T"4WC 3NN:<@IQ
MR1:-'F]%YBO::/GTYEB2TX7/5NB^!IOJ8*!+3_1*OB"R#62]R@8JO:,1/[M_
M\E_C'I+J*/?V*JW =$$%VX+Z"YN&6VWY.;UG0[AL+[@5.SG</QL,I#_>Q#&3
M9N45&;<;X;/'K0JUEV"2)@+OZ #<^*DT,(,#2^3#E%M7>E4<WE(&T'@=6"B'
M_8W:TQ>YNXR.(%X%_<G&WVH7"9B-59TO>=]"U!9-B2O/4QH+:CX$%Q%[">E(
ME/90=C.Q/9!"S?>;!#YCP(>$'7LA)X^JK!6%(V(+Y#7@!!,7U\+C&?5)C[#/
M'/$9&'\77@^>:H6+UI-[P5WHQ9PG.:8SL,!C@?<6.0_PQAG:M@+N@[S&BVV1
M,G*5EB-]T(\#F6TB&ESM_L1Z]"\!L[QMI($7,Z'^NS+XCD,03)."_PBOFE"R
M/^.CHZZZ\XL%KD*.S5/?2]Z0:<D<.K"8=\+U'XYRW4V%>*'!4*3Z:'&K@7P(
MGY"I]&5IK*OW>.TCM^=XHK)Q/<<W+#4=$I*1C)#I&N'JX!/4.)UA+;W7<J&I
M5+%4/H*Y4\Y&)[HR4SYO=$TP%4S34$X'C_XL3Q61[=DY_+*WB61-6=,KGRZ>
MA/S/BK+!1..![A3?*>D'ON2LX,QAELSWBEVY]&W)ZQK[P!U[7ZS*X!6#)-'*
MCRM=.N)TFV=.,R*R@&59-0&*-':BO7BOT?9I:=NP[C @66"XXNJZDGYM_'%=
MIUT&H;J_;K.#/;U),$SC[O[%177%\<O(=L2(!1/^$<@>'4LX_9?H7Y,+N6RJ
MHL.]#\M'_%[?OQK?UR.C*HKT,!;QUAU6Y.GB;Y)XDH,U+S$UA-$M>)YM<"_P
MU>(K-_1*8OLE5^F-C7T%?=K^PV[@O N9A8PM.(TFL<#@.(:QEUROMKZ;IZ%3
MD\<?HH"66^+A6<P%EDXF[.BS$\_6(>IO%[;F8(L,'X <SDV"A\D&E-)&[MN5
M>M?WSCB) R6[62^CB2>Y*>VC?3DH2H%*6J6F*US <>C*9++C>HP81SLP-7ME
MV57@EM(WJ[P[WM$6H\)7=)KC\"GV8<-Z QNIH5VM20C?0&PT'-.NO:@XMS)8
MH$<.W/GV/8$[QY<K'M;D;XNMR,#2@MO'&+*5R[K:A;KEWK,, _!5&ZRHK<8?
MK^T<SWGV0'=3R4^;SZ1LCC^[JYL-/&5HY!C?\5'HE$4XX)+11**_*!=T3%3
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MX#Q4'^)7/-P0BY,%U^;ZU/+ 4SH%SPR#[E*"&7*%Y#&H4 ^A4T8EYO/S&HO
M-.'?)=\\^#J!&3*<5+&#UGI2.,3+N-KX5>CT?7,*WX5#GK]OLPQGR5E\:7J
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MZ)J/$3Q\6$[+@O3.'+5@<0Y63^7+QF4$PY<>XAOU+["Z##SRC#0<3J:NI_&
M-!EG/7/FL"*("OOGE[87>$":J/!A9@_44-ALF.K(8&67V-!ESMQHXFDV*!/A
MD!&LP</<B.*J(]_V$+C[:-ZV\'E@8\@MUQ8 %O8Z]FMN02<'+ _XU3C:$KKT
M(HM<K1RR:$?\;]HJ+V(=Q2B":/%4M!.'1CHA;]'7#*:+"P>P&-H=Q*CYFQ7;
M"Q902W@N:6!&4PR8  G,ZA%A2EM.E!08:8)K9VU 0QE=IV,3307--$*JHW,
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MJF8JQ@P=O+BPJ_26;FN0OT2C#7KSQ4!N]9YA@)%S@L1<X&[1\%HF++1D^2O
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M;/VO.;[^UWTUEPN*<.].^:AUO+!P>9,IKSK(YP_5;6LD!,G]=Y6E_1(F[)!
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M\(O.8+J[1F!J>=R0=FLHQ=H4%V5*&BG%D@JBN;\2N_1>&37YH"*"*%[R>.)
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MD<C03?4L<+@>T#*(,OC"]6_<" :,%(-GQ5DBKKY<GA]VVAVX/;Y.W E1%G\
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M OJ,LC"_"50UA"4)J2+H*$ :O"<>IBZ(42*O,UCEQ,E,R\X-^KFC0HMEX@7
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M&T&F=S+OU&\@ ^MSW"&YJ8VD/;_\+5Y?W J7P=)E K_I($TVA3_Q"OF73+Q
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MA)V(C#L><"0".G$ _3-?X*E#<'_BXI .<?=0#%T%5Q0T16I2\U;\4%I^ QO
M16)*4GT!=5 WC7([K:/:(.ND.WB_L"/Q/3.I'KVPI)][<?P"R>^K3JNWZ!U/
M.1 0EG%.(DHS63RBSBF-"+O,MQ[11WCWQ/2RQ!@RKV/W9L[&YGV$E0AT"WI]
M+WR?);H/_3!3()U*:0MY_N5*@:'][4H[2D!_$M<@\?69+)*.^<+N^1X(-6Z
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MK7+CBI8D2D'64+\=O$3X@5^@"1I=<'(/AX82BBCA5BA!=M27(T"1PF@F66B
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M## NS\UT-HF2%:4'^<*W8T0LB4$,)J"5&%S,;U3%'B9Z*>7^I=)K=(GGJ8>
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MW[@!T^KU#_1R'*#O2F66@ )BNT3"F*_;B19ZX3/SPOYU\6Q;_$D_AAGBW@)
M\6+D::%-8!(RNP[9IX " L%=F*0/)B$%&0[\"H\:G5?F!?9HPK2I%_7R^H%K
M_OF17DH%!(]$5E510*A(%AHH" 440 Z0_:JB@.B/+#155Y#2'0.2'\FT(:;3
MM;_L5*#]QZ^1-[']9\,3-=B+8NUN:K;V(WN9NI[AO5W]9V8';W>&=^L]!$;
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MY(K#_7*C0"MP!310$&(H@!P@^U5%@5;,"FB@("B-+ R#NWS+(7NI<LCY%\@
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M>2S[-66.S_R/]#J,I#=>7@RH-G;MP#&5JC.CBE-]MXBFVH5D5,&KV !<JC"
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M7V'__&ES.7\:6M.!8PT2MC0\_#UZ_K3>U%N-!IGC79*SE<C(&XU!<J#9XK$
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MD\D[C^9HMLB/,T._T4&Y9I T2!HD#9(&26\AZ=25GUE)FO*@#I!TJ4D:@SK
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M >:N I9@[N*8.W6#Z1&8>\-!Q6;FKNN]?E]OMGH@[K.0/QK$C3.,PJ$ ;U<
M2QQD%,;:J3M.C\':Z\\TMK%VM]G2ZSD6'52%M96,12*V21I/,=;IMT",J^>_
MM>S7_1:?6.M?]]&M^..L,0 F_U3F;;< V1\B[QU^8$PS3''!J>&\<='D?PGX
M]P>N-K8=PS%M8\+7:03LA3^K?[F\]@*VFQ+"XBOKC>DJFT\'XGJ]%R[HV8M6
M-.6&^&+D,>//"V/,%_31F/PTWK@A_XWL7N_W$.'^C=R)M??>9]WHV_OKH7;W
MC\']]\'PZL?C]7#P[4'7KF^&*;4YWT5*IG]X'#Q>?;^Z>7SX8WA[\\^K^\?K
MS]^N_KB[O_IZ=7]_]>6/A\?;X?_YXX&;E_DKM=NO6NS%VOS%FGRQ-K@)__6/
MVV]?KNX?Y+C%[N_:U?_]<?WXW]K[+U=?KX?7CQ^T4IG?][:C!<_NS.<^D*]K
M[)?).-U+KTHS7KB?$?@?BC. (;E*K@W=$^E@F6PR$0X(YXOYSZ%K(W]./.A'
M8Q:XOX?.#7<L)L;49Q^C?_RNA0Y0K19>_)8J9#A1L4FCM74R]U'#\[,-XO*J
M[ZP1NV) [G>W<(^70\$?CB^<8]%Y1Z!(L-ZZ[&^!*MK'M9'RKI9Z1[6)$^%!
M2&:%;>@Z/+H-;&XH<^"G<UGUG<?&S/.8I3T$KOEGX<6"IPB-:>P\"8N]L $R
M\;73>)(3\RF 2@(E/V$'4UWN_2?&I^W+'6]+J!"=OKRX#EB%@K)4*PX@#,3<
M:C5.:+44*+W+>N;[<TMLI@9\N\3AD3&IDM-OV!9_K,+-,J5[4&@@ _--&8A"
MS7>W\]<*F673G+W,)D;QX]Q@I2A;J2IM<('6IWO9@O.XT4II\KIP+3%CMG#+
M!8L$OXD"$(7Z33U8KC1,CVY0J8A7IB&?^=<SS_^OPNTR/,KLEW]6I)2$=#%#
MM8B5-!2%4.O:<[#N9:.U_WT7U3XHDTT4F6_51:Q0 I.625$03%"P>.W+#BS>
MOFD3614-BU<MB[=3J1D *+:$#(1#G7 ZETT0SGFZV$C[D+2+N[GB54* FL7K
M'!HK5<[B$7&Q8?'H6SRX>E0-W_:2W<K9M:$QM<.32^0.8+!@L(@9K"ZZBI.H
M?6%CV[2+]\1@L%"<6AU#M+U>M7*&Z)OK(P-&#Q98*UBK[36JE;-65_^9V<&;
M]CYTGXJ^N!*6ZY"2S>"HUYBM5:NPA+.DV__9F!B.R30CT/ZWX<P,[TVKZYH8
MITMNDG/U^(7 GN]P8E+D&&(2Q;/%P]39K6"6R@3S0J#+,,"\M3S _)&]3%V/
M&TGE6*B"@-CD\@VCRL./>(@F* \GAN_?CF5'R>"7[4<OB,V/FP]5DR_ZSL2T
M=#'IO+L\Z?SZYNOF6><UO5-OZ*U^G\RP\TT6!P:E>!2.P[78=;#M'C!EOA;]
M: BU=JO3!M%NN_$\P;/M+3P[-#Q/7$F@RE$&0>#9HYF<1?WHWLF N2#BO6AN
MXEW--PT!=O/=ITY?;S:[8%]BHDJ?!TY9Y Y4=D7EA,-3 0I<IO.'J;U;NP'\
MIOT2%)UEQTF-RY5NRR')B=#M<KD7YHC;GI)^TOPK#DE)Z)UN0Z_UX!-1$T.B
M%@09"=!K\3#1RTBT=VMKJ32SRAO$&B2UJTK*0]7&@5G +(7#1(]9NHF^(3!+
M/KGN[G+(%I\IJ.*NG *U@17=22 &]5\[8=/3EG3V(F?=:S81G!&3-ZK&'!0*
M"BT<)HH4VD5PMNWBX_TYM'<R#KUG@6$[S+HR/(<C[&\C3REO%SL>"K=:>JO5
M L<2$\C,70*@5]!KB?6"'KUV$OV9H%?D/@G#0-/&@5G +(7#1(]9NHE>6C!+
M3H%;_Z# +:>HJZEWZG5$7<2D*1%U96L!/EIG_>$MP/7F99?T]E_[_DPV KMC
M[8%Y-O^RH3:-ZN#YFKF>ZLLW/95K"Y2SH/ZK.2P06V%'VV*Z?N"+W_QE7ZO7
MJ,VK]%S/-E,]A&)GH]T?BF_)H9=!(3A<U\?0J]5K=?F/S2= ]7XO-SMY-.6$
M"UO(KE>+G8BBH/J^*^V%[E\UW:KM9(^9]67F\5V_X[;4M50U]0T+;L=Y&^L=
M&L_6&^QM==9-O=[MZHUN?@XO3$JI30KH%+)?5114=S?H=)^<3JN^;4C*:D+]
MIS&9,;X.^9?":73G1NYF5^\W\ANC H-2:H."1F[BJ*"1FQ H,%B%HZ#ZM"OM
M 1U8, $%*;6"(#R&[%<5!=5J#'( .10/ TD% 3E ]JN*@NH6!CF '(J'@:2"
M@!P@^U5%0?7!@AQ #L7#0%)!0 Z0_:JBH+HX00X@A^)A(*D@( ?(?E514(V8
M( >00_$PE/ZB4O(M>E>_F&?:ONQ2-.4<>M69J+E348:9^69RS%<HVWR%:ELF
M$BB@.0W#=ZC 0%)!0 Z0_:JB@%8KD ,5&$@J"%J'B*."UB%"H,!@%8X"6H>R
MS")IK)R(MV[^B/SCK<IU1;DPZYCW.F8?/%)OUO1:"]<[4I-1HM8#L3!DOZHH
MH*\*L3 5&$@J",@!LE]5%-!7E6$F57/'J$H.H3IF4#6PMMS!N.LHWFY^,Z=@
M,$IM,$"6D/VJHH ^,T125& @J2 @!\A^55% GQG(@0H,)!4$Y #9KRH*Z#/+
MD&9K'3/-AN38.0M37MUR1^M>K$"WG-2XBY'!]4QTRTV9XQM2L]DO\6]&KZ,4
M#@CZ>"N* KKET.A.!0:2"@)R@.Q7%05TRX$<J,! 4D'0+4<<%73+$0(%!JMP
M%- M!T:G @-)!4&X!]FO*@IH" ,Y4(&!I(* '"#[544!#6$9*E7:RY4J ^O?
M,S\0[5O^HSNP5G9IR9D;\OA\&#L]OV?_F=D^W_T'YKW:)E,E+O?,=)\<^2FR
MVH5:_UBKDU^-# Q,J0T,R!6R7U44T$"&R(L*#"05!.0 V:\J"F@@ SE0@8&D
M@H <(/M510$-9!G2<AU":3DDT\Y:^*A<SY;H+HNJW\(-3M2_R65-N2@[0:F[
MT&Y8H$U<O["[V>*NR0GP.#<MH=(<NPF::-^J;<]((*7:U'(!J\RN4,&#5G;2
MJKC!@V:!CBH'!>CH[)%2C7&@(]#1&6-#@(YV:I\#7=&":GU/'9"B25=P+,X%
M*=6?!\<"CL498T. K1#G%@\%Z.CLD5(=@: CT-$98P,Z A2@HS(@I7H004>@
MHS/&!G0$*$!'94!*=>V!CK:@]W[_ MWN<H'NG>>.[>";Z_LY=;C?L\"P'69=
M&9[#P?5W;FV7,G?Q3A/+-H*_O;-_\5V:O5AN$+XP7K';J.O-3I/,+1%@Y@UB
M^@&D3  %HJ8>I'PN2*EN29 R:?1 1-2A 1L5#P78Z.R14NV98*/\0\1>IA 1
M\5UE:341WY7N5L#5>Q_?PY$[L0X#(^O.?S8FAF,RS0BT+\R4B1:M6=<UH8/T
M^I>/,TR"!A)$AQC$+);843@S-&%*-F%F1ZK,GLP&1^;7R)O8OI@BX2<\F?ZR
M)_/(7J:N9WAO*H$M!T_XM[/ #PQ'(+-'"GPX,7S_=BRO9(VGOX>N\\J\P!Y-
MV)W'QLSSF"5?%,N#+[M'US=?-[E%G^I-O=OKZ]UN#5,JB$DE48."P4U@V^)A
M^@LYA)+MI2#:7*8^M6M;>'9H>-X;QV/PPD$.!D'@V:-98'"*?'3O9+Q<$/&*
MO,1.Z8AZK:LW.AW0+S%9I4\$N+V2(BKK.VT!"GPFP+2E?1:.4SX9BG9]V7,:
MNB\OKB/]ED.R$YL*]&)?<4A.0N_5&GJ]V8)/1$P,B5H0I"1 K\7#1"\ED>P$
M!K/BE@+",-"T<6 6,$OA,-%CEF13+Y@EGV1W8SEDDY'4LSOAF^RKN.MD=X5F
MSV?KS5X=D1LQ8:1JZ<&OX-?"8:+(KUU$;KG7G[>;)R/8#:W*AU>P=]IZK]8%
MQQ(3R,S-R*!7T&N)]8(>O2;[C4&O2(P2AH&FC0.S@%D*AXD>LR1[A\$L.05N
MK8,"MYRBKI;>:J!.EYHTY= B?+1) H>W")._LO7:]V>R4=@=:P_,L_F7#37#
ML;0OVC2JE><KY]HJ<"KO/BB/0?W788'8#CO:&M/U U_\YB_[6KY&;3Y5S_5L
M,]5E*/8U0F HON60;@?Q#0K"X<"QOJQK=>A'LQCZFV^^KC?;9(8LP(^EM>O5
MHBBB**C6\$J[HAGJJML[&61F?9EY?-?ON#UU+55O?<."VW%NUGKWWK3U!GM;
M)79;;_5Z>J^9G]<+DU)JDP(ZA>Q7%075  XZW2NQT]DV1V4UH?[3F,P87X?\
M2^$TNG-M7+>F=_L-D"DQL25J4-#J31P5M'H3 @4&JW 45"=WI3V@@J_Q@H*0
M5A"$QY#]JJ*@FI%!#B"'XF$@J2 @!\A^55%0_<0@!Y!#\3"05!"0 V2_JBBH
M9EB0 \BA>!A(*@C( ;)?5114*R?( >10/ PD%03D -FO*@JJ&Q/D '(H'H9E
M!5G7JOAB6]:$G>>%IN2[]*Y^,<^T?=FM:,IA]:HW47.GHA+3I]?,"_9&"W5%
M44!_&H;P4(&!I(* '"#[544!W58@!RHPD%00= \11P7=0X1 @<$J' 5T#V49
M1])=.1EOW0@2^<=;E>N*<F'6,2]_S#Y[I-YKZ+5>#_/VB,DH4>N!6!BR7U44
MT%J%6)@*#"05!.0 V:\J"FBMRC"6JK=C5"7G4!TSJ!I86RYJW'T:+RYEI":7
M1"T&V!*R7U44T&N&4(H*#"05!.0 V:\J"N@U SE0@8&D@H <(/M510&]9AGR
M;/UCYMF0'3MK:=J]92[ [7Y'PD"JW,7(X(HF^N6FS/$-J=KLE_@WH]=6"@\$
MS;P510']<NAVIP(#204!.4#VJXH"^N5 #E1@(*D@Z)<CC@KZY0B! H-5. KH
MEP.C4X&!I((@W(/L5Q4%M(2!'*C 0%)!0 Z0_:JB@):P_4M5.K7E4I6!]>^9
M'X@&+O_1'5@K^[3DU UY?#Z,G9[?L__,;)_O_@/S7FV3J1J7>V:Z3X[\%%GN
M0J.#;/V$CGCYC%[KMW(KH('U*;7U ?-"]JN* MK+$)91@8&D@H <(/M510'M
M92 '*C"05!"0 V2_JBB@O2Q#SJY.*&>'3%N5;$:V5K5#6P<3?6E1W5RXP8G*
M.;FL*9=S)RAU_]H-"[2)ZQ=VKUO<;SD!'N>F)53::C=!$^U;M>T9":14@ULN
M8)793RIX1LM.6A4W>- LT%'EH  =G3U2JJ4.= 0Z.F-L"-#13HUWH"M:4*WO
MQ@-2-.D*CL6Y(*4Z^^!8P+$X8VP(L!7BW.*A !V=/5*JEQ!T!#HZ8VQ 1X "
M=%0&I%3W(N@(='3&V(".  7HJ Q(J98^T-$6]-[O7[W;6*[>O?/<L1U\<WT_
MI][X>Q88ML.L*\-S.+C^SM>J2IF[V+%FM]'1>[TFF?LEP,P;Q/0#2)D "D1-
M/4CY7)!2K90@9=+H@8BH0P,V*AX*L-'9(Z5Z-\%&^8>(S4PA(N*[RM)J(KXK
MW7V"J_<^OH<C=V(=!D;6G?]L3 S'9)H1:%^8*1,M6K.N:T('Z?4O'V?2! TD
MB$XXB%DLL:-P9FC"E&S"S(Y4F3V9#8[,KY$WL7TQ8L)/>#*M94_FD;U,7<_P
MWE0"6TZE\&]G@1\8CD!FCQ3X<&+X_NU87N8:3W\/7>>5>8$]FK [CXV9YS%+
MOBB6!U]VCZYOOFYRBS[5^WJCV],[M0ZF5!"32J(&!5.=P+;%P_07<@@EVTM!
MM/F,A&IOX=FAX7EO'(_!"P<Y& 2!9X]F@<$I\M&]D_%R0<2[^X@H3K^U=@_T
M2TQ6Z1,![KVDB,KZ3EN  I\),&UIGX7CE%.&HK/L.0W=EQ?7D7[+(=F)305Z
ML:\X)">A]WLMO=%HP"<B)H9$+0A2$J#7XF&BEY)(=@*#67&% 6$8:-HX, N8
MI7"8Z#%+LJD7S))/LKN['++)2.K9G?!-]E7<=;);1C/GLQLX3"8HC%0M/?@5
M_%HX3!3YM8O(+?_Z\][)"'9#J_+A%>Q]SK']&CB6F$!F;D8&O8)>2ZP7].@U
MV6\,>D5BE# ,-&T<F 7,4CA,])@EV3L,9LDI<.L?%+CE%'75]%H/E[E2DZ8<
M6H2/-DG@\!9A\E>V7HOKE(V)-IV-)K:IN>,Q\_A>\']P?1358'S97%7)#7F
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M0//L_ES9JU'DRC4U?_E6Y<GL.X)0:B),U+B 6"'[544!#;&XL8P*#"05!.0
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MFWJNR7R?;X3/#,]\U@S'XF;GE4W<J;"-]'J"X?FA$[NB**#1#[-]J,! 4D%
M#I#]JJ* 1C^0 Q482"H(&OV(HX)&/T*@P& 5C@(:_;)<#=G;ZVK(@<CZ^3+W
M?[Q;JPZZX['7K>NM?@O3^HB))E&C@1 8LE]5%-#\B!"8"@PD%03D -FO*@IH
M?LPP^[R_S^SS(\12:^JR\AV'WM=[K2;B*V+"2M2,@$(A^U5% 3V+B*^HP$!2
M04 .D/VJHH">19 #%1A(*@C( ;)?5130L[A_\JU?.T+R#2FS2BD_+A \-097
MOYAGVGZZU="=2MVDUXD+MP3]SQ5% 0UUF+-#!0:2"@)R@.Q7%04TU($<J,!
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MX,"QOBL3^'8[_FYX?[) W)WZP,S0+!X]RUFOZ?PS<=1*3=BH&@+0(*2_NC"
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MRA='HC'KSFT+?_;0MUPD.Z6_&AF+K?75(J/$;=9BA>%V2;=2J"H/ECR?$\-
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M.MZ-EY3,0X9TKYSRQS<O,?3L8SLF&<-)//J%>/0+\>B*.W19%KL -<DX8=L
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M0DH*C87$Z%%EYM/?<S)3("$! @0DZ$1,]+BJ0,H\K]]Y99[3)&O4LF&#1G]
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MB#6^Q:%&:;E]?5AK]0>U7E/]46P$Z.>W3!MN<B- 5P8E"- OA56Y,V$(S\O
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MP;'>'86V&?">@?B+;\$G6P#;NF?5XK\\P>[BS-BB6T1[\7S'>K$M5L/RNP/
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MH$6[-/P2U@?:-Q49!%<<H!;)2EY;%3(A:M7P;&8_2X1,=/! T *"!/&RC?2
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M."\*(.W< HBF2@%$6ZE]%*AI'%S,R#MP<4W'*WH7<+PB>;8E=<#BP.,-%Q\
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M-(2%.(85&*[HZ]]2+UD2JM7/\/_.- $HPN";,4=C!3_Z$;-^MXV1[=BAS0+
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MI9YR^A:?+%K3@%B3,F[[R^.46]M7>#.7,U\68),U[9?<3I2<KDSN3X"^V9@
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M#92MWL<WR8Q)6^.;<!.X^)7[]!E-8"FIZD08/FA2=5PUF:(.-#*PE11\5=E
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M*D]U4I[+7)T.Q,.AJS[C:Y]G/.)ELIQD.;?<<E:WR7(^&7INIP6M0RKOJXJ
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M?!B*S^D/7UAJ 2J) .]B\E,0N(NPOJ*03UB?4400UF<($07 ^N 96^WKS(G
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M6=ME62/DD9#'IU_9OA9 !^O<"\^3;DCO;>]._$B@(X&.IG">0$=CMH) QT*
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M'E"RS%<KM[R1VFR#(/=1?0UNF8$S<B>EJKRGSM[]4HZQ(FO\Z[\ 4$L#!!0
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MZXT>T52Q6:F)-H&W#[8!";#702R N9.GE(0F1%RB5&MYI!FI10\:/%B[R'\
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MG='2V^;N%MO'A4R[)&FE6\[EM>!)XLHMC7<HB$;(#>7F?UG+JFUEAS"#;66
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M[.9$S5RUVJ-3H(%HK$.LOOWOT%3-5[!6GSA8@*.M[@T;+@Q,G%?B=%(BW<
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M&4;2_;Y5"(-UH')9[!MZY)/?B,V*?."O[O D"U=TF"G"N\D">3%3R?M@P2)
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MG@4G<PA)5F"TQ(N".YC.1D\MLAP^TOA,VN#O%L1^2K$ >_VQM,3<I8D(\4Z
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M*0"^<;":DRRB /26BYR&:0\#>768(T5\=1B(&>)-*>3KPX+,$39,1?#EL$3
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M4_R?V]($IU&CLB0C@E;_FV-@EK4VJTP0R<)FR&JA^,U?*1PY/T7VS=X"N3X
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M/E9O['T7&//X0TV1G2H J$!0!QY/*9M3J'(&FQC_R+N?D&TE(P8]TY+K:>4
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M^NBWCK]MB#')@[[KS*#HS6_'R8>^PC=%PTZUO:SKS\F_2,.]O_P_4$L#!!0
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M]4O:.#P85U8,+(/AFT?\_#:",1\3^:$Y$O+1WS\D>9R_G),E2!J@2\+DZW_
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MX Q]<=4!F+"JZGR%!(U$PYY#_(+1/LF#].5CC(B=Z'G"P9?'Z+M!S)GMEWP
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M/$_CAWU.[_C>XYL@)2+8&1A_YD?&E>;"K,[@8YPD_*4GHD_;7 S/44]/A=&
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M<UGV4# &G#-8*^'I:VFWUB3G9;T>5I!EF+ZH)$&LKZ3;,A70D4LDNZ.V:I>
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MLPGFPU=ZGP;JIU&5R)F';07R]LVN8,KF8(DM$'SYC<BBVMW@7_LQ>>O@C@T
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ME:@\P,6M#WK;<]X W/9I6$F]RP&R;=IL:0$_^^: =L.5.O0^!S&B(GW$Z5U
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M*L431F2FR'@AI5M(A81<'3L4*VT0M<B-7//WDW?1JXVQ$/Z7429^^)0.=MA
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MG45Y\HS>>X;I<TR7V>M-BQ(R^B@N:_^5_MM/NWS-T;8IQS1^ZDG6S(GA8)?
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M3!;]*Y"]9$8TZ^LFZZ '(V,&5N <)\\PS6-:(;YDS5'RPZE40,,:6O08(-3
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MYSW;MA.)L:=7MD]([$\QO/[B<J88&92!HRH71U13'$W-9_?20?+X(]PN8E8
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ME4'S:="*>"<:R5$9M!HN#2AG^'P>M![>NAO@F Q:!U??[V0@?1FH)BZZM<M
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MN\?)W>7%]-O]P]6O5W>/-[]=W4X?'^4N4>7I]N1258)Q T&MWR&:+Z@-F;Q
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M?XE+1.3&8YE"A/T_T^@OP&.7J0^43[KUZ*RP?Z#L;O\@]YNR<"@/9/+1C,-
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MO@4<J6P'-;I=27K28"&JT1TO\;N_Q!>:J!8[O?73P6N 8OG&'DH' 5$4%:S
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M;ANU7E"_"5 K6R[\W,AL M8G*1[V#BSI'^.F7L")KZVDRY=%J!F1*GH.D(L
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M4<XAQ]' R=%L$NX%7BY1W-B*"DY5/#.FT'<8$/JR<IL-TI<T744IC.:+01#
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M4ADB4_(>6B:->O6_1$9D,(2@Z#RFT%G ,L,#*K1'3M*@UKXQ"'PH_,!U#]\
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M3S+!TG'_\Y2/N27->K5Q%,R.-X\]!*69?N;@Z_]\LZ/O]H>CL].S;F=T-KB
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MF,A.:N[)E[_#((5#*0CV<+=W7MVC"5'./.55[(6AX#H3K,(P1/23(59^N*D
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M<'1Y,6QK<VUH8F$P,# P,#,N:G!G4$L! A0#%     @ HX)W4LI;"^753@
M@EL  !8              ( !*'8  &=P='DQ;&MS;6AB83 P,# P-"YJ<&=0
M2P$"% ,4    " "C@G=2LV],:M]#   "3   %@              @ $QQ0
M9W!T>3%L:W-M:&)A,# P,# U+FIP9U!+ 0(4 Q0    ( *."=U).S.'^$Q
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M+FIP9U!+ 0(4 Q0    ( *."=U)Y_$$:XA4  !P;   6              "
M ;PB P!G<'1Y,6QK<VUH8F$P,# P,34N:G!G4$L! A0#%     @ HX)W4OPT
M3K*,7   @V0  !8              ( !TC@# &=P='DQ;&MS;6AB83 P,# Q
M-BYJ<&=02P$"% ,4    " "C@G=2'=^>]YQ%  !R5@  %@
M@ &2E0, 9W!T>3%L:W-M:&)A,# P,#$W+FIP9U!+ 0(4 Q0    ( *."=U*5
M7C!#&QL  %X=   6              "  6+; P!G<'1Y,6QK<VUH8F$P,# P
M,3@N:G!G4$L! A0#%     @ HX)W4A'UU]5I%0  $!L  !8
M ( !L?8# &=P='DQ;&MS;6AB83 P,# Q.2YJ<&=02P$"% ,4    " "C@G=2
M#]FPE $2   L&   %@              @ %.# 0 9W!T>3%L:W-M:&)A,# P
M,#(P+FIP9U!+ 0(4 Q0    ( *."=U*2B470S#8  'TW   6
M  "  8,>! !G<'1Y,6QK<VUH8F$P,# P,C$N:G!G4$L! A0#%     @ HX)W
M4BWU'*@6=0  !GH  !8              ( !@U4$ &=P='DQ;&MS;6AB83 P
M,# R,BYJ<&=02P$"% ,4    " "C@G=29A\Z<3(A  !E)   %@
M    @ '-R@0 9W!T>3%L:W-M:&)A,# P,#(S+FIP9U!+ 0(4 Q0    ( *."
M=U)35-"PR28  .,O   6              "  3/L! !G<'1Y,6QK<VUH8F$P
M,# P,C0N:G!G4$L! A0#%     @ HX)W4J\(B6_<1   8DL  !8
M     ( !,!,% &=P='DQ;&MS;6AB83 P,# R-2YJ<&=02P$"% ,4    " "C
M@G=2!L;,H.XE  !:*P  %@              @ % 6 4 9W!T>3%L:W-M:&)A
M,# P,#(V+FIP9U!+ 0(4 Q0    ( *."=U)TK;&G\SL  ")-   6
M      "  6)^!0!G<'1Y,6QK<VUH8F$P,# P,C<N:G!G4$L! A0#%     @
MHX)W4M(S4UI.1@  7U$  !8              ( !B;H% &=P='DQ;&MS;6AB
M83 P,# R."YJ<&=02P$"% ,4    " "C@G=2_]0'H04I  "K.0  %@
M        @ $+ 08 9W!T>3%L:W-M:&)A,# P,#(Y+FIP9U!+ 0(4 Q0    (
M *."=U+@V46NW#D  &%,   6              "  40J!@!G<'1Y,6QK<VUH
M8F$P,# P,S N:G!G4$L! A0#%     @ HX)W4F@4FW-U1@  <DD  !8
M         ( !5&0& &=P='DQ;&MS;6AB83 P,# S,2YJ<&=02P$"% ,4
M" "C@G=2BJ-60$\S  !_-P  %@              @ ']J@8 9W!T>3%L:W-M
M:&)A,# P,#,R+FIP9U!+ 0(4 Q0    ( *."=U)RN_ZJFU<   -L   6
M          "  8#>!@!G<'1Y,6QK<VUH8F$P,# P,S,N:G!G4$L! A0#%
M  @ HX)W4B4.'>9I4P  +EL  !8              ( !3S8' &=P='DQ;&MS
M;6AB83 P,# S-"YJ<&=02P$"% ,4    " "C@G=2D!M"D+T[   &1@  %@
M            @ 'LB0< 9W!T>3%L:W-M:&)A,# P,#,U+FIP9U!+ 0(4 Q0
M   ( *."=U)7@"BCKV(  *%L   6              "  =W%!P!G<'1Y,6QK
M<VUH8F$P,# P,S8N:G!G4$L! A0#%     @ HX)W4CE/-(1 8P  N6T  !8
M             ( !P"@( &=P='DQ;&MS;6AB83 P,# S-RYJ<&=02P$"% ,4
M    " "C@G=2E(2+?F0P   (-0  %@              @ $TC @ 9W!T>3%L
M:W-M:&)A,# P,#,X+FIP9U!+ 0(4 Q0    ( *."=U+A. "BO"D  /,N   6
M              "  <R\" !G<'1Y,6QK<VUH8F$P,# P,SDN:G!G4$L! A0#
M%     @ HX)W4D"D9)Y64   (EL  !8              ( !O.8( &=P='DQ
M;&MS;6AB83 P,# T,"YJ<&=02P$"% ,4    " "C@G=2S24DQ5,P  !Y0
M%@              @ %&-PD 9W!T>3%L:W-M:&)A,# P,#0Q+FIP9U!+ 0(4
M Q0    ( *."=U+412_@L34  &9*   6              "  <UG"0!G<'1Y
M,6QK<VUH8F$P,# P-#(N:G!G4$L! A0#%     @ HX)W4KKV('2C1@  35
M !8              ( !LIT) &=P='DQ;&MS;6AB83 P,# T,RYJ<&=02P$"
M% ,4    " "C@G=2O$H:GU%%! !N$S@ %0              @ &)Y D ;W)I
M8RTQ,&M?,C R,#$R,S$N:'1M4$L! A0#%     @ HX)W4K70%M%R$P  ?](
M !$              ( !#2H. &]R:6,M,C R,#$R,S$N>'-D4$L! A0#%
M  @ HX)W4ISEL%NM#0  Y;<  !4              ( !KCT. &]R:6,M,C R
M,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( *."=U*T_PD<RR(   !/ @ 5
M          "  8Y+#@!O<FEC+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4
M" "C@G=2_C+*$REL  !LHP8 %0              @ &,;@X ;W)I8RTR,#(P
M,3(S,5]L86(N>&UL4$L! A0#%     @ HX)W4GOOU5PD00  #-T$ !4
M         ( !Z-H. &]R:6,M,C R,#$R,S%?<')E+GAM;%!+ 0(4 Q0    (
M *."=U+3N27K( ,  -((   3              "  3\<#P!O<FEC+65X,C,Q
M7S(T,S0N:'1M4$L! A0#%     @ HX)W4H/A#WQ]"   J4<  !
M     ( !D!\/ &]R:6,M97@S,3%?."YH=&U02P$"% ,4    " "C@G=2!$HL
MTV<(  "A1P  $               @ $[* \ ;W)I8RUE>#,Q,E\Y+FAT;5!+
M 0(4 Q0    ( *."=U+9PG9+-04  (PD   0              "  = P#P!O
M<FEC+65X,S(Q7S8N:'1M4$L! A0#%     @ HX)W4LOFG5XD!0  ?R0  !
M             ( !,S8/ &]R:6,M97@S,C)?-RYH=&U02P4&     #8 -@ S
)#@  A3L/

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
